enhancement of humoral immune responses to inactivated newcastle disease and druga by oral administration of drugb in chickens .
false
the objective of this study was to evaluate the effect of oral administration of druga ( drugb ) on the humoral immune responses of chickens to drugn and drugn drugn .
false
the objective of this study was to evaluate the effect of oral administration of druga ( drugn ) on the humoral immune responses of chickens to drugb and drugn .
false
the objective of this study was to evaluate the effect of oral administration of druga ( drugn ) on the humoral immune responses of chickens to drugn and drugb .
false
the objective of this study was to evaluate the effect of oral administration of drugn ( druga ) on the humoral immune responses of chickens to drugb and drugn .
false
the objective of this study was to evaluate the effect of oral administration of drugn ( druga ) on the humoral immune responses of chickens to drugn and drugb .
false
the objective of this study was to evaluate the effect of oral administration of drugn ( drugn ) on the humoral immune responses of chickens to druga and drugb .
false
in experiment 1 , oral administration of druga at a dose of 5 mg/kg of bw for 7 d on the immune response in chickens intramuscularly injected with drugb was evaluated .
false
in experiment 2 , the same regimen of druga was administered to chickens inoculated with drugb , and an enhanced serum antibody response to ai vaccination was also observed .
effect
considering the safety of druga , because no adverse effect was found throughout the experiments , drugb may be a promising oral adjuvant to improve immunization in poultry .
false
[ influence of druga and drugb on mptp-evoked behavior violations in c57bl/6 mice ] .
false
the effects of druga drugb [ drugn ] ( 10 mg/kg , p . o . )
false
the effects of druga drugn [ drugb ] ( 10 mg/kg , p . o . )
false
the effects of drugn druga [ drugb ] ( 10 mg/kg , p . o . )
false
and/or druga drugb ( 100 mg/kg , p . o . ) , as well as that of neurotoxin drugn ( drugn ) ( 4 x 20 mg/kg , i. p . )
false
and/or druga drugn ( 100 mg/kg , p . o . ) , as well as that of neurotoxin drugb ( drugn ) ( 4 x 20 mg/kg , i. p . )
false
and/or druga drugn ( 100 mg/kg , p . o . ) , as well as that of neurotoxin drugn ( drugb ) ( 4 x 20 mg/kg , i. p . )
false
and/or drugn druga ( 100 mg/kg , p . o . ) , as well as that of neurotoxin drugb ( drugn ) ( 4 x 20 mg/kg , i. p . )
false
and/or drugn druga ( 100 mg/kg , p . o . ) , as well as that of neurotoxin drugn ( drugb ) ( 4 x 20 mg/kg , i. p . )
false
and/or drugn drugn ( 100 mg/kg , p . o . ) , as well as that of neurotoxin druga ( drugb ) ( 4 x 20 mg/kg , i. p . )
false
acute administration of druga or drugb failed to influence locomotion in mice , while their combination normalized motor activity .
effect
to determine whether the co-injection of extracellular matrix degrading enzymes improves retinal transduction following intravitreal delivery of druga ( drugb ) .
false
druga containing cdna encoding enhanced green fluorescent protein ( gfp ) , under the control of a chicken -actin promoter , was delivered by intravitreal injection to adult mice in conjunction with enzymes including drugb , drugn , drugn , or drugn .
false
druga containing cdna encoding enhanced green fluorescent protein ( gfp ) , under the control of a chicken -actin promoter , was delivered by intravitreal injection to adult mice in conjunction with enzymes including drugn , drugb , drugn , or drugn .
false
druga containing cdna encoding enhanced green fluorescent protein ( gfp ) , under the control of a chicken -actin promoter , was delivered by intravitreal injection to adult mice in conjunction with enzymes including drugn , drugn , drugb , or drugn .
false
druga containing cdna encoding enhanced green fluorescent protein ( gfp ) , under the control of a chicken -actin promoter , was delivered by intravitreal injection to adult mice in conjunction with enzymes including drugn , drugn , drugn , or drugb .
false
drugn containing cdna encoding enhanced green fluorescent protein ( gfp ) , under the control of a chicken -actin promoter , was delivered by intravitreal injection to adult mice in conjunction with enzymes including druga , drugb , drugn , or drugn .
false
drugn containing cdna encoding enhanced green fluorescent protein ( gfp ) , under the control of a chicken -actin promoter , was delivered by intravitreal injection to adult mice in conjunction with enzymes including druga , drugn , drugb , or drugn .
false
drugn containing cdna encoding enhanced green fluorescent protein ( gfp ) , under the control of a chicken -actin promoter , was delivered by intravitreal injection to adult mice in conjunction with enzymes including druga , drugn , drugn , or drugb .
false
drugn containing cdna encoding enhanced green fluorescent protein ( gfp ) , under the control of a chicken -actin promoter , was delivered by intravitreal injection to adult mice in conjunction with enzymes including drugn , druga , drugb , or drugn .
false
drugn containing cdna encoding enhanced green fluorescent protein ( gfp ) , under the control of a chicken -actin promoter , was delivered by intravitreal injection to adult mice in conjunction with enzymes including drugn , druga , drugn , or drugb .
false
drugn containing cdna encoding enhanced green fluorescent protein ( gfp ) , under the control of a chicken -actin promoter , was delivered by intravitreal injection to adult mice in conjunction with enzymes including drugn , drugn , druga , or drugb .
false
the addition of druga or drugb greatly enhanced transduction of the retinal ganglion cell layer and increased the depth of transduction into the outer retina .
false
druga had a limited effect and drugb was ineffective .
false
electroretinograms survived with higher concentrations of druga and drugb than were required for optimal retinal transduction .
false
druga -mediated retinal transduction is improved by co-injection of drugb or drugn .
effect
druga -mediated retinal transduction is improved by co-injection of drugn or drugb .
effect
drugn -mediated retinal transduction is improved by co-injection of druga or drugb .
false
the aim of the present study was to investigate whether hb-egf is a therapeutic target for t-all , and to further elucidate the antitumor effects of a specific inhibitor of hb-egf , druga ( drugb ) .
false
we elucidated the expression of hb-egf in t-all cell lines , and evaluated the effect of druga on these cells alone or in combination with drugb .
false
druga induced apoptosis , and furthermore , the combination of drugb plus drugn enhanced cytotoxicity in a t-all cell line .
false
druga induced apoptosis , and furthermore , the combination of drugn plus drugb enhanced cytotoxicity in a t-all cell line .
false
drugn induced apoptosis , and furthermore , the combination of druga plus drugb enhanced cytotoxicity in a t-all cell line .
effect
distinct synergistic action of druga and drugb against pseudomonas aeruginosa .
false
results revealed that the strains were resistant to many drugs at high levels , only druga , drugb , drugn and drugn showed resistances at comparatively lower levels .
false
results revealed that the strains were resistant to many drugs at high levels , only druga , drugn , drugb and drugn showed resistances at comparatively lower levels .
false
results revealed that the strains were resistant to many drugs at high levels , only druga , drugn , drugn and drugb showed resistances at comparatively lower levels .
false
results revealed that the strains were resistant to many drugs at high levels , only drugn , druga , drugb and drugn showed resistances at comparatively lower levels .
false
results revealed that the strains were resistant to many drugs at high levels , only drugn , druga , drugn and drugb showed resistances at comparatively lower levels .
false
results revealed that the strains were resistant to many drugs at high levels , only drugn , drugn , druga and drugb showed resistances at comparatively lower levels .
false
distinct and statistically significant synergism was observed between druga and drugb by disc diffusion tests when compared with their individual effects .
effect
synergism was also noted when druga was combined with drugb and drugn .
effect
synergism was also noted when druga was combined with drugn and drugb .
effect
synergism was also noted when drugn was combined with druga and drugb .
false
improved parathyroid hormone control by druga is associated with reduction in drugb requirement in patients with end-stage renal disease .
false
uncontrolled hy-per-parathyroidism causes bone marrow fibrosis , leading to druga ( drugb ) resistance .
false
medical treatment with druga is effective in reducing plasma parathyroid hormone ( pth ) levels , but its effect on drugb dosing is unknown .
false
the primary objective of the study was to ascertain the difference in druga responsiveness before and after 12 months of drugb therapy .
false
reduction of pth by druga is associated with a decrease in drugb requirement .
effect
druga , an drugb , is the standard hormone treatment for breast cancer .
false
druga and drugb reduce the plasma concentration of drugn by about 50 % .
false
druga and drugn reduce the plasma concentration of drugb by about 50 % .
mechanism
drugn and druga reduce the plasma concentration of drugb by about 50 % .
mechanism
it is better to avoid prescribing isoenzyme cyp 2d6 inhibitors to women treated with druga for breast cancer , especially drugb such as drugn and drugn .
advise
it is better to avoid prescribing isoenzyme cyp 2d6 inhibitors to women treated with druga for breast cancer , especially drugn such as drugb and drugn .
advise
it is better to avoid prescribing isoenzyme cyp 2d6 inhibitors to women treated with druga for breast cancer , especially drugn such as drugn and drugb .
advise
it is better to avoid prescribing isoenzyme cyp 2d6 inhibitors to women treated with drugn for breast cancer , especially druga such as drugb and drugn .
false
it is better to avoid prescribing isoenzyme cyp 2d6 inhibitors to women treated with drugn for breast cancer , especially druga such as drugn and drugb .
false
it is better to avoid prescribing isoenzyme cyp 2d6 inhibitors to women treated with drugn for breast cancer , especially drugn such as druga and drugb .
false
depression does not always require druga therapy , and drugb have no proven preventive impact on hot flushes linked to the menopause .
false
if in certain cases , an druga is considered necessary , it may be advisable to replace drugb with drugn .
advise
if in certain cases , an druga is considered necessary , it may be advisable to replace drugn with drugb .
false
if in certain cases , an drugn is considered necessary , it may be advisable to replace druga with drugb .
false
druga failure in an hiv-positive woman on drugb therapy resulting in two ectopic pregnancies .
effect
we present an interesting case of an hiv-positive woman on druga therapy having tubal pregnancies on two separate occasions with drugb in place .
effect
druga enhances the antinociceptive effect of drugb in mice .
effect
the purpose of this study was to evaluate whether the psychostimulant drug druga has any effect on drugb -induced antinociception and locomotor inhibitor activity in mice in acute application .
false
saline + saline , druga ( 10 mg/kg ) + saline , saline + drugb ( 15 g/kg ) and drugn ( 10 mg/kg ) + drugn ( 15 g/kg ) , intraperitoneally , 30 min before hot plate or holed open field tests .
false
saline + saline , druga ( 10 mg/kg ) + saline , saline + drugn ( 15 g/kg ) and drugb ( 10 mg/kg ) + drugn ( 15 g/kg ) , intraperitoneally , 30 min before hot plate or holed open field tests .
false
saline + saline , druga ( 10 mg/kg ) + saline , saline + drugn ( 15 g/kg ) and drugn ( 10 mg/kg ) + drugb ( 15 g/kg ) , intraperitoneally , 30 min before hot plate or holed open field tests .
false
saline + saline , drugn ( 10 mg/kg ) + saline , saline + druga ( 15 g/kg ) and drugb ( 10 mg/kg ) + drugn ( 15 g/kg ) , intraperitoneally , 30 min before hot plate or holed open field tests .
false
saline + saline , drugn ( 10 mg/kg ) + saline , saline + druga ( 15 g/kg ) and drugn ( 10 mg/kg ) + drugb ( 15 g/kg ) , intraperitoneally , 30 min before hot plate or holed open field tests .
false
saline + saline , drugn ( 10 mg/kg ) + saline , saline + drugn ( 15 g/kg ) and druga ( 10 mg/kg ) + drugb ( 15 g/kg ) , intraperitoneally , 30 min before hot plate or holed open field tests .
false
in the hot plate test in mice , co-administration of 15 g/kg druga with 10 mg/kg drugb intraperitoneally not only enhanced , but also prolonged the duration of antinociception induced by drugn .
effect
in the hot plate test in mice , co-administration of 15 g/kg druga with 10 mg/kg drugn intraperitoneally not only enhanced , but also prolonged the duration of antinociception induced by drugb .
false
in the hot plate test in mice , co-administration of 15 g/kg drugn with 10 mg/kg druga intraperitoneally not only enhanced , but also prolonged the duration of antinociception induced by drugb .
false
at the same time , the locomotor inhibitory effect of druga was counteracted by drugb .
effect
we concluded that the combined administration of druga with drugb may have beneficial effects in the treatment of pain without causing sedation , which limits the use of drugn as an drugn in humans .
effect
we concluded that the combined administration of druga with drugn may have beneficial effects in the treatment of pain without causing sedation , which limits the use of drugb as an drugn in humans .
false
we concluded that the combined administration of druga with drugn may have beneficial effects in the treatment of pain without causing sedation , which limits the use of drugn as an drugb in humans .
false
we concluded that the combined administration of drugn with druga may have beneficial effects in the treatment of pain without causing sedation , which limits the use of drugb as an drugn in humans .
false
we concluded that the combined administration of drugn with druga may have beneficial effects in the treatment of pain without causing sedation , which limits the use of drugn as an drugb in humans .
false
we concluded that the combined administration of drugn with drugn may have beneficial effects in the treatment of pain without causing sedation , which limits the use of druga as an drugb in humans .
false
interaction of druga with different drugb is antagonistic in breast but not in other cancer cells .
effect
this study investigates the ability of druga to sensitize cells from different origins to several drugb .
false
the sensitivity , cell cycle , apoptosis and dna damage of five different cancer cell lines ( hela , hct116 , hepg2 , mcf7 and u251 ) to druga , drugb , drugn and drugn drugn following different incubation schedules were analyzed .
false
the sensitivity , cell cycle , apoptosis and dna damage of five different cancer cell lines ( hela , hct116 , hepg2 , mcf7 and u251 ) to druga , drugn , drugb and drugn drugn following different incubation schedules were analyzed .
false
the sensitivity , cell cycle , apoptosis and dna damage of five different cancer cell lines ( hela , hct116 , hepg2 , mcf7 and u251 ) to druga , drugn , drugn and drugb drugn following different incubation schedules were analyzed .
false
the sensitivity , cell cycle , apoptosis and dna damage of five different cancer cell lines ( hela , hct116 , hepg2 , mcf7 and u251 ) to druga , drugn , drugn and drugn drugb following different incubation schedules were analyzed .
false
the sensitivity , cell cycle , apoptosis and dna damage of five different cancer cell lines ( hela , hct116 , hepg2 , mcf7 and u251 ) to drugn , druga , drugb and drugn drugn following different incubation schedules were analyzed .
false
the sensitivity , cell cycle , apoptosis and dna damage of five different cancer cell lines ( hela , hct116 , hepg2 , mcf7 and u251 ) to drugn , druga , drugn and drugb drugn following different incubation schedules were analyzed .
false
the sensitivity , cell cycle , apoptosis and dna damage of five different cancer cell lines ( hela , hct116 , hepg2 , mcf7 and u251 ) to drugn , druga , drugn and drugn drugb following different incubation schedules were analyzed .
false
the sensitivity , cell cycle , apoptosis and dna damage of five different cancer cell lines ( hela , hct116 , hepg2 , mcf7 and u251 ) to drugn , drugn , druga and drugb drugn following different incubation schedules were analyzed .
false
the sensitivity , cell cycle , apoptosis and dna damage of five different cancer cell lines ( hela , hct116 , hepg2 , mcf7 and u251 ) to drugn , drugn , druga and drugn drugb following different incubation schedules were analyzed .
false
the sensitivity , cell cycle , apoptosis and dna damage of five different cancer cell lines ( hela , hct116 , hepg2 , mcf7 and u251 ) to drugn , drugn , drugn and druga drugb following different incubation schedules were analyzed .
false
we found antagonism between druga and the four drugs in the breast cancer cells mcf7 following all incubation schedules and between drugb and drugn in all cell lines except for two combinations in hct116 cells .
false
we found antagonism between druga and the four drugs in the breast cancer cells mcf7 following all incubation schedules and between drugn and drugb in all cell lines except for two combinations in hct116 cells .
false
we found antagonism between drugn and the four drugs in the breast cancer cells mcf7 following all incubation schedules and between druga and drugb in all cell lines except for two combinations in hct116 cells .
effect
these results , if confirmed in-vivo , indicate that druga is not a suitable chemosensitizer for breast cancer or with drugb for other cancers .
false
the druga ( drugb ) , one of s-adenosylhomocysteine ( adohcy ) hydrolase inhibitors , has shown antitumor activities in a broad range of solid tumors and acute myeloid leukemia .
false
we also found that bcl-2 was overexpressed in druga insensitive cells , and cotreatment with drugb and drugn , a bcl-2 family inhibitor , synergistically inhibited growth and induced apoptosis of drugn insensitive mm cells .
false
we also found that bcl-2 was overexpressed in druga insensitive cells , and cotreatment with drugn and drugb , a bcl-2 family inhibitor , synergistically inhibited growth and induced apoptosis of drugn insensitive mm cells .
false
we also found that bcl-2 was overexpressed in druga insensitive cells , and cotreatment with drugn and drugn , a bcl-2 family inhibitor , synergistically inhibited growth and induced apoptosis of drugb insensitive mm cells .
false
we also found that bcl-2 was overexpressed in drugn insensitive cells , and cotreatment with druga and drugb , a bcl-2 family inhibitor , synergistically inhibited growth and induced apoptosis of drugn insensitive mm cells .
effect
we also found that bcl-2 was overexpressed in drugn insensitive cells , and cotreatment with druga and drugn , a bcl-2 family inhibitor , synergistically inhibited growth and induced apoptosis of drugb insensitive mm cells .
false
we also found that bcl-2 was overexpressed in drugn insensitive cells , and cotreatment with drugn and druga , a bcl-2 family inhibitor , synergistically inhibited growth and induced apoptosis of drugb insensitive mm cells .
false
in addition , druga insensitivity might be associated with overexpression of bcl-2 , and the combination of drugb and drugn could synergistically induced apoptosis .
false
in addition , druga insensitivity might be associated with overexpression of bcl-2 , and the combination of drugn and drugb could synergistically induced apoptosis .
false
in addition , drugn insensitivity might be associated with overexpression of bcl-2 , and the combination of druga and drugb could synergistically induced apoptosis .
effect
the incubations were performed in the absence and presence of the non-specific cyp inhibitor , druga ( drugb ) and isoform-specific inhibitors .
false
druga decreased the toxicity of drugb , increased exposure to parent compound , and decreased metabolite levels in a dose-dependent manner .
effect
of the isoform-specific cyp inhibitors tested for an effect on the druga metabolite profile , only drugb was noticeably effective , indicating a role of cyps 2a6 , 2c9 , 2cl9 , and 2e1 .
false
with respect to toxicity , the order of cyp inhibitor effectiveness was druga > drugb ~ drugn > drugn .
false
with respect to toxicity , the order of cyp inhibitor effectiveness was druga > drugn ~ drugb > drugn .
false
with respect to toxicity , the order of cyp inhibitor effectiveness was druga > drugn ~ drugn > drugb .
false
with respect to toxicity , the order of cyp inhibitor effectiveness was drugn > druga ~ drugb > drugn .
false
with respect to toxicity , the order of cyp inhibitor effectiveness was drugn > druga ~ drugn > drugb .
false
with respect to toxicity , the order of cyp inhibitor effectiveness was drugn > drugn ~ druga > drugb .
false
druga and drugb had no effect , while drugn appeared to augment drugn toxicity .
false
druga and drugn had no effect , while drugb appeared to augment drugn toxicity .
false
druga and drugn had no effect , while drugn appeared to augment drugb toxicity .
false
drugn and druga had no effect , while drugb appeared to augment drugn toxicity .
false
drugn and druga had no effect , while drugn appeared to augment drugb toxicity .
false
drugn and drugn had no effect , while druga appeared to augment drugb toxicity .
effect
these results suggest that rat liver slices do not reproduce the reported in vivo biotransformation of druga and therefore may not be an appropriate model for drugb metabolism .
false
druga enhances drugb -mediated antibody-dependent cellular cytotoxicity by up-regulation of cell surface her2 expression .
effect
although it was previously reported that druga combined with drugb improved the progression-free survival rate compared with drugn alone for patients with drugn -refractory her2-positive metastatic breast cancer , the mechanism is purported to be an antiproliferative effect relating to the synergism of these two agents .
effect
although it was previously reported that druga combined with drugn improved the progression-free survival rate compared with drugb alone for patients with drugn -refractory her2-positive metastatic breast cancer , the mechanism is purported to be an antiproliferative effect relating to the synergism of these two agents .
false
although it was previously reported that druga combined with drugn improved the progression-free survival rate compared with drugn alone for patients with drugb -refractory her2-positive metastatic breast cancer , the mechanism is purported to be an antiproliferative effect relating to the synergism of these two agents .
false
although it was previously reported that drugn combined with druga improved the progression-free survival rate compared with drugb alone for patients with drugn -refractory her2-positive metastatic breast cancer , the mechanism is purported to be an antiproliferative effect relating to the synergism of these two agents .
false
although it was previously reported that drugn combined with druga improved the progression-free survival rate compared with drugn alone for patients with drugb -refractory her2-positive metastatic breast cancer , the mechanism is purported to be an antiproliferative effect relating to the synergism of these two agents .
false
although it was previously reported that drugn combined with drugn improved the progression-free survival rate compared with druga alone for patients with drugb -refractory her2-positive metastatic breast cancer , the mechanism is purported to be an antiproliferative effect relating to the synergism of these two agents .
false
we evaluated how druga interacts with drugb in her2-positive breast cancer , with a particular focus on drugn -mediated antibody-dependent cellular cytotoxicity ( adcc ) .
false
we evaluated how druga interacts with drugn in her2-positive breast cancer , with a particular focus on drugb -mediated antibody-dependent cellular cytotoxicity ( adcc ) .
false
we evaluated how drugn interacts with druga in her2-positive breast cancer , with a particular focus on drugb -mediated antibody-dependent cellular cytotoxicity ( adcc ) .
false
in an in vitro assay , druga induced her2 expression at the cell surface of her2-positive breast cancer cell lines , leading to the enhancement of drugb -mediated adcc .
effect
furthermore , we present a case report in which a second druga treatment following drugb resulted in the marked shrinkage of multiple metastatic tumors in her2-positive breast cancer .
effect
druga may have the potential to convert drugb -refractory to drugn -sensitive tumors in her2-positive breast cancer by up-regulation of the cell surface expression of her2 .
false
druga may have the potential to convert drugn -refractory to drugb -sensitive tumors in her2-positive breast cancer by up-regulation of the cell surface expression of her2 .
false
drugn may have the potential to convert druga -refractory to drugb -sensitive tumors in her2-positive breast cancer by up-regulation of the cell surface expression of her2 .
false
[ efficacy of fixed combination druga / drugb in hospitalized patients with hypertensive disease ]
false
efficacy and tolerability of fixed druga / drugb combination was studied in 86 patients with hypertensive disease hospitalized in departments of general internal medicine or cardiology .
false
all patients had indications for antihypertensive therapy and were randomized either to fixed combination druga / drugb ( n=43 ) or to therapy which corresponded to the hospital formulary ( n=43 ) .
false
rate of achievement of target bp with fixed combination druga / drugb ( 93 % ) was comparable with that on traditional therapy ( 90 % ) .
false
but the use of fixed combination druga / drugb compared with traditional therapy was associated with lower clinical and self measured bp , quicker achievement of target bp ( 5.8+/-2.3 and 9.2+/-1.8 days , respectively , 0.05 ) , lesser number of drugn ( 2.5+/-0.6 and 3.0+/-0.9 days , respectively ) , lower rate of concealed inefficacy of treatment ( 12 and 31 % , respectively , 0.05 ) .
effect
but the use of fixed combination druga / drugn compared with traditional therapy was associated with lower clinical and self measured bp , quicker achievement of target bp ( 5.8+/-2.3 and 9.2+/-1.8 days , respectively , 0.05 ) , lesser number of drugb ( 2.5+/-0.6 and 3.0+/-0.9 days , respectively ) , lower rate of concealed inefficacy of treatment ( 12 and 31 % , respectively , 0.05 ) .
false
but the use of fixed combination drugn / druga compared with traditional therapy was associated with lower clinical and self measured bp , quicker achievement of target bp ( 5.8+/-2.3 and 9.2+/-1.8 days , respectively , 0.05 ) , lesser number of drugb ( 2.5+/-0.6 and 3.0+/-0.9 days , respectively ) , lower rate of concealed inefficacy of treatment ( 12 and 31 % , respectively , 0.05 ) .
false
we have demonstrated appropriateness of inhospital administration of fixed druga / drugb combination as an approach allowing to achieve target bp in shorter time , with the use of fewer drugn , and diminishing concealed inefficacy of treatment .
effect
we have demonstrated appropriateness of inhospital administration of fixed druga / drugn combination as an approach allowing to achieve target bp in shorter time , with the use of fewer drugb , and diminishing concealed inefficacy of treatment .
false
we have demonstrated appropriateness of inhospital administration of fixed drugn / druga combination as an approach allowing to achieve target bp in shorter time , with the use of fewer drugb , and diminishing concealed inefficacy of treatment .
false
druga locomotor sensitization and conditioned place preference in adolescent male and female rats neonatally treated with drugb .
false
the objective was to analyze the effects of neonatal druga treatment on effects of drugb in adolescent rats using locomotor sensitization and conditioned place preference procedures .
false
in female rats , neonatal druga treatment enhanced drugb locomotor sensitization compared with drugn -free controls sensitized to drugn .
effect
in female rats , neonatal druga treatment enhanced drugn locomotor sensitization compared with drugb -free controls sensitized to drugn .
false
in female rats , neonatal druga treatment enhanced drugn locomotor sensitization compared with drugn -free controls sensitized to drugb .
false
in female rats , neonatal drugn treatment enhanced druga locomotor sensitization compared with drugb -free controls sensitized to drugn .
false
in female rats , neonatal drugn treatment enhanced druga locomotor sensitization compared with drugn -free controls sensitized to drugb .
false
in female rats , neonatal drugn treatment enhanced drugn locomotor sensitization compared with druga -free controls sensitized to drugb .
false
male rats demonstrated sensitization to druga , although this was muted compared with female rats , and were unaffected by neonatal drugb .
false
rats treated with neonatal druga enhanced time spent in the drugb -paired context compared with drugn -free controls conditioned with drugn , but only female controls conditioned with drugn spent more time in the drug-paired context compared with saline-treated controls .
false
rats treated with neonatal druga enhanced time spent in the drugn -paired context compared with drugb -free controls conditioned with drugn , but only female controls conditioned with drugn spent more time in the drug-paired context compared with saline-treated controls .
false
rats treated with neonatal druga enhanced time spent in the drugn -paired context compared with drugn -free controls conditioned with drugb , but only female controls conditioned with drugn spent more time in the drug-paired context compared with saline-treated controls .
false
rats treated with neonatal druga enhanced time spent in the drugn -paired context compared with drugn -free controls conditioned with drugn , but only female controls conditioned with drugb spent more time in the drug-paired context compared with saline-treated controls .
false
rats treated with neonatal drugn enhanced time spent in the druga -paired context compared with drugb -free controls conditioned with drugn , but only female controls conditioned with drugn spent more time in the drug-paired context compared with saline-treated controls .
false
rats treated with neonatal drugn enhanced time spent in the druga -paired context compared with drugn -free controls conditioned with drugb , but only female controls conditioned with drugn spent more time in the drug-paired context compared with saline-treated controls .
false
rats treated with neonatal drugn enhanced time spent in the druga -paired context compared with drugn -free controls conditioned with drugn , but only female controls conditioned with drugb spent more time in the drug-paired context compared with saline-treated controls .
false
rats treated with neonatal drugn enhanced time spent in the drugn -paired context compared with druga -free controls conditioned with drugb , but only female controls conditioned with drugn spent more time in the drug-paired context compared with saline-treated controls .
false
rats treated with neonatal drugn enhanced time spent in the drugn -paired context compared with druga -free controls conditioned with drugn , but only female controls conditioned with drugb spent more time in the drug-paired context compared with saline-treated controls .
false
rats treated with neonatal drugn enhanced time spent in the drugn -paired context compared with drugn -free controls conditioned with druga , but only female controls conditioned with drugb spent more time in the drug-paired context compared with saline-treated controls .
false
influence of druga on drugb induced antinociception and its pharmacokinetics .
false
in the present study druga ( 10 mg/kg ) significantly increased the dose-dependent antinociceptive activity of drugb evaluated by both drugn writhing and formalin test , when it was administered with drugn .
effect
in the present study druga ( 10 mg/kg ) significantly increased the dose-dependent antinociceptive activity of drugn evaluated by both drugb writhing and formalin test , when it was administered with drugn .
false
in the present study druga ( 10 mg/kg ) significantly increased the dose-dependent antinociceptive activity of drugn evaluated by both drugn writhing and formalin test , when it was administered with drugb .
false
in the present study drugn ( 10 mg/kg ) significantly increased the dose-dependent antinociceptive activity of druga evaluated by both drugb writhing and formalin test , when it was administered with drugn .
false
in the present study drugn ( 10 mg/kg ) significantly increased the dose-dependent antinociceptive activity of druga evaluated by both drugn writhing and formalin test , when it was administered with drugb .
false
in the present study drugn ( 10 mg/kg ) significantly increased the dose-dependent antinociceptive activity of drugn evaluated by both druga writhing and formalin test , when it was administered with drugb .
false
druga plasma concentration was also increased when it was administered with drugb .
mechanism
the synergistic antinociception activity of druga when administered with drugb can be attributed to increased plasma concentration of drugn .
mechanism
the synergistic antinociception activity of druga when administered with drugn can be attributed to increased plasma concentration of drugb .
false
the synergistic antinociception activity of drugn when administered with druga can be attributed to increased plasma concentration of drugb .
false
from this study it can be concluded that druga can be used as a bioenhancer along with drugb .
effect
the role of p27 ( kip1 ) in druga -enhanced drugb cytotoxicity in human ovarian cancer cells .
effect
the effect of druga , an inhibitor of src and abl kinases , on drugb sensitivity was measured in ovarian cancer cells and hey xenografts .
false
the roles of p27 ( kip1 ) , bcl-2 , and cdk1 in apoptosis induced by druga and drugb were assessed using a terminal deoxynucleotidyl transferase-mediated dutp nick-end labeling ( tunel ) assay , sirna knockdown of gene expression , transfection with bcl-2 and cdk1 expression vectors , and flow cytometry .
false
hey cells treated with druga plus drugb formed fewer colonies than did cells treated with either agent alone .
effect
treatment of hey xenograft-bearing mice with druga plus drugb inhibited tumor growth more than treatment with either agent alone ( average tumor volume per mouse , drugn + drugn vs drugn : 0.28 vs. 0.81 cm3 , difference = 0.53 cm3 , 95 % confidence interval [ ci ] = 0.44 to 0.62 cm3 , p = .014 ) ;
effect
treatment of hey xenograft-bearing mice with druga plus drugn inhibited tumor growth more than treatment with either agent alone ( average tumor volume per mouse , drugb + drugn vs drugn : 0.28 vs. 0.81 cm3 , difference = 0.53 cm3 , 95 % confidence interval [ ci ] = 0.44 to 0.62 cm3 , p = .014 ) ;
false
treatment of hey xenograft-bearing mice with druga plus drugn inhibited tumor growth more than treatment with either agent alone ( average tumor volume per mouse , drugn + drugb vs drugn : 0.28 vs. 0.81 cm3 , difference = 0.53 cm3 , 95 % confidence interval [ ci ] = 0.44 to 0.62 cm3 , p = .014 ) ;
false
treatment of hey xenograft-bearing mice with druga plus drugn inhibited tumor growth more than treatment with either agent alone ( average tumor volume per mouse , drugn + drugn vs drugb : 0.28 vs. 0.81 cm3 , difference = 0.53 cm3 , 95 % confidence interval [ ci ] = 0.44 to 0.62 cm3 , p = .014 ) ;
false
treatment of hey xenograft-bearing mice with drugn plus druga inhibited tumor growth more than treatment with either agent alone ( average tumor volume per mouse , drugb + drugn vs drugn : 0.28 vs. 0.81 cm3 , difference = 0.53 cm3 , 95 % confidence interval [ ci ] = 0.44 to 0.62 cm3 , p = .014 ) ;
false
treatment of hey xenograft-bearing mice with drugn plus druga inhibited tumor growth more than treatment with either agent alone ( average tumor volume per mouse , drugn + drugb vs drugn : 0.28 vs. 0.81 cm3 , difference = 0.53 cm3 , 95 % confidence interval [ ci ] = 0.44 to 0.62 cm3 , p = .014 ) ;
false
treatment of hey xenograft-bearing mice with drugn plus druga inhibited tumor growth more than treatment with either agent alone ( average tumor volume per mouse , drugn + drugn vs drugb : 0.28 vs. 0.81 cm3 , difference = 0.53 cm3 , 95 % confidence interval [ ci ] = 0.44 to 0.62 cm3 , p = .014 ) ;
false
treatment of hey xenograft-bearing mice with drugn plus drugn inhibited tumor growth more than treatment with either agent alone ( average tumor volume per mouse , druga + drugb vs drugn : 0.28 vs. 0.81 cm3 , difference = 0.53 cm3 , 95 % confidence interval [ ci ] = 0.44 to 0.62 cm3 , p = .014 ) ;
false
treatment of hey xenograft-bearing mice with drugn plus drugn inhibited tumor growth more than treatment with either agent alone ( average tumor volume per mouse , druga + drugn vs drugb : 0.28 vs. 0.81 cm3 , difference = 0.53 cm3 , 95 % confidence interval [ ci ] = 0.44 to 0.62 cm3 , p = .014 ) ;
false
treatment of hey xenograft-bearing mice with drugn plus drugn inhibited tumor growth more than treatment with either agent alone ( average tumor volume per mouse , drugn + druga vs drugb : 0.28 vs. 0.81 cm3 , difference = 0.53 cm3 , 95 % confidence interval [ ci ] = 0.44 to 0.62 cm3 , p = .014 ) ;
false
druga + drugb vs .
false
the sirna knockdown of p27 ( kip1 ) decreased druga - and drugb -induced apoptosis compared with a negative control sirna ( sub-g1 fraction , control sirna vs. p27 ( kip1 ) sirna : 42.5 % vs. 20.1 % , difference = 22.4 % , 95 % ci = 20.1 % to 24.7 % , p = .017 ) .
false
studies with forced expression and sirna knockdown of bcl-2 and cdk1 suggest that druga -mediated induction of p27 ( kip1 ) enhanced drugb -induced apoptosis by negatively regulating bcl-2 and cdk1 expression .
effect
inhibition of src family and abl kinases with either sirnas or druga enhances drugb sensitivity of ovarian cancer cells through p27 ( kip1 ) -mediated suppression of bcl-2 and cdk1 expression .
effect
synergistic interaction between druga and drugb is sequence dependent in human non-small lung cancer with egfr tkis-resistant mutation .
int
this study was aimed to investigate the efficacy of single use of druga and that of concurrent or sequential administration of drugb and drugn in nsclc cell lines that are resistant to egfr tkis .
false
this study was aimed to investigate the efficacy of single use of druga and that of concurrent or sequential administration of drugn and drugb in nsclc cell lines that are resistant to egfr tkis .
false
this study was aimed to investigate the efficacy of single use of drugn and that of concurrent or sequential administration of druga and drugb in nsclc cell lines that are resistant to egfr tkis .
false
nsclc cell lines with egfr t790m mutation and k-ras mutation were exposed to either druga or drugb or both based on various sequential administrations .
false
druga exhibited dose-dependent growth inhibition in nsclc cell lines and arrested cell cycle at g1 phase , whereas drugb arrested at s phase .
false
although single or concurrent use of druga and drugb has some anti-proliferative effects , the sequential administrations of both drugs remarkably enhanced anti-tumor activity .
effect
when cells were exposed to druga followed by drugb , synergism was observed .
effect
the molecular basis of this synergism is that the signaling pathways that were initially activated by druga exposure were efficiently suppressed by the subsequent exposure to drugb .
effect
druga as a single agent exhibits anti-proliferative effects in vitro in nsclc cell lines with egfr t790m and k-ras mutations but the sequential administration of drugb followed by drugn is superior to drugn followed by drugn and concurrent administration .
false
druga as a single agent exhibits anti-proliferative effects in vitro in nsclc cell lines with egfr t790m and k-ras mutations but the sequential administration of drugn followed by drugb is superior to drugn followed by drugn and concurrent administration .
false
druga as a single agent exhibits anti-proliferative effects in vitro in nsclc cell lines with egfr t790m and k-ras mutations but the sequential administration of drugn followed by drugn is superior to drugb followed by drugn and concurrent administration .
false
druga as a single agent exhibits anti-proliferative effects in vitro in nsclc cell lines with egfr t790m and k-ras mutations but the sequential administration of drugn followed by drugn is superior to drugn followed by drugb and concurrent administration .
false
drugn as a single agent exhibits anti-proliferative effects in vitro in nsclc cell lines with egfr t790m and k-ras mutations but the sequential administration of druga followed by drugb is superior to drugn followed by drugn and concurrent administration .
effect
drugn as a single agent exhibits anti-proliferative effects in vitro in nsclc cell lines with egfr t790m and k-ras mutations but the sequential administration of druga followed by drugn is superior to drugb followed by drugn and concurrent administration .
false
drugn as a single agent exhibits anti-proliferative effects in vitro in nsclc cell lines with egfr t790m and k-ras mutations but the sequential administration of druga followed by drugn is superior to drugn followed by drugb and concurrent administration .
false
drugn as a single agent exhibits anti-proliferative effects in vitro in nsclc cell lines with egfr t790m and k-ras mutations but the sequential administration of drugn followed by druga is superior to drugb followed by drugn and concurrent administration .
false
drugn as a single agent exhibits anti-proliferative effects in vitro in nsclc cell lines with egfr t790m and k-ras mutations but the sequential administration of drugn followed by druga is superior to drugn followed by drugb and concurrent administration .
false
drugn as a single agent exhibits anti-proliferative effects in vitro in nsclc cell lines with egfr t790m and k-ras mutations but the sequential administration of drugn followed by drugn is superior to druga followed by drugb and concurrent administration .
false
druga ( drugb ) -- better than drugn ( drugn )
false
druga ( drugn ) -- better than drugb ( drugn )
false
druga ( drugn ) -- better than drugn ( drugb )
false
drugn ( druga ) -- better than drugb ( drugn )
false
drugn ( druga ) -- better than drugn ( drugb )
false
drugn ( drugn ) -- better than druga ( drugb )
false
the fda has approved druga ( drugb -astrazeneca ) , an oral drugn , for use with low-dose drugn to reduce the rate of thrombotic cardiovascular events in patients with acute coronary syndrome ( acs ) .
false
the fda has approved druga ( drugn -astrazeneca ) , an oral drugb , for use with low-dose drugn to reduce the rate of thrombotic cardiovascular events in patients with acute coronary syndrome ( acs ) .
false
the fda has approved druga ( drugn -astrazeneca ) , an oral drugn , for use with low-dose drugb to reduce the rate of thrombotic cardiovascular events in patients with acute coronary syndrome ( acs ) .
effect
the fda has approved drugn ( druga -astrazeneca ) , an oral drugb , for use with low-dose drugn to reduce the rate of thrombotic cardiovascular events in patients with acute coronary syndrome ( acs ) .
false
the fda has approved drugn ( druga -astrazeneca ) , an oral drugn , for use with low-dose drugb to reduce the rate of thrombotic cardiovascular events in patients with acute coronary syndrome ( acs ) .
effect
the fda has approved drugn ( drugn -astrazeneca ) , an oral druga , for use with low-dose drugb to reduce the rate of thrombotic cardiovascular events in patients with acute coronary syndrome ( acs ) .
false
it will compete with druga ( drugb ) and drugn ( drugn ) for such use .
false
it will compete with druga ( drugn ) and drugb ( drugn ) for such use .
false
it will compete with druga ( drugn ) and drugn ( drugb ) for such use .
false
it will compete with drugn ( druga ) and drugb ( drugn ) for such use .
false
it will compete with drugn ( druga ) and drugn ( drugb ) for such use .
false
it will compete with drugn ( drugn ) and druga ( drugb ) for such use .
false
in the present study , we tested whether the highly specific metabotropic glutamate receptor 5 antagonist , druga , reduces dopaminergic and noradrenergic neuronal loss in monkeys rendered parkinsonian by chronic treatment with low doses of drugb .
false
weekly intramuscular druga injections ( 0.2-0.5 mg/kg body weight ) , in combination with daily administration of drugb or vehicle , were performed until the development of parkinsonian motor symptoms in either of the two experimental groups ( drugn / drugn versus drugn /vehicle ) .
false
weekly intramuscular druga injections ( 0.2-0.5 mg/kg body weight ) , in combination with daily administration of drugn or vehicle , were performed until the development of parkinsonian motor symptoms in either of the two experimental groups ( drugb / drugn versus drugn /vehicle ) .
false
weekly intramuscular druga injections ( 0.2-0.5 mg/kg body weight ) , in combination with daily administration of drugn or vehicle , were performed until the development of parkinsonian motor symptoms in either of the two experimental groups ( drugn / drugb versus drugn /vehicle ) .
false
weekly intramuscular druga injections ( 0.2-0.5 mg/kg body weight ) , in combination with daily administration of drugn or vehicle , were performed until the development of parkinsonian motor symptoms in either of the two experimental groups ( drugn / drugn versus drugb /vehicle ) .
false
weekly intramuscular drugn injections ( 0.2-0.5 mg/kg body weight ) , in combination with daily administration of druga or vehicle , were performed until the development of parkinsonian motor symptoms in either of the two experimental groups ( drugb / drugn versus drugn /vehicle ) .
false
weekly intramuscular drugn injections ( 0.2-0.5 mg/kg body weight ) , in combination with daily administration of druga or vehicle , were performed until the development of parkinsonian motor symptoms in either of the two experimental groups ( drugn / drugb versus drugn /vehicle ) .
false
weekly intramuscular drugn injections ( 0.2-0.5 mg/kg body weight ) , in combination with daily administration of druga or vehicle , were performed until the development of parkinsonian motor symptoms in either of the two experimental groups ( drugn / drugn versus drugb /vehicle ) .
false
weekly intramuscular drugn injections ( 0.2-0.5 mg/kg body weight ) , in combination with daily administration of drugn or vehicle , were performed until the development of parkinsonian motor symptoms in either of the two experimental groups ( druga / drugb versus drugn /vehicle ) .
false
weekly intramuscular drugn injections ( 0.2-0.5 mg/kg body weight ) , in combination with daily administration of drugn or vehicle , were performed until the development of parkinsonian motor symptoms in either of the two experimental groups ( druga / drugn versus drugb /vehicle ) .
false
weekly intramuscular drugn injections ( 0.2-0.5 mg/kg body weight ) , in combination with daily administration of drugn or vehicle , were performed until the development of parkinsonian motor symptoms in either of the two experimental groups ( drugn / druga versus drugb /vehicle ) .
false
after 21 weeks of druga treatment , all drugb /vehicle-treated animals displayed parkinsonian symptoms , whereas none of the drugn / drugn -treated monkeys were significantly affected .
false
after 21 weeks of druga treatment , all drugn /vehicle-treated animals displayed parkinsonian symptoms , whereas none of the drugb / drugn -treated monkeys were significantly affected .
false
after 21 weeks of druga treatment , all drugn /vehicle-treated animals displayed parkinsonian symptoms , whereas none of the drugn / drugb -treated monkeys were significantly affected .
false
after 21 weeks of drugn treatment , all druga /vehicle-treated animals displayed parkinsonian symptoms , whereas none of the drugb / drugn -treated monkeys were significantly affected .
false
after 21 weeks of drugn treatment , all druga /vehicle-treated animals displayed parkinsonian symptoms , whereas none of the drugn / drugb -treated monkeys were significantly affected .
false
after 21 weeks of drugn treatment , all drugn /vehicle-treated animals displayed parkinsonian symptoms , whereas none of the druga / drugb -treated monkeys were significantly affected .
effect
these behavioural observations were consistent with in vivo positron emission tomography dopamine transporter imaging data , and with post-mortem stereological counts of midbrain dopaminergic neurons , as well as striatal intensity measurements of dopamine transporter and tyrosine hydroxylase immunoreactivity , which were all significantly higher in druga / drugb -treated animals than in drugn /vehicle-treated monkeys .
effect
these behavioural observations were consistent with in vivo positron emission tomography dopamine transporter imaging data , and with post-mortem stereological counts of midbrain dopaminergic neurons , as well as striatal intensity measurements of dopamine transporter and tyrosine hydroxylase immunoreactivity , which were all significantly higher in druga / drugn -treated animals than in drugb /vehicle-treated monkeys .
false
these behavioural observations were consistent with in vivo positron emission tomography dopamine transporter imaging data , and with post-mortem stereological counts of midbrain dopaminergic neurons , as well as striatal intensity measurements of dopamine transporter and tyrosine hydroxylase immunoreactivity , which were all significantly higher in drugn / druga -treated animals than in drugb /vehicle-treated monkeys .
false
the druga treatment also had a significant effect on the drugb -induced loss of norepinephrine neurons in the locus coeruleus and adjoining a5 and a7 noradrenaline cell groups .
effect
in druga /vehicle-treated animals , almost 40 % loss of tyrosine hydroxylase-positive norepinephrine neurons was found in locus coeruleus/a5/a7 noradrenaline cell groups , whereas the extent of neuronal loss was lower than 15 % of control values in drugb / drugn -treated monkeys .
false
in druga /vehicle-treated animals , almost 40 % loss of tyrosine hydroxylase-positive norepinephrine neurons was found in locus coeruleus/a5/a7 noradrenaline cell groups , whereas the extent of neuronal loss was lower than 15 % of control values in drugn / drugb -treated monkeys .
false
in drugn /vehicle-treated animals , almost 40 % loss of tyrosine hydroxylase-positive norepinephrine neurons was found in locus coeruleus/a5/a7 noradrenaline cell groups , whereas the extent of neuronal loss was lower than 15 % of control values in druga / drugb -treated monkeys .
effect
our data demonstrate that chronic treatment with the metabotropic glutamate receptor 5 antagonist , druga , significantly reduces drugb toxicity towards dopaminergic and noradrenergic cell groups in non-human primates .
effect
effect of druga -mediated cyp3a4 inhibition on clinical pharmacokinetics of drugb ( drugn ) , an orally active drugn .
false
effect of druga -mediated cyp3a4 inhibition on clinical pharmacokinetics of drugn ( drugb ) , an orally active drugn .
false
effect of druga -mediated cyp3a4 inhibition on clinical pharmacokinetics of drugn ( drugn ) , an orally active drugb .
false
effect of drugn -mediated cyp3a4 inhibition on clinical pharmacokinetics of druga ( drugb ) , an orally active drugn .
false
effect of drugn -mediated cyp3a4 inhibition on clinical pharmacokinetics of druga ( drugn ) , an orally active drugb .
false
effect of drugn -mediated cyp3a4 inhibition on clinical pharmacokinetics of drugn ( druga ) , an orally active drugb .
false
this study evaluated the effect of a potent cyp3a inhibitor , druga , on the pharmacokinetics and safety of drugb .
false
on day 8 , a single druga dose was co-administered with drugb .
false
in the presence of druga , there was 1.6- and 1.8-fold increase in c ( max ) and auc of drugb , respectively .
mechanism
co-administration of druga with cyp3a inhibitors is feasible as the observed increase in drugb pk parameters was not considered clinically relevant .
false
considering the variability in exposure following enzyme inhibition and the fact that chronic dosing of druga was not studied with cyp3a inhibitors , close monitoring of drugb -related adverse events is necessary .
false
druga does not inhibit the absorption of 5 milligrams of drugb or drugn at doses less than 800 milligrams in nonpregnant women .
false
druga does not inhibit the absorption of 5 milligrams of drugn or drugb at doses less than 800 milligrams in nonpregnant women .
false
drugn does not inhibit the absorption of 5 milligrams of druga or drugb at doses less than 800 milligrams in nonpregnant women .
false
druga is the only known component in the diet that may affect absorption of both drugb and drugn .
mechanism
druga is the only known component in the diet that may affect absorption of both drugn and drugb .
mechanism
drugn is the only known component in the diet that may affect absorption of both druga and drugb .
false
however , the evidence for a druga effect on drugb absorption mainly comes from studies that did not isolate the effect of drugn from that of other dietary components , because it was detected in single-meal studies .
mechanism
however , the evidence for a druga effect on drugn absorption mainly comes from studies that did not isolate the effect of drugb from that of other dietary components , because it was detected in single-meal studies .
false
however , the evidence for a drugn effect on druga absorption mainly comes from studies that did not isolate the effect of drugb from that of other dietary components , because it was detected in single-meal studies .
false
our objective was to establish potential effects of druga on absorption of drugb and drugn and the dose response for this effect in the absence of a meal .
false
our objective was to establish potential effects of druga on absorption of drugn and drugb and the dose response for this effect in the absence of a meal .
false
our objective was to establish potential effects of drugn on absorption of druga and drugb and the dose response for this effect in the absence of a meal .
false
we evaluated the effects of druga doses between 200 and 1500 mg on absorption of 5 mg drugb ( as drugn ) .
false
we evaluated the effects of druga doses between 200 and 1500 mg on absorption of 5 mg drugn ( as drugb ) .
false
we evaluated the effects of drugn doses between 200 and 1500 mg on absorption of 5 mg druga ( as drugb ) .
false
we also evaluated the effects of druga doses between 200 and 800 mg on absorption of 5 mg drugb [ as concentrated rbc ( crbc ) ] .
false
druga was administered as drugb in all studies and drugn were ingested on an empty stomach .
false
druga was administered as drugn in all studies and drugb were ingested on an empty stomach .
false
drugn was administered as druga in all studies and drugb were ingested on an empty stomach .
false
druga doses 1000 mg diminished drugb absorption by an average of 49.6 % .
mechanism
a druga dose of 800 mg diminished absorption of 5 mg drugb by 37.7 % .
mechanism
in conclusion , we demonstrated an isolated effect of druga ( as chloride ) on absorption of 5 mg of iron provided as drugb ( as sulfate ) and drugn ( as crbc ) .
mechanism
in conclusion , we demonstrated an isolated effect of druga ( as chloride ) on absorption of 5 mg of iron provided as drugn ( as sulfate ) and ( as crbc ) drugb .
mechanism
in conclusion , we demonstrated an isolated effect of drugn ( as chloride ) on absorption of 5 mg of iron provided as druga ( as sulfate ) and drugb ( as crbc ) .
false
evaluation of antidepressant like activity of druga and its combination with drugb and drugn : an acute and chronic study .
false
evaluation of antidepressant like activity of druga and its combination with drugn and drugb : an acute and chronic study .
false
evaluation of antidepressant like activity of drugn and its combination with druga and drugb : an acute and chronic study .
false
in the present study , the antidepressant like activity of druga and its combination with drugb and drugn was studied in acute model ( three doses 24 , 5 and 1 h before test ) of forced swimming test ( fst ) in glass jar and tail suspension test ( tst ) in mice and in chronic model ( 14 day study ) of fst with water wheel in rats .
false
in the present study , the antidepressant like activity of druga and its combination with drugn and drugb was studied in acute model ( three doses 24 , 5 and 1 h before test ) of forced swimming test ( fst ) in glass jar and tail suspension test ( tst ) in mice and in chronic model ( 14 day study ) of fst with water wheel in rats .
false
in the present study , the antidepressant like activity of drugn and its combination with druga and drugb was studied in acute model ( three doses 24 , 5 and 1 h before test ) of forced swimming test ( fst ) in glass jar and tail suspension test ( tst ) in mice and in chronic model ( 14 day study ) of fst with water wheel in rats .
false
all the tests were carried out in the following seven groups ( n = 6 in each group ) , drugs being given orally ( doses for mice ) : group 1 ( vehicle ) , group 2 ( druga 50 mg/kg ) , group 3 ( drugb 100 mg/kg ) , group 4 ( drugn 20 mg/kg ) , group 5 ( drugn 15 mg/kg ) , group 6 ( drugn 100 mg/kg plus drugn 20 mg/kg ) and group 7 ( drugn 100 mg/kg plus drugn 15 mg/kg ) .
false
all the tests were carried out in the following seven groups ( n = 6 in each group ) , drugs being given orally ( doses for mice ) : group 1 ( vehicle ) , group 2 ( druga 50 mg/kg ) , group 3 ( drugn 100 mg/kg ) , group 4 ( drugb 20 mg/kg ) , group 5 ( drugn 15 mg/kg ) , group 6 ( drugn 100 mg/kg plus drugn 20 mg/kg ) and group 7 ( drugn 100 mg/kg plus drugn 15 mg/kg ) .
false
all the tests were carried out in the following seven groups ( n = 6 in each group ) , drugs being given orally ( doses for mice ) : group 1 ( vehicle ) , group 2 ( druga 50 mg/kg ) , group 3 ( drugn 100 mg/kg ) , group 4 ( drugn 20 mg/kg ) , group 5 ( drugb 15 mg/kg ) , group 6 ( drugn 100 mg/kg plus drugn 20 mg/kg ) and group 7 ( drugn 100 mg/kg plus drugn 15 mg/kg ) .
false
all the tests were carried out in the following seven groups ( n = 6 in each group ) , drugs being given orally ( doses for mice ) : group 1 ( vehicle ) , group 2 ( druga 50 mg/kg ) , group 3 ( drugn 100 mg/kg ) , group 4 ( drugn 20 mg/kg ) , group 5 ( drugn 15 mg/kg ) , group 6 ( drugb 100 mg/kg plus drugn 20 mg/kg ) and group 7 ( drugn 100 mg/kg plus drugn 15 mg/kg ) .
false
all the tests were carried out in the following seven groups ( n = 6 in each group ) , drugs being given orally ( doses for mice ) : group 1 ( vehicle ) , group 2 ( druga 50 mg/kg ) , group 3 ( drugn 100 mg/kg ) , group 4 ( drugn 20 mg/kg ) , group 5 ( drugn 15 mg/kg ) , group 6 ( drugn 100 mg/kg plus drugb 20 mg/kg ) and group 7 ( drugn 100 mg/kg plus drugn 15 mg/kg ) .
false
all the tests were carried out in the following seven groups ( n = 6 in each group ) , drugs being given orally ( doses for mice ) : group 1 ( vehicle ) , group 2 ( druga 50 mg/kg ) , group 3 ( drugn 100 mg/kg ) , group 4 ( drugn 20 mg/kg ) , group 5 ( drugn 15 mg/kg ) , group 6 ( drugn 100 mg/kg plus drugn 20 mg/kg ) and group 7 ( drugb 100 mg/kg plus drugn 15 mg/kg ) .
false
all the tests were carried out in the following seven groups ( n = 6 in each group ) , drugs being given orally ( doses for mice ) : group 1 ( vehicle ) , group 2 ( druga 50 mg/kg ) , group 3 ( drugn 100 mg/kg ) , group 4 ( drugn 20 mg/kg ) , group 5 ( drugn 15 mg/kg ) , group 6 ( drugn 100 mg/kg plus drugn 20 mg/kg ) and group 7 ( drugn 100 mg/kg plus drugb 15 mg/kg ) .
false
all the tests were carried out in the following seven groups ( n = 6 in each group ) , drugs being given orally ( doses for mice ) : group 1 ( vehicle ) , group 2 ( drugn 50 mg/kg ) , group 3 ( druga 100 mg/kg ) , group 4 ( drugb 20 mg/kg ) , group 5 ( drugn 15 mg/kg ) , group 6 ( drugn 100 mg/kg plus drugn 20 mg/kg ) and group 7 ( drugn 100 mg/kg plus drugn 15 mg/kg ) .
false
all the tests were carried out in the following seven groups ( n = 6 in each group ) , drugs being given orally ( doses for mice ) : group 1 ( vehicle ) , group 2 ( drugn 50 mg/kg ) , group 3 ( druga 100 mg/kg ) , group 4 ( drugn 20 mg/kg ) , group 5 ( drugb 15 mg/kg ) , group 6 ( drugn 100 mg/kg plus drugn 20 mg/kg ) and group 7 ( drugn 100 mg/kg plus drugn 15 mg/kg ) .
false
all the tests were carried out in the following seven groups ( n = 6 in each group ) , drugs being given orally ( doses for mice ) : group 1 ( vehicle ) , group 2 ( drugn 50 mg/kg ) , group 3 ( druga 100 mg/kg ) , group 4 ( drugn 20 mg/kg ) , group 5 ( drugn 15 mg/kg ) , group 6 ( drugb 100 mg/kg plus drugn 20 mg/kg ) and group 7 ( drugn 100 mg/kg plus drugn 15 mg/kg ) .
false
all the tests were carried out in the following seven groups ( n = 6 in each group ) , drugs being given orally ( doses for mice ) : group 1 ( vehicle ) , group 2 ( drugn 50 mg/kg ) , group 3 ( druga 100 mg/kg ) , group 4 ( drugn 20 mg/kg ) , group 5 ( drugn 15 mg/kg ) , group 6 ( drugn 100 mg/kg plus drugb 20 mg/kg ) and group 7 ( drugn 100 mg/kg plus drugn 15 mg/kg ) .
false
all the tests were carried out in the following seven groups ( n = 6 in each group ) , drugs being given orally ( doses for mice ) : group 1 ( vehicle ) , group 2 ( drugn 50 mg/kg ) , group 3 ( druga 100 mg/kg ) , group 4 ( drugn 20 mg/kg ) , group 5 ( drugn 15 mg/kg ) , group 6 ( drugn 100 mg/kg plus drugn 20 mg/kg ) and group 7 ( drugb 100 mg/kg plus drugn 15 mg/kg ) .
false
all the tests were carried out in the following seven groups ( n = 6 in each group ) , drugs being given orally ( doses for mice ) : group 1 ( vehicle ) , group 2 ( drugn 50 mg/kg ) , group 3 ( druga 100 mg/kg ) , group 4 ( drugn 20 mg/kg ) , group 5 ( drugn 15 mg/kg ) , group 6 ( drugn 100 mg/kg plus drugn 20 mg/kg ) and group 7 ( drugn 100 mg/kg plus drugb 15 mg/kg ) .
false
all the tests were carried out in the following seven groups ( n = 6 in each group ) , drugs being given orally ( doses for mice ) : group 1 ( vehicle ) , group 2 ( drugn 50 mg/kg ) , group 3 ( drugn 100 mg/kg ) , group 4 ( druga 20 mg/kg ) , group 5 ( drugb 15 mg/kg ) , group 6 ( drugn 100 mg/kg plus drugn 20 mg/kg ) and group 7 ( drugn 100 mg/kg plus drugn 15 mg/kg ) .
false
all the tests were carried out in the following seven groups ( n = 6 in each group ) , drugs being given orally ( doses for mice ) : group 1 ( vehicle ) , group 2 ( drugn 50 mg/kg ) , group 3 ( drugn 100 mg/kg ) , group 4 ( druga 20 mg/kg ) , group 5 ( drugn 15 mg/kg ) , group 6 ( drugb 100 mg/kg plus drugn 20 mg/kg ) and group 7 ( drugn 100 mg/kg plus drugn 15 mg/kg ) .
false
all the tests were carried out in the following seven groups ( n = 6 in each group ) , drugs being given orally ( doses for mice ) : group 1 ( vehicle ) , group 2 ( drugn 50 mg/kg ) , group 3 ( drugn 100 mg/kg ) , group 4 ( druga 20 mg/kg ) , group 5 ( drugn 15 mg/kg ) , group 6 ( drugn 100 mg/kg plus drugb 20 mg/kg ) and group 7 ( drugn 100 mg/kg plus drugn 15 mg/kg ) .
false
all the tests were carried out in the following seven groups ( n = 6 in each group ) , drugs being given orally ( doses for mice ) : group 1 ( vehicle ) , group 2 ( drugn 50 mg/kg ) , group 3 ( drugn 100 mg/kg ) , group 4 ( druga 20 mg/kg ) , group 5 ( drugn 15 mg/kg ) , group 6 ( drugn 100 mg/kg plus drugn 20 mg/kg ) and group 7 ( drugb 100 mg/kg plus drugn 15 mg/kg ) .
false
all the tests were carried out in the following seven groups ( n = 6 in each group ) , drugs being given orally ( doses for mice ) : group 1 ( vehicle ) , group 2 ( drugn 50 mg/kg ) , group 3 ( drugn 100 mg/kg ) , group 4 ( druga 20 mg/kg ) , group 5 ( drugn 15 mg/kg ) , group 6 ( drugn 100 mg/kg plus drugn 20 mg/kg ) and group 7 ( drugn 100 mg/kg plus drugb 15 mg/kg ) .
false
all the tests were carried out in the following seven groups ( n = 6 in each group ) , drugs being given orally ( doses for mice ) : group 1 ( vehicle ) , group 2 ( drugn 50 mg/kg ) , group 3 ( drugn 100 mg/kg ) , group 4 ( drugn 20 mg/kg ) , group 5 ( druga 15 mg/kg ) , group 6 ( drugb 100 mg/kg plus drugn 20 mg/kg ) and group 7 ( drugn 100 mg/kg plus drugn 15 mg/kg ) .
false
all the tests were carried out in the following seven groups ( n = 6 in each group ) , drugs being given orally ( doses for mice ) : group 1 ( vehicle ) , group 2 ( drugn 50 mg/kg ) , group 3 ( drugn 100 mg/kg ) , group 4 ( drugn 20 mg/kg ) , group 5 ( druga 15 mg/kg ) , group 6 ( drugn 100 mg/kg plus drugb 20 mg/kg ) and group 7 ( drugn 100 mg/kg plus drugn 15 mg/kg ) .
false
all the tests were carried out in the following seven groups ( n = 6 in each group ) , drugs being given orally ( doses for mice ) : group 1 ( vehicle ) , group 2 ( drugn 50 mg/kg ) , group 3 ( drugn 100 mg/kg ) , group 4 ( drugn 20 mg/kg ) , group 5 ( druga 15 mg/kg ) , group 6 ( drugn 100 mg/kg plus drugn 20 mg/kg ) and group 7 ( drugb 100 mg/kg plus drugn 15 mg/kg ) .
false
all the tests were carried out in the following seven groups ( n = 6 in each group ) , drugs being given orally ( doses for mice ) : group 1 ( vehicle ) , group 2 ( drugn 50 mg/kg ) , group 3 ( drugn 100 mg/kg ) , group 4 ( drugn 20 mg/kg ) , group 5 ( druga 15 mg/kg ) , group 6 ( drugn 100 mg/kg plus drugn 20 mg/kg ) and group 7 ( drugn 100 mg/kg plus drugb 15 mg/kg ) .
false
all the tests were carried out in the following seven groups ( n = 6 in each group ) , drugs being given orally ( doses for mice ) : group 1 ( vehicle ) , group 2 ( drugn 50 mg/kg ) , group 3 ( drugn 100 mg/kg ) , group 4 ( drugn 20 mg/kg ) , group 5 ( drugn 15 mg/kg ) , group 6 ( druga 100 mg/kg plus drugb 20 mg/kg ) and group 7 ( drugn 100 mg/kg plus drugn 15 mg/kg ) .
false
all the tests were carried out in the following seven groups ( n = 6 in each group ) , drugs being given orally ( doses for mice ) : group 1 ( vehicle ) , group 2 ( drugn 50 mg/kg ) , group 3 ( drugn 100 mg/kg ) , group 4 ( drugn 20 mg/kg ) , group 5 ( drugn 15 mg/kg ) , group 6 ( druga 100 mg/kg plus drugn 20 mg/kg ) and group 7 ( drugb 100 mg/kg plus drugn 15 mg/kg ) .
false
all the tests were carried out in the following seven groups ( n = 6 in each group ) , drugs being given orally ( doses for mice ) : group 1 ( vehicle ) , group 2 ( drugn 50 mg/kg ) , group 3 ( drugn 100 mg/kg ) , group 4 ( drugn 20 mg/kg ) , group 5 ( drugn 15 mg/kg ) , group 6 ( druga 100 mg/kg plus drugn 20 mg/kg ) and group 7 ( drugn 100 mg/kg plus drugb 15 mg/kg ) .
false
all the tests were carried out in the following seven groups ( n = 6 in each group ) , drugs being given orally ( doses for mice ) : group 1 ( vehicle ) , group 2 ( drugn 50 mg/kg ) , group 3 ( drugn 100 mg/kg ) , group 4 ( drugn 20 mg/kg ) , group 5 ( drugn 15 mg/kg ) , group 6 ( drugn 100 mg/kg plus druga 20 mg/kg ) and group 7 ( drugb 100 mg/kg plus drugn 15 mg/kg ) .
false
all the tests were carried out in the following seven groups ( n = 6 in each group ) , drugs being given orally ( doses for mice ) : group 1 ( vehicle ) , group 2 ( drugn 50 mg/kg ) , group 3 ( drugn 100 mg/kg ) , group 4 ( drugn 20 mg/kg ) , group 5 ( drugn 15 mg/kg ) , group 6 ( drugn 100 mg/kg plus druga 20 mg/kg ) and group 7 ( drugn 100 mg/kg plus drugb 15 mg/kg ) .
false
all the tests were carried out in the following seven groups ( n = 6 in each group ) , drugs being given orally ( doses for mice ) : group 1 ( vehicle ) , group 2 ( drugn 50 mg/kg ) , group 3 ( drugn 100 mg/kg ) , group 4 ( drugn 20 mg/kg ) , group 5 ( drugn 15 mg/kg ) , group 6 ( drugn 100 mg/kg plus drugn 20 mg/kg ) and group 7 ( druga 100 mg/kg plus drugb 15 mg/kg ) .
false
the effect of druga ( 100 mg/kg ) was similar to that of drugb and drugn ( p > 0.05 ) but its addition to drugn and drugn did not improve their antidepressant activity ( p > 0.05 ) .
false
the effect of druga ( 100 mg/kg ) was similar to that of drugn and drugb ( p > 0.05 ) but its addition to drugn and drugn did not improve their antidepressant activity ( p > 0.05 ) .
false
the effect of druga ( 100 mg/kg ) was similar to that of drugn and drugn ( p > 0.05 ) but its addition to drugb and drugn did not improve their antidepressant activity ( p > 0.05 ) .
false
the effect of druga ( 100 mg/kg ) was similar to that of drugn and drugn ( p > 0.05 ) but its addition to drugn and drugb did not improve their antidepressant activity ( p > 0.05 ) .
false
the effect of drugn ( 100 mg/kg ) was similar to that of druga and drugb ( p > 0.05 ) but its addition to drugn and drugn did not improve their antidepressant activity ( p > 0.05 ) .
false
the effect of drugn ( 100 mg/kg ) was similar to that of druga and drugn ( p > 0.05 ) but its addition to drugb and drugn did not improve their antidepressant activity ( p > 0.05 ) .
false
the effect of drugn ( 100 mg/kg ) was similar to that of druga and drugn ( p > 0.05 ) but its addition to drugn and drugb did not improve their antidepressant activity ( p > 0.05 ) .
false
the effect of drugn ( 100 mg/kg ) was similar to that of drugn and druga ( p > 0.05 ) but its addition to drugb and drugn did not improve their antidepressant activity ( p > 0.05 ) .
false
the effect of drugn ( 100 mg/kg ) was similar to that of drugn and druga ( p > 0.05 ) but its addition to drugn and drugb did not improve their antidepressant activity ( p > 0.05 ) .
false
the effect of drugn ( 100 mg/kg ) was similar to that of drugn and drugn ( p > 0.05 ) but its addition to druga and drugb did not improve their antidepressant activity ( p > 0.05 ) .
false
druga can be a useful drugb especially in cases which respond to drugs having mixed effects on serotonin and catecholamines levels in the brain .
false
prevention of emergence agitation in seven children receiving low-dose druga and drugb total intravenous anesthesia .
false
we retrospectively reviewed the records of 7 pediatric oncology patients who received low-dose druga in conjunction with drugb for total intravenous anesthesia ( tiva ) repeatedly for radiation therapy .
false
ea signs were observed in all 7 patients in association with druga tiva but did not recur in any of 123 subsequent anesthetics sessions during which low-dose drugb was added to drugn .
false
ea signs were observed in all 7 patients in association with druga tiva but did not recur in any of 123 subsequent anesthetics sessions during which low-dose drugn was added to drugb .
false
ea signs were observed in all 7 patients in association with drugn tiva but did not recur in any of 123 subsequent anesthetics sessions during which low-dose druga was added to drugb .
false
based on this experience , we suggest that low-dose druga added to drugb may be associated with prevention of ea in children with a history of ea with drugn tiva .
effect
based on this experience , we suggest that low-dose druga added to drugn may be associated with prevention of ea in children with a history of ea with drugb tiva .
false
based on this experience , we suggest that low-dose drugn added to druga may be associated with prevention of ea in children with a history of ea with drugb tiva .
false
druga - drugb interaction and associated gastrointestinal bleeding risk in a case-control study .
false
we sought to evaluate whether initiation of an druga increases the risk of hospitalization for gastrointestinal bleeding in drugb users .
false
in total , 430,455 druga users contributed 407,370 person-years of drugb use .
false
druga users had an increased odds ratio of gastrointestinal bleeding upon initiation of drugb ( or = 1.73 [ 95 % ci , 1.25-2.38 ] ) , drugn ( or = 1.63 [ 95 % ci , 1.11-2.38 ] ) , drugn ( or = 1.64 [ 95 % ci , 1.27-2.12 ] ) , drugn ( or = 1.47 [ 95 % ci , 1.02-2.11 ] ) .
effect
druga users had an increased odds ratio of gastrointestinal bleeding upon initiation of drugn ( or = 1.73 [ 95 % ci , 1.25-2.38 ] ) , drugb ( or = 1.63 [ 95 % ci , 1.11-2.38 ] ) , drugn ( or = 1.64 [ 95 % ci , 1.27-2.12 ] ) , drugn ( or = 1.47 [ 95 % ci , 1.02-2.11 ] ) .
effect
druga users had an increased odds ratio of gastrointestinal bleeding upon initiation of drugn ( or = 1.73 [ 95 % ci , 1.25-2.38 ] ) , drugn ( or = 1.63 [ 95 % ci , 1.11-2.38 ] ) , drugb ( or = 1.64 [ 95 % ci , 1.27-2.12 ] ) , drugn ( or = 1.47 [ 95 % ci , 1.02-2.11 ] ) .
effect
druga users had an increased odds ratio of gastrointestinal bleeding upon initiation of drugn ( or = 1.73 [ 95 % ci , 1.25-2.38 ] ) , drugn ( or = 1.63 [ 95 % ci , 1.11-2.38 ] ) , drugn ( or = 1.64 [ 95 % ci , 1.27-2.12 ] ) , drugb ( or = 1.47 [ 95 % ci , 1.02-2.11 ] ) .
effect
drugn users had an increased odds ratio of gastrointestinal bleeding upon initiation of druga ( or = 1.73 [ 95 % ci , 1.25-2.38 ] ) , drugb ( or = 1.63 [ 95 % ci , 1.11-2.38 ] ) , drugn ( or = 1.64 [ 95 % ci , 1.27-2.12 ] ) , drugn ( or = 1.47 [ 95 % ci , 1.02-2.11 ] ) .
false
drugn users had an increased odds ratio of gastrointestinal bleeding upon initiation of druga ( or = 1.73 [ 95 % ci , 1.25-2.38 ] ) , drugn ( or = 1.63 [ 95 % ci , 1.11-2.38 ] ) , drugb ( or = 1.64 [ 95 % ci , 1.27-2.12 ] ) , drugn ( or = 1.47 [ 95 % ci , 1.02-2.11 ] ) .
false
drugn users had an increased odds ratio of gastrointestinal bleeding upon initiation of druga ( or = 1.73 [ 95 % ci , 1.25-2.38 ] ) , drugn ( or = 1.63 [ 95 % ci , 1.11-2.38 ] ) , drugn ( or = 1.64 [ 95 % ci , 1.27-2.12 ] ) , drugb ( or = 1.47 [ 95 % ci , 1.02-2.11 ] ) .
false
drugn users had an increased odds ratio of gastrointestinal bleeding upon initiation of drugn ( or = 1.73 [ 95 % ci , 1.25-2.38 ] ) , druga ( or = 1.63 [ 95 % ci , 1.11-2.38 ] ) , drugb ( or = 1.64 [ 95 % ci , 1.27-2.12 ] ) , drugn ( or = 1.47 [ 95 % ci , 1.02-2.11 ] ) .
false
drugn users had an increased odds ratio of gastrointestinal bleeding upon initiation of drugn ( or = 1.73 [ 95 % ci , 1.25-2.38 ] ) , druga ( or = 1.63 [ 95 % ci , 1.11-2.38 ] ) , drugn ( or = 1.64 [ 95 % ci , 1.27-2.12 ] ) , drugb ( or = 1.47 [ 95 % ci , 1.02-2.11 ] ) .
false
drugn users had an increased odds ratio of gastrointestinal bleeding upon initiation of drugn ( or = 1.73 [ 95 % ci , 1.25-2.38 ] ) , drugn ( or = 1.63 [ 95 % ci , 1.11-2.38 ] ) , druga ( or = 1.64 [ 95 % ci , 1.27-2.12 ] ) , drugb ( or = 1.47 [ 95 % ci , 1.02-2.11 ] ) .
false
also druga , which is not believed to interact with drugb , increased the risk of gi bleeding ( or = 1.75 [ 95 % ci , 1.30-2.35 ] ) .
effect
druga users who initiated drugb , drugn , drugn , drugn , or drugn had an increased risk of hospitalization for gastrointestinal bleeding .
effect
druga users who initiated drugn , drugb , drugn , drugn , or drugn had an increased risk of hospitalization for gastrointestinal bleeding .
effect
druga users who initiated drugn , drugn , drugb , drugn , or drugn had an increased risk of hospitalization for gastrointestinal bleeding .
effect
druga users who initiated drugn , drugn , drugn , drugb , or drugn had an increased risk of hospitalization for gastrointestinal bleeding .
effect
druga users who initiated drugn , drugn , drugn , drugn , or drugb had an increased risk of hospitalization for gastrointestinal bleeding .
effect
drugn users who initiated druga , drugb , drugn , drugn , or drugn had an increased risk of hospitalization for gastrointestinal bleeding .
false
drugn users who initiated druga , drugn , drugb , drugn , or drugn had an increased risk of hospitalization for gastrointestinal bleeding .
false
drugn users who initiated druga , drugn , drugn , drugb , or drugn had an increased risk of hospitalization for gastrointestinal bleeding .
false
drugn users who initiated druga , drugn , drugn , drugn , or drugb had an increased risk of hospitalization for gastrointestinal bleeding .
false
drugn users who initiated drugn , druga , drugb , drugn , or drugn had an increased risk of hospitalization for gastrointestinal bleeding .
false
drugn users who initiated drugn , druga , drugn , drugb , or drugn had an increased risk of hospitalization for gastrointestinal bleeding .
false
drugn users who initiated drugn , druga , drugn , drugn , or drugb had an increased risk of hospitalization for gastrointestinal bleeding .
false
drugn users who initiated drugn , drugn , druga , drugb , or drugn had an increased risk of hospitalization for gastrointestinal bleeding .
false
drugn users who initiated drugn , drugn , druga , drugn , or drugb had an increased risk of hospitalization for gastrointestinal bleeding .
false
drugn users who initiated drugn , drugn , drugn , druga , or drugb had an increased risk of hospitalization for gastrointestinal bleeding .
false
in vitro activity of druga combined with drugb against clinical isolates of drugn -resistant staphylococcus aureus .
false
in vitro activity of druga combined with drugn against clinical isolates of drugb -resistant staphylococcus aureus .
false
in vitro activity of drugn combined with druga against clinical isolates of drugb -resistant staphylococcus aureus .
false
this study aimed to evaluate the in vitro activity of druga combined with drugb against isolates of drugn -resistant staphylococcus aureus ( mrsa ) .
false
this study aimed to evaluate the in vitro activity of druga combined with drugn against isolates of drugb -resistant staphylococcus aureus ( mrsa ) .
false
this study aimed to evaluate the in vitro activity of drugn combined with druga against isolates of drugb -resistant staphylococcus aureus ( mrsa ) .
false
the susceptibility results for druga and drugb were interpreted according to the most relevant criteria .
false
the combination of druga and drugb can be synergistic against mrsa .
effect
in vivo cyp3a activity is significantly lower in druga -treated as compared with drugb -treated renal allograft recipients .
false
in vitro studies have identified druga and drugb as cyp3a inhibitors .
false
systemic and apparent oral druga clearance were 24 % ( 269 73 vs. 354 102 ml/min , p = 0.022 ) and 31 % ( 479 190 vs. 688 265 ml/min , p = 0.013 ) , respectively , lower in drugb -treated patients ( n = 20 ) than in matched drugn -treated patients ( n = 20 ) .
mechanism
systemic and apparent oral druga clearance were 24 % ( 269 73 vs. 354 102 ml/min , p = 0.022 ) and 31 % ( 479 190 vs. 688 265 ml/min , p = 0.013 ) , respectively , lower in drugn -treated patients ( n = 20 ) than in matched drugb -treated patients ( n = 20 ) .
false
systemic and apparent oral drugn clearance were 24 % ( 269 73 vs. 354 102 ml/min , p = 0.022 ) and 31 % ( 479 190 vs. 688 265 ml/min , p = 0.013 ) , respectively , lower in druga -treated patients ( n = 20 ) than in matched drugb -treated patients ( n = 20 ) .
false
the latter displayed druga clearances similar to those in two larger cohorts of nonmatched drugb -treated patients ( n = 58 and n = 80 ) and to those receiving a drugn -free regimen ( n = 6 ) .
false
the latter displayed druga clearances similar to those in two larger cohorts of nonmatched drugn -treated patients ( n = 58 and n = 80 ) and to those receiving a drugb -free regimen ( n = 6 ) .
false
the latter displayed drugn clearances similar to those in two larger cohorts of nonmatched druga -treated patients ( n = 58 and n = 80 ) and to those receiving a drugb -free regimen ( n = 6 ) .
false
this implies that in vivo hepatic and first-pass cyp3a activities are significantly lower in patients receiving druga than in those receiving drugb , indicating that , at the doses generally used in clinical practice , drugn is the stronger of the two with respect to cyp3a inhibition .
false
this implies that in vivo hepatic and first-pass cyp3a activities are significantly lower in patients receiving druga than in those receiving drugn , indicating that , at the doses generally used in clinical practice , drugb is the stronger of the two with respect to cyp3a inhibition .
false
this implies that in vivo hepatic and first-pass cyp3a activities are significantly lower in patients receiving drugn than in those receiving druga , indicating that , at the doses generally used in clinical practice , drugb is the stronger of the two with respect to cyp3a inhibition .
false
phase i trial of druga and drugb in patients with relapsed multiple myeloma : evidence for drugn - drugn interaction via p-glycoprotein .
false
phase i trial of druga and drugn in patients with relapsed multiple myeloma : evidence for drugb - drugn interaction via p-glycoprotein .
false
phase i trial of druga and drugn in patients with relapsed multiple myeloma : evidence for drugn - drugb interaction via p-glycoprotein .
false
phase i trial of drugn and druga in patients with relapsed multiple myeloma : evidence for drugb - drugn interaction via p-glycoprotein .
false
phase i trial of drugn and druga in patients with relapsed multiple myeloma : evidence for drugn - drugb interaction via p-glycoprotein .
false
phase i trial of drugn and drugn in patients with relapsed multiple myeloma : evidence for druga - drugb interaction via p-glycoprotein .
false
the preclinical combination of druga with the mtor inhibitor drugb has displayed synergy in vitro and represents a novel combination in mm .
effect
interaction study of druga and drugb with co-administered drugs .
false
druga and drugb are drugn used in treating urinary and respiratory tract infections .
false
druga and drugn are drugb used in treating urinary and respiratory tract infections .
false
drugn and druga are drugb used in treating urinary and respiratory tract infections .
false
being druga and lomefloxacin drugb the interaction study of was carried out with drugn , drugn , drugn and drugn .
false
being druga and lomefloxacin drugn the interaction study of was carried out with drugb , drugn , drugn and drugn .
false
being druga and lomefloxacin drugn the interaction study of was carried out with drugn , drugb , drugn and drugn .
false
being druga and lomefloxacin drugn the interaction study of was carried out with drugn , drugn , drugb and drugn .
false
being druga and lomefloxacin drugn the interaction study of was carried out with drugn , drugn , drugn and drugb .
false
being drugn and lomefloxacin druga the interaction study of was carried out with drugb , drugn , drugn and drugn .
false
being drugn and lomefloxacin druga the interaction study of was carried out with drugn , drugb , drugn and drugn .
false
being drugn and lomefloxacin druga the interaction study of was carried out with drugn , drugn , drugb and drugn .
false
being drugn and lomefloxacin druga the interaction study of was carried out with drugn , drugn , drugn and drugb .
false
being drugn and lomefloxacin drugn the interaction study of was carried out with druga , drugb , drugn and drugn .
false
being drugn and lomefloxacin drugn the interaction study of was carried out with druga , drugn , drugb and drugn .
false
being drugn and lomefloxacin drugn the interaction study of was carried out with druga , drugn , drugn and drugb .
false
being drugn and lomefloxacin drugn the interaction study of was carried out with drugn , druga , drugb and drugn .
false
being drugn and lomefloxacin drugn the interaction study of was carried out with drugn , druga , drugn and drugb .
false
being drugn and lomefloxacin drugn the interaction study of was carried out with drugn , drugn , druga and drugb .
false
the response of druga and drugb after interaction with co-administered drugs at different conditions and temperature were noted using a shimadzu hplc system with pda detector .
false
druga and drugb reacts faster with drugn and drugn in acidic media whereas with drugn in basic media and drugn in neutral media .
false
druga and drugn reacts faster with drugb and drugn in acidic media whereas with drugn in basic media and drugn in neutral media .
mechanism
druga and drugn reacts faster with drugn and drugb in acidic media whereas with drugn in basic media and drugn in neutral media .
mechanism
druga and drugn reacts faster with drugn and drugn in acidic media whereas with drugb in basic media and drugn in neutral media .
mechanism
druga and drugn reacts faster with drugn and drugn in acidic media whereas with drugn in basic media and drugb in neutral media .
mechanism
drugn and druga reacts faster with drugb and drugn in acidic media whereas with drugn in basic media and drugn in neutral media .
mechanism
drugn and druga reacts faster with drugn and drugb in acidic media whereas with drugn in basic media and drugn in neutral media .
mechanism
drugn and druga reacts faster with drugn and drugn in acidic media whereas with drugb in basic media and drugn in neutral media .
mechanism
drugn and druga reacts faster with drugn and drugn in acidic media whereas with drugn in basic media and drugb in neutral media .
mechanism
drugn and drugn reacts faster with druga and drugb in acidic media whereas with drugn in basic media and drugn in neutral media .
false
drugn and drugn reacts faster with druga and drugn in acidic media whereas with drugb in basic media and drugn in neutral media .
false
drugn and drugn reacts faster with druga and drugn in acidic media whereas with drugn in basic media and drugb in neutral media .
false
drugn and drugn reacts faster with drugn and druga in acidic media whereas with drugb in basic media and drugn in neutral media .
false
drugn and drugn reacts faster with drugn and druga in acidic media whereas with drugn in basic media and drugb in neutral media .
false
drugn and drugn reacts faster with drugn and drugn in acidic media whereas with druga in basic media and drugb in neutral media .
false
interaction of druga and drugb , in vitro and in vivo , in human a375 melanoma cells .
false
we evaluated mechanisms of interaction between the alkyating agent druga ( drugb ) and the pro-oxidant , drugn , in the human a375 melanoma cell line .
false
we evaluated mechanisms of interaction between the alkyating agent druga ( drugn ) and the pro-oxidant , drugb , in the human a375 melanoma cell line .
false
we evaluated mechanisms of interaction between the alkyating agent drugn ( druga ) and the pro-oxidant , drugb , in the human a375 melanoma cell line .
false
the effect of druga and drugb , alone and in combination , was evaluated for growth inhibition ( mtt ) , radiolabeled drug uptake , cellular thiol content ( hplc ) , and dna strand breaks ( comet assay ) .
false
there was a > 75 % reduction in cellular glutathione and cysteine with druga but not drugb .
false
druga and drugb show additive effects in vitro but not in vivo in human a375 melanoma cells .
effect
exposure to oral druga is unaffected by drugb but greatly increased by drugn .
false
exposure to oral druga is unaffected by drugn but greatly increased by drugb .
effect
exposure to oral drugn is unaffected by druga but greatly increased by drugb .
false
this study examined drug-drug interactions of oral druga with the cytochrome p450 ( cyp ) 2b6 inhibitor drugb and the cyp3a inhibitor drugn .
false
this study examined drug-drug interactions of oral druga with the cytochrome p450 ( cyp ) 2b6 inhibitor drugn and the cyp3a inhibitor drugb .
false
this study examined drug-drug interactions of oral drugn with the cytochrome p450 ( cyp ) 2b6 inhibitor druga and the cyp3a inhibitor drugb .
false
in this randomized , blinded , crossover study , 11 healthy volunteers ingested 0.2 mg/kg druga after pretreatments with oral drugb ( 250 mg twice daily ) , drugn ( 200 mg once daily ) , or placebo in 6-day treatment periods at intervals of 4 weeks .
false
in this randomized , blinded , crossover study , 11 healthy volunteers ingested 0.2 mg/kg druga after pretreatments with oral drugn ( 250 mg twice daily ) , drugb ( 200 mg once daily ) , or placebo in 6-day treatment periods at intervals of 4 weeks .
false
in this randomized , blinded , crossover study , 11 healthy volunteers ingested 0.2 mg/kg drugn after pretreatments with oral druga ( 250 mg twice daily ) , drugb ( 200 mg once daily ) , or placebo in 6-day treatment periods at intervals of 4 weeks .
false
druga treatment increased the mean area under the plasma concentration-time curve extrapolated to infinity ( auc ( 0- ) ) of oral drugb by 2.4-fold , whereas drugn treatment did not increase the exposure to drugn .
mechanism
druga treatment increased the mean area under the plasma concentration-time curve extrapolated to infinity ( auc ( 0- ) ) of oral drugn by 2.4-fold , whereas drugb treatment did not increase the exposure to drugn .
false
druga treatment increased the mean area under the plasma concentration-time curve extrapolated to infinity ( auc ( 0- ) ) of oral drugn by 2.4-fold , whereas drugn treatment did not increase the exposure to drugb .
false
drugn treatment increased the mean area under the plasma concentration-time curve extrapolated to infinity ( auc ( 0- ) ) of oral druga by 2.4-fold , whereas drugb treatment did not increase the exposure to drugn .
false
drugn treatment increased the mean area under the plasma concentration-time curve extrapolated to infinity ( auc ( 0- ) ) of oral druga by 2.4-fold , whereas drugn treatment did not increase the exposure to drugb .
false
drugn treatment increased the mean area under the plasma concentration-time curve extrapolated to infinity ( auc ( 0- ) ) of oral drugn by 2.4-fold , whereas druga treatment did not increase the exposure to drugb .
false
the ratio of druga auc ( 0- ) to drugb auc ( 0- ) was significantly decreased in the drugn ( p & lt ; 0.001 ) and drugn phases ( p = 0.006 ) as compared to placebo .
false
the ratio of druga auc ( 0- ) to drugn auc ( 0- ) was significantly decreased in the drugb ( p & lt ; 0.001 ) and drugn phases ( p = 0.006 ) as compared to placebo .
false
the ratio of druga auc ( 0- ) to drugn auc ( 0- ) was significantly decreased in the drugn ( p & lt ; 0.001 ) and drugb phases ( p = 0.006 ) as compared to placebo .
false
the ratio of drugn auc ( 0- ) to druga auc ( 0- ) was significantly decreased in the drugb ( p & lt ; 0.001 ) and drugn phases ( p = 0.006 ) as compared to placebo .
false
the ratio of drugn auc ( 0- ) to druga auc ( 0- ) was significantly decreased in the drugn ( p & lt ; 0.001 ) and drugb phases ( p = 0.006 ) as compared to placebo .
false
the ratio of drugn auc ( 0- ) to drugn auc ( 0- ) was significantly decreased in the druga ( p & lt ; 0.001 ) and drugb phases ( p = 0.006 ) as compared to placebo .
false
in the druga and drugb phases , the areas under the effect-time curves ( self-reported drowsiness and performance ) were significantly higher than those in the placebo phase ( p < 0.05 ) .
false
the findings suggest that the dosage of druga should be reduced in patients receiving drugb .
advise
the authors report the case of an infant with confirmed congenital hypothyroidism on druga who experienced a possible drug interaction with drugb .
int
questioning revealed the child was taking druga drops before feeds while on drugb .
false
drug interaction of druga with drugb has not been reported previously and is not listed in the british national formulary for children .
false
protective effect of druga and drugb against the acute toxicity of diepoxybutane to human lymphocytes .
false
( ii ) druga elicits a significant protective effect on deb induced toxicity , which was potentiated by drugb .
effect
[ interaction between druga and drugb ] .
false
the drug interaction between druga and drugb has been the subject of much study in recent years .
false
contradictory results regarding the effect of druga on platelet reactivity and on clinical outcome in drugb -treated patients have been reported in literature .
false
concomitant use of druga and drugb was found to decrease the exposure ( auc ) to clopidogrel 's active metabolite by 50 % and to sharply increase platelet reactivity , as a result of inhibition by drugn of cyp2c19 , a cytochrome p450 ( cyp ) enzyme .
mechanism
concomitant use of druga and drugn was found to decrease the exposure ( auc ) to clopidogrel 's active metabolite by 50 % and to sharply increase platelet reactivity , as a result of inhibition by drugb of cyp2c19 , a cytochrome p450 ( cyp ) enzyme .
false
concomitant use of drugn and druga was found to decrease the exposure ( auc ) to clopidogrel 's active metabolite by 50 % and to sharply increase platelet reactivity , as a result of inhibition by drugb of cyp2c19 , a cytochrome p450 ( cyp ) enzyme .
false
druga has a much weaker effect on drugb 's pharmacokinetics and on platelet reactivity during concomitant use .
mechanism
the influence of the other druga when used simultaneously with drugb has not yet been investigated in adequately randomized studies .
false
regulatory agencies state that the combination of druga and the cyp2c19 inhibitors drugb and drugn should be avoided .
advise
regulatory agencies state that the combination of druga and the cyp2c19 inhibitors drugn and drugb should be avoided .
advise
regulatory agencies state that the combination of drugn and the cyp2c19 inhibitors druga and drugb should be avoided .
false
to date , there is no conclusive evidence of a clinically-relevant interaction between any of the druga and drugb .
false
a study published in 2002 found that druga causes a statistically significant increase in plasma clearance of drugb .
mechanism
in 1984 , drs rimmer and richens at the university of wales reported that administering druga with drugb lowered the serum drugn concentration in patients with treatment-resistant epilepsy .
mechanism
in 1984 , drs rimmer and richens at the university of wales reported that administering druga with drugn lowered the serum drugb concentration in patients with treatment-resistant epilepsy .
false
in 1984 , drs rimmer and richens at the university of wales reported that administering drugn with druga lowered the serum drugb concentration in patients with treatment-resistant epilepsy .
false
druga : concomitant drugb administration decreased the mean auc of total drugn approximately 55 % .
false
druga : concomitant drugn administration decreased the mean auc of total drugb approximately 55 % .
false
drugn : concomitant druga administration decreased the mean auc of total drugb approximately 55 % .
mechanism
the incremental ldl-c reduction due to adding druga to drugb may be reduced by this interaction .
effect
druga : the safety and effectiveness of drugb administered with drugn have not been established .
false
druga : the safety and effectiveness of drugn administered with drugb have not been established .
false
drugn : the safety and effectiveness of druga administered with drugb have not been established .
false
co-administration of druga with drugb is not recommended until use in patients is studied .
advise
druga : in a pharmacokinetic study , concomitant drugb administration increased total drugn concentrations approximately 1.5-fold .
false
druga : in a pharmacokinetic study , concomitant drugn administration increased total drugb concentrations approximately 1.5-fold .
false
drugn : in a pharmacokinetic study , concomitant druga administration increased total drugb concentrations approximately 1.5-fold .
mechanism
druga : in a pharmacokinetic study , concomitant drugb administration increased total drugn concentrations approximately 1.7-fold .
false
druga : in a pharmacokinetic study , concomitant drugn administration increased total drugb concentrations approximately 1.7-fold .
false
drugn : in a pharmacokinetic study , concomitant druga administration increased total drugb concentrations approximately 1.7-fold .
false
druga : no clinically significant pharmacokinetic interactions were seen when drugb was co-administered with drugn , drugn , drugn , drugn , or drugn .
false
druga : no clinically significant pharmacokinetic interactions were seen when drugn was co-administered with drugb , drugn , drugn , drugn , or drugn .
false
druga : no clinically significant pharmacokinetic interactions were seen when drugn was co-administered with drugn , drugb , drugn , drugn , or drugn .
false
druga : no clinically significant pharmacokinetic interactions were seen when drugn was co-administered with drugn , drugn , drugb , drugn , or drugn .
false
druga : no clinically significant pharmacokinetic interactions were seen when drugn was co-administered with drugn , drugn , drugn , drugb , or drugn .
false
druga : no clinically significant pharmacokinetic interactions were seen when drugn was co-administered with drugn , drugn , drugn , drugn , or drugb .
false
drugn : no clinically significant pharmacokinetic interactions were seen when druga was co-administered with drugb , drugn , drugn , drugn , or drugn .
false
drugn : no clinically significant pharmacokinetic interactions were seen when druga was co-administered with drugn , drugb , drugn , drugn , or drugn .
false
drugn : no clinically significant pharmacokinetic interactions were seen when druga was co-administered with drugn , drugn , drugb , drugn , or drugn .
false
drugn : no clinically significant pharmacokinetic interactions were seen when druga was co-administered with drugn , drugn , drugn , drugb , or drugn .
false
drugn : no clinically significant pharmacokinetic interactions were seen when druga was co-administered with drugn , drugn , drugn , drugn , or drugb .
false
drugn : no clinically significant pharmacokinetic interactions were seen when drugn was co-administered with druga , drugb , drugn , drugn , or drugn .
false
drugn : no clinically significant pharmacokinetic interactions were seen when drugn was co-administered with druga , drugn , drugb , drugn , or drugn .
false
drugn : no clinically significant pharmacokinetic interactions were seen when drugn was co-administered with druga , drugn , drugn , drugb , or drugn .
false
drugn : no clinically significant pharmacokinetic interactions were seen when drugn was co-administered with druga , drugn , drugn , drugn , or drugb .
false
drugn : no clinically significant pharmacokinetic interactions were seen when drugn was co-administered with drugn , druga , drugb , drugn , or drugn .
false
drugn : no clinically significant pharmacokinetic interactions were seen when drugn was co-administered with drugn , druga , drugn , drugb , or drugn .
false
drugn : no clinically significant pharmacokinetic interactions were seen when drugn was co-administered with drugn , druga , drugn , drugn , or drugb .
false
drugn : no clinically significant pharmacokinetic interactions were seen when drugn was co-administered with drugn , drugn , druga , drugb , or drugn .
false
drugn : no clinically significant pharmacokinetic interactions were seen when drugn was co-administered with drugn , drugn , druga , drugn , or drugb .
false
drugn : no clinically significant pharmacokinetic interactions were seen when drugn was co-administered with drugn , drugn , drugn , druga , or drugb .
false
druga : the total drugb level increased 12-fold in one renal transplant patient receiving multiple medications , including drugn .
false
druga : the total drugn level increased 12-fold in one renal transplant patient receiving multiple medications , including drugb .
false
drugn : the total druga level increased 12-fold in one renal transplant patient receiving multiple medications , including drugb .
mechanism
patients who take both druga and drugb should be carefully monitored .
advise
carcinogenesis , mutagenesis , impairment of fertility a 104-week dietary carcinogenicity study with druga was conducted in rats at doses up to 1500 mg/kg/day ( males ) and 500 mg/kg/day ( females ) ( ~20 times the human exposure at 10 mg daily based on auc0-24hr for total drugb ) .
false
a 104-week dietary carcinogenicity study with druga was also conducted in mice at doses up to 500 mg/kg/day ( > 150 times the human exposure at 10 mg daily based on auc0-24hr for total drugb ) .
false
in oral ( gavage ) fertility studies of druga conducted in rats , there was no evidence of reproductive toxicity at doses up to 1000 mg/kg/day in male or female rats ( ~7 times the human exposure at 10 mg daily based on auc0-24hr for total drugb ) .
false
in rabbits treated with druga , an increased incidence of extra thoracic ribs was observed at 1000 mg/kg/day ( 150 times the human exposure at 10 mg daily based on auc0-24hr for total drugb ) .
false
multiple dose studies of druga given in combination with drugb ( drugn ) in rats and rabbits during organogenesis result in higher drugn and statin exposures .
false
multiple dose studies of druga given in combination with drugn ( drugb ) in rats and rabbits during organogenesis result in higher drugn and statin exposures .
false
multiple dose studies of druga given in combination with drugn ( drugn ) in rats and rabbits during organogenesis result in higher drugb and statin exposures .
false
multiple dose studies of drugn given in combination with druga ( drugb ) in rats and rabbits during organogenesis result in higher drugn and statin exposures .
false
multiple dose studies of drugn given in combination with druga ( drugn ) in rats and rabbits during organogenesis result in higher drugb and statin exposures .
false
multiple dose studies of drugn given in combination with drugn ( druga ) in rats and rabbits during organogenesis result in higher drugb and statin exposures .
false
when druga is administered with an drugb in a woman of childbearing potential , refer to the pregnancy category and package labeling for the drugn .
false
when druga is administered with an drugn in a woman of childbearing potential , refer to the pregnancy category and package labeling for the drugb .
false
when drugn is administered with an druga in a woman of childbearing potential , refer to the pregnancy category and package labeling for the drugb .
false
the interaction of druga ( drugb ) with other drugs has not been studied in humans .
false
decreased seizure threshold has been reported in patients receiving druga concomitantly with drugb .
effect
administration of druga in combination with drugb resulted in a two-fold decrease in drugn clearance in a non-human primate study and in a 1.5-fold increase in drugn serum levels in clinical studies .
mechanism
administration of druga in combination with drugn resulted in a two-fold decrease in drugb clearance in a non-human primate study and in a 1.5-fold increase in drugn serum levels in clinical studies .
false
administration of druga in combination with drugn resulted in a two-fold decrease in drugn clearance in a non-human primate study and in a 1.5-fold increase in drugb serum levels in clinical studies .
false
administration of drugn in combination with druga resulted in a two-fold decrease in drugb clearance in a non-human primate study and in a 1.5-fold increase in drugn serum levels in clinical studies .
false
administration of drugn in combination with druga resulted in a two-fold decrease in drugn clearance in a non-human primate study and in a 1.5-fold increase in drugb serum levels in clinical studies .
false
administration of drugn in combination with drugn resulted in a two-fold decrease in druga clearance in a non-human primate study and in a 1.5-fold increase in drugb serum levels in clinical studies .
false
however , druga , a potent inhibitor of cytochrome p450 3a4 , may increase plasma levels of drugb during concomitant dosing .
mechanism
interaction with other druga : drugb should be used with great caution and in reduced dosage in patients who are concurrently receiving other drugn , general drugn , drugn , other drugn , drugn ( including drugn ) , drugn and other drugn ( including drugn ) .
false
interaction with other druga : drugn should be used with great caution and in reduced dosage in patients who are concurrently receiving other drugb , general drugn , drugn , other drugn , drugn ( including drugn ) , drugn and other drugn ( including drugn ) .
false
interaction with other druga : drugn should be used with great caution and in reduced dosage in patients who are concurrently receiving other drugn , general drugb , drugn , other drugn , drugn ( including drugn ) , drugn and other drugn ( including drugn ) .
false
interaction with other druga : drugn should be used with great caution and in reduced dosage in patients who are concurrently receiving other drugn , general drugn , drugb , other drugn , drugn ( including drugn ) , drugn and other drugn ( including drugn ) .
false
interaction with other druga : drugn should be used with great caution and in reduced dosage in patients who are concurrently receiving other drugn , general drugn , drugn , other drugb , drugn ( including drugn ) , drugn and other drugn ( including drugn ) .
false
interaction with other druga : drugn should be used with great caution and in reduced dosage in patients who are concurrently receiving other drugn , general drugn , drugn , other drugn , drugb ( including drugn ) , drugn and other drugn ( including drugn ) .
false
interaction with other druga : drugn should be used with great caution and in reduced dosage in patients who are concurrently receiving other drugn , general drugn , drugn , other drugn , drugn ( including drugb ) , drugn and other drugn ( including drugn ) .
false
interaction with other druga : drugn should be used with great caution and in reduced dosage in patients who are concurrently receiving other drugn , general drugn , drugn , other drugn , drugn ( including drugn ) , drugb and other drugn ( including drugn ) .
false
interaction with other druga : drugn should be used with great caution and in reduced dosage in patients who are concurrently receiving other drugn , general drugn , drugn , other drugn , drugn ( including drugn ) , drugn and other drugb ( including drugn ) .
false
interaction with other druga : drugn should be used with great caution and in reduced dosage in patients who are concurrently receiving other drugn , general drugn , drugn , other drugn , drugn ( including drugn ) , drugn and other drugn ( including drugb ) .
false
interaction with other drugn : druga should be used with great caution and in reduced dosage in patients who are concurrently receiving other drugb , general drugn , drugn , other drugn , drugn ( including drugn ) , drugn and other drugn ( including drugn ) .
advise
interaction with other drugn : druga should be used with great caution and in reduced dosage in patients who are concurrently receiving other drugn , general drugb , drugn , other drugn , drugn ( including drugn ) , drugn and other drugn ( including drugn ) .
advise
interaction with other drugn : druga should be used with great caution and in reduced dosage in patients who are concurrently receiving other drugn , general drugn , drugb , other drugn , drugn ( including drugn ) , drugn and other drugn ( including drugn ) .
advise
interaction with other drugn : druga should be used with great caution and in reduced dosage in patients who are concurrently receiving other drugn , general drugn , drugn , other drugb , drugn ( including drugn ) , drugn and other drugn ( including drugn ) .
advise
interaction with other drugn : druga should be used with great caution and in reduced dosage in patients who are concurrently receiving other drugn , general drugn , drugn , other drugn , drugb ( including drugn ) , drugn and other drugn ( including drugn ) .
advise
interaction with other drugn : druga should be used with great caution and in reduced dosage in patients who are concurrently receiving other drugn , general drugn , drugn , other drugn , drugn ( including drugb ) , drugn and other drugn ( including drugn ) .
advise
interaction with other drugn : druga should be used with great caution and in reduced dosage in patients who are concurrently receiving other drugn , general drugn , drugn , other drugn , drugn ( including drugn ) , drugb and other drugn ( including drugn ) .
advise
interaction with other drugn : druga should be used with great caution and in reduced dosage in patients who are concurrently receiving other drugn , general drugn , drugn , other drugn , drugn ( including drugn ) , drugn and other drugb ( including drugn ) .
advise
interaction with other drugn : druga should be used with great caution and in reduced dosage in patients who are concurrently receiving other drugn , general drugn , drugn , other drugn , drugn ( including drugn ) , drugn and other drugn ( including drugb ) .
advise
interaction with other drugn : drugn should be used with great caution and in reduced dosage in patients who are concurrently receiving other druga , general drugb , drugn , other drugn , drugn ( including drugn ) , drugn and other drugn ( including drugn ) .
false
interaction with other drugn : drugn should be used with great caution and in reduced dosage in patients who are concurrently receiving other druga , general drugn , drugb , other drugn , drugn ( including drugn ) , drugn and other drugn ( including drugn ) .
false
interaction with other drugn : drugn should be used with great caution and in reduced dosage in patients who are concurrently receiving other druga , general drugn , drugn , other drugb , drugn ( including drugn ) , drugn and other drugn ( including drugn ) .
false
interaction with other drugn : drugn should be used with great caution and in reduced dosage in patients who are concurrently receiving other druga , general drugn , drugn , other drugn , drugb ( including drugn ) , drugn and other drugn ( including drugn ) .
false
interaction with other drugn : drugn should be used with great caution and in reduced dosage in patients who are concurrently receiving other druga , general drugn , drugn , other drugn , drugn ( including drugb ) , drugn and other drugn ( including drugn ) .
false
interaction with other drugn : drugn should be used with great caution and in reduced dosage in patients who are concurrently receiving other druga , general drugn , drugn , other drugn , drugn ( including drugn ) , drugb and other drugn ( including drugn ) .
false
interaction with other drugn : drugn should be used with great caution and in reduced dosage in patients who are concurrently receiving other druga , general drugn , drugn , other drugn , drugn ( including drugn ) , drugn and other drugb ( including drugn ) .
false
interaction with other drugn : drugn should be used with great caution and in reduced dosage in patients who are concurrently receiving other druga , general drugn , drugn , other drugn , drugn ( including drugn ) , drugn and other drugn ( including drugb ) .
false
interaction with other drugn : drugn should be used with great caution and in reduced dosage in patients who are concurrently receiving other drugn , general druga , drugb , other drugn , drugn ( including drugn ) , drugn and other drugn ( including drugn ) .
false
interaction with other drugn : drugn should be used with great caution and in reduced dosage in patients who are concurrently receiving other drugn , general druga , drugn , other drugb , drugn ( including drugn ) , drugn and other drugn ( including drugn ) .
false
interaction with other drugn : drugn should be used with great caution and in reduced dosage in patients who are concurrently receiving other drugn , general druga , drugn , other drugn , drugb ( including drugn ) , drugn and other drugn ( including drugn ) .
false
interaction with other drugn : drugn should be used with great caution and in reduced dosage in patients who are concurrently receiving other drugn , general druga , drugn , other drugn , drugn ( including drugb ) , drugn and other drugn ( including drugn ) .
false
interaction with other drugn : drugn should be used with great caution and in reduced dosage in patients who are concurrently receiving other drugn , general druga , drugn , other drugn , drugn ( including drugn ) , drugb and other drugn ( including drugn ) .
false
interaction with other drugn : drugn should be used with great caution and in reduced dosage in patients who are concurrently receiving other drugn , general druga , drugn , other drugn , drugn ( including drugn ) , drugn and other drugb ( including drugn ) .
false
interaction with other drugn : drugn should be used with great caution and in reduced dosage in patients who are concurrently receiving other drugn , general druga , drugn , other drugn , drugn ( including drugn ) , drugn and other drugn ( including drugb ) .
false
interaction with other drugn : drugn should be used with great caution and in reduced dosage in patients who are concurrently receiving other drugn , general drugn , druga , other drugb , drugn ( including drugn ) , drugn and other drugn ( including drugn ) .
false
interaction with other drugn : drugn should be used with great caution and in reduced dosage in patients who are concurrently receiving other drugn , general drugn , druga , other drugn , drugb ( including drugn ) , drugn and other drugn ( including drugn ) .
false
interaction with other drugn : drugn should be used with great caution and in reduced dosage in patients who are concurrently receiving other drugn , general drugn , druga , other drugn , drugn ( including drugb ) , drugn and other drugn ( including drugn ) .
false
interaction with other drugn : drugn should be used with great caution and in reduced dosage in patients who are concurrently receiving other drugn , general drugn , druga , other drugn , drugn ( including drugn ) , drugb and other drugn ( including drugn ) .
false
interaction with other drugn : drugn should be used with great caution and in reduced dosage in patients who are concurrently receiving other drugn , general drugn , druga , other drugn , drugn ( including drugn ) , drugn and other drugb ( including drugn ) .
false
interaction with other drugn : drugn should be used with great caution and in reduced dosage in patients who are concurrently receiving other drugn , general drugn , druga , other drugn , drugn ( including drugn ) , drugn and other drugn ( including drugb ) .
false
interaction with other drugn : drugn should be used with great caution and in reduced dosage in patients who are concurrently receiving other drugn , general drugn , drugn , other druga , drugb ( including drugn ) , drugn and other drugn ( including drugn ) .
false
interaction with other drugn : drugn should be used with great caution and in reduced dosage in patients who are concurrently receiving other drugn , general drugn , drugn , other druga , drugn ( including drugb ) , drugn and other drugn ( including drugn ) .
false
interaction with other drugn : drugn should be used with great caution and in reduced dosage in patients who are concurrently receiving other drugn , general drugn , drugn , other druga , drugn ( including drugn ) , drugb and other drugn ( including drugn ) .
false
interaction with other drugn : drugn should be used with great caution and in reduced dosage in patients who are concurrently receiving other drugn , general drugn , drugn , other druga , drugn ( including drugn ) , drugn and other drugb ( including drugn ) .
false
interaction with other drugn : drugn should be used with great caution and in reduced dosage in patients who are concurrently receiving other drugn , general drugn , drugn , other druga , drugn ( including drugn ) , drugn and other drugn ( including drugb ) .
false
interaction with other drugn : drugn should be used with great caution and in reduced dosage in patients who are concurrently receiving other drugn , general drugn , drugn , other drugn , druga ( including drugb ) , drugn and other drugn ( including drugn ) .
false
interaction with other drugn : drugn should be used with great caution and in reduced dosage in patients who are concurrently receiving other drugn , general drugn , drugn , other drugn , druga ( including drugn ) , drugb and other drugn ( including drugn ) .
false
interaction with other drugn : drugn should be used with great caution and in reduced dosage in patients who are concurrently receiving other drugn , general drugn , drugn , other drugn , druga ( including drugn ) , drugn and other drugb ( including drugn ) .
false
interaction with other drugn : drugn should be used with great caution and in reduced dosage in patients who are concurrently receiving other drugn , general drugn , drugn , other drugn , druga ( including drugn ) , drugn and other drugn ( including drugb ) .
false
interaction with other drugn : drugn should be used with great caution and in reduced dosage in patients who are concurrently receiving other drugn , general drugn , drugn , other drugn , drugn ( including druga ) , drugb and other drugn ( including drugn ) .
false
interaction with other drugn : drugn should be used with great caution and in reduced dosage in patients who are concurrently receiving other drugn , general drugn , drugn , other drugn , drugn ( including druga ) , drugn and other drugb ( including drugn ) .
false
interaction with other drugn : drugn should be used with great caution and in reduced dosage in patients who are concurrently receiving other drugn , general drugn , drugn , other drugn , drugn ( including druga ) , drugn and other drugn ( including drugb ) .
false
interaction with other drugn : drugn should be used with great caution and in reduced dosage in patients who are concurrently receiving other drugn , general drugn , drugn , other drugn , drugn ( including drugn ) , druga and other drugb ( including drugn ) .
false
interaction with other drugn : drugn should be used with great caution and in reduced dosage in patients who are concurrently receiving other drugn , general drugn , drugn , other drugn , drugn ( including drugn ) , druga and other drugn ( including drugb ) .
false
interaction with other drugn : drugn should be used with great caution and in reduced dosage in patients who are concurrently receiving other drugn , general drugn , drugn , other drugn , drugn ( including drugn ) , drugn and other druga ( including drugb ) .
false
druga and drugb increase the effects of drugn .
false
druga and drugn increase the effects of drugb .
effect
drugn and druga increase the effects of drugb .
effect
druga may reduce the antihypertensive effects of drugb , drugn , drugn and drugn .
effect
druga may reduce the antihypertensive effects of drugn , drugb , drugn and drugn .
effect
druga may reduce the antihypertensive effects of drugn , drugn , drugb and drugn .
effect
druga may reduce the antihypertensive effects of drugn , drugn , drugn and drugb .
effect
drugn may reduce the antihypertensive effects of druga , drugb , drugn and drugn .
false
drugn may reduce the antihypertensive effects of druga , drugn , drugb and drugn .
false
drugn may reduce the antihypertensive effects of druga , drugn , drugn and drugb .
false
drugn may reduce the antihypertensive effects of drugn , druga , drugb and drugn .
false
drugn may reduce the antihypertensive effects of drugn , druga , drugn and drugb .
false
drugn may reduce the antihypertensive effects of drugn , drugn , druga and drugb .
false
druga : absorption of a single dose of drugb was decreased when administered to 12 stable renal transplant patients also taking drugn - drugn containing drugn ( 30 ml ) : the mean cmax and auc ( 0-t ) values for mpa were 25 % and 37 % lower , respectively , than when drugn was administered alone under fasting conditions .
false
druga : absorption of a single dose of drugn was decreased when administered to 12 stable renal transplant patients also taking drugb - drugn containing drugn ( 30 ml ) : the mean cmax and auc ( 0-t ) values for mpa were 25 % and 37 % lower , respectively , than when drugn was administered alone under fasting conditions .
false
druga : absorption of a single dose of drugn was decreased when administered to 12 stable renal transplant patients also taking drugn - drugb containing drugn ( 30 ml ) : the mean cmax and auc ( 0-t ) values for mpa were 25 % and 37 % lower , respectively , than when drugn was administered alone under fasting conditions .
false
druga : absorption of a single dose of drugn was decreased when administered to 12 stable renal transplant patients also taking drugn - drugn containing drugb ( 30 ml ) : the mean cmax and auc ( 0-t ) values for mpa were 25 % and 37 % lower , respectively , than when drugn was administered alone under fasting conditions .
false
druga : absorption of a single dose of drugn was decreased when administered to 12 stable renal transplant patients also taking drugn - drugn containing drugn ( 30 ml ) : the mean cmax and auc ( 0-t ) values for mpa were 25 % and 37 % lower , respectively , than when drugb was administered alone under fasting conditions .
false
drugn : absorption of a single dose of druga was decreased when administered to 12 stable renal transplant patients also taking drugb - drugn containing drugn ( 30 ml ) : the mean cmax and auc ( 0-t ) values for mpa were 25 % and 37 % lower , respectively , than when drugn was administered alone under fasting conditions .
mechanism
drugn : absorption of a single dose of druga was decreased when administered to 12 stable renal transplant patients also taking drugn - drugb containing drugn ( 30 ml ) : the mean cmax and auc ( 0-t ) values for mpa were 25 % and 37 % lower , respectively , than when drugn was administered alone under fasting conditions .
mechanism
drugn : absorption of a single dose of druga was decreased when administered to 12 stable renal transplant patients also taking drugn - drugn containing drugb ( 30 ml ) : the mean cmax and auc ( 0-t ) values for mpa were 25 % and 37 % lower , respectively , than when drugn was administered alone under fasting conditions .
false
drugn : absorption of a single dose of druga was decreased when administered to 12 stable renal transplant patients also taking drugn - drugn containing drugn ( 30 ml ) : the mean cmax and auc ( 0-t ) values for mpa were 25 % and 37 % lower , respectively , than when drugb was administered alone under fasting conditions .
false
drugn : absorption of a single dose of drugn was decreased when administered to 12 stable renal transplant patients also taking druga - drugb containing drugn ( 30 ml ) : the mean cmax and auc ( 0-t ) values for mpa were 25 % and 37 % lower , respectively , than when drugn was administered alone under fasting conditions .
false
drugn : absorption of a single dose of drugn was decreased when administered to 12 stable renal transplant patients also taking druga - drugn containing drugb ( 30 ml ) : the mean cmax and auc ( 0-t ) values for mpa were 25 % and 37 % lower , respectively , than when drugn was administered alone under fasting conditions .
false
drugn : absorption of a single dose of drugn was decreased when administered to 12 stable renal transplant patients also taking druga - drugn containing drugn ( 30 ml ) : the mean cmax and auc ( 0-t ) values for mpa were 25 % and 37 % lower , respectively , than when drugb was administered alone under fasting conditions .
false
drugn : absorption of a single dose of drugn was decreased when administered to 12 stable renal transplant patients also taking drugn - druga containing drugb ( 30 ml ) : the mean cmax and auc ( 0-t ) values for mpa were 25 % and 37 % lower , respectively , than when drugn was administered alone under fasting conditions .
false
drugn : absorption of a single dose of drugn was decreased when administered to 12 stable renal transplant patients also taking drugn - druga containing drugn ( 30 ml ) : the mean cmax and auc ( 0-t ) values for mpa were 25 % and 37 % lower , respectively , than when drugb was administered alone under fasting conditions .
false
drugn : absorption of a single dose of drugn was decreased when administered to 12 stable renal transplant patients also taking drugn - drugn containing druga ( 30 ml ) : the mean cmax and auc ( 0-t ) values for mpa were 25 % and 37 % lower , respectively , than when drugb was administered alone under fasting conditions .
false
it is recommended that druga and drugb not be administered simultaneously .
advise
druga : when studied in stable renal transplant patients , drugb , usp ( modified ) pharmacokinetics were unaffected by steady state dosing of drugn .
false
druga : when studied in stable renal transplant patients , drugn , usp ( modified ) pharmacokinetics were unaffected by steady state dosing of drugb .
false
drugn : when studied in stable renal transplant patients , druga , usp ( modified ) pharmacokinetics were unaffected by steady state dosing of drugb .
false
druga / drugb : may be taken with drugn ;
false
druga / drugn : may be taken with drugb ;
false
drugn / druga : may be taken with drugb ;
false
both druga / drugb and drugn concentrations are increased in the presence of renal impairment , their coexistence may compete for tubular secretion and further increase in the concentrations of the two .
false
both druga / drugn and drugb concentrations are increased in the presence of renal impairment , their coexistence may compete for tubular secretion and further increase in the concentrations of the two .
false
both drugn / druga and drugb concentrations are increased in the presence of renal impairment , their coexistence may compete for tubular secretion and further increase in the concentrations of the two .
false
druga / drugb : given that drugn and drugn inhibit purine metabolism , it is recommended that drugn not be administered concomitantly with drugn or drugn .
false
druga / drugn : given that drugb and drugn inhibit purine metabolism , it is recommended that drugn not be administered concomitantly with drugn or drugn .
false
druga / drugn : given that drugn and drugb inhibit purine metabolism , it is recommended that drugn not be administered concomitantly with drugn or drugn .
false
druga / drugn : given that drugn and drugn inhibit purine metabolism , it is recommended that drugb not be administered concomitantly with drugn or drugn .
false
druga / drugn : given that drugn and drugn inhibit purine metabolism , it is recommended that drugn not be administered concomitantly with drugb or drugn .
false
druga / drugn : given that drugn and drugn inhibit purine metabolism , it is recommended that drugn not be administered concomitantly with drugn or drugb .
false
drugn / druga : given that drugb and drugn inhibit purine metabolism , it is recommended that drugn not be administered concomitantly with drugn or drugn .
false
drugn / druga : given that drugn and drugb inhibit purine metabolism , it is recommended that drugn not be administered concomitantly with drugn or drugn .
false
drugn / druga : given that drugn and drugn inhibit purine metabolism , it is recommended that drugb not be administered concomitantly with drugn or drugn .
false
drugn / druga : given that drugn and drugn inhibit purine metabolism , it is recommended that drugn not be administered concomitantly with drugb or drugn .
false
drugn / druga : given that drugn and drugn inhibit purine metabolism , it is recommended that drugn not be administered concomitantly with drugn or drugb .
false
drugn / drugn : given that druga and drugb inhibit purine metabolism , it is recommended that drugn not be administered concomitantly with drugn or drugn .
false
drugn / drugn : given that druga and drugn inhibit purine metabolism , it is recommended that drugb not be administered concomitantly with drugn or drugn .
false
drugn / drugn : given that druga and drugn inhibit purine metabolism , it is recommended that drugn not be administered concomitantly with drugb or drugn .
false
drugn / drugn : given that druga and drugn inhibit purine metabolism , it is recommended that drugn not be administered concomitantly with drugn or drugb .
false
drugn / drugn : given that drugn and druga inhibit purine metabolism , it is recommended that drugb not be administered concomitantly with drugn or drugn .
false
drugn / drugn : given that drugn and druga inhibit purine metabolism , it is recommended that drugn not be administered concomitantly with drugb or drugn .
false
drugn / drugn : given that drugn and druga inhibit purine metabolism , it is recommended that drugn not be administered concomitantly with drugn or drugb .
false
drugn / drugn : given that drugn and drugn inhibit purine metabolism , it is recommended that druga not be administered concomitantly with drugb or drugn .
advise
drugn / drugn : given that drugn and drugn inhibit purine metabolism , it is recommended that druga not be administered concomitantly with drugn or drugb .
advise
drugn / drugn : given that drugn and drugn inhibit purine metabolism , it is recommended that drugn not be administered concomitantly with druga or drugb .
false
druga and drugs that bind bile acids : these drugs interrupt enterohepatic recirculation and reduce drugb exposure when coadministered with drugn .
false
druga and drugs that bind bile acids : these drugs interrupt enterohepatic recirculation and reduce drugn exposure when coadministered with drugb .
false
drugn and drugs that bind bile acids : these drugs interrupt enterohepatic recirculation and reduce druga exposure when coadministered with drugb .
false
therefore , do not administer druga with drugb or other agents that may interfere with enterohepatic recirculation or drugs that may bind bile acids , for example bile acid sequestrates or oral drugn , because of the potential to reduce the efficacy of drugn .
advise
therefore , do not administer druga with drugn or other agents that may interfere with enterohepatic recirculation or drugs that may bind bile acids , for example bile acid sequestrates or oral drugb , because of the potential to reduce the efficacy of drugn .
advise
therefore , do not administer druga with drugn or other agents that may interfere with enterohepatic recirculation or drugs that may bind bile acids , for example bile acid sequestrates or oral drugn , because of the potential to reduce the efficacy of drugb .
false
therefore , do not administer drugn with druga or other agents that may interfere with enterohepatic recirculation or drugs that may bind bile acids , for example bile acid sequestrates or oral drugb , because of the potential to reduce the efficacy of drugn .
false
therefore , do not administer drugn with druga or other agents that may interfere with enterohepatic recirculation or drugs that may bind bile acids , for example bile acid sequestrates or oral drugn , because of the potential to reduce the efficacy of drugb .
false
therefore , do not administer drugn with drugn or other agents that may interfere with enterohepatic recirculation or drugs that may bind bile acids , for example bile acid sequestrates or oral druga , because of the potential to reduce the efficacy of drugb .
false
oral druga : given the different metabolism of drugb and oral drugn , no drug interaction between these two classes of drug is expected .
false
oral druga : given the different metabolism of drugn and oral drugb , no drug interaction between these two classes of drug is expected .
false
oral drugn : given the different metabolism of druga and oral drugb , no drug interaction between these two classes of drug is expected .
false
however , in a drug-drug interaction study , mean druga auc was decreased by 15 % when coadministered with drugb .
mechanism
therefore , it is recommended that oral druga are co- administered with drugb with caution and additional birth control methods be considered .
advise
druga : during treatment with drugb , the use of drugn should be avoided and patients should be advised that vaccinations may be less effective .
false
druga : during treatment with drugn , the use of drugb should be avoided and patients should be advised that vaccinations may be less effective .
false
drugn : during treatment with druga , the use of drugb should be avoided and patients should be advised that vaccinations may be less effective .
advise
interference of druga hydrolysis may lead to less drugb available for absorption .
false
do not exceed a 5 mg daily dose of druga when administered with therapeutic doses of drugb or other potent cyp3a4 inhibitors .
advise
patients with congenital or acquired qt prolongation in a study of the effect of druga on the qt interval in 76 healthy women , the qt prolonging effect appeared less with drugb 10 mg than with 30 mg ( three times the maximum recommended dose ) , and the effect of drugn 30 mg did not appear as large as that of the positive control drugn at its therapeutic dose .
false
patients with congenital or acquired qt prolongation in a study of the effect of druga on the qt interval in 76 healthy women , the qt prolonging effect appeared less with drugn 10 mg than with 30 mg ( three times the maximum recommended dose ) , and the effect of drugb 30 mg did not appear as large as that of the positive control drugn at its therapeutic dose .
false
patients with congenital or acquired qt prolongation in a study of the effect of druga on the qt interval in 76 healthy women , the qt prolonging effect appeared less with drugn 10 mg than with 30 mg ( three times the maximum recommended dose ) , and the effect of drugn 30 mg did not appear as large as that of the positive control drugb at its therapeutic dose .
false
patients with congenital or acquired qt prolongation in a study of the effect of drugn on the qt interval in 76 healthy women , the qt prolonging effect appeared less with druga 10 mg than with 30 mg ( three times the maximum recommended dose ) , and the effect of drugb 30 mg did not appear as large as that of the positive control drugn at its therapeutic dose .
false
patients with congenital or acquired qt prolongation in a study of the effect of drugn on the qt interval in 76 healthy women , the qt prolonging effect appeared less with druga 10 mg than with 30 mg ( three times the maximum recommended dose ) , and the effect of drugn 30 mg did not appear as large as that of the positive control drugb at its therapeutic dose .
false
patients with congenital or acquired qt prolongation in a study of the effect of drugn on the qt interval in 76 healthy women , the qt prolonging effect appeared less with drugn 10 mg than with 30 mg ( three times the maximum recommended dose ) , and the effect of druga 30 mg did not appear as large as that of the positive control drugb at its therapeutic dose .
false
if druga replacement is required , the drugb dose should be carefully adjusted .
false
limited published data indicate that druga treatment increases cytochrome p450 ( cp450 ) mediated drugb clearance in man .
mechanism
these data suggest that druga administration may alter the clearance of compounds known to be metabolized by cp450 liver enzymes ( e.g. , drugb , drugn , drugn , drugn ) .
mechanism
these data suggest that druga administration may alter the clearance of compounds known to be metabolized by cp450 liver enzymes ( e.g. , drugn , drugb , drugn , drugn ) .
mechanism
these data suggest that druga administration may alter the clearance of compounds known to be metabolized by cp450 liver enzymes ( e.g. , drugn , drugn , drugb , drugn ) .
mechanism
these data suggest that druga administration may alter the clearance of compounds known to be metabolized by cp450 liver enzymes ( e.g. , drugn , drugn , drugn , drugb ) .
mechanism
these data suggest that drugn administration may alter the clearance of compounds known to be metabolized by cp450 liver enzymes ( e.g. , druga , drugb , drugn , drugn ) .
false
these data suggest that drugn administration may alter the clearance of compounds known to be metabolized by cp450 liver enzymes ( e.g. , druga , drugn , drugb , drugn ) .
false
these data suggest that drugn administration may alter the clearance of compounds known to be metabolized by cp450 liver enzymes ( e.g. , druga , drugn , drugn , drugb ) .
false
these data suggest that drugn administration may alter the clearance of compounds known to be metabolized by cp450 liver enzymes ( e.g. , drugn , druga , drugb , drugn ) .
false
these data suggest that drugn administration may alter the clearance of compounds known to be metabolized by cp450 liver enzymes ( e.g. , drugn , druga , drugn , drugb ) .
false
these data suggest that drugn administration may alter the clearance of compounds known to be metabolized by cp450 liver enzymes ( e.g. , drugn , drugn , druga , drugb ) .
false
druga : spontaneous adverse reaction reports of patients taking concomitant drugb with recommended doses of drugn demonstrate qt interval prolongation and rare serious cardiac events , e.g .
false
druga : spontaneous adverse reaction reports of patients taking concomitant drugn with recommended doses of drugb demonstrate qt interval prolongation and rare serious cardiac events , e.g .
false
drugn : spontaneous adverse reaction reports of patients taking concomitant druga with recommended doses of drugb demonstrate qt interval prolongation and rare serious cardiac events , e.g .
effect
pharmacokinetic data indicate that druga markedly inhibits the metabolism of drugb , resulting in elevated plasma drugn levels .
mechanism
pharmacokinetic data indicate that druga markedly inhibits the metabolism of drugn , resulting in elevated plasma drugb levels .
false
pharmacokinetic data indicate that drugn markedly inhibits the metabolism of druga , resulting in elevated plasma drugb levels .
false
concomitant administration of druga and drugb is contraindicated .
advise
druga : torsades de pointes and elevated parent drugb levels have been reported during concomitant use of drugn and drugn in clinical trials of drugn and from foreign post-marketing sources .
false
druga : torsades de pointes and elevated parent drugn levels have been reported during concomitant use of drugb and drugn in clinical trials of drugn and from foreign post-marketing sources .
false
druga : torsades de pointes and elevated parent drugn levels have been reported during concomitant use of drugn and drugb in clinical trials of drugn and from foreign post-marketing sources .
false
druga : torsades de pointes and elevated parent drugn levels have been reported during concomitant use of drugn and drugn in clinical trials of drugb and from foreign post-marketing sources .
false
drugn : torsades de pointes and elevated parent druga levels have been reported during concomitant use of drugb and drugn in clinical trials of drugn and from foreign post-marketing sources .
false
drugn : torsades de pointes and elevated parent druga levels have been reported during concomitant use of drugn and drugb in clinical trials of drugn and from foreign post-marketing sources .
false
drugn : torsades de pointes and elevated parent druga levels have been reported during concomitant use of drugn and drugn in clinical trials of drugb and from foreign post-marketing sources .
false
drugn : torsades de pointes and elevated parent drugn levels have been reported during concomitant use of druga and drugb in clinical trials of drugn and from foreign post-marketing sources .
mechanism
drugn : torsades de pointes and elevated parent drugn levels have been reported during concomitant use of druga and drugn in clinical trials of drugb and from foreign post-marketing sources .
false
drugn : torsades de pointes and elevated parent drugn levels have been reported during concomitant use of drugn and druga in clinical trials of drugb and from foreign post-marketing sources .
false
concomitant administration of druga and drugb is contraindicated .
advise
due to the chemical similarity of other druga ( including drugb , drugn , and drugn ) to drugn , and drugn , concomitant use of these products with drugn is not recommended pending full examination of potential interactions .
false
due to the chemical similarity of other druga ( including drugn , drugb , and drugn ) to drugn , and drugn , concomitant use of these products with drugn is not recommended pending full examination of potential interactions .
false
due to the chemical similarity of other druga ( including drugn , drugn , and drugb ) to drugn , and drugn , concomitant use of these products with drugn is not recommended pending full examination of potential interactions .
false
due to the chemical similarity of other druga ( including drugn , drugn , and drugn ) to drugb , and drugn , concomitant use of these products with drugn is not recommended pending full examination of potential interactions .
false
due to the chemical similarity of other druga ( including drugn , drugn , and drugn ) to drugn , and drugb , concomitant use of these products with drugn is not recommended pending full examination of potential interactions .
false
due to the chemical similarity of other druga ( including drugn , drugn , and drugn ) to drugn , and drugn , concomitant use of these products with drugb is not recommended pending full examination of potential interactions .
advise
due to the chemical similarity of other drugn ( including druga , drugb , and drugn ) to drugn , and drugn , concomitant use of these products with drugn is not recommended pending full examination of potential interactions .
false
due to the chemical similarity of other drugn ( including druga , drugn , and drugb ) to drugn , and drugn , concomitant use of these products with drugn is not recommended pending full examination of potential interactions .
false
due to the chemical similarity of other drugn ( including druga , drugn , and drugn ) to drugb , and drugn , concomitant use of these products with drugn is not recommended pending full examination of potential interactions .
false
due to the chemical similarity of other drugn ( including druga , drugn , and drugn ) to drugn , and drugb , concomitant use of these products with drugn is not recommended pending full examination of potential interactions .
false
due to the chemical similarity of other drugn ( including druga , drugn , and drugn ) to drugn , and drugn , concomitant use of these products with drugb is not recommended pending full examination of potential interactions .
advise
due to the chemical similarity of other drugn ( including drugn , druga , and drugb ) to drugn , and drugn , concomitant use of these products with drugn is not recommended pending full examination of potential interactions .
false
due to the chemical similarity of other drugn ( including drugn , druga , and drugn ) to drugb , and drugn , concomitant use of these products with drugn is not recommended pending full examination of potential interactions .
false
due to the chemical similarity of other drugn ( including drugn , druga , and drugn ) to drugn , and drugb , concomitant use of these products with drugn is not recommended pending full examination of potential interactions .
false
due to the chemical similarity of other drugn ( including drugn , druga , and drugn ) to drugn , and drugn , concomitant use of these products with drugb is not recommended pending full examination of potential interactions .
advise
due to the chemical similarity of other drugn ( including drugn , drugn , and druga ) to drugb , and drugn , concomitant use of these products with drugn is not recommended pending full examination of potential interactions .
false
due to the chemical similarity of other drugn ( including drugn , drugn , and druga ) to drugn , and drugb , concomitant use of these products with drugn is not recommended pending full examination of potential interactions .
false
due to the chemical similarity of other drugn ( including drugn , drugn , and druga ) to drugn , and drugn , concomitant use of these products with drugb is not recommended pending full examination of potential interactions .
advise
due to the chemical similarity of other drugn ( including drugn , drugn , and drugn ) to druga , and drugb , concomitant use of these products with drugn is not recommended pending full examination of potential interactions .
false
due to the chemical similarity of other drugn ( including drugn , drugn , and drugn ) to druga , and drugn , concomitant use of these products with drugb is not recommended pending full examination of potential interactions .
false
due to the chemical similarity of other drugn ( including drugn , drugn , and drugn ) to drugn , and druga , concomitant use of these products with drugb is not recommended pending full examination of potential interactions .
false
druga : clinical drug interaction studies indicate that drugb and drugn can exert an effect on drugn metabolism by a mechanism which may be similar to that of drugn , but to a lesser extent .
false
druga : clinical drug interaction studies indicate that drugn and drugb can exert an effect on drugn metabolism by a mechanism which may be similar to that of drugn , but to a lesser extent .
false
druga : clinical drug interaction studies indicate that drugn and drugn can exert an effect on drugb metabolism by a mechanism which may be similar to that of drugn , but to a lesser extent .
false
druga : clinical drug interaction studies indicate that drugn and drugn can exert an effect on drugn metabolism by a mechanism which may be similar to that of drugb , but to a lesser extent .
false
drugn : clinical drug interaction studies indicate that druga and drugb can exert an effect on drugn metabolism by a mechanism which may be similar to that of drugn , but to a lesser extent .
false
drugn : clinical drug interaction studies indicate that druga and drugn can exert an effect on drugb metabolism by a mechanism which may be similar to that of drugn , but to a lesser extent .
mechanism
drugn : clinical drug interaction studies indicate that druga and drugn can exert an effect on drugn metabolism by a mechanism which may be similar to that of drugb , but to a lesser extent .
false
drugn : clinical drug interaction studies indicate that drugn and druga can exert an effect on drugb metabolism by a mechanism which may be similar to that of drugn , but to a lesser extent .
mechanism
drugn : clinical drug interaction studies indicate that drugn and druga can exert an effect on drugn metabolism by a mechanism which may be similar to that of drugb , but to a lesser extent .
false
drugn : clinical drug interaction studies indicate that drugn and drugn can exert an effect on druga metabolism by a mechanism which may be similar to that of drugb , but to a lesser extent .
false
a few spontaneous accounts of qt interval prolongation with ventricular arrhythmia including torsades de pointes , have been reported in patients receiving druga or drugb .
false
concomitant administration of druga with drugb , drugn , or drugn is contraindicated : pending full characterization of potential interactions , concomitant administration of drugn with other drugn , including drugn , is not recommended .
advise
concomitant administration of druga with drugn , drugb , or drugn is contraindicated : pending full characterization of potential interactions , concomitant administration of drugn with other drugn , including drugn , is not recommended .
advise
concomitant administration of druga with drugn , drugn , or drugb is contraindicated : pending full characterization of potential interactions , concomitant administration of drugn with other drugn , including drugn , is not recommended .
advise
concomitant administration of druga with drugn , drugn , or drugn is contraindicated : pending full characterization of potential interactions , concomitant administration of drugb with other drugn , including drugn , is not recommended .
false
concomitant administration of druga with drugn , drugn , or drugn is contraindicated : pending full characterization of potential interactions , concomitant administration of drugn with other drugb , including drugn , is not recommended .
false
concomitant administration of druga with drugn , drugn , or drugn is contraindicated : pending full characterization of potential interactions , concomitant administration of drugn with other drugn , including drugb , is not recommended .
false
concomitant administration of drugn with druga , drugb , or drugn is contraindicated : pending full characterization of potential interactions , concomitant administration of drugn with other drugn , including drugn , is not recommended .
false
concomitant administration of drugn with druga , drugn , or drugb is contraindicated : pending full characterization of potential interactions , concomitant administration of drugn with other drugn , including drugn , is not recommended .
false
concomitant administration of drugn with druga , drugn , or drugn is contraindicated : pending full characterization of potential interactions , concomitant administration of drugb with other drugn , including drugn , is not recommended .
false
concomitant administration of drugn with druga , drugn , or drugn is contraindicated : pending full characterization of potential interactions , concomitant administration of drugn with other drugb , including drugn , is not recommended .
false
concomitant administration of drugn with druga , drugn , or drugn is contraindicated : pending full characterization of potential interactions , concomitant administration of drugn with other drugn , including drugb , is not recommended .
false
concomitant administration of drugn with drugn , druga , or drugb is contraindicated : pending full characterization of potential interactions , concomitant administration of drugn with other drugn , including drugn , is not recommended .
false
concomitant administration of drugn with drugn , druga , or drugn is contraindicated : pending full characterization of potential interactions , concomitant administration of drugb with other drugn , including drugn , is not recommended .
false
concomitant administration of drugn with drugn , druga , or drugn is contraindicated : pending full characterization of potential interactions , concomitant administration of drugn with other drugb , including drugn , is not recommended .
false
concomitant administration of drugn with drugn , druga , or drugn is contraindicated : pending full characterization of potential interactions , concomitant administration of drugn with other drugn , including drugb , is not recommended .
false
concomitant administration of drugn with drugn , drugn , or druga is contraindicated : pending full characterization of potential interactions , concomitant administration of drugb with other drugn , including drugn , is not recommended .
false
concomitant administration of drugn with drugn , drugn , or druga is contraindicated : pending full characterization of potential interactions , concomitant administration of drugn with other drugb , including drugn , is not recommended .
false
concomitant administration of drugn with drugn , drugn , or druga is contraindicated : pending full characterization of potential interactions , concomitant administration of drugn with other drugn , including drugb , is not recommended .
false
concomitant administration of drugn with drugn , drugn , or drugn is contraindicated : pending full characterization of potential interactions , concomitant administration of druga with other drugb , including drugn , is not recommended .
advise
concomitant administration of drugn with drugn , drugn , or drugn is contraindicated : pending full characterization of potential interactions , concomitant administration of druga with other drugn , including drugb , is not recommended .
advise
concomitant administration of drugn with drugn , drugn , or drugn is contraindicated : pending full characterization of potential interactions , concomitant administration of drugn with other druga , including drugb , is not recommended .
false
studies to evaluate potential interactions of druga with drugb are in progress .
false
since druga is a substrate for the metabolic pathways involving cyp2d6 and cyp1a2 enzymes , inhibition or induction of either of these enzymes would be expected to alter drugb plasma concentrations .
false
in a formal , single-dose interaction study ( n = 6 males ) the clearance of druga was decreased by 38 % following the coadministration of drugb , an inhibitor of cyp1a2 .
mechanism
in another formal study ( n = 8 extensive and n = 7 poor metabolizers of cyp2d6 ) , coadministration of druga did not alter the kinetics of drugb in the poor cyp2d6 metabolizer group .
false
in this crossover steady state study , the pharmacokinetics of druga were unaffected in either phenotype by the coadministration of drugb .
false
addition of druga to drugb did not lead to further electrocardiographic parameters changes of qrs , qtc , rr , and pr intervals than drugn alone .
false
addition of druga to drugn did not lead to further electrocardiographic parameters changes of qrs , qtc , rr , and pr intervals than drugb alone .
false
addition of drugn to druga did not lead to further electrocardiographic parameters changes of qrs , qtc , rr , and pr intervals than drugb alone .
false
when concomitant administration of either of these two drugs with druga is initiated , the dose of drugb should be slowly titrated to desired effect .
false
in a large compassionate use program druga has been used concurrently with commonly employed antianginal , drugb , and drugn without observed interactions .
false
in a large compassionate use program druga has been used concurrently with commonly employed antianginal , drugn , and drugb without observed interactions .
false
in a large compassionate use program drugn has been used concurrently with commonly employed antianginal , druga , and drugb without observed interactions .
false
a variety of druga such as drugb or drugn were also added , sometimes with improved control of ventricular ectopy .
false
a variety of druga such as drugn or drugb were also added , sometimes with improved control of ventricular ectopy .
false
a variety of drugn such as druga or drugb were also added , sometimes with improved control of ventricular ectopy .
false
when druga or other hepatic enzyme inducers such as drugb and drugn have been taken concurrently with drugn , lowered drugn plasma levels have been reported .
false
when druga or other hepatic enzyme inducers such as drugn and drugb have been taken concurrently with drugn , lowered drugn plasma levels have been reported .
false
when druga or other hepatic enzyme inducers such as drugn and drugn have been taken concurrently with drugb , lowered drugn plasma levels have been reported .
mechanism
when druga or other hepatic enzyme inducers such as drugn and drugn have been taken concurrently with drugn , lowered drugb plasma levels have been reported .
false
when drugn or other hepatic enzyme inducers such as druga and drugb have been taken concurrently with drugn , lowered drugn plasma levels have been reported .
false
when drugn or other hepatic enzyme inducers such as druga and drugn have been taken concurrently with drugb , lowered drugn plasma levels have been reported .
mechanism
when drugn or other hepatic enzyme inducers such as druga and drugn have been taken concurrently with drugn , lowered drugb plasma levels have been reported .
false
when drugn or other hepatic enzyme inducers such as drugn and druga have been taken concurrently with drugb , lowered drugn plasma levels have been reported .
mechanism
when drugn or other hepatic enzyme inducers such as drugn and druga have been taken concurrently with drugn , lowered drugb plasma levels have been reported .
false
when drugn or other hepatic enzyme inducers such as drugn and drugn have been taken concurrently with druga , lowered drugb plasma levels have been reported .
false
in a formal study , druga were shown not to affect drugb plasma concentrations .
false
ecg intervals ( pr , qrs , and qt ) were not affected by concurrent druga and drugb , drugn , or drugn .
false
ecg intervals ( pr , qrs , and qt ) were not affected by concurrent druga and drugn , drugb , or drugn .
false
ecg intervals ( pr , qrs , and qt ) were not affected by concurrent druga and drugn , drugn , or drugb .
false
ecg intervals ( pr , qrs , and qt ) were not affected by concurrent drugn and druga , drugb , or drugn .
false
ecg intervals ( pr , qrs , and qt ) were not affected by concurrent drugn and druga , drugn , or drugb .
false
ecg intervals ( pr , qrs , and qt ) were not affected by concurrent drugn and drugn , druga , or drugb .
false
concurrent administration of druga and drugb has been reported to increase , decrease , or leave unchanged drugn plasma levels ;
mechanism
concurrent administration of druga and drugn has been reported to increase , decrease , or leave unchanged drugb plasma levels ;
false
concurrent administration of drugn and druga has been reported to increase , decrease , or leave unchanged drugb plasma levels ;
false
druga does not alter serum drugb levels but drugn , when used to treat gastrointestinal symptoms due to drugn , has been reported to lower serum drugn levels .
false
druga does not alter serum drugn levels but drugb , when used to treat gastrointestinal symptoms due to drugn , has been reported to lower serum drugn levels .
false
druga does not alter serum drugn levels but drugn , when used to treat gastrointestinal symptoms due to drugb , has been reported to lower serum drugn levels .
false
druga does not alter serum drugn levels but drugn , when used to treat gastrointestinal symptoms due to drugn , has been reported to lower serum drugb levels .
false
drugn does not alter serum druga levels but drugb , when used to treat gastrointestinal symptoms due to drugn , has been reported to lower serum drugn levels .
false
drugn does not alter serum druga levels but drugn , when used to treat gastrointestinal symptoms due to drugb , has been reported to lower serum drugn levels .
false
drugn does not alter serum druga levels but drugn , when used to treat gastrointestinal symptoms due to drugn , has been reported to lower serum drugb levels .
false
drugn does not alter serum drugn levels but druga , when used to treat gastrointestinal symptoms due to drugb , has been reported to lower serum drugn levels .
false
drugn does not alter serum drugn levels but druga , when used to treat gastrointestinal symptoms due to drugn , has been reported to lower serum drugb levels .
mechanism
drugn does not alter serum drugn levels but drugn , when used to treat gastrointestinal symptoms due to druga , has been reported to lower serum drugb levels .
false
concurrent use of druga and drugb may lead to increased plasma drugn levels .
mechanism
concurrent use of druga and drugn may lead to increased plasma drugb levels .
false
concurrent use of drugn and druga may lead to increased plasma drugb levels .
false
this increase was observed at the first test point which was the second day after starting druga . drugb plasma levels returned to pre- drugn values within 48 hours after discontinuing drugn . if drugn and drugn are to be used concurrently , drugn blood levels should be monitored , particularly when the drugn dose is changed .
false
this increase was observed at the first test point which was the second day after starting druga . drugn plasma levels returned to pre- drugb values within 48 hours after discontinuing drugn . if drugn and drugn are to be used concurrently , drugn blood levels should be monitored , particularly when the drugn dose is changed .
false
this increase was observed at the first test point which was the second day after starting druga . drugn plasma levels returned to pre- drugn values within 48 hours after discontinuing drugb . if drugn and drugn are to be used concurrently , drugn blood levels should be monitored , particularly when the drugn dose is changed .
false
this increase was observed at the first test point which was the second day after starting druga . drugn plasma levels returned to pre- drugn values within 48 hours after discontinuing drugn . if drugb and drugn are to be used concurrently , drugn blood levels should be monitored , particularly when the drugn dose is changed .
false
this increase was observed at the first test point which was the second day after starting druga . drugn plasma levels returned to pre- drugn values within 48 hours after discontinuing drugn . if drugn and drugb are to be used concurrently , drugn blood levels should be monitored , particularly when the drugn dose is changed .
false
this increase was observed at the first test point which was the second day after starting druga . drugn plasma levels returned to pre- drugn values within 48 hours after discontinuing drugn . if drugn and drugn are to be used concurrently , drugb blood levels should be monitored , particularly when the drugn dose is changed .
false
this increase was observed at the first test point which was the second day after starting druga . drugn plasma levels returned to pre- drugn values within 48 hours after discontinuing drugn . if drugn and drugn are to be used concurrently , drugn blood levels should be monitored , particularly when the drugb dose is changed .
false
this increase was observed at the first test point which was the second day after starting drugn . druga plasma levels returned to pre- drugb values within 48 hours after discontinuing drugn . if drugn and drugn are to be used concurrently , drugn blood levels should be monitored , particularly when the drugn dose is changed .
false
this increase was observed at the first test point which was the second day after starting drugn . druga plasma levels returned to pre- drugn values within 48 hours after discontinuing drugb . if drugn and drugn are to be used concurrently , drugn blood levels should be monitored , particularly when the drugn dose is changed .
mechanism
this increase was observed at the first test point which was the second day after starting drugn . druga plasma levels returned to pre- drugn values within 48 hours after discontinuing drugn . if drugb and drugn are to be used concurrently , drugn blood levels should be monitored , particularly when the drugn dose is changed .
false
this increase was observed at the first test point which was the second day after starting drugn . druga plasma levels returned to pre- drugn values within 48 hours after discontinuing drugn . if drugn and drugb are to be used concurrently , drugn blood levels should be monitored , particularly when the drugn dose is changed .
false
this increase was observed at the first test point which was the second day after starting drugn . druga plasma levels returned to pre- drugn values within 48 hours after discontinuing drugn . if drugn and drugn are to be used concurrently , drugb blood levels should be monitored , particularly when the drugn dose is changed .
false
this increase was observed at the first test point which was the second day after starting drugn . druga plasma levels returned to pre- drugn values within 48 hours after discontinuing drugn . if drugn and drugn are to be used concurrently , drugn blood levels should be monitored , particularly when the drugb dose is changed .
false
this increase was observed at the first test point which was the second day after starting drugn . drugn plasma levels returned to pre- druga values within 48 hours after discontinuing drugb . if drugn and drugn are to be used concurrently , drugn blood levels should be monitored , particularly when the drugn dose is changed .
false
this increase was observed at the first test point which was the second day after starting drugn . drugn plasma levels returned to pre- druga values within 48 hours after discontinuing drugn . if drugb and drugn are to be used concurrently , drugn blood levels should be monitored , particularly when the drugn dose is changed .
false
this increase was observed at the first test point which was the second day after starting drugn . drugn plasma levels returned to pre- druga values within 48 hours after discontinuing drugn . if drugn and drugb are to be used concurrently , drugn blood levels should be monitored , particularly when the drugn dose is changed .
false
this increase was observed at the first test point which was the second day after starting drugn . drugn plasma levels returned to pre- druga values within 48 hours after discontinuing drugn . if drugn and drugn are to be used concurrently , drugb blood levels should be monitored , particularly when the drugn dose is changed .
false
this increase was observed at the first test point which was the second day after starting drugn . drugn plasma levels returned to pre- druga values within 48 hours after discontinuing drugn . if drugn and drugn are to be used concurrently , drugn blood levels should be monitored , particularly when the drugb dose is changed .
false
this increase was observed at the first test point which was the second day after starting drugn . drugn plasma levels returned to pre- drugn values within 48 hours after discontinuing druga . if drugb and drugn are to be used concurrently , drugn blood levels should be monitored , particularly when the drugn dose is changed .
false
this increase was observed at the first test point which was the second day after starting drugn . drugn plasma levels returned to pre- drugn values within 48 hours after discontinuing druga . if drugn and drugb are to be used concurrently , drugn blood levels should be monitored , particularly when the drugn dose is changed .
false
this increase was observed at the first test point which was the second day after starting drugn . drugn plasma levels returned to pre- drugn values within 48 hours after discontinuing druga . if drugn and drugn are to be used concurrently , drugb blood levels should be monitored , particularly when the drugn dose is changed .
false
this increase was observed at the first test point which was the second day after starting drugn . drugn plasma levels returned to pre- drugn values within 48 hours after discontinuing druga . if drugn and drugn are to be used concurrently , drugn blood levels should be monitored , particularly when the drugb dose is changed .
false
this increase was observed at the first test point which was the second day after starting drugn . drugn plasma levels returned to pre- drugn values within 48 hours after discontinuing drugn . if druga and drugb are to be used concurrently , drugn blood levels should be monitored , particularly when the drugn dose is changed .
advise
this increase was observed at the first test point which was the second day after starting drugn . drugn plasma levels returned to pre- drugn values within 48 hours after discontinuing drugn . if druga and drugn are to be used concurrently , drugb blood levels should be monitored , particularly when the drugn dose is changed .
false
this increase was observed at the first test point which was the second day after starting drugn . drugn plasma levels returned to pre- drugn values within 48 hours after discontinuing drugn . if druga and drugn are to be used concurrently , drugn blood levels should be monitored , particularly when the drugb dose is changed .
false
this increase was observed at the first test point which was the second day after starting drugn . drugn plasma levels returned to pre- drugn values within 48 hours after discontinuing drugn . if drugn and druga are to be used concurrently , drugb blood levels should be monitored , particularly when the drugn dose is changed .
false
this increase was observed at the first test point which was the second day after starting drugn . drugn plasma levels returned to pre- drugn values within 48 hours after discontinuing drugn . if drugn and druga are to be used concurrently , drugn blood levels should be monitored , particularly when the drugb dose is changed .
false
this increase was observed at the first test point which was the second day after starting drugn . drugn plasma levels returned to pre- drugn values within 48 hours after discontinuing drugn . if drugn and drugn are to be used concurrently , druga blood levels should be monitored , particularly when the drugb dose is changed .
false
additionally , in one controlled study in five normal subjects and seven patients , the clearance of druga was decreased 50 % following the administration of drugb .
mechanism
drugs that induce hepatic enzymes such as druga , drugb and drugn may increase the clearance of drugn and may require increases in drugn dose to achieve the desired response .
false
drugs that induce hepatic enzymes such as druga , drugn and drugb may increase the clearance of drugn and may require increases in drugn dose to achieve the desired response .
false
drugs that induce hepatic enzymes such as druga , drugn and drugn may increase the clearance of drugb and may require increases in drugn dose to achieve the desired response .
mechanism
drugs that induce hepatic enzymes such as druga , drugn and drugn may increase the clearance of drugn and may require increases in drugb dose to achieve the desired response .
mechanism
drugs that induce hepatic enzymes such as drugn , druga and drugb may increase the clearance of drugn and may require increases in drugn dose to achieve the desired response .
false
drugs that induce hepatic enzymes such as drugn , druga and drugn may increase the clearance of drugb and may require increases in drugn dose to achieve the desired response .
mechanism
drugs that induce hepatic enzymes such as drugn , druga and drugn may increase the clearance of drugn and may require increases in drugb dose to achieve the desired response .
mechanism
drugs that induce hepatic enzymes such as drugn , drugn and druga may increase the clearance of drugb and may require increases in drugn dose to achieve the desired response .
mechanism
drugs that induce hepatic enzymes such as drugn , drugn and druga may increase the clearance of drugn and may require increases in drugb dose to achieve the desired response .
mechanism
drugs that induce hepatic enzymes such as drugn , drugn and drugn may increase the clearance of druga and may require increases in drugb dose to achieve the desired response .
false
drugs such as druga and drugb may inhibit the metabolism of drugn and thus decrease their clearance .
false
drugs such as druga and drugn may inhibit the metabolism of drugb and thus decrease their clearance .
mechanism
drugs such as drugn and druga may inhibit the metabolism of drugb and thus decrease their clearance .
mechanism
druga may increase the clearance of chronic high dose drugb .
mechanism
this could lead to decreased druga serum levels or increase the risk of drugb toxicity when drugn is withdrawn .
false
this could lead to decreased druga serum levels or increase the risk of drugn toxicity when drugb is withdrawn .
false
this could lead to decreased drugn serum levels or increase the risk of druga toxicity when drugb is withdrawn .
effect
druga should be used cautiously in conjunction with drugb in patients suffering from hypoprothrombinemia .
advise
the effect of druga on oral drugb is variable .
effect
there are reports of enhanced as well as diminished effects of druga when given concurrently with drugb .
effect
druga may interact with drugb ( drugn type ) , drugn ( e.g. , drugn , drugn , drugn , drugn , drugn , drugn ) , drugn , drugn , drugn ( e.g. , drugn ) , other drugn , drugn supplements , drugn , drugn ( e.g. , drugn - drugn ) , drugn ( e.g. , drugn , drugn ) .
false
druga may interact with drugn ( drugb type ) , drugn ( e.g. , drugn , drugn , drugn , drugn , drugn , drugn ) , drugn , drugn , drugn ( e.g. , drugn ) , other drugn , drugn supplements , drugn , drugn ( e.g. , drugn - drugn ) , drugn ( e.g. , drugn , drugn ) .
int
druga may interact with drugn ( drugn type ) , drugb ( e.g. , drugn , drugn , drugn , drugn , drugn , drugn ) , drugn , drugn , drugn ( e.g. , drugn ) , other drugn , drugn supplements , drugn , drugn ( e.g. , drugn - drugn ) , drugn ( e.g. , drugn , drugn ) .
int
druga may interact with drugn ( drugn type ) , drugn ( e.g. , drugb , drugn , drugn , drugn , drugn , drugn ) , drugn , drugn , drugn ( e.g. , drugn ) , other drugn , drugn supplements , drugn , drugn ( e.g. , drugn - drugn ) , drugn ( e.g. , drugn , drugn ) .
int
druga may interact with drugn ( drugn type ) , drugn ( e.g. , drugn , drugb , drugn , drugn , drugn , drugn ) , drugn , drugn , drugn ( e.g. , drugn ) , other drugn , drugn supplements , drugn , drugn ( e.g. , drugn - drugn ) , drugn ( e.g. , drugn , drugn ) .
int
druga may interact with drugn ( drugn type ) , drugn ( e.g. , drugn , drugn , drugb , drugn , drugn , drugn ) , drugn , drugn , drugn ( e.g. , drugn ) , other drugn , drugn supplements , drugn , drugn ( e.g. , drugn - drugn ) , drugn ( e.g. , drugn , drugn ) .
int
druga may interact with drugn ( drugn type ) , drugn ( e.g. , drugn , drugn , drugn , drugb , drugn , drugn ) , drugn , drugn , drugn ( e.g. , drugn ) , other drugn , drugn supplements , drugn , drugn ( e.g. , drugn - drugn ) , drugn ( e.g. , drugn , drugn ) .
int
druga may interact with drugn ( drugn type ) , drugn ( e.g. , drugn , drugn , drugn , drugn , drugb , drugn ) , drugn , drugn , drugn ( e.g. , drugn ) , other drugn , drugn supplements , drugn , drugn ( e.g. , drugn - drugn ) , drugn ( e.g. , drugn , drugn ) .
int
druga may interact with drugn ( drugn type ) , drugn ( e.g. , drugn , drugn , drugn , drugn , drugn , drugb ) , drugn , drugn , drugn ( e.g. , drugn ) , other drugn , drugn supplements , drugn , drugn ( e.g. , drugn - drugn ) , drugn ( e.g. , drugn , drugn ) .
int
druga may interact with drugn ( drugn type ) , drugn ( e.g. , drugn , drugn , drugn , drugn , drugn , drugn ) , drugb , drugn , drugn ( e.g. , drugn ) , other drugn , drugn supplements , drugn , drugn ( e.g. , drugn - drugn ) , drugn ( e.g. , drugn , drugn ) .
int
druga may interact with drugn ( drugn type ) , drugn ( e.g. , drugn , drugn , drugn , drugn , drugn , drugn ) , drugn , drugb , drugn ( e.g. , drugn ) , other drugn , drugn supplements , drugn , drugn ( e.g. , drugn - drugn ) , drugn ( e.g. , drugn , drugn ) .
int
druga may interact with drugn ( drugn type ) , drugn ( e.g. , drugn , drugn , drugn , drugn , drugn , drugn ) , drugn , drugn , drugb ( e.g. , drugn ) , other drugn , drugn supplements , drugn , drugn ( e.g. , drugn - drugn ) , drugn ( e.g. , drugn , drugn ) .
int
druga may interact with drugn ( drugn type ) , drugn ( e.g. , drugn , drugn , drugn , drugn , drugn , drugn ) , drugn , drugn , drugn ( e.g. , drugb ) , other drugn , drugn supplements , drugn , drugn ( e.g. , drugn - drugn ) , drugn ( e.g. , drugn , drugn ) .
int
druga may interact with drugn ( drugn type ) , drugn ( e.g. , drugn , drugn , drugn , drugn , drugn , drugn ) , drugn , drugn , drugn ( e.g. , drugn ) , other drugb , drugn supplements , drugn , drugn ( e.g. , drugn - drugn ) , drugn ( e.g. , drugn , drugn ) .
int
druga may interact with drugn ( drugn type ) , drugn ( e.g. , drugn , drugn , drugn , drugn , drugn , drugn ) , drugn , drugn , drugn ( e.g. , drugn ) , other drugn , drugb supplements , drugn , drugn ( e.g. , drugn - drugn ) , drugn ( e.g. , drugn , drugn ) .
int
druga may interact with drugn ( drugn type ) , drugn ( e.g. , drugn , drugn , drugn , drugn , drugn , drugn ) , drugn , drugn , drugn ( e.g. , drugn ) , other drugn , drugn supplements , drugb , drugn ( e.g. , drugn - drugn ) , drugn ( e.g. , drugn , drugn ) .
int
druga may interact with drugn ( drugn type ) , drugn ( e.g. , drugn , drugn , drugn , drugn , drugn , drugn ) , drugn , drugn , drugn ( e.g. , drugn ) , other drugn , drugn supplements , drugn , drugb ( e.g. , drugn - drugn ) , drugn ( e.g. , drugn , drugn ) .
int
druga may interact with drugn ( drugn type ) , drugn ( e.g. , drugn , drugn , drugn , drugn , drugn , drugn ) , drugn , drugn , drugn ( e.g. , drugn ) , other drugn , drugn supplements , drugn , drugn ( e.g. , drugb - drugn ) , drugn ( e.g. , drugn , drugn ) .
int
druga may interact with drugn ( drugn type ) , drugn ( e.g. , drugn , drugn , drugn , drugn , drugn , drugn ) , drugn , drugn , drugn ( e.g. , drugn ) , other drugn , drugn supplements , drugn , drugn ( e.g. , drugn - drugb ) , drugn ( e.g. , drugn , drugn ) .
int
druga may interact with drugn ( drugn type ) , drugn ( e.g. , drugn , drugn , drugn , drugn , drugn , drugn ) , drugn , drugn , drugn ( e.g. , drugn ) , other drugn , drugn supplements , drugn , drugn ( e.g. , drugn - drugn ) , drugb ( e.g. , drugn , drugn ) .
int
druga may interact with drugn ( drugn type ) , drugn ( e.g. , drugn , drugn , drugn , drugn , drugn , drugn ) , drugn , drugn , drugn ( e.g. , drugn ) , other drugn , drugn supplements , drugn , drugn ( e.g. , drugn - drugn ) , drugn ( e.g. , drugb , drugn ) .
int
druga may interact with drugn ( drugn type ) , drugn ( e.g. , drugn , drugn , drugn , drugn , drugn , drugn ) , drugn , drugn , drugn ( e.g. , drugn ) , other drugn , drugn supplements , drugn , drugn ( e.g. , drugn - drugn ) , drugn ( e.g. , drugn , drugb ) .
int
drugn may interact with druga ( drugb type ) , drugn ( e.g. , drugn , drugn , drugn , drugn , drugn , drugn ) , drugn , drugn , drugn ( e.g. , drugn ) , other drugn , drugn supplements , drugn , drugn ( e.g. , drugn - drugn ) , drugn ( e.g. , drugn , drugn ) .
false
drugn may interact with druga ( drugn type ) , drugb ( e.g. , drugn , drugn , drugn , drugn , drugn , drugn ) , drugn , drugn , drugn ( e.g. , drugn ) , other drugn , drugn supplements , drugn , drugn ( e.g. , drugn - drugn ) , drugn ( e.g. , drugn , drugn ) .
false
drugn may interact with druga ( drugn type ) , drugn ( e.g. , drugb , drugn , drugn , drugn , drugn , drugn ) , drugn , drugn , drugn ( e.g. , drugn ) , other drugn , drugn supplements , drugn , drugn ( e.g. , drugn - drugn ) , drugn ( e.g. , drugn , drugn ) .
false
drugn may interact with druga ( drugn type ) , drugn ( e.g. , drugn , drugb , drugn , drugn , drugn , drugn ) , drugn , drugn , drugn ( e.g. , drugn ) , other drugn , drugn supplements , drugn , drugn ( e.g. , drugn - drugn ) , drugn ( e.g. , drugn , drugn ) .
false
drugn may interact with druga ( drugn type ) , drugn ( e.g. , drugn , drugn , drugb , drugn , drugn , drugn ) , drugn , drugn , drugn ( e.g. , drugn ) , other drugn , drugn supplements , drugn , drugn ( e.g. , drugn - drugn ) , drugn ( e.g. , drugn , drugn ) .
false
drugn may interact with druga ( drugn type ) , drugn ( e.g. , drugn , drugn , drugn , drugb , drugn , drugn ) , drugn , drugn , drugn ( e.g. , drugn ) , other drugn , drugn supplements , drugn , drugn ( e.g. , drugn - drugn ) , drugn ( e.g. , drugn , drugn ) .
false
drugn may interact with druga ( drugn type ) , drugn ( e.g. , drugn , drugn , drugn , drugn , drugb , drugn ) , drugn , drugn , drugn ( e.g. , drugn ) , other drugn , drugn supplements , drugn , drugn ( e.g. , drugn - drugn ) , drugn ( e.g. , drugn , drugn ) .
false
drugn may interact with druga ( drugn type ) , drugn ( e.g. , drugn , drugn , drugn , drugn , drugn , drugb ) , drugn , drugn , drugn ( e.g. , drugn ) , other drugn , drugn supplements , drugn , drugn ( e.g. , drugn - drugn ) , drugn ( e.g. , drugn , drugn ) .
false
drugn may interact with druga ( drugn type ) , drugn ( e.g. , drugn , drugn , drugn , drugn , drugn , drugn ) , drugb , drugn , drugn ( e.g. , drugn ) , other drugn , drugn supplements , drugn , drugn ( e.g. , drugn - drugn ) , drugn ( e.g. , drugn , drugn ) .
false
drugn may interact with druga ( drugn type ) , drugn ( e.g. , drugn , drugn , drugn , drugn , drugn , drugn ) , drugn , drugb , drugn ( e.g. , drugn ) , other drugn , drugn supplements , drugn , drugn ( e.g. , drugn - drugn ) , drugn ( e.g. , drugn , drugn ) .
false
drugn may interact with druga ( drugn type ) , drugn ( e.g. , drugn , drugn , drugn , drugn , drugn , drugn ) , drugn , drugn , drugb ( e.g. , drugn ) , other drugn , drugn supplements , drugn , drugn ( e.g. , drugn - drugn ) , drugn ( e.g. , drugn , drugn ) .
false
drugn may interact with druga ( drugn type ) , drugn ( e.g. , drugn , drugn , drugn , drugn , drugn , drugn ) , drugn , drugn , drugn ( e.g. , drugb ) , other drugn , drugn supplements , drugn , drugn ( e.g. , drugn - drugn ) , drugn ( e.g. , drugn , drugn ) .
false
drugn may interact with druga ( drugn type ) , drugn ( e.g. , drugn , drugn , drugn , drugn , drugn , drugn ) , drugn , drugn , drugn ( e.g. , drugn ) , other drugb , drugn supplements , drugn , drugn ( e.g. , drugn - drugn ) , drugn ( e.g. , drugn , drugn ) .
false
drugn may interact with druga ( drugn type ) , drugn ( e.g. , drugn , drugn , drugn , drugn , drugn , drugn ) , drugn , drugn , drugn ( e.g. , drugn ) , other drugn , drugb supplements , drugn , drugn ( e.g. , drugn - drugn ) , drugn ( e.g. , drugn , drugn ) .
false
drugn may interact with druga ( drugn type ) , drugn ( e.g. , drugn , drugn , drugn , drugn , drugn , drugn ) , drugn , drugn , drugn ( e.g. , drugn ) , other drugn , drugn supplements , drugb , drugn ( e.g. , drugn - drugn ) , drugn ( e.g. , drugn , drugn ) .
false
drugn may interact with druga ( drugn type ) , drugn ( e.g. , drugn , drugn , drugn , drugn , drugn , drugn ) , drugn , drugn , drugn ( e.g. , drugn ) , other drugn , drugn supplements , drugn , drugb ( e.g. , drugn - drugn ) , drugn ( e.g. , drugn , drugn ) .
false
drugn may interact with druga ( drugn type ) , drugn ( e.g. , drugn , drugn , drugn , drugn , drugn , drugn ) , drugn , drugn , drugn ( e.g. , drugn ) , other drugn , drugn supplements , drugn , drugn ( e.g. , drugb - drugn ) , drugn ( e.g. , drugn , drugn ) .
false
drugn may interact with druga ( drugn type ) , drugn ( e.g. , drugn , drugn , drugn , drugn , drugn , drugn ) , drugn , drugn , drugn ( e.g. , drugn ) , other drugn , drugn supplements , drugn , drugn ( e.g. , drugn - drugb ) , drugn ( e.g. , drugn , drugn ) .
false
drugn may interact with druga ( drugn type ) , drugn ( e.g. , drugn , drugn , drugn , drugn , drugn , drugn ) , drugn , drugn , drugn ( e.g. , drugn ) , other drugn , drugn supplements , drugn , drugn ( e.g. , drugn - drugn ) , drugb ( e.g. , drugn , drugn ) .
false
drugn may interact with druga ( drugn type ) , drugn ( e.g. , drugn , drugn , drugn , drugn , drugn , drugn ) , drugn , drugn , drugn ( e.g. , drugn ) , other drugn , drugn supplements , drugn , drugn ( e.g. , drugn - drugn ) , drugn ( e.g. , drugb , drugn ) .
false
drugn may interact with druga ( drugn type ) , drugn ( e.g. , drugn , drugn , drugn , drugn , drugn , drugn ) , drugn , drugn , drugn ( e.g. , drugn ) , other drugn , drugn supplements , drugn , drugn ( e.g. , drugn - drugn ) , drugn ( e.g. , drugn , drugb ) .
false
drugn may interact with drugn ( druga type ) , drugb ( e.g. , drugn , drugn , drugn , drugn , drugn , drugn ) , drugn , drugn , drugn ( e.g. , drugn ) , other drugn , drugn supplements , drugn , drugn ( e.g. , drugn - drugn ) , drugn ( e.g. , drugn , drugn ) .
false
drugn may interact with drugn ( druga type ) , drugn ( e.g. , drugb , drugn , drugn , drugn , drugn , drugn ) , drugn , drugn , drugn ( e.g. , drugn ) , other drugn , drugn supplements , drugn , drugn ( e.g. , drugn - drugn ) , drugn ( e.g. , drugn , drugn ) .
false
drugn may interact with drugn ( druga type ) , drugn ( e.g. , drugn , drugb , drugn , drugn , drugn , drugn ) , drugn , drugn , drugn ( e.g. , drugn ) , other drugn , drugn supplements , drugn , drugn ( e.g. , drugn - drugn ) , drugn ( e.g. , drugn , drugn ) .
false
drugn may interact with drugn ( druga type ) , drugn ( e.g. , drugn , drugn , drugb , drugn , drugn , drugn ) , drugn , drugn , drugn ( e.g. , drugn ) , other drugn , drugn supplements , drugn , drugn ( e.g. , drugn - drugn ) , drugn ( e.g. , drugn , drugn ) .
false
drugn may interact with drugn ( druga type ) , drugn ( e.g. , drugn , drugn , drugn , drugb , drugn , drugn ) , drugn , drugn , drugn ( e.g. , drugn ) , other drugn , drugn supplements , drugn , drugn ( e.g. , drugn - drugn ) , drugn ( e.g. , drugn , drugn ) .
false
drugn may interact with drugn ( druga type ) , drugn ( e.g. , drugn , drugn , drugn , drugn , drugb , drugn ) , drugn , drugn , drugn ( e.g. , drugn ) , other drugn , drugn supplements , drugn , drugn ( e.g. , drugn - drugn ) , drugn ( e.g. , drugn , drugn ) .
false
drugn may interact with drugn ( druga type ) , drugn ( e.g. , drugn , drugn , drugn , drugn , drugn , drugb ) , drugn , drugn , drugn ( e.g. , drugn ) , other drugn , drugn supplements , drugn , drugn ( e.g. , drugn - drugn ) , drugn ( e.g. , drugn , drugn ) .
false
drugn may interact with drugn ( druga type ) , drugn ( e.g. , drugn , drugn , drugn , drugn , drugn , drugn ) , drugb , drugn , drugn ( e.g. , drugn ) , other drugn , drugn supplements , drugn , drugn ( e.g. , drugn - drugn ) , drugn ( e.g. , drugn , drugn ) .
false
drugn may interact with drugn ( druga type ) , drugn ( e.g. , drugn , drugn , drugn , drugn , drugn , drugn ) , drugn , drugb , drugn ( e.g. , drugn ) , other drugn , drugn supplements , drugn , drugn ( e.g. , drugn - drugn ) , drugn ( e.g. , drugn , drugn ) .
false
drugn may interact with drugn ( druga type ) , drugn ( e.g. , drugn , drugn , drugn , drugn , drugn , drugn ) , drugn , drugn , drugb ( e.g. , drugn ) , other drugn , drugn supplements , drugn , drugn ( e.g. , drugn - drugn ) , drugn ( e.g. , drugn , drugn ) .
false
drugn may interact with drugn ( druga type ) , drugn ( e.g. , drugn , drugn , drugn , drugn , drugn , drugn ) , drugn , drugn , drugn ( e.g. , drugb ) , other drugn , drugn supplements , drugn , drugn ( e.g. , drugn - drugn ) , drugn ( e.g. , drugn , drugn ) .
false
drugn may interact with drugn ( druga type ) , drugn ( e.g. , drugn , drugn , drugn , drugn , drugn , drugn ) , drugn , drugn , drugn ( e.g. , drugn ) , other drugb , drugn supplements , drugn , drugn ( e.g. , drugn - drugn ) , drugn ( e.g. , drugn , drugn ) .
false
drugn may interact with drugn ( druga type ) , drugn ( e.g. , drugn , drugn , drugn , drugn , drugn , drugn ) , drugn , drugn , drugn ( e.g. , drugn ) , other drugn , drugb supplements , drugn , drugn ( e.g. , drugn - drugn ) , drugn ( e.g. , drugn , drugn ) .
false
drugn may interact with drugn ( druga type ) , drugn ( e.g. , drugn , drugn , drugn , drugn , drugn , drugn ) , drugn , drugn , drugn ( e.g. , drugn ) , other drugn , drugn supplements , drugb , drugn ( e.g. , drugn - drugn ) , drugn ( e.g. , drugn , drugn ) .
false
drugn may interact with drugn ( druga type ) , drugn ( e.g. , drugn , drugn , drugn , drugn , drugn , drugn ) , drugn , drugn , drugn ( e.g. , drugn ) , other drugn , drugn supplements , drugn , drugb ( e.g. , drugn - drugn ) , drugn ( e.g. , drugn , drugn ) .
false
drugn may interact with drugn ( druga type ) , drugn ( e.g. , drugn , drugn , drugn , drugn , drugn , drugn ) , drugn , drugn , drugn ( e.g. , drugn ) , other drugn , drugn supplements , drugn , drugn ( e.g. , drugb - drugn ) , drugn ( e.g. , drugn , drugn ) .
false
drugn may interact with drugn ( druga type ) , drugn ( e.g. , drugn , drugn , drugn , drugn , drugn , drugn ) , drugn , drugn , drugn ( e.g. , drugn ) , other drugn , drugn supplements , drugn , drugn ( e.g. , drugn - drugb ) , drugn ( e.g. , drugn , drugn ) .
false
drugn may interact with drugn ( druga type ) , drugn ( e.g. , drugn , drugn , drugn , drugn , drugn , drugn ) , drugn , drugn , drugn ( e.g. , drugn ) , other drugn , drugn supplements , drugn , drugn ( e.g. , drugn - drugn ) , drugb ( e.g. , drugn , drugn ) .
false
drugn may interact with drugn ( druga type ) , drugn ( e.g. , drugn , drugn , drugn , drugn , drugn , drugn ) , drugn , drugn , drugn ( e.g. , drugn ) , other drugn , drugn supplements , drugn , drugn ( e.g. , drugn - drugn ) , drugn ( e.g. , drugb , drugn ) .
false
drugn may interact with drugn ( druga type ) , drugn ( e.g. , drugn , drugn , drugn , drugn , drugn , drugn ) , drugn , drugn , drugn ( e.g. , drugn ) , other drugn , drugn supplements , drugn , drugn ( e.g. , drugn - drugn ) , drugn ( e.g. , drugn , drugb ) .
false
drugn may interact with drugn ( drugn type ) , druga ( e.g. , drugb , drugn , drugn , drugn , drugn , drugn ) , drugn , drugn , drugn ( e.g. , drugn ) , other drugn , drugn supplements , drugn , drugn ( e.g. , drugn - drugn ) , drugn ( e.g. , drugn , drugn ) .
false
drugn may interact with drugn ( drugn type ) , druga ( e.g. , drugn , drugb , drugn , drugn , drugn , drugn ) , drugn , drugn , drugn ( e.g. , drugn ) , other drugn , drugn supplements , drugn , drugn ( e.g. , drugn - drugn ) , drugn ( e.g. , drugn , drugn ) .
false
drugn may interact with drugn ( drugn type ) , druga ( e.g. , drugn , drugn , drugb , drugn , drugn , drugn ) , drugn , drugn , drugn ( e.g. , drugn ) , other drugn , drugn supplements , drugn , drugn ( e.g. , drugn - drugn ) , drugn ( e.g. , drugn , drugn ) .
false
drugn may interact with drugn ( drugn type ) , druga ( e.g. , drugn , drugn , drugn , drugb , drugn , drugn ) , drugn , drugn , drugn ( e.g. , drugn ) , other drugn , drugn supplements , drugn , drugn ( e.g. , drugn - drugn ) , drugn ( e.g. , drugn , drugn ) .
false
drugn may interact with drugn ( drugn type ) , druga ( e.g. , drugn , drugn , drugn , drugn , drugb , drugn ) , drugn , drugn , drugn ( e.g. , drugn ) , other drugn , drugn supplements , drugn , drugn ( e.g. , drugn - drugn ) , drugn ( e.g. , drugn , drugn ) .
false
drugn may interact with drugn ( drugn type ) , druga ( e.g. , drugn , drugn , drugn , drugn , drugn , drugb ) , drugn , drugn , drugn ( e.g. , drugn ) , other drugn , drugn supplements , drugn , drugn ( e.g. , drugn - drugn ) , drugn ( e.g. , drugn , drugn ) .
false
drugn may interact with drugn ( drugn type ) , druga ( e.g. , drugn , drugn , drugn , drugn , drugn , drugn ) , drugb , drugn , drugn ( e.g. , drugn ) , other drugn , drugn supplements , drugn , drugn ( e.g. , drugn - drugn ) , drugn ( e.g. , drugn , drugn ) .
false
drugn may interact with drugn ( drugn type ) , druga ( e.g. , drugn , drugn , drugn , drugn , drugn , drugn ) , drugn , drugb , drugn ( e.g. , drugn ) , other drugn , drugn supplements , drugn , drugn ( e.g. , drugn - drugn ) , drugn ( e.g. , drugn , drugn ) .
false
drugn may interact with drugn ( drugn type ) , druga ( e.g. , drugn , drugn , drugn , drugn , drugn , drugn ) , drugn , drugn , drugb ( e.g. , drugn ) , other drugn , drugn supplements , drugn , drugn ( e.g. , drugn - drugn ) , drugn ( e.g. , drugn , drugn ) .
false
drugn may interact with drugn ( drugn type ) , druga ( e.g. , drugn , drugn , drugn , drugn , drugn , drugn ) , drugn , drugn , drugn ( e.g. , drugb ) , other drugn , drugn supplements , drugn , drugn ( e.g. , drugn - drugn ) , drugn ( e.g. , drugn , drugn ) .
false
drugn may interact with drugn ( drugn type ) , druga ( e.g. , drugn , drugn , drugn , drugn , drugn , drugn ) , drugn , drugn , drugn ( e.g. , drugn ) , other drugb , drugn supplements , drugn , drugn ( e.g. , drugn - drugn ) , drugn ( e.g. , drugn , drugn ) .
false
drugn may interact with drugn ( drugn type ) , druga ( e.g. , drugn , drugn , drugn , drugn , drugn , drugn ) , drugn , drugn , drugn ( e.g. , drugn ) , other drugn , drugb supplements , drugn , drugn ( e.g. , drugn - drugn ) , drugn ( e.g. , drugn , drugn ) .
false
drugn may interact with drugn ( drugn type ) , druga ( e.g. , drugn , drugn , drugn , drugn , drugn , drugn ) , drugn , drugn , drugn ( e.g. , drugn ) , other drugn , drugn supplements , drugb , drugn ( e.g. , drugn - drugn ) , drugn ( e.g. , drugn , drugn ) .
false
drugn may interact with drugn ( drugn type ) , druga ( e.g. , drugn , drugn , drugn , drugn , drugn , drugn ) , drugn , drugn , drugn ( e.g. , drugn ) , other drugn , drugn supplements , drugn , drugb ( e.g. , drugn - drugn ) , drugn ( e.g. , drugn , drugn ) .
false
drugn may interact with drugn ( drugn type ) , druga ( e.g. , drugn , drugn , drugn , drugn , drugn , drugn ) , drugn , drugn , drugn ( e.g. , drugn ) , other drugn , drugn supplements , drugn , drugn ( e.g. , drugb - drugn ) , drugn ( e.g. , drugn , drugn ) .
false
drugn may interact with drugn ( drugn type ) , druga ( e.g. , drugn , drugn , drugn , drugn , drugn , drugn ) , drugn , drugn , drugn ( e.g. , drugn ) , other drugn , drugn supplements , drugn , drugn ( e.g. , drugn - drugb ) , drugn ( e.g. , drugn , drugn ) .
false
drugn may interact with drugn ( drugn type ) , druga ( e.g. , drugn , drugn , drugn , drugn , drugn , drugn ) , drugn , drugn , drugn ( e.g. , drugn ) , other drugn , drugn supplements , drugn , drugn ( e.g. , drugn - drugn ) , drugb ( e.g. , drugn , drugn ) .
false
drugn may interact with drugn ( drugn type ) , druga ( e.g. , drugn , drugn , drugn , drugn , drugn , drugn ) , drugn , drugn , drugn ( e.g. , drugn ) , other drugn , drugn supplements , drugn , drugn ( e.g. , drugn - drugn ) , drugn ( e.g. , drugb , drugn ) .
false
drugn may interact with drugn ( drugn type ) , druga ( e.g. , drugn , drugn , drugn , drugn , drugn , drugn ) , drugn , drugn , drugn ( e.g. , drugn ) , other drugn , drugn supplements , drugn , drugn ( e.g. , drugn - drugn ) , drugn ( e.g. , drugn , drugb ) .
false
drugn may interact with drugn ( drugn type ) , drugn ( e.g. , druga , drugb , drugn , drugn , drugn , drugn ) , drugn , drugn , drugn ( e.g. , drugn ) , other drugn , drugn supplements , drugn , drugn ( e.g. , drugn - drugn ) , drugn ( e.g. , drugn , drugn ) .
false
drugn may interact with drugn ( drugn type ) , drugn ( e.g. , druga , drugn , drugb , drugn , drugn , drugn ) , drugn , drugn , drugn ( e.g. , drugn ) , other drugn , drugn supplements , drugn , drugn ( e.g. , drugn - drugn ) , drugn ( e.g. , drugn , drugn ) .
false
drugn may interact with drugn ( drugn type ) , drugn ( e.g. , druga , drugn , drugn , drugb , drugn , drugn ) , drugn , drugn , drugn ( e.g. , drugn ) , other drugn , drugn supplements , drugn , drugn ( e.g. , drugn - drugn ) , drugn ( e.g. , drugn , drugn ) .
false
drugn may interact with drugn ( drugn type ) , drugn ( e.g. , druga , drugn , drugn , drugn , drugb , drugn ) , drugn , drugn , drugn ( e.g. , drugn ) , other drugn , drugn supplements , drugn , drugn ( e.g. , drugn - drugn ) , drugn ( e.g. , drugn , drugn ) .
false
drugn may interact with drugn ( drugn type ) , drugn ( e.g. , druga , drugn , drugn , drugn , drugn , drugb ) , drugn , drugn , drugn ( e.g. , drugn ) , other drugn , drugn supplements , drugn , drugn ( e.g. , drugn - drugn ) , drugn ( e.g. , drugn , drugn ) .
false
drugn may interact with drugn ( drugn type ) , drugn ( e.g. , druga , drugn , drugn , drugn , drugn , drugn ) , drugb , drugn , drugn ( e.g. , drugn ) , other drugn , drugn supplements , drugn , drugn ( e.g. , drugn - drugn ) , drugn ( e.g. , drugn , drugn ) .
false
drugn may interact with drugn ( drugn type ) , drugn ( e.g. , druga , drugn , drugn , drugn , drugn , drugn ) , drugn , drugb , drugn ( e.g. , drugn ) , other drugn , drugn supplements , drugn , drugn ( e.g. , drugn - drugn ) , drugn ( e.g. , drugn , drugn ) .
false
drugn may interact with drugn ( drugn type ) , drugn ( e.g. , druga , drugn , drugn , drugn , drugn , drugn ) , drugn , drugn , drugb ( e.g. , drugn ) , other drugn , drugn supplements , drugn , drugn ( e.g. , drugn - drugn ) , drugn ( e.g. , drugn , drugn ) .
false
drugn may interact with drugn ( drugn type ) , drugn ( e.g. , druga , drugn , drugn , drugn , drugn , drugn ) , drugn , drugn , drugn ( e.g. , drugb ) , other drugn , drugn supplements , drugn , drugn ( e.g. , drugn - drugn ) , drugn ( e.g. , drugn , drugn ) .
false
drugn may interact with drugn ( drugn type ) , drugn ( e.g. , druga , drugn , drugn , drugn , drugn , drugn ) , drugn , drugn , drugn ( e.g. , drugn ) , other drugb , drugn supplements , drugn , drugn ( e.g. , drugn - drugn ) , drugn ( e.g. , drugn , drugn ) .
false
drugn may interact with drugn ( drugn type ) , drugn ( e.g. , druga , drugn , drugn , drugn , drugn , drugn ) , drugn , drugn , drugn ( e.g. , drugn ) , other drugn , drugb supplements , drugn , drugn ( e.g. , drugn - drugn ) , drugn ( e.g. , drugn , drugn ) .
false
drugn may interact with drugn ( drugn type ) , drugn ( e.g. , druga , drugn , drugn , drugn , drugn , drugn ) , drugn , drugn , drugn ( e.g. , drugn ) , other drugn , drugn supplements , drugb , drugn ( e.g. , drugn - drugn ) , drugn ( e.g. , drugn , drugn ) .
false
drugn may interact with drugn ( drugn type ) , drugn ( e.g. , druga , drugn , drugn , drugn , drugn , drugn ) , drugn , drugn , drugn ( e.g. , drugn ) , other drugn , drugn supplements , drugn , drugb ( e.g. , drugn - drugn ) , drugn ( e.g. , drugn , drugn ) .
false
drugn may interact with drugn ( drugn type ) , drugn ( e.g. , druga , drugn , drugn , drugn , drugn , drugn ) , drugn , drugn , drugn ( e.g. , drugn ) , other drugn , drugn supplements , drugn , drugn ( e.g. , drugb - drugn ) , drugn ( e.g. , drugn , drugn ) .
false
drugn may interact with drugn ( drugn type ) , drugn ( e.g. , druga , drugn , drugn , drugn , drugn , drugn ) , drugn , drugn , drugn ( e.g. , drugn ) , other drugn , drugn supplements , drugn , drugn ( e.g. , drugn - drugb ) , drugn ( e.g. , drugn , drugn ) .
false
drugn may interact with drugn ( drugn type ) , drugn ( e.g. , druga , drugn , drugn , drugn , drugn , drugn ) , drugn , drugn , drugn ( e.g. , drugn ) , other drugn , drugn supplements , drugn , drugn ( e.g. , drugn - drugn ) , drugb ( e.g. , drugn , drugn ) .
false
drugn may interact with drugn ( drugn type ) , drugn ( e.g. , druga , drugn , drugn , drugn , drugn , drugn ) , drugn , drugn , drugn ( e.g. , drugn ) , other drugn , drugn supplements , drugn , drugn ( e.g. , drugn - drugn ) , drugn ( e.g. , drugb , drugn ) .
false
drugn may interact with drugn ( drugn type ) , drugn ( e.g. , druga , drugn , drugn , drugn , drugn , drugn ) , drugn , drugn , drugn ( e.g. , drugn ) , other drugn , drugn supplements , drugn , drugn ( e.g. , drugn - drugn ) , drugn ( e.g. , drugn , drugb ) .
false
drugn may interact with drugn ( drugn type ) , drugn ( e.g. , drugn , druga , drugb , drugn , drugn , drugn ) , drugn , drugn , drugn ( e.g. , drugn ) , other drugn , drugn supplements , drugn , drugn ( e.g. , drugn - drugn ) , drugn ( e.g. , drugn , drugn ) .
false
drugn may interact with drugn ( drugn type ) , drugn ( e.g. , drugn , druga , drugn , drugb , drugn , drugn ) , drugn , drugn , drugn ( e.g. , drugn ) , other drugn , drugn supplements , drugn , drugn ( e.g. , drugn - drugn ) , drugn ( e.g. , drugn , drugn ) .
false
drugn may interact with drugn ( drugn type ) , drugn ( e.g. , drugn , druga , drugn , drugn , drugb , drugn ) , drugn , drugn , drugn ( e.g. , drugn ) , other drugn , drugn supplements , drugn , drugn ( e.g. , drugn - drugn ) , drugn ( e.g. , drugn , drugn ) .
false
drugn may interact with drugn ( drugn type ) , drugn ( e.g. , drugn , druga , drugn , drugn , drugn , drugb ) , drugn , drugn , drugn ( e.g. , drugn ) , other drugn , drugn supplements , drugn , drugn ( e.g. , drugn - drugn ) , drugn ( e.g. , drugn , drugn ) .
false
drugn may interact with drugn ( drugn type ) , drugn ( e.g. , drugn , druga , drugn , drugn , drugn , drugn ) , drugb , drugn , drugn ( e.g. , drugn ) , other drugn , drugn supplements , drugn , drugn ( e.g. , drugn - drugn ) , drugn ( e.g. , drugn , drugn ) .
false
drugn may interact with drugn ( drugn type ) , drugn ( e.g. , drugn , druga , drugn , drugn , drugn , drugn ) , drugn , drugb , drugn ( e.g. , drugn ) , other drugn , drugn supplements , drugn , drugn ( e.g. , drugn - drugn ) , drugn ( e.g. , drugn , drugn ) .
false
drugn may interact with drugn ( drugn type ) , drugn ( e.g. , drugn , druga , drugn , drugn , drugn , drugn ) , drugn , drugn , drugb ( e.g. , drugn ) , other drugn , drugn supplements , drugn , drugn ( e.g. , drugn - drugn ) , drugn ( e.g. , drugn , drugn ) .
false
drugn may interact with drugn ( drugn type ) , drugn ( e.g. , drugn , druga , drugn , drugn , drugn , drugn ) , drugn , drugn , drugn ( e.g. , drugb ) , other drugn , drugn supplements , drugn , drugn ( e.g. , drugn - drugn ) , drugn ( e.g. , drugn , drugn ) .
false
drugn may interact with drugn ( drugn type ) , drugn ( e.g. , drugn , druga , drugn , drugn , drugn , drugn ) , drugn , drugn , drugn ( e.g. , drugn ) , other drugb , drugn supplements , drugn , drugn ( e.g. , drugn - drugn ) , drugn ( e.g. , drugn , drugn ) .
false
drugn may interact with drugn ( drugn type ) , drugn ( e.g. , drugn , druga , drugn , drugn , drugn , drugn ) , drugn , drugn , drugn ( e.g. , drugn ) , other drugn , drugb supplements , drugn , drugn ( e.g. , drugn - drugn ) , drugn ( e.g. , drugn , drugn ) .
false
drugn may interact with drugn ( drugn type ) , drugn ( e.g. , drugn , druga , drugn , drugn , drugn , drugn ) , drugn , drugn , drugn ( e.g. , drugn ) , other drugn , drugn supplements , drugb , drugn ( e.g. , drugn - drugn ) , drugn ( e.g. , drugn , drugn ) .
false
drugn may interact with drugn ( drugn type ) , drugn ( e.g. , drugn , druga , drugn , drugn , drugn , drugn ) , drugn , drugn , drugn ( e.g. , drugn ) , other drugn , drugn supplements , drugn , drugb ( e.g. , drugn - drugn ) , drugn ( e.g. , drugn , drugn ) .
false
drugn may interact with drugn ( drugn type ) , drugn ( e.g. , drugn , druga , drugn , drugn , drugn , drugn ) , drugn , drugn , drugn ( e.g. , drugn ) , other drugn , drugn supplements , drugn , drugn ( e.g. , drugb - drugn ) , drugn ( e.g. , drugn , drugn ) .
false
drugn may interact with drugn ( drugn type ) , drugn ( e.g. , drugn , druga , drugn , drugn , drugn , drugn ) , drugn , drugn , drugn ( e.g. , drugn ) , other drugn , drugn supplements , drugn , drugn ( e.g. , drugn - drugb ) , drugn ( e.g. , drugn , drugn ) .
false
drugn may interact with drugn ( drugn type ) , drugn ( e.g. , drugn , druga , drugn , drugn , drugn , drugn ) , drugn , drugn , drugn ( e.g. , drugn ) , other drugn , drugn supplements , drugn , drugn ( e.g. , drugn - drugn ) , drugb ( e.g. , drugn , drugn ) .
false
drugn may interact with drugn ( drugn type ) , drugn ( e.g. , drugn , druga , drugn , drugn , drugn , drugn ) , drugn , drugn , drugn ( e.g. , drugn ) , other drugn , drugn supplements , drugn , drugn ( e.g. , drugn - drugn ) , drugn ( e.g. , drugb , drugn ) .
false
drugn may interact with drugn ( drugn type ) , drugn ( e.g. , drugn , druga , drugn , drugn , drugn , drugn ) , drugn , drugn , drugn ( e.g. , drugn ) , other drugn , drugn supplements , drugn , drugn ( e.g. , drugn - drugn ) , drugn ( e.g. , drugn , drugb ) .
false
drugn may interact with drugn ( drugn type ) , drugn ( e.g. , drugn , drugn , druga , drugb , drugn , drugn ) , drugn , drugn , drugn ( e.g. , drugn ) , other drugn , drugn supplements , drugn , drugn ( e.g. , drugn - drugn ) , drugn ( e.g. , drugn , drugn ) .
false
drugn may interact with drugn ( drugn type ) , drugn ( e.g. , drugn , drugn , druga , drugn , drugb , drugn ) , drugn , drugn , drugn ( e.g. , drugn ) , other drugn , drugn supplements , drugn , drugn ( e.g. , drugn - drugn ) , drugn ( e.g. , drugn , drugn ) .
false
drugn may interact with drugn ( drugn type ) , drugn ( e.g. , drugn , drugn , druga , drugn , drugn , drugb ) , drugn , drugn , drugn ( e.g. , drugn ) , other drugn , drugn supplements , drugn , drugn ( e.g. , drugn - drugn ) , drugn ( e.g. , drugn , drugn ) .
false
drugn may interact with drugn ( drugn type ) , drugn ( e.g. , drugn , drugn , druga , drugn , drugn , drugn ) , drugb , drugn , drugn ( e.g. , drugn ) , other drugn , drugn supplements , drugn , drugn ( e.g. , drugn - drugn ) , drugn ( e.g. , drugn , drugn ) .
false
drugn may interact with drugn ( drugn type ) , drugn ( e.g. , drugn , drugn , druga , drugn , drugn , drugn ) , drugn , drugb , drugn ( e.g. , drugn ) , other drugn , drugn supplements , drugn , drugn ( e.g. , drugn - drugn ) , drugn ( e.g. , drugn , drugn ) .
false
drugn may interact with drugn ( drugn type ) , drugn ( e.g. , drugn , drugn , druga , drugn , drugn , drugn ) , drugn , drugn , drugb ( e.g. , drugn ) , other drugn , drugn supplements , drugn , drugn ( e.g. , drugn - drugn ) , drugn ( e.g. , drugn , drugn ) .
false
drugn may interact with drugn ( drugn type ) , drugn ( e.g. , drugn , drugn , druga , drugn , drugn , drugn ) , drugn , drugn , drugn ( e.g. , drugb ) , other drugn , drugn supplements , drugn , drugn ( e.g. , drugn - drugn ) , drugn ( e.g. , drugn , drugn ) .
false
drugn may interact with drugn ( drugn type ) , drugn ( e.g. , drugn , drugn , druga , drugn , drugn , drugn ) , drugn , drugn , drugn ( e.g. , drugn ) , other drugb , drugn supplements , drugn , drugn ( e.g. , drugn - drugn ) , drugn ( e.g. , drugn , drugn ) .
false
drugn may interact with drugn ( drugn type ) , drugn ( e.g. , drugn , drugn , druga , drugn , drugn , drugn ) , drugn , drugn , drugn ( e.g. , drugn ) , other drugn , drugb supplements , drugn , drugn ( e.g. , drugn - drugn ) , drugn ( e.g. , drugn , drugn ) .
false
drugn may interact with drugn ( drugn type ) , drugn ( e.g. , drugn , drugn , druga , drugn , drugn , drugn ) , drugn , drugn , drugn ( e.g. , drugn ) , other drugn , drugn supplements , drugb , drugn ( e.g. , drugn - drugn ) , drugn ( e.g. , drugn , drugn ) .
false
drugn may interact with drugn ( drugn type ) , drugn ( e.g. , drugn , drugn , druga , drugn , drugn , drugn ) , drugn , drugn , drugn ( e.g. , drugn ) , other drugn , drugn supplements , drugn , drugb ( e.g. , drugn - drugn ) , drugn ( e.g. , drugn , drugn ) .
false
drugn may interact with drugn ( drugn type ) , drugn ( e.g. , drugn , drugn , druga , drugn , drugn , drugn ) , drugn , drugn , drugn ( e.g. , drugn ) , other drugn , drugn supplements , drugn , drugn ( e.g. , drugb - drugn ) , drugn ( e.g. , drugn , drugn ) .
false
drugn may interact with drugn ( drugn type ) , drugn ( e.g. , drugn , drugn , druga , drugn , drugn , drugn ) , drugn , drugn , drugn ( e.g. , drugn ) , other drugn , drugn supplements , drugn , drugn ( e.g. , drugn - drugb ) , drugn ( e.g. , drugn , drugn ) .
false
drugn may interact with drugn ( drugn type ) , drugn ( e.g. , drugn , drugn , druga , drugn , drugn , drugn ) , drugn , drugn , drugn ( e.g. , drugn ) , other drugn , drugn supplements , drugn , drugn ( e.g. , drugn - drugn ) , drugb ( e.g. , drugn , drugn ) .
false
drugn may interact with drugn ( drugn type ) , drugn ( e.g. , drugn , drugn , druga , drugn , drugn , drugn ) , drugn , drugn , drugn ( e.g. , drugn ) , other drugn , drugn supplements , drugn , drugn ( e.g. , drugn - drugn ) , drugn ( e.g. , drugb , drugn ) .
false
drugn may interact with drugn ( drugn type ) , drugn ( e.g. , drugn , drugn , druga , drugn , drugn , drugn ) , drugn , drugn , drugn ( e.g. , drugn ) , other drugn , drugn supplements , drugn , drugn ( e.g. , drugn - drugn ) , drugn ( e.g. , drugn , drugb ) .
false
drugn may interact with drugn ( drugn type ) , drugn ( e.g. , drugn , drugn , drugn , druga , drugb , drugn ) , drugn , drugn , drugn ( e.g. , drugn ) , other drugn , drugn supplements , drugn , drugn ( e.g. , drugn - drugn ) , drugn ( e.g. , drugn , drugn ) .
false
drugn may interact with drugn ( drugn type ) , drugn ( e.g. , drugn , drugn , drugn , druga , drugn , drugb ) , drugn , drugn , drugn ( e.g. , drugn ) , other drugn , drugn supplements , drugn , drugn ( e.g. , drugn - drugn ) , drugn ( e.g. , drugn , drugn ) .
false
drugn may interact with drugn ( drugn type ) , drugn ( e.g. , drugn , drugn , drugn , druga , drugn , drugn ) , drugb , drugn , drugn ( e.g. , drugn ) , other drugn , drugn supplements , drugn , drugn ( e.g. , drugn - drugn ) , drugn ( e.g. , drugn , drugn ) .
false
drugn may interact with drugn ( drugn type ) , drugn ( e.g. , drugn , drugn , drugn , druga , drugn , drugn ) , drugn , drugb , drugn ( e.g. , drugn ) , other drugn , drugn supplements , drugn , drugn ( e.g. , drugn - drugn ) , drugn ( e.g. , drugn , drugn ) .
false
drugn may interact with drugn ( drugn type ) , drugn ( e.g. , drugn , drugn , drugn , druga , drugn , drugn ) , drugn , drugn , drugb ( e.g. , drugn ) , other drugn , drugn supplements , drugn , drugn ( e.g. , drugn - drugn ) , drugn ( e.g. , drugn , drugn ) .
false
drugn may interact with drugn ( drugn type ) , drugn ( e.g. , drugn , drugn , drugn , druga , drugn , drugn ) , drugn , drugn , drugn ( e.g. , drugb ) , other drugn , drugn supplements , drugn , drugn ( e.g. , drugn - drugn ) , drugn ( e.g. , drugn , drugn ) .
false
drugn may interact with drugn ( drugn type ) , drugn ( e.g. , drugn , drugn , drugn , druga , drugn , drugn ) , drugn , drugn , drugn ( e.g. , drugn ) , other drugb , drugn supplements , drugn , drugn ( e.g. , drugn - drugn ) , drugn ( e.g. , drugn , drugn ) .
false
drugn may interact with drugn ( drugn type ) , drugn ( e.g. , drugn , drugn , drugn , druga , drugn , drugn ) , drugn , drugn , drugn ( e.g. , drugn ) , other drugn , drugb supplements , drugn , drugn ( e.g. , drugn - drugn ) , drugn ( e.g. , drugn , drugn ) .
false
drugn may interact with drugn ( drugn type ) , drugn ( e.g. , drugn , drugn , drugn , druga , drugn , drugn ) , drugn , drugn , drugn ( e.g. , drugn ) , other drugn , drugn supplements , drugb , drugn ( e.g. , drugn - drugn ) , drugn ( e.g. , drugn , drugn ) .
false
drugn may interact with drugn ( drugn type ) , drugn ( e.g. , drugn , drugn , drugn , druga , drugn , drugn ) , drugn , drugn , drugn ( e.g. , drugn ) , other drugn , drugn supplements , drugn , drugb ( e.g. , drugn - drugn ) , drugn ( e.g. , drugn , drugn ) .
false
drugn may interact with drugn ( drugn type ) , drugn ( e.g. , drugn , drugn , drugn , druga , drugn , drugn ) , drugn , drugn , drugn ( e.g. , drugn ) , other drugn , drugn supplements , drugn , drugn ( e.g. , drugb - drugn ) , drugn ( e.g. , drugn , drugn ) .
false
drugn may interact with drugn ( drugn type ) , drugn ( e.g. , drugn , drugn , drugn , druga , drugn , drugn ) , drugn , drugn , drugn ( e.g. , drugn ) , other drugn , drugn supplements , drugn , drugn ( e.g. , drugn - drugb ) , drugn ( e.g. , drugn , drugn ) .
false
drugn may interact with drugn ( drugn type ) , drugn ( e.g. , drugn , drugn , drugn , druga , drugn , drugn ) , drugn , drugn , drugn ( e.g. , drugn ) , other drugn , drugn supplements , drugn , drugn ( e.g. , drugn - drugn ) , drugb ( e.g. , drugn , drugn ) .
false
drugn may interact with drugn ( drugn type ) , drugn ( e.g. , drugn , drugn , drugn , druga , drugn , drugn ) , drugn , drugn , drugn ( e.g. , drugn ) , other drugn , drugn supplements , drugn , drugn ( e.g. , drugn - drugn ) , drugn ( e.g. , drugb , drugn ) .
false
drugn may interact with drugn ( drugn type ) , drugn ( e.g. , drugn , drugn , drugn , druga , drugn , drugn ) , drugn , drugn , drugn ( e.g. , drugn ) , other drugn , drugn supplements , drugn , drugn ( e.g. , drugn - drugn ) , drugn ( e.g. , drugn , drugb ) .
false
drugn may interact with drugn ( drugn type ) , drugn ( e.g. , drugn , drugn , drugn , drugn , druga , drugb ) , drugn , drugn , drugn ( e.g. , drugn ) , other drugn , drugn supplements , drugn , drugn ( e.g. , drugn - drugn ) , drugn ( e.g. , drugn , drugn ) .
false
drugn may interact with drugn ( drugn type ) , drugn ( e.g. , drugn , drugn , drugn , drugn , druga , drugn ) , drugb , drugn , drugn ( e.g. , drugn ) , other drugn , drugn supplements , drugn , drugn ( e.g. , drugn - drugn ) , drugn ( e.g. , drugn , drugn ) .
false
drugn may interact with drugn ( drugn type ) , drugn ( e.g. , drugn , drugn , drugn , drugn , druga , drugn ) , drugn , drugb , drugn ( e.g. , drugn ) , other drugn , drugn supplements , drugn , drugn ( e.g. , drugn - drugn ) , drugn ( e.g. , drugn , drugn ) .
false
drugn may interact with drugn ( drugn type ) , drugn ( e.g. , drugn , drugn , drugn , drugn , druga , drugn ) , drugn , drugn , drugb ( e.g. , drugn ) , other drugn , drugn supplements , drugn , drugn ( e.g. , drugn - drugn ) , drugn ( e.g. , drugn , drugn ) .
false
drugn may interact with drugn ( drugn type ) , drugn ( e.g. , drugn , drugn , drugn , drugn , druga , drugn ) , drugn , drugn , drugn ( e.g. , drugb ) , other drugn , drugn supplements , drugn , drugn ( e.g. , drugn - drugn ) , drugn ( e.g. , drugn , drugn ) .
false
drugn may interact with drugn ( drugn type ) , drugn ( e.g. , drugn , drugn , drugn , drugn , druga , drugn ) , drugn , drugn , drugn ( e.g. , drugn ) , other drugb , drugn supplements , drugn , drugn ( e.g. , drugn - drugn ) , drugn ( e.g. , drugn , drugn ) .
false
drugn may interact with drugn ( drugn type ) , drugn ( e.g. , drugn , drugn , drugn , drugn , druga , drugn ) , drugn , drugn , drugn ( e.g. , drugn ) , other drugn , drugb supplements , drugn , drugn ( e.g. , drugn - drugn ) , drugn ( e.g. , drugn , drugn ) .
false
drugn may interact with drugn ( drugn type ) , drugn ( e.g. , drugn , drugn , drugn , drugn , druga , drugn ) , drugn , drugn , drugn ( e.g. , drugn ) , other drugn , drugn supplements , drugb , drugn ( e.g. , drugn - drugn ) , drugn ( e.g. , drugn , drugn ) .
false
drugn may interact with drugn ( drugn type ) , drugn ( e.g. , drugn , drugn , drugn , drugn , druga , drugn ) , drugn , drugn , drugn ( e.g. , drugn ) , other drugn , drugn supplements , drugn , drugb ( e.g. , drugn - drugn ) , drugn ( e.g. , drugn , drugn ) .
false
drugn may interact with drugn ( drugn type ) , drugn ( e.g. , drugn , drugn , drugn , drugn , druga , drugn ) , drugn , drugn , drugn ( e.g. , drugn ) , other drugn , drugn supplements , drugn , drugn ( e.g. , drugb - drugn ) , drugn ( e.g. , drugn , drugn ) .
false
drugn may interact with drugn ( drugn type ) , drugn ( e.g. , drugn , drugn , drugn , drugn , druga , drugn ) , drugn , drugn , drugn ( e.g. , drugn ) , other drugn , drugn supplements , drugn , drugn ( e.g. , drugn - drugb ) , drugn ( e.g. , drugn , drugn ) .
false
drugn may interact with drugn ( drugn type ) , drugn ( e.g. , drugn , drugn , drugn , drugn , druga , drugn ) , drugn , drugn , drugn ( e.g. , drugn ) , other drugn , drugn supplements , drugn , drugn ( e.g. , drugn - drugn ) , drugb ( e.g. , drugn , drugn ) .
false
drugn may interact with drugn ( drugn type ) , drugn ( e.g. , drugn , drugn , drugn , drugn , druga , drugn ) , drugn , drugn , drugn ( e.g. , drugn ) , other drugn , drugn supplements , drugn , drugn ( e.g. , drugn - drugn ) , drugn ( e.g. , drugb , drugn ) .
false
drugn may interact with drugn ( drugn type ) , drugn ( e.g. , drugn , drugn , drugn , drugn , druga , drugn ) , drugn , drugn , drugn ( e.g. , drugn ) , other drugn , drugn supplements , drugn , drugn ( e.g. , drugn - drugn ) , drugn ( e.g. , drugn , drugb ) .
false
drugn may interact with drugn ( drugn type ) , drugn ( e.g. , drugn , drugn , drugn , drugn , drugn , druga ) , drugb , drugn , drugn ( e.g. , drugn ) , other drugn , drugn supplements , drugn , drugn ( e.g. , drugn - drugn ) , drugn ( e.g. , drugn , drugn ) .
false
drugn may interact with drugn ( drugn type ) , drugn ( e.g. , drugn , drugn , drugn , drugn , drugn , druga ) , drugn , drugb , drugn ( e.g. , drugn ) , other drugn , drugn supplements , drugn , drugn ( e.g. , drugn - drugn ) , drugn ( e.g. , drugn , drugn ) .
false
drugn may interact with drugn ( drugn type ) , drugn ( e.g. , drugn , drugn , drugn , drugn , drugn , druga ) , drugn , drugn , drugb ( e.g. , drugn ) , other drugn , drugn supplements , drugn , drugn ( e.g. , drugn - drugn ) , drugn ( e.g. , drugn , drugn ) .
false
drugn may interact with drugn ( drugn type ) , drugn ( e.g. , drugn , drugn , drugn , drugn , drugn , druga ) , drugn , drugn , drugn ( e.g. , drugb ) , other drugn , drugn supplements , drugn , drugn ( e.g. , drugn - drugn ) , drugn ( e.g. , drugn , drugn ) .
false
drugn may interact with drugn ( drugn type ) , drugn ( e.g. , drugn , drugn , drugn , drugn , drugn , druga ) , drugn , drugn , drugn ( e.g. , drugn ) , other drugb , drugn supplements , drugn , drugn ( e.g. , drugn - drugn ) , drugn ( e.g. , drugn , drugn ) .
false
drugn may interact with drugn ( drugn type ) , drugn ( e.g. , drugn , drugn , drugn , drugn , drugn , druga ) , drugn , drugn , drugn ( e.g. , drugn ) , other drugn , drugb supplements , drugn , drugn ( e.g. , drugn - drugn ) , drugn ( e.g. , drugn , drugn ) .
false
drugn may interact with drugn ( drugn type ) , drugn ( e.g. , drugn , drugn , drugn , drugn , drugn , druga ) , drugn , drugn , drugn ( e.g. , drugn ) , other drugn , drugn supplements , drugb , drugn ( e.g. , drugn - drugn ) , drugn ( e.g. , drugn , drugn ) .
false
drugn may interact with drugn ( drugn type ) , drugn ( e.g. , drugn , drugn , drugn , drugn , drugn , druga ) , drugn , drugn , drugn ( e.g. , drugn ) , other drugn , drugn supplements , drugn , drugb ( e.g. , drugn - drugn ) , drugn ( e.g. , drugn , drugn ) .
false
drugn may interact with drugn ( drugn type ) , drugn ( e.g. , drugn , drugn , drugn , drugn , drugn , druga ) , drugn , drugn , drugn ( e.g. , drugn ) , other drugn , drugn supplements , drugn , drugn ( e.g. , drugb - drugn ) , drugn ( e.g. , drugn , drugn ) .
false
drugn may interact with drugn ( drugn type ) , drugn ( e.g. , drugn , drugn , drugn , drugn , drugn , druga ) , drugn , drugn , drugn ( e.g. , drugn ) , other drugn , drugn supplements , drugn , drugn ( e.g. , drugn - drugb ) , drugn ( e.g. , drugn , drugn ) .
false
drugn may interact with drugn ( drugn type ) , drugn ( e.g. , drugn , drugn , drugn , drugn , drugn , druga ) , drugn , drugn , drugn ( e.g. , drugn ) , other drugn , drugn supplements , drugn , drugn ( e.g. , drugn - drugn ) , drugb ( e.g. , drugn , drugn ) .
false
drugn may interact with drugn ( drugn type ) , drugn ( e.g. , drugn , drugn , drugn , drugn , drugn , druga ) , drugn , drugn , drugn ( e.g. , drugn ) , other drugn , drugn supplements , drugn , drugn ( e.g. , drugn - drugn ) , drugn ( e.g. , drugb , drugn ) .
false
drugn may interact with drugn ( drugn type ) , drugn ( e.g. , drugn , drugn , drugn , drugn , drugn , druga ) , drugn , drugn , drugn ( e.g. , drugn ) , other drugn , drugn supplements , drugn , drugn ( e.g. , drugn - drugn ) , drugn ( e.g. , drugn , drugb ) .
false
drugn may interact with drugn ( drugn type ) , drugn ( e.g. , drugn , drugn , drugn , drugn , drugn , drugn ) , druga , drugb , drugn ( e.g. , drugn ) , other drugn , drugn supplements , drugn , drugn ( e.g. , drugn - drugn ) , drugn ( e.g. , drugn , drugn ) .
false
drugn may interact with drugn ( drugn type ) , drugn ( e.g. , drugn , drugn , drugn , drugn , drugn , drugn ) , druga , drugn , drugb ( e.g. , drugn ) , other drugn , drugn supplements , drugn , drugn ( e.g. , drugn - drugn ) , drugn ( e.g. , drugn , drugn ) .
false
drugn may interact with drugn ( drugn type ) , drugn ( e.g. , drugn , drugn , drugn , drugn , drugn , drugn ) , druga , drugn , drugn ( e.g. , drugb ) , other drugn , drugn supplements , drugn , drugn ( e.g. , drugn - drugn ) , drugn ( e.g. , drugn , drugn ) .
false
drugn may interact with drugn ( drugn type ) , drugn ( e.g. , drugn , drugn , drugn , drugn , drugn , drugn ) , druga , drugn , drugn ( e.g. , drugn ) , other drugb , drugn supplements , drugn , drugn ( e.g. , drugn - drugn ) , drugn ( e.g. , drugn , drugn ) .
false
drugn may interact with drugn ( drugn type ) , drugn ( e.g. , drugn , drugn , drugn , drugn , drugn , drugn ) , druga , drugn , drugn ( e.g. , drugn ) , other drugn , drugb supplements , drugn , drugn ( e.g. , drugn - drugn ) , drugn ( e.g. , drugn , drugn ) .
false
drugn may interact with drugn ( drugn type ) , drugn ( e.g. , drugn , drugn , drugn , drugn , drugn , drugn ) , druga , drugn , drugn ( e.g. , drugn ) , other drugn , drugn supplements , drugb , drugn ( e.g. , drugn - drugn ) , drugn ( e.g. , drugn , drugn ) .
false
drugn may interact with drugn ( drugn type ) , drugn ( e.g. , drugn , drugn , drugn , drugn , drugn , drugn ) , druga , drugn , drugn ( e.g. , drugn ) , other drugn , drugn supplements , drugn , drugb ( e.g. , drugn - drugn ) , drugn ( e.g. , drugn , drugn ) .
false
drugn may interact with drugn ( drugn type ) , drugn ( e.g. , drugn , drugn , drugn , drugn , drugn , drugn ) , druga , drugn , drugn ( e.g. , drugn ) , other drugn , drugn supplements , drugn , drugn ( e.g. , drugb - drugn ) , drugn ( e.g. , drugn , drugn ) .
false
drugn may interact with drugn ( drugn type ) , drugn ( e.g. , drugn , drugn , drugn , drugn , drugn , drugn ) , druga , drugn , drugn ( e.g. , drugn ) , other drugn , drugn supplements , drugn , drugn ( e.g. , drugn - drugb ) , drugn ( e.g. , drugn , drugn ) .
false
drugn may interact with drugn ( drugn type ) , drugn ( e.g. , drugn , drugn , drugn , drugn , drugn , drugn ) , druga , drugn , drugn ( e.g. , drugn ) , other drugn , drugn supplements , drugn , drugn ( e.g. , drugn - drugn ) , drugb ( e.g. , drugn , drugn ) .
false
drugn may interact with drugn ( drugn type ) , drugn ( e.g. , drugn , drugn , drugn , drugn , drugn , drugn ) , druga , drugn , drugn ( e.g. , drugn ) , other drugn , drugn supplements , drugn , drugn ( e.g. , drugn - drugn ) , drugn ( e.g. , drugb , drugn ) .
false
drugn may interact with drugn ( drugn type ) , drugn ( e.g. , drugn , drugn , drugn , drugn , drugn , drugn ) , druga , drugn , drugn ( e.g. , drugn ) , other drugn , drugn supplements , drugn , drugn ( e.g. , drugn - drugn ) , drugn ( e.g. , drugn , drugb ) .
false
drugn may interact with drugn ( drugn type ) , drugn ( e.g. , drugn , drugn , drugn , drugn , drugn , drugn ) , drugn , druga , drugb ( e.g. , drugn ) , other drugn , drugn supplements , drugn , drugn ( e.g. , drugn - drugn ) , drugn ( e.g. , drugn , drugn ) .
false
drugn may interact with drugn ( drugn type ) , drugn ( e.g. , drugn , drugn , drugn , drugn , drugn , drugn ) , drugn , druga , drugn ( e.g. , drugb ) , other drugn , drugn supplements , drugn , drugn ( e.g. , drugn - drugn ) , drugn ( e.g. , drugn , drugn ) .
false
drugn may interact with drugn ( drugn type ) , drugn ( e.g. , drugn , drugn , drugn , drugn , drugn , drugn ) , drugn , druga , drugn ( e.g. , drugn ) , other drugb , drugn supplements , drugn , drugn ( e.g. , drugn - drugn ) , drugn ( e.g. , drugn , drugn ) .
false
drugn may interact with drugn ( drugn type ) , drugn ( e.g. , drugn , drugn , drugn , drugn , drugn , drugn ) , drugn , druga , drugn ( e.g. , drugn ) , other drugn , drugb supplements , drugn , drugn ( e.g. , drugn - drugn ) , drugn ( e.g. , drugn , drugn ) .
false
drugn may interact with drugn ( drugn type ) , drugn ( e.g. , drugn , drugn , drugn , drugn , drugn , drugn ) , drugn , druga , drugn ( e.g. , drugn ) , other drugn , drugn supplements , drugb , drugn ( e.g. , drugn - drugn ) , drugn ( e.g. , drugn , drugn ) .
false
drugn may interact with drugn ( drugn type ) , drugn ( e.g. , drugn , drugn , drugn , drugn , drugn , drugn ) , drugn , druga , drugn ( e.g. , drugn ) , other drugn , drugn supplements , drugn , drugb ( e.g. , drugn - drugn ) , drugn ( e.g. , drugn , drugn ) .
false
drugn may interact with drugn ( drugn type ) , drugn ( e.g. , drugn , drugn , drugn , drugn , drugn , drugn ) , drugn , druga , drugn ( e.g. , drugn ) , other drugn , drugn supplements , drugn , drugn ( e.g. , drugb - drugn ) , drugn ( e.g. , drugn , drugn ) .
false
drugn may interact with drugn ( drugn type ) , drugn ( e.g. , drugn , drugn , drugn , drugn , drugn , drugn ) , drugn , druga , drugn ( e.g. , drugn ) , other drugn , drugn supplements , drugn , drugn ( e.g. , drugn - drugb ) , drugn ( e.g. , drugn , drugn ) .
false
drugn may interact with drugn ( drugn type ) , drugn ( e.g. , drugn , drugn , drugn , drugn , drugn , drugn ) , drugn , druga , drugn ( e.g. , drugn ) , other drugn , drugn supplements , drugn , drugn ( e.g. , drugn - drugn ) , drugb ( e.g. , drugn , drugn ) .
false
drugn may interact with drugn ( drugn type ) , drugn ( e.g. , drugn , drugn , drugn , drugn , drugn , drugn ) , drugn , druga , drugn ( e.g. , drugn ) , other drugn , drugn supplements , drugn , drugn ( e.g. , drugn - drugn ) , drugn ( e.g. , drugb , drugn ) .
false
drugn may interact with drugn ( drugn type ) , drugn ( e.g. , drugn , drugn , drugn , drugn , drugn , drugn ) , drugn , druga , drugn ( e.g. , drugn ) , other drugn , drugn supplements , drugn , drugn ( e.g. , drugn - drugn ) , drugn ( e.g. , drugn , drugb ) .
false
drugn may interact with drugn ( drugn type ) , drugn ( e.g. , drugn , drugn , drugn , drugn , drugn , drugn ) , drugn , drugn , druga ( e.g. , drugb ) , other drugn , drugn supplements , drugn , drugn ( e.g. , drugn - drugn ) , drugn ( e.g. , drugn , drugn ) .
false
drugn may interact with drugn ( drugn type ) , drugn ( e.g. , drugn , drugn , drugn , drugn , drugn , drugn ) , drugn , drugn , druga ( e.g. , drugn ) , other drugb , drugn supplements , drugn , drugn ( e.g. , drugn - drugn ) , drugn ( e.g. , drugn , drugn ) .
false
drugn may interact with drugn ( drugn type ) , drugn ( e.g. , drugn , drugn , drugn , drugn , drugn , drugn ) , drugn , drugn , druga ( e.g. , drugn ) , other drugn , drugb supplements , drugn , drugn ( e.g. , drugn - drugn ) , drugn ( e.g. , drugn , drugn ) .
false
drugn may interact with drugn ( drugn type ) , drugn ( e.g. , drugn , drugn , drugn , drugn , drugn , drugn ) , drugn , drugn , druga ( e.g. , drugn ) , other drugn , drugn supplements , drugb , drugn ( e.g. , drugn - drugn ) , drugn ( e.g. , drugn , drugn ) .
false
drugn may interact with drugn ( drugn type ) , drugn ( e.g. , drugn , drugn , drugn , drugn , drugn , drugn ) , drugn , drugn , druga ( e.g. , drugn ) , other drugn , drugn supplements , drugn , drugb ( e.g. , drugn - drugn ) , drugn ( e.g. , drugn , drugn ) .
false
drugn may interact with drugn ( drugn type ) , drugn ( e.g. , drugn , drugn , drugn , drugn , drugn , drugn ) , drugn , drugn , druga ( e.g. , drugn ) , other drugn , drugn supplements , drugn , drugn ( e.g. , drugb - drugn ) , drugn ( e.g. , drugn , drugn ) .
false
drugn may interact with drugn ( drugn type ) , drugn ( e.g. , drugn , drugn , drugn , drugn , drugn , drugn ) , drugn , drugn , druga ( e.g. , drugn ) , other drugn , drugn supplements , drugn , drugn ( e.g. , drugn - drugb ) , drugn ( e.g. , drugn , drugn ) .
false
drugn may interact with drugn ( drugn type ) , drugn ( e.g. , drugn , drugn , drugn , drugn , drugn , drugn ) , drugn , drugn , druga ( e.g. , drugn ) , other drugn , drugn supplements , drugn , drugn ( e.g. , drugn - drugn ) , drugb ( e.g. , drugn , drugn ) .
false
drugn may interact with drugn ( drugn type ) , drugn ( e.g. , drugn , drugn , drugn , drugn , drugn , drugn ) , drugn , drugn , druga ( e.g. , drugn ) , other drugn , drugn supplements , drugn , drugn ( e.g. , drugn - drugn ) , drugn ( e.g. , drugb , drugn ) .
false
drugn may interact with drugn ( drugn type ) , drugn ( e.g. , drugn , drugn , drugn , drugn , drugn , drugn ) , drugn , drugn , druga ( e.g. , drugn ) , other drugn , drugn supplements , drugn , drugn ( e.g. , drugn - drugn ) , drugn ( e.g. , drugn , drugb ) .
false
drugn may interact with drugn ( drugn type ) , drugn ( e.g. , drugn , drugn , drugn , drugn , drugn , drugn ) , drugn , drugn , drugn ( e.g. , druga ) , other drugb , drugn supplements , drugn , drugn ( e.g. , drugn - drugn ) , drugn ( e.g. , drugn , drugn ) .
false
drugn may interact with drugn ( drugn type ) , drugn ( e.g. , drugn , drugn , drugn , drugn , drugn , drugn ) , drugn , drugn , drugn ( e.g. , druga ) , other drugn , drugb supplements , drugn , drugn ( e.g. , drugn - drugn ) , drugn ( e.g. , drugn , drugn ) .
false
drugn may interact with drugn ( drugn type ) , drugn ( e.g. , drugn , drugn , drugn , drugn , drugn , drugn ) , drugn , drugn , drugn ( e.g. , druga ) , other drugn , drugn supplements , drugb , drugn ( e.g. , drugn - drugn ) , drugn ( e.g. , drugn , drugn ) .
false
drugn may interact with drugn ( drugn type ) , drugn ( e.g. , drugn , drugn , drugn , drugn , drugn , drugn ) , drugn , drugn , drugn ( e.g. , druga ) , other drugn , drugn supplements , drugn , drugb ( e.g. , drugn - drugn ) , drugn ( e.g. , drugn , drugn ) .
false
drugn may interact with drugn ( drugn type ) , drugn ( e.g. , drugn , drugn , drugn , drugn , drugn , drugn ) , drugn , drugn , drugn ( e.g. , druga ) , other drugn , drugn supplements , drugn , drugn ( e.g. , drugb - drugn ) , drugn ( e.g. , drugn , drugn ) .
false
drugn may interact with drugn ( drugn type ) , drugn ( e.g. , drugn , drugn , drugn , drugn , drugn , drugn ) , drugn , drugn , drugn ( e.g. , druga ) , other drugn , drugn supplements , drugn , drugn ( e.g. , drugn - drugb ) , drugn ( e.g. , drugn , drugn ) .
false
drugn may interact with drugn ( drugn type ) , drugn ( e.g. , drugn , drugn , drugn , drugn , drugn , drugn ) , drugn , drugn , drugn ( e.g. , druga ) , other drugn , drugn supplements , drugn , drugn ( e.g. , drugn - drugn ) , drugb ( e.g. , drugn , drugn ) .
false
drugn may interact with drugn ( drugn type ) , drugn ( e.g. , drugn , drugn , drugn , drugn , drugn , drugn ) , drugn , drugn , drugn ( e.g. , druga ) , other drugn , drugn supplements , drugn , drugn ( e.g. , drugn - drugn ) , drugn ( e.g. , drugb , drugn ) .
false
drugn may interact with drugn ( drugn type ) , drugn ( e.g. , drugn , drugn , drugn , drugn , drugn , drugn ) , drugn , drugn , drugn ( e.g. , druga ) , other drugn , drugn supplements , drugn , drugn ( e.g. , drugn - drugn ) , drugn ( e.g. , drugn , drugb ) .
false
drugn may interact with drugn ( drugn type ) , drugn ( e.g. , drugn , drugn , drugn , drugn , drugn , drugn ) , drugn , drugn , drugn ( e.g. , drugn ) , other druga , drugb supplements , drugn , drugn ( e.g. , drugn - drugn ) , drugn ( e.g. , drugn , drugn ) .
false
drugn may interact with drugn ( drugn type ) , drugn ( e.g. , drugn , drugn , drugn , drugn , drugn , drugn ) , drugn , drugn , drugn ( e.g. , drugn ) , other druga , drugn supplements , drugb , drugn ( e.g. , drugn - drugn ) , drugn ( e.g. , drugn , drugn ) .
false
drugn may interact with drugn ( drugn type ) , drugn ( e.g. , drugn , drugn , drugn , drugn , drugn , drugn ) , drugn , drugn , drugn ( e.g. , drugn ) , other druga , drugn supplements , drugn , drugb ( e.g. , drugn - drugn ) , drugn ( e.g. , drugn , drugn ) .
false
drugn may interact with drugn ( drugn type ) , drugn ( e.g. , drugn , drugn , drugn , drugn , drugn , drugn ) , drugn , drugn , drugn ( e.g. , drugn ) , other druga , drugn supplements , drugn , drugn ( e.g. , drugb - drugn ) , drugn ( e.g. , drugn , drugn ) .
false
drugn may interact with drugn ( drugn type ) , drugn ( e.g. , drugn , drugn , drugn , drugn , drugn , drugn ) , drugn , drugn , drugn ( e.g. , drugn ) , other druga , drugn supplements , drugn , drugn ( e.g. , drugn - drugb ) , drugn ( e.g. , drugn , drugn ) .
false
drugn may interact with drugn ( drugn type ) , drugn ( e.g. , drugn , drugn , drugn , drugn , drugn , drugn ) , drugn , drugn , drugn ( e.g. , drugn ) , other druga , drugn supplements , drugn , drugn ( e.g. , drugn - drugn ) , drugb ( e.g. , drugn , drugn ) .
false
drugn may interact with drugn ( drugn type ) , drugn ( e.g. , drugn , drugn , drugn , drugn , drugn , drugn ) , drugn , drugn , drugn ( e.g. , drugn ) , other druga , drugn supplements , drugn , drugn ( e.g. , drugn - drugn ) , drugn ( e.g. , drugb , drugn ) .
false
drugn may interact with drugn ( drugn type ) , drugn ( e.g. , drugn , drugn , drugn , drugn , drugn , drugn ) , drugn , drugn , drugn ( e.g. , drugn ) , other druga , drugn supplements , drugn , drugn ( e.g. , drugn - drugn ) , drugn ( e.g. , drugn , drugb ) .
false
drugn may interact with drugn ( drugn type ) , drugn ( e.g. , drugn , drugn , drugn , drugn , drugn , drugn ) , drugn , drugn , drugn ( e.g. , drugn ) , other drugn , druga supplements , drugb , drugn ( e.g. , drugn - drugn ) , drugn ( e.g. , drugn , drugn ) .
false
drugn may interact with drugn ( drugn type ) , drugn ( e.g. , drugn , drugn , drugn , drugn , drugn , drugn ) , drugn , drugn , drugn ( e.g. , drugn ) , other drugn , druga supplements , drugn , drugb ( e.g. , drugn - drugn ) , drugn ( e.g. , drugn , drugn ) .
false
drugn may interact with drugn ( drugn type ) , drugn ( e.g. , drugn , drugn , drugn , drugn , drugn , drugn ) , drugn , drugn , drugn ( e.g. , drugn ) , other drugn , druga supplements , drugn , drugn ( e.g. , drugb - drugn ) , drugn ( e.g. , drugn , drugn ) .
false
drugn may interact with drugn ( drugn type ) , drugn ( e.g. , drugn , drugn , drugn , drugn , drugn , drugn ) , drugn , drugn , drugn ( e.g. , drugn ) , other drugn , druga supplements , drugn , drugn ( e.g. , drugn - drugb ) , drugn ( e.g. , drugn , drugn ) .
false
drugn may interact with drugn ( drugn type ) , drugn ( e.g. , drugn , drugn , drugn , drugn , drugn , drugn ) , drugn , drugn , drugn ( e.g. , drugn ) , other drugn , druga supplements , drugn , drugn ( e.g. , drugn - drugn ) , drugb ( e.g. , drugn , drugn ) .
false
drugn may interact with drugn ( drugn type ) , drugn ( e.g. , drugn , drugn , drugn , drugn , drugn , drugn ) , drugn , drugn , drugn ( e.g. , drugn ) , other drugn , druga supplements , drugn , drugn ( e.g. , drugn - drugn ) , drugn ( e.g. , drugb , drugn ) .
false
drugn may interact with drugn ( drugn type ) , drugn ( e.g. , drugn , drugn , drugn , drugn , drugn , drugn ) , drugn , drugn , drugn ( e.g. , drugn ) , other drugn , druga supplements , drugn , drugn ( e.g. , drugn - drugn ) , drugn ( e.g. , drugn , drugb ) .
false
drugn may interact with drugn ( drugn type ) , drugn ( e.g. , drugn , drugn , drugn , drugn , drugn , drugn ) , drugn , drugn , drugn ( e.g. , drugn ) , other drugn , drugn supplements , druga , drugb ( e.g. , drugn - drugn ) , drugn ( e.g. , drugn , drugn ) .
false
drugn may interact with drugn ( drugn type ) , drugn ( e.g. , drugn , drugn , drugn , drugn , drugn , drugn ) , drugn , drugn , drugn ( e.g. , drugn ) , other drugn , drugn supplements , druga , drugn ( e.g. , drugb - drugn ) , drugn ( e.g. , drugn , drugn ) .
false
drugn may interact with drugn ( drugn type ) , drugn ( e.g. , drugn , drugn , drugn , drugn , drugn , drugn ) , drugn , drugn , drugn ( e.g. , drugn ) , other drugn , drugn supplements , druga , drugn ( e.g. , drugn - drugb ) , drugn ( e.g. , drugn , drugn ) .
false
drugn may interact with drugn ( drugn type ) , drugn ( e.g. , drugn , drugn , drugn , drugn , drugn , drugn ) , drugn , drugn , drugn ( e.g. , drugn ) , other drugn , drugn supplements , druga , drugn ( e.g. , drugn - drugn ) , drugb ( e.g. , drugn , drugn ) .
false
drugn may interact with drugn ( drugn type ) , drugn ( e.g. , drugn , drugn , drugn , drugn , drugn , drugn ) , drugn , drugn , drugn ( e.g. , drugn ) , other drugn , drugn supplements , druga , drugn ( e.g. , drugn - drugn ) , drugn ( e.g. , drugb , drugn ) .
false
drugn may interact with drugn ( drugn type ) , drugn ( e.g. , drugn , drugn , drugn , drugn , drugn , drugn ) , drugn , drugn , drugn ( e.g. , drugn ) , other drugn , drugn supplements , druga , drugn ( e.g. , drugn - drugn ) , drugn ( e.g. , drugn , drugb ) .
false
drugn may interact with drugn ( drugn type ) , drugn ( e.g. , drugn , drugn , drugn , drugn , drugn , drugn ) , drugn , drugn , drugn ( e.g. , drugn ) , other drugn , drugn supplements , drugn , druga ( e.g. , drugb - drugn ) , drugn ( e.g. , drugn , drugn ) .
false
drugn may interact with drugn ( drugn type ) , drugn ( e.g. , drugn , drugn , drugn , drugn , drugn , drugn ) , drugn , drugn , drugn ( e.g. , drugn ) , other drugn , drugn supplements , drugn , druga ( e.g. , drugn - drugb ) , drugn ( e.g. , drugn , drugn ) .
false
drugn may interact with drugn ( drugn type ) , drugn ( e.g. , drugn , drugn , drugn , drugn , drugn , drugn ) , drugn , drugn , drugn ( e.g. , drugn ) , other drugn , drugn supplements , drugn , druga ( e.g. , drugn - drugn ) , drugb ( e.g. , drugn , drugn ) .
false
drugn may interact with drugn ( drugn type ) , drugn ( e.g. , drugn , drugn , drugn , drugn , drugn , drugn ) , drugn , drugn , drugn ( e.g. , drugn ) , other drugn , drugn supplements , drugn , druga ( e.g. , drugn - drugn ) , drugn ( e.g. , drugb , drugn ) .
false
drugn may interact with drugn ( drugn type ) , drugn ( e.g. , drugn , drugn , drugn , drugn , drugn , drugn ) , drugn , drugn , drugn ( e.g. , drugn ) , other drugn , drugn supplements , drugn , druga ( e.g. , drugn - drugn ) , drugn ( e.g. , drugn , drugb ) .
false
drugn may interact with drugn ( drugn type ) , drugn ( e.g. , drugn , drugn , drugn , drugn , drugn , drugn ) , drugn , drugn , drugn ( e.g. , drugn ) , other drugn , drugn supplements , drugn , drugn ( e.g. , druga - drugb ) , drugn ( e.g. , drugn , drugn ) .
false
drugn may interact with drugn ( drugn type ) , drugn ( e.g. , drugn , drugn , drugn , drugn , drugn , drugn ) , drugn , drugn , drugn ( e.g. , drugn ) , other drugn , drugn supplements , drugn , drugn ( e.g. , druga - drugn ) , drugb ( e.g. , drugn , drugn ) .
false
drugn may interact with drugn ( drugn type ) , drugn ( e.g. , drugn , drugn , drugn , drugn , drugn , drugn ) , drugn , drugn , drugn ( e.g. , drugn ) , other drugn , drugn supplements , drugn , drugn ( e.g. , druga - drugn ) , drugn ( e.g. , drugb , drugn ) .
false
drugn may interact with drugn ( drugn type ) , drugn ( e.g. , drugn , drugn , drugn , drugn , drugn , drugn ) , drugn , drugn , drugn ( e.g. , drugn ) , other drugn , drugn supplements , drugn , drugn ( e.g. , druga - drugn ) , drugn ( e.g. , drugn , drugb ) .
false
drugn may interact with drugn ( drugn type ) , drugn ( e.g. , drugn , drugn , drugn , drugn , drugn , drugn ) , drugn , drugn , drugn ( e.g. , drugn ) , other drugn , drugn supplements , drugn , drugn ( e.g. , drugn - druga ) , drugb ( e.g. , drugn , drugn ) .
false
drugn may interact with drugn ( drugn type ) , drugn ( e.g. , drugn , drugn , drugn , drugn , drugn , drugn ) , drugn , drugn , drugn ( e.g. , drugn ) , other drugn , drugn supplements , drugn , drugn ( e.g. , drugn - druga ) , drugn ( e.g. , drugb , drugn ) .
false
drugn may interact with drugn ( drugn type ) , drugn ( e.g. , drugn , drugn , drugn , drugn , drugn , drugn ) , drugn , drugn , drugn ( e.g. , drugn ) , other drugn , drugn supplements , drugn , drugn ( e.g. , drugn - druga ) , drugn ( e.g. , drugn , drugb ) .
false
drugn may interact with drugn ( drugn type ) , drugn ( e.g. , drugn , drugn , drugn , drugn , drugn , drugn ) , drugn , drugn , drugn ( e.g. , drugn ) , other drugn , drugn supplements , drugn , drugn ( e.g. , drugn - drugn ) , druga ( e.g. , drugb , drugn ) .
false
drugn may interact with drugn ( drugn type ) , drugn ( e.g. , drugn , drugn , drugn , drugn , drugn , drugn ) , drugn , drugn , drugn ( e.g. , drugn ) , other drugn , drugn supplements , drugn , drugn ( e.g. , drugn - drugn ) , druga ( e.g. , drugn , drugb ) .
false
drugn may interact with drugn ( drugn type ) , drugn ( e.g. , drugn , drugn , drugn , drugn , drugn , drugn ) , drugn , drugn , drugn ( e.g. , drugn ) , other drugn , drugn supplements , drugn , drugn ( e.g. , drugn - drugn ) , drugn ( e.g. , druga , drugb ) .
false
when administered concurrently , druga may increase the effects of oral drugb ;
effect
druga , particularly drugb , may cause serious cardiac arrhythmias during drugn anesthesia and therefore should be used only with great caution or not at all .
false
druga , particularly drugn , may cause serious cardiac arrhythmias during drugb anesthesia and therefore should be used only with great caution or not at all .
effect
drugn , particularly druga , may cause serious cardiac arrhythmias during drugb anesthesia and therefore should be used only with great caution or not at all .
effect
druga : the pressor effect of drugb is markedly potentiated in patients receiving drugn ( drugn ) .
false
druga : the pressor effect of drugn is markedly potentiated in patients receiving drugb ( drugn ) .
false
druga : the pressor effect of drugn is markedly potentiated in patients receiving drugn ( drugb ) .
false
drugn : the pressor effect of druga is markedly potentiated in patients receiving drugb ( drugn ) .
effect
drugn : the pressor effect of druga is markedly potentiated in patients receiving drugn ( drugb ) .
effect
drugn : the pressor effect of drugn is markedly potentiated in patients receiving druga ( drugb ) .
false
the pressor response of druga may also be potentiated by drugb .
effect
limited evidence suggests that druga may influence the intensity and duration of action of drugb .
mechanism
druga may be used with drugb , drugn and other drugn , and with other drugn .
false
druga may be used with drugn , drugb and other drugn , and with other drugn .
false
druga may be used with drugn , drugn and other drugb , and with other drugn .
false
druga may be used with drugn , drugn and other drugn , and with other drugb .
false
drugn may be used with druga , drugb and other drugn , and with other drugn .
false
drugn may be used with druga , drugn and other drugb , and with other drugn .
false
drugn may be used with druga , drugn and other drugn , and with other drugb .
false
drugn may be used with drugn , druga and other drugb , and with other drugn .
false
drugn may be used with drugn , druga and other drugn , and with other drugb .
false
drugn may be used with drugn , drugn and other druga , and with other drugb .
false
druga ( drugb ) should be administered until normal hematopoiesis is restored .
false
mild hepatotoxicity has been reported in some patients when druga and drugb were administered concomitantly .
effect
druga : prolongation of prothrombin time ( pt ) and international normalized ratio ( inr ) were observed in patients receiving drugb concomitantly with drugn .
false
druga : prolongation of prothrombin time ( pt ) and international normalized ratio ( inr ) were observed in patients receiving drugn concomitantly with drugb .
false
drugn : prolongation of prothrombin time ( pt ) and international normalized ratio ( inr ) were observed in patients receiving druga concomitantly with drugb .
effect
physicians should carefully monitor pt and inr in patients concurrently administered druga and drugb .
advise
other druga severe thrombocytopenia and gastrointestinal bleeding have been reported with concomitant use of drugb and other drugn ( e.g. , drugn ) .
false
other druga severe thrombocytopenia and gastrointestinal bleeding have been reported with concomitant use of drugn and other drugb ( e.g. , drugn ) .
false
other druga severe thrombocytopenia and gastrointestinal bleeding have been reported with concomitant use of drugn and other drugn ( e.g. , drugb ) .
false
other drugn severe thrombocytopenia and gastrointestinal bleeding have been reported with concomitant use of druga and other drugb ( e.g. , drugn ) .
effect
other drugn severe thrombocytopenia and gastrointestinal bleeding have been reported with concomitant use of druga and other drugn ( e.g. , drugb ) .
effect
other drugn severe thrombocytopenia and gastrointestinal bleeding have been reported with concomitant use of drugn and other druga ( e.g. , drugb ) .
false
a multiple dose drug-drug interaction study demonstrated that druga approximately doubled drugb auc0- . since drugn is partially metabolized by cyp3a and drugn le is known to be a strong inhibitor of cytochrome p450 3a enzyme , care should be taken while dosing drugn with drugn and other strong p450 3a inhibitors including drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn or drugn .
mechanism
a multiple dose drug-drug interaction study demonstrated that druga approximately doubled drugn auc0- . since drugb is partially metabolized by cyp3a and drugn le is known to be a strong inhibitor of cytochrome p450 3a enzyme , care should be taken while dosing drugn with drugn and other strong p450 3a inhibitors including drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn or drugn .
false
a multiple dose drug-drug interaction study demonstrated that druga approximately doubled drugn auc0- . since drugn is partially metabolized by cyp3a and drugb le is known to be a strong inhibitor of cytochrome p450 3a enzyme , care should be taken while dosing drugn with drugn and other strong p450 3a inhibitors including drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn or drugn .
false
a multiple dose drug-drug interaction study demonstrated that druga approximately doubled drugn auc0- . since drugn is partially metabolized by cyp3a and drugn le is known to be a strong inhibitor of cytochrome p450 3a enzyme , care should be taken while dosing drugb with drugn and other strong p450 3a inhibitors including drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn or drugn .
false
a multiple dose drug-drug interaction study demonstrated that druga approximately doubled drugn auc0- . since drugn is partially metabolized by cyp3a and drugn le is known to be a strong inhibitor of cytochrome p450 3a enzyme , care should be taken while dosing drugn with drugb and other strong p450 3a inhibitors including drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn or drugn .
false
a multiple dose drug-drug interaction study demonstrated that druga approximately doubled drugn auc0- . since drugn is partially metabolized by cyp3a and drugn le is known to be a strong inhibitor of cytochrome p450 3a enzyme , care should be taken while dosing drugn with drugn and other strong p450 3a inhibitors including drugb , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn or drugn .
false
a multiple dose drug-drug interaction study demonstrated that druga approximately doubled drugn auc0- . since drugn is partially metabolized by cyp3a and drugn le is known to be a strong inhibitor of cytochrome p450 3a enzyme , care should be taken while dosing drugn with drugn and other strong p450 3a inhibitors including drugn , drugb , drugn , drugn , drugn , drugn , drugn , drugn , drugn or drugn .
false
a multiple dose drug-drug interaction study demonstrated that druga approximately doubled drugn auc0- . since drugn is partially metabolized by cyp3a and drugn le is known to be a strong inhibitor of cytochrome p450 3a enzyme , care should be taken while dosing drugn with drugn and other strong p450 3a inhibitors including drugn , drugn , drugb , drugn , drugn , drugn , drugn , drugn , drugn or drugn .
false
a multiple dose drug-drug interaction study demonstrated that druga approximately doubled drugn auc0- . since drugn is partially metabolized by cyp3a and drugn le is known to be a strong inhibitor of cytochrome p450 3a enzyme , care should be taken while dosing drugn with drugn and other strong p450 3a inhibitors including drugn , drugn , drugn , drugb , drugn , drugn , drugn , drugn , drugn or drugn .
false
a multiple dose drug-drug interaction study demonstrated that druga approximately doubled drugn auc0- . since drugn is partially metabolized by cyp3a and drugn le is known to be a strong inhibitor of cytochrome p450 3a enzyme , care should be taken while dosing drugn with drugn and other strong p450 3a inhibitors including drugn , drugn , drugn , drugn , drugb , drugn , drugn , drugn , drugn or drugn .
false
a multiple dose drug-drug interaction study demonstrated that druga approximately doubled drugn auc0- . since drugn is partially metabolized by cyp3a and drugn le is known to be a strong inhibitor of cytochrome p450 3a enzyme , care should be taken while dosing drugn with drugn and other strong p450 3a inhibitors including drugn , drugn , drugn , drugn , drugn , drugb , drugn , drugn , drugn or drugn .
false
a multiple dose drug-drug interaction study demonstrated that druga approximately doubled drugn auc0- . since drugn is partially metabolized by cyp3a and drugn le is known to be a strong inhibitor of cytochrome p450 3a enzyme , care should be taken while dosing drugn with drugn and other strong p450 3a inhibitors including drugn , drugn , drugn , drugn , drugn , drugn , drugb , drugn , drugn or drugn .
false
a multiple dose drug-drug interaction study demonstrated that druga approximately doubled drugn auc0- . since drugn is partially metabolized by cyp3a and drugn le is known to be a strong inhibitor of cytochrome p450 3a enzyme , care should be taken while dosing drugn with drugn and other strong p450 3a inhibitors including drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugb , drugn or drugn .
false
a multiple dose drug-drug interaction study demonstrated that druga approximately doubled drugn auc0- . since drugn is partially metabolized by cyp3a and drugn le is known to be a strong inhibitor of cytochrome p450 3a enzyme , care should be taken while dosing drugn with drugn and other strong p450 3a inhibitors including drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugb or drugn .
false
a multiple dose drug-drug interaction study demonstrated that druga approximately doubled drugn auc0- . since drugn is partially metabolized by cyp3a and drugn le is known to be a strong inhibitor of cytochrome p450 3a enzyme , care should be taken while dosing drugn with drugn and other strong p450 3a inhibitors including drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn or drugb .
false
a multiple dose drug-drug interaction study demonstrated that drugn approximately doubled druga auc0- . since drugb is partially metabolized by cyp3a and drugn le is known to be a strong inhibitor of cytochrome p450 3a enzyme , care should be taken while dosing drugn with drugn and other strong p450 3a inhibitors including drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn or drugn .
false
a multiple dose drug-drug interaction study demonstrated that drugn approximately doubled druga auc0- . since drugn is partially metabolized by cyp3a and drugb le is known to be a strong inhibitor of cytochrome p450 3a enzyme , care should be taken while dosing drugn with drugn and other strong p450 3a inhibitors including drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn or drugn .
false
a multiple dose drug-drug interaction study demonstrated that drugn approximately doubled druga auc0- . since drugn is partially metabolized by cyp3a and drugn le is known to be a strong inhibitor of cytochrome p450 3a enzyme , care should be taken while dosing drugb with drugn and other strong p450 3a inhibitors including drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn or drugn .
false
a multiple dose drug-drug interaction study demonstrated that drugn approximately doubled druga auc0- . since drugn is partially metabolized by cyp3a and drugn le is known to be a strong inhibitor of cytochrome p450 3a enzyme , care should be taken while dosing drugn with drugb and other strong p450 3a inhibitors including drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn or drugn .
false
a multiple dose drug-drug interaction study demonstrated that drugn approximately doubled druga auc0- . since drugn is partially metabolized by cyp3a and drugn le is known to be a strong inhibitor of cytochrome p450 3a enzyme , care should be taken while dosing drugn with drugn and other strong p450 3a inhibitors including drugb , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn or drugn .
false
a multiple dose drug-drug interaction study demonstrated that drugn approximately doubled druga auc0- . since drugn is partially metabolized by cyp3a and drugn le is known to be a strong inhibitor of cytochrome p450 3a enzyme , care should be taken while dosing drugn with drugn and other strong p450 3a inhibitors including drugn , drugb , drugn , drugn , drugn , drugn , drugn , drugn , drugn or drugn .
false
a multiple dose drug-drug interaction study demonstrated that drugn approximately doubled druga auc0- . since drugn is partially metabolized by cyp3a and drugn le is known to be a strong inhibitor of cytochrome p450 3a enzyme , care should be taken while dosing drugn with drugn and other strong p450 3a inhibitors including drugn , drugn , drugb , drugn , drugn , drugn , drugn , drugn , drugn or drugn .
false
a multiple dose drug-drug interaction study demonstrated that drugn approximately doubled druga auc0- . since drugn is partially metabolized by cyp3a and drugn le is known to be a strong inhibitor of cytochrome p450 3a enzyme , care should be taken while dosing drugn with drugn and other strong p450 3a inhibitors including drugn , drugn , drugn , drugb , drugn , drugn , drugn , drugn , drugn or drugn .
false
a multiple dose drug-drug interaction study demonstrated that drugn approximately doubled druga auc0- . since drugn is partially metabolized by cyp3a and drugn le is known to be a strong inhibitor of cytochrome p450 3a enzyme , care should be taken while dosing drugn with drugn and other strong p450 3a inhibitors including drugn , drugn , drugn , drugn , drugb , drugn , drugn , drugn , drugn or drugn .
false
a multiple dose drug-drug interaction study demonstrated that drugn approximately doubled druga auc0- . since drugn is partially metabolized by cyp3a and drugn le is known to be a strong inhibitor of cytochrome p450 3a enzyme , care should be taken while dosing drugn with drugn and other strong p450 3a inhibitors including drugn , drugn , drugn , drugn , drugn , drugb , drugn , drugn , drugn or drugn .
false
a multiple dose drug-drug interaction study demonstrated that drugn approximately doubled druga auc0- . since drugn is partially metabolized by cyp3a and drugn le is known to be a strong inhibitor of cytochrome p450 3a enzyme , care should be taken while dosing drugn with drugn and other strong p450 3a inhibitors including drugn , drugn , drugn , drugn , drugn , drugn , drugb , drugn , drugn or drugn .
false
a multiple dose drug-drug interaction study demonstrated that drugn approximately doubled druga auc0- . since drugn is partially metabolized by cyp3a and drugn le is known to be a strong inhibitor of cytochrome p450 3a enzyme , care should be taken while dosing drugn with drugn and other strong p450 3a inhibitors including drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugb , drugn or drugn .
false
a multiple dose drug-drug interaction study demonstrated that drugn approximately doubled druga auc0- . since drugn is partially metabolized by cyp3a and drugn le is known to be a strong inhibitor of cytochrome p450 3a enzyme , care should be taken while dosing drugn with drugn and other strong p450 3a inhibitors including drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugb or drugn .
false
a multiple dose drug-drug interaction study demonstrated that drugn approximately doubled druga auc0- . since drugn is partially metabolized by cyp3a and drugn le is known to be a strong inhibitor of cytochrome p450 3a enzyme , care should be taken while dosing drugn with drugn and other strong p450 3a inhibitors including drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn or drugb .
false
a multiple dose drug-drug interaction study demonstrated that drugn approximately doubled drugn auc0- . since druga is partially metabolized by cyp3a and drugb le is known to be a strong inhibitor of cytochrome p450 3a enzyme , care should be taken while dosing drugn with drugn and other strong p450 3a inhibitors including drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn or drugn .
false
a multiple dose drug-drug interaction study demonstrated that drugn approximately doubled drugn auc0- . since druga is partially metabolized by cyp3a and drugn le is known to be a strong inhibitor of cytochrome p450 3a enzyme , care should be taken while dosing drugb with drugn and other strong p450 3a inhibitors including drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn or drugn .
false
a multiple dose drug-drug interaction study demonstrated that drugn approximately doubled drugn auc0- . since druga is partially metabolized by cyp3a and drugn le is known to be a strong inhibitor of cytochrome p450 3a enzyme , care should be taken while dosing drugn with drugb and other strong p450 3a inhibitors including drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn or drugn .
false
a multiple dose drug-drug interaction study demonstrated that drugn approximately doubled drugn auc0- . since druga is partially metabolized by cyp3a and drugn le is known to be a strong inhibitor of cytochrome p450 3a enzyme , care should be taken while dosing drugn with drugn and other strong p450 3a inhibitors including drugb , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn or drugn .
false
a multiple dose drug-drug interaction study demonstrated that drugn approximately doubled drugn auc0- . since druga is partially metabolized by cyp3a and drugn le is known to be a strong inhibitor of cytochrome p450 3a enzyme , care should be taken while dosing drugn with drugn and other strong p450 3a inhibitors including drugn , drugb , drugn , drugn , drugn , drugn , drugn , drugn , drugn or drugn .
false
a multiple dose drug-drug interaction study demonstrated that drugn approximately doubled drugn auc0- . since druga is partially metabolized by cyp3a and drugn le is known to be a strong inhibitor of cytochrome p450 3a enzyme , care should be taken while dosing drugn with drugn and other strong p450 3a inhibitors including drugn , drugn , drugb , drugn , drugn , drugn , drugn , drugn , drugn or drugn .
false
a multiple dose drug-drug interaction study demonstrated that drugn approximately doubled drugn auc0- . since druga is partially metabolized by cyp3a and drugn le is known to be a strong inhibitor of cytochrome p450 3a enzyme , care should be taken while dosing drugn with drugn and other strong p450 3a inhibitors including drugn , drugn , drugn , drugb , drugn , drugn , drugn , drugn , drugn or drugn .
false
a multiple dose drug-drug interaction study demonstrated that drugn approximately doubled drugn auc0- . since druga is partially metabolized by cyp3a and drugn le is known to be a strong inhibitor of cytochrome p450 3a enzyme , care should be taken while dosing drugn with drugn and other strong p450 3a inhibitors including drugn , drugn , drugn , drugn , drugb , drugn , drugn , drugn , drugn or drugn .
false
a multiple dose drug-drug interaction study demonstrated that drugn approximately doubled drugn auc0- . since druga is partially metabolized by cyp3a and drugn le is known to be a strong inhibitor of cytochrome p450 3a enzyme , care should be taken while dosing drugn with drugn and other strong p450 3a inhibitors including drugn , drugn , drugn , drugn , drugn , drugb , drugn , drugn , drugn or drugn .
false
a multiple dose drug-drug interaction study demonstrated that drugn approximately doubled drugn auc0- . since druga is partially metabolized by cyp3a and drugn le is known to be a strong inhibitor of cytochrome p450 3a enzyme , care should be taken while dosing drugn with drugn and other strong p450 3a inhibitors including drugn , drugn , drugn , drugn , drugn , drugn , drugb , drugn , drugn or drugn .
false
a multiple dose drug-drug interaction study demonstrated that drugn approximately doubled drugn auc0- . since druga is partially metabolized by cyp3a and drugn le is known to be a strong inhibitor of cytochrome p450 3a enzyme , care should be taken while dosing drugn with drugn and other strong p450 3a inhibitors including drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugb , drugn or drugn .
false
a multiple dose drug-drug interaction study demonstrated that drugn approximately doubled drugn auc0- . since druga is partially metabolized by cyp3a and drugn le is known to be a strong inhibitor of cytochrome p450 3a enzyme , care should be taken while dosing drugn with drugn and other strong p450 3a inhibitors including drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugb or drugn .
false
a multiple dose drug-drug interaction study demonstrated that drugn approximately doubled drugn auc0- . since druga is partially metabolized by cyp3a and drugn le is known to be a strong inhibitor of cytochrome p450 3a enzyme , care should be taken while dosing drugn with drugn and other strong p450 3a inhibitors including drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn or drugb .
false
a multiple dose drug-drug interaction study demonstrated that drugn approximately doubled drugn auc0- . since drugn is partially metabolized by cyp3a and druga le is known to be a strong inhibitor of cytochrome p450 3a enzyme , care should be taken while dosing drugb with drugn and other strong p450 3a inhibitors including drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn or drugn .
false
a multiple dose drug-drug interaction study demonstrated that drugn approximately doubled drugn auc0- . since drugn is partially metabolized by cyp3a and druga le is known to be a strong inhibitor of cytochrome p450 3a enzyme , care should be taken while dosing drugn with drugb and other strong p450 3a inhibitors including drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn or drugn .
false
a multiple dose drug-drug interaction study demonstrated that drugn approximately doubled drugn auc0- . since drugn is partially metabolized by cyp3a and druga le is known to be a strong inhibitor of cytochrome p450 3a enzyme , care should be taken while dosing drugn with drugn and other strong p450 3a inhibitors including drugb , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn or drugn .
false
a multiple dose drug-drug interaction study demonstrated that drugn approximately doubled drugn auc0- . since drugn is partially metabolized by cyp3a and druga le is known to be a strong inhibitor of cytochrome p450 3a enzyme , care should be taken while dosing drugn with drugn and other strong p450 3a inhibitors including drugn , drugb , drugn , drugn , drugn , drugn , drugn , drugn , drugn or drugn .
false
a multiple dose drug-drug interaction study demonstrated that drugn approximately doubled drugn auc0- . since drugn is partially metabolized by cyp3a and druga le is known to be a strong inhibitor of cytochrome p450 3a enzyme , care should be taken while dosing drugn with drugn and other strong p450 3a inhibitors including drugn , drugn , drugb , drugn , drugn , drugn , drugn , drugn , drugn or drugn .
false
a multiple dose drug-drug interaction study demonstrated that drugn approximately doubled drugn auc0- . since drugn is partially metabolized by cyp3a and druga le is known to be a strong inhibitor of cytochrome p450 3a enzyme , care should be taken while dosing drugn with drugn and other strong p450 3a inhibitors including drugn , drugn , drugn , drugb , drugn , drugn , drugn , drugn , drugn or drugn .
false
a multiple dose drug-drug interaction study demonstrated that drugn approximately doubled drugn auc0- . since drugn is partially metabolized by cyp3a and druga le is known to be a strong inhibitor of cytochrome p450 3a enzyme , care should be taken while dosing drugn with drugn and other strong p450 3a inhibitors including drugn , drugn , drugn , drugn , drugb , drugn , drugn , drugn , drugn or drugn .
false
a multiple dose drug-drug interaction study demonstrated that drugn approximately doubled drugn auc0- . since drugn is partially metabolized by cyp3a and druga le is known to be a strong inhibitor of cytochrome p450 3a enzyme , care should be taken while dosing drugn with drugn and other strong p450 3a inhibitors including drugn , drugn , drugn , drugn , drugn , drugb , drugn , drugn , drugn or drugn .
false
a multiple dose drug-drug interaction study demonstrated that drugn approximately doubled drugn auc0- . since drugn is partially metabolized by cyp3a and druga le is known to be a strong inhibitor of cytochrome p450 3a enzyme , care should be taken while dosing drugn with drugn and other strong p450 3a inhibitors including drugn , drugn , drugn , drugn , drugn , drugn , drugb , drugn , drugn or drugn .
false
a multiple dose drug-drug interaction study demonstrated that drugn approximately doubled drugn auc0- . since drugn is partially metabolized by cyp3a and druga le is known to be a strong inhibitor of cytochrome p450 3a enzyme , care should be taken while dosing drugn with drugn and other strong p450 3a inhibitors including drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugb , drugn or drugn .
false
a multiple dose drug-drug interaction study demonstrated that drugn approximately doubled drugn auc0- . since drugn is partially metabolized by cyp3a and druga le is known to be a strong inhibitor of cytochrome p450 3a enzyme , care should be taken while dosing drugn with drugn and other strong p450 3a inhibitors including drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugb or drugn .
false
a multiple dose drug-drug interaction study demonstrated that drugn approximately doubled drugn auc0- . since drugn is partially metabolized by cyp3a and druga le is known to be a strong inhibitor of cytochrome p450 3a enzyme , care should be taken while dosing drugn with drugn and other strong p450 3a inhibitors including drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn or drugb .
false
a multiple dose drug-drug interaction study demonstrated that drugn approximately doubled drugn auc0- . since drugn is partially metabolized by cyp3a and drugn le is known to be a strong inhibitor of cytochrome p450 3a enzyme , care should be taken while dosing druga with drugb and other strong p450 3a inhibitors including drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn or drugn .
advise
a multiple dose drug-drug interaction study demonstrated that drugn approximately doubled drugn auc0- . since drugn is partially metabolized by cyp3a and drugn le is known to be a strong inhibitor of cytochrome p450 3a enzyme , care should be taken while dosing druga with drugn and other strong p450 3a inhibitors including drugb , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn or drugn .
advise
a multiple dose drug-drug interaction study demonstrated that drugn approximately doubled drugn auc0- . since drugn is partially metabolized by cyp3a and drugn le is known to be a strong inhibitor of cytochrome p450 3a enzyme , care should be taken while dosing druga with drugn and other strong p450 3a inhibitors including drugn , drugb , drugn , drugn , drugn , drugn , drugn , drugn , drugn or drugn .
advise
a multiple dose drug-drug interaction study demonstrated that drugn approximately doubled drugn auc0- . since drugn is partially metabolized by cyp3a and drugn le is known to be a strong inhibitor of cytochrome p450 3a enzyme , care should be taken while dosing druga with drugn and other strong p450 3a inhibitors including drugn , drugn , drugb , drugn , drugn , drugn , drugn , drugn , drugn or drugn .
advise
a multiple dose drug-drug interaction study demonstrated that drugn approximately doubled drugn auc0- . since drugn is partially metabolized by cyp3a and drugn le is known to be a strong inhibitor of cytochrome p450 3a enzyme , care should be taken while dosing druga with drugn and other strong p450 3a inhibitors including drugn , drugn , drugn , drugb , drugn , drugn , drugn , drugn , drugn or drugn .
advise
a multiple dose drug-drug interaction study demonstrated that drugn approximately doubled drugn auc0- . since drugn is partially metabolized by cyp3a and drugn le is known to be a strong inhibitor of cytochrome p450 3a enzyme , care should be taken while dosing druga with drugn and other strong p450 3a inhibitors including drugn , drugn , drugn , drugn , drugb , drugn , drugn , drugn , drugn or drugn .
advise
a multiple dose drug-drug interaction study demonstrated that drugn approximately doubled drugn auc0- . since drugn is partially metabolized by cyp3a and drugn le is known to be a strong inhibitor of cytochrome p450 3a enzyme , care should be taken while dosing druga with drugn and other strong p450 3a inhibitors including drugn , drugn , drugn , drugn , drugn , drugb , drugn , drugn , drugn or drugn .
advise
a multiple dose drug-drug interaction study demonstrated that drugn approximately doubled drugn auc0- . since drugn is partially metabolized by cyp3a and drugn le is known to be a strong inhibitor of cytochrome p450 3a enzyme , care should be taken while dosing druga with drugn and other strong p450 3a inhibitors including drugn , drugn , drugn , drugn , drugn , drugn , drugb , drugn , drugn or drugn .
advise
a multiple dose drug-drug interaction study demonstrated that drugn approximately doubled drugn auc0- . since drugn is partially metabolized by cyp3a and drugn le is known to be a strong inhibitor of cytochrome p450 3a enzyme , care should be taken while dosing druga with drugn and other strong p450 3a inhibitors including drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugb , drugn or drugn .
advise
a multiple dose drug-drug interaction study demonstrated that drugn approximately doubled drugn auc0- . since drugn is partially metabolized by cyp3a and drugn le is known to be a strong inhibitor of cytochrome p450 3a enzyme , care should be taken while dosing druga with drugn and other strong p450 3a inhibitors including drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugb or drugn .
advise
a multiple dose drug-drug interaction study demonstrated that drugn approximately doubled drugn auc0- . since drugn is partially metabolized by cyp3a and drugn le is known to be a strong inhibitor of cytochrome p450 3a enzyme , care should be taken while dosing druga with drugn and other strong p450 3a inhibitors including drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn or drugb .
advise
a multiple dose drug-drug interaction study demonstrated that drugn approximately doubled drugn auc0- . since drugn is partially metabolized by cyp3a and drugn le is known to be a strong inhibitor of cytochrome p450 3a enzyme , care should be taken while dosing drugn with druga and other strong p450 3a inhibitors including drugb , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn or drugn .
false
a multiple dose drug-drug interaction study demonstrated that drugn approximately doubled drugn auc0- . since drugn is partially metabolized by cyp3a and drugn le is known to be a strong inhibitor of cytochrome p450 3a enzyme , care should be taken while dosing drugn with druga and other strong p450 3a inhibitors including drugn , drugb , drugn , drugn , drugn , drugn , drugn , drugn , drugn or drugn .
false
a multiple dose drug-drug interaction study demonstrated that drugn approximately doubled drugn auc0- . since drugn is partially metabolized by cyp3a and drugn le is known to be a strong inhibitor of cytochrome p450 3a enzyme , care should be taken while dosing drugn with druga and other strong p450 3a inhibitors including drugn , drugn , drugb , drugn , drugn , drugn , drugn , drugn , drugn or drugn .
false
a multiple dose drug-drug interaction study demonstrated that drugn approximately doubled drugn auc0- . since drugn is partially metabolized by cyp3a and drugn le is known to be a strong inhibitor of cytochrome p450 3a enzyme , care should be taken while dosing drugn with druga and other strong p450 3a inhibitors including drugn , drugn , drugn , drugb , drugn , drugn , drugn , drugn , drugn or drugn .
false
a multiple dose drug-drug interaction study demonstrated that drugn approximately doubled drugn auc0- . since drugn is partially metabolized by cyp3a and drugn le is known to be a strong inhibitor of cytochrome p450 3a enzyme , care should be taken while dosing drugn with druga and other strong p450 3a inhibitors including drugn , drugn , drugn , drugn , drugb , drugn , drugn , drugn , drugn or drugn .
false
a multiple dose drug-drug interaction study demonstrated that drugn approximately doubled drugn auc0- . since drugn is partially metabolized by cyp3a and drugn le is known to be a strong inhibitor of cytochrome p450 3a enzyme , care should be taken while dosing drugn with druga and other strong p450 3a inhibitors including drugn , drugn , drugn , drugn , drugn , drugb , drugn , drugn , drugn or drugn .
false
a multiple dose drug-drug interaction study demonstrated that drugn approximately doubled drugn auc0- . since drugn is partially metabolized by cyp3a and drugn le is known to be a strong inhibitor of cytochrome p450 3a enzyme , care should be taken while dosing drugn with druga and other strong p450 3a inhibitors including drugn , drugn , drugn , drugn , drugn , drugn , drugb , drugn , drugn or drugn .
false
a multiple dose drug-drug interaction study demonstrated that drugn approximately doubled drugn auc0- . since drugn is partially metabolized by cyp3a and drugn le is known to be a strong inhibitor of cytochrome p450 3a enzyme , care should be taken while dosing drugn with druga and other strong p450 3a inhibitors including drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugb , drugn or drugn .
false
a multiple dose drug-drug interaction study demonstrated that drugn approximately doubled drugn auc0- . since drugn is partially metabolized by cyp3a and drugn le is known to be a strong inhibitor of cytochrome p450 3a enzyme , care should be taken while dosing drugn with druga and other strong p450 3a inhibitors including drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugb or drugn .
false
a multiple dose drug-drug interaction study demonstrated that drugn approximately doubled drugn auc0- . since drugn is partially metabolized by cyp3a and drugn le is known to be a strong inhibitor of cytochrome p450 3a enzyme , care should be taken while dosing drugn with druga and other strong p450 3a inhibitors including drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn or drugb .
false
a multiple dose drug-drug interaction study demonstrated that drugn approximately doubled drugn auc0- . since drugn is partially metabolized by cyp3a and drugn le is known to be a strong inhibitor of cytochrome p450 3a enzyme , care should be taken while dosing drugn with drugn and other strong p450 3a inhibitors including druga , drugb , drugn , drugn , drugn , drugn , drugn , drugn , drugn or drugn .
false
a multiple dose drug-drug interaction study demonstrated that drugn approximately doubled drugn auc0- . since drugn is partially metabolized by cyp3a and drugn le is known to be a strong inhibitor of cytochrome p450 3a enzyme , care should be taken while dosing drugn with drugn and other strong p450 3a inhibitors including druga , drugn , drugb , drugn , drugn , drugn , drugn , drugn , drugn or drugn .
false
a multiple dose drug-drug interaction study demonstrated that drugn approximately doubled drugn auc0- . since drugn is partially metabolized by cyp3a and drugn le is known to be a strong inhibitor of cytochrome p450 3a enzyme , care should be taken while dosing drugn with drugn and other strong p450 3a inhibitors including druga , drugn , drugn , drugb , drugn , drugn , drugn , drugn , drugn or drugn .
false
a multiple dose drug-drug interaction study demonstrated that drugn approximately doubled drugn auc0- . since drugn is partially metabolized by cyp3a and drugn le is known to be a strong inhibitor of cytochrome p450 3a enzyme , care should be taken while dosing drugn with drugn and other strong p450 3a inhibitors including druga , drugn , drugn , drugn , drugb , drugn , drugn , drugn , drugn or drugn .
false
a multiple dose drug-drug interaction study demonstrated that drugn approximately doubled drugn auc0- . since drugn is partially metabolized by cyp3a and drugn le is known to be a strong inhibitor of cytochrome p450 3a enzyme , care should be taken while dosing drugn with drugn and other strong p450 3a inhibitors including druga , drugn , drugn , drugn , drugn , drugb , drugn , drugn , drugn or drugn .
false
a multiple dose drug-drug interaction study demonstrated that drugn approximately doubled drugn auc0- . since drugn is partially metabolized by cyp3a and drugn le is known to be a strong inhibitor of cytochrome p450 3a enzyme , care should be taken while dosing drugn with drugn and other strong p450 3a inhibitors including druga , drugn , drugn , drugn , drugn , drugn , drugb , drugn , drugn or drugn .
false
a multiple dose drug-drug interaction study demonstrated that drugn approximately doubled drugn auc0- . since drugn is partially metabolized by cyp3a and drugn le is known to be a strong inhibitor of cytochrome p450 3a enzyme , care should be taken while dosing drugn with drugn and other strong p450 3a inhibitors including druga , drugn , drugn , drugn , drugn , drugn , drugn , drugb , drugn or drugn .
false
a multiple dose drug-drug interaction study demonstrated that drugn approximately doubled drugn auc0- . since drugn is partially metabolized by cyp3a and drugn le is known to be a strong inhibitor of cytochrome p450 3a enzyme , care should be taken while dosing drugn with drugn and other strong p450 3a inhibitors including druga , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugb or drugn .
false
a multiple dose drug-drug interaction study demonstrated that drugn approximately doubled drugn auc0- . since drugn is partially metabolized by cyp3a and drugn le is known to be a strong inhibitor of cytochrome p450 3a enzyme , care should be taken while dosing drugn with drugn and other strong p450 3a inhibitors including druga , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn or drugb .
false
a multiple dose drug-drug interaction study demonstrated that drugn approximately doubled drugn auc0- . since drugn is partially metabolized by cyp3a and drugn le is known to be a strong inhibitor of cytochrome p450 3a enzyme , care should be taken while dosing drugn with drugn and other strong p450 3a inhibitors including drugn , druga , drugb , drugn , drugn , drugn , drugn , drugn , drugn or drugn .
false
a multiple dose drug-drug interaction study demonstrated that drugn approximately doubled drugn auc0- . since drugn is partially metabolized by cyp3a and drugn le is known to be a strong inhibitor of cytochrome p450 3a enzyme , care should be taken while dosing drugn with drugn and other strong p450 3a inhibitors including drugn , druga , drugn , drugb , drugn , drugn , drugn , drugn , drugn or drugn .
false
a multiple dose drug-drug interaction study demonstrated that drugn approximately doubled drugn auc0- . since drugn is partially metabolized by cyp3a and drugn le is known to be a strong inhibitor of cytochrome p450 3a enzyme , care should be taken while dosing drugn with drugn and other strong p450 3a inhibitors including drugn , druga , drugn , drugn , drugb , drugn , drugn , drugn , drugn or drugn .
false
a multiple dose drug-drug interaction study demonstrated that drugn approximately doubled drugn auc0- . since drugn is partially metabolized by cyp3a and drugn le is known to be a strong inhibitor of cytochrome p450 3a enzyme , care should be taken while dosing drugn with drugn and other strong p450 3a inhibitors including drugn , druga , drugn , drugn , drugn , drugb , drugn , drugn , drugn or drugn .
false
a multiple dose drug-drug interaction study demonstrated that drugn approximately doubled drugn auc0- . since drugn is partially metabolized by cyp3a and drugn le is known to be a strong inhibitor of cytochrome p450 3a enzyme , care should be taken while dosing drugn with drugn and other strong p450 3a inhibitors including drugn , druga , drugn , drugn , drugn , drugn , drugb , drugn , drugn or drugn .
false
a multiple dose drug-drug interaction study demonstrated that drugn approximately doubled drugn auc0- . since drugn is partially metabolized by cyp3a and drugn le is known to be a strong inhibitor of cytochrome p450 3a enzyme , care should be taken while dosing drugn with drugn and other strong p450 3a inhibitors including drugn , druga , drugn , drugn , drugn , drugn , drugn , drugb , drugn or drugn .
false
a multiple dose drug-drug interaction study demonstrated that drugn approximately doubled drugn auc0- . since drugn is partially metabolized by cyp3a and drugn le is known to be a strong inhibitor of cytochrome p450 3a enzyme , care should be taken while dosing drugn with drugn and other strong p450 3a inhibitors including drugn , druga , drugn , drugn , drugn , drugn , drugn , drugn , drugb or drugn .
false
a multiple dose drug-drug interaction study demonstrated that drugn approximately doubled drugn auc0- . since drugn is partially metabolized by cyp3a and drugn le is known to be a strong inhibitor of cytochrome p450 3a enzyme , care should be taken while dosing drugn with drugn and other strong p450 3a inhibitors including drugn , druga , drugn , drugn , drugn , drugn , drugn , drugn , drugn or drugb .
false
a multiple dose drug-drug interaction study demonstrated that drugn approximately doubled drugn auc0- . since drugn is partially metabolized by cyp3a and drugn le is known to be a strong inhibitor of cytochrome p450 3a enzyme , care should be taken while dosing drugn with drugn and other strong p450 3a inhibitors including drugn , drugn , druga , drugb , drugn , drugn , drugn , drugn , drugn or drugn .
false
a multiple dose drug-drug interaction study demonstrated that drugn approximately doubled drugn auc0- . since drugn is partially metabolized by cyp3a and drugn le is known to be a strong inhibitor of cytochrome p450 3a enzyme , care should be taken while dosing drugn with drugn and other strong p450 3a inhibitors including drugn , drugn , druga , drugn , drugb , drugn , drugn , drugn , drugn or drugn .
false
a multiple dose drug-drug interaction study demonstrated that drugn approximately doubled drugn auc0- . since drugn is partially metabolized by cyp3a and drugn le is known to be a strong inhibitor of cytochrome p450 3a enzyme , care should be taken while dosing drugn with drugn and other strong p450 3a inhibitors including drugn , drugn , druga , drugn , drugn , drugb , drugn , drugn , drugn or drugn .
false
a multiple dose drug-drug interaction study demonstrated that drugn approximately doubled drugn auc0- . since drugn is partially metabolized by cyp3a and drugn le is known to be a strong inhibitor of cytochrome p450 3a enzyme , care should be taken while dosing drugn with drugn and other strong p450 3a inhibitors including drugn , drugn , druga , drugn , drugn , drugn , drugb , drugn , drugn or drugn .
false
a multiple dose drug-drug interaction study demonstrated that drugn approximately doubled drugn auc0- . since drugn is partially metabolized by cyp3a and drugn le is known to be a strong inhibitor of cytochrome p450 3a enzyme , care should be taken while dosing drugn with drugn and other strong p450 3a inhibitors including drugn , drugn , druga , drugn , drugn , drugn , drugn , drugb , drugn or drugn .
false
a multiple dose drug-drug interaction study demonstrated that drugn approximately doubled drugn auc0- . since drugn is partially metabolized by cyp3a and drugn le is known to be a strong inhibitor of cytochrome p450 3a enzyme , care should be taken while dosing drugn with drugn and other strong p450 3a inhibitors including drugn , drugn , druga , drugn , drugn , drugn , drugn , drugn , drugb or drugn .
false
a multiple dose drug-drug interaction study demonstrated that drugn approximately doubled drugn auc0- . since drugn is partially metabolized by cyp3a and drugn le is known to be a strong inhibitor of cytochrome p450 3a enzyme , care should be taken while dosing drugn with drugn and other strong p450 3a inhibitors including drugn , drugn , druga , drugn , drugn , drugn , drugn , drugn , drugn or drugb .
false
a multiple dose drug-drug interaction study demonstrated that drugn approximately doubled drugn auc0- . since drugn is partially metabolized by cyp3a and drugn le is known to be a strong inhibitor of cytochrome p450 3a enzyme , care should be taken while dosing drugn with drugn and other strong p450 3a inhibitors including drugn , drugn , drugn , druga , drugb , drugn , drugn , drugn , drugn or drugn .
false
a multiple dose drug-drug interaction study demonstrated that drugn approximately doubled drugn auc0- . since drugn is partially metabolized by cyp3a and drugn le is known to be a strong inhibitor of cytochrome p450 3a enzyme , care should be taken while dosing drugn with drugn and other strong p450 3a inhibitors including drugn , drugn , drugn , druga , drugn , drugb , drugn , drugn , drugn or drugn .
false
a multiple dose drug-drug interaction study demonstrated that drugn approximately doubled drugn auc0- . since drugn is partially metabolized by cyp3a and drugn le is known to be a strong inhibitor of cytochrome p450 3a enzyme , care should be taken while dosing drugn with drugn and other strong p450 3a inhibitors including drugn , drugn , drugn , druga , drugn , drugn , drugb , drugn , drugn or drugn .
false
a multiple dose drug-drug interaction study demonstrated that drugn approximately doubled drugn auc0- . since drugn is partially metabolized by cyp3a and drugn le is known to be a strong inhibitor of cytochrome p450 3a enzyme , care should be taken while dosing drugn with drugn and other strong p450 3a inhibitors including drugn , drugn , drugn , druga , drugn , drugn , drugn , drugb , drugn or drugn .
false
a multiple dose drug-drug interaction study demonstrated that drugn approximately doubled drugn auc0- . since drugn is partially metabolized by cyp3a and drugn le is known to be a strong inhibitor of cytochrome p450 3a enzyme , care should be taken while dosing drugn with drugn and other strong p450 3a inhibitors including drugn , drugn , drugn , druga , drugn , drugn , drugn , drugn , drugb or drugn .
false
a multiple dose drug-drug interaction study demonstrated that drugn approximately doubled drugn auc0- . since drugn is partially metabolized by cyp3a and drugn le is known to be a strong inhibitor of cytochrome p450 3a enzyme , care should be taken while dosing drugn with drugn and other strong p450 3a inhibitors including drugn , drugn , drugn , druga , drugn , drugn , drugn , drugn , drugn or drugb .
false
a multiple dose drug-drug interaction study demonstrated that drugn approximately doubled drugn auc0- . since drugn is partially metabolized by cyp3a and drugn le is known to be a strong inhibitor of cytochrome p450 3a enzyme , care should be taken while dosing drugn with drugn and other strong p450 3a inhibitors including drugn , drugn , drugn , drugn , druga , drugb , drugn , drugn , drugn or drugn .
false
a multiple dose drug-drug interaction study demonstrated that drugn approximately doubled drugn auc0- . since drugn is partially metabolized by cyp3a and drugn le is known to be a strong inhibitor of cytochrome p450 3a enzyme , care should be taken while dosing drugn with drugn and other strong p450 3a inhibitors including drugn , drugn , drugn , drugn , druga , drugn , drugb , drugn , drugn or drugn .
false
a multiple dose drug-drug interaction study demonstrated that drugn approximately doubled drugn auc0- . since drugn is partially metabolized by cyp3a and drugn le is known to be a strong inhibitor of cytochrome p450 3a enzyme , care should be taken while dosing drugn with drugn and other strong p450 3a inhibitors including drugn , drugn , drugn , drugn , druga , drugn , drugn , drugb , drugn or drugn .
false
a multiple dose drug-drug interaction study demonstrated that drugn approximately doubled drugn auc0- . since drugn is partially metabolized by cyp3a and drugn le is known to be a strong inhibitor of cytochrome p450 3a enzyme , care should be taken while dosing drugn with drugn and other strong p450 3a inhibitors including drugn , drugn , drugn , drugn , druga , drugn , drugn , drugn , drugb or drugn .
false
a multiple dose drug-drug interaction study demonstrated that drugn approximately doubled drugn auc0- . since drugn is partially metabolized by cyp3a and drugn le is known to be a strong inhibitor of cytochrome p450 3a enzyme , care should be taken while dosing drugn with drugn and other strong p450 3a inhibitors including drugn , drugn , drugn , drugn , druga , drugn , drugn , drugn , drugn or drugb .
false
a multiple dose drug-drug interaction study demonstrated that drugn approximately doubled drugn auc0- . since drugn is partially metabolized by cyp3a and drugn le is known to be a strong inhibitor of cytochrome p450 3a enzyme , care should be taken while dosing drugn with drugn and other strong p450 3a inhibitors including drugn , drugn , drugn , drugn , drugn , druga , drugb , drugn , drugn or drugn .
false
a multiple dose drug-drug interaction study demonstrated that drugn approximately doubled drugn auc0- . since drugn is partially metabolized by cyp3a and drugn le is known to be a strong inhibitor of cytochrome p450 3a enzyme , care should be taken while dosing drugn with drugn and other strong p450 3a inhibitors including drugn , drugn , drugn , drugn , drugn , druga , drugn , drugb , drugn or drugn .
false
a multiple dose drug-drug interaction study demonstrated that drugn approximately doubled drugn auc0- . since drugn is partially metabolized by cyp3a and drugn le is known to be a strong inhibitor of cytochrome p450 3a enzyme , care should be taken while dosing drugn with drugn and other strong p450 3a inhibitors including drugn , drugn , drugn , drugn , drugn , druga , drugn , drugn , drugb or drugn .
false
a multiple dose drug-drug interaction study demonstrated that drugn approximately doubled drugn auc0- . since drugn is partially metabolized by cyp3a and drugn le is known to be a strong inhibitor of cytochrome p450 3a enzyme , care should be taken while dosing drugn with drugn and other strong p450 3a inhibitors including drugn , drugn , drugn , drugn , drugn , druga , drugn , drugn , drugn or drugb .
false
a multiple dose drug-drug interaction study demonstrated that drugn approximately doubled drugn auc0- . since drugn is partially metabolized by cyp3a and drugn le is known to be a strong inhibitor of cytochrome p450 3a enzyme , care should be taken while dosing drugn with drugn and other strong p450 3a inhibitors including drugn , drugn , drugn , drugn , drugn , drugn , druga , drugb , drugn or drugn .
false
a multiple dose drug-drug interaction study demonstrated that drugn approximately doubled drugn auc0- . since drugn is partially metabolized by cyp3a and drugn le is known to be a strong inhibitor of cytochrome p450 3a enzyme , care should be taken while dosing drugn with drugn and other strong p450 3a inhibitors including drugn , drugn , drugn , drugn , drugn , drugn , druga , drugn , drugb or drugn .
false
a multiple dose drug-drug interaction study demonstrated that drugn approximately doubled drugn auc0- . since drugn is partially metabolized by cyp3a and drugn le is known to be a strong inhibitor of cytochrome p450 3a enzyme , care should be taken while dosing drugn with drugn and other strong p450 3a inhibitors including drugn , drugn , drugn , drugn , drugn , drugn , druga , drugn , drugn or drugb .
false
a multiple dose drug-drug interaction study demonstrated that drugn approximately doubled drugn auc0- . since drugn is partially metabolized by cyp3a and drugn le is known to be a strong inhibitor of cytochrome p450 3a enzyme , care should be taken while dosing drugn with drugn and other strong p450 3a inhibitors including drugn , drugn , drugn , drugn , drugn , drugn , drugn , druga , drugb or drugn .
false
a multiple dose drug-drug interaction study demonstrated that drugn approximately doubled drugn auc0- . since drugn is partially metabolized by cyp3a and drugn le is known to be a strong inhibitor of cytochrome p450 3a enzyme , care should be taken while dosing drugn with drugn and other strong p450 3a inhibitors including drugn , drugn , drugn , drugn , drugn , drugn , drugn , druga , drugn or drugb .
false
a multiple dose drug-drug interaction study demonstrated that drugn approximately doubled drugn auc0- . since drugn is partially metabolized by cyp3a and drugn le is known to be a strong inhibitor of cytochrome p450 3a enzyme , care should be taken while dosing drugn with drugn and other strong p450 3a inhibitors including drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , druga or drugb .
false
dose adjustment of druga capsules may be required , and ipth and serum calcium concentrations should be closely monitored if a patient initiates or discontinues therapy with a strong cyp3a4 inhibitor such as drugb .
advise
drugs that impair intestinal absorption of druga , such as drugb , may interfere with the absorption of drugn capsules .
mechanism
drugs that impair intestinal absorption of druga , such as drugn , may interfere with the absorption of drugb capsules .
false
drugs that impair intestinal absorption of drugn , such as druga , may interfere with the absorption of drugb capsules .
mechanism
the cns depressant effects of druga may be additive with that of other drugb ..
effect
reduced absorption of druga and drugb have been reported when those agents were administered concomitantly with drugn .
false
reduced absorption of druga and drugn have been reported when those agents were administered concomitantly with drugb .
mechanism
reduced absorption of drugn and druga have been reported when those agents were administered concomitantly with drugb .
mechanism
when daily doses of druga 2 g and weekly doses of drugb 7.5 mg were coadministered to 15 rheumatoid arthritis patients in a drug-drug interaction study , the pharmacokinetic disposition of the drugs was not altered .
false
daily doses of druga 2 g ( maximum 3 g ) and weekly doses of drugb 7.5 mg ( maximum 15 mg ) were administered alone or in combination to 310 rheumatoid arthritis patients in two controlled 52-week clinical studies .
false
druga can interact with the drugs of the following categories : - blood dyscrasia : can cause unpredictable myelotoxicity - bone marrow depressants : can cause a predictable dose-related myelotoxicity - radiation therapy : may cause marrow depression - neurotoxic medications : can cause neurologic toxicity - drugb : can increase seizure activity - drugn : may potentiate the replication of the drugn virus , may increase the side effects of the vaccination , and decrease patient 's response to the vaccine - drugn : may cause shortness of breath and bronchospasm - drugn : may decrease patient 's response to the drugn
int
druga can interact with the drugs of the following categories : - blood dyscrasia : can cause unpredictable myelotoxicity - bone marrow depressants : can cause a predictable dose-related myelotoxicity - radiation therapy : may cause marrow depression - neurotoxic medications : can cause neurologic toxicity - drugn : can increase seizure activity - drugb : may potentiate the replication of the drugn virus , may increase the side effects of the vaccination , and decrease patient 's response to the vaccine - drugn : may cause shortness of breath and bronchospasm - drugn : may decrease patient 's response to the drugn
int
druga can interact with the drugs of the following categories : - blood dyscrasia : can cause unpredictable myelotoxicity - bone marrow depressants : can cause a predictable dose-related myelotoxicity - radiation therapy : may cause marrow depression - neurotoxic medications : can cause neurologic toxicity - drugn : can increase seizure activity - drugn : may potentiate the replication of the drugb virus , may increase the side effects of the vaccination , and decrease patient 's response to the vaccine - drugn : may cause shortness of breath and bronchospasm - drugn : may decrease patient 's response to the drugn
false
druga can interact with the drugs of the following categories : - blood dyscrasia : can cause unpredictable myelotoxicity - bone marrow depressants : can cause a predictable dose-related myelotoxicity - radiation therapy : may cause marrow depression - neurotoxic medications : can cause neurologic toxicity - drugn : can increase seizure activity - drugn : may potentiate the replication of the drugn virus , may increase the side effects of the vaccination , and decrease patient 's response to the vaccine - drugb : may cause shortness of breath and bronchospasm - drugn : may decrease patient 's response to the drugn
int
druga can interact with the drugs of the following categories : - blood dyscrasia : can cause unpredictable myelotoxicity - bone marrow depressants : can cause a predictable dose-related myelotoxicity - radiation therapy : may cause marrow depression - neurotoxic medications : can cause neurologic toxicity - drugn : can increase seizure activity - drugn : may potentiate the replication of the drugn virus , may increase the side effects of the vaccination , and decrease patient 's response to the vaccine - drugn : may cause shortness of breath and bronchospasm - drugb : may decrease patient 's response to the drugn
int
druga can interact with the drugs of the following categories : - blood dyscrasia : can cause unpredictable myelotoxicity - bone marrow depressants : can cause a predictable dose-related myelotoxicity - radiation therapy : may cause marrow depression - neurotoxic medications : can cause neurologic toxicity - drugn : can increase seizure activity - drugn : may potentiate the replication of the drugn virus , may increase the side effects of the vaccination , and decrease patient 's response to the vaccine - drugn : may cause shortness of breath and bronchospasm - drugn : may decrease patient 's response to the drugb
false
drugn can interact with the drugs of the following categories : - blood dyscrasia : can cause unpredictable myelotoxicity - bone marrow depressants : can cause a predictable dose-related myelotoxicity - radiation therapy : may cause marrow depression - neurotoxic medications : can cause neurologic toxicity - druga : can increase seizure activity - drugb : may potentiate the replication of the drugn virus , may increase the side effects of the vaccination , and decrease patient 's response to the vaccine - drugn : may cause shortness of breath and bronchospasm - drugn : may decrease patient 's response to the drugn
false
drugn can interact with the drugs of the following categories : - blood dyscrasia : can cause unpredictable myelotoxicity - bone marrow depressants : can cause a predictable dose-related myelotoxicity - radiation therapy : may cause marrow depression - neurotoxic medications : can cause neurologic toxicity - druga : can increase seizure activity - drugn : may potentiate the replication of the drugb virus , may increase the side effects of the vaccination , and decrease patient 's response to the vaccine - drugn : may cause shortness of breath and bronchospasm - drugn : may decrease patient 's response to the drugn
false
drugn can interact with the drugs of the following categories : - blood dyscrasia : can cause unpredictable myelotoxicity - bone marrow depressants : can cause a predictable dose-related myelotoxicity - radiation therapy : may cause marrow depression - neurotoxic medications : can cause neurologic toxicity - druga : can increase seizure activity - drugn : may potentiate the replication of the drugn virus , may increase the side effects of the vaccination , and decrease patient 's response to the vaccine - drugb : may cause shortness of breath and bronchospasm - drugn : may decrease patient 's response to the drugn
false
drugn can interact with the drugs of the following categories : - blood dyscrasia : can cause unpredictable myelotoxicity - bone marrow depressants : can cause a predictable dose-related myelotoxicity - radiation therapy : may cause marrow depression - neurotoxic medications : can cause neurologic toxicity - druga : can increase seizure activity - drugn : may potentiate the replication of the drugn virus , may increase the side effects of the vaccination , and decrease patient 's response to the vaccine - drugn : may cause shortness of breath and bronchospasm - drugb : may decrease patient 's response to the drugn
false
drugn can interact with the drugs of the following categories : - blood dyscrasia : can cause unpredictable myelotoxicity - bone marrow depressants : can cause a predictable dose-related myelotoxicity - radiation therapy : may cause marrow depression - neurotoxic medications : can cause neurologic toxicity - druga : can increase seizure activity - drugn : may potentiate the replication of the drugn virus , may increase the side effects of the vaccination , and decrease patient 's response to the vaccine - drugn : may cause shortness of breath and bronchospasm - drugn : may decrease patient 's response to the drugb
false
drugn can interact with the drugs of the following categories : - blood dyscrasia : can cause unpredictable myelotoxicity - bone marrow depressants : can cause a predictable dose-related myelotoxicity - radiation therapy : may cause marrow depression - neurotoxic medications : can cause neurologic toxicity - drugn : can increase seizure activity - druga : may potentiate the replication of the drugb virus , may increase the side effects of the vaccination , and decrease patient 's response to the vaccine - drugn : may cause shortness of breath and bronchospasm - drugn : may decrease patient 's response to the drugn
false
drugn can interact with the drugs of the following categories : - blood dyscrasia : can cause unpredictable myelotoxicity - bone marrow depressants : can cause a predictable dose-related myelotoxicity - radiation therapy : may cause marrow depression - neurotoxic medications : can cause neurologic toxicity - drugn : can increase seizure activity - druga : may potentiate the replication of the drugn virus , may increase the side effects of the vaccination , and decrease patient 's response to the vaccine - drugb : may cause shortness of breath and bronchospasm - drugn : may decrease patient 's response to the drugn
false
drugn can interact with the drugs of the following categories : - blood dyscrasia : can cause unpredictable myelotoxicity - bone marrow depressants : can cause a predictable dose-related myelotoxicity - radiation therapy : may cause marrow depression - neurotoxic medications : can cause neurologic toxicity - drugn : can increase seizure activity - druga : may potentiate the replication of the drugn virus , may increase the side effects of the vaccination , and decrease patient 's response to the vaccine - drugn : may cause shortness of breath and bronchospasm - drugb : may decrease patient 's response to the drugn
false
drugn can interact with the drugs of the following categories : - blood dyscrasia : can cause unpredictable myelotoxicity - bone marrow depressants : can cause a predictable dose-related myelotoxicity - radiation therapy : may cause marrow depression - neurotoxic medications : can cause neurologic toxicity - drugn : can increase seizure activity - druga : may potentiate the replication of the drugn virus , may increase the side effects of the vaccination , and decrease patient 's response to the vaccine - drugn : may cause shortness of breath and bronchospasm - drugn : may decrease patient 's response to the drugb
false
drugn can interact with the drugs of the following categories : - blood dyscrasia : can cause unpredictable myelotoxicity - bone marrow depressants : can cause a predictable dose-related myelotoxicity - radiation therapy : may cause marrow depression - neurotoxic medications : can cause neurologic toxicity - drugn : can increase seizure activity - drugn : may potentiate the replication of the druga virus , may increase the side effects of the vaccination , and decrease patient 's response to the vaccine - drugb : may cause shortness of breath and bronchospasm - drugn : may decrease patient 's response to the drugn
false
drugn can interact with the drugs of the following categories : - blood dyscrasia : can cause unpredictable myelotoxicity - bone marrow depressants : can cause a predictable dose-related myelotoxicity - radiation therapy : may cause marrow depression - neurotoxic medications : can cause neurologic toxicity - drugn : can increase seizure activity - drugn : may potentiate the replication of the druga virus , may increase the side effects of the vaccination , and decrease patient 's response to the vaccine - drugn : may cause shortness of breath and bronchospasm - drugb : may decrease patient 's response to the drugn
false
drugn can interact with the drugs of the following categories : - blood dyscrasia : can cause unpredictable myelotoxicity - bone marrow depressants : can cause a predictable dose-related myelotoxicity - radiation therapy : may cause marrow depression - neurotoxic medications : can cause neurologic toxicity - drugn : can increase seizure activity - drugn : may potentiate the replication of the druga virus , may increase the side effects of the vaccination , and decrease patient 's response to the vaccine - drugn : may cause shortness of breath and bronchospasm - drugn : may decrease patient 's response to the drugb
false
drugn can interact with the drugs of the following categories : - blood dyscrasia : can cause unpredictable myelotoxicity - bone marrow depressants : can cause a predictable dose-related myelotoxicity - radiation therapy : may cause marrow depression - neurotoxic medications : can cause neurologic toxicity - drugn : can increase seizure activity - drugn : may potentiate the replication of the drugn virus , may increase the side effects of the vaccination , and decrease patient 's response to the vaccine - druga : may cause shortness of breath and bronchospasm - drugb : may decrease patient 's response to the drugn
false
drugn can interact with the drugs of the following categories : - blood dyscrasia : can cause unpredictable myelotoxicity - bone marrow depressants : can cause a predictable dose-related myelotoxicity - radiation therapy : may cause marrow depression - neurotoxic medications : can cause neurologic toxicity - drugn : can increase seizure activity - drugn : may potentiate the replication of the drugn virus , may increase the side effects of the vaccination , and decrease patient 's response to the vaccine - druga : may cause shortness of breath and bronchospasm - drugn : may decrease patient 's response to the drugb
false
drugn can interact with the drugs of the following categories : - blood dyscrasia : can cause unpredictable myelotoxicity - bone marrow depressants : can cause a predictable dose-related myelotoxicity - radiation therapy : may cause marrow depression - neurotoxic medications : can cause neurologic toxicity - drugn : can increase seizure activity - drugn : may potentiate the replication of the drugn virus , may increase the side effects of the vaccination , and decrease patient 's response to the vaccine - drugn : may cause shortness of breath and bronchospasm - druga : may decrease patient 's response to the drugb
false
druga has been reported to prolong the elimination half-life of drugb and may lead to severe bone marrow suppression ;
mechanism
a reduction of the druga dosage should be considered in patients receiving drugb concurrently .
advise
the concurrent use of druga and drugb has been reported in one case to result in reduced drugn cytotoxicity .
effect
the concurrent use of druga and drugn has been reported in one case to result in reduced drugb cytotoxicity .
false
the concurrent use of drugn and druga has been reported in one case to result in reduced drugb cytotoxicity .
false
druga should be used with caution in patients receiving other local drugb or agents structurally related to drugn , since the toxic effects of these drugs are additive .
advise
druga should be used with caution in patients receiving other local drugn or agents structurally related to drugb , since the toxic effects of these drugs are additive .
false
drugn should be used with caution in patients receiving other local druga or agents structurally related to drugb , since the toxic effects of these drugs are additive .
false
in vivo , the plasma clearance of druga was reduced by 70 % during coadministration of drugb ( 25 mg bid for 2 days ) , a selective and potent cyp1a2 inhibitor .
mechanism
thus strong inhibitors of cytochrome p4501a2 , such as druga , given concomitantly during administration of drugb , can interact with drugn leading to increased drugn plasma levels .
int
thus strong inhibitors of cytochrome p4501a2 , such as druga , given concomitantly during administration of drugn , can interact with drugb leading to increased drugn plasma levels .
false
thus strong inhibitors of cytochrome p4501a2 , such as druga , given concomitantly during administration of drugn , can interact with drugn leading to increased drugb plasma levels .
false
thus strong inhibitors of cytochrome p4501a2 , such as drugn , given concomitantly during administration of druga , can interact with drugb leading to increased drugn plasma levels .
false
thus strong inhibitors of cytochrome p4501a2 , such as drugn , given concomitantly during administration of druga , can interact with drugn leading to increased drugb plasma levels .
false
thus strong inhibitors of cytochrome p4501a2 , such as drugn , given concomitantly during administration of drugn , can interact with druga leading to increased drugb plasma levels .
false
possible interactions with drugs known to be metabolized by cyp1a2 via competitive inhibition such as druga and drugb may also occur .
false
coadministration of a selective and potent inhibitor of cyp3a4 , druga ( 100 mg bid for 2 days with drugb infusion administered 1 hour after drugn ) caused a 15 % reduction in in-vivo plasma clearance of drugn .
false
coadministration of a selective and potent inhibitor of cyp3a4 , druga ( 100 mg bid for 2 days with drugn infusion administered 1 hour after drugb ) caused a 15 % reduction in in-vivo plasma clearance of drugn .
false
coadministration of a selective and potent inhibitor of cyp3a4 , druga ( 100 mg bid for 2 days with drugn infusion administered 1 hour after drugn ) caused a 15 % reduction in in-vivo plasma clearance of drugb .
mechanism
coadministration of a selective and potent inhibitor of cyp3a4 , drugn ( 100 mg bid for 2 days with druga infusion administered 1 hour after drugb ) caused a 15 % reduction in in-vivo plasma clearance of drugn .
false
coadministration of a selective and potent inhibitor of cyp3a4 , drugn ( 100 mg bid for 2 days with druga infusion administered 1 hour after drugn ) caused a 15 % reduction in in-vivo plasma clearance of drugb .
false
coadministration of a selective and potent inhibitor of cyp3a4 , drugn ( 100 mg bid for 2 days with drugn infusion administered 1 hour after druga ) caused a 15 % reduction in in-vivo plasma clearance of drugb .
false
the interaction of druga , drugb , with other drugs has not been well studied .
false
use of druga and drugb -- drugn , drugn , alone or in combination with drugn and drugn , may cause bleeding complications .
false
use of druga and drugn -- drugb , drugn , alone or in combination with drugn and drugn , may cause bleeding complications .
false
use of druga and drugn -- drugn , drugb , alone or in combination with drugn and drugn , may cause bleeding complications .
false
use of druga and drugn -- drugn , drugn , alone or in combination with drugb and drugn , may cause bleeding complications .
false
use of druga and drugn -- drugn , drugn , alone or in combination with drugn and drugb , may cause bleeding complications .
false
use of drugn and druga -- drugb , drugn , alone or in combination with drugn and drugn , may cause bleeding complications .
false
use of drugn and druga -- drugn , drugb , alone or in combination with drugn and drugn , may cause bleeding complications .
false
use of drugn and druga -- drugn , drugn , alone or in combination with drugb and drugn , may cause bleeding complications .
false
use of drugn and druga -- drugn , drugn , alone or in combination with drugn and drugb , may cause bleeding complications .
false
use of drugn and drugn -- druga , drugb , alone or in combination with drugn and drugn , may cause bleeding complications .
false
use of drugn and drugn -- druga , drugn , alone or in combination with drugb and drugn , may cause bleeding complications .
effect
use of drugn and drugn -- druga , drugn , alone or in combination with drugn and drugb , may cause bleeding complications .
effect
use of drugn and drugn -- drugn , druga , alone or in combination with drugb and drugn , may cause bleeding complications .
effect
use of drugn and drugn -- drugn , druga , alone or in combination with drugn and drugb , may cause bleeding complications .
effect
use of drugn and drugn -- drugn , drugn , alone or in combination with druga and drugb , may cause bleeding complications .
false
in the treatment of acute mi , druga , when not otherwise contraindicated , should be administered with drugb ( see below ) .
false
anticoagulation and druga after treatment for myocardial infarction -- in the treatment of acute myocardial infarction , the use of drugb has been shown to reduce the incidence of reinfarction and stroke .
false
the addition of druga to drugb causes a minimal increase in the risk of minor bleeding ( 3.9 % vs. 3.1 % ) , but does not appear to increase the incidence of major bleeding ( see
effect
concomitant administration of substances that are also tubularly secreted ( e.g. , druga ) could potentially result in delayed clearance of drugb .
mechanism
although druga ( 400 mg qid ) can be administered with drugb in patients with normal renal function ( creatinine clearance 80 ml/min ) , caution should be used when administering drugn concurrently with drugn to patients with mild to moderate renal insufficiency ( creatinine clearance from 45 to 79 ml/min ) .
false
although druga ( 400 mg qid ) can be administered with drugn in patients with normal renal function ( creatinine clearance 80 ml/min ) , caution should be used when administering drugb concurrently with drugn to patients with mild to moderate renal insufficiency ( creatinine clearance from 45 to 79 ml/min ) .
false
although druga ( 400 mg qid ) can be administered with drugn in patients with normal renal function ( creatinine clearance 80 ml/min ) , caution should be used when administering drugn concurrently with drugb to patients with mild to moderate renal insufficiency ( creatinine clearance from 45 to 79 ml/min ) .
false
although drugn ( 400 mg qid ) can be administered with druga in patients with normal renal function ( creatinine clearance 80 ml/min ) , caution should be used when administering drugb concurrently with drugn to patients with mild to moderate renal insufficiency ( creatinine clearance from 45 to 79 ml/min ) .
false
although drugn ( 400 mg qid ) can be administered with druga in patients with normal renal function ( creatinine clearance 80 ml/min ) , caution should be used when administering drugn concurrently with drugb to patients with mild to moderate renal insufficiency ( creatinine clearance from 45 to 79 ml/min ) .
false
although drugn ( 400 mg qid ) can be administered with drugn in patients with normal renal function ( creatinine clearance 80 ml/min ) , caution should be used when administering druga concurrently with drugb to patients with mild to moderate renal insufficiency ( creatinine clearance from 45 to 79 ml/min ) .
advise
patients with mild to moderate renal insufficiency should avoid taking druga with short elimination half-lives for a period of 2 days before , the day of , and 2 days following administration of drugb .
advise
in the absence of data regarding potential interaction between druga and drugb with longer half-lives , all patients taking these drugn should interrupt dosing for at least 5 days before , the day of , and 2 days following drugn administration .
false
in the absence of data regarding potential interaction between druga and drugn with longer half-lives , all patients taking these drugb should interrupt dosing for at least 5 days before , the day of , and 2 days following drugn administration .
false
in the absence of data regarding potential interaction between druga and drugn with longer half-lives , all patients taking these drugn should interrupt dosing for at least 5 days before , the day of , and 2 days following drugb administration .
false
in the absence of data regarding potential interaction between drugn and druga with longer half-lives , all patients taking these drugb should interrupt dosing for at least 5 days before , the day of , and 2 days following drugn administration .
false
in the absence of data regarding potential interaction between drugn and druga with longer half-lives , all patients taking these drugn should interrupt dosing for at least 5 days before , the day of , and 2 days following drugb administration .
false
in the absence of data regarding potential interaction between drugn and drugn with longer half-lives , all patients taking these druga should interrupt dosing for at least 5 days before , the day of , and 2 days following drugb administration .
advise
druga ( oral ) : the activity of oral drugb may be potentiated by anti-vitamin-k activity attributed to drugn .
false
druga ( oral ) : the activity of oral drugn may be potentiated by anti-vitamin-k activity attributed to drugb .
false
drugn ( oral ) : the activity of oral druga may be potentiated by anti-vitamin-k activity attributed to drugb .
effect
druga : serum digitalis levels may be increased when hyperthyroid patients on a stable drugb regimen become euthyroid ;
false
druga : drugb clearance may decrease when hyperthyroid patients on a stable drugn regimen become euthyroid ;
false
druga : drugn clearance may decrease when hyperthyroid patients on a stable drugb regimen become euthyroid ;
false
drugn : druga clearance may decrease when hyperthyroid patients on a stable drugb regimen become euthyroid ;
false
however , in patients with paget 's disease prior druga use appears to reduce the anti-resorptive response to drugb nasal spray .
effect
interactions for druga ( drugb ) : drugn - impairs the intestinal absorption of drugn
false
interactions for druga ( drugn ) : drugb - impairs the intestinal absorption of drugn
false
interactions for druga ( drugn ) : drugn - impairs the intestinal absorption of drugb
false
interactions for drugn ( druga ) : drugb - impairs the intestinal absorption of drugn
false
interactions for drugn ( druga ) : drugn - impairs the intestinal absorption of drugb
false
interactions for drugn ( drugn ) : druga - impairs the intestinal absorption of drugb
mechanism
druga - concurrent use decreases gastrointestinal absorption of drugb ;
mechanism
requirements for druga may be increased in patients receiving drugb .
effect
druga competes with drugb for active tubular secretion and thus inhibits the renal excretion of drugn .
mechanism
druga competes with drugn for active tubular secretion and thus inhibits the renal excretion of drugb .
false
drugn competes with druga for active tubular secretion and thus inhibits the renal excretion of drugb .
false
therefore , the coadministration of druga with drugb is not recommended .
advise
there is evidence that druga may reduce serum levels of drugb to subtherapeutic levels ( therapeutic range considered to be 50 to 100 g/ml total drugn ) .
mechanism
there is evidence that druga may reduce serum levels of drugn to subtherapeutic levels ( therapeutic range considered to be 50 to 100 g/ml total drugb ) .
false
there is evidence that drugn may reduce serum levels of druga to subtherapeutic levels ( therapeutic range considered to be 50 to 100 g/ml total drugb ) .
false
druga inhibits some of the liver 's ability to metabolize some other drugs - drugb , drugn , drugn , drugn , and drugn .
mechanism
druga inhibits some of the liver 's ability to metabolize some other drugs - drugn , drugb , drugn , drugn , and drugn .
mechanism
druga inhibits some of the liver 's ability to metabolize some other drugs - drugn , drugn , drugb , drugn , and drugn .
mechanism
druga inhibits some of the liver 's ability to metabolize some other drugs - drugn , drugn , drugn , drugb , and drugn .
mechanism
druga inhibits some of the liver 's ability to metabolize some other drugs - drugn , drugn , drugn , drugn , and drugb .
mechanism
drugn inhibits some of the liver 's ability to metabolize some other drugs - druga , drugb , drugn , drugn , and drugn .
false
drugn inhibits some of the liver 's ability to metabolize some other drugs - druga , drugn , drugb , drugn , and drugn .
false
drugn inhibits some of the liver 's ability to metabolize some other drugs - druga , drugn , drugn , drugb , and drugn .
false
drugn inhibits some of the liver 's ability to metabolize some other drugs - druga , drugn , drugn , drugn , and drugb .
false
drugn inhibits some of the liver 's ability to metabolize some other drugs - drugn , druga , drugb , drugn , and drugn .
false
drugn inhibits some of the liver 's ability to metabolize some other drugs - drugn , druga , drugn , drugb , and drugn .
false
drugn inhibits some of the liver 's ability to metabolize some other drugs - drugn , druga , drugn , drugn , and drugb .
false
drugn inhibits some of the liver 's ability to metabolize some other drugs - drugn , drugn , druga , drugb , and drugn .
false
drugn inhibits some of the liver 's ability to metabolize some other drugs - drugn , drugn , druga , drugn , and drugb .
false
drugn inhibits some of the liver 's ability to metabolize some other drugs - drugn , drugn , drugn , druga , and drugb .
false
the concomitant use of druga with other drugb that produce dry mouth , constipation , and other anticholinergic pharmacological effects may increase the frequency and/or severity of such effects .
effect
drugs eliminated by active tubular secretion : although studies to assess drug-drug interactions with druga have not been conducted , drugb has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion ( e.g . drugn , drugn , drugn , drugn , drugn , drugn and drugn ) .
false
drugs eliminated by active tubular secretion : although studies to assess drug-drug interactions with druga have not been conducted , drugn has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion ( e.g . drugb , drugn , drugn , drugn , drugn , drugn and drugn ) .
false
drugs eliminated by active tubular secretion : although studies to assess drug-drug interactions with druga have not been conducted , drugn has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion ( e.g . drugn , drugb , drugn , drugn , drugn , drugn and drugn ) .
false
drugs eliminated by active tubular secretion : although studies to assess drug-drug interactions with druga have not been conducted , drugn has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion ( e.g . drugn , drugn , drugb , drugn , drugn , drugn and drugn ) .
false
drugs eliminated by active tubular secretion : although studies to assess drug-drug interactions with druga have not been conducted , drugn has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion ( e.g . drugn , drugn , drugn , drugb , drugn , drugn and drugn ) .
false
drugs eliminated by active tubular secretion : although studies to assess drug-drug interactions with druga have not been conducted , drugn has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion ( e.g . drugn , drugn , drugn , drugn , drugb , drugn and drugn ) .
false
drugs eliminated by active tubular secretion : although studies to assess drug-drug interactions with druga have not been conducted , drugn has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion ( e.g . drugn , drugn , drugn , drugn , drugn , drugb and drugn ) .
false
drugs eliminated by active tubular secretion : although studies to assess drug-drug interactions with druga have not been conducted , drugn has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion ( e.g . drugn , drugn , drugn , drugn , drugn , drugn and drugb ) .
false
drugs eliminated by active tubular secretion : although studies to assess drug-drug interactions with drugn have not been conducted , druga has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion ( e.g . drugb , drugn , drugn , drugn , drugn , drugn and drugn ) .
mechanism
drugs eliminated by active tubular secretion : although studies to assess drug-drug interactions with drugn have not been conducted , druga has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion ( e.g . drugn , drugb , drugn , drugn , drugn , drugn and drugn ) .
mechanism
drugs eliminated by active tubular secretion : although studies to assess drug-drug interactions with drugn have not been conducted , druga has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion ( e.g . drugn , drugn , drugb , drugn , drugn , drugn and drugn ) .
mechanism
drugs eliminated by active tubular secretion : although studies to assess drug-drug interactions with drugn have not been conducted , druga has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion ( e.g . drugn , drugn , drugn , drugb , drugn , drugn and drugn ) .
mechanism
drugs eliminated by active tubular secretion : although studies to assess drug-drug interactions with drugn have not been conducted , druga has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion ( e.g . drugn , drugn , drugn , drugn , drugb , drugn and drugn ) .
mechanism
drugs eliminated by active tubular secretion : although studies to assess drug-drug interactions with drugn have not been conducted , druga has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion ( e.g . drugn , drugn , drugn , drugn , drugn , drugb and drugn ) .
mechanism
drugs eliminated by active tubular secretion : although studies to assess drug-drug interactions with drugn have not been conducted , druga has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion ( e.g . drugn , drugn , drugn , drugn , drugn , drugn and drugb ) .
mechanism
drugs eliminated by active tubular secretion : although studies to assess drug-drug interactions with drugn have not been conducted , drugn has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion ( e.g . druga , drugb , drugn , drugn , drugn , drugn and drugn ) .
false
drugs eliminated by active tubular secretion : although studies to assess drug-drug interactions with drugn have not been conducted , drugn has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion ( e.g . druga , drugn , drugb , drugn , drugn , drugn and drugn ) .
false
drugs eliminated by active tubular secretion : although studies to assess drug-drug interactions with drugn have not been conducted , drugn has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion ( e.g . druga , drugn , drugn , drugb , drugn , drugn and drugn ) .
false
drugs eliminated by active tubular secretion : although studies to assess drug-drug interactions with drugn have not been conducted , drugn has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion ( e.g . druga , drugn , drugn , drugn , drugb , drugn and drugn ) .
false
drugs eliminated by active tubular secretion : although studies to assess drug-drug interactions with drugn have not been conducted , drugn has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion ( e.g . druga , drugn , drugn , drugn , drugn , drugb and drugn ) .
false
drugs eliminated by active tubular secretion : although studies to assess drug-drug interactions with drugn have not been conducted , drugn has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion ( e.g . druga , drugn , drugn , drugn , drugn , drugn and drugb ) .
false
drugs eliminated by active tubular secretion : although studies to assess drug-drug interactions with drugn have not been conducted , drugn has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion ( e.g . drugn , druga , drugb , drugn , drugn , drugn and drugn ) .
false
drugs eliminated by active tubular secretion : although studies to assess drug-drug interactions with drugn have not been conducted , drugn has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion ( e.g . drugn , druga , drugn , drugb , drugn , drugn and drugn ) .
false
drugs eliminated by active tubular secretion : although studies to assess drug-drug interactions with drugn have not been conducted , drugn has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion ( e.g . drugn , druga , drugn , drugn , drugb , drugn and drugn ) .
false
drugs eliminated by active tubular secretion : although studies to assess drug-drug interactions with drugn have not been conducted , drugn has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion ( e.g . drugn , druga , drugn , drugn , drugn , drugb and drugn ) .
false
drugs eliminated by active tubular secretion : although studies to assess drug-drug interactions with drugn have not been conducted , drugn has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion ( e.g . drugn , druga , drugn , drugn , drugn , drugn and drugb ) .
false
drugs eliminated by active tubular secretion : although studies to assess drug-drug interactions with drugn have not been conducted , drugn has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion ( e.g . drugn , drugn , druga , drugb , drugn , drugn and drugn ) .
false
drugs eliminated by active tubular secretion : although studies to assess drug-drug interactions with drugn have not been conducted , drugn has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion ( e.g . drugn , drugn , druga , drugn , drugb , drugn and drugn ) .
false
drugs eliminated by active tubular secretion : although studies to assess drug-drug interactions with drugn have not been conducted , drugn has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion ( e.g . drugn , drugn , druga , drugn , drugn , drugb and drugn ) .
false
drugs eliminated by active tubular secretion : although studies to assess drug-drug interactions with drugn have not been conducted , drugn has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion ( e.g . drugn , drugn , druga , drugn , drugn , drugn and drugb ) .
false
drugs eliminated by active tubular secretion : although studies to assess drug-drug interactions with drugn have not been conducted , drugn has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion ( e.g . drugn , drugn , drugn , druga , drugb , drugn and drugn ) .
false
drugs eliminated by active tubular secretion : although studies to assess drug-drug interactions with drugn have not been conducted , drugn has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion ( e.g . drugn , drugn , drugn , druga , drugn , drugb and drugn ) .
false
drugs eliminated by active tubular secretion : although studies to assess drug-drug interactions with drugn have not been conducted , drugn has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion ( e.g . drugn , drugn , drugn , druga , drugn , drugn and drugb ) .
false
drugs eliminated by active tubular secretion : although studies to assess drug-drug interactions with drugn have not been conducted , drugn has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion ( e.g . drugn , drugn , drugn , drugn , druga , drugb and drugn ) .
false
drugs eliminated by active tubular secretion : although studies to assess drug-drug interactions with drugn have not been conducted , drugn has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion ( e.g . drugn , drugn , drugn , drugn , druga , drugn and drugb ) .
false
drugs eliminated by active tubular secretion : although studies to assess drug-drug interactions with drugn have not been conducted , drugn has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion ( e.g . drugn , drugn , drugn , drugn , drugn , druga and drugb ) .
false
coadministration of druga with drugs that are eliminated by active renal tubular secretion may increase the serum concentration of drugb and/or the coadministered drug due to competition for this elimination pathway .
false
druga , particularly drugb , may cause serious cardiac arrhythmias during drugn anesthesia and therefore should be used only with great caution or not at all .
false
druga , particularly drugn , may cause serious cardiac arrhythmias during drugb anesthesia and therefore should be used only with great caution or not at all .
effect
drugn , particularly druga , may cause serious cardiac arrhythmias during drugb anesthesia and therefore should be used only with great caution or not at all .
effect
druga - the pressor effect of drugb is markedly potentiated in patients receiving drugn ( drugn ) .
false
druga - the pressor effect of drugn is markedly potentiated in patients receiving drugb ( drugn ) .
false
druga - the pressor effect of drugn is markedly potentiated in patients receiving drugn ( drugb ) .
false
drugn - the pressor effect of druga is markedly potentiated in patients receiving drugb ( drugn ) .
effect
drugn - the pressor effect of druga is markedly potentiated in patients receiving drugn ( drugb ) .
effect
drugn - the pressor effect of drugn is markedly potentiated in patients receiving druga ( drugb ) .
false
the pressor response of druga may also be potentiated by drugb .
effect
these include druga , drugb , and oral and inhaled drugn .
false
these include druga , drugn , and oral and inhaled drugb .
false
these include drugn , druga , and oral and inhaled drugb .
false
however , the co administration of druga with other drugb containing drugs ( e.g. , drugn ) has not been studied and is therefore not recommended .
advise
however , the co administration of druga with other drugn containing drugs ( e.g. , drugb ) has not been studied and is therefore not recommended .
advise
however , the co administration of drugn with other druga containing drugs ( e.g. , drugb ) has not been studied and is therefore not recommended .
false
druga has been reported to accelerate the metabolism of drugb by the mechanism of hepatic microsomal enzyme induction , leading to an increase in dosage requirements for drugn .
mechanism
druga has been reported to accelerate the metabolism of drugn by the mechanism of hepatic microsomal enzyme induction , leading to an increase in dosage requirements for drugb .
false
drugn has been reported to accelerate the metabolism of druga by the mechanism of hepatic microsomal enzyme induction , leading to an increase in dosage requirements for drugb .
false
therefore , physicians should closely monitor patients for a change in druga dosage requirements when administering drugb to patients on drugn .
false
therefore , physicians should closely monitor patients for a change in druga dosage requirements when administering drugn to patients on drugb .
false
therefore , physicians should closely monitor patients for a change in drugn dosage requirements when administering druga to patients on drugb .
advise
pharmacokinetic properties of druga were not altered by the addition of either drugb or drugn or the combination of drugn and drugn .
false
pharmacokinetic properties of druga were not altered by the addition of either drugn or drugb or the combination of drugn and drugn .
false
pharmacokinetic properties of druga were not altered by the addition of either drugn or drugn or the combination of drugb and drugn .
false
pharmacokinetic properties of druga were not altered by the addition of either drugn or drugn or the combination of drugn and drugb .
false
pharmacokinetic properties of drugn were not altered by the addition of either druga or drugb or the combination of drugn and drugn .
false
pharmacokinetic properties of drugn were not altered by the addition of either druga or drugn or the combination of drugb and drugn .
false
pharmacokinetic properties of drugn were not altered by the addition of either druga or drugn or the combination of drugn and drugb .
false
pharmacokinetic properties of drugn were not altered by the addition of either drugn or druga or the combination of drugb and drugn .
false
pharmacokinetic properties of drugn were not altered by the addition of either drugn or druga or the combination of drugn and drugb .
false
pharmacokinetic properties of drugn were not altered by the addition of either drugn or drugn or the combination of druga and drugb .
false
no clinically significant changes to druga or drugb pharmacokinetics were observed following concomitant administration of drugn .
false
no clinically significant changes to druga or drugn pharmacokinetics were observed following concomitant administration of drugb .
false
no clinically significant changes to drugn or druga pharmacokinetics were observed following concomitant administration of drugb .
false
druga has no effect on the pharmacokinetic properties of drugb .
false
druga decreases the elimination of drugb causing an increase in overall exposure . the addition of drugn has no clinically significant effect on the pharmacokinetic properties of drugn .
mechanism
druga decreases the elimination of drugn causing an increase in overall exposure . the addition of drugb has no clinically significant effect on the pharmacokinetic properties of drugn .
false
druga decreases the elimination of drugn causing an increase in overall exposure . the addition of drugn has no clinically significant effect on the pharmacokinetic properties of drugb .
false
drugn decreases the elimination of druga causing an increase in overall exposure . the addition of drugb has no clinically significant effect on the pharmacokinetic properties of drugn .
false
drugn decreases the elimination of druga causing an increase in overall exposure . the addition of drugn has no clinically significant effect on the pharmacokinetic properties of drugb .
false
drugn decreases the elimination of drugn causing an increase in overall exposure . the addition of druga has no clinically significant effect on the pharmacokinetic properties of drugb .
false
in a study of 11 hiv-infected patients receiving druga -maintenance therapy ( 40 mg and 90 mg daily ) with 600 mg of drugb twice daily ( twice the currently recommended dose ) , oral drugn clearance increased 22 % ( 90 % ci 6 % to 42 % ) .
mechanism
in a study of 11 hiv-infected patients receiving druga -maintenance therapy ( 40 mg and 90 mg daily ) with 600 mg of drugn twice daily ( twice the currently recommended dose ) , oral drugb clearance increased 22 % ( 90 % ci 6 % to 42 % ) .
false
in a study of 11 hiv-infected patients receiving drugn -maintenance therapy ( 40 mg and 90 mg daily ) with 600 mg of druga twice daily ( twice the currently recommended dose ) , oral drugb clearance increased 22 % ( 90 % ci 6 % to 42 % ) .
false
druga / drugb : drugn / drugn does not influence the pharmacokinetics of drugn in healthy volunteers ( n= 10 ) .
false
druga / drugn : drugb / drugn does not influence the pharmacokinetics of drugn in healthy volunteers ( n= 10 ) .
false
druga / drugn : drugn / drugb does not influence the pharmacokinetics of drugn in healthy volunteers ( n= 10 ) .
false
druga / drugn : drugn / drugn does not influence the pharmacokinetics of drugb in healthy volunteers ( n= 10 ) .
false
drugn / druga : drugb / drugn does not influence the pharmacokinetics of drugn in healthy volunteers ( n= 10 ) .
false
drugn / druga : drugn / drugb does not influence the pharmacokinetics of drugn in healthy volunteers ( n= 10 ) .
false
drugn / druga : drugn / drugn does not influence the pharmacokinetics of drugb in healthy volunteers ( n= 10 ) .
false
drugn / drugn : druga / drugb does not influence the pharmacokinetics of drugn in healthy volunteers ( n= 10 ) .
false
drugn / drugn : druga / drugn does not influence the pharmacokinetics of drugb in healthy volunteers ( n= 10 ) .
false
drugn / drugn : drugn / druga does not influence the pharmacokinetics of drugb in healthy volunteers ( n= 10 ) .
false
druga : in healthy volunteers ( n= 11 ) , drugb did not influence the pharmacokinetics of drugn .
false
druga : in healthy volunteers ( n= 11 ) , drugn did not influence the pharmacokinetics of drugb .
false
drugn : in healthy volunteers ( n= 11 ) , druga did not influence the pharmacokinetics of drugb .
false
druga : population pharmacokinetic analysis suggests that drugb is unlikely to alter the oral clearance of drugn ( n= 54 ) .
false
druga : population pharmacokinetic analysis suggests that drugn is unlikely to alter the oral clearance of drugb ( n= 54 ) .
false
drugn : population pharmacokinetic analysis suggests that druga is unlikely to alter the oral clearance of drugb ( n= 54 ) .
false
druga : drugb , a known inhibitor of renal tubular secretion of organic bases via the cationic transport system , caused a 50 % increase in drugn auc and a 40 % increase in half-life ( n= 12 ) .
false
druga : drugn , a known inhibitor of renal tubular secretion of organic bases via the cationic transport system , caused a 50 % increase in drugb auc and a 40 % increase in half-life ( n= 12 ) .
false
drugn : druga , a known inhibitor of renal tubular secretion of organic bases via the cationic transport system , caused a 50 % increase in drugb auc and a 40 % increase in half-life ( n= 12 ) .
mechanism
druga : drugb , a known inhibitor of renal tubular secretion of organic acids via the aruonic transporter , did not noticeably influence drugn pharmacokinetics ( n= 12 ) .
false
druga : drugn , a known inhibitor of renal tubular secretion of organic acids via the aruonic transporter , did not noticeably influence drugb pharmacokinetics ( n= 12 ) .
false
drugn : druga , a known inhibitor of renal tubular secretion of organic acids via the aruonic transporter , did not noticeably influence drugb pharmacokinetics ( n= 12 ) .
false
other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , druga , drugb , drugn , drugn , drugn , drugn , and drugn ) decreases the oral clearance of drugn by about 20 % , while those secreted by the anionic transport system ( e.g. , drugn , drugn , drugn , drugn , and drugn ) are likely to have little effect on the oral clearance of drugn .
false
other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , druga , drugn , drugb , drugn , drugn , drugn , and drugn ) decreases the oral clearance of drugn by about 20 % , while those secreted by the anionic transport system ( e.g. , drugn , drugn , drugn , drugn , and drugn ) are likely to have little effect on the oral clearance of drugn .
false
other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , druga , drugn , drugn , drugb , drugn , drugn , and drugn ) decreases the oral clearance of drugn by about 20 % , while those secreted by the anionic transport system ( e.g. , drugn , drugn , drugn , drugn , and drugn ) are likely to have little effect on the oral clearance of drugn .
false
other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , druga , drugn , drugn , drugn , drugb , drugn , and drugn ) decreases the oral clearance of drugn by about 20 % , while those secreted by the anionic transport system ( e.g. , drugn , drugn , drugn , drugn , and drugn ) are likely to have little effect on the oral clearance of drugn .
false
other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , druga , drugn , drugn , drugn , drugn , drugb , and drugn ) decreases the oral clearance of drugn by about 20 % , while those secreted by the anionic transport system ( e.g. , drugn , drugn , drugn , drugn , and drugn ) are likely to have little effect on the oral clearance of drugn .
false
other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , druga , drugn , drugn , drugn , drugn , drugn , and drugb ) decreases the oral clearance of drugn by about 20 % , while those secreted by the anionic transport system ( e.g. , drugn , drugn , drugn , drugn , and drugn ) are likely to have little effect on the oral clearance of drugn .
false
other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , druga , drugn , drugn , drugn , drugn , drugn , and drugn ) decreases the oral clearance of drugb by about 20 % , while those secreted by the anionic transport system ( e.g. , drugn , drugn , drugn , drugn , and drugn ) are likely to have little effect on the oral clearance of drugn .
mechanism
other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , druga , drugn , drugn , drugn , drugn , drugn , and drugn ) decreases the oral clearance of drugn by about 20 % , while those secreted by the anionic transport system ( e.g. , drugb , drugn , drugn , drugn , and drugn ) are likely to have little effect on the oral clearance of drugn .
false
other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , druga , drugn , drugn , drugn , drugn , drugn , and drugn ) decreases the oral clearance of drugn by about 20 % , while those secreted by the anionic transport system ( e.g. , drugn , drugb , drugn , drugn , and drugn ) are likely to have little effect on the oral clearance of drugn .
false
other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , druga , drugn , drugn , drugn , drugn , drugn , and drugn ) decreases the oral clearance of drugn by about 20 % , while those secreted by the anionic transport system ( e.g. , drugn , drugn , drugb , drugn , and drugn ) are likely to have little effect on the oral clearance of drugn .
false
other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , druga , drugn , drugn , drugn , drugn , drugn , and drugn ) decreases the oral clearance of drugn by about 20 % , while those secreted by the anionic transport system ( e.g. , drugn , drugn , drugn , drugb , and drugn ) are likely to have little effect on the oral clearance of drugn .
false
other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , druga , drugn , drugn , drugn , drugn , drugn , and drugn ) decreases the oral clearance of drugn by about 20 % , while those secreted by the anionic transport system ( e.g. , drugn , drugn , drugn , drugn , and drugb ) are likely to have little effect on the oral clearance of drugn .
false
other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , druga , drugn , drugn , drugn , drugn , drugn , and drugn ) decreases the oral clearance of drugn by about 20 % , while those secreted by the anionic transport system ( e.g. , drugn , drugn , drugn , drugn , and drugn ) are likely to have little effect on the oral clearance of drugb .
false
other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , drugn , druga , drugb , drugn , drugn , drugn , and drugn ) decreases the oral clearance of drugn by about 20 % , while those secreted by the anionic transport system ( e.g. , drugn , drugn , drugn , drugn , and drugn ) are likely to have little effect on the oral clearance of drugn .
false
other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , drugn , druga , drugn , drugb , drugn , drugn , and drugn ) decreases the oral clearance of drugn by about 20 % , while those secreted by the anionic transport system ( e.g. , drugn , drugn , drugn , drugn , and drugn ) are likely to have little effect on the oral clearance of drugn .
false
other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , drugn , druga , drugn , drugn , drugb , drugn , and drugn ) decreases the oral clearance of drugn by about 20 % , while those secreted by the anionic transport system ( e.g. , drugn , drugn , drugn , drugn , and drugn ) are likely to have little effect on the oral clearance of drugn .
false
other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , drugn , druga , drugn , drugn , drugn , drugb , and drugn ) decreases the oral clearance of drugn by about 20 % , while those secreted by the anionic transport system ( e.g. , drugn , drugn , drugn , drugn , and drugn ) are likely to have little effect on the oral clearance of drugn .
false
other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , drugn , druga , drugn , drugn , drugn , drugn , and drugb ) decreases the oral clearance of drugn by about 20 % , while those secreted by the anionic transport system ( e.g. , drugn , drugn , drugn , drugn , and drugn ) are likely to have little effect on the oral clearance of drugn .
false
other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , drugn , druga , drugn , drugn , drugn , drugn , and drugn ) decreases the oral clearance of drugb by about 20 % , while those secreted by the anionic transport system ( e.g. , drugn , drugn , drugn , drugn , and drugn ) are likely to have little effect on the oral clearance of drugn .
mechanism
other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , drugn , druga , drugn , drugn , drugn , drugn , and drugn ) decreases the oral clearance of drugn by about 20 % , while those secreted by the anionic transport system ( e.g. , drugb , drugn , drugn , drugn , and drugn ) are likely to have little effect on the oral clearance of drugn .
false
other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , drugn , druga , drugn , drugn , drugn , drugn , and drugn ) decreases the oral clearance of drugn by about 20 % , while those secreted by the anionic transport system ( e.g. , drugn , drugb , drugn , drugn , and drugn ) are likely to have little effect on the oral clearance of drugn .
false
other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , drugn , druga , drugn , drugn , drugn , drugn , and drugn ) decreases the oral clearance of drugn by about 20 % , while those secreted by the anionic transport system ( e.g. , drugn , drugn , drugb , drugn , and drugn ) are likely to have little effect on the oral clearance of drugn .
false
other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , drugn , druga , drugn , drugn , drugn , drugn , and drugn ) decreases the oral clearance of drugn by about 20 % , while those secreted by the anionic transport system ( e.g. , drugn , drugn , drugn , drugb , and drugn ) are likely to have little effect on the oral clearance of drugn .
false
other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , drugn , druga , drugn , drugn , drugn , drugn , and drugn ) decreases the oral clearance of drugn by about 20 % , while those secreted by the anionic transport system ( e.g. , drugn , drugn , drugn , drugn , and drugb ) are likely to have little effect on the oral clearance of drugn .
false
other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , drugn , druga , drugn , drugn , drugn , drugn , and drugn ) decreases the oral clearance of drugn by about 20 % , while those secreted by the anionic transport system ( e.g. , drugn , drugn , drugn , drugn , and drugn ) are likely to have little effect on the oral clearance of drugb .
false
other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , drugn , drugn , druga , drugb , drugn , drugn , and drugn ) decreases the oral clearance of drugn by about 20 % , while those secreted by the anionic transport system ( e.g. , drugn , drugn , drugn , drugn , and drugn ) are likely to have little effect on the oral clearance of drugn .
false
other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , drugn , drugn , druga , drugn , drugb , drugn , and drugn ) decreases the oral clearance of drugn by about 20 % , while those secreted by the anionic transport system ( e.g. , drugn , drugn , drugn , drugn , and drugn ) are likely to have little effect on the oral clearance of drugn .
false
other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , drugn , drugn , druga , drugn , drugn , drugb , and drugn ) decreases the oral clearance of drugn by about 20 % , while those secreted by the anionic transport system ( e.g. , drugn , drugn , drugn , drugn , and drugn ) are likely to have little effect on the oral clearance of drugn .
false
other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , drugn , drugn , druga , drugn , drugn , drugn , and drugb ) decreases the oral clearance of drugn by about 20 % , while those secreted by the anionic transport system ( e.g. , drugn , drugn , drugn , drugn , and drugn ) are likely to have little effect on the oral clearance of drugn .
false
other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , drugn , drugn , druga , drugn , drugn , drugn , and drugn ) decreases the oral clearance of drugb by about 20 % , while those secreted by the anionic transport system ( e.g. , drugn , drugn , drugn , drugn , and drugn ) are likely to have little effect on the oral clearance of drugn .
mechanism
other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , drugn , drugn , druga , drugn , drugn , drugn , and drugn ) decreases the oral clearance of drugn by about 20 % , while those secreted by the anionic transport system ( e.g. , drugb , drugn , drugn , drugn , and drugn ) are likely to have little effect on the oral clearance of drugn .
false
other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , drugn , drugn , druga , drugn , drugn , drugn , and drugn ) decreases the oral clearance of drugn by about 20 % , while those secreted by the anionic transport system ( e.g. , drugn , drugb , drugn , drugn , and drugn ) are likely to have little effect on the oral clearance of drugn .
false
other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , drugn , drugn , druga , drugn , drugn , drugn , and drugn ) decreases the oral clearance of drugn by about 20 % , while those secreted by the anionic transport system ( e.g. , drugn , drugn , drugb , drugn , and drugn ) are likely to have little effect on the oral clearance of drugn .
false
other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , drugn , drugn , druga , drugn , drugn , drugn , and drugn ) decreases the oral clearance of drugn by about 20 % , while those secreted by the anionic transport system ( e.g. , drugn , drugn , drugn , drugb , and drugn ) are likely to have little effect on the oral clearance of drugn .
false
other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , drugn , drugn , druga , drugn , drugn , drugn , and drugn ) decreases the oral clearance of drugn by about 20 % , while those secreted by the anionic transport system ( e.g. , drugn , drugn , drugn , drugn , and drugb ) are likely to have little effect on the oral clearance of drugn .
false
other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , drugn , drugn , druga , drugn , drugn , drugn , and drugn ) decreases the oral clearance of drugn by about 20 % , while those secreted by the anionic transport system ( e.g. , drugn , drugn , drugn , drugn , and drugn ) are likely to have little effect on the oral clearance of drugb .
false
other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , drugn , drugn , drugn , druga , drugb , drugn , and drugn ) decreases the oral clearance of drugn by about 20 % , while those secreted by the anionic transport system ( e.g. , drugn , drugn , drugn , drugn , and drugn ) are likely to have little effect on the oral clearance of drugn .
false
other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , drugn , drugn , drugn , druga , drugn , drugb , and drugn ) decreases the oral clearance of drugn by about 20 % , while those secreted by the anionic transport system ( e.g. , drugn , drugn , drugn , drugn , and drugn ) are likely to have little effect on the oral clearance of drugn .
false
other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , drugn , drugn , drugn , druga , drugn , drugn , and drugb ) decreases the oral clearance of drugn by about 20 % , while those secreted by the anionic transport system ( e.g. , drugn , drugn , drugn , drugn , and drugn ) are likely to have little effect on the oral clearance of drugn .
false
other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , drugn , drugn , drugn , druga , drugn , drugn , and drugn ) decreases the oral clearance of drugb by about 20 % , while those secreted by the anionic transport system ( e.g. , drugn , drugn , drugn , drugn , and drugn ) are likely to have little effect on the oral clearance of drugn .
mechanism
other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , drugn , drugn , drugn , druga , drugn , drugn , and drugn ) decreases the oral clearance of drugn by about 20 % , while those secreted by the anionic transport system ( e.g. , drugb , drugn , drugn , drugn , and drugn ) are likely to have little effect on the oral clearance of drugn .
false
other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , drugn , drugn , drugn , druga , drugn , drugn , and drugn ) decreases the oral clearance of drugn by about 20 % , while those secreted by the anionic transport system ( e.g. , drugn , drugb , drugn , drugn , and drugn ) are likely to have little effect on the oral clearance of drugn .
false
other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , drugn , drugn , drugn , druga , drugn , drugn , and drugn ) decreases the oral clearance of drugn by about 20 % , while those secreted by the anionic transport system ( e.g. , drugn , drugn , drugb , drugn , and drugn ) are likely to have little effect on the oral clearance of drugn .
false
other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , drugn , drugn , drugn , druga , drugn , drugn , and drugn ) decreases the oral clearance of drugn by about 20 % , while those secreted by the anionic transport system ( e.g. , drugn , drugn , drugn , drugb , and drugn ) are likely to have little effect on the oral clearance of drugn .
false
other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , drugn , drugn , drugn , druga , drugn , drugn , and drugn ) decreases the oral clearance of drugn by about 20 % , while those secreted by the anionic transport system ( e.g. , drugn , drugn , drugn , drugn , and drugb ) are likely to have little effect on the oral clearance of drugn .
false
other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , drugn , drugn , drugn , druga , drugn , drugn , and drugn ) decreases the oral clearance of drugn by about 20 % , while those secreted by the anionic transport system ( e.g. , drugn , drugn , drugn , drugn , and drugn ) are likely to have little effect on the oral clearance of drugb .
false
other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , drugn , drugn , drugn , drugn , druga , drugb , and drugn ) decreases the oral clearance of drugn by about 20 % , while those secreted by the anionic transport system ( e.g. , drugn , drugn , drugn , drugn , and drugn ) are likely to have little effect on the oral clearance of drugn .
false
other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , drugn , drugn , drugn , drugn , druga , drugn , and drugb ) decreases the oral clearance of drugn by about 20 % , while those secreted by the anionic transport system ( e.g. , drugn , drugn , drugn , drugn , and drugn ) are likely to have little effect on the oral clearance of drugn .
false
other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , drugn , drugn , drugn , drugn , druga , drugn , and drugn ) decreases the oral clearance of drugb by about 20 % , while those secreted by the anionic transport system ( e.g. , drugn , drugn , drugn , drugn , and drugn ) are likely to have little effect on the oral clearance of drugn .
mechanism
other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , drugn , drugn , drugn , drugn , druga , drugn , and drugn ) decreases the oral clearance of drugn by about 20 % , while those secreted by the anionic transport system ( e.g. , drugb , drugn , drugn , drugn , and drugn ) are likely to have little effect on the oral clearance of drugn .
false
other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , drugn , drugn , drugn , drugn , druga , drugn , and drugn ) decreases the oral clearance of drugn by about 20 % , while those secreted by the anionic transport system ( e.g. , drugn , drugb , drugn , drugn , and drugn ) are likely to have little effect on the oral clearance of drugn .
false
other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , drugn , drugn , drugn , drugn , druga , drugn , and drugn ) decreases the oral clearance of drugn by about 20 % , while those secreted by the anionic transport system ( e.g. , drugn , drugn , drugb , drugn , and drugn ) are likely to have little effect on the oral clearance of drugn .
false
other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , drugn , drugn , drugn , drugn , druga , drugn , and drugn ) decreases the oral clearance of drugn by about 20 % , while those secreted by the anionic transport system ( e.g. , drugn , drugn , drugn , drugb , and drugn ) are likely to have little effect on the oral clearance of drugn .
false
other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , drugn , drugn , drugn , drugn , druga , drugn , and drugn ) decreases the oral clearance of drugn by about 20 % , while those secreted by the anionic transport system ( e.g. , drugn , drugn , drugn , drugn , and drugb ) are likely to have little effect on the oral clearance of drugn .
false
other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , drugn , drugn , drugn , drugn , druga , drugn , and drugn ) decreases the oral clearance of drugn by about 20 % , while those secreted by the anionic transport system ( e.g. , drugn , drugn , drugn , drugn , and drugn ) are likely to have little effect on the oral clearance of drugb .
false
other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , drugn , drugn , drugn , drugn , drugn , druga , and drugb ) decreases the oral clearance of drugn by about 20 % , while those secreted by the anionic transport system ( e.g. , drugn , drugn , drugn , drugn , and drugn ) are likely to have little effect on the oral clearance of drugn .
false
other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , drugn , drugn , drugn , drugn , drugn , druga , and drugn ) decreases the oral clearance of drugb by about 20 % , while those secreted by the anionic transport system ( e.g. , drugn , drugn , drugn , drugn , and drugn ) are likely to have little effect on the oral clearance of drugn .
mechanism
other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , drugn , drugn , drugn , drugn , drugn , druga , and drugn ) decreases the oral clearance of drugn by about 20 % , while those secreted by the anionic transport system ( e.g. , drugb , drugn , drugn , drugn , and drugn ) are likely to have little effect on the oral clearance of drugn .
false
other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , drugn , drugn , drugn , drugn , drugn , druga , and drugn ) decreases the oral clearance of drugn by about 20 % , while those secreted by the anionic transport system ( e.g. , drugn , drugb , drugn , drugn , and drugn ) are likely to have little effect on the oral clearance of drugn .
false
other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , drugn , drugn , drugn , drugn , drugn , druga , and drugn ) decreases the oral clearance of drugn by about 20 % , while those secreted by the anionic transport system ( e.g. , drugn , drugn , drugb , drugn , and drugn ) are likely to have little effect on the oral clearance of drugn .
false
other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , drugn , drugn , drugn , drugn , drugn , druga , and drugn ) decreases the oral clearance of drugn by about 20 % , while those secreted by the anionic transport system ( e.g. , drugn , drugn , drugn , drugb , and drugn ) are likely to have little effect on the oral clearance of drugn .
false
other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , drugn , drugn , drugn , drugn , drugn , druga , and drugn ) decreases the oral clearance of drugn by about 20 % , while those secreted by the anionic transport system ( e.g. , drugn , drugn , drugn , drugn , and drugb ) are likely to have little effect on the oral clearance of drugn .
false
other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , drugn , drugn , drugn , drugn , drugn , druga , and drugn ) decreases the oral clearance of drugn by about 20 % , while those secreted by the anionic transport system ( e.g. , drugn , drugn , drugn , drugn , and drugn ) are likely to have little effect on the oral clearance of drugb .
false
other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , drugn , drugn , drugn , drugn , drugn , drugn , and druga ) decreases the oral clearance of drugb by about 20 % , while those secreted by the anionic transport system ( e.g. , drugn , drugn , drugn , drugn , and drugn ) are likely to have little effect on the oral clearance of drugn .
mechanism
other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , drugn , drugn , drugn , drugn , drugn , drugn , and druga ) decreases the oral clearance of drugn by about 20 % , while those secreted by the anionic transport system ( e.g. , drugb , drugn , drugn , drugn , and drugn ) are likely to have little effect on the oral clearance of drugn .
false
other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , drugn , drugn , drugn , drugn , drugn , drugn , and druga ) decreases the oral clearance of drugn by about 20 % , while those secreted by the anionic transport system ( e.g. , drugn , drugb , drugn , drugn , and drugn ) are likely to have little effect on the oral clearance of drugn .
false
other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , drugn , drugn , drugn , drugn , drugn , drugn , and druga ) decreases the oral clearance of drugn by about 20 % , while those secreted by the anionic transport system ( e.g. , drugn , drugn , drugb , drugn , and drugn ) are likely to have little effect on the oral clearance of drugn .
false
other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , drugn , drugn , drugn , drugn , drugn , drugn , and druga ) decreases the oral clearance of drugn by about 20 % , while those secreted by the anionic transport system ( e.g. , drugn , drugn , drugn , drugb , and drugn ) are likely to have little effect on the oral clearance of drugn .
false
other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , drugn , drugn , drugn , drugn , drugn , drugn , and druga ) decreases the oral clearance of drugn by about 20 % , while those secreted by the anionic transport system ( e.g. , drugn , drugn , drugn , drugn , and drugb ) are likely to have little effect on the oral clearance of drugn .
false
other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , drugn , drugn , drugn , drugn , drugn , drugn , and druga ) decreases the oral clearance of drugn by about 20 % , while those secreted by the anionic transport system ( e.g. , drugn , drugn , drugn , drugn , and drugn ) are likely to have little effect on the oral clearance of drugb .
false
other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , drugn , drugn , drugn , drugn , drugn , drugn , and drugn ) decreases the oral clearance of druga by about 20 % , while those secreted by the anionic transport system ( e.g. , drugb , drugn , drugn , drugn , and drugn ) are likely to have little effect on the oral clearance of drugn .
false
other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , drugn , drugn , drugn , drugn , drugn , drugn , and drugn ) decreases the oral clearance of druga by about 20 % , while those secreted by the anionic transport system ( e.g. , drugn , drugb , drugn , drugn , and drugn ) are likely to have little effect on the oral clearance of drugn .
false
other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , drugn , drugn , drugn , drugn , drugn , drugn , and drugn ) decreases the oral clearance of druga by about 20 % , while those secreted by the anionic transport system ( e.g. , drugn , drugn , drugb , drugn , and drugn ) are likely to have little effect on the oral clearance of drugn .
false
other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , drugn , drugn , drugn , drugn , drugn , drugn , and drugn ) decreases the oral clearance of druga by about 20 % , while those secreted by the anionic transport system ( e.g. , drugn , drugn , drugn , drugb , and drugn ) are likely to have little effect on the oral clearance of drugn .
false
other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , drugn , drugn , drugn , drugn , drugn , drugn , and drugn ) decreases the oral clearance of druga by about 20 % , while those secreted by the anionic transport system ( e.g. , drugn , drugn , drugn , drugn , and drugb ) are likely to have little effect on the oral clearance of drugn .
false
other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , drugn , drugn , drugn , drugn , drugn , drugn , and drugn ) decreases the oral clearance of druga by about 20 % , while those secreted by the anionic transport system ( e.g. , drugn , drugn , drugn , drugn , and drugn ) are likely to have little effect on the oral clearance of drugb .
false
other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , drugn , drugn , drugn , drugn , drugn , drugn , and drugn ) decreases the oral clearance of drugn by about 20 % , while those secreted by the anionic transport system ( e.g. , druga , drugb , drugn , drugn , and drugn ) are likely to have little effect on the oral clearance of drugn .
false
other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , drugn , drugn , drugn , drugn , drugn , drugn , and drugn ) decreases the oral clearance of drugn by about 20 % , while those secreted by the anionic transport system ( e.g. , druga , drugn , drugb , drugn , and drugn ) are likely to have little effect on the oral clearance of drugn .
false
other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , drugn , drugn , drugn , drugn , drugn , drugn , and drugn ) decreases the oral clearance of drugn by about 20 % , while those secreted by the anionic transport system ( e.g. , druga , drugn , drugn , drugb , and drugn ) are likely to have little effect on the oral clearance of drugn .
false
other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , drugn , drugn , drugn , drugn , drugn , drugn , and drugn ) decreases the oral clearance of drugn by about 20 % , while those secreted by the anionic transport system ( e.g. , druga , drugn , drugn , drugn , and drugb ) are likely to have little effect on the oral clearance of drugn .
false
other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , drugn , drugn , drugn , drugn , drugn , drugn , and drugn ) decreases the oral clearance of drugn by about 20 % , while those secreted by the anionic transport system ( e.g. , druga , drugn , drugn , drugn , and drugn ) are likely to have little effect on the oral clearance of drugb .
mechanism
other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , drugn , drugn , drugn , drugn , drugn , drugn , and drugn ) decreases the oral clearance of drugn by about 20 % , while those secreted by the anionic transport system ( e.g. , drugn , druga , drugb , drugn , and drugn ) are likely to have little effect on the oral clearance of drugn .
false
other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , drugn , drugn , drugn , drugn , drugn , drugn , and drugn ) decreases the oral clearance of drugn by about 20 % , while those secreted by the anionic transport system ( e.g. , drugn , druga , drugn , drugb , and drugn ) are likely to have little effect on the oral clearance of drugn .
false
other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , drugn , drugn , drugn , drugn , drugn , drugn , and drugn ) decreases the oral clearance of drugn by about 20 % , while those secreted by the anionic transport system ( e.g. , drugn , druga , drugn , drugn , and drugb ) are likely to have little effect on the oral clearance of drugn .
false
other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , drugn , drugn , drugn , drugn , drugn , drugn , and drugn ) decreases the oral clearance of drugn by about 20 % , while those secreted by the anionic transport system ( e.g. , drugn , druga , drugn , drugn , and drugn ) are likely to have little effect on the oral clearance of drugb .
mechanism
other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , drugn , drugn , drugn , drugn , drugn , drugn , and drugn ) decreases the oral clearance of drugn by about 20 % , while those secreted by the anionic transport system ( e.g. , drugn , drugn , druga , drugb , and drugn ) are likely to have little effect on the oral clearance of drugn .
false
other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , drugn , drugn , drugn , drugn , drugn , drugn , and drugn ) decreases the oral clearance of drugn by about 20 % , while those secreted by the anionic transport system ( e.g. , drugn , drugn , druga , drugn , and drugb ) are likely to have little effect on the oral clearance of drugn .
false
other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , drugn , drugn , drugn , drugn , drugn , drugn , and drugn ) decreases the oral clearance of drugn by about 20 % , while those secreted by the anionic transport system ( e.g. , drugn , drugn , druga , drugn , and drugn ) are likely to have little effect on the oral clearance of drugb .
mechanism
other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , drugn , drugn , drugn , drugn , drugn , drugn , and drugn ) decreases the oral clearance of drugn by about 20 % , while those secreted by the anionic transport system ( e.g. , drugn , drugn , drugn , druga , and drugb ) are likely to have little effect on the oral clearance of drugn .
false
other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , drugn , drugn , drugn , drugn , drugn , drugn , and drugn ) decreases the oral clearance of drugn by about 20 % , while those secreted by the anionic transport system ( e.g. , drugn , drugn , drugn , druga , and drugn ) are likely to have little effect on the oral clearance of drugb .
mechanism
other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , drugn , drugn , drugn , drugn , drugn , drugn , and drugn ) decreases the oral clearance of drugn by about 20 % , while those secreted by the anionic transport system ( e.g. , drugn , drugn , drugn , drugn , and druga ) are likely to have little effect on the oral clearance of drugb .
mechanism
cyp interactions : inhibitors of cytochrome p450 enzymes would not be expected to affect druga elimination because drugb is not appreciably metabolized by these enzymes in vivo or in vitro .
false
druga : since drugb is a drugn , it is possible that drugn , such as the drugn ( drugn , drugn , drugn ) or drugn , may diminish the effectiveness of drugn .
false
druga : since drugn is a drugb , it is possible that drugn , such as the drugn ( drugn , drugn , drugn ) or drugn , may diminish the effectiveness of drugn .
false
druga : since drugn is a drugn , it is possible that drugb , such as the drugn ( drugn , drugn , drugn ) or drugn , may diminish the effectiveness of drugn .
false
druga : since drugn is a drugn , it is possible that drugn , such as the drugb ( drugn , drugn , drugn ) or drugn , may diminish the effectiveness of drugn .
false
druga : since drugn is a drugn , it is possible that drugn , such as the drugn ( drugb , drugn , drugn ) or drugn , may diminish the effectiveness of drugn .
false
druga : since drugn is a drugn , it is possible that drugn , such as the drugn ( drugn , drugb , drugn ) or drugn , may diminish the effectiveness of drugn .
false
druga : since drugn is a drugn , it is possible that drugn , such as the drugn ( drugn , drugn , drugb ) or drugn , may diminish the effectiveness of drugn .
false
druga : since drugn is a drugn , it is possible that drugn , such as the drugn ( drugn , drugn , drugn ) or drugb , may diminish the effectiveness of drugn .
false
druga : since drugn is a drugn , it is possible that drugn , such as the drugn ( drugn , drugn , drugn ) or drugn , may diminish the effectiveness of drugb .
false
drugn : since druga is a drugb , it is possible that drugn , such as the drugn ( drugn , drugn , drugn ) or drugn , may diminish the effectiveness of drugn .
false
drugn : since druga is a drugn , it is possible that drugb , such as the drugn ( drugn , drugn , drugn ) or drugn , may diminish the effectiveness of drugn .
false
drugn : since druga is a drugn , it is possible that drugn , such as the drugb ( drugn , drugn , drugn ) or drugn , may diminish the effectiveness of drugn .
false
drugn : since druga is a drugn , it is possible that drugn , such as the drugn ( drugb , drugn , drugn ) or drugn , may diminish the effectiveness of drugn .
false
drugn : since druga is a drugn , it is possible that drugn , such as the drugn ( drugn , drugb , drugn ) or drugn , may diminish the effectiveness of drugn .
false
drugn : since druga is a drugn , it is possible that drugn , such as the drugn ( drugn , drugn , drugb ) or drugn , may diminish the effectiveness of drugn .
false
drugn : since druga is a drugn , it is possible that drugn , such as the drugn ( drugn , drugn , drugn ) or drugb , may diminish the effectiveness of drugn .
false
drugn : since druga is a drugn , it is possible that drugn , such as the drugn ( drugn , drugn , drugn ) or drugn , may diminish the effectiveness of drugb .
false
drugn : since drugn is a druga , it is possible that drugb , such as the drugn ( drugn , drugn , drugn ) or drugn , may diminish the effectiveness of drugn .
false
drugn : since drugn is a druga , it is possible that drugn , such as the drugb ( drugn , drugn , drugn ) or drugn , may diminish the effectiveness of drugn .
false
drugn : since drugn is a druga , it is possible that drugn , such as the drugn ( drugb , drugn , drugn ) or drugn , may diminish the effectiveness of drugn .
false
drugn : since drugn is a druga , it is possible that drugn , such as the drugn ( drugn , drugb , drugn ) or drugn , may diminish the effectiveness of drugn .
false
drugn : since drugn is a druga , it is possible that drugn , such as the drugn ( drugn , drugn , drugb ) or drugn , may diminish the effectiveness of drugn .
false
drugn : since drugn is a druga , it is possible that drugn , such as the drugn ( drugn , drugn , drugn ) or drugb , may diminish the effectiveness of drugn .
false
drugn : since drugn is a druga , it is possible that drugn , such as the drugn ( drugn , drugn , drugn ) or drugn , may diminish the effectiveness of drugb .
false
drugn : since drugn is a drugn , it is possible that druga , such as the drugb ( drugn , drugn , drugn ) or drugn , may diminish the effectiveness of drugn .
false
drugn : since drugn is a drugn , it is possible that druga , such as the drugn ( drugb , drugn , drugn ) or drugn , may diminish the effectiveness of drugn .
false
drugn : since drugn is a drugn , it is possible that druga , such as the drugn ( drugn , drugb , drugn ) or drugn , may diminish the effectiveness of drugn .
false
drugn : since drugn is a drugn , it is possible that druga , such as the drugn ( drugn , drugn , drugb ) or drugn , may diminish the effectiveness of drugn .
false
drugn : since drugn is a drugn , it is possible that druga , such as the drugn ( drugn , drugn , drugn ) or drugb , may diminish the effectiveness of drugn .
false
drugn : since drugn is a drugn , it is possible that druga , such as the drugn ( drugn , drugn , drugn ) or drugn , may diminish the effectiveness of drugb .
effect
drugn : since drugn is a drugn , it is possible that drugn , such as the druga ( drugb , drugn , drugn ) or drugn , may diminish the effectiveness of drugn .
false
drugn : since drugn is a drugn , it is possible that drugn , such as the druga ( drugn , drugb , drugn ) or drugn , may diminish the effectiveness of drugn .
false
drugn : since drugn is a drugn , it is possible that drugn , such as the druga ( drugn , drugn , drugb ) or drugn , may diminish the effectiveness of drugn .
false
drugn : since drugn is a drugn , it is possible that drugn , such as the druga ( drugn , drugn , drugn ) or drugb , may diminish the effectiveness of drugn .
false
drugn : since drugn is a drugn , it is possible that drugn , such as the druga ( drugn , drugn , drugn ) or drugn , may diminish the effectiveness of drugb .
effect
drugn : since drugn is a drugn , it is possible that drugn , such as the drugn ( druga , drugb , drugn ) or drugn , may diminish the effectiveness of drugn .
false
drugn : since drugn is a drugn , it is possible that drugn , such as the drugn ( druga , drugn , drugb ) or drugn , may diminish the effectiveness of drugn .
false
drugn : since drugn is a drugn , it is possible that drugn , such as the drugn ( druga , drugn , drugn ) or drugb , may diminish the effectiveness of drugn .
false
drugn : since drugn is a drugn , it is possible that drugn , such as the drugn ( druga , drugn , drugn ) or drugn , may diminish the effectiveness of drugb .
effect
drugn : since drugn is a drugn , it is possible that drugn , such as the drugn ( drugn , druga , drugb ) or drugn , may diminish the effectiveness of drugn .
false
drugn : since drugn is a drugn , it is possible that drugn , such as the drugn ( drugn , druga , drugn ) or drugb , may diminish the effectiveness of drugn .
false
drugn : since drugn is a drugn , it is possible that drugn , such as the drugn ( drugn , druga , drugn ) or drugn , may diminish the effectiveness of drugb .
effect
drugn : since drugn is a drugn , it is possible that drugn , such as the drugn ( drugn , drugn , druga ) or drugb , may diminish the effectiveness of drugn .
false
drugn : since drugn is a drugn , it is possible that drugn , such as the drugn ( drugn , drugn , druga ) or drugn , may diminish the effectiveness of drugb .
effect
drugn : since drugn is a drugn , it is possible that drugn , such as the drugn ( drugn , drugn , drugn ) or druga , may diminish the effectiveness of drugb .
effect
caution is advised for patients receiving high-dose druga and drugb concomitantly , as anorexia , tachypnea , lethargy , coma and death have been reported with concomitant use of high-dose drugn and drugn .
advise
caution is advised for patients receiving high-dose druga and drugn concomitantly , as anorexia , tachypnea , lethargy , coma and death have been reported with concomitant use of high-dose drugb and drugn .
false
caution is advised for patients receiving high-dose druga and drugn concomitantly , as anorexia , tachypnea , lethargy , coma and death have been reported with concomitant use of high-dose drugn and drugb .
false
caution is advised for patients receiving high-dose drugn and druga concomitantly , as anorexia , tachypnea , lethargy , coma and death have been reported with concomitant use of high-dose drugb and drugn .
false
caution is advised for patients receiving high-dose drugn and druga concomitantly , as anorexia , tachypnea , lethargy , coma and death have been reported with concomitant use of high-dose drugn and drugb .
false
caution is advised for patients receiving high-dose drugn and drugn concomitantly , as anorexia , tachypnea , lethargy , coma and death have been reported with concomitant use of high-dose druga and drugb .
effect
caution should be exercised when administering druga therapy in combination with other drugb .
advise
druga , a bacteriostatic drugb , may antagonize the bactericidal effect of drugn and concurrent use of these drugs should be avoided .
false
druga , a bacteriostatic drugn , may antagonize the bactericidal effect of drugb and concurrent use of these drugs should be avoided .
effect
drugn , a bacteriostatic druga , may antagonize the bactericidal effect of drugb and concurrent use of these drugs should be avoided .
false
drug interactions : women on oral druga have shown a significant increase in plasma drugb levels .
mechanism
druga can interact with drugb , drugn , drugn , drugn , and drugn .
int
druga can interact with drugn , drugb , drugn , drugn , and drugn .
int
druga can interact with drugn , drugn , drugb , drugn , and drugn .
int
druga can interact with drugn , drugn , drugn , drugb , and drugn .
int
druga can interact with drugn , drugn , drugn , drugn , and drugb .
int
drugn can interact with druga , drugb , drugn , drugn , and drugn .
false
drugn can interact with druga , drugn , drugb , drugn , and drugn .
false
drugn can interact with druga , drugn , drugn , drugb , and drugn .
false
drugn can interact with druga , drugn , drugn , drugn , and drugb .
false
drugn can interact with drugn , druga , drugb , drugn , and drugn .
false
drugn can interact with drugn , druga , drugn , drugb , and drugn .
false
drugn can interact with drugn , druga , drugn , drugn , and drugb .
false
drugn can interact with drugn , drugn , druga , drugb , and drugn .
false
drugn can interact with drugn , drugn , druga , drugn , and drugb .
false
drugn can interact with drugn , drugn , drugn , druga , and drugb .
false
druga may decrease the effectiveness of oral drugb , certain drugn , drugn , drugn , drugn , drugn , and drugn .
int
druga may decrease the effectiveness of oral drugn , certain drugb , drugn , drugn , drugn , drugn , and drugn .
int
druga may decrease the effectiveness of oral drugn , certain drugn , drugb , drugn , drugn , drugn , and drugn .
int
druga may decrease the effectiveness of oral drugn , certain drugn , drugn , drugb , drugn , drugn , and drugn .
int
druga may decrease the effectiveness of oral drugn , certain drugn , drugn , drugn , drugb , drugn , and drugn .
int
druga may decrease the effectiveness of oral drugn , certain drugn , drugn , drugn , drugn , drugb , and drugn .
int
druga may decrease the effectiveness of oral drugn , certain drugn , drugn , drugn , drugn , drugn , and drugb .
int
drugn may decrease the effectiveness of oral druga , certain drugb , drugn , drugn , drugn , drugn , and drugn .
false
drugn may decrease the effectiveness of oral druga , certain drugn , drugb , drugn , drugn , drugn , and drugn .
false
drugn may decrease the effectiveness of oral druga , certain drugn , drugn , drugb , drugn , drugn , and drugn .
false
drugn may decrease the effectiveness of oral druga , certain drugn , drugn , drugn , drugb , drugn , and drugn .
false
drugn may decrease the effectiveness of oral druga , certain drugn , drugn , drugn , drugn , drugb , and drugn .
false
drugn may decrease the effectiveness of oral druga , certain drugn , drugn , drugn , drugn , drugn , and drugb .
false
drugn may decrease the effectiveness of oral drugn , certain druga , drugb , drugn , drugn , drugn , and drugn .
false
drugn may decrease the effectiveness of oral drugn , certain druga , drugn , drugb , drugn , drugn , and drugn .
false
drugn may decrease the effectiveness of oral drugn , certain druga , drugn , drugn , drugb , drugn , and drugn .
false
drugn may decrease the effectiveness of oral drugn , certain druga , drugn , drugn , drugn , drugb , and drugn .
false
drugn may decrease the effectiveness of oral drugn , certain druga , drugn , drugn , drugn , drugn , and drugb .
false
drugn may decrease the effectiveness of oral drugn , certain drugn , druga , drugb , drugn , drugn , and drugn .
false
drugn may decrease the effectiveness of oral drugn , certain drugn , druga , drugn , drugb , drugn , and drugn .
false
drugn may decrease the effectiveness of oral drugn , certain drugn , druga , drugn , drugn , drugb , and drugn .
false
drugn may decrease the effectiveness of oral drugn , certain drugn , druga , drugn , drugn , drugn , and drugb .
false
drugn may decrease the effectiveness of oral drugn , certain drugn , drugn , druga , drugb , drugn , and drugn .
false
drugn may decrease the effectiveness of oral drugn , certain drugn , drugn , druga , drugn , drugb , and drugn .
false
drugn may decrease the effectiveness of oral drugn , certain drugn , drugn , druga , drugn , drugn , and drugb .
false
drugn may decrease the effectiveness of oral drugn , certain drugn , drugn , drugn , druga , drugb , and drugn .
false
drugn may decrease the effectiveness of oral drugn , certain drugn , drugn , drugn , druga , drugn , and drugb .
false
drugn may decrease the effectiveness of oral drugn , certain drugn , drugn , drugn , drugn , druga , and drugb .
false
druga may inhibit the hepatic metabolism of drugb .
mechanism
druga , given at a common clinical dosage , increased the drugb half-life by 51 % and decreased the drugn metabolic clearance rate by 30 % .
mechanism
druga , given at a common clinical dosage , increased the drugn half-life by 51 % and decreased the drugb metabolic clearance rate by 30 % .
mechanism
drugn , given at a common clinical dosage , increased the druga half-life by 51 % and decreased the drugb metabolic clearance rate by 30 % .
false
druga may decrease the hypotensive effect of drugb .
effect
human pharmacologic studies have shown that druga may inhibit the metabolism of drugb , drugn ( drugn , drugn , drugn ) , drugn , and drugn ( drugn , drugn , drugn ) .
mechanism
human pharmacologic studies have shown that druga may inhibit the metabolism of drugn , drugb ( drugn , drugn , drugn ) , drugn , and drugn ( drugn , drugn , drugn ) .
mechanism
human pharmacologic studies have shown that druga may inhibit the metabolism of drugn , drugn ( drugb , drugn , drugn ) , drugn , and drugn ( drugn , drugn , drugn ) .
mechanism
human pharmacologic studies have shown that druga may inhibit the metabolism of drugn , drugn ( drugn , drugb , drugn ) , drugn , and drugn ( drugn , drugn , drugn ) .
mechanism
human pharmacologic studies have shown that druga may inhibit the metabolism of drugn , drugn ( drugn , drugn , drugb ) , drugn , and drugn ( drugn , drugn , drugn ) .
mechanism
human pharmacologic studies have shown that druga may inhibit the metabolism of drugn , drugn ( drugn , drugn , drugn ) , drugb , and drugn ( drugn , drugn , drugn ) .
mechanism
human pharmacologic studies have shown that druga may inhibit the metabolism of drugn , drugn ( drugn , drugn , drugn ) , drugn , and drugb ( drugn , drugn , drugn ) .
mechanism
human pharmacologic studies have shown that druga may inhibit the metabolism of drugn , drugn ( drugn , drugn , drugn ) , drugn , and drugn ( drugb , drugn , drugn ) .
mechanism
human pharmacologic studies have shown that druga may inhibit the metabolism of drugn , drugn ( drugn , drugn , drugn ) , drugn , and drugn ( drugn , drugb , drugn ) .
mechanism
human pharmacologic studies have shown that druga may inhibit the metabolism of drugn , drugn ( drugn , drugn , drugn ) , drugn , and drugn ( drugn , drugn , drugb ) .
mechanism
human pharmacologic studies have shown that drugn may inhibit the metabolism of druga , drugb ( drugn , drugn , drugn ) , drugn , and drugn ( drugn , drugn , drugn ) .
false
human pharmacologic studies have shown that drugn may inhibit the metabolism of druga , drugn ( drugb , drugn , drugn ) , drugn , and drugn ( drugn , drugn , drugn ) .
false
human pharmacologic studies have shown that drugn may inhibit the metabolism of druga , drugn ( drugn , drugb , drugn ) , drugn , and drugn ( drugn , drugn , drugn ) .
false
human pharmacologic studies have shown that drugn may inhibit the metabolism of druga , drugn ( drugn , drugn , drugb ) , drugn , and drugn ( drugn , drugn , drugn ) .
false
human pharmacologic studies have shown that drugn may inhibit the metabolism of druga , drugn ( drugn , drugn , drugn ) , drugb , and drugn ( drugn , drugn , drugn ) .
false
human pharmacologic studies have shown that drugn may inhibit the metabolism of druga , drugn ( drugn , drugn , drugn ) , drugn , and drugb ( drugn , drugn , drugn ) .
false
human pharmacologic studies have shown that drugn may inhibit the metabolism of druga , drugn ( drugn , drugn , drugn ) , drugn , and drugn ( drugb , drugn , drugn ) .
false
human pharmacologic studies have shown that drugn may inhibit the metabolism of druga , drugn ( drugn , drugn , drugn ) , drugn , and drugn ( drugn , drugb , drugn ) .
false
human pharmacologic studies have shown that drugn may inhibit the metabolism of druga , drugn ( drugn , drugn , drugn ) , drugn , and drugn ( drugn , drugn , drugb ) .
false
human pharmacologic studies have shown that drugn may inhibit the metabolism of drugn , druga ( drugb , drugn , drugn ) , drugn , and drugn ( drugn , drugn , drugn ) .
false
human pharmacologic studies have shown that drugn may inhibit the metabolism of drugn , druga ( drugn , drugb , drugn ) , drugn , and drugn ( drugn , drugn , drugn ) .
false
human pharmacologic studies have shown that drugn may inhibit the metabolism of drugn , druga ( drugn , drugn , drugb ) , drugn , and drugn ( drugn , drugn , drugn ) .
false
human pharmacologic studies have shown that drugn may inhibit the metabolism of drugn , druga ( drugn , drugn , drugn ) , drugb , and drugn ( drugn , drugn , drugn ) .
false
human pharmacologic studies have shown that drugn may inhibit the metabolism of drugn , druga ( drugn , drugn , drugn ) , drugn , and drugb ( drugn , drugn , drugn ) .
false
human pharmacologic studies have shown that drugn may inhibit the metabolism of drugn , druga ( drugn , drugn , drugn ) , drugn , and drugn ( drugb , drugn , drugn ) .
false
human pharmacologic studies have shown that drugn may inhibit the metabolism of drugn , druga ( drugn , drugn , drugn ) , drugn , and drugn ( drugn , drugb , drugn ) .
false
human pharmacologic studies have shown that drugn may inhibit the metabolism of drugn , druga ( drugn , drugn , drugn ) , drugn , and drugn ( drugn , drugn , drugb ) .
false
human pharmacologic studies have shown that drugn may inhibit the metabolism of drugn , drugn ( druga , drugb , drugn ) , drugn , and drugn ( drugn , drugn , drugn ) .
false
human pharmacologic studies have shown that drugn may inhibit the metabolism of drugn , drugn ( druga , drugn , drugb ) , drugn , and drugn ( drugn , drugn , drugn ) .
false
human pharmacologic studies have shown that drugn may inhibit the metabolism of drugn , drugn ( druga , drugn , drugn ) , drugb , and drugn ( drugn , drugn , drugn ) .
false
human pharmacologic studies have shown that drugn may inhibit the metabolism of drugn , drugn ( druga , drugn , drugn ) , drugn , and drugb ( drugn , drugn , drugn ) .
false
human pharmacologic studies have shown that drugn may inhibit the metabolism of drugn , drugn ( druga , drugn , drugn ) , drugn , and drugn ( drugb , drugn , drugn ) .
false
human pharmacologic studies have shown that drugn may inhibit the metabolism of drugn , drugn ( druga , drugn , drugn ) , drugn , and drugn ( drugn , drugb , drugn ) .
false
human pharmacologic studies have shown that drugn may inhibit the metabolism of drugn , drugn ( druga , drugn , drugn ) , drugn , and drugn ( drugn , drugn , drugb ) .
false
human pharmacologic studies have shown that drugn may inhibit the metabolism of drugn , drugn ( drugn , druga , drugb ) , drugn , and drugn ( drugn , drugn , drugn ) .
false
human pharmacologic studies have shown that drugn may inhibit the metabolism of drugn , drugn ( drugn , druga , drugn ) , drugb , and drugn ( drugn , drugn , drugn ) .
false
human pharmacologic studies have shown that drugn may inhibit the metabolism of drugn , drugn ( drugn , druga , drugn ) , drugn , and drugb ( drugn , drugn , drugn ) .
false
human pharmacologic studies have shown that drugn may inhibit the metabolism of drugn , drugn ( drugn , druga , drugn ) , drugn , and drugn ( drugb , drugn , drugn ) .
false
human pharmacologic studies have shown that drugn may inhibit the metabolism of drugn , drugn ( drugn , druga , drugn ) , drugn , and drugn ( drugn , drugb , drugn ) .
false
human pharmacologic studies have shown that drugn may inhibit the metabolism of drugn , drugn ( drugn , druga , drugn ) , drugn , and drugn ( drugn , drugn , drugb ) .
false
human pharmacologic studies have shown that drugn may inhibit the metabolism of drugn , drugn ( drugn , drugn , druga ) , drugb , and drugn ( drugn , drugn , drugn ) .
false
human pharmacologic studies have shown that drugn may inhibit the metabolism of drugn , drugn ( drugn , drugn , druga ) , drugn , and drugb ( drugn , drugn , drugn ) .
false
human pharmacologic studies have shown that drugn may inhibit the metabolism of drugn , drugn ( drugn , drugn , druga ) , drugn , and drugn ( drugb , drugn , drugn ) .
false
human pharmacologic studies have shown that drugn may inhibit the metabolism of drugn , drugn ( drugn , drugn , druga ) , drugn , and drugn ( drugn , drugb , drugn ) .
false
human pharmacologic studies have shown that drugn may inhibit the metabolism of drugn , drugn ( drugn , drugn , druga ) , drugn , and drugn ( drugn , drugn , drugb ) .
false
human pharmacologic studies have shown that drugn may inhibit the metabolism of drugn , drugn ( drugn , drugn , drugn ) , druga , and drugb ( drugn , drugn , drugn ) .
false
human pharmacologic studies have shown that drugn may inhibit the metabolism of drugn , drugn ( drugn , drugn , drugn ) , druga , and drugn ( drugb , drugn , drugn ) .
false
human pharmacologic studies have shown that drugn may inhibit the metabolism of drugn , drugn ( drugn , drugn , drugn ) , druga , and drugn ( drugn , drugb , drugn ) .
false
human pharmacologic studies have shown that drugn may inhibit the metabolism of drugn , drugn ( drugn , drugn , drugn ) , druga , and drugn ( drugn , drugn , drugb ) .
false
human pharmacologic studies have shown that drugn may inhibit the metabolism of drugn , drugn ( drugn , drugn , drugn ) , drugn , and druga ( drugb , drugn , drugn ) .
false
human pharmacologic studies have shown that drugn may inhibit the metabolism of drugn , drugn ( drugn , drugn , drugn ) , drugn , and druga ( drugn , drugb , drugn ) .
false
human pharmacologic studies have shown that drugn may inhibit the metabolism of drugn , drugn ( drugn , drugn , drugn ) , drugn , and druga ( drugn , drugn , drugb ) .
false
human pharmacologic studies have shown that drugn may inhibit the metabolism of drugn , drugn ( drugn , drugn , drugn ) , drugn , and drugn ( druga , drugb , drugn ) .
false
human pharmacologic studies have shown that drugn may inhibit the metabolism of drugn , drugn ( drugn , drugn , drugn ) , drugn , and drugn ( druga , drugn , drugb ) .
false
human pharmacologic studies have shown that drugn may inhibit the metabolism of drugn , drugn ( drugn , drugn , drugn ) , drugn , and drugn ( drugn , druga , drugb ) .
false
the safety of using druga in combination with drugb or other centrally acting drugn has not been systemically evaluated .
false
the safety of using druga in combination with drugn or other centrally acting drugb has not been systemically evaluated .
false
the safety of using drugn in combination with druga or other centrally acting drugb has not been systemically evaluated .
false
in a study in which 34 different drugs were tested , therapeutically relevant concentrations of druga , drugb and drugn displaced protein-bound drugn in fresh human serum to a small but significant extent .
false
in a study in which 34 different drugs were tested , therapeutically relevant concentrations of druga , drugn and drugb displaced protein-bound drugn in fresh human serum to a small but significant extent .
false
in a study in which 34 different drugs were tested , therapeutically relevant concentrations of druga , drugn and drugn displaced protein-bound drugb in fresh human serum to a small but significant extent .
mechanism
in a study in which 34 different drugs were tested , therapeutically relevant concentrations of drugn , druga and drugb displaced protein-bound drugn in fresh human serum to a small but significant extent .
false
in a study in which 34 different drugs were tested , therapeutically relevant concentrations of drugn , druga and drugn displaced protein-bound drugb in fresh human serum to a small but significant extent .
mechanism
in a study in which 34 different drugs were tested , therapeutically relevant concentrations of drugn , drugn and druga displaced protein-bound drugb in fresh human serum to a small but significant extent .
mechanism
therefore , caution should be used in administering druga ( drugb injection ) to patients receiving these other agents .
false
there was no change in the plasma kinetics of druga when coadministered with drugb .
false
an increase in intracellular levels of druga was observed in vitro in the presence of drugb .
mechanism
patients receiving druga and drugb generally should not be treated with drugn .
false
patients receiving druga and drugn generally should not be treated with drugb .
advise
patients receiving drugn and druga generally should not be treated with drugb .
advise
the action of druga may be potentiated by anesthesia , other drugb and drugn .
effect
the action of druga may be potentiated by anesthesia , other drugn and drugb .
effect
the action of drugn may be potentiated by anesthesia , other druga and drugb .
false
preliminary evidence suggests that druga inhibits drugb metabolism and may result in an increase in plasma concentrations of drugn .
mechanism
preliminary evidence suggests that druga inhibits drugn metabolism and may result in an increase in plasma concentrations of drugb .
false
preliminary evidence suggests that drugn inhibits druga metabolism and may result in an increase in plasma concentrations of drugb .
false
in vitro studies with human liver microsomes showed that druga does not inhibit the metabolism of drugb , drugn , drugn , and drugn .
false
in vitro studies with human liver microsomes showed that druga does not inhibit the metabolism of drugn , drugb , drugn , and drugn .
false
in vitro studies with human liver microsomes showed that druga does not inhibit the metabolism of drugn , drugn , drugb , and drugn .
false
in vitro studies with human liver microsomes showed that druga does not inhibit the metabolism of drugn , drugn , drugn , and drugb .
false
in vitro studies with human liver microsomes showed that drugn does not inhibit the metabolism of druga , drugb , drugn , and drugn .
false
in vitro studies with human liver microsomes showed that drugn does not inhibit the metabolism of druga , drugn , drugb , and drugn .
false
in vitro studies with human liver microsomes showed that drugn does not inhibit the metabolism of druga , drugn , drugn , and drugb .
false
in vitro studies with human liver microsomes showed that drugn does not inhibit the metabolism of drugn , druga , drugb , and drugn .
false
in vitro studies with human liver microsomes showed that drugn does not inhibit the metabolism of drugn , druga , drugn , and drugb .
false
in vitro studies with human liver microsomes showed that drugn does not inhibit the metabolism of drugn , drugn , druga , and drugb .
false
this may be of clinical relevance for compounds predominantly metabolized by this enzyme , such as druga , -blockers , drugb ( drugn ) , and drugn , if they have a narrow therapeutic window .
false
this may be of clinical relevance for compounds predominantly metabolized by this enzyme , such as druga , -blockers , drugn ( drugb ) , and drugn , if they have a narrow therapeutic window .
false
this may be of clinical relevance for compounds predominantly metabolized by this enzyme , such as druga , -blockers , drugn ( drugn ) , and drugb , if they have a narrow therapeutic window .
false
this may be of clinical relevance for compounds predominantly metabolized by this enzyme , such as drugn , -blockers , druga ( drugb ) , and drugn , if they have a narrow therapeutic window .
false
this may be of clinical relevance for compounds predominantly metabolized by this enzyme , such as drugn , -blockers , druga ( drugn ) , and drugb , if they have a narrow therapeutic window .
false
this may be of clinical relevance for compounds predominantly metabolized by this enzyme , such as drugn , -blockers , drugn ( druga ) , and drugb , if they have a narrow therapeutic window .
false
in vivo drug-drug interaction studies conducted in normal volunteer subjects showed that druga does not affect the clearance of drugb or drugn .
false
in vivo drug-drug interaction studies conducted in normal volunteer subjects showed that druga does not affect the clearance of drugn or drugb .
false
in vivo drug-drug interaction studies conducted in normal volunteer subjects showed that drugn does not affect the clearance of druga or drugb .
false
druga decreases the clearance of drugb by 19 % .
mechanism
druga increases the clearance of drugb by 15 % .
mechanism
there have been spontaneous reports of increase or decrease in prothrombin times in patients concomitantly taking oral druga and drugb , however , a causal relationship between drugn tablets and these changes has not been established .
effect
there have been spontaneous reports of increase or decrease in prothrombin times in patients concomitantly taking oral druga and drugn , however , a causal relationship between drugb tablets and these changes has not been established .
false
there have been spontaneous reports of increase or decrease in prothrombin times in patients concomitantly taking oral drugn and druga , however , a causal relationship between drugb tablets and these changes has not been established .
false
druga clearance is increased 100 % by drugb , a cyp450 enzyme inducer , and decreased 33 % by drugn , a cyp450 enzyme inhibitor .
mechanism
druga clearance is increased 100 % by drugn , a cyp450 enzyme inducer , and decreased 33 % by drugb , a cyp450 enzyme inhibitor .
mechanism
drugn clearance is increased 100 % by druga , a cyp450 enzyme inducer , and decreased 33 % by drugb , a cyp450 enzyme inhibitor .
false
druga clearance is unaffected by drugb .
false
there is no information available from adequate drug-drug interaction studies with the following classes of drugs : oral druga , hormone replacement therapies , drugb , drugn , drugn , drugn , drugn , and drugn .
false
there is no information available from adequate drug-drug interaction studies with the following classes of drugs : oral druga , hormone replacement therapies , drugn , drugb , drugn , drugn , drugn , and drugn .
false
there is no information available from adequate drug-drug interaction studies with the following classes of drugs : oral druga , hormone replacement therapies , drugn , drugn , drugb , drugn , drugn , and drugn .
false
there is no information available from adequate drug-drug interaction studies with the following classes of drugs : oral druga , hormone replacement therapies , drugn , drugn , drugn , drugb , drugn , and drugn .
false
there is no information available from adequate drug-drug interaction studies with the following classes of drugs : oral druga , hormone replacement therapies , drugn , drugn , drugn , drugn , drugb , and drugn .
false
there is no information available from adequate drug-drug interaction studies with the following classes of drugs : oral druga , hormone replacement therapies , drugn , drugn , drugn , drugn , drugn , and drugb .
false
there is no information available from adequate drug-drug interaction studies with the following classes of drugs : oral drugn , hormone replacement therapies , druga , drugb , drugn , drugn , drugn , and drugn .
false
there is no information available from adequate drug-drug interaction studies with the following classes of drugs : oral drugn , hormone replacement therapies , druga , drugn , drugb , drugn , drugn , and drugn .
false
there is no information available from adequate drug-drug interaction studies with the following classes of drugs : oral drugn , hormone replacement therapies , druga , drugn , drugn , drugb , drugn , and drugn .
false
there is no information available from adequate drug-drug interaction studies with the following classes of drugs : oral drugn , hormone replacement therapies , druga , drugn , drugn , drugn , drugb , and drugn .
false
there is no information available from adequate drug-drug interaction studies with the following classes of drugs : oral drugn , hormone replacement therapies , druga , drugn , drugn , drugn , drugn , and drugb .
false
there is no information available from adequate drug-drug interaction studies with the following classes of drugs : oral drugn , hormone replacement therapies , drugn , druga , drugb , drugn , drugn , and drugn .
false
there is no information available from adequate drug-drug interaction studies with the following classes of drugs : oral drugn , hormone replacement therapies , drugn , druga , drugn , drugb , drugn , and drugn .
false
there is no information available from adequate drug-drug interaction studies with the following classes of drugs : oral drugn , hormone replacement therapies , drugn , druga , drugn , drugn , drugb , and drugn .
false
there is no information available from adequate drug-drug interaction studies with the following classes of drugs : oral drugn , hormone replacement therapies , drugn , druga , drugn , drugn , drugn , and drugb .
false
there is no information available from adequate drug-drug interaction studies with the following classes of drugs : oral drugn , hormone replacement therapies , drugn , drugn , druga , drugb , drugn , and drugn .
false
there is no information available from adequate drug-drug interaction studies with the following classes of drugs : oral drugn , hormone replacement therapies , drugn , drugn , druga , drugn , drugb , and drugn .
false
there is no information available from adequate drug-drug interaction studies with the following classes of drugs : oral drugn , hormone replacement therapies , drugn , drugn , druga , drugn , drugn , and drugb .
false
there is no information available from adequate drug-drug interaction studies with the following classes of drugs : oral drugn , hormone replacement therapies , drugn , drugn , drugn , druga , drugb , and drugn .
false
there is no information available from adequate drug-drug interaction studies with the following classes of drugs : oral drugn , hormone replacement therapies , drugn , drugn , drugn , druga , drugn , and drugb .
false
there is no information available from adequate drug-drug interaction studies with the following classes of drugs : oral drugn , hormone replacement therapies , drugn , drugn , drugn , drugn , druga , and drugb .
false
druga drugb may increase sensitivity to oral drugn .
false
druga drugn may increase sensitivity to oral drugb .
false
drugn druga may increase sensitivity to oral drugb .
effect
druga : a multidose study of drugb , given as 5 or 10 mg bid in 15 healthy subjects concurrently treated with drugn , resulted in a mean increase in drugn half-life from 26 to 48 hours and auc from 4.55 to 12.08 ng*hr/ml : similar increases in drugn half-life and auc were also detected .
false
druga : a multidose study of drugn , given as 5 or 10 mg bid in 15 healthy subjects concurrently treated with drugb , resulted in a mean increase in drugn half-life from 26 to 48 hours and auc from 4.55 to 12.08 ng*hr/ml : similar increases in drugn half-life and auc were also detected .
false
druga : a multidose study of drugn , given as 5 or 10 mg bid in 15 healthy subjects concurrently treated with drugn , resulted in a mean increase in drugb half-life from 26 to 48 hours and auc from 4.55 to 12.08 ng*hr/ml : similar increases in drugn half-life and auc were also detected .
false
druga : a multidose study of drugn , given as 5 or 10 mg bid in 15 healthy subjects concurrently treated with drugn , resulted in a mean increase in drugn half-life from 26 to 48 hours and auc from 4.55 to 12.08 ng*hr/ml : similar increases in drugb half-life and auc were also detected .
false
drugn : a multidose study of druga , given as 5 or 10 mg bid in 15 healthy subjects concurrently treated with drugb , resulted in a mean increase in drugn half-life from 26 to 48 hours and auc from 4.55 to 12.08 ng*hr/ml : similar increases in drugn half-life and auc were also detected .
mechanism
drugn : a multidose study of druga , given as 5 or 10 mg bid in 15 healthy subjects concurrently treated with drugn , resulted in a mean increase in drugb half-life from 26 to 48 hours and auc from 4.55 to 12.08 ng*hr/ml : similar increases in drugn half-life and auc were also detected .
false
drugn : a multidose study of druga , given as 5 or 10 mg bid in 15 healthy subjects concurrently treated with drugn , resulted in a mean increase in drugn half-life from 26 to 48 hours and auc from 4.55 to 12.08 ng*hr/ml : similar increases in drugb half-life and auc were also detected .
false
drugn : a multidose study of drugn , given as 5 or 10 mg bid in 15 healthy subjects concurrently treated with druga , resulted in a mean increase in drugb half-life from 26 to 48 hours and auc from 4.55 to 12.08 ng*hr/ml : similar increases in drugn half-life and auc were also detected .
false
drugn : a multidose study of drugn , given as 5 or 10 mg bid in 15 healthy subjects concurrently treated with druga , resulted in a mean increase in drugn half-life from 26 to 48 hours and auc from 4.55 to 12.08 ng*hr/ml : similar increases in drugb half-life and auc were also detected .
false
drugn : a multidose study of drugn , given as 5 or 10 mg bid in 15 healthy subjects concurrently treated with drugn , resulted in a mean increase in druga half-life from 26 to 48 hours and auc from 4.55 to 12.08 ng*hr/ml : similar increases in drugb half-life and auc were also detected .
false
a 5.5-fold decrease in the mean druga dose from 6.13 mg/day to 1.13 mg/day ( approximately 80-85 % reduction of drugb dose ) , was necessary to maintain a target inr of 1.5 .
false
when druga therapy is initiated in a patient already receiving treatment with drugb , the inr or prothrombin time ( pt ) should be monitored closely and the dose of drugn adjusted as necessary until a stable target inr or pt has been achieved .
advise
when druga therapy is initiated in a patient already receiving treatment with drugn , the inr or prothrombin time ( pt ) should be monitored closely and the dose of drugb adjusted as necessary until a stable target inr or pt has been achieved .
false
when drugn therapy is initiated in a patient already receiving treatment with druga , the inr or prothrombin time ( pt ) should be monitored closely and the dose of drugb adjusted as necessary until a stable target inr or pt has been achieved .
false
furthermore , in patients receiving both drugs , careful monitoring of the inr or pt , and adjustment of the druga dosage if indicated are recommended when the drugb dose is changed or discontinued .
advise
oral druga drugb may inhibit the metabolism of oral drugn .
false
oral druga drugn may inhibit the metabolism of oral drugb .
false
oral drugn druga may inhibit the metabolism of oral drugb .
mechanism
druga or drugb in patients with edema , concomitant administration with drugn or drugn may increase the edema .
false
druga or drugn in patients with edema , concomitant administration with drugb or drugn may increase the edema .
false
druga or drugn in patients with edema , concomitant administration with drugn or drugb may increase the edema .
false
drugn or druga in patients with edema , concomitant administration with drugb or drugn may increase the edema .
false
drugn or druga in patients with edema , concomitant administration with drugn or drugb may increase the edema .
false
drugn or drugn in patients with edema , concomitant administration with druga or drugb may increase the edema .
false
druga may reverse the analgesic activity of drugb .
effect
concurrent use with druga including drugb , drugn , and drugn ( e.g . smoking ) may result in enhanced vasoconstriction .
false
concurrent use with druga including drugn , drugb , and drugn ( e.g . smoking ) may result in enhanced vasoconstriction .
false
concurrent use with druga including drugn , drugn , and drugb ( e.g . smoking ) may result in enhanced vasoconstriction .
false
concurrent use with drugn including druga , drugb , and drugn ( e.g . smoking ) may result in enhanced vasoconstriction .
false
concurrent use with drugn including druga , drugn , and drugb ( e.g . smoking ) may result in enhanced vasoconstriction .
false
concurrent use with drugn including drugn , druga , and drugb ( e.g . smoking ) may result in enhanced vasoconstriction .
false
although this has not occurred in in vitro studies with druga , interactions with drugb have been reported with drugn since marketing , therefore , physicians should closely monitor patients for a change in dosage requirements when administering drugn to patients on drugn and other highly protein-bound drugs .
false
although this has not occurred in in vitro studies with druga , interactions with drugn have been reported with drugb since marketing , therefore , physicians should closely monitor patients for a change in dosage requirements when administering drugn to patients on drugn and other highly protein-bound drugs .
false
although this has not occurred in in vitro studies with druga , interactions with drugn have been reported with drugn since marketing , therefore , physicians should closely monitor patients for a change in dosage requirements when administering drugb to patients on drugn and other highly protein-bound drugs .
false
although this has not occurred in in vitro studies with druga , interactions with drugn have been reported with drugn since marketing , therefore , physicians should closely monitor patients for a change in dosage requirements when administering drugn to patients on drugb and other highly protein-bound drugs .
false
although this has not occurred in in vitro studies with drugn , interactions with druga have been reported with drugb since marketing , therefore , physicians should closely monitor patients for a change in dosage requirements when administering drugn to patients on drugn and other highly protein-bound drugs .
int
although this has not occurred in in vitro studies with drugn , interactions with druga have been reported with drugn since marketing , therefore , physicians should closely monitor patients for a change in dosage requirements when administering drugb to patients on drugn and other highly protein-bound drugs .
false
although this has not occurred in in vitro studies with drugn , interactions with druga have been reported with drugn since marketing , therefore , physicians should closely monitor patients for a change in dosage requirements when administering drugn to patients on drugb and other highly protein-bound drugs .
false
although this has not occurred in in vitro studies with drugn , interactions with drugn have been reported with druga since marketing , therefore , physicians should closely monitor patients for a change in dosage requirements when administering drugb to patients on drugn and other highly protein-bound drugs .
false
although this has not occurred in in vitro studies with drugn , interactions with drugn have been reported with druga since marketing , therefore , physicians should closely monitor patients for a change in dosage requirements when administering drugn to patients on drugb and other highly protein-bound drugs .
false
although this has not occurred in in vitro studies with drugn , interactions with drugn have been reported with drugn since marketing , therefore , physicians should closely monitor patients for a change in dosage requirements when administering druga to patients on drugb and other highly protein-bound drugs .
advise
plasma levels of druga are depressed to approximately 80 % of their normal values when drugb is administered in conjunction with drugn ( 3900 mg/day ) , but concomitant administration of drugn has no effect on drugn plasma levels . drugn , including drugn , have been reported to increase steady state plasma drugn levels .
false
plasma levels of druga are depressed to approximately 80 % of their normal values when drugn is administered in conjunction with drugb ( 3900 mg/day ) , but concomitant administration of drugn has no effect on drugn plasma levels . drugn , including drugn , have been reported to increase steady state plasma drugn levels .
false
plasma levels of druga are depressed to approximately 80 % of their normal values when drugn is administered in conjunction with drugn ( 3900 mg/day ) , but concomitant administration of drugb has no effect on drugn plasma levels . drugn , including drugn , have been reported to increase steady state plasma drugn levels .
false
plasma levels of druga are depressed to approximately 80 % of their normal values when drugn is administered in conjunction with drugn ( 3900 mg/day ) , but concomitant administration of drugn has no effect on drugb plasma levels . drugn , including drugn , have been reported to increase steady state plasma drugn levels .
false
plasma levels of druga are depressed to approximately 80 % of their normal values when drugn is administered in conjunction with drugn ( 3900 mg/day ) , but concomitant administration of drugn has no effect on drugn plasma levels . drugb , including drugn , have been reported to increase steady state plasma drugn levels .
false
plasma levels of druga are depressed to approximately 80 % of their normal values when drugn is administered in conjunction with drugn ( 3900 mg/day ) , but concomitant administration of drugn has no effect on drugn plasma levels . drugn , including drugb , have been reported to increase steady state plasma drugn levels .
false
plasma levels of druga are depressed to approximately 80 % of their normal values when drugn is administered in conjunction with drugn ( 3900 mg/day ) , but concomitant administration of drugn has no effect on drugn plasma levels . drugn , including drugn , have been reported to increase steady state plasma drugb levels .
false
plasma levels of drugn are depressed to approximately 80 % of their normal values when druga is administered in conjunction with drugb ( 3900 mg/day ) , but concomitant administration of drugn has no effect on drugn plasma levels . drugn , including drugn , have been reported to increase steady state plasma drugn levels .
mechanism
plasma levels of drugn are depressed to approximately 80 % of their normal values when druga is administered in conjunction with drugn ( 3900 mg/day ) , but concomitant administration of drugb has no effect on drugn plasma levels . drugn , including drugn , have been reported to increase steady state plasma drugn levels .
false
plasma levels of drugn are depressed to approximately 80 % of their normal values when druga is administered in conjunction with drugn ( 3900 mg/day ) , but concomitant administration of drugn has no effect on drugb plasma levels . drugn , including drugn , have been reported to increase steady state plasma drugn levels .
false
plasma levels of drugn are depressed to approximately 80 % of their normal values when druga is administered in conjunction with drugn ( 3900 mg/day ) , but concomitant administration of drugn has no effect on drugn plasma levels . drugb , including drugn , have been reported to increase steady state plasma drugn levels .
false
plasma levels of drugn are depressed to approximately 80 % of their normal values when druga is administered in conjunction with drugn ( 3900 mg/day ) , but concomitant administration of drugn has no effect on drugn plasma levels . drugn , including drugb , have been reported to increase steady state plasma drugn levels .
false
plasma levels of drugn are depressed to approximately 80 % of their normal values when druga is administered in conjunction with drugn ( 3900 mg/day ) , but concomitant administration of drugn has no effect on drugn plasma levels . drugn , including drugn , have been reported to increase steady state plasma drugb levels .
false
plasma levels of drugn are depressed to approximately 80 % of their normal values when drugn is administered in conjunction with druga ( 3900 mg/day ) , but concomitant administration of drugb has no effect on drugn plasma levels . drugn , including drugn , have been reported to increase steady state plasma drugn levels .
false
plasma levels of drugn are depressed to approximately 80 % of their normal values when drugn is administered in conjunction with druga ( 3900 mg/day ) , but concomitant administration of drugn has no effect on drugb plasma levels . drugn , including drugn , have been reported to increase steady state plasma drugn levels .
false
plasma levels of drugn are depressed to approximately 80 % of their normal values when drugn is administered in conjunction with druga ( 3900 mg/day ) , but concomitant administration of drugn has no effect on drugn plasma levels . drugb , including drugn , have been reported to increase steady state plasma drugn levels .
false
plasma levels of drugn are depressed to approximately 80 % of their normal values when drugn is administered in conjunction with druga ( 3900 mg/day ) , but concomitant administration of drugn has no effect on drugn plasma levels . drugn , including drugb , have been reported to increase steady state plasma drugn levels .
false
plasma levels of drugn are depressed to approximately 80 % of their normal values when drugn is administered in conjunction with druga ( 3900 mg/day ) , but concomitant administration of drugn has no effect on drugn plasma levels . drugn , including drugn , have been reported to increase steady state plasma drugb levels .
false
plasma levels of drugn are depressed to approximately 80 % of their normal values when drugn is administered in conjunction with drugn ( 3900 mg/day ) , but concomitant administration of druga has no effect on drugb plasma levels . drugn , including drugn , have been reported to increase steady state plasma drugn levels .
false
plasma levels of drugn are depressed to approximately 80 % of their normal values when drugn is administered in conjunction with drugn ( 3900 mg/day ) , but concomitant administration of druga has no effect on drugn plasma levels . drugb , including drugn , have been reported to increase steady state plasma drugn levels .
false
plasma levels of drugn are depressed to approximately 80 % of their normal values when drugn is administered in conjunction with drugn ( 3900 mg/day ) , but concomitant administration of druga has no effect on drugn plasma levels . drugn , including drugb , have been reported to increase steady state plasma drugn levels .
false
plasma levels of drugn are depressed to approximately 80 % of their normal values when drugn is administered in conjunction with drugn ( 3900 mg/day ) , but concomitant administration of druga has no effect on drugn plasma levels . drugn , including drugn , have been reported to increase steady state plasma drugb levels .
false
plasma levels of drugn are depressed to approximately 80 % of their normal values when drugn is administered in conjunction with drugn ( 3900 mg/day ) , but concomitant administration of drugn has no effect on druga plasma levels . drugb , including drugn , have been reported to increase steady state plasma drugn levels .
false
plasma levels of drugn are depressed to approximately 80 % of their normal values when drugn is administered in conjunction with drugn ( 3900 mg/day ) , but concomitant administration of drugn has no effect on druga plasma levels . drugn , including drugb , have been reported to increase steady state plasma drugn levels .
false
plasma levels of drugn are depressed to approximately 80 % of their normal values when drugn is administered in conjunction with drugn ( 3900 mg/day ) , but concomitant administration of drugn has no effect on druga plasma levels . drugn , including drugn , have been reported to increase steady state plasma drugb levels .
false
plasma levels of drugn are depressed to approximately 80 % of their normal values when drugn is administered in conjunction with drugn ( 3900 mg/day ) , but concomitant administration of drugn has no effect on drugn plasma levels . druga , including drugb , have been reported to increase steady state plasma drugn levels .
false
plasma levels of drugn are depressed to approximately 80 % of their normal values when drugn is administered in conjunction with drugn ( 3900 mg/day ) , but concomitant administration of drugn has no effect on drugn plasma levels . druga , including drugn , have been reported to increase steady state plasma drugb levels .
mechanism
plasma levels of drugn are depressed to approximately 80 % of their normal values when drugn is administered in conjunction with drugn ( 3900 mg/day ) , but concomitant administration of drugn has no effect on drugn plasma levels . drugn , including druga , have been reported to increase steady state plasma drugb levels .
mechanism
it is recommended that plasma druga levels be monitored when initiating , adjusting and discontinuing drugb .
advise
the effects of druga on gastrointestinal motility are antagonized by drugb and drugn .
effect
the effects of druga on gastrointestinal motility are antagonized by drugn and drugb .
effect
the effects of drugn on gastrointestinal motility are antagonized by druga and drugb .
false
additive sedative effects can occur when druga is given with drugb , drugn , drugn , drugn , or drugn .
effect
additive sedative effects can occur when druga is given with drugn , drugb , drugn , drugn , or drugn .
effect
additive sedative effects can occur when druga is given with drugn , drugn , drugb , drugn , or drugn .
effect
additive sedative effects can occur when druga is given with drugn , drugn , drugn , drugb , or drugn .
effect
additive sedative effects can occur when druga is given with drugn , drugn , drugn , drugn , or drugb .
effect
additive sedative effects can occur when drugn is given with druga , drugb , drugn , drugn , or drugn .
false
additive sedative effects can occur when drugn is given with druga , drugn , drugb , drugn , or drugn .
false
additive sedative effects can occur when drugn is given with druga , drugn , drugn , drugb , or drugn .
false
additive sedative effects can occur when drugn is given with druga , drugn , drugn , drugn , or drugb .
false
additive sedative effects can occur when drugn is given with drugn , druga , drugb , drugn , or drugn .
false
additive sedative effects can occur when drugn is given with drugn , druga , drugn , drugb , or drugn .
false
additive sedative effects can occur when drugn is given with drugn , druga , drugn , drugn , or drugb .
false
additive sedative effects can occur when drugn is given with drugn , drugn , druga , drugb , or drugn .
false
additive sedative effects can occur when drugn is given with drugn , drugn , druga , drugn , or drugb .
false
additive sedative effects can occur when drugn is given with drugn , drugn , drugn , druga , or drugb .
false
the finding that druga releases catecholamines in patients with essential hypertension suggests that it should be used cautiously , if at all , in patients receiving drugb .
advise
absorption of drugs from the stomach may be diminished ( e.g. , druga ) by drugb , whereas the rate and/or extent of absorption of drugs from the small bowel may be increased ( e.g. , drugn , drugn , drugn , drugn , drugn ) .
mechanism
absorption of drugs from the stomach may be diminished ( e.g. , druga ) by drugn , whereas the rate and/or extent of absorption of drugs from the small bowel may be increased ( e.g. , drugb , drugn , drugn , drugn , drugn ) .
false
absorption of drugs from the stomach may be diminished ( e.g. , druga ) by drugn , whereas the rate and/or extent of absorption of drugs from the small bowel may be increased ( e.g. , drugn , drugb , drugn , drugn , drugn ) .
false
absorption of drugs from the stomach may be diminished ( e.g. , druga ) by drugn , whereas the rate and/or extent of absorption of drugs from the small bowel may be increased ( e.g. , drugn , drugn , drugb , drugn , drugn ) .
false
absorption of drugs from the stomach may be diminished ( e.g. , druga ) by drugn , whereas the rate and/or extent of absorption of drugs from the small bowel may be increased ( e.g. , drugn , drugn , drugn , drugb , drugn ) .
false
absorption of drugs from the stomach may be diminished ( e.g. , druga ) by drugn , whereas the rate and/or extent of absorption of drugs from the small bowel may be increased ( e.g. , drugn , drugn , drugn , drugn , drugb ) .
false
absorption of drugs from the stomach may be diminished ( e.g. , drugn ) by druga , whereas the rate and/or extent of absorption of drugs from the small bowel may be increased ( e.g. , drugb , drugn , drugn , drugn , drugn ) .
mechanism
absorption of drugs from the stomach may be diminished ( e.g. , drugn ) by druga , whereas the rate and/or extent of absorption of drugs from the small bowel may be increased ( e.g. , drugn , drugb , drugn , drugn , drugn ) .
false
absorption of drugs from the stomach may be diminished ( e.g. , drugn ) by druga , whereas the rate and/or extent of absorption of drugs from the small bowel may be increased ( e.g. , drugn , drugn , drugb , drugn , drugn ) .
false
absorption of drugs from the stomach may be diminished ( e.g. , drugn ) by druga , whereas the rate and/or extent of absorption of drugs from the small bowel may be increased ( e.g. , drugn , drugn , drugn , drugb , drugn ) .
false
absorption of drugs from the stomach may be diminished ( e.g. , drugn ) by druga , whereas the rate and/or extent of absorption of drugs from the small bowel may be increased ( e.g. , drugn , drugn , drugn , drugn , drugb ) .
false
absorption of drugs from the stomach may be diminished ( e.g. , drugn ) by drugn , whereas the rate and/or extent of absorption of drugs from the small bowel may be increased ( e.g. , druga , drugb , drugn , drugn , drugn ) .
false
absorption of drugs from the stomach may be diminished ( e.g. , drugn ) by drugn , whereas the rate and/or extent of absorption of drugs from the small bowel may be increased ( e.g. , druga , drugn , drugb , drugn , drugn ) .
false
absorption of drugs from the stomach may be diminished ( e.g. , drugn ) by drugn , whereas the rate and/or extent of absorption of drugs from the small bowel may be increased ( e.g. , druga , drugn , drugn , drugb , drugn ) .
false
absorption of drugs from the stomach may be diminished ( e.g. , drugn ) by drugn , whereas the rate and/or extent of absorption of drugs from the small bowel may be increased ( e.g. , druga , drugn , drugn , drugn , drugb ) .
false
absorption of drugs from the stomach may be diminished ( e.g. , drugn ) by drugn , whereas the rate and/or extent of absorption of drugs from the small bowel may be increased ( e.g. , drugn , druga , drugb , drugn , drugn ) .
false
absorption of drugs from the stomach may be diminished ( e.g. , drugn ) by drugn , whereas the rate and/or extent of absorption of drugs from the small bowel may be increased ( e.g. , drugn , druga , drugn , drugb , drugn ) .
false
absorption of drugs from the stomach may be diminished ( e.g. , drugn ) by drugn , whereas the rate and/or extent of absorption of drugs from the small bowel may be increased ( e.g. , drugn , druga , drugn , drugn , drugb ) .
false
absorption of drugs from the stomach may be diminished ( e.g. , drugn ) by drugn , whereas the rate and/or extent of absorption of drugs from the small bowel may be increased ( e.g. , drugn , drugn , druga , drugb , drugn ) .
false
absorption of drugs from the stomach may be diminished ( e.g. , drugn ) by drugn , whereas the rate and/or extent of absorption of drugs from the small bowel may be increased ( e.g. , drugn , drugn , druga , drugn , drugb ) .
false
absorption of drugs from the stomach may be diminished ( e.g. , drugn ) by drugn , whereas the rate and/or extent of absorption of drugs from the small bowel may be increased ( e.g. , drugn , drugn , drugn , druga , drugb ) .
false
because the action of druga will influence the delivery of food to the intestines and thus the rate of absorption , drugb dosage or timing of dosage may require adjustment .
advise
druga at a dose of 10 mg once daily dosed to pharmacokinetic steady state - did not cause clinically significant changes in the kinetics of a single intravenous dose of drugb ( predominantly a cytochrome p450 1a2 substrate ) .
false
- did not change the pharmacokinetic profile of druga ( a substrate of cytochromes p450 2a6 and 2c9 ) or influence the effect of a single 30-mg oral dose of drugb on prothrombin time or the inr ( international normalized ratio ) .
false
- did not change the plasma concentration profile of druga ( a substrate of cytochrome p450 3a4 ) or drugb , its carboxylated metabolite , and did not prolong the qtc interval following co-administration with drugn 60 mg twice daily .
false
- did not change the plasma concentration profile of druga ( a substrate of cytochrome p450 3a4 ) or drugn , its carboxylated metabolite , and did not prolong the qtc interval following co-administration with drugb 60 mg twice daily .
false
- did not change the plasma concentration profile of drugn ( a substrate of cytochrome p450 3a4 ) or druga , its carboxylated metabolite , and did not prolong the qtc interval following co-administration with drugb 60 mg twice daily .
false
druga at doses of 100 mg daily dosed to pharmacokinetic steady state : - did not significantly alter the plasma concentrations of either component of an oral drugb containing drugn 1 mg/ethinyl drugn 35 mcg .
false
druga at doses of 100 mg daily dosed to pharmacokinetic steady state : - did not significantly alter the plasma concentrations of either component of an oral drugn containing drugb 1 mg/ethinyl drugn 35 mcg .
false
druga at doses of 100 mg daily dosed to pharmacokinetic steady state : - did not significantly alter the plasma concentrations of either component of an oral drugn containing drugn 1 mg/ethinyl drugb 35 mcg .
false
drugn at doses of 100 mg daily dosed to pharmacokinetic steady state : - did not significantly alter the plasma concentrations of either component of an oral druga containing drugb 1 mg/ethinyl drugn 35 mcg .
false
drugn at doses of 100 mg daily dosed to pharmacokinetic steady state : - did not significantly alter the plasma concentrations of either component of an oral druga containing drugn 1 mg/ethinyl drugb 35 mcg .
false
drugn at doses of 100 mg daily dosed to pharmacokinetic steady state : - did not significantly alter the plasma concentrations of either component of an oral drugn containing druga 1 mg/ethinyl drugb 35 mcg .
false
- did not cause any clinically significant change in plasma profiles of druga or drugb following administration of either oral drugn or intravenous drugn .
false
- did not cause any clinically significant change in plasma profiles of druga or drugn following administration of either oral drugb or intravenous drugn .
false
- did not cause any clinically significant change in plasma profiles of druga or drugn following administration of either oral drugn or intravenous drugb .
false
- did not cause any clinically significant change in plasma profiles of drugn or druga following administration of either oral drugb or intravenous drugn .
false
- did not cause any clinically significant change in plasma profiles of drugn or druga following administration of either oral drugn or intravenous drugb .
false
- did not cause any clinically significant change in plasma profiles of drugn or drugn following administration of either oral druga or intravenous drugb .
false
druga , which induces hepatic metabolism , decreased the auc of drugb approximately 40 % following a single 10-mg dose of drugn .
false
druga , which induces hepatic metabolism , decreased the auc of drugn approximately 40 % following a single 10-mg dose of drugb .
false
drugn , which induces hepatic metabolism , decreased the auc of druga approximately 40 % following a single 10-mg dose of drugb .
false
it is reasonable to employ appropriate clinical monitoring when potent cytochrome p450 enzyme inducers , such as druga or drugb , are co-administered with drugn .
false
it is reasonable to employ appropriate clinical monitoring when potent cytochrome p450 enzyme inducers , such as druga or drugn , are co-administered with drugb .
advise
it is reasonable to employ appropriate clinical monitoring when potent cytochrome p450 enzyme inducers , such as drugn or druga , are co-administered with drugb .
advise
in drug-interaction studies , the recommended clinical dose of druga did not have clinically important effects on the pharmacokinetics of the following drugs : drugb , drugn , drugn , oral drugn ( drugn 1 mg/ drugn 35 mcg ) , drugn , drugn , and drugn .
false
in drug-interaction studies , the recommended clinical dose of druga did not have clinically important effects on the pharmacokinetics of the following drugs : drugn , drugb , drugn , oral drugn ( drugn 1 mg/ drugn 35 mcg ) , drugn , drugn , and drugn .
false
in drug-interaction studies , the recommended clinical dose of druga did not have clinically important effects on the pharmacokinetics of the following drugs : drugn , drugn , drugb , oral drugn ( drugn 1 mg/ drugn 35 mcg ) , drugn , drugn , and drugn .
false
in drug-interaction studies , the recommended clinical dose of druga did not have clinically important effects on the pharmacokinetics of the following drugs : drugn , drugn , drugn , oral drugb ( drugn 1 mg/ drugn 35 mcg ) , drugn , drugn , and drugn .
false
in drug-interaction studies , the recommended clinical dose of druga did not have clinically important effects on the pharmacokinetics of the following drugs : drugn , drugn , drugn , oral drugn ( drugb 1 mg/ drugn 35 mcg ) , drugn , drugn , and drugn .
false
in drug-interaction studies , the recommended clinical dose of druga did not have clinically important effects on the pharmacokinetics of the following drugs : drugn , drugn , drugn , oral drugn ( drugn 1 mg/ drugb 35 mcg ) , drugn , drugn , and drugn .
false
in drug-interaction studies , the recommended clinical dose of druga did not have clinically important effects on the pharmacokinetics of the following drugs : drugn , drugn , drugn , oral drugn ( drugn 1 mg/ drugn 35 mcg ) , drugb , drugn , and drugn .
false
in drug-interaction studies , the recommended clinical dose of druga did not have clinically important effects on the pharmacokinetics of the following drugs : drugn , drugn , drugn , oral drugn ( drugn 1 mg/ drugn 35 mcg ) , drugn , drugb , and drugn .
false
in drug-interaction studies , the recommended clinical dose of druga did not have clinically important effects on the pharmacokinetics of the following drugs : drugn , drugn , drugn , oral drugn ( drugn 1 mg/ drugn 35 mcg ) , drugn , drugn , and drugb .
false
in drug-interaction studies , the recommended clinical dose of drugn did not have clinically important effects on the pharmacokinetics of the following drugs : druga , drugb , drugn , oral drugn ( drugn 1 mg/ drugn 35 mcg ) , drugn , drugn , and drugn .
false
in drug-interaction studies , the recommended clinical dose of drugn did not have clinically important effects on the pharmacokinetics of the following drugs : druga , drugn , drugb , oral drugn ( drugn 1 mg/ drugn 35 mcg ) , drugn , drugn , and drugn .
false
in drug-interaction studies , the recommended clinical dose of drugn did not have clinically important effects on the pharmacokinetics of the following drugs : druga , drugn , drugn , oral drugb ( drugn 1 mg/ drugn 35 mcg ) , drugn , drugn , and drugn .
false
in drug-interaction studies , the recommended clinical dose of drugn did not have clinically important effects on the pharmacokinetics of the following drugs : druga , drugn , drugn , oral drugn ( drugb 1 mg/ drugn 35 mcg ) , drugn , drugn , and drugn .
false
in drug-interaction studies , the recommended clinical dose of drugn did not have clinically important effects on the pharmacokinetics of the following drugs : druga , drugn , drugn , oral drugn ( drugn 1 mg/ drugb 35 mcg ) , drugn , drugn , and drugn .
false
in drug-interaction studies , the recommended clinical dose of drugn did not have clinically important effects on the pharmacokinetics of the following drugs : druga , drugn , drugn , oral drugn ( drugn 1 mg/ drugn 35 mcg ) , drugb , drugn , and drugn .
false
in drug-interaction studies , the recommended clinical dose of drugn did not have clinically important effects on the pharmacokinetics of the following drugs : druga , drugn , drugn , oral drugn ( drugn 1 mg/ drugn 35 mcg ) , drugn , drugb , and drugn .
false
in drug-interaction studies , the recommended clinical dose of drugn did not have clinically important effects on the pharmacokinetics of the following drugs : druga , drugn , drugn , oral drugn ( drugn 1 mg/ drugn 35 mcg ) , drugn , drugn , and drugb .
false
in drug-interaction studies , the recommended clinical dose of drugn did not have clinically important effects on the pharmacokinetics of the following drugs : drugn , druga , drugb , oral drugn ( drugn 1 mg/ drugn 35 mcg ) , drugn , drugn , and drugn .
false
in drug-interaction studies , the recommended clinical dose of drugn did not have clinically important effects on the pharmacokinetics of the following drugs : drugn , druga , drugn , oral drugb ( drugn 1 mg/ drugn 35 mcg ) , drugn , drugn , and drugn .
false
in drug-interaction studies , the recommended clinical dose of drugn did not have clinically important effects on the pharmacokinetics of the following drugs : drugn , druga , drugn , oral drugn ( drugb 1 mg/ drugn 35 mcg ) , drugn , drugn , and drugn .
false
in drug-interaction studies , the recommended clinical dose of drugn did not have clinically important effects on the pharmacokinetics of the following drugs : drugn , druga , drugn , oral drugn ( drugn 1 mg/ drugb 35 mcg ) , drugn , drugn , and drugn .
false
in drug-interaction studies , the recommended clinical dose of drugn did not have clinically important effects on the pharmacokinetics of the following drugs : drugn , druga , drugn , oral drugn ( drugn 1 mg/ drugn 35 mcg ) , drugb , drugn , and drugn .
false
in drug-interaction studies , the recommended clinical dose of drugn did not have clinically important effects on the pharmacokinetics of the following drugs : drugn , druga , drugn , oral drugn ( drugn 1 mg/ drugn 35 mcg ) , drugn , drugb , and drugn .
false
in drug-interaction studies , the recommended clinical dose of drugn did not have clinically important effects on the pharmacokinetics of the following drugs : drugn , druga , drugn , oral drugn ( drugn 1 mg/ drugn 35 mcg ) , drugn , drugn , and drugb .
false
in drug-interaction studies , the recommended clinical dose of drugn did not have clinically important effects on the pharmacokinetics of the following drugs : drugn , drugn , druga , oral drugb ( drugn 1 mg/ drugn 35 mcg ) , drugn , drugn , and drugn .
false
in drug-interaction studies , the recommended clinical dose of drugn did not have clinically important effects on the pharmacokinetics of the following drugs : drugn , drugn , druga , oral drugn ( drugb 1 mg/ drugn 35 mcg ) , drugn , drugn , and drugn .
false
in drug-interaction studies , the recommended clinical dose of drugn did not have clinically important effects on the pharmacokinetics of the following drugs : drugn , drugn , druga , oral drugn ( drugn 1 mg/ drugb 35 mcg ) , drugn , drugn , and drugn .
false
in drug-interaction studies , the recommended clinical dose of drugn did not have clinically important effects on the pharmacokinetics of the following drugs : drugn , drugn , druga , oral drugn ( drugn 1 mg/ drugn 35 mcg ) , drugb , drugn , and drugn .
false
in drug-interaction studies , the recommended clinical dose of drugn did not have clinically important effects on the pharmacokinetics of the following drugs : drugn , drugn , druga , oral drugn ( drugn 1 mg/ drugn 35 mcg ) , drugn , drugb , and drugn .
false
in drug-interaction studies , the recommended clinical dose of drugn did not have clinically important effects on the pharmacokinetics of the following drugs : drugn , drugn , druga , oral drugn ( drugn 1 mg/ drugn 35 mcg ) , drugn , drugn , and drugb .
false
in drug-interaction studies , the recommended clinical dose of drugn did not have clinically important effects on the pharmacokinetics of the following drugs : drugn , drugn , drugn , oral druga ( drugb 1 mg/ drugn 35 mcg ) , drugn , drugn , and drugn .
false
in drug-interaction studies , the recommended clinical dose of drugn did not have clinically important effects on the pharmacokinetics of the following drugs : drugn , drugn , drugn , oral druga ( drugn 1 mg/ drugb 35 mcg ) , drugn , drugn , and drugn .
false
in drug-interaction studies , the recommended clinical dose of drugn did not have clinically important effects on the pharmacokinetics of the following drugs : drugn , drugn , drugn , oral druga ( drugn 1 mg/ drugn 35 mcg ) , drugb , drugn , and drugn .
false
in drug-interaction studies , the recommended clinical dose of drugn did not have clinically important effects on the pharmacokinetics of the following drugs : drugn , drugn , drugn , oral druga ( drugn 1 mg/ drugn 35 mcg ) , drugn , drugb , and drugn .
false
in drug-interaction studies , the recommended clinical dose of drugn did not have clinically important effects on the pharmacokinetics of the following drugs : drugn , drugn , drugn , oral druga ( drugn 1 mg/ drugn 35 mcg ) , drugn , drugn , and drugb .
false
in drug-interaction studies , the recommended clinical dose of drugn did not have clinically important effects on the pharmacokinetics of the following drugs : drugn , drugn , drugn , oral drugn ( druga 1 mg/ drugb 35 mcg ) , drugn , drugn , and drugn .
false
in drug-interaction studies , the recommended clinical dose of drugn did not have clinically important effects on the pharmacokinetics of the following drugs : drugn , drugn , drugn , oral drugn ( druga 1 mg/ drugn 35 mcg ) , drugb , drugn , and drugn .
false
in drug-interaction studies , the recommended clinical dose of drugn did not have clinically important effects on the pharmacokinetics of the following drugs : drugn , drugn , drugn , oral drugn ( druga 1 mg/ drugn 35 mcg ) , drugn , drugb , and drugn .
false
in drug-interaction studies , the recommended clinical dose of drugn did not have clinically important effects on the pharmacokinetics of the following drugs : drugn , drugn , drugn , oral drugn ( druga 1 mg/ drugn 35 mcg ) , drugn , drugn , and drugb .
false
in drug-interaction studies , the recommended clinical dose of drugn did not have clinically important effects on the pharmacokinetics of the following drugs : drugn , drugn , drugn , oral drugn ( drugn 1 mg/ druga 35 mcg ) , drugb , drugn , and drugn .
false
in drug-interaction studies , the recommended clinical dose of drugn did not have clinically important effects on the pharmacokinetics of the following drugs : drugn , drugn , drugn , oral drugn ( drugn 1 mg/ druga 35 mcg ) , drugn , drugb , and drugn .
false
in drug-interaction studies , the recommended clinical dose of drugn did not have clinically important effects on the pharmacokinetics of the following drugs : drugn , drugn , drugn , oral drugn ( drugn 1 mg/ druga 35 mcg ) , drugn , drugn , and drugb .
false
in drug-interaction studies , the recommended clinical dose of drugn did not have clinically important effects on the pharmacokinetics of the following drugs : drugn , drugn , drugn , oral drugn ( drugn 1 mg/ drugn 35 mcg ) , druga , drugb , and drugn .
false
in drug-interaction studies , the recommended clinical dose of drugn did not have clinically important effects on the pharmacokinetics of the following drugs : drugn , drugn , drugn , oral drugn ( drugn 1 mg/ drugn 35 mcg ) , druga , drugn , and drugb .
false
in drug-interaction studies , the recommended clinical dose of drugn did not have clinically important effects on the pharmacokinetics of the following drugs : drugn , drugn , drugn , oral drugn ( drugn 1 mg/ drugn 35 mcg ) , drugn , druga , and drugb .
false
these medications included druga , drugb , drugn , drugn , and drugn .
false
these medications included druga , drugn , drugb , drugn , and drugn .
false
these medications included druga , drugn , drugn , drugb , and drugn .
false
these medications included druga , drugn , drugn , drugn , and drugb .
false
these medications included drugn , druga , drugb , drugn , and drugn .
false
these medications included drugn , druga , drugn , drugb , and drugn .
false
these medications included drugn , druga , drugn , drugn , and drugb .
false
these medications included drugn , drugn , druga , drugb , and drugn .
false
these medications included drugn , drugn , druga , drugn , and drugb .
false
these medications included drugn , drugn , drugn , druga , and drugb .
false
druga , which induces hepatic metabolism , decreased the auc of drugb approximately 40 % following a single 10-mg dose of drugn .
false
druga , which induces hepatic metabolism , decreased the auc of drugn approximately 40 % following a single 10-mg dose of drugb .
false
drugn , which induces hepatic metabolism , decreased the auc of druga approximately 40 % following a single 10-mg dose of drugb .
false
it is reasonable to employ appropriate clinical monitoring when potent cytochrome p450 enzyme inducers , such as druga or drugb , are co-administered with drugn .
false
it is reasonable to employ appropriate clinical monitoring when potent cytochrome p450 enzyme inducers , such as druga or drugn , are co-administered with drugb .
advise
it is reasonable to employ appropriate clinical monitoring when potent cytochrome p450 enzyme inducers , such as drugn or druga , are co-administered with drugb .
advise
no pharmacokinetic interaction between 85 mg/m2 druga and infusional drugb has been observed in patients treated every 2 weeks .
false
increases of druga plasma concentrations by approximately 20 % have been observed with doses of 130 mg/m2 drugb dosed every 3 weeks .
mechanism
the concomitant use of druga with other drugb or with other agents which produce dry mouth , constipation , somnolence ( drowsiness ) , and/or other anticholinergic-like effects may increase the frequency and/or severity of such effects .
effect
mean druga plasma concentrations were approximately 2 fold higher when drugb was administered with drugn , a potent cyp3a4 inhibitor .
false
mean druga plasma concentrations were approximately 2 fold higher when drugn was administered with drugb , a potent cyp3a4 inhibitor .
false
mean drugn plasma concentrations were approximately 2 fold higher when druga was administered with drugb , a potent cyp3a4 inhibitor .
mechanism
other inhibitors of the cytochrome p450 3a4 enzyme system , such as druga ( e.g. , drugb and drugn ) or drugn ( e.g. , drugn and drugn ) , may alter drugn mean pharmacokinetic parameters ( i.e. , cmax and auc ) .
false
other inhibitors of the cytochrome p450 3a4 enzyme system , such as druga ( e.g. , drugn and drugb ) or drugn ( e.g. , drugn and drugn ) , may alter drugn mean pharmacokinetic parameters ( i.e. , cmax and auc ) .
false
other inhibitors of the cytochrome p450 3a4 enzyme system , such as druga ( e.g. , drugn and drugn ) or drugb ( e.g. , drugn and drugn ) , may alter drugn mean pharmacokinetic parameters ( i.e. , cmax and auc ) .
false
other inhibitors of the cytochrome p450 3a4 enzyme system , such as druga ( e.g. , drugn and drugn ) or drugn ( e.g. , drugb and drugn ) , may alter drugn mean pharmacokinetic parameters ( i.e. , cmax and auc ) .
false
other inhibitors of the cytochrome p450 3a4 enzyme system , such as druga ( e.g. , drugn and drugn ) or drugn ( e.g. , drugn and drugb ) , may alter drugn mean pharmacokinetic parameters ( i.e. , cmax and auc ) .
false
other inhibitors of the cytochrome p450 3a4 enzyme system , such as druga ( e.g. , drugn and drugn ) or drugn ( e.g. , drugn and drugn ) , may alter drugb mean pharmacokinetic parameters ( i.e. , cmax and auc ) .
mechanism
other inhibitors of the cytochrome p450 3a4 enzyme system , such as drugn ( e.g. , druga and drugb ) or drugn ( e.g. , drugn and drugn ) , may alter drugn mean pharmacokinetic parameters ( i.e. , cmax and auc ) .
false
other inhibitors of the cytochrome p450 3a4 enzyme system , such as drugn ( e.g. , druga and drugn ) or drugb ( e.g. , drugn and drugn ) , may alter drugn mean pharmacokinetic parameters ( i.e. , cmax and auc ) .
false
other inhibitors of the cytochrome p450 3a4 enzyme system , such as drugn ( e.g. , druga and drugn ) or drugn ( e.g. , drugb and drugn ) , may alter drugn mean pharmacokinetic parameters ( i.e. , cmax and auc ) .
false
other inhibitors of the cytochrome p450 3a4 enzyme system , such as drugn ( e.g. , druga and drugn ) or drugn ( e.g. , drugn and drugb ) , may alter drugn mean pharmacokinetic parameters ( i.e. , cmax and auc ) .
false
other inhibitors of the cytochrome p450 3a4 enzyme system , such as drugn ( e.g. , druga and drugn ) or drugn ( e.g. , drugn and drugn ) , may alter drugb mean pharmacokinetic parameters ( i.e. , cmax and auc ) .
mechanism
other inhibitors of the cytochrome p450 3a4 enzyme system , such as drugn ( e.g. , drugn and druga ) or drugb ( e.g. , drugn and drugn ) , may alter drugn mean pharmacokinetic parameters ( i.e. , cmax and auc ) .
false
other inhibitors of the cytochrome p450 3a4 enzyme system , such as drugn ( e.g. , drugn and druga ) or drugn ( e.g. , drugb and drugn ) , may alter drugn mean pharmacokinetic parameters ( i.e. , cmax and auc ) .
false
other inhibitors of the cytochrome p450 3a4 enzyme system , such as drugn ( e.g. , drugn and druga ) or drugn ( e.g. , drugn and drugb ) , may alter drugn mean pharmacokinetic parameters ( i.e. , cmax and auc ) .
false
other inhibitors of the cytochrome p450 3a4 enzyme system , such as drugn ( e.g. , drugn and druga ) or drugn ( e.g. , drugn and drugn ) , may alter drugb mean pharmacokinetic parameters ( i.e. , cmax and auc ) .
mechanism
other inhibitors of the cytochrome p450 3a4 enzyme system , such as drugn ( e.g. , drugn and drugn ) or druga ( e.g. , drugb and drugn ) , may alter drugn mean pharmacokinetic parameters ( i.e. , cmax and auc ) .
false
other inhibitors of the cytochrome p450 3a4 enzyme system , such as drugn ( e.g. , drugn and drugn ) or druga ( e.g. , drugn and drugb ) , may alter drugn mean pharmacokinetic parameters ( i.e. , cmax and auc ) .
false
other inhibitors of the cytochrome p450 3a4 enzyme system , such as drugn ( e.g. , drugn and drugn ) or druga ( e.g. , drugn and drugn ) , may alter drugb mean pharmacokinetic parameters ( i.e. , cmax and auc ) .
mechanism
other inhibitors of the cytochrome p450 3a4 enzyme system , such as drugn ( e.g. , drugn and drugn ) or drugn ( e.g. , druga and drugb ) , may alter drugn mean pharmacokinetic parameters ( i.e. , cmax and auc ) .
false
other inhibitors of the cytochrome p450 3a4 enzyme system , such as drugn ( e.g. , drugn and drugn ) or drugn ( e.g. , druga and drugn ) , may alter drugb mean pharmacokinetic parameters ( i.e. , cmax and auc ) .
mechanism
other inhibitors of the cytochrome p450 3a4 enzyme system , such as drugn ( e.g. , drugn and drugn ) or drugn ( e.g. , drugn and druga ) , may alter drugb mean pharmacokinetic parameters ( i.e. , cmax and auc ) .
mechanism
concurrent ingestion of druga ( 20 ml of drugb containing drugn , drugn , and drugn ) did not significantly affect the exposure of drugn or drugn .
false
concurrent ingestion of druga ( 20 ml of drugn containing drugb , drugn , and drugn ) did not significantly affect the exposure of drugn or drugn .
false
concurrent ingestion of druga ( 20 ml of drugn containing drugn , drugb , and drugn ) did not significantly affect the exposure of drugn or drugn .
false
concurrent ingestion of druga ( 20 ml of drugn containing drugn , drugn , and drugb ) did not significantly affect the exposure of drugn or drugn .
false
concurrent ingestion of druga ( 20 ml of drugn containing drugn , drugn , and drugn ) did not significantly affect the exposure of drugb or drugn .
false
concurrent ingestion of druga ( 20 ml of drugn containing drugn , drugn , and drugn ) did not significantly affect the exposure of drugn or drugb .
false
concurrent ingestion of drugn ( 20 ml of druga containing drugb , drugn , and drugn ) did not significantly affect the exposure of drugn or drugn .
false
concurrent ingestion of drugn ( 20 ml of druga containing drugn , drugb , and drugn ) did not significantly affect the exposure of drugn or drugn .
false
concurrent ingestion of drugn ( 20 ml of druga containing drugn , drugn , and drugb ) did not significantly affect the exposure of drugn or drugn .
false
concurrent ingestion of drugn ( 20 ml of druga containing drugn , drugn , and drugn ) did not significantly affect the exposure of drugb or drugn .
false
concurrent ingestion of drugn ( 20 ml of druga containing drugn , drugn , and drugn ) did not significantly affect the exposure of drugn or drugb .
false
concurrent ingestion of drugn ( 20 ml of drugn containing druga , drugb , and drugn ) did not significantly affect the exposure of drugn or drugn .
false
concurrent ingestion of drugn ( 20 ml of drugn containing druga , drugn , and drugb ) did not significantly affect the exposure of drugn or drugn .
false
concurrent ingestion of drugn ( 20 ml of drugn containing druga , drugn , and drugn ) did not significantly affect the exposure of drugb or drugn .
false
concurrent ingestion of drugn ( 20 ml of drugn containing druga , drugn , and drugn ) did not significantly affect the exposure of drugn or drugb .
false
concurrent ingestion of drugn ( 20 ml of drugn containing drugn , druga , and drugb ) did not significantly affect the exposure of drugn or drugn .
false
concurrent ingestion of drugn ( 20 ml of drugn containing drugn , druga , and drugn ) did not significantly affect the exposure of drugb or drugn .
false
concurrent ingestion of drugn ( 20 ml of drugn containing drugn , druga , and drugn ) did not significantly affect the exposure of drugn or drugb .
false
concurrent ingestion of drugn ( 20 ml of drugn containing drugn , drugn , and druga ) did not significantly affect the exposure of drugb or drugn .
false
concurrent ingestion of drugn ( 20 ml of drugn containing drugn , drugn , and druga ) did not significantly affect the exposure of drugn or drugb .
false
concurrent ingestion of drugn ( 20 ml of drugn containing drugn , drugn , and drugn ) did not significantly affect the exposure of druga or drugb .
false
although druga ( a mixture of three stereoisomers ) has been administered safely following succinylcholine-facilitated tracheal intubation , the interaction between drugb and drugn has not been systematically studied .
false
although druga ( a mixture of three stereoisomers ) has been administered safely following succinylcholine-facilitated tracheal intubation , the interaction between drugn and drugb has not been systematically studied .
false
although drugn ( a mixture of three stereoisomers ) has been administered safely following succinylcholine-facilitated tracheal intubation , the interaction between druga and drugb has not been systematically studied .
false
prior administration of druga can potentiate the neuromuscular blocking effects of drugb .
effect
evidence of spontaneous recovery from druga should be observed before the administration of drugb .
advise
the use of druga before drugb to attenuate some of the side effects of drugn has not been studied .
false
the use of druga before drugn to attenuate some of the side effects of drugb has not been studied .
false
the use of drugn before druga to attenuate some of the side effects of drugb has not been studied .
false
there are no clinical data on the use of druga with other drugb .
false
druga and drugb ( administered with drugn / drugn to achieve 1.25 m.c .
false
druga and drugn ( administered with drugb / drugn to achieve 1.25 m.c .
false
druga and drugn ( administered with drugn / drugb to achieve 1.25 m.c .
false
drugn and druga ( administered with drugb / drugn to achieve 1.25 m.c .
false
drugn and druga ( administered with drugn / drugb to achieve 1.25 m.c .
false
drugn and drugn ( administered with druga / drugb to achieve 1.25 m.c .
false
a greater potentiation of the neuromuscular blocking effects of druga may be expected with higher concentrations of drugb or drugn .
false
a greater potentiation of the neuromuscular blocking effects of druga may be expected with higher concentrations of drugn or drugb .
false
a greater potentiation of the neuromuscular blocking effects of drugn may be expected with higher concentrations of druga or drugb .
false
other drugs which may enhance the neuromuscular blocking action of druga such as drugb include certain drugn ( e.g. , drugn , drugn , drugn , drugn , drugn , drugn , drugn , and drugn ) , drugn salts , drugn , local drugn , drugn , and drugn .
false
other drugs which may enhance the neuromuscular blocking action of druga such as drugn include certain drugb ( e.g. , drugn , drugn , drugn , drugn , drugn , drugn , drugn , and drugn ) , drugn salts , drugn , local drugn , drugn , and drugn .
int
other drugs which may enhance the neuromuscular blocking action of druga such as drugn include certain drugn ( e.g. , drugb , drugn , drugn , drugn , drugn , drugn , drugn , and drugn ) , drugn salts , drugn , local drugn , drugn , and drugn .
int
other drugs which may enhance the neuromuscular blocking action of druga such as drugn include certain drugn ( e.g. , drugn , drugb , drugn , drugn , drugn , drugn , drugn , and drugn ) , drugn salts , drugn , local drugn , drugn , and drugn .
int
other drugs which may enhance the neuromuscular blocking action of druga such as drugn include certain drugn ( e.g. , drugn , drugn , drugb , drugn , drugn , drugn , drugn , and drugn ) , drugn salts , drugn , local drugn , drugn , and drugn .
int
other drugs which may enhance the neuromuscular blocking action of druga such as drugn include certain drugn ( e.g. , drugn , drugn , drugn , drugb , drugn , drugn , drugn , and drugn ) , drugn salts , drugn , local drugn , drugn , and drugn .
int
other drugs which may enhance the neuromuscular blocking action of druga such as drugn include certain drugn ( e.g. , drugn , drugn , drugn , drugn , drugb , drugn , drugn , and drugn ) , drugn salts , drugn , local drugn , drugn , and drugn .
int
other drugs which may enhance the neuromuscular blocking action of druga such as drugn include certain drugn ( e.g. , drugn , drugn , drugn , drugn , drugn , drugb , drugn , and drugn ) , drugn salts , drugn , local drugn , drugn , and drugn .
int
other drugs which may enhance the neuromuscular blocking action of druga such as drugn include certain drugn ( e.g. , drugn , drugn , drugn , drugn , drugn , drugn , drugb , and drugn ) , drugn salts , drugn , local drugn , drugn , and drugn .
int
other drugs which may enhance the neuromuscular blocking action of druga such as drugn include certain drugn ( e.g. , drugn , drugn , drugn , drugn , drugn , drugn , drugn , and drugb ) , drugn salts , drugn , local drugn , drugn , and drugn .
int
other drugs which may enhance the neuromuscular blocking action of druga such as drugn include certain drugn ( e.g. , drugn , drugn , drugn , drugn , drugn , drugn , drugn , and drugn ) , drugb salts , drugn , local drugn , drugn , and drugn .
int
other drugs which may enhance the neuromuscular blocking action of druga such as drugn include certain drugn ( e.g. , drugn , drugn , drugn , drugn , drugn , drugn , drugn , and drugn ) , drugn salts , drugb , local drugn , drugn , and drugn .
int
other drugs which may enhance the neuromuscular blocking action of druga such as drugn include certain drugn ( e.g. , drugn , drugn , drugn , drugn , drugn , drugn , drugn , and drugn ) , drugn salts , drugn , local drugb , drugn , and drugn .
int
other drugs which may enhance the neuromuscular blocking action of druga such as drugn include certain drugn ( e.g. , drugn , drugn , drugn , drugn , drugn , drugn , drugn , and drugn ) , drugn salts , drugn , local drugn , drugb , and drugn .
int
other drugs which may enhance the neuromuscular blocking action of druga such as drugn include certain drugn ( e.g. , drugn , drugn , drugn , drugn , drugn , drugn , drugn , and drugn ) , drugn salts , drugn , local drugn , drugn , and drugb .
int
other drugs which may enhance the neuromuscular blocking action of drugn such as druga include certain drugb ( e.g. , drugn , drugn , drugn , drugn , drugn , drugn , drugn , and drugn ) , drugn salts , drugn , local drugn , drugn , and drugn .
int
other drugs which may enhance the neuromuscular blocking action of drugn such as druga include certain drugn ( e.g. , drugb , drugn , drugn , drugn , drugn , drugn , drugn , and drugn ) , drugn salts , drugn , local drugn , drugn , and drugn .
int
other drugs which may enhance the neuromuscular blocking action of drugn such as druga include certain drugn ( e.g. , drugn , drugb , drugn , drugn , drugn , drugn , drugn , and drugn ) , drugn salts , drugn , local drugn , drugn , and drugn .
int
other drugs which may enhance the neuromuscular blocking action of drugn such as druga include certain drugn ( e.g. , drugn , drugn , drugb , drugn , drugn , drugn , drugn , and drugn ) , drugn salts , drugn , local drugn , drugn , and drugn .
int
other drugs which may enhance the neuromuscular blocking action of drugn such as druga include certain drugn ( e.g. , drugn , drugn , drugn , drugb , drugn , drugn , drugn , and drugn ) , drugn salts , drugn , local drugn , drugn , and drugn .
int
other drugs which may enhance the neuromuscular blocking action of drugn such as druga include certain drugn ( e.g. , drugn , drugn , drugn , drugn , drugb , drugn , drugn , and drugn ) , drugn salts , drugn , local drugn , drugn , and drugn .
int
other drugs which may enhance the neuromuscular blocking action of drugn such as druga include certain drugn ( e.g. , drugn , drugn , drugn , drugn , drugn , drugb , drugn , and drugn ) , drugn salts , drugn , local drugn , drugn , and drugn .
int
other drugs which may enhance the neuromuscular blocking action of drugn such as druga include certain drugn ( e.g. , drugn , drugn , drugn , drugn , drugn , drugn , drugb , and drugn ) , drugn salts , drugn , local drugn , drugn , and drugn .
int
other drugs which may enhance the neuromuscular blocking action of drugn such as druga include certain drugn ( e.g. , drugn , drugn , drugn , drugn , drugn , drugn , drugn , and drugb ) , drugn salts , drugn , local drugn , drugn , and drugn .
int
other drugs which may enhance the neuromuscular blocking action of drugn such as druga include certain drugn ( e.g. , drugn , drugn , drugn , drugn , drugn , drugn , drugn , and drugn ) , drugb salts , drugn , local drugn , drugn , and drugn .
int
other drugs which may enhance the neuromuscular blocking action of drugn such as druga include certain drugn ( e.g. , drugn , drugn , drugn , drugn , drugn , drugn , drugn , and drugn ) , drugn salts , drugb , local drugn , drugn , and drugn .
int
other drugs which may enhance the neuromuscular blocking action of drugn such as druga include certain drugn ( e.g. , drugn , drugn , drugn , drugn , drugn , drugn , drugn , and drugn ) , drugn salts , drugn , local drugb , drugn , and drugn .
int
other drugs which may enhance the neuromuscular blocking action of drugn such as druga include certain drugn ( e.g. , drugn , drugn , drugn , drugn , drugn , drugn , drugn , and drugn ) , drugn salts , drugn , local drugn , drugb , and drugn .
int
other drugs which may enhance the neuromuscular blocking action of drugn such as druga include certain drugn ( e.g. , drugn , drugn , drugn , drugn , drugn , drugn , drugn , and drugn ) , drugn salts , drugn , local drugn , drugn , and drugb .
int
other drugs which may enhance the neuromuscular blocking action of drugn such as drugn include certain druga ( e.g. , drugb , drugn , drugn , drugn , drugn , drugn , drugn , and drugn ) , drugn salts , drugn , local drugn , drugn , and drugn .
false
other drugs which may enhance the neuromuscular blocking action of drugn such as drugn include certain druga ( e.g. , drugn , drugb , drugn , drugn , drugn , drugn , drugn , and drugn ) , drugn salts , drugn , local drugn , drugn , and drugn .
false
other drugs which may enhance the neuromuscular blocking action of drugn such as drugn include certain druga ( e.g. , drugn , drugn , drugb , drugn , drugn , drugn , drugn , and drugn ) , drugn salts , drugn , local drugn , drugn , and drugn .
false
other drugs which may enhance the neuromuscular blocking action of drugn such as drugn include certain druga ( e.g. , drugn , drugn , drugn , drugb , drugn , drugn , drugn , and drugn ) , drugn salts , drugn , local drugn , drugn , and drugn .
false
other drugs which may enhance the neuromuscular blocking action of drugn such as drugn include certain druga ( e.g. , drugn , drugn , drugn , drugn , drugb , drugn , drugn , and drugn ) , drugn salts , drugn , local drugn , drugn , and drugn .
false
other drugs which may enhance the neuromuscular blocking action of drugn such as drugn include certain druga ( e.g. , drugn , drugn , drugn , drugn , drugn , drugb , drugn , and drugn ) , drugn salts , drugn , local drugn , drugn , and drugn .
false
other drugs which may enhance the neuromuscular blocking action of drugn such as drugn include certain druga ( e.g. , drugn , drugn , drugn , drugn , drugn , drugn , drugb , and drugn ) , drugn salts , drugn , local drugn , drugn , and drugn .
false
other drugs which may enhance the neuromuscular blocking action of drugn such as drugn include certain druga ( e.g. , drugn , drugn , drugn , drugn , drugn , drugn , drugn , and drugb ) , drugn salts , drugn , local drugn , drugn , and drugn .
false
other drugs which may enhance the neuromuscular blocking action of drugn such as drugn include certain druga ( e.g. , drugn , drugn , drugn , drugn , drugn , drugn , drugn , and drugn ) , drugb salts , drugn , local drugn , drugn , and drugn .
false
other drugs which may enhance the neuromuscular blocking action of drugn such as drugn include certain druga ( e.g. , drugn , drugn , drugn , drugn , drugn , drugn , drugn , and drugn ) , drugn salts , drugb , local drugn , drugn , and drugn .
false
other drugs which may enhance the neuromuscular blocking action of drugn such as drugn include certain druga ( e.g. , drugn , drugn , drugn , drugn , drugn , drugn , drugn , and drugn ) , drugn salts , drugn , local drugb , drugn , and drugn .
false
other drugs which may enhance the neuromuscular blocking action of drugn such as drugn include certain druga ( e.g. , drugn , drugn , drugn , drugn , drugn , drugn , drugn , and drugn ) , drugn salts , drugn , local drugn , drugb , and drugn .
false
other drugs which may enhance the neuromuscular blocking action of drugn such as drugn include certain druga ( e.g. , drugn , drugn , drugn , drugn , drugn , drugn , drugn , and drugn ) , drugn salts , drugn , local drugn , drugn , and drugb .
false
other drugs which may enhance the neuromuscular blocking action of drugn such as drugn include certain drugn ( e.g. , druga , drugb , drugn , drugn , drugn , drugn , drugn , and drugn ) , drugn salts , drugn , local drugn , drugn , and drugn .
false
other drugs which may enhance the neuromuscular blocking action of drugn such as drugn include certain drugn ( e.g. , druga , drugn , drugb , drugn , drugn , drugn , drugn , and drugn ) , drugn salts , drugn , local drugn , drugn , and drugn .
false
other drugs which may enhance the neuromuscular blocking action of drugn such as drugn include certain drugn ( e.g. , druga , drugn , drugn , drugb , drugn , drugn , drugn , and drugn ) , drugn salts , drugn , local drugn , drugn , and drugn .
false
other drugs which may enhance the neuromuscular blocking action of drugn such as drugn include certain drugn ( e.g. , druga , drugn , drugn , drugn , drugb , drugn , drugn , and drugn ) , drugn salts , drugn , local drugn , drugn , and drugn .
false
other drugs which may enhance the neuromuscular blocking action of drugn such as drugn include certain drugn ( e.g. , druga , drugn , drugn , drugn , drugn , drugb , drugn , and drugn ) , drugn salts , drugn , local drugn , drugn , and drugn .
false
other drugs which may enhance the neuromuscular blocking action of drugn such as drugn include certain drugn ( e.g. , druga , drugn , drugn , drugn , drugn , drugn , drugb , and drugn ) , drugn salts , drugn , local drugn , drugn , and drugn .
false
other drugs which may enhance the neuromuscular blocking action of drugn such as drugn include certain drugn ( e.g. , druga , drugn , drugn , drugn , drugn , drugn , drugn , and drugb ) , drugn salts , drugn , local drugn , drugn , and drugn .
false
other drugs which may enhance the neuromuscular blocking action of drugn such as drugn include certain drugn ( e.g. , druga , drugn , drugn , drugn , drugn , drugn , drugn , and drugn ) , drugb salts , drugn , local drugn , drugn , and drugn .
false
other drugs which may enhance the neuromuscular blocking action of drugn such as drugn include certain drugn ( e.g. , druga , drugn , drugn , drugn , drugn , drugn , drugn , and drugn ) , drugn salts , drugb , local drugn , drugn , and drugn .
false
other drugs which may enhance the neuromuscular blocking action of drugn such as drugn include certain drugn ( e.g. , druga , drugn , drugn , drugn , drugn , drugn , drugn , and drugn ) , drugn salts , drugn , local drugb , drugn , and drugn .
false
other drugs which may enhance the neuromuscular blocking action of drugn such as drugn include certain drugn ( e.g. , druga , drugn , drugn , drugn , drugn , drugn , drugn , and drugn ) , drugn salts , drugn , local drugn , drugb , and drugn .
false
other drugs which may enhance the neuromuscular blocking action of drugn such as drugn include certain drugn ( e.g. , druga , drugn , drugn , drugn , drugn , drugn , drugn , and drugn ) , drugn salts , drugn , local drugn , drugn , and drugb .
false
other drugs which may enhance the neuromuscular blocking action of drugn such as drugn include certain drugn ( e.g. , drugn , druga , drugb , drugn , drugn , drugn , drugn , and drugn ) , drugn salts , drugn , local drugn , drugn , and drugn .
false
other drugs which may enhance the neuromuscular blocking action of drugn such as drugn include certain drugn ( e.g. , drugn , druga , drugn , drugb , drugn , drugn , drugn , and drugn ) , drugn salts , drugn , local drugn , drugn , and drugn .
false
other drugs which may enhance the neuromuscular blocking action of drugn such as drugn include certain drugn ( e.g. , drugn , druga , drugn , drugn , drugb , drugn , drugn , and drugn ) , drugn salts , drugn , local drugn , drugn , and drugn .
false
other drugs which may enhance the neuromuscular blocking action of drugn such as drugn include certain drugn ( e.g. , drugn , druga , drugn , drugn , drugn , drugb , drugn , and drugn ) , drugn salts , drugn , local drugn , drugn , and drugn .
false
other drugs which may enhance the neuromuscular blocking action of drugn such as drugn include certain drugn ( e.g. , drugn , druga , drugn , drugn , drugn , drugn , drugb , and drugn ) , drugn salts , drugn , local drugn , drugn , and drugn .
false
other drugs which may enhance the neuromuscular blocking action of drugn such as drugn include certain drugn ( e.g. , drugn , druga , drugn , drugn , drugn , drugn , drugn , and drugb ) , drugn salts , drugn , local drugn , drugn , and drugn .
false
other drugs which may enhance the neuromuscular blocking action of drugn such as drugn include certain drugn ( e.g. , drugn , druga , drugn , drugn , drugn , drugn , drugn , and drugn ) , drugb salts , drugn , local drugn , drugn , and drugn .
false
other drugs which may enhance the neuromuscular blocking action of drugn such as drugn include certain drugn ( e.g. , drugn , druga , drugn , drugn , drugn , drugn , drugn , and drugn ) , drugn salts , drugb , local drugn , drugn , and drugn .
false
other drugs which may enhance the neuromuscular blocking action of drugn such as drugn include certain drugn ( e.g. , drugn , druga , drugn , drugn , drugn , drugn , drugn , and drugn ) , drugn salts , drugn , local drugb , drugn , and drugn .
false
other drugs which may enhance the neuromuscular blocking action of drugn such as drugn include certain drugn ( e.g. , drugn , druga , drugn , drugn , drugn , drugn , drugn , and drugn ) , drugn salts , drugn , local drugn , drugb , and drugn .
false
other drugs which may enhance the neuromuscular blocking action of drugn such as drugn include certain drugn ( e.g. , drugn , druga , drugn , drugn , drugn , drugn , drugn , and drugn ) , drugn salts , drugn , local drugn , drugn , and drugb .
false
other drugs which may enhance the neuromuscular blocking action of drugn such as drugn include certain drugn ( e.g. , drugn , drugn , druga , drugb , drugn , drugn , drugn , and drugn ) , drugn salts , drugn , local drugn , drugn , and drugn .
false
other drugs which may enhance the neuromuscular blocking action of drugn such as drugn include certain drugn ( e.g. , drugn , drugn , druga , drugn , drugb , drugn , drugn , and drugn ) , drugn salts , drugn , local drugn , drugn , and drugn .
false
other drugs which may enhance the neuromuscular blocking action of drugn such as drugn include certain drugn ( e.g. , drugn , drugn , druga , drugn , drugn , drugb , drugn , and drugn ) , drugn salts , drugn , local drugn , drugn , and drugn .
false
other drugs which may enhance the neuromuscular blocking action of drugn such as drugn include certain drugn ( e.g. , drugn , drugn , druga , drugn , drugn , drugn , drugb , and drugn ) , drugn salts , drugn , local drugn , drugn , and drugn .
false
other drugs which may enhance the neuromuscular blocking action of drugn such as drugn include certain drugn ( e.g. , drugn , drugn , druga , drugn , drugn , drugn , drugn , and drugb ) , drugn salts , drugn , local drugn , drugn , and drugn .
false
other drugs which may enhance the neuromuscular blocking action of drugn such as drugn include certain drugn ( e.g. , drugn , drugn , druga , drugn , drugn , drugn , drugn , and drugn ) , drugb salts , drugn , local drugn , drugn , and drugn .
false
other drugs which may enhance the neuromuscular blocking action of drugn such as drugn include certain drugn ( e.g. , drugn , drugn , druga , drugn , drugn , drugn , drugn , and drugn ) , drugn salts , drugb , local drugn , drugn , and drugn .
false
other drugs which may enhance the neuromuscular blocking action of drugn such as drugn include certain drugn ( e.g. , drugn , drugn , druga , drugn , drugn , drugn , drugn , and drugn ) , drugn salts , drugn , local drugb , drugn , and drugn .
false
other drugs which may enhance the neuromuscular blocking action of drugn such as drugn include certain drugn ( e.g. , drugn , drugn , druga , drugn , drugn , drugn , drugn , and drugn ) , drugn salts , drugn , local drugn , drugb , and drugn .
false
other drugs which may enhance the neuromuscular blocking action of drugn such as drugn include certain drugn ( e.g. , drugn , drugn , druga , drugn , drugn , drugn , drugn , and drugn ) , drugn salts , drugn , local drugn , drugn , and drugb .
false
other drugs which may enhance the neuromuscular blocking action of drugn such as drugn include certain drugn ( e.g. , drugn , drugn , drugn , druga , drugb , drugn , drugn , and drugn ) , drugn salts , drugn , local drugn , drugn , and drugn .
false
other drugs which may enhance the neuromuscular blocking action of drugn such as drugn include certain drugn ( e.g. , drugn , drugn , drugn , druga , drugn , drugb , drugn , and drugn ) , drugn salts , drugn , local drugn , drugn , and drugn .
false
other drugs which may enhance the neuromuscular blocking action of drugn such as drugn include certain drugn ( e.g. , drugn , drugn , drugn , druga , drugn , drugn , drugb , and drugn ) , drugn salts , drugn , local drugn , drugn , and drugn .
false
other drugs which may enhance the neuromuscular blocking action of drugn such as drugn include certain drugn ( e.g. , drugn , drugn , drugn , druga , drugn , drugn , drugn , and drugb ) , drugn salts , drugn , local drugn , drugn , and drugn .
false
other drugs which may enhance the neuromuscular blocking action of drugn such as drugn include certain drugn ( e.g. , drugn , drugn , drugn , druga , drugn , drugn , drugn , and drugn ) , drugb salts , drugn , local drugn , drugn , and drugn .
false
other drugs which may enhance the neuromuscular blocking action of drugn such as drugn include certain drugn ( e.g. , drugn , drugn , drugn , druga , drugn , drugn , drugn , and drugn ) , drugn salts , drugb , local drugn , drugn , and drugn .
false
other drugs which may enhance the neuromuscular blocking action of drugn such as drugn include certain drugn ( e.g. , drugn , drugn , drugn , druga , drugn , drugn , drugn , and drugn ) , drugn salts , drugn , local drugb , drugn , and drugn .
false
other drugs which may enhance the neuromuscular blocking action of drugn such as drugn include certain drugn ( e.g. , drugn , drugn , drugn , druga , drugn , drugn , drugn , and drugn ) , drugn salts , drugn , local drugn , drugb , and drugn .
false
other drugs which may enhance the neuromuscular blocking action of drugn such as drugn include certain drugn ( e.g. , drugn , drugn , drugn , druga , drugn , drugn , drugn , and drugn ) , drugn salts , drugn , local drugn , drugn , and drugb .
false
other drugs which may enhance the neuromuscular blocking action of drugn such as drugn include certain drugn ( e.g. , drugn , drugn , drugn , drugn , druga , drugb , drugn , and drugn ) , drugn salts , drugn , local drugn , drugn , and drugn .
false
other drugs which may enhance the neuromuscular blocking action of drugn such as drugn include certain drugn ( e.g. , drugn , drugn , drugn , drugn , druga , drugn , drugb , and drugn ) , drugn salts , drugn , local drugn , drugn , and drugn .
false
other drugs which may enhance the neuromuscular blocking action of drugn such as drugn include certain drugn ( e.g. , drugn , drugn , drugn , drugn , druga , drugn , drugn , and drugb ) , drugn salts , drugn , local drugn , drugn , and drugn .
false
other drugs which may enhance the neuromuscular blocking action of drugn such as drugn include certain drugn ( e.g. , drugn , drugn , drugn , drugn , druga , drugn , drugn , and drugn ) , drugb salts , drugn , local drugn , drugn , and drugn .
false
other drugs which may enhance the neuromuscular blocking action of drugn such as drugn include certain drugn ( e.g. , drugn , drugn , drugn , drugn , druga , drugn , drugn , and drugn ) , drugn salts , drugb , local drugn , drugn , and drugn .
false
other drugs which may enhance the neuromuscular blocking action of drugn such as drugn include certain drugn ( e.g. , drugn , drugn , drugn , drugn , druga , drugn , drugn , and drugn ) , drugn salts , drugn , local drugb , drugn , and drugn .
false
other drugs which may enhance the neuromuscular blocking action of drugn such as drugn include certain drugn ( e.g. , drugn , drugn , drugn , drugn , druga , drugn , drugn , and drugn ) , drugn salts , drugn , local drugn , drugb , and drugn .
false
other drugs which may enhance the neuromuscular blocking action of drugn such as drugn include certain drugn ( e.g. , drugn , drugn , drugn , drugn , druga , drugn , drugn , and drugn ) , drugn salts , drugn , local drugn , drugn , and drugb .
false
other drugs which may enhance the neuromuscular blocking action of drugn such as drugn include certain drugn ( e.g. , drugn , drugn , drugn , drugn , drugn , druga , drugb , and drugn ) , drugn salts , drugn , local drugn , drugn , and drugn .
false
other drugs which may enhance the neuromuscular blocking action of drugn such as drugn include certain drugn ( e.g. , drugn , drugn , drugn , drugn , drugn , druga , drugn , and drugb ) , drugn salts , drugn , local drugn , drugn , and drugn .
false
other drugs which may enhance the neuromuscular blocking action of drugn such as drugn include certain drugn ( e.g. , drugn , drugn , drugn , drugn , drugn , druga , drugn , and drugn ) , drugb salts , drugn , local drugn , drugn , and drugn .
false
other drugs which may enhance the neuromuscular blocking action of drugn such as drugn include certain drugn ( e.g. , drugn , drugn , drugn , drugn , drugn , druga , drugn , and drugn ) , drugn salts , drugb , local drugn , drugn , and drugn .
false
other drugs which may enhance the neuromuscular blocking action of drugn such as drugn include certain drugn ( e.g. , drugn , drugn , drugn , drugn , drugn , druga , drugn , and drugn ) , drugn salts , drugn , local drugb , drugn , and drugn .
false
other drugs which may enhance the neuromuscular blocking action of drugn such as drugn include certain drugn ( e.g. , drugn , drugn , drugn , drugn , drugn , druga , drugn , and drugn ) , drugn salts , drugn , local drugn , drugb , and drugn .
false
other drugs which may enhance the neuromuscular blocking action of drugn such as drugn include certain drugn ( e.g. , drugn , drugn , drugn , drugn , drugn , druga , drugn , and drugn ) , drugn salts , drugn , local drugn , drugn , and drugb .
false
other drugs which may enhance the neuromuscular blocking action of drugn such as drugn include certain drugn ( e.g. , drugn , drugn , drugn , drugn , drugn , drugn , druga , and drugb ) , drugn salts , drugn , local drugn , drugn , and drugn .
false
other drugs which may enhance the neuromuscular blocking action of drugn such as drugn include certain drugn ( e.g. , drugn , drugn , drugn , drugn , drugn , drugn , druga , and drugn ) , drugb salts , drugn , local drugn , drugn , and drugn .
false
other drugs which may enhance the neuromuscular blocking action of drugn such as drugn include certain drugn ( e.g. , drugn , drugn , drugn , drugn , drugn , drugn , druga , and drugn ) , drugn salts , drugb , local drugn , drugn , and drugn .
false
other drugs which may enhance the neuromuscular blocking action of drugn such as drugn include certain drugn ( e.g. , drugn , drugn , drugn , drugn , drugn , drugn , druga , and drugn ) , drugn salts , drugn , local drugb , drugn , and drugn .
false
other drugs which may enhance the neuromuscular blocking action of drugn such as drugn include certain drugn ( e.g. , drugn , drugn , drugn , drugn , drugn , drugn , druga , and drugn ) , drugn salts , drugn , local drugn , drugb , and drugn .
false
other drugs which may enhance the neuromuscular blocking action of drugn such as drugn include certain drugn ( e.g. , drugn , drugn , drugn , drugn , drugn , drugn , druga , and drugn ) , drugn salts , drugn , local drugn , drugn , and drugb .
false
other drugs which may enhance the neuromuscular blocking action of drugn such as drugn include certain drugn ( e.g. , drugn , drugn , drugn , drugn , drugn , drugn , drugn , and druga ) , drugb salts , drugn , local drugn , drugn , and drugn .
false
other drugs which may enhance the neuromuscular blocking action of drugn such as drugn include certain drugn ( e.g. , drugn , drugn , drugn , drugn , drugn , drugn , drugn , and druga ) , drugn salts , drugb , local drugn , drugn , and drugn .
false
other drugs which may enhance the neuromuscular blocking action of drugn such as drugn include certain drugn ( e.g. , drugn , drugn , drugn , drugn , drugn , drugn , drugn , and druga ) , drugn salts , drugn , local drugb , drugn , and drugn .
false
other drugs which may enhance the neuromuscular blocking action of drugn such as drugn include certain drugn ( e.g. , drugn , drugn , drugn , drugn , drugn , drugn , drugn , and druga ) , drugn salts , drugn , local drugn , drugb , and drugn .
false
other drugs which may enhance the neuromuscular blocking action of drugn such as drugn include certain drugn ( e.g. , drugn , drugn , drugn , drugn , drugn , drugn , drugn , and druga ) , drugn salts , drugn , local drugn , drugn , and drugb .
false
other drugs which may enhance the neuromuscular blocking action of drugn such as drugn include certain drugn ( e.g. , drugn , drugn , drugn , drugn , drugn , drugn , drugn , and drugn ) , druga salts , drugb , local drugn , drugn , and drugn .
false
other drugs which may enhance the neuromuscular blocking action of drugn such as drugn include certain drugn ( e.g. , drugn , drugn , drugn , drugn , drugn , drugn , drugn , and drugn ) , druga salts , drugn , local drugb , drugn , and drugn .
false
other drugs which may enhance the neuromuscular blocking action of drugn such as drugn include certain drugn ( e.g. , drugn , drugn , drugn , drugn , drugn , drugn , drugn , and drugn ) , druga salts , drugn , local drugn , drugb , and drugn .
false
other drugs which may enhance the neuromuscular blocking action of drugn such as drugn include certain drugn ( e.g. , drugn , drugn , drugn , drugn , drugn , drugn , drugn , and drugn ) , druga salts , drugn , local drugn , drugn , and drugb .
false
other drugs which may enhance the neuromuscular blocking action of drugn such as drugn include certain drugn ( e.g. , drugn , drugn , drugn , drugn , drugn , drugn , drugn , and drugn ) , drugn salts , druga , local drugb , drugn , and drugn .
false
other drugs which may enhance the neuromuscular blocking action of drugn such as drugn include certain drugn ( e.g. , drugn , drugn , drugn , drugn , drugn , drugn , drugn , and drugn ) , drugn salts , druga , local drugn , drugb , and drugn .
false
other drugs which may enhance the neuromuscular blocking action of drugn such as drugn include certain drugn ( e.g. , drugn , drugn , drugn , drugn , drugn , drugn , drugn , and drugn ) , drugn salts , druga , local drugn , drugn , and drugb .
false
other drugs which may enhance the neuromuscular blocking action of drugn such as drugn include certain drugn ( e.g. , drugn , drugn , drugn , drugn , drugn , drugn , drugn , and drugn ) , drugn salts , drugn , local druga , drugb , and drugn .
false
other drugs which may enhance the neuromuscular blocking action of drugn such as drugn include certain drugn ( e.g. , drugn , drugn , drugn , drugn , drugn , drugn , drugn , and drugn ) , drugn salts , drugn , local druga , drugn , and drugb .
false
other drugs which may enhance the neuromuscular blocking action of drugn such as drugn include certain drugn ( e.g. , drugn , drugn , drugn , drugn , drugn , drugn , drugn , and drugn ) , drugn salts , drugn , local drugn , druga , and drugb .
false
the neuromuscular blocking effect of druga may be enhanced by drugs that reduce plasma cholinesterase activity ( e.g. , chronically administered oral drugb , drugn , or certain drugn ) or by drugs that irreversibly inhibit plasma cholinesterase . resistance to the neuromuscular blocking action of nondepolarizing drugn has been demonstrated in patients chronically administered drugn or drugn .
effect
the neuromuscular blocking effect of druga may be enhanced by drugs that reduce plasma cholinesterase activity ( e.g. , chronically administered oral drugn , drugb , or certain drugn ) or by drugs that irreversibly inhibit plasma cholinesterase . resistance to the neuromuscular blocking action of nondepolarizing drugn has been demonstrated in patients chronically administered drugn or drugn .
effect
the neuromuscular blocking effect of druga may be enhanced by drugs that reduce plasma cholinesterase activity ( e.g. , chronically administered oral drugn , drugn , or certain drugb ) or by drugs that irreversibly inhibit plasma cholinesterase . resistance to the neuromuscular blocking action of nondepolarizing drugn has been demonstrated in patients chronically administered drugn or drugn .
effect
the neuromuscular blocking effect of druga may be enhanced by drugs that reduce plasma cholinesterase activity ( e.g. , chronically administered oral drugn , drugn , or certain drugn ) or by drugs that irreversibly inhibit plasma cholinesterase . resistance to the neuromuscular blocking action of nondepolarizing drugb has been demonstrated in patients chronically administered drugn or drugn .
false
the neuromuscular blocking effect of druga may be enhanced by drugs that reduce plasma cholinesterase activity ( e.g. , chronically administered oral drugn , drugn , or certain drugn ) or by drugs that irreversibly inhibit plasma cholinesterase . resistance to the neuromuscular blocking action of nondepolarizing drugn has been demonstrated in patients chronically administered drugb or drugn .
false
the neuromuscular blocking effect of druga may be enhanced by drugs that reduce plasma cholinesterase activity ( e.g. , chronically administered oral drugn , drugn , or certain drugn ) or by drugs that irreversibly inhibit plasma cholinesterase . resistance to the neuromuscular blocking action of nondepolarizing drugn has been demonstrated in patients chronically administered drugn or drugb .
false
the neuromuscular blocking effect of drugn may be enhanced by drugs that reduce plasma cholinesterase activity ( e.g. , chronically administered oral druga , drugb , or certain drugn ) or by drugs that irreversibly inhibit plasma cholinesterase . resistance to the neuromuscular blocking action of nondepolarizing drugn has been demonstrated in patients chronically administered drugn or drugn .
false
the neuromuscular blocking effect of drugn may be enhanced by drugs that reduce plasma cholinesterase activity ( e.g. , chronically administered oral druga , drugn , or certain drugb ) or by drugs that irreversibly inhibit plasma cholinesterase . resistance to the neuromuscular blocking action of nondepolarizing drugn has been demonstrated in patients chronically administered drugn or drugn .
false
the neuromuscular blocking effect of drugn may be enhanced by drugs that reduce plasma cholinesterase activity ( e.g. , chronically administered oral druga , drugn , or certain drugn ) or by drugs that irreversibly inhibit plasma cholinesterase . resistance to the neuromuscular blocking action of nondepolarizing drugb has been demonstrated in patients chronically administered drugn or drugn .
false
the neuromuscular blocking effect of drugn may be enhanced by drugs that reduce plasma cholinesterase activity ( e.g. , chronically administered oral druga , drugn , or certain drugn ) or by drugs that irreversibly inhibit plasma cholinesterase . resistance to the neuromuscular blocking action of nondepolarizing drugn has been demonstrated in patients chronically administered drugb or drugn .
false
the neuromuscular blocking effect of drugn may be enhanced by drugs that reduce plasma cholinesterase activity ( e.g. , chronically administered oral druga , drugn , or certain drugn ) or by drugs that irreversibly inhibit plasma cholinesterase . resistance to the neuromuscular blocking action of nondepolarizing drugn has been demonstrated in patients chronically administered drugn or drugb .
false
the neuromuscular blocking effect of drugn may be enhanced by drugs that reduce plasma cholinesterase activity ( e.g. , chronically administered oral drugn , druga , or certain drugb ) or by drugs that irreversibly inhibit plasma cholinesterase . resistance to the neuromuscular blocking action of nondepolarizing drugn has been demonstrated in patients chronically administered drugn or drugn .
false
the neuromuscular blocking effect of drugn may be enhanced by drugs that reduce plasma cholinesterase activity ( e.g. , chronically administered oral drugn , druga , or certain drugn ) or by drugs that irreversibly inhibit plasma cholinesterase . resistance to the neuromuscular blocking action of nondepolarizing drugb has been demonstrated in patients chronically administered drugn or drugn .
false
the neuromuscular blocking effect of drugn may be enhanced by drugs that reduce plasma cholinesterase activity ( e.g. , chronically administered oral drugn , druga , or certain drugn ) or by drugs that irreversibly inhibit plasma cholinesterase . resistance to the neuromuscular blocking action of nondepolarizing drugn has been demonstrated in patients chronically administered drugb or drugn .
false
the neuromuscular blocking effect of drugn may be enhanced by drugs that reduce plasma cholinesterase activity ( e.g. , chronically administered oral drugn , druga , or certain drugn ) or by drugs that irreversibly inhibit plasma cholinesterase . resistance to the neuromuscular blocking action of nondepolarizing drugn has been demonstrated in patients chronically administered drugn or drugb .
false
the neuromuscular blocking effect of drugn may be enhanced by drugs that reduce plasma cholinesterase activity ( e.g. , chronically administered oral drugn , drugn , or certain druga ) or by drugs that irreversibly inhibit plasma cholinesterase . resistance to the neuromuscular blocking action of nondepolarizing drugb has been demonstrated in patients chronically administered drugn or drugn .
false
the neuromuscular blocking effect of drugn may be enhanced by drugs that reduce plasma cholinesterase activity ( e.g. , chronically administered oral drugn , drugn , or certain druga ) or by drugs that irreversibly inhibit plasma cholinesterase . resistance to the neuromuscular blocking action of nondepolarizing drugn has been demonstrated in patients chronically administered drugb or drugn .
false
the neuromuscular blocking effect of drugn may be enhanced by drugs that reduce plasma cholinesterase activity ( e.g. , chronically administered oral drugn , drugn , or certain druga ) or by drugs that irreversibly inhibit plasma cholinesterase . resistance to the neuromuscular blocking action of nondepolarizing drugn has been demonstrated in patients chronically administered drugn or drugb .
false
the neuromuscular blocking effect of drugn may be enhanced by drugs that reduce plasma cholinesterase activity ( e.g. , chronically administered oral drugn , drugn , or certain drugn ) or by drugs that irreversibly inhibit plasma cholinesterase . resistance to the neuromuscular blocking action of nondepolarizing druga has been demonstrated in patients chronically administered drugb or drugn .
effect
the neuromuscular blocking effect of drugn may be enhanced by drugs that reduce plasma cholinesterase activity ( e.g. , chronically administered oral drugn , drugn , or certain drugn ) or by drugs that irreversibly inhibit plasma cholinesterase . resistance to the neuromuscular blocking action of nondepolarizing druga has been demonstrated in patients chronically administered drugn or drugb .
effect
the neuromuscular blocking effect of drugn may be enhanced by drugs that reduce plasma cholinesterase activity ( e.g. , chronically administered oral drugn , drugn , or certain drugn ) or by drugs that irreversibly inhibit plasma cholinesterase . resistance to the neuromuscular blocking action of nondepolarizing drugn has been demonstrated in patients chronically administered druga or drugb .
false
while the effects of chronic druga or drugb therapy on the action of drugn are unknown , slightly shorter durations of neuromuscular block may be anticipated and infusion rate requirements may be higher .
false
while the effects of chronic druga or drugn therapy on the action of drugb are unknown , slightly shorter durations of neuromuscular block may be anticipated and infusion rate requirements may be higher .
effect
while the effects of chronic drugn or druga therapy on the action of drugb are unknown , slightly shorter durations of neuromuscular block may be anticipated and infusion rate requirements may be higher .
effect
some drug interactions are : - birth control pills - druga - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as drugb or drugn - certain drugn given by injection - drugn - drugn - drugn - drugn or drugn - local drugn such as drugn - general drugn - drugn or other drugn
false
some drug interactions are : - birth control pills - druga - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as drugn or drugb - certain drugn given by injection - drugn - drugn - drugn - drugn or drugn - local drugn such as drugn - general drugn - drugn or other drugn
false
some drug interactions are : - birth control pills - druga - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as drugn or drugn - certain drugb given by injection - drugn - drugn - drugn - drugn or drugn - local drugn such as drugn - general drugn - drugn or other drugn
false
some drug interactions are : - birth control pills - druga - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as drugn or drugn - certain drugn given by injection - drugb - drugn - drugn - drugn or drugn - local drugn such as drugn - general drugn - drugn or other drugn
false
some drug interactions are : - birth control pills - druga - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as drugn or drugn - certain drugn given by injection - drugn - drugb - drugn - drugn or drugn - local drugn such as drugn - general drugn - drugn or other drugn
false
some drug interactions are : - birth control pills - druga - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as drugn or drugn - certain drugn given by injection - drugn - drugn - drugb - drugn or drugn - local drugn such as drugn - general drugn - drugn or other drugn
false
some drug interactions are : - birth control pills - druga - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as drugn or drugn - certain drugn given by injection - drugn - drugn - drugn - drugb or drugn - local drugn such as drugn - general drugn - drugn or other drugn
false
some drug interactions are : - birth control pills - druga - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as drugn or drugn - certain drugn given by injection - drugn - drugn - drugn - drugn or drugb - local drugn such as drugn - general drugn - drugn or other drugn
false
some drug interactions are : - birth control pills - druga - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as drugn or drugn - certain drugn given by injection - drugn - drugn - drugn - drugn or drugn - local drugb such as drugn - general drugn - drugn or other drugn
false
some drug interactions are : - birth control pills - druga - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as drugn or drugn - certain drugn given by injection - drugn - drugn - drugn - drugn or drugn - local drugn such as drugb - general drugn - drugn or other drugn
false
some drug interactions are : - birth control pills - druga - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as drugn or drugn - certain drugn given by injection - drugn - drugn - drugn - drugn or drugn - local drugn such as drugn - general drugb - drugn or other drugn
false
some drug interactions are : - birth control pills - druga - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as drugn or drugn - certain drugn given by injection - drugn - drugn - drugn - drugn or drugn - local drugn such as drugn - general drugn - drugb or other drugn
false
some drug interactions are : - birth control pills - druga - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as drugn or drugn - certain drugn given by injection - drugn - drugn - drugn - drugn or drugn - local drugn such as drugn - general drugn - drugn or other drugb
false
some drug interactions are : - birth control pills - drugn - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as druga or drugb - certain drugn given by injection - drugn - drugn - drugn - drugn or drugn - local drugn such as drugn - general drugn - drugn or other drugn
false
some drug interactions are : - birth control pills - drugn - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as druga or drugn - certain drugb given by injection - drugn - drugn - drugn - drugn or drugn - local drugn such as drugn - general drugn - drugn or other drugn
false
some drug interactions are : - birth control pills - drugn - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as druga or drugn - certain drugn given by injection - drugb - drugn - drugn - drugn or drugn - local drugn such as drugn - general drugn - drugn or other drugn
false
some drug interactions are : - birth control pills - drugn - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as druga or drugn - certain drugn given by injection - drugn - drugb - drugn - drugn or drugn - local drugn such as drugn - general drugn - drugn or other drugn
false
some drug interactions are : - birth control pills - drugn - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as druga or drugn - certain drugn given by injection - drugn - drugn - drugb - drugn or drugn - local drugn such as drugn - general drugn - drugn or other drugn
false
some drug interactions are : - birth control pills - drugn - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as druga or drugn - certain drugn given by injection - drugn - drugn - drugn - drugb or drugn - local drugn such as drugn - general drugn - drugn or other drugn
false
some drug interactions are : - birth control pills - drugn - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as druga or drugn - certain drugn given by injection - drugn - drugn - drugn - drugn or drugb - local drugn such as drugn - general drugn - drugn or other drugn
false
some drug interactions are : - birth control pills - drugn - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as druga or drugn - certain drugn given by injection - drugn - drugn - drugn - drugn or drugn - local drugb such as drugn - general drugn - drugn or other drugn
false
some drug interactions are : - birth control pills - drugn - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as druga or drugn - certain drugn given by injection - drugn - drugn - drugn - drugn or drugn - local drugn such as drugb - general drugn - drugn or other drugn
false
some drug interactions are : - birth control pills - drugn - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as druga or drugn - certain drugn given by injection - drugn - drugn - drugn - drugn or drugn - local drugn such as drugn - general drugb - drugn or other drugn
false
some drug interactions are : - birth control pills - drugn - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as druga or drugn - certain drugn given by injection - drugn - drugn - drugn - drugn or drugn - local drugn such as drugn - general drugn - drugb or other drugn
false
some drug interactions are : - birth control pills - drugn - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as druga or drugn - certain drugn given by injection - drugn - drugn - drugn - drugn or drugn - local drugn such as drugn - general drugn - drugn or other drugb
false
some drug interactions are : - birth control pills - drugn - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as drugn or druga - certain drugb given by injection - drugn - drugn - drugn - drugn or drugn - local drugn such as drugn - general drugn - drugn or other drugn
false
some drug interactions are : - birth control pills - drugn - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as drugn or druga - certain drugn given by injection - drugb - drugn - drugn - drugn or drugn - local drugn such as drugn - general drugn - drugn or other drugn
false
some drug interactions are : - birth control pills - drugn - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as drugn or druga - certain drugn given by injection - drugn - drugb - drugn - drugn or drugn - local drugn such as drugn - general drugn - drugn or other drugn
false
some drug interactions are : - birth control pills - drugn - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as drugn or druga - certain drugn given by injection - drugn - drugn - drugb - drugn or drugn - local drugn such as drugn - general drugn - drugn or other drugn
false
some drug interactions are : - birth control pills - drugn - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as drugn or druga - certain drugn given by injection - drugn - drugn - drugn - drugb or drugn - local drugn such as drugn - general drugn - drugn or other drugn
false
some drug interactions are : - birth control pills - drugn - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as drugn or druga - certain drugn given by injection - drugn - drugn - drugn - drugn or drugb - local drugn such as drugn - general drugn - drugn or other drugn
false
some drug interactions are : - birth control pills - drugn - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as drugn or druga - certain drugn given by injection - drugn - drugn - drugn - drugn or drugn - local drugb such as drugn - general drugn - drugn or other drugn
false
some drug interactions are : - birth control pills - drugn - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as drugn or druga - certain drugn given by injection - drugn - drugn - drugn - drugn or drugn - local drugn such as drugb - general drugn - drugn or other drugn
false
some drug interactions are : - birth control pills - drugn - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as drugn or druga - certain drugn given by injection - drugn - drugn - drugn - drugn or drugn - local drugn such as drugn - general drugb - drugn or other drugn
false
some drug interactions are : - birth control pills - drugn - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as drugn or druga - certain drugn given by injection - drugn - drugn - drugn - drugn or drugn - local drugn such as drugn - general drugn - drugb or other drugn
false
some drug interactions are : - birth control pills - drugn - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as drugn or druga - certain drugn given by injection - drugn - drugn - drugn - drugn or drugn - local drugn such as drugn - general drugn - drugn or other drugb
false
some drug interactions are : - birth control pills - drugn - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as drugn or drugn - certain druga given by injection - drugb - drugn - drugn - drugn or drugn - local drugn such as drugn - general drugn - drugn or other drugn
false
some drug interactions are : - birth control pills - drugn - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as drugn or drugn - certain druga given by injection - drugn - drugb - drugn - drugn or drugn - local drugn such as drugn - general drugn - drugn or other drugn
false
some drug interactions are : - birth control pills - drugn - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as drugn or drugn - certain druga given by injection - drugn - drugn - drugb - drugn or drugn - local drugn such as drugn - general drugn - drugn or other drugn
false
some drug interactions are : - birth control pills - drugn - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as drugn or drugn - certain druga given by injection - drugn - drugn - drugn - drugb or drugn - local drugn such as drugn - general drugn - drugn or other drugn
false
some drug interactions are : - birth control pills - drugn - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as drugn or drugn - certain druga given by injection - drugn - drugn - drugn - drugn or drugb - local drugn such as drugn - general drugn - drugn or other drugn
false
some drug interactions are : - birth control pills - drugn - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as drugn or drugn - certain druga given by injection - drugn - drugn - drugn - drugn or drugn - local drugb such as drugn - general drugn - drugn or other drugn
false
some drug interactions are : - birth control pills - drugn - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as drugn or drugn - certain druga given by injection - drugn - drugn - drugn - drugn or drugn - local drugn such as drugb - general drugn - drugn or other drugn
false
some drug interactions are : - birth control pills - drugn - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as drugn or drugn - certain druga given by injection - drugn - drugn - drugn - drugn or drugn - local drugn such as drugn - general drugb - drugn or other drugn
false
some drug interactions are : - birth control pills - drugn - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as drugn or drugn - certain druga given by injection - drugn - drugn - drugn - drugn or drugn - local drugn such as drugn - general drugn - drugb or other drugn
false
some drug interactions are : - birth control pills - drugn - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as drugn or drugn - certain druga given by injection - drugn - drugn - drugn - drugn or drugn - local drugn such as drugn - general drugn - drugn or other drugb
false
some drug interactions are : - birth control pills - drugn - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as drugn or drugn - certain drugn given by injection - druga - drugb - drugn - drugn or drugn - local drugn such as drugn - general drugn - drugn or other drugn
false
some drug interactions are : - birth control pills - drugn - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as drugn or drugn - certain drugn given by injection - druga - drugn - drugb - drugn or drugn - local drugn such as drugn - general drugn - drugn or other drugn
false
some drug interactions are : - birth control pills - drugn - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as drugn or drugn - certain drugn given by injection - druga - drugn - drugn - drugb or drugn - local drugn such as drugn - general drugn - drugn or other drugn
false
some drug interactions are : - birth control pills - drugn - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as drugn or drugn - certain drugn given by injection - druga - drugn - drugn - drugn or drugb - local drugn such as drugn - general drugn - drugn or other drugn
false
some drug interactions are : - birth control pills - drugn - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as drugn or drugn - certain drugn given by injection - druga - drugn - drugn - drugn or drugn - local drugb such as drugn - general drugn - drugn or other drugn
false
some drug interactions are : - birth control pills - drugn - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as drugn or drugn - certain drugn given by injection - druga - drugn - drugn - drugn or drugn - local drugn such as drugb - general drugn - drugn or other drugn
false
some drug interactions are : - birth control pills - drugn - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as drugn or drugn - certain drugn given by injection - druga - drugn - drugn - drugn or drugn - local drugn such as drugn - general drugb - drugn or other drugn
false
some drug interactions are : - birth control pills - drugn - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as drugn or drugn - certain drugn given by injection - druga - drugn - drugn - drugn or drugn - local drugn such as drugn - general drugn - drugb or other drugn
false
some drug interactions are : - birth control pills - drugn - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as drugn or drugn - certain drugn given by injection - druga - drugn - drugn - drugn or drugn - local drugn such as drugn - general drugn - drugn or other drugb
false
some drug interactions are : - birth control pills - drugn - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as drugn or drugn - certain drugn given by injection - drugn - druga - drugb - drugn or drugn - local drugn such as drugn - general drugn - drugn or other drugn
false
some drug interactions are : - birth control pills - drugn - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as drugn or drugn - certain drugn given by injection - drugn - druga - drugn - drugb or drugn - local drugn such as drugn - general drugn - drugn or other drugn
false
some drug interactions are : - birth control pills - drugn - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as drugn or drugn - certain drugn given by injection - drugn - druga - drugn - drugn or drugb - local drugn such as drugn - general drugn - drugn or other drugn
false
some drug interactions are : - birth control pills - drugn - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as drugn or drugn - certain drugn given by injection - drugn - druga - drugn - drugn or drugn - local drugb such as drugn - general drugn - drugn or other drugn
false
some drug interactions are : - birth control pills - drugn - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as drugn or drugn - certain drugn given by injection - drugn - druga - drugn - drugn or drugn - local drugn such as drugb - general drugn - drugn or other drugn
false
some drug interactions are : - birth control pills - drugn - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as drugn or drugn - certain drugn given by injection - drugn - druga - drugn - drugn or drugn - local drugn such as drugn - general drugb - drugn or other drugn
false
some drug interactions are : - birth control pills - drugn - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as drugn or drugn - certain drugn given by injection - drugn - druga - drugn - drugn or drugn - local drugn such as drugn - general drugn - drugb or other drugn
false
some drug interactions are : - birth control pills - drugn - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as drugn or drugn - certain drugn given by injection - drugn - druga - drugn - drugn or drugn - local drugn such as drugn - general drugn - drugn or other drugb
false
some drug interactions are : - birth control pills - drugn - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as drugn or drugn - certain drugn given by injection - drugn - drugn - druga - drugb or drugn - local drugn such as drugn - general drugn - drugn or other drugn
false
some drug interactions are : - birth control pills - drugn - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as drugn or drugn - certain drugn given by injection - drugn - drugn - druga - drugn or drugb - local drugn such as drugn - general drugn - drugn or other drugn
false
some drug interactions are : - birth control pills - drugn - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as drugn or drugn - certain drugn given by injection - drugn - drugn - druga - drugn or drugn - local drugb such as drugn - general drugn - drugn or other drugn
false
some drug interactions are : - birth control pills - drugn - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as drugn or drugn - certain drugn given by injection - drugn - drugn - druga - drugn or drugn - local drugn such as drugb - general drugn - drugn or other drugn
false
some drug interactions are : - birth control pills - drugn - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as drugn or drugn - certain drugn given by injection - drugn - drugn - druga - drugn or drugn - local drugn such as drugn - general drugb - drugn or other drugn
false
some drug interactions are : - birth control pills - drugn - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as drugn or drugn - certain drugn given by injection - drugn - drugn - druga - drugn or drugn - local drugn such as drugn - general drugn - drugb or other drugn
false
some drug interactions are : - birth control pills - drugn - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as drugn or drugn - certain drugn given by injection - drugn - drugn - druga - drugn or drugn - local drugn such as drugn - general drugn - drugn or other drugb
false
some drug interactions are : - birth control pills - drugn - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as drugn or drugn - certain drugn given by injection - drugn - drugn - drugn - druga or drugb - local drugn such as drugn - general drugn - drugn or other drugn
false
some drug interactions are : - birth control pills - drugn - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as drugn or drugn - certain drugn given by injection - drugn - drugn - drugn - druga or drugn - local drugb such as drugn - general drugn - drugn or other drugn
false
some drug interactions are : - birth control pills - drugn - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as drugn or drugn - certain drugn given by injection - drugn - drugn - drugn - druga or drugn - local drugn such as drugb - general drugn - drugn or other drugn
false
some drug interactions are : - birth control pills - drugn - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as drugn or drugn - certain drugn given by injection - drugn - drugn - drugn - druga or drugn - local drugn such as drugn - general drugb - drugn or other drugn
false
some drug interactions are : - birth control pills - drugn - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as drugn or drugn - certain drugn given by injection - drugn - drugn - drugn - druga or drugn - local drugn such as drugn - general drugn - drugb or other drugn
false
some drug interactions are : - birth control pills - drugn - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as drugn or drugn - certain drugn given by injection - drugn - drugn - drugn - druga or drugn - local drugn such as drugn - general drugn - drugn or other drugb
false
some drug interactions are : - birth control pills - drugn - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as drugn or drugn - certain drugn given by injection - drugn - drugn - drugn - drugn or druga - local drugb such as drugn - general drugn - drugn or other drugn
false
some drug interactions are : - birth control pills - drugn - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as drugn or drugn - certain drugn given by injection - drugn - drugn - drugn - drugn or druga - local drugn such as drugb - general drugn - drugn or other drugn
false
some drug interactions are : - birth control pills - drugn - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as drugn or drugn - certain drugn given by injection - drugn - drugn - drugn - drugn or druga - local drugn such as drugn - general drugb - drugn or other drugn
false
some drug interactions are : - birth control pills - drugn - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as drugn or drugn - certain drugn given by injection - drugn - drugn - drugn - drugn or druga - local drugn such as drugn - general drugn - drugb or other drugn
false
some drug interactions are : - birth control pills - drugn - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as drugn or drugn - certain drugn given by injection - drugn - drugn - drugn - drugn or druga - local drugn such as drugn - general drugn - drugn or other drugb
false
some drug interactions are : - birth control pills - drugn - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as drugn or drugn - certain drugn given by injection - drugn - drugn - drugn - drugn or drugn - local druga such as drugb - general drugn - drugn or other drugn
false
some drug interactions are : - birth control pills - drugn - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as drugn or drugn - certain drugn given by injection - drugn - drugn - drugn - drugn or drugn - local druga such as drugn - general drugb - drugn or other drugn
false
some drug interactions are : - birth control pills - drugn - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as drugn or drugn - certain drugn given by injection - drugn - drugn - drugn - drugn or drugn - local druga such as drugn - general drugn - drugb or other drugn
false
some drug interactions are : - birth control pills - drugn - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as drugn or drugn - certain drugn given by injection - drugn - drugn - drugn - drugn or drugn - local druga such as drugn - general drugn - drugn or other drugb
false
some drug interactions are : - birth control pills - drugn - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as drugn or drugn - certain drugn given by injection - drugn - drugn - drugn - drugn or drugn - local drugn such as druga - general drugb - drugn or other drugn
false
some drug interactions are : - birth control pills - drugn - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as drugn or drugn - certain drugn given by injection - drugn - drugn - drugn - drugn or drugn - local drugn such as druga - general drugn - drugb or other drugn
false
some drug interactions are : - birth control pills - drugn - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as drugn or drugn - certain drugn given by injection - drugn - drugn - drugn - drugn or drugn - local drugn such as druga - general drugn - drugn or other drugb
false
some drug interactions are : - birth control pills - drugn - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as drugn or drugn - certain drugn given by injection - drugn - drugn - drugn - drugn or drugn - local drugn such as drugn - general druga - drugb or other drugn
false
some drug interactions are : - birth control pills - drugn - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as drugn or drugn - certain drugn given by injection - drugn - drugn - drugn - drugn or drugn - local drugn such as drugn - general druga - drugn or other drugb
false
some drug interactions are : - birth control pills - drugn - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as drugn or drugn - certain drugn given by injection - drugn - drugn - drugn - drugn or drugn - local drugn such as drugn - general drugn - druga or other drugb
false
druga has been reported to enhance the sedative activity of drugb , drugn , drugn , and drugn .
effect
druga has been reported to enhance the sedative activity of drugn , drugb , drugn , and drugn .
false
druga has been reported to enhance the sedative activity of drugn , drugn , drugb , and drugn .
false
druga has been reported to enhance the sedative activity of drugn , drugn , drugn , and drugb .
false
drugn has been reported to enhance the sedative activity of druga , drugb , drugn , and drugn .
false
drugn has been reported to enhance the sedative activity of druga , drugn , drugb , and drugn .
false
drugn has been reported to enhance the sedative activity of druga , drugn , drugn , and drugb .
false
drugn has been reported to enhance the sedative activity of drugn , druga , drugb , and drugn .
false
drugn has been reported to enhance the sedative activity of drugn , druga , drugn , and drugb .
false
drugn has been reported to enhance the sedative activity of drugn , drugn , druga , and drugb .
false
oral druga : in 10 healthy women , the pharmacokinetic profiles of drugb and drugn following administration of a single dose containing 1.0 mg of drugn and 75 g of drugn were studied .
false
oral druga : in 10 healthy women , the pharmacokinetic profiles of drugn and drugb following administration of a single dose containing 1.0 mg of drugn and 75 g of drugn were studied .
false
oral druga : in 10 healthy women , the pharmacokinetic profiles of drugn and drugn following administration of a single dose containing 1.0 mg of drugb and 75 g of drugn were studied .
false
oral druga : in 10 healthy women , the pharmacokinetic profiles of drugn and drugn following administration of a single dose containing 1.0 mg of drugn and 75 g of drugb were studied .
false
oral drugn : in 10 healthy women , the pharmacokinetic profiles of druga and drugb following administration of a single dose containing 1.0 mg of drugn and 75 g of drugn were studied .
false
oral drugn : in 10 healthy women , the pharmacokinetic profiles of druga and drugn following administration of a single dose containing 1.0 mg of drugb and 75 g of drugn were studied .
false
oral drugn : in 10 healthy women , the pharmacokinetic profiles of druga and drugn following administration of a single dose containing 1.0 mg of drugn and 75 g of drugb were studied .
false
oral drugn : in 10 healthy women , the pharmacokinetic profiles of drugn and druga following administration of a single dose containing 1.0 mg of drugb and 75 g of drugn were studied .
false
oral drugn : in 10 healthy women , the pharmacokinetic profiles of drugn and druga following administration of a single dose containing 1.0 mg of drugn and 75 g of drugb were studied .
false
oral drugn : in 10 healthy women , the pharmacokinetic profiles of drugn and drugn following administration of a single dose containing 1.0 mg of druga and 75 g of drugb were studied .
false
important non- druga drug interactions drugs that interfere with drugb : concomitant use of drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , or certain herbal supplements such as st .
false
important non- druga drug interactions drugs that interfere with drugn : concomitant use of drugb , drugn , drugn , drugn , drugn , drugn , drugn , drugn , or certain herbal supplements such as st .
false
important non- druga drug interactions drugs that interfere with drugn : concomitant use of drugn , drugb , drugn , drugn , drugn , drugn , drugn , drugn , or certain herbal supplements such as st .
false
important non- druga drug interactions drugs that interfere with drugn : concomitant use of drugn , drugn , drugb , drugn , drugn , drugn , drugn , drugn , or certain herbal supplements such as st .
false
important non- druga drug interactions drugs that interfere with drugn : concomitant use of drugn , drugn , drugn , drugb , drugn , drugn , drugn , drugn , or certain herbal supplements such as st .
false
important non- druga drug interactions drugs that interfere with drugn : concomitant use of drugn , drugn , drugn , drugn , drugb , drugn , drugn , drugn , or certain herbal supplements such as st .
false
important non- druga drug interactions drugs that interfere with drugn : concomitant use of drugn , drugn , drugn , drugn , drugn , drugb , drugn , drugn , or certain herbal supplements such as st .
false
important non- druga drug interactions drugs that interfere with drugn : concomitant use of drugn , drugn , drugn , drugn , drugn , drugn , drugb , drugn , or certain herbal supplements such as st .
false
important non- druga drug interactions drugs that interfere with drugn : concomitant use of drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugb , or certain herbal supplements such as st .
false
important non- drugn drug interactions drugs that interfere with druga : concomitant use of drugb , drugn , drugn , drugn , drugn , drugn , drugn , drugn , or certain herbal supplements such as st .
false
important non- drugn drug interactions drugs that interfere with druga : concomitant use of drugn , drugb , drugn , drugn , drugn , drugn , drugn , drugn , or certain herbal supplements such as st .
false
important non- drugn drug interactions drugs that interfere with druga : concomitant use of drugn , drugn , drugb , drugn , drugn , drugn , drugn , drugn , or certain herbal supplements such as st .
false
important non- drugn drug interactions drugs that interfere with druga : concomitant use of drugn , drugn , drugn , drugb , drugn , drugn , drugn , drugn , or certain herbal supplements such as st .
false
important non- drugn drug interactions drugs that interfere with druga : concomitant use of drugn , drugn , drugn , drugn , drugb , drugn , drugn , drugn , or certain herbal supplements such as st .
false
important non- drugn drug interactions drugs that interfere with druga : concomitant use of drugn , drugn , drugn , drugn , drugn , drugb , drugn , drugn , or certain herbal supplements such as st .
false
important non- drugn drug interactions drugs that interfere with druga : concomitant use of drugn , drugn , drugn , drugn , drugn , drugn , drugb , drugn , or certain herbal supplements such as st .
false
important non- drugn drug interactions drugs that interfere with druga : concomitant use of drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugb , or certain herbal supplements such as st .
false
important non- drugn drug interactions drugs that interfere with drugn : concomitant use of druga , drugb , drugn , drugn , drugn , drugn , drugn , drugn , or certain herbal supplements such as st .
false
important non- drugn drug interactions drugs that interfere with drugn : concomitant use of druga , drugn , drugb , drugn , drugn , drugn , drugn , drugn , or certain herbal supplements such as st .
false
important non- drugn drug interactions drugs that interfere with drugn : concomitant use of druga , drugn , drugn , drugb , drugn , drugn , drugn , drugn , or certain herbal supplements such as st .
false
important non- drugn drug interactions drugs that interfere with drugn : concomitant use of druga , drugn , drugn , drugn , drugb , drugn , drugn , drugn , or certain herbal supplements such as st .
false
important non- drugn drug interactions drugs that interfere with drugn : concomitant use of druga , drugn , drugn , drugn , drugn , drugb , drugn , drugn , or certain herbal supplements such as st .
false
important non- drugn drug interactions drugs that interfere with drugn : concomitant use of druga , drugn , drugn , drugn , drugn , drugn , drugb , drugn , or certain herbal supplements such as st .
false
important non- drugn drug interactions drugs that interfere with drugn : concomitant use of druga , drugn , drugn , drugn , drugn , drugn , drugn , drugb , or certain herbal supplements such as st .
false
important non- drugn drug interactions drugs that interfere with drugn : concomitant use of drugn , druga , drugb , drugn , drugn , drugn , drugn , drugn , or certain herbal supplements such as st .
false
important non- drugn drug interactions drugs that interfere with drugn : concomitant use of drugn , druga , drugn , drugb , drugn , drugn , drugn , drugn , or certain herbal supplements such as st .
false
important non- drugn drug interactions drugs that interfere with drugn : concomitant use of drugn , druga , drugn , drugn , drugb , drugn , drugn , drugn , or certain herbal supplements such as st .
false
important non- drugn drug interactions drugs that interfere with drugn : concomitant use of drugn , druga , drugn , drugn , drugn , drugb , drugn , drugn , or certain herbal supplements such as st .
false
important non- drugn drug interactions drugs that interfere with drugn : concomitant use of drugn , druga , drugn , drugn , drugn , drugn , drugb , drugn , or certain herbal supplements such as st .
false
important non- drugn drug interactions drugs that interfere with drugn : concomitant use of drugn , druga , drugn , drugn , drugn , drugn , drugn , drugb , or certain herbal supplements such as st .
false
important non- drugn drug interactions drugs that interfere with drugn : concomitant use of drugn , drugn , druga , drugb , drugn , drugn , drugn , drugn , or certain herbal supplements such as st .
false
important non- drugn drug interactions drugs that interfere with drugn : concomitant use of drugn , drugn , druga , drugn , drugb , drugn , drugn , drugn , or certain herbal supplements such as st .
false
important non- drugn drug interactions drugs that interfere with drugn : concomitant use of drugn , drugn , druga , drugn , drugn , drugb , drugn , drugn , or certain herbal supplements such as st .
false
important non- drugn drug interactions drugs that interfere with drugn : concomitant use of drugn , drugn , druga , drugn , drugn , drugn , drugb , drugn , or certain herbal supplements such as st .
false
important non- drugn drug interactions drugs that interfere with drugn : concomitant use of drugn , drugn , druga , drugn , drugn , drugn , drugn , drugb , or certain herbal supplements such as st .
false
important non- drugn drug interactions drugs that interfere with drugn : concomitant use of drugn , drugn , drugn , druga , drugb , drugn , drugn , drugn , or certain herbal supplements such as st .
false
important non- drugn drug interactions drugs that interfere with drugn : concomitant use of drugn , drugn , drugn , druga , drugn , drugb , drugn , drugn , or certain herbal supplements such as st .
false
important non- drugn drug interactions drugs that interfere with drugn : concomitant use of drugn , drugn , drugn , druga , drugn , drugn , drugb , drugn , or certain herbal supplements such as st .
false
important non- drugn drug interactions drugs that interfere with drugn : concomitant use of drugn , drugn , drugn , druga , drugn , drugn , drugn , drugb , or certain herbal supplements such as st .
false
important non- drugn drug interactions drugs that interfere with drugn : concomitant use of drugn , drugn , drugn , drugn , druga , drugb , drugn , drugn , or certain herbal supplements such as st .
false
important non- drugn drug interactions drugs that interfere with drugn : concomitant use of drugn , drugn , drugn , drugn , druga , drugn , drugb , drugn , or certain herbal supplements such as st .
false
important non- drugn drug interactions drugs that interfere with drugn : concomitant use of drugn , drugn , drugn , drugn , druga , drugn , drugn , drugb , or certain herbal supplements such as st .
false
important non- drugn drug interactions drugs that interfere with drugn : concomitant use of drugn , drugn , drugn , drugn , drugn , druga , drugb , drugn , or certain herbal supplements such as st .
false
important non- drugn drug interactions drugs that interfere with drugn : concomitant use of drugn , drugn , drugn , drugn , drugn , druga , drugn , drugb , or certain herbal supplements such as st .
false
important non- drugn drug interactions drugs that interfere with drugn : concomitant use of drugn , drugn , drugn , drugn , drugn , drugn , druga , drugb , or certain herbal supplements such as st .
false
druga with drugb may reduce the effectiveness of the contraception and up to one month after discontinuation of these concomitant therapies .
effect
pharmacokinetic studies show that there are no significant alterations in pharmacokinetic parameters of druga or drugb to warrant dosage adjustment when drugn is administered with these drugs .
false
pharmacokinetic studies show that there are no significant alterations in pharmacokinetic parameters of druga or drugn to warrant dosage adjustment when drugb is administered with these drugs .
false
pharmacokinetic studies show that there are no significant alterations in pharmacokinetic parameters of drugn or druga to warrant dosage adjustment when drugb is administered with these drugs .
false
a pharmacokinetic study demonstrated that coadministration of druga and drugb results in a significant decrease in the pharmacokinetic parameters ( ~36 % for cmax and ~28 % for auc ) of drugn .
mechanism
a pharmacokinetic study demonstrated that coadministration of druga and drugn results in a significant decrease in the pharmacokinetic parameters ( ~36 % for cmax and ~28 % for auc ) of drugb .
false
a pharmacokinetic study demonstrated that coadministration of drugn and druga results in a significant decrease in the pharmacokinetic parameters ( ~36 % for cmax and ~28 % for auc ) of drugb .
false
administration of a higher dose of druga should be considered when coadministering with drugb .
advise
the effects of druga , drugb or drugn on the pharmacokinetics of drugn were not studied .
false
the effects of druga , drugn or drugb on the pharmacokinetics of drugn were not studied .
false
the effects of druga , drugn or drugn on the pharmacokinetics of drugb were not studied .
false
the effects of drugn , druga or drugb on the pharmacokinetics of drugn were not studied .
false
the effects of drugn , druga or drugn on the pharmacokinetics of drugb were not studied .
false
the effects of drugn , drugn or druga on the pharmacokinetics of drugb were not studied .
false
druga : there was a slight increase in the area under the curve ( auc , 11 % ) and mean peak drug concentration ( cmax , 18 % ) of drugb with the co-administration of 100 mg drugn for 10 days .
false
druga : there was a slight increase in the area under the curve ( auc , 11 % ) and mean peak drug concentration ( cmax , 18 % ) of drugn with the co-administration of 100 mg drugb for 10 days .
false
drugn : there was a slight increase in the area under the curve ( auc , 11 % ) and mean peak drug concentration ( cmax , 18 % ) of druga with the co-administration of 100 mg drugb for 10 days .
mechanism
no dosage adjustment of druga or drugb is recommended .
false
druga may increase the effects of drugb , drugn , and drugn .
effect
druga may increase the effects of drugn , drugb , and drugn .
effect
druga may increase the effects of drugn , drugn , and drugb .
effect
drugn may increase the effects of druga , drugb , and drugn .
false
drugn may increase the effects of druga , drugn , and drugb .
false
drugn may increase the effects of drugn , druga , and drugb .
false
it may also interact with druga ( increased thrombocytopenia ) , drugb ( increased nephrotoxicity ) , drugn ( increased hypoglycemic response ) , drugn ( increased anticoagulant effect ) , drugn ( decreased renal excretion of drugn ) , drugn ( decreased hepatic clearance of drugn ) .
false
it may also interact with druga ( increased thrombocytopenia ) , drugn ( increased nephrotoxicity ) , drugb ( increased hypoglycemic response ) , drugn ( increased anticoagulant effect ) , drugn ( decreased renal excretion of drugn ) , drugn ( decreased hepatic clearance of drugn ) .
false
it may also interact with druga ( increased thrombocytopenia ) , drugn ( increased nephrotoxicity ) , drugn ( increased hypoglycemic response ) , drugb ( increased anticoagulant effect ) , drugn ( decreased renal excretion of drugn ) , drugn ( decreased hepatic clearance of drugn ) .
false
it may also interact with druga ( increased thrombocytopenia ) , drugn ( increased nephrotoxicity ) , drugn ( increased hypoglycemic response ) , drugn ( increased anticoagulant effect ) , drugb ( decreased renal excretion of drugn ) , drugn ( decreased hepatic clearance of drugn ) .
false
it may also interact with druga ( increased thrombocytopenia ) , drugn ( increased nephrotoxicity ) , drugn ( increased hypoglycemic response ) , drugn ( increased anticoagulant effect ) , drugn ( decreased renal excretion of drugb ) , drugn ( decreased hepatic clearance of drugn ) .
false
it may also interact with druga ( increased thrombocytopenia ) , drugn ( increased nephrotoxicity ) , drugn ( increased hypoglycemic response ) , drugn ( increased anticoagulant effect ) , drugn ( decreased renal excretion of drugn ) , drugb ( decreased hepatic clearance of drugn ) .
false
it may also interact with druga ( increased thrombocytopenia ) , drugn ( increased nephrotoxicity ) , drugn ( increased hypoglycemic response ) , drugn ( increased anticoagulant effect ) , drugn ( decreased renal excretion of drugn ) , drugn ( decreased hepatic clearance of drugb ) .
false
it may also interact with drugn ( increased thrombocytopenia ) , druga ( increased nephrotoxicity ) , drugb ( increased hypoglycemic response ) , drugn ( increased anticoagulant effect ) , drugn ( decreased renal excretion of drugn ) , drugn ( decreased hepatic clearance of drugn ) .
false
it may also interact with drugn ( increased thrombocytopenia ) , druga ( increased nephrotoxicity ) , drugn ( increased hypoglycemic response ) , drugb ( increased anticoagulant effect ) , drugn ( decreased renal excretion of drugn ) , drugn ( decreased hepatic clearance of drugn ) .
false
it may also interact with drugn ( increased thrombocytopenia ) , druga ( increased nephrotoxicity ) , drugn ( increased hypoglycemic response ) , drugn ( increased anticoagulant effect ) , drugb ( decreased renal excretion of drugn ) , drugn ( decreased hepatic clearance of drugn ) .
false
it may also interact with drugn ( increased thrombocytopenia ) , druga ( increased nephrotoxicity ) , drugn ( increased hypoglycemic response ) , drugn ( increased anticoagulant effect ) , drugn ( decreased renal excretion of drugb ) , drugn ( decreased hepatic clearance of drugn ) .
false
it may also interact with drugn ( increased thrombocytopenia ) , druga ( increased nephrotoxicity ) , drugn ( increased hypoglycemic response ) , drugn ( increased anticoagulant effect ) , drugn ( decreased renal excretion of drugn ) , drugb ( decreased hepatic clearance of drugn ) .
false
it may also interact with drugn ( increased thrombocytopenia ) , druga ( increased nephrotoxicity ) , drugn ( increased hypoglycemic response ) , drugn ( increased anticoagulant effect ) , drugn ( decreased renal excretion of drugn ) , drugn ( decreased hepatic clearance of drugb ) .
false
it may also interact with drugn ( increased thrombocytopenia ) , drugn ( increased nephrotoxicity ) , druga ( increased hypoglycemic response ) , drugb ( increased anticoagulant effect ) , drugn ( decreased renal excretion of drugn ) , drugn ( decreased hepatic clearance of drugn ) .
false
it may also interact with drugn ( increased thrombocytopenia ) , drugn ( increased nephrotoxicity ) , druga ( increased hypoglycemic response ) , drugn ( increased anticoagulant effect ) , drugb ( decreased renal excretion of drugn ) , drugn ( decreased hepatic clearance of drugn ) .
false
it may also interact with drugn ( increased thrombocytopenia ) , drugn ( increased nephrotoxicity ) , druga ( increased hypoglycemic response ) , drugn ( increased anticoagulant effect ) , drugn ( decreased renal excretion of drugb ) , drugn ( decreased hepatic clearance of drugn ) .
false
it may also interact with drugn ( increased thrombocytopenia ) , drugn ( increased nephrotoxicity ) , druga ( increased hypoglycemic response ) , drugn ( increased anticoagulant effect ) , drugn ( decreased renal excretion of drugn ) , drugb ( decreased hepatic clearance of drugn ) .
false
it may also interact with drugn ( increased thrombocytopenia ) , drugn ( increased nephrotoxicity ) , druga ( increased hypoglycemic response ) , drugn ( increased anticoagulant effect ) , drugn ( decreased renal excretion of drugn ) , drugn ( decreased hepatic clearance of drugb ) .
false
it may also interact with drugn ( increased thrombocytopenia ) , drugn ( increased nephrotoxicity ) , drugn ( increased hypoglycemic response ) , druga ( increased anticoagulant effect ) , drugb ( decreased renal excretion of drugn ) , drugn ( decreased hepatic clearance of drugn ) .
false
it may also interact with drugn ( increased thrombocytopenia ) , drugn ( increased nephrotoxicity ) , drugn ( increased hypoglycemic response ) , druga ( increased anticoagulant effect ) , drugn ( decreased renal excretion of drugb ) , drugn ( decreased hepatic clearance of drugn ) .
false
it may also interact with drugn ( increased thrombocytopenia ) , drugn ( increased nephrotoxicity ) , drugn ( increased hypoglycemic response ) , druga ( increased anticoagulant effect ) , drugn ( decreased renal excretion of drugn ) , drugb ( decreased hepatic clearance of drugn ) .
false
it may also interact with drugn ( increased thrombocytopenia ) , drugn ( increased nephrotoxicity ) , drugn ( increased hypoglycemic response ) , druga ( increased anticoagulant effect ) , drugn ( decreased renal excretion of drugn ) , drugn ( decreased hepatic clearance of drugb ) .
false
it may also interact with drugn ( increased thrombocytopenia ) , drugn ( increased nephrotoxicity ) , drugn ( increased hypoglycemic response ) , drugn ( increased anticoagulant effect ) , druga ( decreased renal excretion of drugb ) , drugn ( decreased hepatic clearance of drugn ) .
false
it may also interact with drugn ( increased thrombocytopenia ) , drugn ( increased nephrotoxicity ) , drugn ( increased hypoglycemic response ) , drugn ( increased anticoagulant effect ) , druga ( decreased renal excretion of drugn ) , drugb ( decreased hepatic clearance of drugn ) .
false
it may also interact with drugn ( increased thrombocytopenia ) , drugn ( increased nephrotoxicity ) , drugn ( increased hypoglycemic response ) , drugn ( increased anticoagulant effect ) , druga ( decreased renal excretion of drugn ) , drugn ( decreased hepatic clearance of drugb ) .
false
it may also interact with drugn ( increased thrombocytopenia ) , drugn ( increased nephrotoxicity ) , drugn ( increased hypoglycemic response ) , drugn ( increased anticoagulant effect ) , drugn ( decreased renal excretion of druga ) , drugb ( decreased hepatic clearance of drugn ) .
false
it may also interact with drugn ( increased thrombocytopenia ) , drugn ( increased nephrotoxicity ) , drugn ( increased hypoglycemic response ) , drugn ( increased anticoagulant effect ) , drugn ( decreased renal excretion of druga ) , drugn ( decreased hepatic clearance of drugb ) .
false
it may also interact with drugn ( increased thrombocytopenia ) , drugn ( increased nephrotoxicity ) , drugn ( increased hypoglycemic response ) , drugn ( increased anticoagulant effect ) , drugn ( decreased renal excretion of drugn ) , druga ( decreased hepatic clearance of drugb ) .
false
patients receiving druga and drugb should have more frequent monitoring of neutrophil counts .
advise
other druga should not be used concomitantly with drugb because they may have additive effects .
advise
concomitant administration of druga and drugb has been associated with erythema and histamine-like flushing and anaphylactoid reactions .
effect
concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs , such as druga , drugb , drugn , drugn , drugn , drugn , or drugn , when indicated , requires careful monitoring .
false
concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs , such as druga , drugn , drugb , drugn , drugn , drugn , or drugn , when indicated , requires careful monitoring .
false
concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs , such as druga , drugn , drugn , drugb , drugn , drugn , or drugn , when indicated , requires careful monitoring .
false
concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs , such as druga , drugn , drugn , drugn , drugb , drugn , or drugn , when indicated , requires careful monitoring .
false
concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs , such as druga , drugn , drugn , drugn , drugn , drugb , or drugn , when indicated , requires careful monitoring .
false
concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs , such as druga , drugn , drugn , drugn , drugn , drugn , or drugb , when indicated , requires careful monitoring .
false
concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs , such as drugn , druga , drugb , drugn , drugn , drugn , or drugn , when indicated , requires careful monitoring .
false
concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs , such as drugn , druga , drugn , drugb , drugn , drugn , or drugn , when indicated , requires careful monitoring .
false
concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs , such as drugn , druga , drugn , drugn , drugb , drugn , or drugn , when indicated , requires careful monitoring .
false
concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs , such as drugn , druga , drugn , drugn , drugn , drugb , or drugn , when indicated , requires careful monitoring .
false
concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs , such as drugn , druga , drugn , drugn , drugn , drugn , or drugb , when indicated , requires careful monitoring .
false
concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs , such as drugn , drugn , druga , drugb , drugn , drugn , or drugn , when indicated , requires careful monitoring .
false
concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs , such as drugn , drugn , druga , drugn , drugb , drugn , or drugn , when indicated , requires careful monitoring .
false
concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs , such as drugn , drugn , druga , drugn , drugn , drugb , or drugn , when indicated , requires careful monitoring .
false
concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs , such as drugn , drugn , druga , drugn , drugn , drugn , or drugb , when indicated , requires careful monitoring .
false
concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs , such as drugn , drugn , drugn , druga , drugb , drugn , or drugn , when indicated , requires careful monitoring .
false
concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs , such as drugn , drugn , drugn , druga , drugn , drugb , or drugn , when indicated , requires careful monitoring .
false
concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs , such as drugn , drugn , drugn , druga , drugn , drugn , or drugb , when indicated , requires careful monitoring .
false
concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs , such as drugn , drugn , drugn , drugn , druga , drugb , or drugn , when indicated , requires careful monitoring .
false
concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs , such as drugn , drugn , drugn , drugn , druga , drugn , or drugb , when indicated , requires careful monitoring .
false
concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs , such as drugn , drugn , drugn , drugn , drugn , druga , or drugb , when indicated , requires careful monitoring .
false
interactions for druga ( drugb ) : drugn , oral drugn , drugn , drugn
false
interactions for druga ( drugn ) : drugb , oral drugn , drugn , drugn
int
interactions for druga ( drugn ) : drugn , oral drugb , drugn , drugn
int
interactions for druga ( drugn ) : drugn , oral drugn , drugb , drugn
int
interactions for druga ( drugn ) : drugn , oral drugn , drugn , drugb
int
interactions for drugn ( druga ) : drugb , oral drugn , drugn , drugn
int
interactions for drugn ( druga ) : drugn , oral drugb , drugn , drugn
int
interactions for drugn ( druga ) : drugn , oral drugn , drugb , drugn
int
interactions for drugn ( druga ) : drugn , oral drugn , drugn , drugb
int
interactions for drugn ( drugn ) : druga , oral drugb , drugn , drugn
false
interactions for drugn ( drugn ) : druga , oral drugn , drugb , drugn
false
interactions for drugn ( drugn ) : druga , oral drugn , drugn , drugb
false
interactions for drugn ( drugn ) : drugn , oral druga , drugb , drugn
false
interactions for drugn ( drugn ) : drugn , oral druga , drugn , drugb
false
interactions for drugn ( drugn ) : drugn , oral drugn , druga , drugb
false
acromegalic patients with diabetes mellitus being treated with druga and/or oral drugb agents may require dose reductions of these therapeutic agents after the initiation of therapy with drugn .
false
acromegalic patients with diabetes mellitus being treated with druga and/or oral drugn agents may require dose reductions of these therapeutic agents after the initiation of therapy with drugb .
advise
acromegalic patients with diabetes mellitus being treated with drugn and/or oral druga agents may require dose reductions of these therapeutic agents after the initiation of therapy with drugb .
advise
in clinical studies , patients on druga often needed higher serum drugb concentrations to achieve appropriate igf-i suppression compared with patients not receiving drugn .
mechanism
in clinical studies , patients on druga often needed higher serum drugn concentrations to achieve appropriate igf-i suppression compared with patients not receiving drugb .
false
in clinical studies , patients on drugn often needed higher serum druga concentrations to achieve appropriate igf-i suppression compared with patients not receiving drugb .
false
you can not take druga if you have taken a drugb ( drugn ) such as drugn ( drugn ) , drugn ( drugn ) , or drugn ( drugn ) in the last 14 days .
advise
you can not take druga if you have taken a drugn ( drugb ) such as drugn ( drugn ) , drugn ( drugn ) , or drugn ( drugn ) in the last 14 days .
advise
you can not take druga if you have taken a drugn ( drugn ) such as drugb ( drugn ) , drugn ( drugn ) , or drugn ( drugn ) in the last 14 days .
advise
you can not take druga if you have taken a drugn ( drugn ) such as drugn ( drugb ) , drugn ( drugn ) , or drugn ( drugn ) in the last 14 days .
advise
you can not take druga if you have taken a drugn ( drugn ) such as drugn ( drugn ) , drugb ( drugn ) , or drugn ( drugn ) in the last 14 days .
advise
you can not take druga if you have taken a drugn ( drugn ) such as drugn ( drugn ) , drugn ( drugb ) , or drugn ( drugn ) in the last 14 days .
advise
you can not take druga if you have taken a drugn ( drugn ) such as drugn ( drugn ) , drugn ( drugn ) , or drugb ( drugn ) in the last 14 days .
advise
you can not take druga if you have taken a drugn ( drugn ) such as drugn ( drugn ) , drugn ( drugn ) , or drugn ( drugb ) in the last 14 days .
advise
you can not take drugn if you have taken a druga ( drugb ) such as drugn ( drugn ) , drugn ( drugn ) , or drugn ( drugn ) in the last 14 days .
false
you can not take drugn if you have taken a druga ( drugn ) such as drugb ( drugn ) , drugn ( drugn ) , or drugn ( drugn ) in the last 14 days .
false
you can not take drugn if you have taken a druga ( drugn ) such as drugn ( drugb ) , drugn ( drugn ) , or drugn ( drugn ) in the last 14 days .
false
you can not take drugn if you have taken a druga ( drugn ) such as drugn ( drugn ) , drugb ( drugn ) , or drugn ( drugn ) in the last 14 days .
false
you can not take drugn if you have taken a druga ( drugn ) such as drugn ( drugn ) , drugn ( drugb ) , or drugn ( drugn ) in the last 14 days .
false
you can not take drugn if you have taken a druga ( drugn ) such as drugn ( drugn ) , drugn ( drugn ) , or drugb ( drugn ) in the last 14 days .
false
you can not take drugn if you have taken a druga ( drugn ) such as drugn ( drugn ) , drugn ( drugn ) , or drugn ( drugb ) in the last 14 days .
false
you can not take drugn if you have taken a drugn ( druga ) such as drugb ( drugn ) , drugn ( drugn ) , or drugn ( drugn ) in the last 14 days .
false
you can not take drugn if you have taken a drugn ( druga ) such as drugn ( drugb ) , drugn ( drugn ) , or drugn ( drugn ) in the last 14 days .
false
you can not take drugn if you have taken a drugn ( druga ) such as drugn ( drugn ) , drugb ( drugn ) , or drugn ( drugn ) in the last 14 days .
false
you can not take drugn if you have taken a drugn ( druga ) such as drugn ( drugn ) , drugn ( drugb ) , or drugn ( drugn ) in the last 14 days .
false
you can not take drugn if you have taken a drugn ( druga ) such as drugn ( drugn ) , drugn ( drugn ) , or drugb ( drugn ) in the last 14 days .
false
you can not take drugn if you have taken a drugn ( druga ) such as drugn ( drugn ) , drugn ( drugn ) , or drugn ( drugb ) in the last 14 days .
false
you can not take drugn if you have taken a drugn ( drugn ) such as druga ( drugb ) , drugn ( drugn ) , or drugn ( drugn ) in the last 14 days .
false
you can not take drugn if you have taken a drugn ( drugn ) such as druga ( drugn ) , drugb ( drugn ) , or drugn ( drugn ) in the last 14 days .
false
you can not take drugn if you have taken a drugn ( drugn ) such as druga ( drugn ) , drugn ( drugb ) , or drugn ( drugn ) in the last 14 days .
false
you can not take drugn if you have taken a drugn ( drugn ) such as druga ( drugn ) , drugn ( drugn ) , or drugb ( drugn ) in the last 14 days .
false
you can not take drugn if you have taken a drugn ( drugn ) such as druga ( drugn ) , drugn ( drugn ) , or drugn ( drugb ) in the last 14 days .
false
you can not take drugn if you have taken a drugn ( drugn ) such as drugn ( druga ) , drugb ( drugn ) , or drugn ( drugn ) in the last 14 days .
false
you can not take drugn if you have taken a drugn ( drugn ) such as drugn ( druga ) , drugn ( drugb ) , or drugn ( drugn ) in the last 14 days .
false
you can not take drugn if you have taken a drugn ( drugn ) such as drugn ( druga ) , drugn ( drugn ) , or drugb ( drugn ) in the last 14 days .
false
you can not take drugn if you have taken a drugn ( drugn ) such as drugn ( druga ) , drugn ( drugn ) , or drugn ( drugb ) in the last 14 days .
false
you can not take drugn if you have taken a drugn ( drugn ) such as drugn ( drugn ) , druga ( drugb ) , or drugn ( drugn ) in the last 14 days .
false
you can not take drugn if you have taken a drugn ( drugn ) such as drugn ( drugn ) , druga ( drugn ) , or drugb ( drugn ) in the last 14 days .
false
you can not take drugn if you have taken a drugn ( drugn ) such as drugn ( drugn ) , druga ( drugn ) , or drugn ( drugb ) in the last 14 days .
false
you can not take drugn if you have taken a drugn ( drugn ) such as drugn ( drugn ) , drugn ( druga ) , or drugb ( drugn ) in the last 14 days .
false
you can not take drugn if you have taken a drugn ( drugn ) such as drugn ( drugn ) , drugn ( druga ) , or drugn ( drugb ) in the last 14 days .
false
you can not take drugn if you have taken a drugn ( drugn ) such as drugn ( drugn ) , drugn ( drugn ) , or druga ( drugb ) in the last 14 days .
false
changes in druga and other diabetes drug therapies may be necessary during treatment with drugb .
advise
druga may reduce the effects of drugb ( drugn ) .
effect
druga may reduce the effects of drugn ( drugb ) .
effect
drugn may reduce the effects of druga ( drugb ) .
false
before taking this medication , tell your doctor if you are taking a druga such as drugb ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , or drugn ( drugn ) .
false
before taking this medication , tell your doctor if you are taking a druga such as drugn ( drugb ) , drugn ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , or drugn ( drugn ) .
false
before taking this medication , tell your doctor if you are taking a druga such as drugn ( drugn ) , drugb ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , or drugn ( drugn ) .
false
before taking this medication , tell your doctor if you are taking a druga such as drugn ( drugn ) , drugn ( drugb ) , drugn ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , or drugn ( drugn ) .
false
before taking this medication , tell your doctor if you are taking a druga such as drugn ( drugn ) , drugn ( drugn ) , drugb ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , or drugn ( drugn ) .
false
before taking this medication , tell your doctor if you are taking a druga such as drugn ( drugn ) , drugn ( drugn ) , drugn ( drugb ) , drugn ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , or drugn ( drugn ) .
false
before taking this medication , tell your doctor if you are taking a druga such as drugn ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , drugb ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , or drugn ( drugn ) .
false
before taking this medication , tell your doctor if you are taking a druga such as drugn ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , drugn ( drugb ) , drugn ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , or drugn ( drugn ) .
false
before taking this medication , tell your doctor if you are taking a druga such as drugn ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , drugb ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , or drugn ( drugn ) .
false
before taking this medication , tell your doctor if you are taking a druga such as drugn ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , drugn ( drugb ) , drugn ( drugn ) , drugn ( drugn ) , or drugn ( drugn ) .
false
before taking this medication , tell your doctor if you are taking a druga such as drugn ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , drugb ( drugn ) , drugn ( drugn ) , or drugn ( drugn ) .
false
before taking this medication , tell your doctor if you are taking a druga such as drugn ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , drugn ( drugb ) , drugn ( drugn ) , or drugn ( drugn ) .
false
before taking this medication , tell your doctor if you are taking a druga such as drugn ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , drugb ( drugn ) , or drugn ( drugn ) .
false
before taking this medication , tell your doctor if you are taking a druga such as drugn ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , drugn ( drugb ) , or drugn ( drugn ) .
false
before taking this medication , tell your doctor if you are taking a druga such as drugn ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , or drugb ( drugn ) .
false
before taking this medication , tell your doctor if you are taking a druga such as drugn ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , or drugn ( drugb ) .
false
before taking this medication , tell your doctor if you are taking a drugn such as druga ( drugb ) , drugn ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , or drugn ( drugn ) .
false
before taking this medication , tell your doctor if you are taking a drugn such as druga ( drugn ) , drugb ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , or drugn ( drugn ) .
false
before taking this medication , tell your doctor if you are taking a drugn such as druga ( drugn ) , drugn ( drugb ) , drugn ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , or drugn ( drugn ) .
false
before taking this medication , tell your doctor if you are taking a drugn such as druga ( drugn ) , drugn ( drugn ) , drugb ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , or drugn ( drugn ) .
false
before taking this medication , tell your doctor if you are taking a drugn such as druga ( drugn ) , drugn ( drugn ) , drugn ( drugb ) , drugn ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , or drugn ( drugn ) .
false
before taking this medication , tell your doctor if you are taking a drugn such as druga ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , drugb ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , or drugn ( drugn ) .
false
before taking this medication , tell your doctor if you are taking a drugn such as druga ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , drugn ( drugb ) , drugn ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , or drugn ( drugn ) .
false
before taking this medication , tell your doctor if you are taking a drugn such as druga ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , drugb ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , or drugn ( drugn ) .
false
before taking this medication , tell your doctor if you are taking a drugn such as druga ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , drugn ( drugb ) , drugn ( drugn ) , drugn ( drugn ) , or drugn ( drugn ) .
false
before taking this medication , tell your doctor if you are taking a drugn such as druga ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , drugb ( drugn ) , drugn ( drugn ) , or drugn ( drugn ) .
false
before taking this medication , tell your doctor if you are taking a drugn such as druga ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , drugn ( drugb ) , drugn ( drugn ) , or drugn ( drugn ) .
false
before taking this medication , tell your doctor if you are taking a drugn such as druga ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , drugb ( drugn ) , or drugn ( drugn ) .
false
before taking this medication , tell your doctor if you are taking a drugn such as druga ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , drugn ( drugb ) , or drugn ( drugn ) .
false
before taking this medication , tell your doctor if you are taking a drugn such as druga ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , or drugb ( drugn ) .
false
before taking this medication , tell your doctor if you are taking a drugn such as druga ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , or drugn ( drugb ) .
false
before taking this medication , tell your doctor if you are taking a drugn such as drugn ( druga ) , drugb ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , or drugn ( drugn ) .
false
before taking this medication , tell your doctor if you are taking a drugn such as drugn ( druga ) , drugn ( drugb ) , drugn ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , or drugn ( drugn ) .
false
before taking this medication , tell your doctor if you are taking a drugn such as drugn ( druga ) , drugn ( drugn ) , drugb ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , or drugn ( drugn ) .
false
before taking this medication , tell your doctor if you are taking a drugn such as drugn ( druga ) , drugn ( drugn ) , drugn ( drugb ) , drugn ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , or drugn ( drugn ) .
false
before taking this medication , tell your doctor if you are taking a drugn such as drugn ( druga ) , drugn ( drugn ) , drugn ( drugn ) , drugb ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , or drugn ( drugn ) .
false
before taking this medication , tell your doctor if you are taking a drugn such as drugn ( druga ) , drugn ( drugn ) , drugn ( drugn ) , drugn ( drugb ) , drugn ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , or drugn ( drugn ) .
false
before taking this medication , tell your doctor if you are taking a drugn such as drugn ( druga ) , drugn ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , drugb ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , or drugn ( drugn ) .
false
before taking this medication , tell your doctor if you are taking a drugn such as drugn ( druga ) , drugn ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , drugn ( drugb ) , drugn ( drugn ) , drugn ( drugn ) , or drugn ( drugn ) .
false
before taking this medication , tell your doctor if you are taking a drugn such as drugn ( druga ) , drugn ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , drugb ( drugn ) , drugn ( drugn ) , or drugn ( drugn ) .
false
before taking this medication , tell your doctor if you are taking a drugn such as drugn ( druga ) , drugn ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , drugn ( drugb ) , drugn ( drugn ) , or drugn ( drugn ) .
false
before taking this medication , tell your doctor if you are taking a drugn such as drugn ( druga ) , drugn ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , drugb ( drugn ) , or drugn ( drugn ) .
false
before taking this medication , tell your doctor if you are taking a drugn such as drugn ( druga ) , drugn ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , drugn ( drugb ) , or drugn ( drugn ) .
false
before taking this medication , tell your doctor if you are taking a drugn such as drugn ( druga ) , drugn ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , or drugb ( drugn ) .
false
before taking this medication , tell your doctor if you are taking a drugn such as drugn ( druga ) , drugn ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , or drugn ( drugb ) .
false
before taking this medication , tell your doctor if you are taking a drugn such as drugn ( drugn ) , druga ( drugb ) , drugn ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , or drugn ( drugn ) .
false
before taking this medication , tell your doctor if you are taking a drugn such as drugn ( drugn ) , druga ( drugn ) , drugb ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , or drugn ( drugn ) .
false
before taking this medication , tell your doctor if you are taking a drugn such as drugn ( drugn ) , druga ( drugn ) , drugn ( drugb ) , drugn ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , or drugn ( drugn ) .
false
before taking this medication , tell your doctor if you are taking a drugn such as drugn ( drugn ) , druga ( drugn ) , drugn ( drugn ) , drugb ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , or drugn ( drugn ) .
false
before taking this medication , tell your doctor if you are taking a drugn such as drugn ( drugn ) , druga ( drugn ) , drugn ( drugn ) , drugn ( drugb ) , drugn ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , or drugn ( drugn ) .
false
before taking this medication , tell your doctor if you are taking a drugn such as drugn ( drugn ) , druga ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , drugb ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , or drugn ( drugn ) .
false
before taking this medication , tell your doctor if you are taking a drugn such as drugn ( drugn ) , druga ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , drugn ( drugb ) , drugn ( drugn ) , drugn ( drugn ) , or drugn ( drugn ) .
false
before taking this medication , tell your doctor if you are taking a drugn such as drugn ( drugn ) , druga ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , drugb ( drugn ) , drugn ( drugn ) , or drugn ( drugn ) .
false
before taking this medication , tell your doctor if you are taking a drugn such as drugn ( drugn ) , druga ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , drugn ( drugb ) , drugn ( drugn ) , or drugn ( drugn ) .
false
before taking this medication , tell your doctor if you are taking a drugn such as drugn ( drugn ) , druga ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , drugb ( drugn ) , or drugn ( drugn ) .
false
before taking this medication , tell your doctor if you are taking a drugn such as drugn ( drugn ) , druga ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , drugn ( drugb ) , or drugn ( drugn ) .
false
before taking this medication , tell your doctor if you are taking a drugn such as drugn ( drugn ) , druga ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , or drugb ( drugn ) .
false
before taking this medication , tell your doctor if you are taking a drugn such as drugn ( drugn ) , druga ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , or drugn ( drugb ) .
false
before taking this medication , tell your doctor if you are taking a drugn such as drugn ( drugn ) , drugn ( druga ) , drugb ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , or drugn ( drugn ) .
false
before taking this medication , tell your doctor if you are taking a drugn such as drugn ( drugn ) , drugn ( druga ) , drugn ( drugb ) , drugn ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , or drugn ( drugn ) .
false
before taking this medication , tell your doctor if you are taking a drugn such as drugn ( drugn ) , drugn ( druga ) , drugn ( drugn ) , drugb ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , or drugn ( drugn ) .
false
before taking this medication , tell your doctor if you are taking a drugn such as drugn ( drugn ) , drugn ( druga ) , drugn ( drugn ) , drugn ( drugb ) , drugn ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , or drugn ( drugn ) .
false
before taking this medication , tell your doctor if you are taking a drugn such as drugn ( drugn ) , drugn ( druga ) , drugn ( drugn ) , drugn ( drugn ) , drugb ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , or drugn ( drugn ) .
false
before taking this medication , tell your doctor if you are taking a drugn such as drugn ( drugn ) , drugn ( druga ) , drugn ( drugn ) , drugn ( drugn ) , drugn ( drugb ) , drugn ( drugn ) , drugn ( drugn ) , or drugn ( drugn ) .
false
before taking this medication , tell your doctor if you are taking a drugn such as drugn ( drugn ) , drugn ( druga ) , drugn ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , drugb ( drugn ) , drugn ( drugn ) , or drugn ( drugn ) .
false
before taking this medication , tell your doctor if you are taking a drugn such as drugn ( drugn ) , drugn ( druga ) , drugn ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , drugn ( drugb ) , drugn ( drugn ) , or drugn ( drugn ) .
false
before taking this medication , tell your doctor if you are taking a drugn such as drugn ( drugn ) , drugn ( druga ) , drugn ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , drugb ( drugn ) , or drugn ( drugn ) .
false
before taking this medication , tell your doctor if you are taking a drugn such as drugn ( drugn ) , drugn ( druga ) , drugn ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , drugn ( drugb ) , or drugn ( drugn ) .
false
before taking this medication , tell your doctor if you are taking a drugn such as drugn ( drugn ) , drugn ( druga ) , drugn ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , or drugb ( drugn ) .
false
before taking this medication , tell your doctor if you are taking a drugn such as drugn ( drugn ) , drugn ( druga ) , drugn ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , or drugn ( drugb ) .
false
before taking this medication , tell your doctor if you are taking a drugn such as drugn ( drugn ) , drugn ( drugn ) , druga ( drugb ) , drugn ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , or drugn ( drugn ) .
false
before taking this medication , tell your doctor if you are taking a drugn such as drugn ( drugn ) , drugn ( drugn ) , druga ( drugn ) , drugb ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , or drugn ( drugn ) .
false
before taking this medication , tell your doctor if you are taking a drugn such as drugn ( drugn ) , drugn ( drugn ) , druga ( drugn ) , drugn ( drugb ) , drugn ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , or drugn ( drugn ) .
false
before taking this medication , tell your doctor if you are taking a drugn such as drugn ( drugn ) , drugn ( drugn ) , druga ( drugn ) , drugn ( drugn ) , drugb ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , or drugn ( drugn ) .
false
before taking this medication , tell your doctor if you are taking a drugn such as drugn ( drugn ) , drugn ( drugn ) , druga ( drugn ) , drugn ( drugn ) , drugn ( drugb ) , drugn ( drugn ) , drugn ( drugn ) , or drugn ( drugn ) .
false
before taking this medication , tell your doctor if you are taking a drugn such as drugn ( drugn ) , drugn ( drugn ) , druga ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , drugb ( drugn ) , drugn ( drugn ) , or drugn ( drugn ) .
false
before taking this medication , tell your doctor if you are taking a drugn such as drugn ( drugn ) , drugn ( drugn ) , druga ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , drugn ( drugb ) , drugn ( drugn ) , or drugn ( drugn ) .
false
before taking this medication , tell your doctor if you are taking a drugn such as drugn ( drugn ) , drugn ( drugn ) , druga ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , drugb ( drugn ) , or drugn ( drugn ) .
false
before taking this medication , tell your doctor if you are taking a drugn such as drugn ( drugn ) , drugn ( drugn ) , druga ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , drugn ( drugb ) , or drugn ( drugn ) .
false
before taking this medication , tell your doctor if you are taking a drugn such as drugn ( drugn ) , drugn ( drugn ) , druga ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , or drugb ( drugn ) .
false
before taking this medication , tell your doctor if you are taking a drugn such as drugn ( drugn ) , drugn ( drugn ) , druga ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , or drugn ( drugb ) .
false
before taking this medication , tell your doctor if you are taking a drugn such as drugn ( drugn ) , drugn ( drugn ) , drugn ( druga ) , drugb ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , or drugn ( drugn ) .
false
before taking this medication , tell your doctor if you are taking a drugn such as drugn ( drugn ) , drugn ( drugn ) , drugn ( druga ) , drugn ( drugb ) , drugn ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , or drugn ( drugn ) .
false
before taking this medication , tell your doctor if you are taking a drugn such as drugn ( drugn ) , drugn ( drugn ) , drugn ( druga ) , drugn ( drugn ) , drugb ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , or drugn ( drugn ) .
false
before taking this medication , tell your doctor if you are taking a drugn such as drugn ( drugn ) , drugn ( drugn ) , drugn ( druga ) , drugn ( drugn ) , drugn ( drugb ) , drugn ( drugn ) , drugn ( drugn ) , or drugn ( drugn ) .
false
before taking this medication , tell your doctor if you are taking a drugn such as drugn ( drugn ) , drugn ( drugn ) , drugn ( druga ) , drugn ( drugn ) , drugn ( drugn ) , drugb ( drugn ) , drugn ( drugn ) , or drugn ( drugn ) .
false
before taking this medication , tell your doctor if you are taking a drugn such as drugn ( drugn ) , drugn ( drugn ) , drugn ( druga ) , drugn ( drugn ) , drugn ( drugn ) , drugn ( drugb ) , drugn ( drugn ) , or drugn ( drugn ) .
false
before taking this medication , tell your doctor if you are taking a drugn such as drugn ( drugn ) , drugn ( drugn ) , drugn ( druga ) , drugn ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , drugb ( drugn ) , or drugn ( drugn ) .
false
before taking this medication , tell your doctor if you are taking a drugn such as drugn ( drugn ) , drugn ( drugn ) , drugn ( druga ) , drugn ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , drugn ( drugb ) , or drugn ( drugn ) .
false
before taking this medication , tell your doctor if you are taking a drugn such as drugn ( drugn ) , drugn ( drugn ) , drugn ( druga ) , drugn ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , or drugb ( drugn ) .
false
before taking this medication , tell your doctor if you are taking a drugn such as drugn ( drugn ) , drugn ( drugn ) , drugn ( druga ) , drugn ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , or drugn ( drugb ) .
false
before taking this medication , tell your doctor if you are taking a drugn such as drugn ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , druga ( drugb ) , drugn ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , or drugn ( drugn ) .
false
before taking this medication , tell your doctor if you are taking a drugn such as drugn ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , druga ( drugn ) , drugb ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , or drugn ( drugn ) .
false
before taking this medication , tell your doctor if you are taking a drugn such as drugn ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , druga ( drugn ) , drugn ( drugb ) , drugn ( drugn ) , drugn ( drugn ) , or drugn ( drugn ) .
false
before taking this medication , tell your doctor if you are taking a drugn such as drugn ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , druga ( drugn ) , drugn ( drugn ) , drugb ( drugn ) , drugn ( drugn ) , or drugn ( drugn ) .
false
before taking this medication , tell your doctor if you are taking a drugn such as drugn ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , druga ( drugn ) , drugn ( drugn ) , drugn ( drugb ) , drugn ( drugn ) , or drugn ( drugn ) .
false
before taking this medication , tell your doctor if you are taking a drugn such as drugn ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , druga ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , drugb ( drugn ) , or drugn ( drugn ) .
false
before taking this medication , tell your doctor if you are taking a drugn such as drugn ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , druga ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , drugn ( drugb ) , or drugn ( drugn ) .
false
before taking this medication , tell your doctor if you are taking a drugn such as drugn ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , druga ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , or drugb ( drugn ) .
false
before taking this medication , tell your doctor if you are taking a drugn such as drugn ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , druga ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , or drugn ( drugb ) .
false
before taking this medication , tell your doctor if you are taking a drugn such as drugn ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , drugn ( druga ) , drugb ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , or drugn ( drugn ) .
false
before taking this medication , tell your doctor if you are taking a drugn such as drugn ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , drugn ( druga ) , drugn ( drugb ) , drugn ( drugn ) , drugn ( drugn ) , or drugn ( drugn ) .
false
before taking this medication , tell your doctor if you are taking a drugn such as drugn ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , drugn ( druga ) , drugn ( drugn ) , drugb ( drugn ) , drugn ( drugn ) , or drugn ( drugn ) .
false
before taking this medication , tell your doctor if you are taking a drugn such as drugn ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , drugn ( druga ) , drugn ( drugn ) , drugn ( drugb ) , drugn ( drugn ) , or drugn ( drugn ) .
false
before taking this medication , tell your doctor if you are taking a drugn such as drugn ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , drugn ( druga ) , drugn ( drugn ) , drugn ( drugn ) , drugb ( drugn ) , or drugn ( drugn ) .
false
before taking this medication , tell your doctor if you are taking a drugn such as drugn ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , drugn ( druga ) , drugn ( drugn ) , drugn ( drugn ) , drugn ( drugb ) , or drugn ( drugn ) .
false
before taking this medication , tell your doctor if you are taking a drugn such as drugn ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , drugn ( druga ) , drugn ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , or drugb ( drugn ) .
false
before taking this medication , tell your doctor if you are taking a drugn such as drugn ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , drugn ( druga ) , drugn ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , or drugn ( drugb ) .
false
before taking this medication , tell your doctor if you are taking a drugn such as drugn ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , druga ( drugb ) , drugn ( drugn ) , drugn ( drugn ) , or drugn ( drugn ) .
false
before taking this medication , tell your doctor if you are taking a drugn such as drugn ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , druga ( drugn ) , drugb ( drugn ) , drugn ( drugn ) , or drugn ( drugn ) .
false
before taking this medication , tell your doctor if you are taking a drugn such as drugn ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , druga ( drugn ) , drugn ( drugb ) , drugn ( drugn ) , or drugn ( drugn ) .
false
before taking this medication , tell your doctor if you are taking a drugn such as drugn ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , druga ( drugn ) , drugn ( drugn ) , drugb ( drugn ) , or drugn ( drugn ) .
false
before taking this medication , tell your doctor if you are taking a drugn such as drugn ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , druga ( drugn ) , drugn ( drugn ) , drugn ( drugb ) , or drugn ( drugn ) .
false
before taking this medication , tell your doctor if you are taking a drugn such as drugn ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , druga ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , or drugb ( drugn ) .
false
before taking this medication , tell your doctor if you are taking a drugn such as drugn ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , druga ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , or drugn ( drugb ) .
false
before taking this medication , tell your doctor if you are taking a drugn such as drugn ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , drugn ( druga ) , drugb ( drugn ) , drugn ( drugn ) , or drugn ( drugn ) .
false
before taking this medication , tell your doctor if you are taking a drugn such as drugn ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , drugn ( druga ) , drugn ( drugb ) , drugn ( drugn ) , or drugn ( drugn ) .
false
before taking this medication , tell your doctor if you are taking a drugn such as drugn ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , drugn ( druga ) , drugn ( drugn ) , drugb ( drugn ) , or drugn ( drugn ) .
false
before taking this medication , tell your doctor if you are taking a drugn such as drugn ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , drugn ( druga ) , drugn ( drugn ) , drugn ( drugb ) , or drugn ( drugn ) .
false
before taking this medication , tell your doctor if you are taking a drugn such as drugn ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , drugn ( druga ) , drugn ( drugn ) , drugn ( drugn ) , or drugb ( drugn ) .
false
before taking this medication , tell your doctor if you are taking a drugn such as drugn ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , drugn ( druga ) , drugn ( drugn ) , drugn ( drugn ) , or drugn ( drugb ) .
false
before taking this medication , tell your doctor if you are taking a drugn such as drugn ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , druga ( drugb ) , drugn ( drugn ) , or drugn ( drugn ) .
false
before taking this medication , tell your doctor if you are taking a drugn such as drugn ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , druga ( drugn ) , drugb ( drugn ) , or drugn ( drugn ) .
false
before taking this medication , tell your doctor if you are taking a drugn such as drugn ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , druga ( drugn ) , drugn ( drugb ) , or drugn ( drugn ) .
false
before taking this medication , tell your doctor if you are taking a drugn such as drugn ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , druga ( drugn ) , drugn ( drugn ) , or drugb ( drugn ) .
false
before taking this medication , tell your doctor if you are taking a drugn such as drugn ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , druga ( drugn ) , drugn ( drugn ) , or drugn ( drugb ) .
false
before taking this medication , tell your doctor if you are taking a drugn such as drugn ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , drugn ( druga ) , drugb ( drugn ) , or drugn ( drugn ) .
false
before taking this medication , tell your doctor if you are taking a drugn such as drugn ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , drugn ( druga ) , drugn ( drugb ) , or drugn ( drugn ) .
false
before taking this medication , tell your doctor if you are taking a drugn such as drugn ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , drugn ( druga ) , drugn ( drugn ) , or drugb ( drugn ) .
false
before taking this medication , tell your doctor if you are taking a drugn such as drugn ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , drugn ( druga ) , drugn ( drugn ) , or drugn ( drugb ) .
false
before taking this medication , tell your doctor if you are taking a drugn such as drugn ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , druga ( drugb ) , or drugn ( drugn ) .
false
before taking this medication , tell your doctor if you are taking a drugn such as drugn ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , druga ( drugn ) , or drugb ( drugn ) .
false
before taking this medication , tell your doctor if you are taking a drugn such as drugn ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , druga ( drugn ) , or drugn ( drugb ) .
false
before taking this medication , tell your doctor if you are taking a drugn such as drugn ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , drugn ( druga ) , or drugb ( drugn ) .
false
before taking this medication , tell your doctor if you are taking a drugn such as drugn ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , drugn ( druga ) , or drugn ( drugb ) .
false
before taking this medication , tell your doctor if you are taking a drugn such as drugn ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , drugn ( drugn ) , or druga ( drugb ) .
false
drugs which may potentiate the myeloproliferative effects of druga , such as drugb and drugn , should be used with caution .
effect
drugs which may potentiate the myeloproliferative effects of druga , such as drugn and drugb , should be used with caution .
effect
drugs which may potentiate the myeloproliferative effects of drugn , such as druga and drugb , should be used with caution .
false
these are described in greater detail below : oral druga , drugb , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , oral drugn : clinically significant hypoglycemia may be precipitated by the use of drugn with oral drugn ;
false
these are described in greater detail below : oral druga , drugn , drugb , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , oral drugn : clinically significant hypoglycemia may be precipitated by the use of drugn with oral drugn ;
false
these are described in greater detail below : oral druga , drugn , drugn , drugb , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , oral drugn : clinically significant hypoglycemia may be precipitated by the use of drugn with oral drugn ;
false
these are described in greater detail below : oral druga , drugn , drugn , drugn , drugb , drugn , drugn , drugn , drugn , drugn , drugn , drugn , oral drugn : clinically significant hypoglycemia may be precipitated by the use of drugn with oral drugn ;
false
these are described in greater detail below : oral druga , drugn , drugn , drugn , drugn , drugb , drugn , drugn , drugn , drugn , drugn , drugn , oral drugn : clinically significant hypoglycemia may be precipitated by the use of drugn with oral drugn ;
false
these are described in greater detail below : oral druga , drugn , drugn , drugn , drugn , drugn , drugb , drugn , drugn , drugn , drugn , drugn , oral drugn : clinically significant hypoglycemia may be precipitated by the use of drugn with oral drugn ;
false
these are described in greater detail below : oral druga , drugn , drugn , drugn , drugn , drugn , drugn , drugb , drugn , drugn , drugn , drugn , oral drugn : clinically significant hypoglycemia may be precipitated by the use of drugn with oral drugn ;
false
these are described in greater detail below : oral druga , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugb , drugn , drugn , drugn , oral drugn : clinically significant hypoglycemia may be precipitated by the use of drugn with oral drugn ;
false
these are described in greater detail below : oral druga , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugb , drugn , drugn , oral drugn : clinically significant hypoglycemia may be precipitated by the use of drugn with oral drugn ;
false
these are described in greater detail below : oral druga , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugb , drugn , oral drugn : clinically significant hypoglycemia may be precipitated by the use of drugn with oral drugn ;
false
these are described in greater detail below : oral druga , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugb , oral drugn : clinically significant hypoglycemia may be precipitated by the use of drugn with oral drugn ;
false
these are described in greater detail below : oral druga , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , oral drugb : clinically significant hypoglycemia may be precipitated by the use of drugn with oral drugn ;
false
these are described in greater detail below : oral druga , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , oral drugn : clinically significant hypoglycemia may be precipitated by the use of drugb with oral drugn ;
false
these are described in greater detail below : oral druga , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , oral drugn : clinically significant hypoglycemia may be precipitated by the use of drugn with oral drugb ;
false
these are described in greater detail below : oral drugn , druga , drugb , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , oral drugn : clinically significant hypoglycemia may be precipitated by the use of drugn with oral drugn ;
false
these are described in greater detail below : oral drugn , druga , drugn , drugb , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , oral drugn : clinically significant hypoglycemia may be precipitated by the use of drugn with oral drugn ;
false
these are described in greater detail below : oral drugn , druga , drugn , drugn , drugb , drugn , drugn , drugn , drugn , drugn , drugn , drugn , oral drugn : clinically significant hypoglycemia may be precipitated by the use of drugn with oral drugn ;
false
these are described in greater detail below : oral drugn , druga , drugn , drugn , drugn , drugb , drugn , drugn , drugn , drugn , drugn , drugn , oral drugn : clinically significant hypoglycemia may be precipitated by the use of drugn with oral drugn ;
false
these are described in greater detail below : oral drugn , druga , drugn , drugn , drugn , drugn , drugb , drugn , drugn , drugn , drugn , drugn , oral drugn : clinically significant hypoglycemia may be precipitated by the use of drugn with oral drugn ;
false
these are described in greater detail below : oral drugn , druga , drugn , drugn , drugn , drugn , drugn , drugb , drugn , drugn , drugn , drugn , oral drugn : clinically significant hypoglycemia may be precipitated by the use of drugn with oral drugn ;
false
these are described in greater detail below : oral drugn , druga , drugn , drugn , drugn , drugn , drugn , drugn , drugb , drugn , drugn , drugn , oral drugn : clinically significant hypoglycemia may be precipitated by the use of drugn with oral drugn ;
false
these are described in greater detail below : oral drugn , druga , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugb , drugn , drugn , oral drugn : clinically significant hypoglycemia may be precipitated by the use of drugn with oral drugn ;
false
these are described in greater detail below : oral drugn , druga , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugb , drugn , oral drugn : clinically significant hypoglycemia may be precipitated by the use of drugn with oral drugn ;
false
these are described in greater detail below : oral drugn , druga , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugb , oral drugn : clinically significant hypoglycemia may be precipitated by the use of drugn with oral drugn ;
false
these are described in greater detail below : oral drugn , druga , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , oral drugb : clinically significant hypoglycemia may be precipitated by the use of drugn with oral drugn ;
false
these are described in greater detail below : oral drugn , druga , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , oral drugn : clinically significant hypoglycemia may be precipitated by the use of drugb with oral drugn ;
false
these are described in greater detail below : oral drugn , druga , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , oral drugn : clinically significant hypoglycemia may be precipitated by the use of drugn with oral drugb ;
false
these are described in greater detail below : oral drugn , drugn , druga , drugb , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , oral drugn : clinically significant hypoglycemia may be precipitated by the use of drugn with oral drugn ;
false
these are described in greater detail below : oral drugn , drugn , druga , drugn , drugb , drugn , drugn , drugn , drugn , drugn , drugn , drugn , oral drugn : clinically significant hypoglycemia may be precipitated by the use of drugn with oral drugn ;
false
these are described in greater detail below : oral drugn , drugn , druga , drugn , drugn , drugb , drugn , drugn , drugn , drugn , drugn , drugn , oral drugn : clinically significant hypoglycemia may be precipitated by the use of drugn with oral drugn ;
false
these are described in greater detail below : oral drugn , drugn , druga , drugn , drugn , drugn , drugb , drugn , drugn , drugn , drugn , drugn , oral drugn : clinically significant hypoglycemia may be precipitated by the use of drugn with oral drugn ;
false
these are described in greater detail below : oral drugn , drugn , druga , drugn , drugn , drugn , drugn , drugb , drugn , drugn , drugn , drugn , oral drugn : clinically significant hypoglycemia may be precipitated by the use of drugn with oral drugn ;
false
these are described in greater detail below : oral drugn , drugn , druga , drugn , drugn , drugn , drugn , drugn , drugb , drugn , drugn , drugn , oral drugn : clinically significant hypoglycemia may be precipitated by the use of drugn with oral drugn ;
false
these are described in greater detail below : oral drugn , drugn , druga , drugn , drugn , drugn , drugn , drugn , drugn , drugb , drugn , drugn , oral drugn : clinically significant hypoglycemia may be precipitated by the use of drugn with oral drugn ;
false
these are described in greater detail below : oral drugn , drugn , druga , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugb , drugn , oral drugn : clinically significant hypoglycemia may be precipitated by the use of drugn with oral drugn ;
false
these are described in greater detail below : oral drugn , drugn , druga , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugb , oral drugn : clinically significant hypoglycemia may be precipitated by the use of drugn with oral drugn ;
false
these are described in greater detail below : oral drugn , drugn , druga , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , oral drugb : clinically significant hypoglycemia may be precipitated by the use of drugn with oral drugn ;
false
these are described in greater detail below : oral drugn , drugn , druga , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , oral drugn : clinically significant hypoglycemia may be precipitated by the use of drugb with oral drugn ;
false
these are described in greater detail below : oral drugn , drugn , druga , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , oral drugn : clinically significant hypoglycemia may be precipitated by the use of drugn with oral drugb ;
false
these are described in greater detail below : oral drugn , drugn , drugn , druga , drugb , drugn , drugn , drugn , drugn , drugn , drugn , drugn , oral drugn : clinically significant hypoglycemia may be precipitated by the use of drugn with oral drugn ;
false
these are described in greater detail below : oral drugn , drugn , drugn , druga , drugn , drugb , drugn , drugn , drugn , drugn , drugn , drugn , oral drugn : clinically significant hypoglycemia may be precipitated by the use of drugn with oral drugn ;
false
these are described in greater detail below : oral drugn , drugn , drugn , druga , drugn , drugn , drugb , drugn , drugn , drugn , drugn , drugn , oral drugn : clinically significant hypoglycemia may be precipitated by the use of drugn with oral drugn ;
false
these are described in greater detail below : oral drugn , drugn , drugn , druga , drugn , drugn , drugn , drugb , drugn , drugn , drugn , drugn , oral drugn : clinically significant hypoglycemia may be precipitated by the use of drugn with oral drugn ;
false
these are described in greater detail below : oral drugn , drugn , drugn , druga , drugn , drugn , drugn , drugn , drugb , drugn , drugn , drugn , oral drugn : clinically significant hypoglycemia may be precipitated by the use of drugn with oral drugn ;
false
these are described in greater detail below : oral drugn , drugn , drugn , druga , drugn , drugn , drugn , drugn , drugn , drugb , drugn , drugn , oral drugn : clinically significant hypoglycemia may be precipitated by the use of drugn with oral drugn ;
false
these are described in greater detail below : oral drugn , drugn , drugn , druga , drugn , drugn , drugn , drugn , drugn , drugn , drugb , drugn , oral drugn : clinically significant hypoglycemia may be precipitated by the use of drugn with oral drugn ;
false
these are described in greater detail below : oral drugn , drugn , drugn , druga , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugb , oral drugn : clinically significant hypoglycemia may be precipitated by the use of drugn with oral drugn ;
false
these are described in greater detail below : oral drugn , drugn , drugn , druga , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , oral drugb : clinically significant hypoglycemia may be precipitated by the use of drugn with oral drugn ;
false
these are described in greater detail below : oral drugn , drugn , drugn , druga , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , oral drugn : clinically significant hypoglycemia may be precipitated by the use of drugb with oral drugn ;
false
these are described in greater detail below : oral drugn , drugn , drugn , druga , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , oral drugn : clinically significant hypoglycemia may be precipitated by the use of drugn with oral drugb ;
false
these are described in greater detail below : oral drugn , drugn , drugn , drugn , druga , drugb , drugn , drugn , drugn , drugn , drugn , drugn , oral drugn : clinically significant hypoglycemia may be precipitated by the use of drugn with oral drugn ;
false
these are described in greater detail below : oral drugn , drugn , drugn , drugn , druga , drugn , drugb , drugn , drugn , drugn , drugn , drugn , oral drugn : clinically significant hypoglycemia may be precipitated by the use of drugn with oral drugn ;
false
these are described in greater detail below : oral drugn , drugn , drugn , drugn , druga , drugn , drugn , drugb , drugn , drugn , drugn , drugn , oral drugn : clinically significant hypoglycemia may be precipitated by the use of drugn with oral drugn ;
false
these are described in greater detail below : oral drugn , drugn , drugn , drugn , druga , drugn , drugn , drugn , drugb , drugn , drugn , drugn , oral drugn : clinically significant hypoglycemia may be precipitated by the use of drugn with oral drugn ;
false
these are described in greater detail below : oral drugn , drugn , drugn , drugn , druga , drugn , drugn , drugn , drugn , drugb , drugn , drugn , oral drugn : clinically significant hypoglycemia may be precipitated by the use of drugn with oral drugn ;
false
these are described in greater detail below : oral drugn , drugn , drugn , drugn , druga , drugn , drugn , drugn , drugn , drugn , drugb , drugn , oral drugn : clinically significant hypoglycemia may be precipitated by the use of drugn with oral drugn ;
false
these are described in greater detail below : oral drugn , drugn , drugn , drugn , druga , drugn , drugn , drugn , drugn , drugn , drugn , drugb , oral drugn : clinically significant hypoglycemia may be precipitated by the use of drugn with oral drugn ;
false
these are described in greater detail below : oral drugn , drugn , drugn , drugn , druga , drugn , drugn , drugn , drugn , drugn , drugn , drugn , oral drugb : clinically significant hypoglycemia may be precipitated by the use of drugn with oral drugn ;
false
these are described in greater detail below : oral drugn , drugn , drugn , drugn , druga , drugn , drugn , drugn , drugn , drugn , drugn , drugn , oral drugn : clinically significant hypoglycemia may be precipitated by the use of drugb with oral drugn ;
false
these are described in greater detail below : oral drugn , drugn , drugn , drugn , druga , drugn , drugn , drugn , drugn , drugn , drugn , drugn , oral drugn : clinically significant hypoglycemia may be precipitated by the use of drugn with oral drugb ;
false
these are described in greater detail below : oral drugn , drugn , drugn , drugn , drugn , druga , drugb , drugn , drugn , drugn , drugn , drugn , oral drugn : clinically significant hypoglycemia may be precipitated by the use of drugn with oral drugn ;
false
these are described in greater detail below : oral drugn , drugn , drugn , drugn , drugn , druga , drugn , drugb , drugn , drugn , drugn , drugn , oral drugn : clinically significant hypoglycemia may be precipitated by the use of drugn with oral drugn ;
false
these are described in greater detail below : oral drugn , drugn , drugn , drugn , drugn , druga , drugn , drugn , drugb , drugn , drugn , drugn , oral drugn : clinically significant hypoglycemia may be precipitated by the use of drugn with oral drugn ;
false
these are described in greater detail below : oral drugn , drugn , drugn , drugn , drugn , druga , drugn , drugn , drugn , drugb , drugn , drugn , oral drugn : clinically significant hypoglycemia may be precipitated by the use of drugn with oral drugn ;
false
these are described in greater detail below : oral drugn , drugn , drugn , drugn , drugn , druga , drugn , drugn , drugn , drugn , drugb , drugn , oral drugn : clinically significant hypoglycemia may be precipitated by the use of drugn with oral drugn ;
false
these are described in greater detail below : oral drugn , drugn , drugn , drugn , drugn , druga , drugn , drugn , drugn , drugn , drugn , drugb , oral drugn : clinically significant hypoglycemia may be precipitated by the use of drugn with oral drugn ;
false
these are described in greater detail below : oral drugn , drugn , drugn , drugn , drugn , druga , drugn , drugn , drugn , drugn , drugn , drugn , oral drugb : clinically significant hypoglycemia may be precipitated by the use of drugn with oral drugn ;
false
these are described in greater detail below : oral drugn , drugn , drugn , drugn , drugn , druga , drugn , drugn , drugn , drugn , drugn , drugn , oral drugn : clinically significant hypoglycemia may be precipitated by the use of drugb with oral drugn ;
false
these are described in greater detail below : oral drugn , drugn , drugn , drugn , drugn , druga , drugn , drugn , drugn , drugn , drugn , drugn , oral drugn : clinically significant hypoglycemia may be precipitated by the use of drugn with oral drugb ;
false
these are described in greater detail below : oral drugn , drugn , drugn , drugn , drugn , drugn , druga , drugb , drugn , drugn , drugn , drugn , oral drugn : clinically significant hypoglycemia may be precipitated by the use of drugn with oral drugn ;
false
these are described in greater detail below : oral drugn , drugn , drugn , drugn , drugn , drugn , druga , drugn , drugb , drugn , drugn , drugn , oral drugn : clinically significant hypoglycemia may be precipitated by the use of drugn with oral drugn ;
false
these are described in greater detail below : oral drugn , drugn , drugn , drugn , drugn , drugn , druga , drugn , drugn , drugb , drugn , drugn , oral drugn : clinically significant hypoglycemia may be precipitated by the use of drugn with oral drugn ;
false
these are described in greater detail below : oral drugn , drugn , drugn , drugn , drugn , drugn , druga , drugn , drugn , drugn , drugb , drugn , oral drugn : clinically significant hypoglycemia may be precipitated by the use of drugn with oral drugn ;
false
these are described in greater detail below : oral drugn , drugn , drugn , drugn , drugn , drugn , druga , drugn , drugn , drugn , drugn , drugb , oral drugn : clinically significant hypoglycemia may be precipitated by the use of drugn with oral drugn ;
false
these are described in greater detail below : oral drugn , drugn , drugn , drugn , drugn , drugn , druga , drugn , drugn , drugn , drugn , drugn , oral drugb : clinically significant hypoglycemia may be precipitated by the use of drugn with oral drugn ;
false
these are described in greater detail below : oral drugn , drugn , drugn , drugn , drugn , drugn , druga , drugn , drugn , drugn , drugn , drugn , oral drugn : clinically significant hypoglycemia may be precipitated by the use of drugb with oral drugn ;
false
these are described in greater detail below : oral drugn , drugn , drugn , drugn , drugn , drugn , druga , drugn , drugn , drugn , drugn , drugn , oral drugn : clinically significant hypoglycemia may be precipitated by the use of drugn with oral drugb ;
false
these are described in greater detail below : oral drugn , drugn , drugn , drugn , drugn , drugn , drugn , druga , drugb , drugn , drugn , drugn , oral drugn : clinically significant hypoglycemia may be precipitated by the use of drugn with oral drugn ;
false
these are described in greater detail below : oral drugn , drugn , drugn , drugn , drugn , drugn , drugn , druga , drugn , drugb , drugn , drugn , oral drugn : clinically significant hypoglycemia may be precipitated by the use of drugn with oral drugn ;
false
these are described in greater detail below : oral drugn , drugn , drugn , drugn , drugn , drugn , drugn , druga , drugn , drugn , drugb , drugn , oral drugn : clinically significant hypoglycemia may be precipitated by the use of drugn with oral drugn ;
false
these are described in greater detail below : oral drugn , drugn , drugn , drugn , drugn , drugn , drugn , druga , drugn , drugn , drugn , drugb , oral drugn : clinically significant hypoglycemia may be precipitated by the use of drugn with oral drugn ;
false
these are described in greater detail below : oral drugn , drugn , drugn , drugn , drugn , drugn , drugn , druga , drugn , drugn , drugn , drugn , oral drugb : clinically significant hypoglycemia may be precipitated by the use of drugn with oral drugn ;
false
these are described in greater detail below : oral drugn , drugn , drugn , drugn , drugn , drugn , drugn , druga , drugn , drugn , drugn , drugn , oral drugn : clinically significant hypoglycemia may be precipitated by the use of drugb with oral drugn ;
false
these are described in greater detail below : oral drugn , drugn , drugn , drugn , drugn , drugn , drugn , druga , drugn , drugn , drugn , drugn , oral drugn : clinically significant hypoglycemia may be precipitated by the use of drugn with oral drugb ;
false
these are described in greater detail below : oral drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , druga , drugb , drugn , drugn , oral drugn : clinically significant hypoglycemia may be precipitated by the use of drugn with oral drugn ;
false
these are described in greater detail below : oral drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , druga , drugn , drugb , drugn , oral drugn : clinically significant hypoglycemia may be precipitated by the use of drugn with oral drugn ;
false
these are described in greater detail below : oral drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , druga , drugn , drugn , drugb , oral drugn : clinically significant hypoglycemia may be precipitated by the use of drugn with oral drugn ;
false
these are described in greater detail below : oral drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , druga , drugn , drugn , drugn , oral drugb : clinically significant hypoglycemia may be precipitated by the use of drugn with oral drugn ;
false
these are described in greater detail below : oral drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , druga , drugn , drugn , drugn , oral drugn : clinically significant hypoglycemia may be precipitated by the use of drugb with oral drugn ;
false
these are described in greater detail below : oral drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , druga , drugn , drugn , drugn , oral drugn : clinically significant hypoglycemia may be precipitated by the use of drugn with oral drugb ;
false
these are described in greater detail below : oral drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , druga , drugb , drugn , oral drugn : clinically significant hypoglycemia may be precipitated by the use of drugn with oral drugn ;
false
these are described in greater detail below : oral drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , druga , drugn , drugb , oral drugn : clinically significant hypoglycemia may be precipitated by the use of drugn with oral drugn ;
false
these are described in greater detail below : oral drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , druga , drugn , drugn , oral drugb : clinically significant hypoglycemia may be precipitated by the use of drugn with oral drugn ;
false
these are described in greater detail below : oral drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , druga , drugn , drugn , oral drugn : clinically significant hypoglycemia may be precipitated by the use of drugb with oral drugn ;
false
these are described in greater detail below : oral drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , druga , drugn , drugn , oral drugn : clinically significant hypoglycemia may be precipitated by the use of drugn with oral drugb ;
false
these are described in greater detail below : oral drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , druga , drugb , oral drugn : clinically significant hypoglycemia may be precipitated by the use of drugn with oral drugn ;
false
these are described in greater detail below : oral drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , druga , drugn , oral drugb : clinically significant hypoglycemia may be precipitated by the use of drugn with oral drugn ;
false
these are described in greater detail below : oral drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , druga , drugn , oral drugn : clinically significant hypoglycemia may be precipitated by the use of drugb with oral drugn ;
false
these are described in greater detail below : oral drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , druga , drugn , oral drugn : clinically significant hypoglycemia may be precipitated by the use of drugn with oral drugb ;
false
these are described in greater detail below : oral drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , druga , oral drugb : clinically significant hypoglycemia may be precipitated by the use of drugn with oral drugn ;
false
these are described in greater detail below : oral drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , druga , oral drugn : clinically significant hypoglycemia may be precipitated by the use of drugb with oral drugn ;
false
these are described in greater detail below : oral drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , druga , oral drugn : clinically significant hypoglycemia may be precipitated by the use of drugn with oral drugb ;
false
these are described in greater detail below : oral drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , oral druga : clinically significant hypoglycemia may be precipitated by the use of drugb with oral drugn ;
false
these are described in greater detail below : oral drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , oral druga : clinically significant hypoglycemia may be precipitated by the use of drugn with oral drugb ;
false
these are described in greater detail below : oral drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , oral drugn : clinically significant hypoglycemia may be precipitated by the use of druga with oral drugb ;
effect
one fatality has been reported from hypoglycemia in association with combined druga and drugb use .
effect
druga reduces the metabolism of drugb , drugn , and drugn and increases the plasma concentration of these agents .
mechanism
druga reduces the metabolism of drugn , drugb , and drugn and increases the plasma concentration of these agents .
mechanism
druga reduces the metabolism of drugn , drugn , and drugb and increases the plasma concentration of these agents .
mechanism
drugn reduces the metabolism of druga , drugb , and drugn and increases the plasma concentration of these agents .
false
drugn reduces the metabolism of druga , drugn , and drugb and increases the plasma concentration of these agents .
false
drugn reduces the metabolism of drugn , druga , and drugb and increases the plasma concentration of these agents .
false
when druga is used concomitantly with these or other drugb , blood glucose concentrations should be carefully monitored and the dose of the drugn should be adjusted as necessary .
advise
when druga is used concomitantly with these or other drugn , blood glucose concentrations should be carefully monitored and the dose of the drugb should be adjusted as necessary .
false
when drugn is used concomitantly with these or other druga , blood glucose concentrations should be carefully monitored and the dose of the drugb should be adjusted as necessary .
false
druga : prothrombin time may be increased in patients receiving concomitant drugb and drugn .
false
druga : prothrombin time may be increased in patients receiving concomitant drugn and drugb .
false
drugn : prothrombin time may be increased in patients receiving concomitant druga and drugb .
effect
in post-marketing experience , as with other druga , bleeding events ( bruising , epistaxis , gastrointestinal bleeding , hematuria , and melena ) have been reported in association with increases in prothrombin time in patients receiving drugb concurrently with drugn .
false
in post-marketing experience , as with other druga , bleeding events ( bruising , epistaxis , gastrointestinal bleeding , hematuria , and melena ) have been reported in association with increases in prothrombin time in patients receiving drugn concurrently with drugb .
false
in post-marketing experience , as with other drugn , bleeding events ( bruising , epistaxis , gastrointestinal bleeding , hematuria , and melena ) have been reported in association with increases in prothrombin time in patients receiving druga concurrently with drugb .
effect
careful monitoring of prothrombin time in patients receiving druga and drugb is recommended .
advise
druga : drugb increases the plasma concentrations of drugn .
false
druga : drugn increases the plasma concentrations of drugb .
false
drugn : druga increases the plasma concentrations of drugb .
mechanism
careful monitoring of druga concentrations in patients receiving drugb and drugn is recommended .
false
careful monitoring of druga concentrations in patients receiving drugn and drugb is recommended .
false
careful monitoring of drugn concentrations in patients receiving druga and drugb is recommended .
advise
druga : drugb may significantly increase drugn levels in renal transplant patients with or without renal impairment .
false
druga : drugn may significantly increase drugb levels in renal transplant patients with or without renal impairment .
false
drugn : druga may significantly increase drugb levels in renal transplant patients with or without renal impairment .
mechanism
careful monitoring of druga concentrations and serum creatinine is recommended in patients receiving drugb and drugn .
false
careful monitoring of druga concentrations and serum creatinine is recommended in patients receiving drugn and drugb .
false
careful monitoring of drugn concentrations and serum creatinine is recommended in patients receiving druga and drugb .
advise
druga : drugb enhances the metabolism of concurrently administered drugn .
false
druga : drugn enhances the metabolism of concurrently administered drugb .
false
drugn : druga enhances the metabolism of concurrently administered drugb .
mechanism
depending on clinical circumstances , consideration should be given to increasing the dose of druga when it is administered with drugb .
advise
druga : drugb increases the serum concentrations of drugn .
false
druga : drugn increases the serum concentrations of drugb .
false
drugn : druga increases the serum concentrations of drugb .
mechanism
careful monitoring of serum druga concentrations in patients receiving drugb and drugn is recommended .
false
careful monitoring of serum druga concentrations in patients receiving drugn and drugb is recommended .
false
careful monitoring of serum drugn concentrations in patients receiving druga and drugb is recommended .
advise
druga : because of the occurrence of serious cardiac dysrhythmias secondary to prolongation of the qtc interval in patients receiving drugb in conjunction with drugn , interaction studies have been performed .
false
druga : because of the occurrence of serious cardiac dysrhythmias secondary to prolongation of the qtc interval in patients receiving drugn in conjunction with drugb , interaction studies have been performed .
false
drugn : because of the occurrence of serious cardiac dysrhythmias secondary to prolongation of the qtc interval in patients receiving druga in conjunction with drugb , interaction studies have been performed .
effect
another study at a 400-mg and 800-mg daily dose of druga demonstrated that drugb taken in doses of 400 mg per day or greater significantly increases plasma levels of drugn when taken concomitantly .
false
another study at a 400-mg and 800-mg daily dose of druga demonstrated that drugn taken in doses of 400 mg per day or greater significantly increases plasma levels of drugb when taken concomitantly .
false
another study at a 400-mg and 800-mg daily dose of drugn demonstrated that druga taken in doses of 400 mg per day or greater significantly increases plasma levels of drugb when taken concomitantly .
mechanism
the combined use of druga at doses of 400 mg or greater with drugb is contraindicated .
advise
the coadministration of druga at doses lower than 400 mg/day with drugb should be carefully monitored .
advise
druga : there have been reports of cardiac events , including torsade de pointes in patients to whom drugb and drugn were coadministered .
false
druga : there have been reports of cardiac events , including torsade de pointes in patients to whom drugn and drugb were coadministered .
false
drugn : there have been reports of cardiac events , including torsade de pointes in patients to whom druga and drugb were coadministered .
effect
a controlled study found that concomitant druga 200 mg once daily and drugb 20 mg four times a day yielded a significant increase in drugn plasma levels and prolongation of qtc interval .
mechanism
a controlled study found that concomitant druga 200 mg once daily and drugn 20 mg four times a day yielded a significant increase in drugb plasma levels and prolongation of qtc interval .
false
a controlled study found that concomitant drugn 200 mg once daily and druga 20 mg four times a day yielded a significant increase in drugb plasma levels and prolongation of qtc interval .
false
the combined use of druga with drugb is contraindicated .
advise
druga : the use of drugb in patients concurrently taking drugn or other drugs metabolized by the cytochrome p450 system may be associated with elevations in serum levels of these drugs .
false
druga : the use of drugn in patients concurrently taking drugb or other drugs metabolized by the cytochrome p450 system may be associated with elevations in serum levels of these drugs .
false
drugn : the use of druga in patients concurrently taking drugb or other drugs metabolized by the cytochrome p450 system may be associated with elevations in serum levels of these drugs .
mechanism
druga : there have been reports of uveitis in patients to whom drugb and drugn were coadministered .
false
druga : there have been reports of uveitis in patients to whom drugn and drugb were coadministered .
false
drugn : there have been reports of uveitis in patients to whom druga and drugb were coadministered .
effect
patients receiving druga and drugb concomitantly should be carefully monitored .
advise
druga : there have been reports of nephrotoxicity in patients to whom drugb and drugn were coadministered .
false
druga : there have been reports of nephrotoxicity in patients to whom drugn and drugb were coadministered .
false
drugn : there have been reports of nephrotoxicity in patients to whom druga and drugb were coadministered .
effect
patients receiving druga and drugb concomitantly should be carefully monitored .
advise
druga : following oral administration of drugb , drugn resulted in substantial increases in drugn concentrations and psychomotor effects .
false
druga : following oral administration of drugn , drugb resulted in substantial increases in drugn concentrations and psychomotor effects .
false
druga : following oral administration of drugn , drugn resulted in substantial increases in drugb concentrations and psychomotor effects .
false
drugn : following oral administration of druga , drugb resulted in substantial increases in drugn concentrations and psychomotor effects .
mechanism
drugn : following oral administration of druga , drugn resulted in substantial increases in drugb concentrations and psychomotor effects .
false
drugn : following oral administration of drugn , druga resulted in substantial increases in drugb concentrations and psychomotor effects .
false
this effect on druga appears to be more pronounced following oral administration of drugb than with drugn administered intravenously .
effect
this effect on druga appears to be more pronounced following oral administration of drugn than with drugb administered intravenously .
false
this effect on drugn appears to be more pronounced following oral administration of druga than with drugb administered intravenously .
false
if druga , which are metabolized by the cytochrome p450 system , are concomitantly administered with drugb , consideration should be given to decreasing the drugn dosage , and the patients should be appropriately monitored .
advise
if druga , which are metabolized by the cytochrome p450 system , are concomitantly administered with drugn , consideration should be given to decreasing the drugb dosage , and the patients should be appropriately monitored .
false
if drugn , which are metabolized by the cytochrome p450 system , are concomitantly administered with druga , consideration should be given to decreasing the drugb dosage , and the patients should be appropriately monitored .
false
druga tablets coadministered with drugb - and drugn -containing oral drugn produced an overall mean increase in drugn and drugn levels ;
mechanism
druga tablets coadministered with drugn - and drugb -containing oral drugn produced an overall mean increase in drugn and drugn levels ;
mechanism
druga tablets coadministered with drugn - and drugn -containing oral drugb produced an overall mean increase in drugn and drugn levels ;
false
druga tablets coadministered with drugn - and drugn -containing oral drugn produced an overall mean increase in drugb and drugn levels ;
false
druga tablets coadministered with drugn - and drugn -containing oral drugn produced an overall mean increase in drugn and drugb levels ;
false
drugn tablets coadministered with druga - and drugb -containing oral drugn produced an overall mean increase in drugn and drugn levels ;
false
drugn tablets coadministered with druga - and drugn -containing oral drugb produced an overall mean increase in drugn and drugn levels ;
false
drugn tablets coadministered with druga - and drugn -containing oral drugn produced an overall mean increase in drugb and drugn levels ;
false
drugn tablets coadministered with druga - and drugn -containing oral drugn produced an overall mean increase in drugn and drugb levels ;
false
drugn tablets coadministered with drugn - and druga -containing oral drugb produced an overall mean increase in drugn and drugn levels ;
false
drugn tablets coadministered with drugn - and druga -containing oral drugn produced an overall mean increase in drugb and drugn levels ;
false
drugn tablets coadministered with drugn - and druga -containing oral drugn produced an overall mean increase in drugn and drugb levels ;
false
drugn tablets coadministered with drugn - and drugn -containing oral druga produced an overall mean increase in drugb and drugn levels ;
false
drugn tablets coadministered with drugn - and drugn -containing oral druga produced an overall mean increase in drugn and drugb levels ;
false
drugn tablets coadministered with drugn - and drugn -containing oral drugn produced an overall mean increase in druga and drugb levels ;
false
however , in some patients there were decreases up to 47 % and 33 % of druga and drugb levels .
false
the data presently available indicate that the decreases in some individual druga and drugb auc values with drugn treatment are likely the result of random variation .
false
the data presently available indicate that the decreases in some individual druga and drugn auc values with drugb treatment are likely the result of random variation .
false
the data presently available indicate that the decreases in some individual drugn and druga auc values with drugb treatment are likely the result of random variation .
false
while there is evidence that druga can inhibit the metabolism of drugb and drugn , there is no evidence that drugn is a net inducer of drugn or drugn metabolism .
mechanism
while there is evidence that druga can inhibit the metabolism of drugn and drugb , there is no evidence that drugn is a net inducer of drugn or drugn metabolism .
mechanism
while there is evidence that druga can inhibit the metabolism of drugn and drugn , there is no evidence that drugb is a net inducer of drugn or drugn metabolism .
false
while there is evidence that druga can inhibit the metabolism of drugn and drugn , there is no evidence that drugn is a net inducer of drugb or drugn metabolism .
false
while there is evidence that druga can inhibit the metabolism of drugn and drugn , there is no evidence that drugn is a net inducer of drugn or drugb metabolism .
false
while there is evidence that drugn can inhibit the metabolism of druga and drugb , there is no evidence that drugn is a net inducer of drugn or drugn metabolism .
false
while there is evidence that drugn can inhibit the metabolism of druga and drugn , there is no evidence that drugb is a net inducer of drugn or drugn metabolism .
false
while there is evidence that drugn can inhibit the metabolism of druga and drugn , there is no evidence that drugn is a net inducer of drugb or drugn metabolism .
false
while there is evidence that drugn can inhibit the metabolism of druga and drugn , there is no evidence that drugn is a net inducer of drugn or drugb metabolism .
false
while there is evidence that drugn can inhibit the metabolism of drugn and druga , there is no evidence that drugb is a net inducer of drugn or drugn metabolism .
false
while there is evidence that drugn can inhibit the metabolism of drugn and druga , there is no evidence that drugn is a net inducer of drugb or drugn metabolism .
false
while there is evidence that drugn can inhibit the metabolism of drugn and druga , there is no evidence that drugn is a net inducer of drugn or drugb metabolism .
false
while there is evidence that drugn can inhibit the metabolism of drugn and drugn , there is no evidence that druga is a net inducer of drugb or drugn metabolism .
false
while there is evidence that drugn can inhibit the metabolism of drugn and drugn , there is no evidence that druga is a net inducer of drugn or drugb metabolism .
false
while there is evidence that drugn can inhibit the metabolism of drugn and drugn , there is no evidence that drugn is a net inducer of druga or drugb metabolism .
false
since druga is metabolized by a p450 enzyme system , drugs that induce or inhibit this drug metabolizing enzyme system may elicit important drug-drug interactions that may alter drugb plasma concentrations .
false
agents that might be coadministered with druga in aids patients for other indications that could elicit this activity include drugb , drugn , drugn , drugn , and drugn .
effect
agents that might be coadministered with druga in aids patients for other indications that could elicit this activity include drugn , drugb , drugn , drugn , and drugn .
effect
agents that might be coadministered with druga in aids patients for other indications that could elicit this activity include drugn , drugn , drugb , drugn , and drugn .
effect
agents that might be coadministered with druga in aids patients for other indications that could elicit this activity include drugn , drugn , drugn , drugb , and drugn .
effect
agents that might be coadministered with druga in aids patients for other indications that could elicit this activity include drugn , drugn , drugn , drugn , and drugb .
effect
agents that might be coadministered with drugn in aids patients for other indications that could elicit this activity include druga , drugb , drugn , drugn , and drugn .
false
agents that might be coadministered with drugn in aids patients for other indications that could elicit this activity include druga , drugn , drugb , drugn , and drugn .
false
agents that might be coadministered with drugn in aids patients for other indications that could elicit this activity include druga , drugn , drugn , drugb , and drugn .
false
agents that might be coadministered with drugn in aids patients for other indications that could elicit this activity include druga , drugn , drugn , drugn , and drugb .
false
agents that might be coadministered with drugn in aids patients for other indications that could elicit this activity include drugn , druga , drugb , drugn , and drugn .
false
agents that might be coadministered with drugn in aids patients for other indications that could elicit this activity include drugn , druga , drugn , drugb , and drugn .
false
agents that might be coadministered with drugn in aids patients for other indications that could elicit this activity include drugn , druga , drugn , drugn , and drugb .
false
agents that might be coadministered with drugn in aids patients for other indications that could elicit this activity include drugn , drugn , druga , drugb , and drugn .
false
agents that might be coadministered with drugn in aids patients for other indications that could elicit this activity include drugn , drugn , druga , drugn , and drugb .
false
agents that might be coadministered with drugn in aids patients for other indications that could elicit this activity include drugn , drugn , drugn , druga , and drugb .
false
in vitro perfusion of isolated rat liver has shown that druga caused a significant reduction in drugb metabolism and that drugn altered the relative concentration of trimetrexate metabolites possibly by competing for sulfate metabolites .
mechanism
in vitro perfusion of isolated rat liver has shown that druga caused a significant reduction in drugn metabolism and that drugb altered the relative concentration of trimetrexate metabolites possibly by competing for sulfate metabolites .
false
in vitro perfusion of isolated rat liver has shown that drugn caused a significant reduction in druga metabolism and that drugb altered the relative concentration of trimetrexate metabolites possibly by competing for sulfate metabolites .
false
based on an in vitro rat liver model , nitrogen substituted druga ( drugb , drugn , drugn ) were potent , non-competitive inhibitors of drugn metabolism .
false
based on an in vitro rat liver model , nitrogen substituted druga ( drugn , drugb , drugn ) were potent , non-competitive inhibitors of drugn metabolism .
false
based on an in vitro rat liver model , nitrogen substituted druga ( drugn , drugn , drugb ) were potent , non-competitive inhibitors of drugn metabolism .
false
based on an in vitro rat liver model , nitrogen substituted druga ( drugn , drugn , drugn ) were potent , non-competitive inhibitors of drugb metabolism .
mechanism
based on an in vitro rat liver model , nitrogen substituted drugn ( druga , drugb , drugn ) were potent , non-competitive inhibitors of drugn metabolism .
false
based on an in vitro rat liver model , nitrogen substituted drugn ( druga , drugn , drugb ) were potent , non-competitive inhibitors of drugn metabolism .
false
based on an in vitro rat liver model , nitrogen substituted drugn ( druga , drugn , drugn ) were potent , non-competitive inhibitors of drugb metabolism .
mechanism
based on an in vitro rat liver model , nitrogen substituted drugn ( drugn , druga , drugb ) were potent , non-competitive inhibitors of drugn metabolism .
false
based on an in vitro rat liver model , nitrogen substituted drugn ( drugn , druga , drugn ) were potent , non-competitive inhibitors of drugb metabolism .
mechanism
based on an in vitro rat liver model , nitrogen substituted drugn ( drugn , drugn , druga ) were potent , non-competitive inhibitors of drugb metabolism .
mechanism
caution is recommended when administering druga with compounds that are metabolized/eliminated predominantly by the ugt1a1 pathway ( e.g . drugb ) .
advise
concomitant treatment with druga resulted in a 21 % increase in the auc of drugb .
mechanism
caution is recommended when administering druga with drugb .
advise
druga : patients on drugb , and especially those started recently , may occasionally experience an excessive reduction of blood pressure after initiation of drugn tablets therapy .
false
druga : patients on drugn , and especially those started recently , may occasionally experience an excessive reduction of blood pressure after initiation of drugb tablets therapy .
false
drugn : patients on druga , and especially those started recently , may occasionally experience an excessive reduction of blood pressure after initiation of drugb tablets therapy .
effect
the possibility of hypotensive effects can be minimized by either discontinuing the druga or increasing the salt intake prior to initiation of treatment with drugb .
effect
if druga can not be interrupted , close medical supervision should be provided with the first dose of drugb tablets , for at least two hours and until blood pressure has stabilized for another hour .
advise
the rate and extent of druga absorption and elimination are not affected by concomitant drugb .
false
the bioavailability of druga was reduced by drugb , however , and this was associated with a decrease in plasma ace inhibition .
false
druga supplements and drugb : drugn tablets may increase serum potassium because of its potential to decrease aldosterone production .
false
druga supplements and drugn : drugb tablets may increase serum potassium because of its potential to decrease aldosterone production .
false
drugn supplements and druga : drugb tablets may increase serum potassium because of its potential to decrease aldosterone production .
false
use of druga ( drugb , drugn , drugn and others ) , drugn supplements or other drugs capable of increasing serum potassium ( drugn , drugn , drugn and others ) can increase the risk of hyperkalemia .
false
use of druga ( drugn , drugb , drugn and others ) , drugn supplements or other drugs capable of increasing serum potassium ( drugn , drugn , drugn and others ) can increase the risk of hyperkalemia .
false
use of druga ( drugn , drugn , drugb and others ) , drugn supplements or other drugs capable of increasing serum potassium ( drugn , drugn , drugn and others ) can increase the risk of hyperkalemia .
false
use of druga ( drugn , drugn , drugn and others ) , drugb supplements or other drugs capable of increasing serum potassium ( drugn , drugn , drugn and others ) can increase the risk of hyperkalemia .
false
use of druga ( drugn , drugn , drugn and others ) , drugn supplements or other drugs capable of increasing serum potassium ( drugb , drugn , drugn and others ) can increase the risk of hyperkalemia .
false
use of druga ( drugn , drugn , drugn and others ) , drugn supplements or other drugs capable of increasing serum potassium ( drugn , drugb , drugn and others ) can increase the risk of hyperkalemia .
false
use of druga ( drugn , drugn , drugn and others ) , drugn supplements or other drugs capable of increasing serum potassium ( drugn , drugn , drugb and others ) can increase the risk of hyperkalemia .
false
use of drugn ( druga , drugb , drugn and others ) , drugn supplements or other drugs capable of increasing serum potassium ( drugn , drugn , drugn and others ) can increase the risk of hyperkalemia .
false
use of drugn ( druga , drugn , drugb and others ) , drugn supplements or other drugs capable of increasing serum potassium ( drugn , drugn , drugn and others ) can increase the risk of hyperkalemia .
false
use of drugn ( druga , drugn , drugn and others ) , drugb supplements or other drugs capable of increasing serum potassium ( drugn , drugn , drugn and others ) can increase the risk of hyperkalemia .
false
use of drugn ( druga , drugn , drugn and others ) , drugn supplements or other drugs capable of increasing serum potassium ( drugb , drugn , drugn and others ) can increase the risk of hyperkalemia .
false
use of drugn ( druga , drugn , drugn and others ) , drugn supplements or other drugs capable of increasing serum potassium ( drugn , drugb , drugn and others ) can increase the risk of hyperkalemia .
false
use of drugn ( druga , drugn , drugn and others ) , drugn supplements or other drugs capable of increasing serum potassium ( drugn , drugn , drugb and others ) can increase the risk of hyperkalemia .
false
use of drugn ( drugn , druga , drugb and others ) , drugn supplements or other drugs capable of increasing serum potassium ( drugn , drugn , drugn and others ) can increase the risk of hyperkalemia .
false
use of drugn ( drugn , druga , drugn and others ) , drugb supplements or other drugs capable of increasing serum potassium ( drugn , drugn , drugn and others ) can increase the risk of hyperkalemia .
false
use of drugn ( drugn , druga , drugn and others ) , drugn supplements or other drugs capable of increasing serum potassium ( drugb , drugn , drugn and others ) can increase the risk of hyperkalemia .
false
use of drugn ( drugn , druga , drugn and others ) , drugn supplements or other drugs capable of increasing serum potassium ( drugn , drugb , drugn and others ) can increase the risk of hyperkalemia .
false
use of drugn ( drugn , druga , drugn and others ) , drugn supplements or other drugs capable of increasing serum potassium ( drugn , drugn , drugb and others ) can increase the risk of hyperkalemia .
false
use of drugn ( drugn , drugn , druga and others ) , drugb supplements or other drugs capable of increasing serum potassium ( drugn , drugn , drugn and others ) can increase the risk of hyperkalemia .
false
use of drugn ( drugn , drugn , druga and others ) , drugn supplements or other drugs capable of increasing serum potassium ( drugb , drugn , drugn and others ) can increase the risk of hyperkalemia .
false
use of drugn ( drugn , drugn , druga and others ) , drugn supplements or other drugs capable of increasing serum potassium ( drugn , drugb , drugn and others ) can increase the risk of hyperkalemia .
false
use of drugn ( drugn , drugn , druga and others ) , drugn supplements or other drugs capable of increasing serum potassium ( drugn , drugn , drugb and others ) can increase the risk of hyperkalemia .
false
use of drugn ( drugn , drugn , drugn and others ) , druga supplements or other drugs capable of increasing serum potassium ( drugb , drugn , drugn and others ) can increase the risk of hyperkalemia .
false
use of drugn ( drugn , drugn , drugn and others ) , druga supplements or other drugs capable of increasing serum potassium ( drugn , drugb , drugn and others ) can increase the risk of hyperkalemia .
false
use of drugn ( drugn , drugn , drugn and others ) , druga supplements or other drugs capable of increasing serum potassium ( drugn , drugn , drugb and others ) can increase the risk of hyperkalemia .
false
use of drugn ( drugn , drugn , drugn and others ) , drugn supplements or other drugs capable of increasing serum potassium ( druga , drugb , drugn and others ) can increase the risk of hyperkalemia .
false
use of drugn ( drugn , drugn , drugn and others ) , drugn supplements or other drugs capable of increasing serum potassium ( druga , drugn , drugb and others ) can increase the risk of hyperkalemia .
false
use of drugn ( drugn , drugn , drugn and others ) , drugn supplements or other drugs capable of increasing serum potassium ( drugn , druga , drugb and others ) can increase the risk of hyperkalemia .
false
druga : increased serum drugb and symptoms of drugn toxicity have been reported in patients receiving concomitant drugn and ace inhibitor therapy .
false
druga : increased serum drugn and symptoms of drugb toxicity have been reported in patients receiving concomitant drugn and ace inhibitor therapy .
false
druga : increased serum drugn and symptoms of drugn toxicity have been reported in patients receiving concomitant drugb and ace inhibitor therapy .
false
drugn : increased serum druga and symptoms of drugb toxicity have been reported in patients receiving concomitant drugn and ace inhibitor therapy .
false
drugn : increased serum druga and symptoms of drugn toxicity have been reported in patients receiving concomitant drugb and ace inhibitor therapy .
false
drugn : increased serum drugn and symptoms of druga toxicity have been reported in patients receiving concomitant drugb and ace inhibitor therapy .
false
use of a druga may further increase the risk of drugb toxicity .
false
druga : a controlled pharmacokinetic study has shown no effect on plasma drugb concentrations when coadministered with drugn tablets , but an effect of drugn on the plasma concentration of drugn / drugn has not been excluded .
false
druga : a controlled pharmacokinetic study has shown no effect on plasma drugn concentrations when coadministered with drugb tablets , but an effect of drugn on the plasma concentration of drugn / drugn has not been excluded .
false
druga : a controlled pharmacokinetic study has shown no effect on plasma drugn concentrations when coadministered with drugn tablets , but an effect of drugb on the plasma concentration of drugn / drugn has not been excluded .
false
druga : a controlled pharmacokinetic study has shown no effect on plasma drugn concentrations when coadministered with drugn tablets , but an effect of drugn on the plasma concentration of drugb / drugn has not been excluded .
false
druga : a controlled pharmacokinetic study has shown no effect on plasma drugn concentrations when coadministered with drugn tablets , but an effect of drugn on the plasma concentration of drugn / drugb has not been excluded .
false
drugn : a controlled pharmacokinetic study has shown no effect on plasma druga concentrations when coadministered with drugb tablets , but an effect of drugn on the plasma concentration of drugn / drugn has not been excluded .
false
drugn : a controlled pharmacokinetic study has shown no effect on plasma druga concentrations when coadministered with drugn tablets , but an effect of drugb on the plasma concentration of drugn / drugn has not been excluded .
false
drugn : a controlled pharmacokinetic study has shown no effect on plasma druga concentrations when coadministered with drugn tablets , but an effect of drugn on the plasma concentration of drugb / drugn has not been excluded .
false
drugn : a controlled pharmacokinetic study has shown no effect on plasma druga concentrations when coadministered with drugn tablets , but an effect of drugn on the plasma concentration of drugn / drugb has not been excluded .
false
drugn : a controlled pharmacokinetic study has shown no effect on plasma drugn concentrations when coadministered with druga tablets , but an effect of drugb on the plasma concentration of drugn / drugn has not been excluded .
false
drugn : a controlled pharmacokinetic study has shown no effect on plasma drugn concentrations when coadministered with druga tablets , but an effect of drugn on the plasma concentration of drugb / drugn has not been excluded .
false
drugn : a controlled pharmacokinetic study has shown no effect on plasma drugn concentrations when coadministered with druga tablets , but an effect of drugn on the plasma concentration of drugn / drugb has not been excluded .
false
drugn : a controlled pharmacokinetic study has shown no effect on plasma drugn concentrations when coadministered with drugn tablets , but an effect of druga on the plasma concentration of drugb / drugn has not been excluded .
mechanism
drugn : a controlled pharmacokinetic study has shown no effect on plasma drugn concentrations when coadministered with drugn tablets , but an effect of druga on the plasma concentration of drugn / drugb has not been excluded .
mechanism
drugn : a controlled pharmacokinetic study has shown no effect on plasma drugn concentrations when coadministered with drugn tablets , but an effect of drugn on the plasma concentration of druga / drugb has not been excluded .
false
druga : animal data have suggested the possibility of interaction between drugb and drugn .
false
druga : animal data have suggested the possibility of interaction between drugn and drugb .
false
drugn : animal data have suggested the possibility of interaction between druga and drugb .
int
food interaction : oral administration of druga tablets with food does not significantly lower the rate or extent of drugb absorption relative to the fasted state .
false
however , the extent of biotransformation of druga to the active metabolite , drugb , is reduced approximately 43 % , resulting in a reduction in the plasma ace inhibition curve of approximately 20 % , probably clinically insignificant .
false
interaction with druga : although drugb does not itself cause orthostatic hypotension , its administration to patients already receiving drugn can result in profound orthostatic effects .
false
interaction with druga : although drugn does not itself cause orthostatic hypotension , its administration to patients already receiving drugb can result in profound orthostatic effects .
false
interaction with drugn : although druga does not itself cause orthostatic hypotension , its administration to patients already receiving drugb can result in profound orthostatic effects .
effect
if at all possible druga should be discontinued well before drugb is begun .
advise
when administered concomitantly with druga , drugb may enhance or precipitate bradycardia , a.v .
effect
the use of drugs that stimulate alpha-adrenergic receptors ( e.g. , druga , drugb , drugn , drugn or drugn ) may enhance or potentiate the pressor effects of drugn . therefore , caution should be used when drugn is administered concomitantly with agents that cause vasoconstriction .
false
the use of drugs that stimulate alpha-adrenergic receptors ( e.g. , druga , drugn , drugb , drugn or drugn ) may enhance or potentiate the pressor effects of drugn . therefore , caution should be used when drugn is administered concomitantly with agents that cause vasoconstriction .
false
the use of drugs that stimulate alpha-adrenergic receptors ( e.g. , druga , drugn , drugn , drugb or drugn ) may enhance or potentiate the pressor effects of drugn . therefore , caution should be used when drugn is administered concomitantly with agents that cause vasoconstriction .
false
the use of drugs that stimulate alpha-adrenergic receptors ( e.g. , druga , drugn , drugn , drugn or drugb ) may enhance or potentiate the pressor effects of drugn . therefore , caution should be used when drugn is administered concomitantly with agents that cause vasoconstriction .
false
the use of drugs that stimulate alpha-adrenergic receptors ( e.g. , druga , drugn , drugn , drugn or drugn ) may enhance or potentiate the pressor effects of drugb . therefore , caution should be used when drugn is administered concomitantly with agents that cause vasoconstriction .
effect
the use of drugs that stimulate alpha-adrenergic receptors ( e.g. , druga , drugn , drugn , drugn or drugn ) may enhance or potentiate the pressor effects of drugn . therefore , caution should be used when drugb is administered concomitantly with agents that cause vasoconstriction .
false
the use of drugs that stimulate alpha-adrenergic receptors ( e.g. , drugn , druga , drugb , drugn or drugn ) may enhance or potentiate the pressor effects of drugn . therefore , caution should be used when drugn is administered concomitantly with agents that cause vasoconstriction .
false
the use of drugs that stimulate alpha-adrenergic receptors ( e.g. , drugn , druga , drugn , drugb or drugn ) may enhance or potentiate the pressor effects of drugn . therefore , caution should be used when drugn is administered concomitantly with agents that cause vasoconstriction .
false
the use of drugs that stimulate alpha-adrenergic receptors ( e.g. , drugn , druga , drugn , drugn or drugb ) may enhance or potentiate the pressor effects of drugn . therefore , caution should be used when drugn is administered concomitantly with agents that cause vasoconstriction .
false
the use of drugs that stimulate alpha-adrenergic receptors ( e.g. , drugn , druga , drugn , drugn or drugn ) may enhance or potentiate the pressor effects of drugb . therefore , caution should be used when drugn is administered concomitantly with agents that cause vasoconstriction .
effect
the use of drugs that stimulate alpha-adrenergic receptors ( e.g. , drugn , druga , drugn , drugn or drugn ) may enhance or potentiate the pressor effects of drugn . therefore , caution should be used when drugb is administered concomitantly with agents that cause vasoconstriction .
false
the use of drugs that stimulate alpha-adrenergic receptors ( e.g. , drugn , drugn , druga , drugb or drugn ) may enhance or potentiate the pressor effects of drugn . therefore , caution should be used when drugn is administered concomitantly with agents that cause vasoconstriction .
false
the use of drugs that stimulate alpha-adrenergic receptors ( e.g. , drugn , drugn , druga , drugn or drugb ) may enhance or potentiate the pressor effects of drugn . therefore , caution should be used when drugn is administered concomitantly with agents that cause vasoconstriction .
false
the use of drugs that stimulate alpha-adrenergic receptors ( e.g. , drugn , drugn , druga , drugn or drugn ) may enhance or potentiate the pressor effects of drugb . therefore , caution should be used when drugn is administered concomitantly with agents that cause vasoconstriction .
effect
the use of drugs that stimulate alpha-adrenergic receptors ( e.g. , drugn , drugn , druga , drugn or drugn ) may enhance or potentiate the pressor effects of drugn . therefore , caution should be used when drugb is administered concomitantly with agents that cause vasoconstriction .
false
the use of drugs that stimulate alpha-adrenergic receptors ( e.g. , drugn , drugn , drugn , druga or drugb ) may enhance or potentiate the pressor effects of drugn . therefore , caution should be used when drugn is administered concomitantly with agents that cause vasoconstriction .
false
the use of drugs that stimulate alpha-adrenergic receptors ( e.g. , drugn , drugn , drugn , druga or drugn ) may enhance or potentiate the pressor effects of drugb . therefore , caution should be used when drugn is administered concomitantly with agents that cause vasoconstriction .
effect
the use of drugs that stimulate alpha-adrenergic receptors ( e.g. , drugn , drugn , drugn , druga or drugn ) may enhance or potentiate the pressor effects of drugn . therefore , caution should be used when drugb is administered concomitantly with agents that cause vasoconstriction .
false
the use of drugs that stimulate alpha-adrenergic receptors ( e.g. , drugn , drugn , drugn , drugn or druga ) may enhance or potentiate the pressor effects of drugb . therefore , caution should be used when drugn is administered concomitantly with agents that cause vasoconstriction .
effect
the use of drugs that stimulate alpha-adrenergic receptors ( e.g. , drugn , drugn , drugn , drugn or druga ) may enhance or potentiate the pressor effects of drugn . therefore , caution should be used when drugb is administered concomitantly with agents that cause vasoconstriction .
false
the use of drugs that stimulate alpha-adrenergic receptors ( e.g. , drugn , drugn , drugn , drugn or drugn ) may enhance or potentiate the pressor effects of druga . therefore , caution should be used when drugb is administered concomitantly with agents that cause vasoconstriction .
false
druga has been used in patients concomitantly treated with salt-retaining steroid therapy ( i.e. , drugb ) , with or without salt supplementation .
false
druga . drugb , such as drugn , drugn , and drugn , can antagonize the effects of drugn . potential for drug interactions : it appears possible , although there is no supporting experimental evidence , that the high renal clearance of drugn ( a base ) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as drugn , drugn , drugn , drugn , drugn , drugn , and drugn .
false
druga . drugn , such as drugb , drugn , and drugn , can antagonize the effects of drugn . potential for drug interactions : it appears possible , although there is no supporting experimental evidence , that the high renal clearance of drugn ( a base ) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as drugn , drugn , drugn , drugn , drugn , drugn , and drugn .
false
druga . drugn , such as drugn , drugb , and drugn , can antagonize the effects of drugn . potential for drug interactions : it appears possible , although there is no supporting experimental evidence , that the high renal clearance of drugn ( a base ) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as drugn , drugn , drugn , drugn , drugn , drugn , and drugn .
false
druga . drugn , such as drugn , drugn , and drugb , can antagonize the effects of drugn . potential for drug interactions : it appears possible , although there is no supporting experimental evidence , that the high renal clearance of drugn ( a base ) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as drugn , drugn , drugn , drugn , drugn , drugn , and drugn .
false
druga . drugn , such as drugn , drugn , and drugn , can antagonize the effects of drugb . potential for drug interactions : it appears possible , although there is no supporting experimental evidence , that the high renal clearance of drugn ( a base ) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as drugn , drugn , drugn , drugn , drugn , drugn , and drugn .
false
druga . drugn , such as drugn , drugn , and drugn , can antagonize the effects of drugn . potential for drug interactions : it appears possible , although there is no supporting experimental evidence , that the high renal clearance of drugb ( a base ) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as drugn , drugn , drugn , drugn , drugn , drugn , and drugn .
false
druga . drugn , such as drugn , drugn , and drugn , can antagonize the effects of drugn . potential for drug interactions : it appears possible , although there is no supporting experimental evidence , that the high renal clearance of drugn ( a base ) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as drugb , drugn , drugn , drugn , drugn , drugn , and drugn .
false
druga . drugn , such as drugn , drugn , and drugn , can antagonize the effects of drugn . potential for drug interactions : it appears possible , although there is no supporting experimental evidence , that the high renal clearance of drugn ( a base ) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as drugn , drugb , drugn , drugn , drugn , drugn , and drugn .
false
druga . drugn , such as drugn , drugn , and drugn , can antagonize the effects of drugn . potential for drug interactions : it appears possible , although there is no supporting experimental evidence , that the high renal clearance of drugn ( a base ) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as drugn , drugn , drugb , drugn , drugn , drugn , and drugn .
false
druga . drugn , such as drugn , drugn , and drugn , can antagonize the effects of drugn . potential for drug interactions : it appears possible , although there is no supporting experimental evidence , that the high renal clearance of drugn ( a base ) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as drugn , drugn , drugn , drugb , drugn , drugn , and drugn .
false
druga . drugn , such as drugn , drugn , and drugn , can antagonize the effects of drugn . potential for drug interactions : it appears possible , although there is no supporting experimental evidence , that the high renal clearance of drugn ( a base ) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as drugn , drugn , drugn , drugn , drugb , drugn , and drugn .
false
druga . drugn , such as drugn , drugn , and drugn , can antagonize the effects of drugn . potential for drug interactions : it appears possible , although there is no supporting experimental evidence , that the high renal clearance of drugn ( a base ) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as drugn , drugn , drugn , drugn , drugn , drugb , and drugn .
false
druga . drugn , such as drugn , drugn , and drugn , can antagonize the effects of drugn . potential for drug interactions : it appears possible , although there is no supporting experimental evidence , that the high renal clearance of drugn ( a base ) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as drugn , drugn , drugn , drugn , drugn , drugn , and drugb .
false
drugn . druga , such as drugb , drugn , and drugn , can antagonize the effects of drugn . potential for drug interactions : it appears possible , although there is no supporting experimental evidence , that the high renal clearance of drugn ( a base ) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as drugn , drugn , drugn , drugn , drugn , drugn , and drugn .
false
drugn . druga , such as drugn , drugb , and drugn , can antagonize the effects of drugn . potential for drug interactions : it appears possible , although there is no supporting experimental evidence , that the high renal clearance of drugn ( a base ) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as drugn , drugn , drugn , drugn , drugn , drugn , and drugn .
false
drugn . druga , such as drugn , drugn , and drugb , can antagonize the effects of drugn . potential for drug interactions : it appears possible , although there is no supporting experimental evidence , that the high renal clearance of drugn ( a base ) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as drugn , drugn , drugn , drugn , drugn , drugn , and drugn .
false
drugn . druga , such as drugn , drugn , and drugn , can antagonize the effects of drugb . potential for drug interactions : it appears possible , although there is no supporting experimental evidence , that the high renal clearance of drugn ( a base ) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as drugn , drugn , drugn , drugn , drugn , drugn , and drugn .
effect
drugn . druga , such as drugn , drugn , and drugn , can antagonize the effects of drugn . potential for drug interactions : it appears possible , although there is no supporting experimental evidence , that the high renal clearance of drugb ( a base ) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as drugn , drugn , drugn , drugn , drugn , drugn , and drugn .
false
drugn . druga , such as drugn , drugn , and drugn , can antagonize the effects of drugn . potential for drug interactions : it appears possible , although there is no supporting experimental evidence , that the high renal clearance of drugn ( a base ) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as drugb , drugn , drugn , drugn , drugn , drugn , and drugn .
false
drugn . druga , such as drugn , drugn , and drugn , can antagonize the effects of drugn . potential for drug interactions : it appears possible , although there is no supporting experimental evidence , that the high renal clearance of drugn ( a base ) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as drugn , drugb , drugn , drugn , drugn , drugn , and drugn .
false
drugn . druga , such as drugn , drugn , and drugn , can antagonize the effects of drugn . potential for drug interactions : it appears possible , although there is no supporting experimental evidence , that the high renal clearance of drugn ( a base ) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as drugn , drugn , drugb , drugn , drugn , drugn , and drugn .
false
drugn . druga , such as drugn , drugn , and drugn , can antagonize the effects of drugn . potential for drug interactions : it appears possible , although there is no supporting experimental evidence , that the high renal clearance of drugn ( a base ) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as drugn , drugn , drugn , drugb , drugn , drugn , and drugn .
false
drugn . druga , such as drugn , drugn , and drugn , can antagonize the effects of drugn . potential for drug interactions : it appears possible , although there is no supporting experimental evidence , that the high renal clearance of drugn ( a base ) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as drugn , drugn , drugn , drugn , drugb , drugn , and drugn .
false
drugn . druga , such as drugn , drugn , and drugn , can antagonize the effects of drugn . potential for drug interactions : it appears possible , although there is no supporting experimental evidence , that the high renal clearance of drugn ( a base ) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as drugn , drugn , drugn , drugn , drugn , drugb , and drugn .
false
drugn . druga , such as drugn , drugn , and drugn , can antagonize the effects of drugn . potential for drug interactions : it appears possible , although there is no supporting experimental evidence , that the high renal clearance of drugn ( a base ) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as drugn , drugn , drugn , drugn , drugn , drugn , and drugb .
false
drugn . drugn , such as druga , drugb , and drugn , can antagonize the effects of drugn . potential for drug interactions : it appears possible , although there is no supporting experimental evidence , that the high renal clearance of drugn ( a base ) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as drugn , drugn , drugn , drugn , drugn , drugn , and drugn .
false
drugn . drugn , such as druga , drugn , and drugb , can antagonize the effects of drugn . potential for drug interactions : it appears possible , although there is no supporting experimental evidence , that the high renal clearance of drugn ( a base ) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as drugn , drugn , drugn , drugn , drugn , drugn , and drugn .
false
drugn . drugn , such as druga , drugn , and drugn , can antagonize the effects of drugb . potential for drug interactions : it appears possible , although there is no supporting experimental evidence , that the high renal clearance of drugn ( a base ) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as drugn , drugn , drugn , drugn , drugn , drugn , and drugn .
effect
drugn . drugn , such as druga , drugn , and drugn , can antagonize the effects of drugn . potential for drug interactions : it appears possible , although there is no supporting experimental evidence , that the high renal clearance of drugb ( a base ) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as drugn , drugn , drugn , drugn , drugn , drugn , and drugn .
false
drugn . drugn , such as druga , drugn , and drugn , can antagonize the effects of drugn . potential for drug interactions : it appears possible , although there is no supporting experimental evidence , that the high renal clearance of drugn ( a base ) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as drugb , drugn , drugn , drugn , drugn , drugn , and drugn .
false
drugn . drugn , such as druga , drugn , and drugn , can antagonize the effects of drugn . potential for drug interactions : it appears possible , although there is no supporting experimental evidence , that the high renal clearance of drugn ( a base ) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as drugn , drugb , drugn , drugn , drugn , drugn , and drugn .
false
drugn . drugn , such as druga , drugn , and drugn , can antagonize the effects of drugn . potential for drug interactions : it appears possible , although there is no supporting experimental evidence , that the high renal clearance of drugn ( a base ) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as drugn , drugn , drugb , drugn , drugn , drugn , and drugn .
false
drugn . drugn , such as druga , drugn , and drugn , can antagonize the effects of drugn . potential for drug interactions : it appears possible , although there is no supporting experimental evidence , that the high renal clearance of drugn ( a base ) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as drugn , drugn , drugn , drugb , drugn , drugn , and drugn .
false
drugn . drugn , such as druga , drugn , and drugn , can antagonize the effects of drugn . potential for drug interactions : it appears possible , although there is no supporting experimental evidence , that the high renal clearance of drugn ( a base ) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as drugn , drugn , drugn , drugn , drugb , drugn , and drugn .
false
drugn . drugn , such as druga , drugn , and drugn , can antagonize the effects of drugn . potential for drug interactions : it appears possible , although there is no supporting experimental evidence , that the high renal clearance of drugn ( a base ) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as drugn , drugn , drugn , drugn , drugn , drugb , and drugn .
false
drugn . drugn , such as druga , drugn , and drugn , can antagonize the effects of drugn . potential for drug interactions : it appears possible , although there is no supporting experimental evidence , that the high renal clearance of drugn ( a base ) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as drugn , drugn , drugn , drugn , drugn , drugn , and drugb .
false
drugn . drugn , such as drugn , druga , and drugb , can antagonize the effects of drugn . potential for drug interactions : it appears possible , although there is no supporting experimental evidence , that the high renal clearance of drugn ( a base ) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as drugn , drugn , drugn , drugn , drugn , drugn , and drugn .
false
drugn . drugn , such as drugn , druga , and drugn , can antagonize the effects of drugb . potential for drug interactions : it appears possible , although there is no supporting experimental evidence , that the high renal clearance of drugn ( a base ) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as drugn , drugn , drugn , drugn , drugn , drugn , and drugn .
effect
drugn . drugn , such as drugn , druga , and drugn , can antagonize the effects of drugn . potential for drug interactions : it appears possible , although there is no supporting experimental evidence , that the high renal clearance of drugb ( a base ) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as drugn , drugn , drugn , drugn , drugn , drugn , and drugn .
false
drugn . drugn , such as drugn , druga , and drugn , can antagonize the effects of drugn . potential for drug interactions : it appears possible , although there is no supporting experimental evidence , that the high renal clearance of drugn ( a base ) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as drugb , drugn , drugn , drugn , drugn , drugn , and drugn .
false
drugn . drugn , such as drugn , druga , and drugn , can antagonize the effects of drugn . potential for drug interactions : it appears possible , although there is no supporting experimental evidence , that the high renal clearance of drugn ( a base ) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as drugn , drugb , drugn , drugn , drugn , drugn , and drugn .
false
drugn . drugn , such as drugn , druga , and drugn , can antagonize the effects of drugn . potential for drug interactions : it appears possible , although there is no supporting experimental evidence , that the high renal clearance of drugn ( a base ) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as drugn , drugn , drugb , drugn , drugn , drugn , and drugn .
false
drugn . drugn , such as drugn , druga , and drugn , can antagonize the effects of drugn . potential for drug interactions : it appears possible , although there is no supporting experimental evidence , that the high renal clearance of drugn ( a base ) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as drugn , drugn , drugn , drugb , drugn , drugn , and drugn .
false
drugn . drugn , such as drugn , druga , and drugn , can antagonize the effects of drugn . potential for drug interactions : it appears possible , although there is no supporting experimental evidence , that the high renal clearance of drugn ( a base ) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as drugn , drugn , drugn , drugn , drugb , drugn , and drugn .
false
drugn . drugn , such as drugn , druga , and drugn , can antagonize the effects of drugn . potential for drug interactions : it appears possible , although there is no supporting experimental evidence , that the high renal clearance of drugn ( a base ) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as drugn , drugn , drugn , drugn , drugn , drugb , and drugn .
false
drugn . drugn , such as drugn , druga , and drugn , can antagonize the effects of drugn . potential for drug interactions : it appears possible , although there is no supporting experimental evidence , that the high renal clearance of drugn ( a base ) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as drugn , drugn , drugn , drugn , drugn , drugn , and drugb .
false
drugn . drugn , such as drugn , drugn , and druga , can antagonize the effects of drugb . potential for drug interactions : it appears possible , although there is no supporting experimental evidence , that the high renal clearance of drugn ( a base ) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as drugn , drugn , drugn , drugn , drugn , drugn , and drugn .
effect
drugn . drugn , such as drugn , drugn , and druga , can antagonize the effects of drugn . potential for drug interactions : it appears possible , although there is no supporting experimental evidence , that the high renal clearance of drugb ( a base ) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as drugn , drugn , drugn , drugn , drugn , drugn , and drugn .
false
drugn . drugn , such as drugn , drugn , and druga , can antagonize the effects of drugn . potential for drug interactions : it appears possible , although there is no supporting experimental evidence , that the high renal clearance of drugn ( a base ) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as drugb , drugn , drugn , drugn , drugn , drugn , and drugn .
false
drugn . drugn , such as drugn , drugn , and druga , can antagonize the effects of drugn . potential for drug interactions : it appears possible , although there is no supporting experimental evidence , that the high renal clearance of drugn ( a base ) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as drugn , drugb , drugn , drugn , drugn , drugn , and drugn .
false
drugn . drugn , such as drugn , drugn , and druga , can antagonize the effects of drugn . potential for drug interactions : it appears possible , although there is no supporting experimental evidence , that the high renal clearance of drugn ( a base ) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as drugn , drugn , drugb , drugn , drugn , drugn , and drugn .
false
drugn . drugn , such as drugn , drugn , and druga , can antagonize the effects of drugn . potential for drug interactions : it appears possible , although there is no supporting experimental evidence , that the high renal clearance of drugn ( a base ) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as drugn , drugn , drugn , drugb , drugn , drugn , and drugn .
false
drugn . drugn , such as drugn , drugn , and druga , can antagonize the effects of drugn . potential for drug interactions : it appears possible , although there is no supporting experimental evidence , that the high renal clearance of drugn ( a base ) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as drugn , drugn , drugn , drugn , drugb , drugn , and drugn .
false
drugn . drugn , such as drugn , drugn , and druga , can antagonize the effects of drugn . potential for drug interactions : it appears possible , although there is no supporting experimental evidence , that the high renal clearance of drugn ( a base ) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as drugn , drugn , drugn , drugn , drugn , drugb , and drugn .
false
drugn . drugn , such as drugn , drugn , and druga , can antagonize the effects of drugn . potential for drug interactions : it appears possible , although there is no supporting experimental evidence , that the high renal clearance of drugn ( a base ) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as drugn , drugn , drugn , drugn , drugn , drugn , and drugb .
false
drugn . drugn , such as drugn , drugn , and drugn , can antagonize the effects of druga . potential for drug interactions : it appears possible , although there is no supporting experimental evidence , that the high renal clearance of drugb ( a base ) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as drugn , drugn , drugn , drugn , drugn , drugn , and drugn .
false
drugn . drugn , such as drugn , drugn , and drugn , can antagonize the effects of druga . potential for drug interactions : it appears possible , although there is no supporting experimental evidence , that the high renal clearance of drugn ( a base ) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as drugb , drugn , drugn , drugn , drugn , drugn , and drugn .
false
drugn . drugn , such as drugn , drugn , and drugn , can antagonize the effects of druga . potential for drug interactions : it appears possible , although there is no supporting experimental evidence , that the high renal clearance of drugn ( a base ) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as drugn , drugb , drugn , drugn , drugn , drugn , and drugn .
false
drugn . drugn , such as drugn , drugn , and drugn , can antagonize the effects of druga . potential for drug interactions : it appears possible , although there is no supporting experimental evidence , that the high renal clearance of drugn ( a base ) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as drugn , drugn , drugb , drugn , drugn , drugn , and drugn .
false
drugn . drugn , such as drugn , drugn , and drugn , can antagonize the effects of druga . potential for drug interactions : it appears possible , although there is no supporting experimental evidence , that the high renal clearance of drugn ( a base ) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as drugn , drugn , drugn , drugb , drugn , drugn , and drugn .
false
drugn . drugn , such as drugn , drugn , and drugn , can antagonize the effects of druga . potential for drug interactions : it appears possible , although there is no supporting experimental evidence , that the high renal clearance of drugn ( a base ) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as drugn , drugn , drugn , drugn , drugb , drugn , and drugn .
false
drugn . drugn , such as drugn , drugn , and drugn , can antagonize the effects of druga . potential for drug interactions : it appears possible , although there is no supporting experimental evidence , that the high renal clearance of drugn ( a base ) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as drugn , drugn , drugn , drugn , drugn , drugb , and drugn .
false
drugn . drugn , such as drugn , drugn , and drugn , can antagonize the effects of druga . potential for drug interactions : it appears possible , although there is no supporting experimental evidence , that the high renal clearance of drugn ( a base ) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as drugn , drugn , drugn , drugn , drugn , drugn , and drugb .
false
drugn . drugn , such as drugn , drugn , and drugn , can antagonize the effects of drugn . potential for drug interactions : it appears possible , although there is no supporting experimental evidence , that the high renal clearance of druga ( a base ) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as drugb , drugn , drugn , drugn , drugn , drugn , and drugn .
mechanism
drugn . drugn , such as drugn , drugn , and drugn , can antagonize the effects of drugn . potential for drug interactions : it appears possible , although there is no supporting experimental evidence , that the high renal clearance of druga ( a base ) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as drugn , drugb , drugn , drugn , drugn , drugn , and drugn .
mechanism
drugn . drugn , such as drugn , drugn , and drugn , can antagonize the effects of drugn . potential for drug interactions : it appears possible , although there is no supporting experimental evidence , that the high renal clearance of druga ( a base ) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as drugn , drugn , drugb , drugn , drugn , drugn , and drugn .
mechanism
drugn . drugn , such as drugn , drugn , and drugn , can antagonize the effects of drugn . potential for drug interactions : it appears possible , although there is no supporting experimental evidence , that the high renal clearance of druga ( a base ) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as drugn , drugn , drugn , drugb , drugn , drugn , and drugn .
mechanism
drugn . drugn , such as drugn , drugn , and drugn , can antagonize the effects of drugn . potential for drug interactions : it appears possible , although there is no supporting experimental evidence , that the high renal clearance of druga ( a base ) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as drugn , drugn , drugn , drugn , drugb , drugn , and drugn .
mechanism
drugn . drugn , such as drugn , drugn , and drugn , can antagonize the effects of drugn . potential for drug interactions : it appears possible , although there is no supporting experimental evidence , that the high renal clearance of druga ( a base ) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as drugn , drugn , drugn , drugn , drugn , drugb , and drugn .
mechanism
drugn . drugn , such as drugn , drugn , and drugn , can antagonize the effects of drugn . potential for drug interactions : it appears possible , although there is no supporting experimental evidence , that the high renal clearance of druga ( a base ) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as drugn , drugn , drugn , drugn , drugn , drugn , and drugb .
mechanism
drugn . drugn , such as drugn , drugn , and drugn , can antagonize the effects of drugn . potential for drug interactions : it appears possible , although there is no supporting experimental evidence , that the high renal clearance of drugn ( a base ) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as druga , drugb , drugn , drugn , drugn , drugn , and drugn .
false
drugn . drugn , such as drugn , drugn , and drugn , can antagonize the effects of drugn . potential for drug interactions : it appears possible , although there is no supporting experimental evidence , that the high renal clearance of drugn ( a base ) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as druga , drugn , drugb , drugn , drugn , drugn , and drugn .
false
drugn . drugn , such as drugn , drugn , and drugn , can antagonize the effects of drugn . potential for drug interactions : it appears possible , although there is no supporting experimental evidence , that the high renal clearance of drugn ( a base ) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as druga , drugn , drugn , drugb , drugn , drugn , and drugn .
false
drugn . drugn , such as drugn , drugn , and drugn , can antagonize the effects of drugn . potential for drug interactions : it appears possible , although there is no supporting experimental evidence , that the high renal clearance of drugn ( a base ) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as druga , drugn , drugn , drugn , drugb , drugn , and drugn .
false
drugn . drugn , such as drugn , drugn , and drugn , can antagonize the effects of drugn . potential for drug interactions : it appears possible , although there is no supporting experimental evidence , that the high renal clearance of drugn ( a base ) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as druga , drugn , drugn , drugn , drugn , drugb , and drugn .
false
drugn . drugn , such as drugn , drugn , and drugn , can antagonize the effects of drugn . potential for drug interactions : it appears possible , although there is no supporting experimental evidence , that the high renal clearance of drugn ( a base ) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as druga , drugn , drugn , drugn , drugn , drugn , and drugb .
false
drugn . drugn , such as drugn , drugn , and drugn , can antagonize the effects of drugn . potential for drug interactions : it appears possible , although there is no supporting experimental evidence , that the high renal clearance of drugn ( a base ) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as drugn , druga , drugb , drugn , drugn , drugn , and drugn .
false
drugn . drugn , such as drugn , drugn , and drugn , can antagonize the effects of drugn . potential for drug interactions : it appears possible , although there is no supporting experimental evidence , that the high renal clearance of drugn ( a base ) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as drugn , druga , drugn , drugb , drugn , drugn , and drugn .
false
drugn . drugn , such as drugn , drugn , and drugn , can antagonize the effects of drugn . potential for drug interactions : it appears possible , although there is no supporting experimental evidence , that the high renal clearance of drugn ( a base ) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as drugn , druga , drugn , drugn , drugb , drugn , and drugn .
false
drugn . drugn , such as drugn , drugn , and drugn , can antagonize the effects of drugn . potential for drug interactions : it appears possible , although there is no supporting experimental evidence , that the high renal clearance of drugn ( a base ) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as drugn , druga , drugn , drugn , drugn , drugb , and drugn .
false
drugn . drugn , such as drugn , drugn , and drugn , can antagonize the effects of drugn . potential for drug interactions : it appears possible , although there is no supporting experimental evidence , that the high renal clearance of drugn ( a base ) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as drugn , druga , drugn , drugn , drugn , drugn , and drugb .
false
drugn . drugn , such as drugn , drugn , and drugn , can antagonize the effects of drugn . potential for drug interactions : it appears possible , although there is no supporting experimental evidence , that the high renal clearance of drugn ( a base ) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as drugn , drugn , druga , drugb , drugn , drugn , and drugn .
false
drugn . drugn , such as drugn , drugn , and drugn , can antagonize the effects of drugn . potential for drug interactions : it appears possible , although there is no supporting experimental evidence , that the high renal clearance of drugn ( a base ) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as drugn , drugn , druga , drugn , drugb , drugn , and drugn .
false
drugn . drugn , such as drugn , drugn , and drugn , can antagonize the effects of drugn . potential for drug interactions : it appears possible , although there is no supporting experimental evidence , that the high renal clearance of drugn ( a base ) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as drugn , drugn , druga , drugn , drugn , drugb , and drugn .
false
drugn . drugn , such as drugn , drugn , and drugn , can antagonize the effects of drugn . potential for drug interactions : it appears possible , although there is no supporting experimental evidence , that the high renal clearance of drugn ( a base ) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as drugn , drugn , druga , drugn , drugn , drugn , and drugb .
false
drugn . drugn , such as drugn , drugn , and drugn , can antagonize the effects of drugn . potential for drug interactions : it appears possible , although there is no supporting experimental evidence , that the high renal clearance of drugn ( a base ) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as drugn , drugn , drugn , druga , drugb , drugn , and drugn .
false
drugn . drugn , such as drugn , drugn , and drugn , can antagonize the effects of drugn . potential for drug interactions : it appears possible , although there is no supporting experimental evidence , that the high renal clearance of drugn ( a base ) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as drugn , drugn , drugn , druga , drugn , drugb , and drugn .
false
drugn . drugn , such as drugn , drugn , and drugn , can antagonize the effects of drugn . potential for drug interactions : it appears possible , although there is no supporting experimental evidence , that the high renal clearance of drugn ( a base ) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as drugn , drugn , drugn , druga , drugn , drugn , and drugb .
false
drugn . drugn , such as drugn , drugn , and drugn , can antagonize the effects of drugn . potential for drug interactions : it appears possible , although there is no supporting experimental evidence , that the high renal clearance of drugn ( a base ) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as drugn , drugn , drugn , drugn , druga , drugb , and drugn .
false
drugn . drugn , such as drugn , drugn , and drugn , can antagonize the effects of drugn . potential for drug interactions : it appears possible , although there is no supporting experimental evidence , that the high renal clearance of drugn ( a base ) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as drugn , drugn , drugn , drugn , druga , drugn , and drugb .
false
drugn . drugn , such as drugn , drugn , and drugn , can antagonize the effects of drugn . potential for drug interactions : it appears possible , although there is no supporting experimental evidence , that the high renal clearance of drugn ( a base ) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as drugn , drugn , drugn , drugn , drugn , druga , and drugb .
false
because druga is metabolized by hepatic cytochrome p-450 drug-metabolizing enzymes ( cyp3a4 , cyp2d6 , cyp1a2 ) , inducers or inhibitors of these enzymes may change the clearance and , hence , the half-life of drugb .
false
druga , drugb , and drugn : in patients treated with potent inducers of cyp3a4 ( i.e. , drugn , drugn , and drugn ) , the clearance of drugn was significantly increased and drugn blood concentrations were decreased .
false
druga , drugn , and drugb : in patients treated with potent inducers of cyp3a4 ( i.e. , drugn , drugn , and drugn ) , the clearance of drugn was significantly increased and drugn blood concentrations were decreased .
false
druga , drugn , and drugn : in patients treated with potent inducers of cyp3a4 ( i.e. , drugb , drugn , and drugn ) , the clearance of drugn was significantly increased and drugn blood concentrations were decreased .
false
druga , drugn , and drugn : in patients treated with potent inducers of cyp3a4 ( i.e. , drugn , drugb , and drugn ) , the clearance of drugn was significantly increased and drugn blood concentrations were decreased .
false
druga , drugn , and drugn : in patients treated with potent inducers of cyp3a4 ( i.e. , drugn , drugn , and drugb ) , the clearance of drugn was significantly increased and drugn blood concentrations were decreased .
false
druga , drugn , and drugn : in patients treated with potent inducers of cyp3a4 ( i.e. , drugn , drugn , and drugn ) , the clearance of drugb was significantly increased and drugn blood concentrations were decreased .
false
druga , drugn , and drugn : in patients treated with potent inducers of cyp3a4 ( i.e. , drugn , drugn , and drugn ) , the clearance of drugn was significantly increased and drugb blood concentrations were decreased .
false
drugn , druga , and drugb : in patients treated with potent inducers of cyp3a4 ( i.e. , drugn , drugn , and drugn ) , the clearance of drugn was significantly increased and drugn blood concentrations were decreased .
false
drugn , druga , and drugn : in patients treated with potent inducers of cyp3a4 ( i.e. , drugb , drugn , and drugn ) , the clearance of drugn was significantly increased and drugn blood concentrations were decreased .
false
drugn , druga , and drugn : in patients treated with potent inducers of cyp3a4 ( i.e. , drugn , drugb , and drugn ) , the clearance of drugn was significantly increased and drugn blood concentrations were decreased .
false
drugn , druga , and drugn : in patients treated with potent inducers of cyp3a4 ( i.e. , drugn , drugn , and drugb ) , the clearance of drugn was significantly increased and drugn blood concentrations were decreased .
false
drugn , druga , and drugn : in patients treated with potent inducers of cyp3a4 ( i.e. , drugn , drugn , and drugn ) , the clearance of drugb was significantly increased and drugn blood concentrations were decreased .
false
drugn , druga , and drugn : in patients treated with potent inducers of cyp3a4 ( i.e. , drugn , drugn , and drugn ) , the clearance of drugn was significantly increased and drugb blood concentrations were decreased .
false
drugn , drugn , and druga : in patients treated with potent inducers of cyp3a4 ( i.e. , drugb , drugn , and drugn ) , the clearance of drugn was significantly increased and drugn blood concentrations were decreased .
false
drugn , drugn , and druga : in patients treated with potent inducers of cyp3a4 ( i.e. , drugn , drugb , and drugn ) , the clearance of drugn was significantly increased and drugn blood concentrations were decreased .
false
drugn , drugn , and druga : in patients treated with potent inducers of cyp3a4 ( i.e. , drugn , drugn , and drugb ) , the clearance of drugn was significantly increased and drugn blood concentrations were decreased .
false
drugn , drugn , and druga : in patients treated with potent inducers of cyp3a4 ( i.e. , drugn , drugn , and drugn ) , the clearance of drugb was significantly increased and drugn blood concentrations were decreased .
false
drugn , drugn , and druga : in patients treated with potent inducers of cyp3a4 ( i.e. , drugn , drugn , and drugn ) , the clearance of drugn was significantly increased and drugb blood concentrations were decreased .
false
drugn , drugn , and drugn : in patients treated with potent inducers of cyp3a4 ( i.e. , druga , drugb , and drugn ) , the clearance of drugn was significantly increased and drugn blood concentrations were decreased .
false
drugn , drugn , and drugn : in patients treated with potent inducers of cyp3a4 ( i.e. , druga , drugn , and drugb ) , the clearance of drugn was significantly increased and drugn blood concentrations were decreased .
false
drugn , drugn , and drugn : in patients treated with potent inducers of cyp3a4 ( i.e. , druga , drugn , and drugn ) , the clearance of drugb was significantly increased and drugn blood concentrations were decreased .
mechanism
drugn , drugn , and drugn : in patients treated with potent inducers of cyp3a4 ( i.e. , druga , drugn , and drugn ) , the clearance of drugn was significantly increased and drugb blood concentrations were decreased .
mechanism
drugn , drugn , and drugn : in patients treated with potent inducers of cyp3a4 ( i.e. , drugn , druga , and drugb ) , the clearance of drugn was significantly increased and drugn blood concentrations were decreased .
false
drugn , drugn , and drugn : in patients treated with potent inducers of cyp3a4 ( i.e. , drugn , druga , and drugn ) , the clearance of drugb was significantly increased and drugn blood concentrations were decreased .
mechanism
drugn , drugn , and drugn : in patients treated with potent inducers of cyp3a4 ( i.e. , drugn , druga , and drugn ) , the clearance of drugn was significantly increased and drugb blood concentrations were decreased .
mechanism
drugn , drugn , and drugn : in patients treated with potent inducers of cyp3a4 ( i.e. , drugn , drugn , and druga ) , the clearance of drugb was significantly increased and drugn blood concentrations were decreased .
mechanism
drugn , drugn , and drugn : in patients treated with potent inducers of cyp3a4 ( i.e. , drugn , drugn , and druga ) , the clearance of drugn was significantly increased and drugb blood concentrations were decreased .
mechanism
drugn , drugn , and drugn : in patients treated with potent inducers of cyp3a4 ( i.e. , drugn , drugn , and drugn ) , the clearance of druga was significantly increased and drugb blood concentrations were decreased .
false
however , on the basis of available data , no dosage adjustment for druga is recommended for patients on these drugs.1,3 drugb : although no pharmacokinetic drug interaction between drugn and drugn has been observed , data from 2 small studies indicate that drugn may be associated with an increase in patient controlled administration of drugn .4,5 chemotherapy : tumor response to chemotherapy in the p 388 mouse leukemia model is not affected by drugn .
false
however , on the basis of available data , no dosage adjustment for druga is recommended for patients on these drugs.1,3 drugn : although no pharmacokinetic drug interaction between drugb and drugn has been observed , data from 2 small studies indicate that drugn may be associated with an increase in patient controlled administration of drugn .4,5 chemotherapy : tumor response to chemotherapy in the p 388 mouse leukemia model is not affected by drugn .
false
however , on the basis of available data , no dosage adjustment for druga is recommended for patients on these drugs.1,3 drugn : although no pharmacokinetic drug interaction between drugn and drugb has been observed , data from 2 small studies indicate that drugn may be associated with an increase in patient controlled administration of drugn .4,5 chemotherapy : tumor response to chemotherapy in the p 388 mouse leukemia model is not affected by drugn .
false
however , on the basis of available data , no dosage adjustment for druga is recommended for patients on these drugs.1,3 drugn : although no pharmacokinetic drug interaction between drugn and drugn has been observed , data from 2 small studies indicate that drugb may be associated with an increase in patient controlled administration of drugn .4,5 chemotherapy : tumor response to chemotherapy in the p 388 mouse leukemia model is not affected by drugn .
false
however , on the basis of available data , no dosage adjustment for druga is recommended for patients on these drugs.1,3 drugn : although no pharmacokinetic drug interaction between drugn and drugn has been observed , data from 2 small studies indicate that drugn may be associated with an increase in patient controlled administration of drugb .4,5 chemotherapy : tumor response to chemotherapy in the p 388 mouse leukemia model is not affected by drugn .
false
however , on the basis of available data , no dosage adjustment for druga is recommended for patients on these drugs.1,3 drugn : although no pharmacokinetic drug interaction between drugn and drugn has been observed , data from 2 small studies indicate that drugn may be associated with an increase in patient controlled administration of drugn .4,5 chemotherapy : tumor response to chemotherapy in the p 388 mouse leukemia model is not affected by drugb .
false
however , on the basis of available data , no dosage adjustment for drugn is recommended for patients on these drugs.1,3 druga : although no pharmacokinetic drug interaction between drugb and drugn has been observed , data from 2 small studies indicate that drugn may be associated with an increase in patient controlled administration of drugn .4,5 chemotherapy : tumor response to chemotherapy in the p 388 mouse leukemia model is not affected by drugn .
false
however , on the basis of available data , no dosage adjustment for drugn is recommended for patients on these drugs.1,3 druga : although no pharmacokinetic drug interaction between drugn and drugb has been observed , data from 2 small studies indicate that drugn may be associated with an increase in patient controlled administration of drugn .4,5 chemotherapy : tumor response to chemotherapy in the p 388 mouse leukemia model is not affected by drugn .
false
however , on the basis of available data , no dosage adjustment for drugn is recommended for patients on these drugs.1,3 druga : although no pharmacokinetic drug interaction between drugn and drugn has been observed , data from 2 small studies indicate that drugb may be associated with an increase in patient controlled administration of drugn .4,5 chemotherapy : tumor response to chemotherapy in the p 388 mouse leukemia model is not affected by drugn .
false
however , on the basis of available data , no dosage adjustment for drugn is recommended for patients on these drugs.1,3 druga : although no pharmacokinetic drug interaction between drugn and drugn has been observed , data from 2 small studies indicate that drugn may be associated with an increase in patient controlled administration of drugb .4,5 chemotherapy : tumor response to chemotherapy in the p 388 mouse leukemia model is not affected by drugn .
false
however , on the basis of available data , no dosage adjustment for drugn is recommended for patients on these drugs.1,3 druga : although no pharmacokinetic drug interaction between drugn and drugn has been observed , data from 2 small studies indicate that drugn may be associated with an increase in patient controlled administration of drugn .4,5 chemotherapy : tumor response to chemotherapy in the p 388 mouse leukemia model is not affected by drugb .
false
however , on the basis of available data , no dosage adjustment for drugn is recommended for patients on these drugs.1,3 drugn : although no pharmacokinetic drug interaction between druga and drugb has been observed , data from 2 small studies indicate that drugn may be associated with an increase in patient controlled administration of drugn .4,5 chemotherapy : tumor response to chemotherapy in the p 388 mouse leukemia model is not affected by drugn .
false
however , on the basis of available data , no dosage adjustment for drugn is recommended for patients on these drugs.1,3 drugn : although no pharmacokinetic drug interaction between druga and drugn has been observed , data from 2 small studies indicate that drugb may be associated with an increase in patient controlled administration of drugn .4,5 chemotherapy : tumor response to chemotherapy in the p 388 mouse leukemia model is not affected by drugn .
false
however , on the basis of available data , no dosage adjustment for drugn is recommended for patients on these drugs.1,3 drugn : although no pharmacokinetic drug interaction between druga and drugn has been observed , data from 2 small studies indicate that drugn may be associated with an increase in patient controlled administration of drugb .4,5 chemotherapy : tumor response to chemotherapy in the p 388 mouse leukemia model is not affected by drugn .
false
however , on the basis of available data , no dosage adjustment for drugn is recommended for patients on these drugs.1,3 drugn : although no pharmacokinetic drug interaction between druga and drugn has been observed , data from 2 small studies indicate that drugn may be associated with an increase in patient controlled administration of drugn .4,5 chemotherapy : tumor response to chemotherapy in the p 388 mouse leukemia model is not affected by drugb .
false
however , on the basis of available data , no dosage adjustment for drugn is recommended for patients on these drugs.1,3 drugn : although no pharmacokinetic drug interaction between drugn and druga has been observed , data from 2 small studies indicate that drugb may be associated with an increase in patient controlled administration of drugn .4,5 chemotherapy : tumor response to chemotherapy in the p 388 mouse leukemia model is not affected by drugn .
false
however , on the basis of available data , no dosage adjustment for drugn is recommended for patients on these drugs.1,3 drugn : although no pharmacokinetic drug interaction between drugn and druga has been observed , data from 2 small studies indicate that drugn may be associated with an increase in patient controlled administration of drugb .4,5 chemotherapy : tumor response to chemotherapy in the p 388 mouse leukemia model is not affected by drugn .
false
however , on the basis of available data , no dosage adjustment for drugn is recommended for patients on these drugs.1,3 drugn : although no pharmacokinetic drug interaction between drugn and druga has been observed , data from 2 small studies indicate that drugn may be associated with an increase in patient controlled administration of drugn .4,5 chemotherapy : tumor response to chemotherapy in the p 388 mouse leukemia model is not affected by drugb .
false
however , on the basis of available data , no dosage adjustment for drugn is recommended for patients on these drugs.1,3 drugn : although no pharmacokinetic drug interaction between drugn and drugn has been observed , data from 2 small studies indicate that druga may be associated with an increase in patient controlled administration of drugb .4,5 chemotherapy : tumor response to chemotherapy in the p 388 mouse leukemia model is not affected by drugn .
effect
however , on the basis of available data , no dosage adjustment for drugn is recommended for patients on these drugs.1,3 drugn : although no pharmacokinetic drug interaction between drugn and drugn has been observed , data from 2 small studies indicate that druga may be associated with an increase in patient controlled administration of drugn .4,5 chemotherapy : tumor response to chemotherapy in the p 388 mouse leukemia model is not affected by drugb .
false
however , on the basis of available data , no dosage adjustment for drugn is recommended for patients on these drugs.1,3 drugn : although no pharmacokinetic drug interaction between drugn and drugn has been observed , data from 2 small studies indicate that drugn may be associated with an increase in patient controlled administration of druga .4,5 chemotherapy : tumor response to chemotherapy in the p 388 mouse leukemia model is not affected by drugb .
false
in humans , druga , drugb , and drugn do not affect the pharmacokinetics of drugn .
false
in humans , druga , drugn , and drugb do not affect the pharmacokinetics of drugn .
false
in humans , druga , drugn , and drugn do not affect the pharmacokinetics of drugb .
false
in humans , drugn , druga , and drugb do not affect the pharmacokinetics of drugn .
false
in humans , drugn , druga , and drugn do not affect the pharmacokinetics of drugb .
false
in humans , drugn , drugn , and druga do not affect the pharmacokinetics of drugb .
false
druga did not increase blood levels of high-dose drugb .
false
the concomitant use of other druga including drugb , drugn , drugn , general drugn , drugn , other drugn , drugn , drugn , and drugn may produce additive cns depressant effects .
false
the concomitant use of other druga including drugn , drugb , drugn , general drugn , drugn , other drugn , drugn , drugn , and drugn may produce additive cns depressant effects .
false
the concomitant use of other druga including drugn , drugn , drugb , general drugn , drugn , other drugn , drugn , drugn , and drugn may produce additive cns depressant effects .
false
the concomitant use of other druga including drugn , drugn , drugn , general drugb , drugn , other drugn , drugn , drugn , and drugn may produce additive cns depressant effects .
false
the concomitant use of other druga including drugn , drugn , drugn , general drugn , drugb , other drugn , drugn , drugn , and drugn may produce additive cns depressant effects .
false
the concomitant use of other druga including drugn , drugn , drugn , general drugn , drugn , other drugb , drugn , drugn , and drugn may produce additive cns depressant effects .
false
the concomitant use of other druga including drugn , drugn , drugn , general drugn , drugn , other drugn , drugb , drugn , and drugn may produce additive cns depressant effects .
false
the concomitant use of other druga including drugn , drugn , drugn , general drugn , drugn , other drugn , drugn , drugb , and drugn may produce additive cns depressant effects .
false
the concomitant use of other druga including drugn , drugn , drugn , general drugn , drugn , other drugn , drugn , drugn , and drugb may produce additive cns depressant effects .
false
the concomitant use of other drugn including druga , drugb , drugn , general drugn , drugn , other drugn , drugn , drugn , and drugn may produce additive cns depressant effects .
false
the concomitant use of other drugn including druga , drugn , drugb , general drugn , drugn , other drugn , drugn , drugn , and drugn may produce additive cns depressant effects .
false
the concomitant use of other drugn including druga , drugn , drugn , general drugb , drugn , other drugn , drugn , drugn , and drugn may produce additive cns depressant effects .
false
the concomitant use of other drugn including druga , drugn , drugn , general drugn , drugb , other drugn , drugn , drugn , and drugn may produce additive cns depressant effects .
false
the concomitant use of other drugn including druga , drugn , drugn , general drugn , drugn , other drugb , drugn , drugn , and drugn may produce additive cns depressant effects .
false
the concomitant use of other drugn including druga , drugn , drugn , general drugn , drugn , other drugn , drugb , drugn , and drugn may produce additive cns depressant effects .
false
the concomitant use of other drugn including druga , drugn , drugn , general drugn , drugn , other drugn , drugn , drugb , and drugn may produce additive cns depressant effects .
false
the concomitant use of other drugn including druga , drugn , drugn , general drugn , drugn , other drugn , drugn , drugn , and drugb may produce additive cns depressant effects .
false
the concomitant use of other drugn including drugn , druga , drugb , general drugn , drugn , other drugn , drugn , drugn , and drugn may produce additive cns depressant effects .
false
the concomitant use of other drugn including drugn , druga , drugn , general drugb , drugn , other drugn , drugn , drugn , and drugn may produce additive cns depressant effects .
false
the concomitant use of other drugn including drugn , druga , drugn , general drugn , drugb , other drugn , drugn , drugn , and drugn may produce additive cns depressant effects .
false
the concomitant use of other drugn including drugn , druga , drugn , general drugn , drugn , other drugb , drugn , drugn , and drugn may produce additive cns depressant effects .
false
the concomitant use of other drugn including drugn , druga , drugn , general drugn , drugn , other drugn , drugb , drugn , and drugn may produce additive cns depressant effects .
false
the concomitant use of other drugn including drugn , druga , drugn , general drugn , drugn , other drugn , drugn , drugb , and drugn may produce additive cns depressant effects .
false
the concomitant use of other drugn including drugn , druga , drugn , general drugn , drugn , other drugn , drugn , drugn , and drugb may produce additive cns depressant effects .
false
the concomitant use of other drugn including drugn , drugn , druga , general drugb , drugn , other drugn , drugn , drugn , and drugn may produce additive cns depressant effects .
false
the concomitant use of other drugn including drugn , drugn , druga , general drugn , drugb , other drugn , drugn , drugn , and drugn may produce additive cns depressant effects .
false
the concomitant use of other drugn including drugn , drugn , druga , general drugn , drugn , other drugb , drugn , drugn , and drugn may produce additive cns depressant effects .
false
the concomitant use of other drugn including drugn , drugn , druga , general drugn , drugn , other drugn , drugb , drugn , and drugn may produce additive cns depressant effects .
false
the concomitant use of other drugn including drugn , drugn , druga , general drugn , drugn , other drugn , drugn , drugb , and drugn may produce additive cns depressant effects .
false
the concomitant use of other drugn including drugn , drugn , druga , general drugn , drugn , other drugn , drugn , drugn , and drugb may produce additive cns depressant effects .
false
the concomitant use of other drugn including drugn , drugn , drugn , general druga , drugb , other drugn , drugn , drugn , and drugn may produce additive cns depressant effects .
false
the concomitant use of other drugn including drugn , drugn , drugn , general druga , drugn , other drugb , drugn , drugn , and drugn may produce additive cns depressant effects .
false
the concomitant use of other drugn including drugn , drugn , drugn , general druga , drugn , other drugn , drugb , drugn , and drugn may produce additive cns depressant effects .
false
the concomitant use of other drugn including drugn , drugn , drugn , general druga , drugn , other drugn , drugn , drugb , and drugn may produce additive cns depressant effects .
false
the concomitant use of other drugn including drugn , drugn , drugn , general druga , drugn , other drugn , drugn , drugn , and drugb may produce additive cns depressant effects .
false
the concomitant use of other drugn including drugn , drugn , drugn , general drugn , druga , other drugb , drugn , drugn , and drugn may produce additive cns depressant effects .
false
the concomitant use of other drugn including drugn , drugn , drugn , general drugn , druga , other drugn , drugb , drugn , and drugn may produce additive cns depressant effects .
false
the concomitant use of other drugn including drugn , drugn , drugn , general drugn , druga , other drugn , drugn , drugb , and drugn may produce additive cns depressant effects .
false
the concomitant use of other drugn including drugn , drugn , drugn , general drugn , druga , other drugn , drugn , drugn , and drugb may produce additive cns depressant effects .
false
the concomitant use of other drugn including drugn , drugn , drugn , general drugn , drugn , other druga , drugb , drugn , and drugn may produce additive cns depressant effects .
false
the concomitant use of other drugn including drugn , drugn , drugn , general drugn , drugn , other druga , drugn , drugb , and drugn may produce additive cns depressant effects .
false
the concomitant use of other drugn including drugn , drugn , drugn , general drugn , drugn , other druga , drugn , drugn , and drugb may produce additive cns depressant effects .
false
the concomitant use of other drugn including drugn , drugn , drugn , general drugn , drugn , other drugn , druga , drugb , and drugn may produce additive cns depressant effects .
false
the concomitant use of other drugn including drugn , drugn , drugn , general drugn , drugn , other drugn , druga , drugn , and drugb may produce additive cns depressant effects .
false
the concomitant use of other drugn including drugn , drugn , drugn , general drugn , drugn , other drugn , drugn , druga , and drugb may produce additive cns depressant effects .
false
druga or other medications with anticholinergic activity when used concurrently with drugb may result in increased risk of urinary retention and/or severe constipation , which may lead to paralytic ileus .
effect
it has been reported that the incidence of bradycardia was increased when druga was combined with drugb for induction of anesthesia .
effect
in addition , cns toxicity has been reported ( confusion , disorientation , respiratory depression , apnea , seizures ) following coadministration of druga with drugb ;
effect
patients studied in clinical trials of druga were routinely treated with drugb and drugn .
false
patients studied in clinical trials of druga were routinely treated with drugn and drugb .
false
patients studied in clinical trials of drugn were routinely treated with druga and drugb .
false
druga ( such as drugb and drugn ) and drugs that alter platelet function ( such as drugn , drugn , and gp iib/iiia inhibitors ) may increase the risk of bleeding if administered prior to , during , or after drugn therapy .
false
druga ( such as drugn and drugb ) and drugs that alter platelet function ( such as drugn , drugn , and gp iib/iiia inhibitors ) may increase the risk of bleeding if administered prior to , during , or after drugn therapy .
false
druga ( such as drugn and drugn ) and drugs that alter platelet function ( such as drugb , drugn , and gp iib/iiia inhibitors ) may increase the risk of bleeding if administered prior to , during , or after drugn therapy .
false
druga ( such as drugn and drugn ) and drugs that alter platelet function ( such as drugn , drugb , and gp iib/iiia inhibitors ) may increase the risk of bleeding if administered prior to , during , or after drugn therapy .
false
druga ( such as drugn and drugn ) and drugs that alter platelet function ( such as drugn , drugn , and gp iib/iiia inhibitors ) may increase the risk of bleeding if administered prior to , during , or after drugb therapy .
effect
drugn ( such as druga and drugb ) and drugs that alter platelet function ( such as drugn , drugn , and gp iib/iiia inhibitors ) may increase the risk of bleeding if administered prior to , during , or after drugn therapy .
false
drugn ( such as druga and drugn ) and drugs that alter platelet function ( such as drugb , drugn , and gp iib/iiia inhibitors ) may increase the risk of bleeding if administered prior to , during , or after drugn therapy .
false
drugn ( such as druga and drugn ) and drugs that alter platelet function ( such as drugn , drugb , and gp iib/iiia inhibitors ) may increase the risk of bleeding if administered prior to , during , or after drugn therapy .
false
drugn ( such as druga and drugn ) and drugs that alter platelet function ( such as drugn , drugn , and gp iib/iiia inhibitors ) may increase the risk of bleeding if administered prior to , during , or after drugb therapy .
effect
drugn ( such as drugn and druga ) and drugs that alter platelet function ( such as drugb , drugn , and gp iib/iiia inhibitors ) may increase the risk of bleeding if administered prior to , during , or after drugn therapy .
false
drugn ( such as drugn and druga ) and drugs that alter platelet function ( such as drugn , drugb , and gp iib/iiia inhibitors ) may increase the risk of bleeding if administered prior to , during , or after drugn therapy .
false
drugn ( such as drugn and druga ) and drugs that alter platelet function ( such as drugn , drugn , and gp iib/iiia inhibitors ) may increase the risk of bleeding if administered prior to , during , or after drugb therapy .
effect
drugn ( such as drugn and drugn ) and drugs that alter platelet function ( such as druga , drugb , and gp iib/iiia inhibitors ) may increase the risk of bleeding if administered prior to , during , or after drugn therapy .
false
drugn ( such as drugn and drugn ) and drugs that alter platelet function ( such as druga , drugn , and gp iib/iiia inhibitors ) may increase the risk of bleeding if administered prior to , during , or after drugb therapy .
effect
drugn ( such as drugn and drugn ) and drugs that alter platelet function ( such as drugn , druga , and gp iib/iiia inhibitors ) may increase the risk of bleeding if administered prior to , during , or after drugb therapy .
effect
catecholamine-depleting drugs ( e.g. , druga ) may have an additive effect when given with drugb .
effect
drug-drug interactions effect of druga ( drugb ) on the metabolism of other drugs : drugn is primarily metabolized through hydrolysis by esterases .
false
drug-drug interactions effect of druga ( drugn ) on the metabolism of other drugs : drugb is primarily metabolized through hydrolysis by esterases .
false
drug-drug interactions effect of drugn ( druga ) on the metabolism of other drugs : drugb is primarily metabolized through hydrolysis by esterases .
false
no pharmacokinetic interaction was observed between druga and drugb , drugn , drugn , or drugn in studies in healthy volunteers .
false
no pharmacokinetic interaction was observed between druga and drugn , drugb , drugn , or drugn in studies in healthy volunteers .
false
no pharmacokinetic interaction was observed between druga and drugn , drugn , drugb , or drugn in studies in healthy volunteers .
false
no pharmacokinetic interaction was observed between druga and drugn , drugn , drugn , or drugb in studies in healthy volunteers .
false
no pharmacokinetic interaction was observed between drugn and druga , drugb , drugn , or drugn in studies in healthy volunteers .
false
no pharmacokinetic interaction was observed between drugn and druga , drugn , drugb , or drugn in studies in healthy volunteers .
false
no pharmacokinetic interaction was observed between drugn and druga , drugn , drugn , or drugb in studies in healthy volunteers .
false
no pharmacokinetic interaction was observed between drugn and drugn , druga , drugb , or drugn in studies in healthy volunteers .
false
no pharmacokinetic interaction was observed between drugn and drugn , druga , drugn , or drugb in studies in healthy volunteers .
false
no pharmacokinetic interaction was observed between drugn and drugn , drugn , druga , or drugb in studies in healthy volunteers .
false
the elevation of prothrombin time induced by druga is not affected by administration of drugb .
false
effect of other drugs on the metabolism of druga : drugs that induce or inhibit cyp450 metabolism are not expected to alter the metabolism of drugb .
false
single dose pharmacokinetic studies demonstrated that the metabolism of druga is not significantly affected by concurrent administration of drugb , drugn , drugn , or drugn .
false
single dose pharmacokinetic studies demonstrated that the metabolism of druga is not significantly affected by concurrent administration of drugn , drugb , drugn , or drugn .
false
single dose pharmacokinetic studies demonstrated that the metabolism of druga is not significantly affected by concurrent administration of drugn , drugn , drugb , or drugn .
false
single dose pharmacokinetic studies demonstrated that the metabolism of druga is not significantly affected by concurrent administration of drugn , drugn , drugn , or drugb .
false
single dose pharmacokinetic studies demonstrated that the metabolism of drugn is not significantly affected by concurrent administration of druga , drugb , drugn , or drugn .
false
single dose pharmacokinetic studies demonstrated that the metabolism of drugn is not significantly affected by concurrent administration of druga , drugn , drugb , or drugn .
false
single dose pharmacokinetic studies demonstrated that the metabolism of drugn is not significantly affected by concurrent administration of druga , drugn , drugn , or drugb .
false
single dose pharmacokinetic studies demonstrated that the metabolism of drugn is not significantly affected by concurrent administration of drugn , druga , drugb , or drugn .
false
single dose pharmacokinetic studies demonstrated that the metabolism of drugn is not significantly affected by concurrent administration of drugn , druga , drugn , or drugb .
false
single dose pharmacokinetic studies demonstrated that the metabolism of drugn is not significantly affected by concurrent administration of drugn , drugn , druga , or drugb .
false
population pk analysis with a database of 625 patients showed that the pharmacokinetics of druga were not influenced by commonly prescribed medications such as drugb ( n=77 ) , drugn ( n=72 ) , drugn ( n=75 ) , drugn ( n=21 ) , drugn ( n=79 ) , drugn ( n=70 ) , drugn ( n=177 ) , drugn ( n=35 ) , and drugn ( n=15 ) .
false
population pk analysis with a database of 625 patients showed that the pharmacokinetics of druga were not influenced by commonly prescribed medications such as drugn ( n=77 ) , drugb ( n=72 ) , drugn ( n=75 ) , drugn ( n=21 ) , drugn ( n=79 ) , drugn ( n=70 ) , drugn ( n=177 ) , drugn ( n=35 ) , and drugn ( n=15 ) .
false
population pk analysis with a database of 625 patients showed that the pharmacokinetics of druga were not influenced by commonly prescribed medications such as drugn ( n=77 ) , drugn ( n=72 ) , drugb ( n=75 ) , drugn ( n=21 ) , drugn ( n=79 ) , drugn ( n=70 ) , drugn ( n=177 ) , drugn ( n=35 ) , and drugn ( n=15 ) .
false
population pk analysis with a database of 625 patients showed that the pharmacokinetics of druga were not influenced by commonly prescribed medications such as drugn ( n=77 ) , drugn ( n=72 ) , drugn ( n=75 ) , drugb ( n=21 ) , drugn ( n=79 ) , drugn ( n=70 ) , drugn ( n=177 ) , drugn ( n=35 ) , and drugn ( n=15 ) .
false
population pk analysis with a database of 625 patients showed that the pharmacokinetics of druga were not influenced by commonly prescribed medications such as drugn ( n=77 ) , drugn ( n=72 ) , drugn ( n=75 ) , drugn ( n=21 ) , drugb ( n=79 ) , drugn ( n=70 ) , drugn ( n=177 ) , drugn ( n=35 ) , and drugn ( n=15 ) .
false
population pk analysis with a database of 625 patients showed that the pharmacokinetics of druga were not influenced by commonly prescribed medications such as drugn ( n=77 ) , drugn ( n=72 ) , drugn ( n=75 ) , drugn ( n=21 ) , drugn ( n=79 ) , drugb ( n=70 ) , drugn ( n=177 ) , drugn ( n=35 ) , and drugn ( n=15 ) .
false
population pk analysis with a database of 625 patients showed that the pharmacokinetics of druga were not influenced by commonly prescribed medications such as drugn ( n=77 ) , drugn ( n=72 ) , drugn ( n=75 ) , drugn ( n=21 ) , drugn ( n=79 ) , drugn ( n=70 ) , drugb ( n=177 ) , drugn ( n=35 ) , and drugn ( n=15 ) .
false
population pk analysis with a database of 625 patients showed that the pharmacokinetics of druga were not influenced by commonly prescribed medications such as drugn ( n=77 ) , drugn ( n=72 ) , drugn ( n=75 ) , drugn ( n=21 ) , drugn ( n=79 ) , drugn ( n=70 ) , drugn ( n=177 ) , drugb ( n=35 ) , and drugn ( n=15 ) .
false
population pk analysis with a database of 625 patients showed that the pharmacokinetics of druga were not influenced by commonly prescribed medications such as drugn ( n=77 ) , drugn ( n=72 ) , drugn ( n=75 ) , drugn ( n=21 ) , drugn ( n=79 ) , drugn ( n=70 ) , drugn ( n=177 ) , drugn ( n=35 ) , and drugb ( n=15 ) .
false
population pk analysis with a database of 625 patients showed that the pharmacokinetics of drugn were not influenced by commonly prescribed medications such as druga ( n=77 ) , drugb ( n=72 ) , drugn ( n=75 ) , drugn ( n=21 ) , drugn ( n=79 ) , drugn ( n=70 ) , drugn ( n=177 ) , drugn ( n=35 ) , and drugn ( n=15 ) .
false
population pk analysis with a database of 625 patients showed that the pharmacokinetics of drugn were not influenced by commonly prescribed medications such as druga ( n=77 ) , drugn ( n=72 ) , drugb ( n=75 ) , drugn ( n=21 ) , drugn ( n=79 ) , drugn ( n=70 ) , drugn ( n=177 ) , drugn ( n=35 ) , and drugn ( n=15 ) .
false
population pk analysis with a database of 625 patients showed that the pharmacokinetics of drugn were not influenced by commonly prescribed medications such as druga ( n=77 ) , drugn ( n=72 ) , drugn ( n=75 ) , drugb ( n=21 ) , drugn ( n=79 ) , drugn ( n=70 ) , drugn ( n=177 ) , drugn ( n=35 ) , and drugn ( n=15 ) .
false
population pk analysis with a database of 625 patients showed that the pharmacokinetics of drugn were not influenced by commonly prescribed medications such as druga ( n=77 ) , drugn ( n=72 ) , drugn ( n=75 ) , drugn ( n=21 ) , drugb ( n=79 ) , drugn ( n=70 ) , drugn ( n=177 ) , drugn ( n=35 ) , and drugn ( n=15 ) .
false
population pk analysis with a database of 625 patients showed that the pharmacokinetics of drugn were not influenced by commonly prescribed medications such as druga ( n=77 ) , drugn ( n=72 ) , drugn ( n=75 ) , drugn ( n=21 ) , drugn ( n=79 ) , drugb ( n=70 ) , drugn ( n=177 ) , drugn ( n=35 ) , and drugn ( n=15 ) .
false
population pk analysis with a database of 625 patients showed that the pharmacokinetics of drugn were not influenced by commonly prescribed medications such as druga ( n=77 ) , drugn ( n=72 ) , drugn ( n=75 ) , drugn ( n=21 ) , drugn ( n=79 ) , drugn ( n=70 ) , drugb ( n=177 ) , drugn ( n=35 ) , and drugn ( n=15 ) .
false
population pk analysis with a database of 625 patients showed that the pharmacokinetics of drugn were not influenced by commonly prescribed medications such as druga ( n=77 ) , drugn ( n=72 ) , drugn ( n=75 ) , drugn ( n=21 ) , drugn ( n=79 ) , drugn ( n=70 ) , drugn ( n=177 ) , drugb ( n=35 ) , and drugn ( n=15 ) .
false
population pk analysis with a database of 625 patients showed that the pharmacokinetics of drugn were not influenced by commonly prescribed medications such as druga ( n=77 ) , drugn ( n=72 ) , drugn ( n=75 ) , drugn ( n=21 ) , drugn ( n=79 ) , drugn ( n=70 ) , drugn ( n=177 ) , drugn ( n=35 ) , and drugb ( n=15 ) .
false
population pk analysis with a database of 625 patients showed that the pharmacokinetics of drugn were not influenced by commonly prescribed medications such as drugn ( n=77 ) , druga ( n=72 ) , drugb ( n=75 ) , drugn ( n=21 ) , drugn ( n=79 ) , drugn ( n=70 ) , drugn ( n=177 ) , drugn ( n=35 ) , and drugn ( n=15 ) .
false
population pk analysis with a database of 625 patients showed that the pharmacokinetics of drugn were not influenced by commonly prescribed medications such as drugn ( n=77 ) , druga ( n=72 ) , drugn ( n=75 ) , drugb ( n=21 ) , drugn ( n=79 ) , drugn ( n=70 ) , drugn ( n=177 ) , drugn ( n=35 ) , and drugn ( n=15 ) .
false
population pk analysis with a database of 625 patients showed that the pharmacokinetics of drugn were not influenced by commonly prescribed medications such as drugn ( n=77 ) , druga ( n=72 ) , drugn ( n=75 ) , drugn ( n=21 ) , drugb ( n=79 ) , drugn ( n=70 ) , drugn ( n=177 ) , drugn ( n=35 ) , and drugn ( n=15 ) .
false
population pk analysis with a database of 625 patients showed that the pharmacokinetics of drugn were not influenced by commonly prescribed medications such as drugn ( n=77 ) , druga ( n=72 ) , drugn ( n=75 ) , drugn ( n=21 ) , drugn ( n=79 ) , drugb ( n=70 ) , drugn ( n=177 ) , drugn ( n=35 ) , and drugn ( n=15 ) .
false
population pk analysis with a database of 625 patients showed that the pharmacokinetics of drugn were not influenced by commonly prescribed medications such as drugn ( n=77 ) , druga ( n=72 ) , drugn ( n=75 ) , drugn ( n=21 ) , drugn ( n=79 ) , drugn ( n=70 ) , drugb ( n=177 ) , drugn ( n=35 ) , and drugn ( n=15 ) .
false
population pk analysis with a database of 625 patients showed that the pharmacokinetics of drugn were not influenced by commonly prescribed medications such as drugn ( n=77 ) , druga ( n=72 ) , drugn ( n=75 ) , drugn ( n=21 ) , drugn ( n=79 ) , drugn ( n=70 ) , drugn ( n=177 ) , drugb ( n=35 ) , and drugn ( n=15 ) .
false
population pk analysis with a database of 625 patients showed that the pharmacokinetics of drugn were not influenced by commonly prescribed medications such as drugn ( n=77 ) , druga ( n=72 ) , drugn ( n=75 ) , drugn ( n=21 ) , drugn ( n=79 ) , drugn ( n=70 ) , drugn ( n=177 ) , drugn ( n=35 ) , and drugb ( n=15 ) .
false
population pk analysis with a database of 625 patients showed that the pharmacokinetics of drugn were not influenced by commonly prescribed medications such as drugn ( n=77 ) , drugn ( n=72 ) , druga ( n=75 ) , drugb ( n=21 ) , drugn ( n=79 ) , drugn ( n=70 ) , drugn ( n=177 ) , drugn ( n=35 ) , and drugn ( n=15 ) .
false
population pk analysis with a database of 625 patients showed that the pharmacokinetics of drugn were not influenced by commonly prescribed medications such as drugn ( n=77 ) , drugn ( n=72 ) , druga ( n=75 ) , drugn ( n=21 ) , drugb ( n=79 ) , drugn ( n=70 ) , drugn ( n=177 ) , drugn ( n=35 ) , and drugn ( n=15 ) .
false
population pk analysis with a database of 625 patients showed that the pharmacokinetics of drugn were not influenced by commonly prescribed medications such as drugn ( n=77 ) , drugn ( n=72 ) , druga ( n=75 ) , drugn ( n=21 ) , drugn ( n=79 ) , drugb ( n=70 ) , drugn ( n=177 ) , drugn ( n=35 ) , and drugn ( n=15 ) .
false
population pk analysis with a database of 625 patients showed that the pharmacokinetics of drugn were not influenced by commonly prescribed medications such as drugn ( n=77 ) , drugn ( n=72 ) , druga ( n=75 ) , drugn ( n=21 ) , drugn ( n=79 ) , drugn ( n=70 ) , drugb ( n=177 ) , drugn ( n=35 ) , and drugn ( n=15 ) .
false
population pk analysis with a database of 625 patients showed that the pharmacokinetics of drugn were not influenced by commonly prescribed medications such as drugn ( n=77 ) , drugn ( n=72 ) , druga ( n=75 ) , drugn ( n=21 ) , drugn ( n=79 ) , drugn ( n=70 ) , drugn ( n=177 ) , drugb ( n=35 ) , and drugn ( n=15 ) .
false
population pk analysis with a database of 625 patients showed that the pharmacokinetics of drugn were not influenced by commonly prescribed medications such as drugn ( n=77 ) , drugn ( n=72 ) , druga ( n=75 ) , drugn ( n=21 ) , drugn ( n=79 ) , drugn ( n=70 ) , drugn ( n=177 ) , drugn ( n=35 ) , and drugb ( n=15 ) .
false
population pk analysis with a database of 625 patients showed that the pharmacokinetics of drugn were not influenced by commonly prescribed medications such as drugn ( n=77 ) , drugn ( n=72 ) , drugn ( n=75 ) , druga ( n=21 ) , drugb ( n=79 ) , drugn ( n=70 ) , drugn ( n=177 ) , drugn ( n=35 ) , and drugn ( n=15 ) .
false
population pk analysis with a database of 625 patients showed that the pharmacokinetics of drugn were not influenced by commonly prescribed medications such as drugn ( n=77 ) , drugn ( n=72 ) , drugn ( n=75 ) , druga ( n=21 ) , drugn ( n=79 ) , drugb ( n=70 ) , drugn ( n=177 ) , drugn ( n=35 ) , and drugn ( n=15 ) .
false
population pk analysis with a database of 625 patients showed that the pharmacokinetics of drugn were not influenced by commonly prescribed medications such as drugn ( n=77 ) , drugn ( n=72 ) , drugn ( n=75 ) , druga ( n=21 ) , drugn ( n=79 ) , drugn ( n=70 ) , drugb ( n=177 ) , drugn ( n=35 ) , and drugn ( n=15 ) .
false
population pk analysis with a database of 625 patients showed that the pharmacokinetics of drugn were not influenced by commonly prescribed medications such as drugn ( n=77 ) , drugn ( n=72 ) , drugn ( n=75 ) , druga ( n=21 ) , drugn ( n=79 ) , drugn ( n=70 ) , drugn ( n=177 ) , drugb ( n=35 ) , and drugn ( n=15 ) .
false
population pk analysis with a database of 625 patients showed that the pharmacokinetics of drugn were not influenced by commonly prescribed medications such as drugn ( n=77 ) , drugn ( n=72 ) , drugn ( n=75 ) , druga ( n=21 ) , drugn ( n=79 ) , drugn ( n=70 ) , drugn ( n=177 ) , drugn ( n=35 ) , and drugb ( n=15 ) .
false
population pk analysis with a database of 625 patients showed that the pharmacokinetics of drugn were not influenced by commonly prescribed medications such as drugn ( n=77 ) , drugn ( n=72 ) , drugn ( n=75 ) , drugn ( n=21 ) , druga ( n=79 ) , drugb ( n=70 ) , drugn ( n=177 ) , drugn ( n=35 ) , and drugn ( n=15 ) .
false
population pk analysis with a database of 625 patients showed that the pharmacokinetics of drugn were not influenced by commonly prescribed medications such as drugn ( n=77 ) , drugn ( n=72 ) , drugn ( n=75 ) , drugn ( n=21 ) , druga ( n=79 ) , drugn ( n=70 ) , drugb ( n=177 ) , drugn ( n=35 ) , and drugn ( n=15 ) .
false
population pk analysis with a database of 625 patients showed that the pharmacokinetics of drugn were not influenced by commonly prescribed medications such as drugn ( n=77 ) , drugn ( n=72 ) , drugn ( n=75 ) , drugn ( n=21 ) , druga ( n=79 ) , drugn ( n=70 ) , drugn ( n=177 ) , drugb ( n=35 ) , and drugn ( n=15 ) .
false
population pk analysis with a database of 625 patients showed that the pharmacokinetics of drugn were not influenced by commonly prescribed medications such as drugn ( n=77 ) , drugn ( n=72 ) , drugn ( n=75 ) , drugn ( n=21 ) , druga ( n=79 ) , drugn ( n=70 ) , drugn ( n=177 ) , drugn ( n=35 ) , and drugb ( n=15 ) .
false
population pk analysis with a database of 625 patients showed that the pharmacokinetics of drugn were not influenced by commonly prescribed medications such as drugn ( n=77 ) , drugn ( n=72 ) , drugn ( n=75 ) , drugn ( n=21 ) , drugn ( n=79 ) , druga ( n=70 ) , drugb ( n=177 ) , drugn ( n=35 ) , and drugn ( n=15 ) .
false
population pk analysis with a database of 625 patients showed that the pharmacokinetics of drugn were not influenced by commonly prescribed medications such as drugn ( n=77 ) , drugn ( n=72 ) , drugn ( n=75 ) , drugn ( n=21 ) , drugn ( n=79 ) , druga ( n=70 ) , drugn ( n=177 ) , drugb ( n=35 ) , and drugn ( n=15 ) .
false
population pk analysis with a database of 625 patients showed that the pharmacokinetics of drugn were not influenced by commonly prescribed medications such as drugn ( n=77 ) , drugn ( n=72 ) , drugn ( n=75 ) , drugn ( n=21 ) , drugn ( n=79 ) , druga ( n=70 ) , drugn ( n=177 ) , drugn ( n=35 ) , and drugb ( n=15 ) .
false
population pk analysis with a database of 625 patients showed that the pharmacokinetics of drugn were not influenced by commonly prescribed medications such as drugn ( n=77 ) , drugn ( n=72 ) , drugn ( n=75 ) , drugn ( n=21 ) , drugn ( n=79 ) , drugn ( n=70 ) , druga ( n=177 ) , drugb ( n=35 ) , and drugn ( n=15 ) .
false
population pk analysis with a database of 625 patients showed that the pharmacokinetics of drugn were not influenced by commonly prescribed medications such as drugn ( n=77 ) , drugn ( n=72 ) , drugn ( n=75 ) , drugn ( n=21 ) , drugn ( n=79 ) , drugn ( n=70 ) , druga ( n=177 ) , drugn ( n=35 ) , and drugb ( n=15 ) .
false
population pk analysis with a database of 625 patients showed that the pharmacokinetics of drugn were not influenced by commonly prescribed medications such as drugn ( n=77 ) , drugn ( n=72 ) , drugn ( n=75 ) , drugn ( n=21 ) , drugn ( n=79 ) , drugn ( n=70 ) , drugn ( n=177 ) , druga ( n=35 ) , and drugb ( n=15 ) .
false
use with druga : because of their mechanism of action , drugb have the potential to interfere with the activity of drugn .
false
use with druga : because of their mechanism of action , drugn have the potential to interfere with the activity of drugb .
false
use with drugn : because of their mechanism of action , druga have the potential to interfere with the activity of drugb .
int
use with druga and other drugb : a synergistic effect may be expected when drugn are given concurrently with drugn , similar drugn or drugn such as drugn .
false
use with druga and other drugn : a synergistic effect may be expected when drugb are given concurrently with drugn , similar drugn or drugn such as drugn .
false
use with druga and other drugn : a synergistic effect may be expected when drugn are given concurrently with drugb , similar drugn or drugn such as drugn .
false
use with druga and other drugn : a synergistic effect may be expected when drugn are given concurrently with drugn , similar drugb or drugn such as drugn .
false
use with druga and other drugn : a synergistic effect may be expected when drugn are given concurrently with drugn , similar drugn or drugb such as drugn .
false
use with druga and other drugn : a synergistic effect may be expected when drugn are given concurrently with drugn , similar drugn or drugn such as drugb .
false
use with drugn and other druga : a synergistic effect may be expected when drugb are given concurrently with drugn , similar drugn or drugn such as drugn .
false
use with drugn and other druga : a synergistic effect may be expected when drugn are given concurrently with drugb , similar drugn or drugn such as drugn .
false
use with drugn and other druga : a synergistic effect may be expected when drugn are given concurrently with drugn , similar drugb or drugn such as drugn .
false
use with drugn and other druga : a synergistic effect may be expected when drugn are given concurrently with drugn , similar drugn or drugb such as drugn .
false
use with drugn and other druga : a synergistic effect may be expected when drugn are given concurrently with drugn , similar drugn or drugn such as drugb .
false
use with drugn and other drugn : a synergistic effect may be expected when druga are given concurrently with drugb , similar drugn or drugn such as drugn .
effect
use with drugn and other drugn : a synergistic effect may be expected when druga are given concurrently with drugn , similar drugb or drugn such as drugn .
effect
use with drugn and other drugn : a synergistic effect may be expected when druga are given concurrently with drugn , similar drugn or drugb such as drugn .
effect
use with drugn and other drugn : a synergistic effect may be expected when druga are given concurrently with drugn , similar drugn or drugn such as drugb .
effect
use with drugn and other drugn : a synergistic effect may be expected when drugn are given concurrently with druga , similar drugb or drugn such as drugn .
false
use with drugn and other drugn : a synergistic effect may be expected when drugn are given concurrently with druga , similar drugn or drugb such as drugn .
false
use with drugn and other drugn : a synergistic effect may be expected when drugn are given concurrently with druga , similar drugn or drugn such as drugb .
false
use with drugn and other drugn : a synergistic effect may be expected when drugn are given concurrently with drugn , similar druga or drugb such as drugn .
false
use with drugn and other drugn : a synergistic effect may be expected when drugn are given concurrently with drugn , similar druga or drugn such as drugb .
false
use with drugn and other drugn : a synergistic effect may be expected when drugn are given concurrently with drugn , similar drugn or druga such as drugb .
false
concurrent administration of druga ( e.g. , drugb , drugn ) may diminish the bactericidal effects of drugn by slowing the rate of bacterial growth .
false
concurrent administration of druga ( e.g. , drugn , drugb ) may diminish the bactericidal effects of drugn by slowing the rate of bacterial growth .
false
concurrent administration of druga ( e.g. , drugn , drugn ) may diminish the bactericidal effects of drugb by slowing the rate of bacterial growth .
effect
concurrent administration of drugn ( e.g. , druga , drugb ) may diminish the bactericidal effects of drugn by slowing the rate of bacterial growth .
false
concurrent administration of drugn ( e.g. , druga , drugn ) may diminish the bactericidal effects of drugb by slowing the rate of bacterial growth .
effect
concurrent administration of drugn ( e.g. , drugn , druga ) may diminish the bactericidal effects of drugb by slowing the rate of bacterial growth .
effect
druga blood levels may be prolonged by concurrent administration of drugb which blocks the renal tubular secretion of drugn .
mechanism
druga blood levels may be prolonged by concurrent administration of drugn which blocks the renal tubular secretion of drugb .
false
drugn blood levels may be prolonged by concurrent administration of druga which blocks the renal tubular secretion of drugb .
false
displacement of druga from plasma protein binding sites will elevate the level of free drugb in the serum .
false
in a pharmacokinetic study of 18 chronic hepatitis c patients concomitantly receiving druga , treatment with drugb once weekly for 4 weeks was associated with a mean increase of 16 % in drugn auc ;
mechanism
in a pharmacokinetic study of 18 chronic hepatitis c patients concomitantly receiving druga , treatment with drugn once weekly for 4 weeks was associated with a mean increase of 16 % in drugb auc ;
false
in a pharmacokinetic study of 18 chronic hepatitis c patients concomitantly receiving drugn , treatment with druga once weekly for 4 weeks was associated with a mean increase of 16 % in drugb auc ;
false
in elderly patients concurrently receiving certain druga , primarily drugb , an increased incidence of thrombopenia with purpura has been reported .
false
it has been reported that druga may prolong the prothrombin time in patients who are receiving the drugb drugn .
false
it has been reported that druga may prolong the prothrombin time in patients who are receiving the drugn drugb .
effect
it has been reported that drugn may prolong the prothrombin time in patients who are receiving the druga drugb .
false
druga may inhibit the hepatic metabolism of drugb .
mechanism
at a 1.6-g dose , druga produced a slight but significant increase in the half-life of drugb but did not produce a corresponding decrease in the metabolic clearance rate .
mechanism
druga can also displace drugb from plasma protein-binding sites , thus increasing free drugn concentrations .
mechanism
druga can also displace drugn from plasma protein-binding sites , thus increasing free drugb concentrations .
false
drugn can also displace druga from plasma protein-binding sites , thus increasing free drugb concentrations .
false
usage with druga : due to the potential for increased cns depressants effects , drugb should be used with caution in patients who are currently receiving drugn .
false
usage with druga : due to the potential for increased cns depressants effects , drugn should be used with caution in patients who are currently receiving drugb .
false
usage with drugn : due to the potential for increased cns depressants effects , druga should be used with caution in patients who are currently receiving drugb .
advise
druga : concurrent use of drugb and drugn may result in increased systemic toxicity since drugn inhibit the breakdown of drugn .
false
druga : concurrent use of drugn and drugb may result in increased systemic toxicity since drugn inhibit the breakdown of drugn .
false
druga : concurrent use of drugn and drugn may result in increased systemic toxicity since drugb inhibit the breakdown of drugn .
false
druga : concurrent use of drugn and drugn may result in increased systemic toxicity since drugn inhibit the breakdown of drugb .
false
drugn : concurrent use of druga and drugb may result in increased systemic toxicity since drugn inhibit the breakdown of drugn .
effect
drugn : concurrent use of druga and drugn may result in increased systemic toxicity since drugb inhibit the breakdown of drugn .
false
drugn : concurrent use of druga and drugn may result in increased systemic toxicity since drugn inhibit the breakdown of drugb .
false
drugn : concurrent use of drugn and druga may result in increased systemic toxicity since drugb inhibit the breakdown of drugn .
false
drugn : concurrent use of drugn and druga may result in increased systemic toxicity since drugn inhibit the breakdown of drugb .
false
drugn : concurrent use of drugn and drugn may result in increased systemic toxicity since druga inhibit the breakdown of drugb .
mechanism
druga medications : concurrent use of drugb and drugn may result in additive depressant effects .
false
druga medications : concurrent use of drugn and drugb may result in additive depressant effects .
false
drugn medications : concurrent use of druga and drugb may result in additive depressant effects .
effect
druga : drugb may increase the diffusion rate of drugn , resulting in a decreased time of onset , but an increase in systemic toxicity .
false
druga : drugn may increase the diffusion rate of drugb , resulting in a decreased time of onset , but an increase in systemic toxicity .
false
drugn : druga may increase the diffusion rate of drugb , resulting in a decreased time of onset , but an increase in systemic toxicity .
mechanism
druga ( such as drugb ) : concurrent use of drugn and drugn may result in prolongation or enhancement of the neuromuscular blockade .
false
druga ( such as drugn ) : concurrent use of drugb and drugn may result in prolongation or enhancement of the neuromuscular blockade .
false
druga ( such as drugn ) : concurrent use of drugn and drugb may result in prolongation or enhancement of the neuromuscular blockade .
false
drugn ( such as druga ) : concurrent use of drugb and drugn may result in prolongation or enhancement of the neuromuscular blockade .
false
drugn ( such as druga ) : concurrent use of drugn and drugb may result in prolongation or enhancement of the neuromuscular blockade .
false
drugn ( such as drugn ) : concurrent use of druga and drugb may result in prolongation or enhancement of the neuromuscular blockade .
effect
druga : concurrent use of drugb and drugn may result in a reduction of the antibacterial action of the drugn .
false
druga : concurrent use of drugn and drugb may result in a reduction of the antibacterial action of the drugn .
false
druga : concurrent use of drugn and drugn may result in a reduction of the antibacterial action of the drugb .
false
drugn : concurrent use of druga and drugb may result in a reduction of the antibacterial action of the drugn .
effect
drugn : concurrent use of druga and drugn may result in a reduction of the antibacterial action of the drugb .
false
drugn : concurrent use of drugn and druga may result in a reduction of the antibacterial action of the drugb .
false
druga : concurrent use of drugb and drugn may extend the plasma half-life of drugn .
false
druga : concurrent use of drugn and drugb may extend the plasma half-life of drugn .
false
druga : concurrent use of drugn and drugn may extend the plasma half-life of drugb .
false
drugn : concurrent use of druga and drugb may extend the plasma half-life of drugn .
mechanism
drugn : concurrent use of druga and drugn may extend the plasma half-life of drugb .
false
drugn : concurrent use of drugn and druga may extend the plasma half-life of drugb .
false
druga may interact with the following drugs : drugb and other drugn ( may lower drugn levels ) , drugn ( bioavailability of oral drugn is increased with coadministration ) , drugn ( may decrease drugn levels ) , drugn ( reports of psychotic episodes when coadministered ) , drugn ( coadministration of drugn with drugn can inhibit ovarian function in women ) , drugn and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and drugn ( coadministration of drugn and drugn may interfere with the efficacy of the drugn ) .
int
druga may interact with the following drugs : drugn and other drugb ( may lower drugn levels ) , drugn ( bioavailability of oral drugn is increased with coadministration ) , drugn ( may decrease drugn levels ) , drugn ( reports of psychotic episodes when coadministered ) , drugn ( coadministration of drugn with drugn can inhibit ovarian function in women ) , drugn and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and drugn ( coadministration of drugn and drugn may interfere with the efficacy of the drugn ) .
int
druga may interact with the following drugs : drugn and other drugn ( may lower drugb levels ) , drugn ( bioavailability of oral drugn is increased with coadministration ) , drugn ( may decrease drugn levels ) , drugn ( reports of psychotic episodes when coadministered ) , drugn ( coadministration of drugn with drugn can inhibit ovarian function in women ) , drugn and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and drugn ( coadministration of drugn and drugn may interfere with the efficacy of the drugn ) .
false
druga may interact with the following drugs : drugn and other drugn ( may lower drugn levels ) , drugb ( bioavailability of oral drugn is increased with coadministration ) , drugn ( may decrease drugn levels ) , drugn ( reports of psychotic episodes when coadministered ) , drugn ( coadministration of drugn with drugn can inhibit ovarian function in women ) , drugn and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and drugn ( coadministration of drugn and drugn may interfere with the efficacy of the drugn ) .
int
druga may interact with the following drugs : drugn and other drugn ( may lower drugn levels ) , drugn ( bioavailability of oral drugb is increased with coadministration ) , drugn ( may decrease drugn levels ) , drugn ( reports of psychotic episodes when coadministered ) , drugn ( coadministration of drugn with drugn can inhibit ovarian function in women ) , drugn and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and drugn ( coadministration of drugn and drugn may interfere with the efficacy of the drugn ) .
false
druga may interact with the following drugs : drugn and other drugn ( may lower drugn levels ) , drugn ( bioavailability of oral drugn is increased with coadministration ) , drugb ( may decrease drugn levels ) , drugn ( reports of psychotic episodes when coadministered ) , drugn ( coadministration of drugn with drugn can inhibit ovarian function in women ) , drugn and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and drugn ( coadministration of drugn and drugn may interfere with the efficacy of the drugn ) .
int
druga may interact with the following drugs : drugn and other drugn ( may lower drugn levels ) , drugn ( bioavailability of oral drugn is increased with coadministration ) , drugn ( may decrease drugb levels ) , drugn ( reports of psychotic episodes when coadministered ) , drugn ( coadministration of drugn with drugn can inhibit ovarian function in women ) , drugn and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and drugn ( coadministration of drugn and drugn may interfere with the efficacy of the drugn ) .
false
druga may interact with the following drugs : drugn and other drugn ( may lower drugn levels ) , drugn ( bioavailability of oral drugn is increased with coadministration ) , drugn ( may decrease drugn levels ) , drugb ( reports of psychotic episodes when coadministered ) , drugn ( coadministration of drugn with drugn can inhibit ovarian function in women ) , drugn and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and drugn ( coadministration of drugn and drugn may interfere with the efficacy of the drugn ) .
int
druga may interact with the following drugs : drugn and other drugn ( may lower drugn levels ) , drugn ( bioavailability of oral drugn is increased with coadministration ) , drugn ( may decrease drugn levels ) , drugn ( reports of psychotic episodes when coadministered ) , drugb ( coadministration of drugn with drugn can inhibit ovarian function in women ) , drugn and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and drugn ( coadministration of drugn and drugn may interfere with the efficacy of the drugn ) .
int
druga may interact with the following drugs : drugn and other drugn ( may lower drugn levels ) , drugn ( bioavailability of oral drugn is increased with coadministration ) , drugn ( may decrease drugn levels ) , drugn ( reports of psychotic episodes when coadministered ) , drugn ( coadministration of drugb with drugn can inhibit ovarian function in women ) , drugn and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and drugn ( coadministration of drugn and drugn may interfere with the efficacy of the drugn ) .
false
druga may interact with the following drugs : drugn and other drugn ( may lower drugn levels ) , drugn ( bioavailability of oral drugn is increased with coadministration ) , drugn ( may decrease drugn levels ) , drugn ( reports of psychotic episodes when coadministered ) , drugn ( coadministration of drugn with drugb can inhibit ovarian function in women ) , drugn and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and drugn ( coadministration of drugn and drugn may interfere with the efficacy of the drugn ) .
false
druga may interact with the following drugs : drugn and other drugn ( may lower drugn levels ) , drugn ( bioavailability of oral drugn is increased with coadministration ) , drugn ( may decrease drugn levels ) , drugn ( reports of psychotic episodes when coadministered ) , drugn ( coadministration of drugn with drugn can inhibit ovarian function in women ) , drugb and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and drugn ( coadministration of drugn and drugn may interfere with the efficacy of the drugn ) .
int
druga may interact with the following drugs : drugn and other drugn ( may lower drugn levels ) , drugn ( bioavailability of oral drugn is increased with coadministration ) , drugn ( may decrease drugn levels ) , drugn ( reports of psychotic episodes when coadministered ) , drugn ( coadministration of drugn with drugn can inhibit ovarian function in women ) , drugn and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and drugb ( coadministration of drugn and drugn may interfere with the efficacy of the drugn ) .
int
druga may interact with the following drugs : drugn and other drugn ( may lower drugn levels ) , drugn ( bioavailability of oral drugn is increased with coadministration ) , drugn ( may decrease drugn levels ) , drugn ( reports of psychotic episodes when coadministered ) , drugn ( coadministration of drugn with drugn can inhibit ovarian function in women ) , drugn and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and drugn ( coadministration of drugb and drugn may interfere with the efficacy of the drugn ) .
false
druga may interact with the following drugs : drugn and other drugn ( may lower drugn levels ) , drugn ( bioavailability of oral drugn is increased with coadministration ) , drugn ( may decrease drugn levels ) , drugn ( reports of psychotic episodes when coadministered ) , drugn ( coadministration of drugn with drugn can inhibit ovarian function in women ) , drugn and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and drugn ( coadministration of drugn and drugb may interfere with the efficacy of the drugn ) .
false
druga may interact with the following drugs : drugn and other drugn ( may lower drugn levels ) , drugn ( bioavailability of oral drugn is increased with coadministration ) , drugn ( may decrease drugn levels ) , drugn ( reports of psychotic episodes when coadministered ) , drugn ( coadministration of drugn with drugn can inhibit ovarian function in women ) , drugn and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and drugn ( coadministration of drugn and drugn may interfere with the efficacy of the drugb ) .
false
drugn may interact with the following drugs : druga and other drugb ( may lower drugn levels ) , drugn ( bioavailability of oral drugn is increased with coadministration ) , drugn ( may decrease drugn levels ) , drugn ( reports of psychotic episodes when coadministered ) , drugn ( coadministration of drugn with drugn can inhibit ovarian function in women ) , drugn and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and drugn ( coadministration of drugn and drugn may interfere with the efficacy of the drugn ) .
false
drugn may interact with the following drugs : druga and other drugn ( may lower drugb levels ) , drugn ( bioavailability of oral drugn is increased with coadministration ) , drugn ( may decrease drugn levels ) , drugn ( reports of psychotic episodes when coadministered ) , drugn ( coadministration of drugn with drugn can inhibit ovarian function in women ) , drugn and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and drugn ( coadministration of drugn and drugn may interfere with the efficacy of the drugn ) .
false
drugn may interact with the following drugs : druga and other drugn ( may lower drugn levels ) , drugb ( bioavailability of oral drugn is increased with coadministration ) , drugn ( may decrease drugn levels ) , drugn ( reports of psychotic episodes when coadministered ) , drugn ( coadministration of drugn with drugn can inhibit ovarian function in women ) , drugn and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and drugn ( coadministration of drugn and drugn may interfere with the efficacy of the drugn ) .
false
drugn may interact with the following drugs : druga and other drugn ( may lower drugn levels ) , drugn ( bioavailability of oral drugb is increased with coadministration ) , drugn ( may decrease drugn levels ) , drugn ( reports of psychotic episodes when coadministered ) , drugn ( coadministration of drugn with drugn can inhibit ovarian function in women ) , drugn and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and drugn ( coadministration of drugn and drugn may interfere with the efficacy of the drugn ) .
false
drugn may interact with the following drugs : druga and other drugn ( may lower drugn levels ) , drugn ( bioavailability of oral drugn is increased with coadministration ) , drugb ( may decrease drugn levels ) , drugn ( reports of psychotic episodes when coadministered ) , drugn ( coadministration of drugn with drugn can inhibit ovarian function in women ) , drugn and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and drugn ( coadministration of drugn and drugn may interfere with the efficacy of the drugn ) .
false
drugn may interact with the following drugs : druga and other drugn ( may lower drugn levels ) , drugn ( bioavailability of oral drugn is increased with coadministration ) , drugn ( may decrease drugb levels ) , drugn ( reports of psychotic episodes when coadministered ) , drugn ( coadministration of drugn with drugn can inhibit ovarian function in women ) , drugn and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and drugn ( coadministration of drugn and drugn may interfere with the efficacy of the drugn ) .
false
drugn may interact with the following drugs : druga and other drugn ( may lower drugn levels ) , drugn ( bioavailability of oral drugn is increased with coadministration ) , drugn ( may decrease drugn levels ) , drugb ( reports of psychotic episodes when coadministered ) , drugn ( coadministration of drugn with drugn can inhibit ovarian function in women ) , drugn and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and drugn ( coadministration of drugn and drugn may interfere with the efficacy of the drugn ) .
false
drugn may interact with the following drugs : druga and other drugn ( may lower drugn levels ) , drugn ( bioavailability of oral drugn is increased with coadministration ) , drugn ( may decrease drugn levels ) , drugn ( reports of psychotic episodes when coadministered ) , drugb ( coadministration of drugn with drugn can inhibit ovarian function in women ) , drugn and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and drugn ( coadministration of drugn and drugn may interfere with the efficacy of the drugn ) .
false
drugn may interact with the following drugs : druga and other drugn ( may lower drugn levels ) , drugn ( bioavailability of oral drugn is increased with coadministration ) , drugn ( may decrease drugn levels ) , drugn ( reports of psychotic episodes when coadministered ) , drugn ( coadministration of drugb with drugn can inhibit ovarian function in women ) , drugn and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and drugn ( coadministration of drugn and drugn may interfere with the efficacy of the drugn ) .
false
drugn may interact with the following drugs : druga and other drugn ( may lower drugn levels ) , drugn ( bioavailability of oral drugn is increased with coadministration ) , drugn ( may decrease drugn levels ) , drugn ( reports of psychotic episodes when coadministered ) , drugn ( coadministration of drugn with drugb can inhibit ovarian function in women ) , drugn and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and drugn ( coadministration of drugn and drugn may interfere with the efficacy of the drugn ) .
false
drugn may interact with the following drugs : druga and other drugn ( may lower drugn levels ) , drugn ( bioavailability of oral drugn is increased with coadministration ) , drugn ( may decrease drugn levels ) , drugn ( reports of psychotic episodes when coadministered ) , drugn ( coadministration of drugn with drugn can inhibit ovarian function in women ) , drugb and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and drugn ( coadministration of drugn and drugn may interfere with the efficacy of the drugn ) .
false
drugn may interact with the following drugs : druga and other drugn ( may lower drugn levels ) , drugn ( bioavailability of oral drugn is increased with coadministration ) , drugn ( may decrease drugn levels ) , drugn ( reports of psychotic episodes when coadministered ) , drugn ( coadministration of drugn with drugn can inhibit ovarian function in women ) , drugn and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and drugb ( coadministration of drugn and drugn may interfere with the efficacy of the drugn ) .
false
drugn may interact with the following drugs : druga and other drugn ( may lower drugn levels ) , drugn ( bioavailability of oral drugn is increased with coadministration ) , drugn ( may decrease drugn levels ) , drugn ( reports of psychotic episodes when coadministered ) , drugn ( coadministration of drugn with drugn can inhibit ovarian function in women ) , drugn and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and drugn ( coadministration of drugb and drugn may interfere with the efficacy of the drugn ) .
false
drugn may interact with the following drugs : druga and other drugn ( may lower drugn levels ) , drugn ( bioavailability of oral drugn is increased with coadministration ) , drugn ( may decrease drugn levels ) , drugn ( reports of psychotic episodes when coadministered ) , drugn ( coadministration of drugn with drugn can inhibit ovarian function in women ) , drugn and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and drugn ( coadministration of drugn and drugb may interfere with the efficacy of the drugn ) .
false
drugn may interact with the following drugs : druga and other drugn ( may lower drugn levels ) , drugn ( bioavailability of oral drugn is increased with coadministration ) , drugn ( may decrease drugn levels ) , drugn ( reports of psychotic episodes when coadministered ) , drugn ( coadministration of drugn with drugn can inhibit ovarian function in women ) , drugn and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and drugn ( coadministration of drugn and drugn may interfere with the efficacy of the drugb ) .
false
drugn may interact with the following drugs : drugn and other druga ( may lower drugb levels ) , drugn ( bioavailability of oral drugn is increased with coadministration ) , drugn ( may decrease drugn levels ) , drugn ( reports of psychotic episodes when coadministered ) , drugn ( coadministration of drugn with drugn can inhibit ovarian function in women ) , drugn and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and drugn ( coadministration of drugn and drugn may interfere with the efficacy of the drugn ) .
false
drugn may interact with the following drugs : drugn and other druga ( may lower drugn levels ) , drugb ( bioavailability of oral drugn is increased with coadministration ) , drugn ( may decrease drugn levels ) , drugn ( reports of psychotic episodes when coadministered ) , drugn ( coadministration of drugn with drugn can inhibit ovarian function in women ) , drugn and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and drugn ( coadministration of drugn and drugn may interfere with the efficacy of the drugn ) .
false
drugn may interact with the following drugs : drugn and other druga ( may lower drugn levels ) , drugn ( bioavailability of oral drugb is increased with coadministration ) , drugn ( may decrease drugn levels ) , drugn ( reports of psychotic episodes when coadministered ) , drugn ( coadministration of drugn with drugn can inhibit ovarian function in women ) , drugn and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and drugn ( coadministration of drugn and drugn may interfere with the efficacy of the drugn ) .
false
drugn may interact with the following drugs : drugn and other druga ( may lower drugn levels ) , drugn ( bioavailability of oral drugn is increased with coadministration ) , drugb ( may decrease drugn levels ) , drugn ( reports of psychotic episodes when coadministered ) , drugn ( coadministration of drugn with drugn can inhibit ovarian function in women ) , drugn and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and drugn ( coadministration of drugn and drugn may interfere with the efficacy of the drugn ) .
false
drugn may interact with the following drugs : drugn and other druga ( may lower drugn levels ) , drugn ( bioavailability of oral drugn is increased with coadministration ) , drugn ( may decrease drugb levels ) , drugn ( reports of psychotic episodes when coadministered ) , drugn ( coadministration of drugn with drugn can inhibit ovarian function in women ) , drugn and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and drugn ( coadministration of drugn and drugn may interfere with the efficacy of the drugn ) .
false
drugn may interact with the following drugs : drugn and other druga ( may lower drugn levels ) , drugn ( bioavailability of oral drugn is increased with coadministration ) , drugn ( may decrease drugn levels ) , drugb ( reports of psychotic episodes when coadministered ) , drugn ( coadministration of drugn with drugn can inhibit ovarian function in women ) , drugn and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and drugn ( coadministration of drugn and drugn may interfere with the efficacy of the drugn ) .
false
drugn may interact with the following drugs : drugn and other druga ( may lower drugn levels ) , drugn ( bioavailability of oral drugn is increased with coadministration ) , drugn ( may decrease drugn levels ) , drugn ( reports of psychotic episodes when coadministered ) , drugb ( coadministration of drugn with drugn can inhibit ovarian function in women ) , drugn and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and drugn ( coadministration of drugn and drugn may interfere with the efficacy of the drugn ) .
false
drugn may interact with the following drugs : drugn and other druga ( may lower drugn levels ) , drugn ( bioavailability of oral drugn is increased with coadministration ) , drugn ( may decrease drugn levels ) , drugn ( reports of psychotic episodes when coadministered ) , drugn ( coadministration of drugb with drugn can inhibit ovarian function in women ) , drugn and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and drugn ( coadministration of drugn and drugn may interfere with the efficacy of the drugn ) .
false
drugn may interact with the following drugs : drugn and other druga ( may lower drugn levels ) , drugn ( bioavailability of oral drugn is increased with coadministration ) , drugn ( may decrease drugn levels ) , drugn ( reports of psychotic episodes when coadministered ) , drugn ( coadministration of drugn with drugb can inhibit ovarian function in women ) , drugn and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and drugn ( coadministration of drugn and drugn may interfere with the efficacy of the drugn ) .
false
drugn may interact with the following drugs : drugn and other druga ( may lower drugn levels ) , drugn ( bioavailability of oral drugn is increased with coadministration ) , drugn ( may decrease drugn levels ) , drugn ( reports of psychotic episodes when coadministered ) , drugn ( coadministration of drugn with drugn can inhibit ovarian function in women ) , drugb and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and drugn ( coadministration of drugn and drugn may interfere with the efficacy of the drugn ) .
false
drugn may interact with the following drugs : drugn and other druga ( may lower drugn levels ) , drugn ( bioavailability of oral drugn is increased with coadministration ) , drugn ( may decrease drugn levels ) , drugn ( reports of psychotic episodes when coadministered ) , drugn ( coadministration of drugn with drugn can inhibit ovarian function in women ) , drugn and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and drugb ( coadministration of drugn and drugn may interfere with the efficacy of the drugn ) .
false
drugn may interact with the following drugs : drugn and other druga ( may lower drugn levels ) , drugn ( bioavailability of oral drugn is increased with coadministration ) , drugn ( may decrease drugn levels ) , drugn ( reports of psychotic episodes when coadministered ) , drugn ( coadministration of drugn with drugn can inhibit ovarian function in women ) , drugn and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and drugn ( coadministration of drugb and drugn may interfere with the efficacy of the drugn ) .
false
drugn may interact with the following drugs : drugn and other druga ( may lower drugn levels ) , drugn ( bioavailability of oral drugn is increased with coadministration ) , drugn ( may decrease drugn levels ) , drugn ( reports of psychotic episodes when coadministered ) , drugn ( coadministration of drugn with drugn can inhibit ovarian function in women ) , drugn and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and drugn ( coadministration of drugn and drugb may interfere with the efficacy of the drugn ) .
false
drugn may interact with the following drugs : drugn and other druga ( may lower drugn levels ) , drugn ( bioavailability of oral drugn is increased with coadministration ) , drugn ( may decrease drugn levels ) , drugn ( reports of psychotic episodes when coadministered ) , drugn ( coadministration of drugn with drugn can inhibit ovarian function in women ) , drugn and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and drugn ( coadministration of drugn and drugn may interfere with the efficacy of the drugb ) .
false
drugn may interact with the following drugs : drugn and other drugn ( may lower druga levels ) , drugb ( bioavailability of oral drugn is increased with coadministration ) , drugn ( may decrease drugn levels ) , drugn ( reports of psychotic episodes when coadministered ) , drugn ( coadministration of drugn with drugn can inhibit ovarian function in women ) , drugn and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and drugn ( coadministration of drugn and drugn may interfere with the efficacy of the drugn ) .
false
drugn may interact with the following drugs : drugn and other drugn ( may lower druga levels ) , drugn ( bioavailability of oral drugb is increased with coadministration ) , drugn ( may decrease drugn levels ) , drugn ( reports of psychotic episodes when coadministered ) , drugn ( coadministration of drugn with drugn can inhibit ovarian function in women ) , drugn and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and drugn ( coadministration of drugn and drugn may interfere with the efficacy of the drugn ) .
false
drugn may interact with the following drugs : drugn and other drugn ( may lower druga levels ) , drugn ( bioavailability of oral drugn is increased with coadministration ) , drugb ( may decrease drugn levels ) , drugn ( reports of psychotic episodes when coadministered ) , drugn ( coadministration of drugn with drugn can inhibit ovarian function in women ) , drugn and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and drugn ( coadministration of drugn and drugn may interfere with the efficacy of the drugn ) .
false
drugn may interact with the following drugs : drugn and other drugn ( may lower druga levels ) , drugn ( bioavailability of oral drugn is increased with coadministration ) , drugn ( may decrease drugb levels ) , drugn ( reports of psychotic episodes when coadministered ) , drugn ( coadministration of drugn with drugn can inhibit ovarian function in women ) , drugn and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and drugn ( coadministration of drugn and drugn may interfere with the efficacy of the drugn ) .
false
drugn may interact with the following drugs : drugn and other drugn ( may lower druga levels ) , drugn ( bioavailability of oral drugn is increased with coadministration ) , drugn ( may decrease drugn levels ) , drugb ( reports of psychotic episodes when coadministered ) , drugn ( coadministration of drugn with drugn can inhibit ovarian function in women ) , drugn and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and drugn ( coadministration of drugn and drugn may interfere with the efficacy of the drugn ) .
false
drugn may interact with the following drugs : drugn and other drugn ( may lower druga levels ) , drugn ( bioavailability of oral drugn is increased with coadministration ) , drugn ( may decrease drugn levels ) , drugn ( reports of psychotic episodes when coadministered ) , drugb ( coadministration of drugn with drugn can inhibit ovarian function in women ) , drugn and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and drugn ( coadministration of drugn and drugn may interfere with the efficacy of the drugn ) .
false
drugn may interact with the following drugs : drugn and other drugn ( may lower druga levels ) , drugn ( bioavailability of oral drugn is increased with coadministration ) , drugn ( may decrease drugn levels ) , drugn ( reports of psychotic episodes when coadministered ) , drugn ( coadministration of drugb with drugn can inhibit ovarian function in women ) , drugn and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and drugn ( coadministration of drugn and drugn may interfere with the efficacy of the drugn ) .
false
drugn may interact with the following drugs : drugn and other drugn ( may lower druga levels ) , drugn ( bioavailability of oral drugn is increased with coadministration ) , drugn ( may decrease drugn levels ) , drugn ( reports of psychotic episodes when coadministered ) , drugn ( coadministration of drugn with drugb can inhibit ovarian function in women ) , drugn and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and drugn ( coadministration of drugn and drugn may interfere with the efficacy of the drugn ) .
false
drugn may interact with the following drugs : drugn and other drugn ( may lower druga levels ) , drugn ( bioavailability of oral drugn is increased with coadministration ) , drugn ( may decrease drugn levels ) , drugn ( reports of psychotic episodes when coadministered ) , drugn ( coadministration of drugn with drugn can inhibit ovarian function in women ) , drugb and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and drugn ( coadministration of drugn and drugn may interfere with the efficacy of the drugn ) .
false
drugn may interact with the following drugs : drugn and other drugn ( may lower druga levels ) , drugn ( bioavailability of oral drugn is increased with coadministration ) , drugn ( may decrease drugn levels ) , drugn ( reports of psychotic episodes when coadministered ) , drugn ( coadministration of drugn with drugn can inhibit ovarian function in women ) , drugn and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and drugb ( coadministration of drugn and drugn may interfere with the efficacy of the drugn ) .
false
drugn may interact with the following drugs : drugn and other drugn ( may lower druga levels ) , drugn ( bioavailability of oral drugn is increased with coadministration ) , drugn ( may decrease drugn levels ) , drugn ( reports of psychotic episodes when coadministered ) , drugn ( coadministration of drugn with drugn can inhibit ovarian function in women ) , drugn and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and drugn ( coadministration of drugb and drugn may interfere with the efficacy of the drugn ) .
false
drugn may interact with the following drugs : drugn and other drugn ( may lower druga levels ) , drugn ( bioavailability of oral drugn is increased with coadministration ) , drugn ( may decrease drugn levels ) , drugn ( reports of psychotic episodes when coadministered ) , drugn ( coadministration of drugn with drugn can inhibit ovarian function in women ) , drugn and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and drugn ( coadministration of drugn and drugb may interfere with the efficacy of the drugn ) .
false
drugn may interact with the following drugs : drugn and other drugn ( may lower druga levels ) , drugn ( bioavailability of oral drugn is increased with coadministration ) , drugn ( may decrease drugn levels ) , drugn ( reports of psychotic episodes when coadministered ) , drugn ( coadministration of drugn with drugn can inhibit ovarian function in women ) , drugn and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and drugn ( coadministration of drugn and drugn may interfere with the efficacy of the drugb ) .
false
drugn may interact with the following drugs : drugn and other drugn ( may lower drugn levels ) , druga ( bioavailability of oral drugb is increased with coadministration ) , drugn ( may decrease drugn levels ) , drugn ( reports of psychotic episodes when coadministered ) , drugn ( coadministration of drugn with drugn can inhibit ovarian function in women ) , drugn and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and drugn ( coadministration of drugn and drugn may interfere with the efficacy of the drugn ) .
false
drugn may interact with the following drugs : drugn and other drugn ( may lower drugn levels ) , druga ( bioavailability of oral drugn is increased with coadministration ) , drugb ( may decrease drugn levels ) , drugn ( reports of psychotic episodes when coadministered ) , drugn ( coadministration of drugn with drugn can inhibit ovarian function in women ) , drugn and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and drugn ( coadministration of drugn and drugn may interfere with the efficacy of the drugn ) .
false
drugn may interact with the following drugs : drugn and other drugn ( may lower drugn levels ) , druga ( bioavailability of oral drugn is increased with coadministration ) , drugn ( may decrease drugb levels ) , drugn ( reports of psychotic episodes when coadministered ) , drugn ( coadministration of drugn with drugn can inhibit ovarian function in women ) , drugn and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and drugn ( coadministration of drugn and drugn may interfere with the efficacy of the drugn ) .
false
drugn may interact with the following drugs : drugn and other drugn ( may lower drugn levels ) , druga ( bioavailability of oral drugn is increased with coadministration ) , drugn ( may decrease drugn levels ) , drugb ( reports of psychotic episodes when coadministered ) , drugn ( coadministration of drugn with drugn can inhibit ovarian function in women ) , drugn and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and drugn ( coadministration of drugn and drugn may interfere with the efficacy of the drugn ) .
false
drugn may interact with the following drugs : drugn and other drugn ( may lower drugn levels ) , druga ( bioavailability of oral drugn is increased with coadministration ) , drugn ( may decrease drugn levels ) , drugn ( reports of psychotic episodes when coadministered ) , drugb ( coadministration of drugn with drugn can inhibit ovarian function in women ) , drugn and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and drugn ( coadministration of drugn and drugn may interfere with the efficacy of the drugn ) .
false
drugn may interact with the following drugs : drugn and other drugn ( may lower drugn levels ) , druga ( bioavailability of oral drugn is increased with coadministration ) , drugn ( may decrease drugn levels ) , drugn ( reports of psychotic episodes when coadministered ) , drugn ( coadministration of drugb with drugn can inhibit ovarian function in women ) , drugn and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and drugn ( coadministration of drugn and drugn may interfere with the efficacy of the drugn ) .
false
drugn may interact with the following drugs : drugn and other drugn ( may lower drugn levels ) , druga ( bioavailability of oral drugn is increased with coadministration ) , drugn ( may decrease drugn levels ) , drugn ( reports of psychotic episodes when coadministered ) , drugn ( coadministration of drugn with drugb can inhibit ovarian function in women ) , drugn and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and drugn ( coadministration of drugn and drugn may interfere with the efficacy of the drugn ) .
false
drugn may interact with the following drugs : drugn and other drugn ( may lower drugn levels ) , druga ( bioavailability of oral drugn is increased with coadministration ) , drugn ( may decrease drugn levels ) , drugn ( reports of psychotic episodes when coadministered ) , drugn ( coadministration of drugn with drugn can inhibit ovarian function in women ) , drugb and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and drugn ( coadministration of drugn and drugn may interfere with the efficacy of the drugn ) .
false
drugn may interact with the following drugs : drugn and other drugn ( may lower drugn levels ) , druga ( bioavailability of oral drugn is increased with coadministration ) , drugn ( may decrease drugn levels ) , drugn ( reports of psychotic episodes when coadministered ) , drugn ( coadministration of drugn with drugn can inhibit ovarian function in women ) , drugn and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and drugb ( coadministration of drugn and drugn may interfere with the efficacy of the drugn ) .
false
drugn may interact with the following drugs : drugn and other drugn ( may lower drugn levels ) , druga ( bioavailability of oral drugn is increased with coadministration ) , drugn ( may decrease drugn levels ) , drugn ( reports of psychotic episodes when coadministered ) , drugn ( coadministration of drugn with drugn can inhibit ovarian function in women ) , drugn and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and drugn ( coadministration of drugb and drugn may interfere with the efficacy of the drugn ) .
false
drugn may interact with the following drugs : drugn and other drugn ( may lower drugn levels ) , druga ( bioavailability of oral drugn is increased with coadministration ) , drugn ( may decrease drugn levels ) , drugn ( reports of psychotic episodes when coadministered ) , drugn ( coadministration of drugn with drugn can inhibit ovarian function in women ) , drugn and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and drugn ( coadministration of drugn and drugb may interfere with the efficacy of the drugn ) .
false
drugn may interact with the following drugs : drugn and other drugn ( may lower drugn levels ) , druga ( bioavailability of oral drugn is increased with coadministration ) , drugn ( may decrease drugn levels ) , drugn ( reports of psychotic episodes when coadministered ) , drugn ( coadministration of drugn with drugn can inhibit ovarian function in women ) , drugn and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and drugn ( coadministration of drugn and drugn may interfere with the efficacy of the drugb ) .
false
drugn may interact with the following drugs : drugn and other drugn ( may lower drugn levels ) , drugn ( bioavailability of oral druga is increased with coadministration ) , drugb ( may decrease drugn levels ) , drugn ( reports of psychotic episodes when coadministered ) , drugn ( coadministration of drugn with drugn can inhibit ovarian function in women ) , drugn and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and drugn ( coadministration of drugn and drugn may interfere with the efficacy of the drugn ) .
false
drugn may interact with the following drugs : drugn and other drugn ( may lower drugn levels ) , drugn ( bioavailability of oral druga is increased with coadministration ) , drugn ( may decrease drugb levels ) , drugn ( reports of psychotic episodes when coadministered ) , drugn ( coadministration of drugn with drugn can inhibit ovarian function in women ) , drugn and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and drugn ( coadministration of drugn and drugn may interfere with the efficacy of the drugn ) .
false
drugn may interact with the following drugs : drugn and other drugn ( may lower drugn levels ) , drugn ( bioavailability of oral druga is increased with coadministration ) , drugn ( may decrease drugn levels ) , drugb ( reports of psychotic episodes when coadministered ) , drugn ( coadministration of drugn with drugn can inhibit ovarian function in women ) , drugn and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and drugn ( coadministration of drugn and drugn may interfere with the efficacy of the drugn ) .
false
drugn may interact with the following drugs : drugn and other drugn ( may lower drugn levels ) , drugn ( bioavailability of oral druga is increased with coadministration ) , drugn ( may decrease drugn levels ) , drugn ( reports of psychotic episodes when coadministered ) , drugb ( coadministration of drugn with drugn can inhibit ovarian function in women ) , drugn and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and drugn ( coadministration of drugn and drugn may interfere with the efficacy of the drugn ) .
false
drugn may interact with the following drugs : drugn and other drugn ( may lower drugn levels ) , drugn ( bioavailability of oral druga is increased with coadministration ) , drugn ( may decrease drugn levels ) , drugn ( reports of psychotic episodes when coadministered ) , drugn ( coadministration of drugb with drugn can inhibit ovarian function in women ) , drugn and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and drugn ( coadministration of drugn and drugn may interfere with the efficacy of the drugn ) .
false
drugn may interact with the following drugs : drugn and other drugn ( may lower drugn levels ) , drugn ( bioavailability of oral druga is increased with coadministration ) , drugn ( may decrease drugn levels ) , drugn ( reports of psychotic episodes when coadministered ) , drugn ( coadministration of drugn with drugb can inhibit ovarian function in women ) , drugn and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and drugn ( coadministration of drugn and drugn may interfere with the efficacy of the drugn ) .
false
drugn may interact with the following drugs : drugn and other drugn ( may lower drugn levels ) , drugn ( bioavailability of oral druga is increased with coadministration ) , drugn ( may decrease drugn levels ) , drugn ( reports of psychotic episodes when coadministered ) , drugn ( coadministration of drugn with drugn can inhibit ovarian function in women ) , drugb and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and drugn ( coadministration of drugn and drugn may interfere with the efficacy of the drugn ) .
false
drugn may interact with the following drugs : drugn and other drugn ( may lower drugn levels ) , drugn ( bioavailability of oral druga is increased with coadministration ) , drugn ( may decrease drugn levels ) , drugn ( reports of psychotic episodes when coadministered ) , drugn ( coadministration of drugn with drugn can inhibit ovarian function in women ) , drugn and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and drugb ( coadministration of drugn and drugn may interfere with the efficacy of the drugn ) .
false
drugn may interact with the following drugs : drugn and other drugn ( may lower drugn levels ) , drugn ( bioavailability of oral druga is increased with coadministration ) , drugn ( may decrease drugn levels ) , drugn ( reports of psychotic episodes when coadministered ) , drugn ( coadministration of drugn with drugn can inhibit ovarian function in women ) , drugn and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and drugn ( coadministration of drugb and drugn may interfere with the efficacy of the drugn ) .
false
drugn may interact with the following drugs : drugn and other drugn ( may lower drugn levels ) , drugn ( bioavailability of oral druga is increased with coadministration ) , drugn ( may decrease drugn levels ) , drugn ( reports of psychotic episodes when coadministered ) , drugn ( coadministration of drugn with drugn can inhibit ovarian function in women ) , drugn and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and drugn ( coadministration of drugn and drugb may interfere with the efficacy of the drugn ) .
false
drugn may interact with the following drugs : drugn and other drugn ( may lower drugn levels ) , drugn ( bioavailability of oral druga is increased with coadministration ) , drugn ( may decrease drugn levels ) , drugn ( reports of psychotic episodes when coadministered ) , drugn ( coadministration of drugn with drugn can inhibit ovarian function in women ) , drugn and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and drugn ( coadministration of drugn and drugn may interfere with the efficacy of the drugb ) .
false
drugn may interact with the following drugs : drugn and other drugn ( may lower drugn levels ) , drugn ( bioavailability of oral drugn is increased with coadministration ) , druga ( may decrease drugb levels ) , drugn ( reports of psychotic episodes when coadministered ) , drugn ( coadministration of drugn with drugn can inhibit ovarian function in women ) , drugn and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and drugn ( coadministration of drugn and drugn may interfere with the efficacy of the drugn ) .
false
drugn may interact with the following drugs : drugn and other drugn ( may lower drugn levels ) , drugn ( bioavailability of oral drugn is increased with coadministration ) , druga ( may decrease drugn levels ) , drugb ( reports of psychotic episodes when coadministered ) , drugn ( coadministration of drugn with drugn can inhibit ovarian function in women ) , drugn and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and drugn ( coadministration of drugn and drugn may interfere with the efficacy of the drugn ) .
false
drugn may interact with the following drugs : drugn and other drugn ( may lower drugn levels ) , drugn ( bioavailability of oral drugn is increased with coadministration ) , druga ( may decrease drugn levels ) , drugn ( reports of psychotic episodes when coadministered ) , drugb ( coadministration of drugn with drugn can inhibit ovarian function in women ) , drugn and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and drugn ( coadministration of drugn and drugn may interfere with the efficacy of the drugn ) .
false
drugn may interact with the following drugs : drugn and other drugn ( may lower drugn levels ) , drugn ( bioavailability of oral drugn is increased with coadministration ) , druga ( may decrease drugn levels ) , drugn ( reports of psychotic episodes when coadministered ) , drugn ( coadministration of drugb with drugn can inhibit ovarian function in women ) , drugn and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and drugn ( coadministration of drugn and drugn may interfere with the efficacy of the drugn ) .
false
drugn may interact with the following drugs : drugn and other drugn ( may lower drugn levels ) , drugn ( bioavailability of oral drugn is increased with coadministration ) , druga ( may decrease drugn levels ) , drugn ( reports of psychotic episodes when coadministered ) , drugn ( coadministration of drugn with drugb can inhibit ovarian function in women ) , drugn and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and drugn ( coadministration of drugn and drugn may interfere with the efficacy of the drugn ) .
false
drugn may interact with the following drugs : drugn and other drugn ( may lower drugn levels ) , drugn ( bioavailability of oral drugn is increased with coadministration ) , druga ( may decrease drugn levels ) , drugn ( reports of psychotic episodes when coadministered ) , drugn ( coadministration of drugn with drugn can inhibit ovarian function in women ) , drugb and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and drugn ( coadministration of drugn and drugn may interfere with the efficacy of the drugn ) .
false
drugn may interact with the following drugs : drugn and other drugn ( may lower drugn levels ) , drugn ( bioavailability of oral drugn is increased with coadministration ) , druga ( may decrease drugn levels ) , drugn ( reports of psychotic episodes when coadministered ) , drugn ( coadministration of drugn with drugn can inhibit ovarian function in women ) , drugn and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and drugb ( coadministration of drugn and drugn may interfere with the efficacy of the drugn ) .
false
drugn may interact with the following drugs : drugn and other drugn ( may lower drugn levels ) , drugn ( bioavailability of oral drugn is increased with coadministration ) , druga ( may decrease drugn levels ) , drugn ( reports of psychotic episodes when coadministered ) , drugn ( coadministration of drugn with drugn can inhibit ovarian function in women ) , drugn and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and drugn ( coadministration of drugb and drugn may interfere with the efficacy of the drugn ) .
false
drugn may interact with the following drugs : drugn and other drugn ( may lower drugn levels ) , drugn ( bioavailability of oral drugn is increased with coadministration ) , druga ( may decrease drugn levels ) , drugn ( reports of psychotic episodes when coadministered ) , drugn ( coadministration of drugn with drugn can inhibit ovarian function in women ) , drugn and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and drugn ( coadministration of drugn and drugb may interfere with the efficacy of the drugn ) .
false
drugn may interact with the following drugs : drugn and other drugn ( may lower drugn levels ) , drugn ( bioavailability of oral drugn is increased with coadministration ) , druga ( may decrease drugn levels ) , drugn ( reports of psychotic episodes when coadministered ) , drugn ( coadministration of drugn with drugn can inhibit ovarian function in women ) , drugn and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and drugn ( coadministration of drugn and drugn may interfere with the efficacy of the drugb ) .
false
drugn may interact with the following drugs : drugn and other drugn ( may lower drugn levels ) , drugn ( bioavailability of oral drugn is increased with coadministration ) , drugn ( may decrease druga levels ) , drugb ( reports of psychotic episodes when coadministered ) , drugn ( coadministration of drugn with drugn can inhibit ovarian function in women ) , drugn and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and drugn ( coadministration of drugn and drugn may interfere with the efficacy of the drugn ) .
false
drugn may interact with the following drugs : drugn and other drugn ( may lower drugn levels ) , drugn ( bioavailability of oral drugn is increased with coadministration ) , drugn ( may decrease druga levels ) , drugn ( reports of psychotic episodes when coadministered ) , drugb ( coadministration of drugn with drugn can inhibit ovarian function in women ) , drugn and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and drugn ( coadministration of drugn and drugn may interfere with the efficacy of the drugn ) .
false
drugn may interact with the following drugs : drugn and other drugn ( may lower drugn levels ) , drugn ( bioavailability of oral drugn is increased with coadministration ) , drugn ( may decrease druga levels ) , drugn ( reports of psychotic episodes when coadministered ) , drugn ( coadministration of drugb with drugn can inhibit ovarian function in women ) , drugn and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and drugn ( coadministration of drugn and drugn may interfere with the efficacy of the drugn ) .
false
drugn may interact with the following drugs : drugn and other drugn ( may lower drugn levels ) , drugn ( bioavailability of oral drugn is increased with coadministration ) , drugn ( may decrease druga levels ) , drugn ( reports of psychotic episodes when coadministered ) , drugn ( coadministration of drugn with drugb can inhibit ovarian function in women ) , drugn and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and drugn ( coadministration of drugn and drugn may interfere with the efficacy of the drugn ) .
false
drugn may interact with the following drugs : drugn and other drugn ( may lower drugn levels ) , drugn ( bioavailability of oral drugn is increased with coadministration ) , drugn ( may decrease druga levels ) , drugn ( reports of psychotic episodes when coadministered ) , drugn ( coadministration of drugn with drugn can inhibit ovarian function in women ) , drugb and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and drugn ( coadministration of drugn and drugn may interfere with the efficacy of the drugn ) .
false
drugn may interact with the following drugs : drugn and other drugn ( may lower drugn levels ) , drugn ( bioavailability of oral drugn is increased with coadministration ) , drugn ( may decrease druga levels ) , drugn ( reports of psychotic episodes when coadministered ) , drugn ( coadministration of drugn with drugn can inhibit ovarian function in women ) , drugn and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and drugb ( coadministration of drugn and drugn may interfere with the efficacy of the drugn ) .
false
drugn may interact with the following drugs : drugn and other drugn ( may lower drugn levels ) , drugn ( bioavailability of oral drugn is increased with coadministration ) , drugn ( may decrease druga levels ) , drugn ( reports of psychotic episodes when coadministered ) , drugn ( coadministration of drugn with drugn can inhibit ovarian function in women ) , drugn and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and drugn ( coadministration of drugb and drugn may interfere with the efficacy of the drugn ) .
false
drugn may interact with the following drugs : drugn and other drugn ( may lower drugn levels ) , drugn ( bioavailability of oral drugn is increased with coadministration ) , drugn ( may decrease druga levels ) , drugn ( reports of psychotic episodes when coadministered ) , drugn ( coadministration of drugn with drugn can inhibit ovarian function in women ) , drugn and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and drugn ( coadministration of drugn and drugb may interfere with the efficacy of the drugn ) .
false
drugn may interact with the following drugs : drugn and other drugn ( may lower drugn levels ) , drugn ( bioavailability of oral drugn is increased with coadministration ) , drugn ( may decrease druga levels ) , drugn ( reports of psychotic episodes when coadministered ) , drugn ( coadministration of drugn with drugn can inhibit ovarian function in women ) , drugn and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and drugn ( coadministration of drugn and drugn may interfere with the efficacy of the drugb ) .
false
drugn may interact with the following drugs : drugn and other drugn ( may lower drugn levels ) , drugn ( bioavailability of oral drugn is increased with coadministration ) , drugn ( may decrease drugn levels ) , druga ( reports of psychotic episodes when coadministered ) , drugb ( coadministration of drugn with drugn can inhibit ovarian function in women ) , drugn and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and drugn ( coadministration of drugn and drugn may interfere with the efficacy of the drugn ) .
false
drugn may interact with the following drugs : drugn and other drugn ( may lower drugn levels ) , drugn ( bioavailability of oral drugn is increased with coadministration ) , drugn ( may decrease drugn levels ) , druga ( reports of psychotic episodes when coadministered ) , drugn ( coadministration of drugb with drugn can inhibit ovarian function in women ) , drugn and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and drugn ( coadministration of drugn and drugn may interfere with the efficacy of the drugn ) .
false
drugn may interact with the following drugs : drugn and other drugn ( may lower drugn levels ) , drugn ( bioavailability of oral drugn is increased with coadministration ) , drugn ( may decrease drugn levels ) , druga ( reports of psychotic episodes when coadministered ) , drugn ( coadministration of drugn with drugb can inhibit ovarian function in women ) , drugn and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and drugn ( coadministration of drugn and drugn may interfere with the efficacy of the drugn ) .
false
drugn may interact with the following drugs : drugn and other drugn ( may lower drugn levels ) , drugn ( bioavailability of oral drugn is increased with coadministration ) , drugn ( may decrease drugn levels ) , druga ( reports of psychotic episodes when coadministered ) , drugn ( coadministration of drugn with drugn can inhibit ovarian function in women ) , drugb and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and drugn ( coadministration of drugn and drugn may interfere with the efficacy of the drugn ) .
false
drugn may interact with the following drugs : drugn and other drugn ( may lower drugn levels ) , drugn ( bioavailability of oral drugn is increased with coadministration ) , drugn ( may decrease drugn levels ) , druga ( reports of psychotic episodes when coadministered ) , drugn ( coadministration of drugn with drugn can inhibit ovarian function in women ) , drugn and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and drugb ( coadministration of drugn and drugn may interfere with the efficacy of the drugn ) .
false
drugn may interact with the following drugs : drugn and other drugn ( may lower drugn levels ) , drugn ( bioavailability of oral drugn is increased with coadministration ) , drugn ( may decrease drugn levels ) , druga ( reports of psychotic episodes when coadministered ) , drugn ( coadministration of drugn with drugn can inhibit ovarian function in women ) , drugn and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and drugn ( coadministration of drugb and drugn may interfere with the efficacy of the drugn ) .
false
drugn may interact with the following drugs : drugn and other drugn ( may lower drugn levels ) , drugn ( bioavailability of oral drugn is increased with coadministration ) , drugn ( may decrease drugn levels ) , druga ( reports of psychotic episodes when coadministered ) , drugn ( coadministration of drugn with drugn can inhibit ovarian function in women ) , drugn and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and drugn ( coadministration of drugn and drugb may interfere with the efficacy of the drugn ) .
false
drugn may interact with the following drugs : drugn and other drugn ( may lower drugn levels ) , drugn ( bioavailability of oral drugn is increased with coadministration ) , drugn ( may decrease drugn levels ) , druga ( reports of psychotic episodes when coadministered ) , drugn ( coadministration of drugn with drugn can inhibit ovarian function in women ) , drugn and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and drugn ( coadministration of drugn and drugn may interfere with the efficacy of the drugb ) .
false
drugn may interact with the following drugs : drugn and other drugn ( may lower drugn levels ) , drugn ( bioavailability of oral drugn is increased with coadministration ) , drugn ( may decrease drugn levels ) , drugn ( reports of psychotic episodes when coadministered ) , druga ( coadministration of drugb with drugn can inhibit ovarian function in women ) , drugn and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and drugn ( coadministration of drugn and drugn may interfere with the efficacy of the drugn ) .
false
drugn may interact with the following drugs : drugn and other drugn ( may lower drugn levels ) , drugn ( bioavailability of oral drugn is increased with coadministration ) , drugn ( may decrease drugn levels ) , drugn ( reports of psychotic episodes when coadministered ) , druga ( coadministration of drugn with drugb can inhibit ovarian function in women ) , drugn and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and drugn ( coadministration of drugn and drugn may interfere with the efficacy of the drugn ) .
false
drugn may interact with the following drugs : drugn and other drugn ( may lower drugn levels ) , drugn ( bioavailability of oral drugn is increased with coadministration ) , drugn ( may decrease drugn levels ) , drugn ( reports of psychotic episodes when coadministered ) , druga ( coadministration of drugn with drugn can inhibit ovarian function in women ) , drugb and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and drugn ( coadministration of drugn and drugn may interfere with the efficacy of the drugn ) .
false
drugn may interact with the following drugs : drugn and other drugn ( may lower drugn levels ) , drugn ( bioavailability of oral drugn is increased with coadministration ) , drugn ( may decrease drugn levels ) , drugn ( reports of psychotic episodes when coadministered ) , druga ( coadministration of drugn with drugn can inhibit ovarian function in women ) , drugn and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and drugb ( coadministration of drugn and drugn may interfere with the efficacy of the drugn ) .
false
drugn may interact with the following drugs : drugn and other drugn ( may lower drugn levels ) , drugn ( bioavailability of oral drugn is increased with coadministration ) , drugn ( may decrease drugn levels ) , drugn ( reports of psychotic episodes when coadministered ) , druga ( coadministration of drugn with drugn can inhibit ovarian function in women ) , drugn and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and drugn ( coadministration of drugb and drugn may interfere with the efficacy of the drugn ) .
false
drugn may interact with the following drugs : drugn and other drugn ( may lower drugn levels ) , drugn ( bioavailability of oral drugn is increased with coadministration ) , drugn ( may decrease drugn levels ) , drugn ( reports of psychotic episodes when coadministered ) , druga ( coadministration of drugn with drugn can inhibit ovarian function in women ) , drugn and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and drugn ( coadministration of drugn and drugb may interfere with the efficacy of the drugn ) .
false
drugn may interact with the following drugs : drugn and other drugn ( may lower drugn levels ) , drugn ( bioavailability of oral drugn is increased with coadministration ) , drugn ( may decrease drugn levels ) , drugn ( reports of psychotic episodes when coadministered ) , druga ( coadministration of drugn with drugn can inhibit ovarian function in women ) , drugn and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and drugn ( coadministration of drugn and drugn may interfere with the efficacy of the drugb ) .
false
drugn may interact with the following drugs : drugn and other drugn ( may lower drugn levels ) , drugn ( bioavailability of oral drugn is increased with coadministration ) , drugn ( may decrease drugn levels ) , drugn ( reports of psychotic episodes when coadministered ) , drugn ( coadministration of druga with drugb can inhibit ovarian function in women ) , drugn and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and drugn ( coadministration of drugn and drugn may interfere with the efficacy of the drugn ) .
effect
drugn may interact with the following drugs : drugn and other drugn ( may lower drugn levels ) , drugn ( bioavailability of oral drugn is increased with coadministration ) , drugn ( may decrease drugn levels ) , drugn ( reports of psychotic episodes when coadministered ) , drugn ( coadministration of druga with drugn can inhibit ovarian function in women ) , drugb and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and drugn ( coadministration of drugn and drugn may interfere with the efficacy of the drugn ) .
false
drugn may interact with the following drugs : drugn and other drugn ( may lower drugn levels ) , drugn ( bioavailability of oral drugn is increased with coadministration ) , drugn ( may decrease drugn levels ) , drugn ( reports of psychotic episodes when coadministered ) , drugn ( coadministration of druga with drugn can inhibit ovarian function in women ) , drugn and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and drugb ( coadministration of drugn and drugn may interfere with the efficacy of the drugn ) .
false
drugn may interact with the following drugs : drugn and other drugn ( may lower drugn levels ) , drugn ( bioavailability of oral drugn is increased with coadministration ) , drugn ( may decrease drugn levels ) , drugn ( reports of psychotic episodes when coadministered ) , drugn ( coadministration of druga with drugn can inhibit ovarian function in women ) , drugn and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and drugn ( coadministration of drugb and drugn may interfere with the efficacy of the drugn ) .
false
drugn may interact with the following drugs : drugn and other drugn ( may lower drugn levels ) , drugn ( bioavailability of oral drugn is increased with coadministration ) , drugn ( may decrease drugn levels ) , drugn ( reports of psychotic episodes when coadministered ) , drugn ( coadministration of druga with drugn can inhibit ovarian function in women ) , drugn and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and drugn ( coadministration of drugn and drugb may interfere with the efficacy of the drugn ) .
false
drugn may interact with the following drugs : drugn and other drugn ( may lower drugn levels ) , drugn ( bioavailability of oral drugn is increased with coadministration ) , drugn ( may decrease drugn levels ) , drugn ( reports of psychotic episodes when coadministered ) , drugn ( coadministration of druga with drugn can inhibit ovarian function in women ) , drugn and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and drugn ( coadministration of drugn and drugn may interfere with the efficacy of the drugb ) .
false
drugn may interact with the following drugs : drugn and other drugn ( may lower drugn levels ) , drugn ( bioavailability of oral drugn is increased with coadministration ) , drugn ( may decrease drugn levels ) , drugn ( reports of psychotic episodes when coadministered ) , drugn ( coadministration of drugn with druga can inhibit ovarian function in women ) , drugb and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and drugn ( coadministration of drugn and drugn may interfere with the efficacy of the drugn ) .
false
drugn may interact with the following drugs : drugn and other drugn ( may lower drugn levels ) , drugn ( bioavailability of oral drugn is increased with coadministration ) , drugn ( may decrease drugn levels ) , drugn ( reports of psychotic episodes when coadministered ) , drugn ( coadministration of drugn with druga can inhibit ovarian function in women ) , drugn and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and drugb ( coadministration of drugn and drugn may interfere with the efficacy of the drugn ) .
false
drugn may interact with the following drugs : drugn and other drugn ( may lower drugn levels ) , drugn ( bioavailability of oral drugn is increased with coadministration ) , drugn ( may decrease drugn levels ) , drugn ( reports of psychotic episodes when coadministered ) , drugn ( coadministration of drugn with druga can inhibit ovarian function in women ) , drugn and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and drugn ( coadministration of drugb and drugn may interfere with the efficacy of the drugn ) .
false
drugn may interact with the following drugs : drugn and other drugn ( may lower drugn levels ) , drugn ( bioavailability of oral drugn is increased with coadministration ) , drugn ( may decrease drugn levels ) , drugn ( reports of psychotic episodes when coadministered ) , drugn ( coadministration of drugn with druga can inhibit ovarian function in women ) , drugn and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and drugn ( coadministration of drugn and drugb may interfere with the efficacy of the drugn ) .
false
drugn may interact with the following drugs : drugn and other drugn ( may lower drugn levels ) , drugn ( bioavailability of oral drugn is increased with coadministration ) , drugn ( may decrease drugn levels ) , drugn ( reports of psychotic episodes when coadministered ) , drugn ( coadministration of drugn with druga can inhibit ovarian function in women ) , drugn and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and drugn ( coadministration of drugn and drugn may interfere with the efficacy of the drugb ) .
false
drugn may interact with the following drugs : drugn and other drugn ( may lower drugn levels ) , drugn ( bioavailability of oral drugn is increased with coadministration ) , drugn ( may decrease drugn levels ) , drugn ( reports of psychotic episodes when coadministered ) , drugn ( coadministration of drugn with drugn can inhibit ovarian function in women ) , druga and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and drugb ( coadministration of drugn and drugn may interfere with the efficacy of the drugn ) .
false
drugn may interact with the following drugs : drugn and other drugn ( may lower drugn levels ) , drugn ( bioavailability of oral drugn is increased with coadministration ) , drugn ( may decrease drugn levels ) , drugn ( reports of psychotic episodes when coadministered ) , drugn ( coadministration of drugn with drugn can inhibit ovarian function in women ) , druga and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and drugn ( coadministration of drugb and drugn may interfere with the efficacy of the drugn ) .
false
drugn may interact with the following drugs : drugn and other drugn ( may lower drugn levels ) , drugn ( bioavailability of oral drugn is increased with coadministration ) , drugn ( may decrease drugn levels ) , drugn ( reports of psychotic episodes when coadministered ) , drugn ( coadministration of drugn with drugn can inhibit ovarian function in women ) , druga and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and drugn ( coadministration of drugn and drugb may interfere with the efficacy of the drugn ) .
false
drugn may interact with the following drugs : drugn and other drugn ( may lower drugn levels ) , drugn ( bioavailability of oral drugn is increased with coadministration ) , drugn ( may decrease drugn levels ) , drugn ( reports of psychotic episodes when coadministered ) , drugn ( coadministration of drugn with drugn can inhibit ovarian function in women ) , druga and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and drugn ( coadministration of drugn and drugn may interfere with the efficacy of the drugb ) .
false
drugn may interact with the following drugs : drugn and other drugn ( may lower drugn levels ) , drugn ( bioavailability of oral drugn is increased with coadministration ) , drugn ( may decrease drugn levels ) , drugn ( reports of psychotic episodes when coadministered ) , drugn ( coadministration of drugn with drugn can inhibit ovarian function in women ) , drugn and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and druga ( coadministration of drugb and drugn may interfere with the efficacy of the drugn ) .
false
drugn may interact with the following drugs : drugn and other drugn ( may lower drugn levels ) , drugn ( bioavailability of oral drugn is increased with coadministration ) , drugn ( may decrease drugn levels ) , drugn ( reports of psychotic episodes when coadministered ) , drugn ( coadministration of drugn with drugn can inhibit ovarian function in women ) , drugn and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and druga ( coadministration of drugn and drugb may interfere with the efficacy of the drugn ) .
false
drugn may interact with the following drugs : drugn and other drugn ( may lower drugn levels ) , drugn ( bioavailability of oral drugn is increased with coadministration ) , drugn ( may decrease drugn levels ) , drugn ( reports of psychotic episodes when coadministered ) , drugn ( coadministration of drugn with drugn can inhibit ovarian function in women ) , drugn and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and druga ( coadministration of drugn and drugn may interfere with the efficacy of the drugb ) .
false
drugn may interact with the following drugs : drugn and other drugn ( may lower drugn levels ) , drugn ( bioavailability of oral drugn is increased with coadministration ) , drugn ( may decrease drugn levels ) , drugn ( reports of psychotic episodes when coadministered ) , drugn ( coadministration of drugn with drugn can inhibit ovarian function in women ) , drugn and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and drugn ( coadministration of druga and drugb may interfere with the efficacy of the drugn ) .
effect
drugn may interact with the following drugs : drugn and other drugn ( may lower drugn levels ) , drugn ( bioavailability of oral drugn is increased with coadministration ) , drugn ( may decrease drugn levels ) , drugn ( reports of psychotic episodes when coadministered ) , drugn ( coadministration of drugn with drugn can inhibit ovarian function in women ) , drugn and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and drugn ( coadministration of druga and drugn may interfere with the efficacy of the drugb ) .
false
drugn may interact with the following drugs : drugn and other drugn ( may lower drugn levels ) , drugn ( bioavailability of oral drugn is increased with coadministration ) , drugn ( may decrease drugn levels ) , drugn ( reports of psychotic episodes when coadministered ) , drugn ( coadministration of drugn with drugn can inhibit ovarian function in women ) , drugn and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and drugn ( coadministration of drugn and druga may interfere with the efficacy of the drugb ) .
false
dosages of concomitantly administered druga should be reduced by approximately half , because drugb amplifies the therapeutic actions and side-effects of drugn .
effect
dosages of concomitantly administered druga should be reduced by approximately half , because drugn amplifies the therapeutic actions and side-effects of drugb .
false
dosages of concomitantly administered drugn should be reduced by approximately half , because druga amplifies the therapeutic actions and side-effects of drugb .
effect
combination with druga ( drugb ) is associated with increased risk of seizures .
false
additive sedative effects and confusional states may emerge if druga is given with drugb or drugn .
effect
additive sedative effects and confusional states may emerge if druga is given with drugn or drugb .
effect
additive sedative effects and confusional states may emerge if drugn is given with druga or drugb .
false
exert particular caution in combining druga with other drugb ( drugn and drugn ) : particularly the elderly may develop delirium , high fever , severe obstipation , even ileus and glaucoma .
advise
exert particular caution in combining druga with other drugn ( drugb and drugn ) : particularly the elderly may develop delirium , high fever , severe obstipation , even ileus and glaucoma .
advise
exert particular caution in combining druga with other drugn ( drugn and drugb ) : particularly the elderly may develop delirium , high fever , severe obstipation , even ileus and glaucoma .
advise
exert particular caution in combining drugn with other druga ( drugb and drugn ) : particularly the elderly may develop delirium , high fever , severe obstipation , even ileus and glaucoma .
false
exert particular caution in combining drugn with other druga ( drugn and drugb ) : particularly the elderly may develop delirium , high fever , severe obstipation , even ileus and glaucoma .
false
exert particular caution in combining drugn with other drugn ( druga and drugb ) : particularly the elderly may develop delirium , high fever , severe obstipation , even ileus and glaucoma .
false
druga and/or stimulantes of the drugb / drugn type may counteract the specific actions of drugn .
false
druga and/or stimulantes of the drugn / drugb type may counteract the specific actions of drugn .
false
druga and/or stimulantes of the drugn / drugn type may counteract the specific actions of drugb .
effect
drugn and/or stimulantes of the druga / drugb type may counteract the specific actions of drugn .
false
drugn and/or stimulantes of the druga / drugn type may counteract the specific actions of drugb .
effect
drugn and/or stimulantes of the drugn / druga type may counteract the specific actions of drugb .
effect
druga administered concomitantly with drugb may significantly decrease the serum concentrations of drugn .
mechanism
druga administered concomitantly with drugn may significantly decrease the serum concentrations of drugb .
false
drugn administered concomitantly with druga may significantly decrease the serum concentrations of drugb .
false
the occurrence of stupor , muscular rigidity , severe agitation , and elevated temperature has been reported in some patients receiving the combination of druga and drugb .
effect
this is typical of the interaction of druga and drugb .
int
severe toxicity has also been reported in patients receiving the combination of druga and drugb and drugn and drugn .
effect
severe toxicity has also been reported in patients receiving the combination of druga and drugn and drugb and drugn .
false
severe toxicity has also been reported in patients receiving the combination of druga and drugn and drugn and drugb .
false
severe toxicity has also been reported in patients receiving the combination of drugn and druga and drugb and drugn .
false
severe toxicity has also been reported in patients receiving the combination of drugn and druga and drugn and drugb .
false
severe toxicity has also been reported in patients receiving the combination of drugn and drugn and druga and drugb .
effect
one case of hypertensive crisis has been reported in a patient taking the recommended doses of druga and a drugb ( drugn ) .
effect
one case of hypertensive crisis has been reported in a patient taking the recommended doses of druga and a drugn ( drugb ) .
effect
one case of hypertensive crisis has been reported in a patient taking the recommended doses of drugn and a druga ( drugb ) .
false
the bioavailability of druga is decreased 80 % by drugb , when drugn and drugn are administered at the same time , and 60 % by some drugn - or drugn -containing drugn , when administered 1 hour before drugn .
mechanism
the bioavailability of druga is decreased 80 % by drugn , when drugb and drugn are administered at the same time , and 60 % by some drugn - or drugn -containing drugn , when administered 1 hour before drugn .
false
the bioavailability of druga is decreased 80 % by drugn , when drugn and drugb are administered at the same time , and 60 % by some drugn - or drugn -containing drugn , when administered 1 hour before drugn .
false
the bioavailability of druga is decreased 80 % by drugn , when drugn and drugn are administered at the same time , and 60 % by some drugb - or drugn -containing drugn , when administered 1 hour before drugn .
false
the bioavailability of druga is decreased 80 % by drugn , when drugn and drugn are administered at the same time , and 60 % by some drugn - or drugb -containing drugn , when administered 1 hour before drugn .
false
the bioavailability of druga is decreased 80 % by drugn , when drugn and drugn are administered at the same time , and 60 % by some drugn - or drugn -containing drugb , when administered 1 hour before drugn .
false
the bioavailability of druga is decreased 80 % by drugn , when drugn and drugn are administered at the same time , and 60 % by some drugn - or drugn -containing drugn , when administered 1 hour before drugb .
false
the bioavailability of drugn is decreased 80 % by druga , when drugb and drugn are administered at the same time , and 60 % by some drugn - or drugn -containing drugn , when administered 1 hour before drugn .
false
the bioavailability of drugn is decreased 80 % by druga , when drugn and drugb are administered at the same time , and 60 % by some drugn - or drugn -containing drugn , when administered 1 hour before drugn .
false
the bioavailability of drugn is decreased 80 % by druga , when drugn and drugn are administered at the same time , and 60 % by some drugb - or drugn -containing drugn , when administered 1 hour before drugn .
false
the bioavailability of drugn is decreased 80 % by druga , when drugn and drugn are administered at the same time , and 60 % by some drugn - or drugb -containing drugn , when administered 1 hour before drugn .
false
the bioavailability of drugn is decreased 80 % by druga , when drugn and drugn are administered at the same time , and 60 % by some drugn - or drugn -containing drugb , when administered 1 hour before drugn .
false
the bioavailability of drugn is decreased 80 % by druga , when drugn and drugn are administered at the same time , and 60 % by some drugn - or drugn -containing drugn , when administered 1 hour before drugb .
false
the bioavailability of drugn is decreased 80 % by drugn , when druga and drugb are administered at the same time , and 60 % by some drugn - or drugn -containing drugn , when administered 1 hour before drugn .
false
the bioavailability of drugn is decreased 80 % by drugn , when druga and drugn are administered at the same time , and 60 % by some drugb - or drugn -containing drugn , when administered 1 hour before drugn .
false
the bioavailability of drugn is decreased 80 % by drugn , when druga and drugn are administered at the same time , and 60 % by some drugn - or drugb -containing drugn , when administered 1 hour before drugn .
false
the bioavailability of drugn is decreased 80 % by drugn , when druga and drugn are administered at the same time , and 60 % by some drugn - or drugn -containing drugb , when administered 1 hour before drugn .
false
the bioavailability of drugn is decreased 80 % by drugn , when druga and drugn are administered at the same time , and 60 % by some drugn - or drugn -containing drugn , when administered 1 hour before drugb .
false
the bioavailability of drugn is decreased 80 % by drugn , when drugn and druga are administered at the same time , and 60 % by some drugb - or drugn -containing drugn , when administered 1 hour before drugn .
false
the bioavailability of drugn is decreased 80 % by drugn , when drugn and druga are administered at the same time , and 60 % by some drugn - or drugb -containing drugn , when administered 1 hour before drugn .
false
the bioavailability of drugn is decreased 80 % by drugn , when drugn and druga are administered at the same time , and 60 % by some drugn - or drugn -containing drugb , when administered 1 hour before drugn .
false
the bioavailability of drugn is decreased 80 % by drugn , when drugn and druga are administered at the same time , and 60 % by some drugn - or drugn -containing drugn , when administered 1 hour before drugb .
false
the bioavailability of drugn is decreased 80 % by drugn , when drugn and drugn are administered at the same time , and 60 % by some druga - or drugb -containing drugn , when administered 1 hour before drugn .
false
the bioavailability of drugn is decreased 80 % by drugn , when drugn and drugn are administered at the same time , and 60 % by some druga - or drugn -containing drugb , when administered 1 hour before drugn .
false
the bioavailability of drugn is decreased 80 % by drugn , when drugn and drugn are administered at the same time , and 60 % by some druga - or drugn -containing drugn , when administered 1 hour before drugb .
mechanism
the bioavailability of drugn is decreased 80 % by drugn , when drugn and drugn are administered at the same time , and 60 % by some drugn - or druga -containing drugb , when administered 1 hour before drugn .
false
the bioavailability of drugn is decreased 80 % by drugn , when drugn and drugn are administered at the same time , and 60 % by some drugn - or druga -containing drugn , when administered 1 hour before drugb .
mechanism
the bioavailability of drugn is decreased 80 % by drugn , when drugn and drugn are administered at the same time , and 60 % by some drugn - or drugn -containing druga , when administered 1 hour before drugb .
false
druga may decrease bioavailability of drugb by up to 50 % when taken 2 hours after drugn .
mechanism
druga may decrease bioavailability of drugn by up to 50 % when taken 2 hours after drugb .
false
drugn may decrease bioavailability of druga by up to 50 % when taken 2 hours after drugb .
false
the bioavailability of druga is increased 2-4 fold by drugb but is not significantly altered by coadministration of drugn .
mechanism
the bioavailability of druga is increased 2-4 fold by drugn but is not significantly altered by coadministration of drugb .
false
the bioavailability of drugn is increased 2-4 fold by druga but is not significantly altered by coadministration of drugb .
false
the pharmacokinetic parameters of druga are not significantly modified by drugb coadministration .
false
in vitro studies show that druga does not displace drugb from its binding site on protein .
false
druga : in a multiple-dose study in 30 normal weight subjects , coadministration of drugb and 40 grams of drugn ( e.g. , approximately 3 glasses of wine ) did not result in alteration of drugn pharmacokinetics , drugn pharmacodynamics ( fecal fat excretion ) , or systemic exposure to drugn .
false
druga : in a multiple-dose study in 30 normal weight subjects , coadministration of drugn and 40 grams of drugb ( e.g. , approximately 3 glasses of wine ) did not result in alteration of drugn pharmacokinetics , drugn pharmacodynamics ( fecal fat excretion ) , or systemic exposure to drugn .
false
druga : in a multiple-dose study in 30 normal weight subjects , coadministration of drugn and 40 grams of drugn ( e.g. , approximately 3 glasses of wine ) did not result in alteration of drugb pharmacokinetics , drugn pharmacodynamics ( fecal fat excretion ) , or systemic exposure to drugn .
false
druga : in a multiple-dose study in 30 normal weight subjects , coadministration of drugn and 40 grams of drugn ( e.g. , approximately 3 glasses of wine ) did not result in alteration of drugn pharmacokinetics , drugb pharmacodynamics ( fecal fat excretion ) , or systemic exposure to drugn .
false
druga : in a multiple-dose study in 30 normal weight subjects , coadministration of drugn and 40 grams of drugn ( e.g. , approximately 3 glasses of wine ) did not result in alteration of drugn pharmacokinetics , drugn pharmacodynamics ( fecal fat excretion ) , or systemic exposure to drugb .
false
drugn : in a multiple-dose study in 30 normal weight subjects , coadministration of druga and 40 grams of drugb ( e.g. , approximately 3 glasses of wine ) did not result in alteration of drugn pharmacokinetics , drugn pharmacodynamics ( fecal fat excretion ) , or systemic exposure to drugn .
false
drugn : in a multiple-dose study in 30 normal weight subjects , coadministration of druga and 40 grams of drugn ( e.g. , approximately 3 glasses of wine ) did not result in alteration of drugb pharmacokinetics , drugn pharmacodynamics ( fecal fat excretion ) , or systemic exposure to drugn .
false
drugn : in a multiple-dose study in 30 normal weight subjects , coadministration of druga and 40 grams of drugn ( e.g. , approximately 3 glasses of wine ) did not result in alteration of drugn pharmacokinetics , drugb pharmacodynamics ( fecal fat excretion ) , or systemic exposure to drugn .
false
drugn : in a multiple-dose study in 30 normal weight subjects , coadministration of druga and 40 grams of drugn ( e.g. , approximately 3 glasses of wine ) did not result in alteration of drugn pharmacokinetics , drugn pharmacodynamics ( fecal fat excretion ) , or systemic exposure to drugb .
false
drugn : in a multiple-dose study in 30 normal weight subjects , coadministration of drugn and 40 grams of druga ( e.g. , approximately 3 glasses of wine ) did not result in alteration of drugb pharmacokinetics , drugn pharmacodynamics ( fecal fat excretion ) , or systemic exposure to drugn .
false
drugn : in a multiple-dose study in 30 normal weight subjects , coadministration of drugn and 40 grams of druga ( e.g. , approximately 3 glasses of wine ) did not result in alteration of drugn pharmacokinetics , drugb pharmacodynamics ( fecal fat excretion ) , or systemic exposure to drugn .
false
drugn : in a multiple-dose study in 30 normal weight subjects , coadministration of drugn and 40 grams of druga ( e.g. , approximately 3 glasses of wine ) did not result in alteration of drugn pharmacokinetics , drugn pharmacodynamics ( fecal fat excretion ) , or systemic exposure to drugb .
false
drugn : in a multiple-dose study in 30 normal weight subjects , coadministration of drugn and 40 grams of drugn ( e.g. , approximately 3 glasses of wine ) did not result in alteration of druga pharmacokinetics , drugb pharmacodynamics ( fecal fat excretion ) , or systemic exposure to drugn .
false
drugn : in a multiple-dose study in 30 normal weight subjects , coadministration of drugn and 40 grams of drugn ( e.g. , approximately 3 glasses of wine ) did not result in alteration of druga pharmacokinetics , drugn pharmacodynamics ( fecal fat excretion ) , or systemic exposure to drugb .
false
drugn : in a multiple-dose study in 30 normal weight subjects , coadministration of drugn and 40 grams of drugn ( e.g. , approximately 3 glasses of wine ) did not result in alteration of drugn pharmacokinetics , druga pharmacodynamics ( fecal fat excretion ) , or systemic exposure to drugb .
false
druga : preliminary data from a drugb and drugn drug interaction study indicate a reduction in drugn plasma levels when drugn was coadministered with drugn .
false
druga : preliminary data from a drugn and drugb drug interaction study indicate a reduction in drugn plasma levels when drugn was coadministered with drugn .
false
druga : preliminary data from a drugn and drugn drug interaction study indicate a reduction in drugb plasma levels when drugn was coadministered with drugn .
false
druga : preliminary data from a drugn and drugn drug interaction study indicate a reduction in drugn plasma levels when drugb was coadministered with drugn .
false
druga : preliminary data from a drugn and drugn drug interaction study indicate a reduction in drugn plasma levels when drugn was coadministered with drugb .
false
drugn : preliminary data from a druga and drugb drug interaction study indicate a reduction in drugn plasma levels when drugn was coadministered with drugn .
false
drugn : preliminary data from a druga and drugn drug interaction study indicate a reduction in drugb plasma levels when drugn was coadministered with drugn .
false
drugn : preliminary data from a druga and drugn drug interaction study indicate a reduction in drugn plasma levels when drugb was coadministered with drugn .
false
drugn : preliminary data from a druga and drugn drug interaction study indicate a reduction in drugn plasma levels when drugn was coadministered with drugb .
false
drugn : preliminary data from a drugn and druga drug interaction study indicate a reduction in drugb plasma levels when drugn was coadministered with drugn .
false
drugn : preliminary data from a drugn and druga drug interaction study indicate a reduction in drugn plasma levels when drugb was coadministered with drugn .
false
drugn : preliminary data from a drugn and druga drug interaction study indicate a reduction in drugn plasma levels when drugn was coadministered with drugb .
false
drugn : preliminary data from a drugn and drugn drug interaction study indicate a reduction in druga plasma levels when drugb was coadministered with drugn .
false
drugn : preliminary data from a drugn and drugn drug interaction study indicate a reduction in druga plasma levels when drugn was coadministered with drugb .
false
drugn : preliminary data from a drugn and drugn drug interaction study indicate a reduction in drugn plasma levels when druga was coadministered with drugb .
mechanism
druga : in 12 normal-weight subjects receiving drugb 120 mg three times a day for 6 days , drugn did not alter the pharmacokinetics of a single dose of drugn .
false
druga : in 12 normal-weight subjects receiving drugn 120 mg three times a day for 6 days , drugb did not alter the pharmacokinetics of a single dose of drugn .
false
druga : in 12 normal-weight subjects receiving drugn 120 mg three times a day for 6 days , drugn did not alter the pharmacokinetics of a single dose of drugb .
false
drugn : in 12 normal-weight subjects receiving druga 120 mg three times a day for 6 days , drugb did not alter the pharmacokinetics of a single dose of drugn .
false
drugn : in 12 normal-weight subjects receiving druga 120 mg three times a day for 6 days , drugn did not alter the pharmacokinetics of a single dose of drugb .
false
drugn : in 12 normal-weight subjects receiving drugn 120 mg three times a day for 6 days , druga did not alter the pharmacokinetics of a single dose of drugb .
false
druga and analogues : a pharmacokinetic interaction study showed a 30 % reduction in drugb supplement absorption when concomitantly administered with drugn .
false
druga and analogues : a pharmacokinetic interaction study showed a 30 % reduction in drugn supplement absorption when concomitantly administered with drugb .
false
drugn and analogues : a pharmacokinetic interaction study showed a 30 % reduction in druga supplement absorption when concomitantly administered with drugb .
mechanism
druga inhibited absorption of a drugb supplement by approximately 60 % .
mechanism
the effect of druga on the absorption of supplemental drugb , drugn , and nutritionally-derived drugn is not known at this time .
false
the effect of druga on the absorption of supplemental drugn , drugb , and nutritionally-derived drugn is not known at this time .
false
the effect of druga on the absorption of supplemental drugn , drugn , and nutritionally-derived drugb is not known at this time .
false
the effect of drugn on the absorption of supplemental druga , drugb , and nutritionally-derived drugn is not known at this time .
false
the effect of drugn on the absorption of supplemental druga , drugn , and nutritionally-derived drugb is not known at this time .
false
the effect of drugn on the absorption of supplemental drugn , druga , and nutritionally-derived drugb is not known at this time .
false
druga : in 12 normal-weight subjects receiving drugb 80 mg three times a day for 5 days , drugn did not alter the pharmacokinetics or pharmacodynamics ( blood glucose-lowering ) of drugn .
false
druga : in 12 normal-weight subjects receiving drugn 80 mg three times a day for 5 days , drugb did not alter the pharmacokinetics or pharmacodynamics ( blood glucose-lowering ) of drugn .
false
druga : in 12 normal-weight subjects receiving drugn 80 mg three times a day for 5 days , drugn did not alter the pharmacokinetics or pharmacodynamics ( blood glucose-lowering ) of drugb .
false
drugn : in 12 normal-weight subjects receiving druga 80 mg three times a day for 5 days , drugb did not alter the pharmacokinetics or pharmacodynamics ( blood glucose-lowering ) of drugn .
false
drugn : in 12 normal-weight subjects receiving druga 80 mg three times a day for 5 days , drugn did not alter the pharmacokinetics or pharmacodynamics ( blood glucose-lowering ) of drugb .
false
drugn : in 12 normal-weight subjects receiving drugn 80 mg three times a day for 5 days , druga did not alter the pharmacokinetics or pharmacodynamics ( blood glucose-lowering ) of drugb .
false
druga ( extended-release tablets ) : in 17 normal-weight subjects receiving drugb 120 mg three times a day for 6 days , drugn did not alter the bioavailability of drugn ( extended-release tablets ) .
false
druga ( extended-release tablets ) : in 17 normal-weight subjects receiving drugn 120 mg three times a day for 6 days , drugb did not alter the bioavailability of drugn ( extended-release tablets ) .
false
druga ( extended-release tablets ) : in 17 normal-weight subjects receiving drugn 120 mg three times a day for 6 days , drugn did not alter the bioavailability of drugb ( extended-release tablets ) .
false
drugn ( extended-release tablets ) : in 17 normal-weight subjects receiving druga 120 mg three times a day for 6 days , drugb did not alter the bioavailability of drugn ( extended-release tablets ) .
false
drugn ( extended-release tablets ) : in 17 normal-weight subjects receiving druga 120 mg three times a day for 6 days , drugn did not alter the bioavailability of drugb ( extended-release tablets ) .
false
drugn ( extended-release tablets ) : in 17 normal-weight subjects receiving drugn 120 mg three times a day for 6 days , druga did not alter the bioavailability of drugb ( extended-release tablets ) .
false
oral druga : in 20 normal-weight female subjects , the treatment of drugb 120 mg three times a day for 23 days resulted in no changes in the ovulation-suppressing action of oral drugn .
false
oral druga : in 20 normal-weight female subjects , the treatment of drugn 120 mg three times a day for 23 days resulted in no changes in the ovulation-suppressing action of oral drugb .
false
oral drugn : in 20 normal-weight female subjects , the treatment of druga 120 mg three times a day for 23 days resulted in no changes in the ovulation-suppressing action of oral drugb .
false
druga : in 12 normal-weight subjects receiving drugb 120 mg three times a day for 7 days , drugn did not alter the pharmacokinetics of a single 300-mg dose of drugn .
false
druga : in 12 normal-weight subjects receiving drugn 120 mg three times a day for 7 days , drugb did not alter the pharmacokinetics of a single 300-mg dose of drugn .
false
druga : in 12 normal-weight subjects receiving drugn 120 mg three times a day for 7 days , drugn did not alter the pharmacokinetics of a single 300-mg dose of drugb .
false
drugn : in 12 normal-weight subjects receiving druga 120 mg three times a day for 7 days , drugb did not alter the pharmacokinetics of a single 300-mg dose of drugn .
false
drugn : in 12 normal-weight subjects receiving druga 120 mg three times a day for 7 days , drugn did not alter the pharmacokinetics of a single 300-mg dose of drugb .
false
drugn : in 12 normal-weight subjects receiving drugn 120 mg three times a day for 7 days , druga did not alter the pharmacokinetics of a single 300-mg dose of drugb .
false
druga : in a 2-way crossover study of 24 normal-weight , mildly hypercholesterolemic patients receiving drugb 120 mg three times a day for 6 days , drugn did not affect the pharmacokinetics of drugn .
false
druga : in a 2-way crossover study of 24 normal-weight , mildly hypercholesterolemic patients receiving drugn 120 mg three times a day for 6 days , drugb did not affect the pharmacokinetics of drugn .
false
druga : in a 2-way crossover study of 24 normal-weight , mildly hypercholesterolemic patients receiving drugn 120 mg three times a day for 6 days , drugn did not affect the pharmacokinetics of drugb .
false
drugn : in a 2-way crossover study of 24 normal-weight , mildly hypercholesterolemic patients receiving druga 120 mg three times a day for 6 days , drugb did not affect the pharmacokinetics of drugn .
false
drugn : in a 2-way crossover study of 24 normal-weight , mildly hypercholesterolemic patients receiving druga 120 mg three times a day for 6 days , drugn did not affect the pharmacokinetics of drugb .
false
drugn : in a 2-way crossover study of 24 normal-weight , mildly hypercholesterolemic patients receiving drugn 120 mg three times a day for 6 days , druga did not affect the pharmacokinetics of drugb .
false
druga : in 12 normal-weight subjects , administration of drugb 120 mg three times a day for 16 days did not result in any change in either drugn pharmacokinetics ( both r- and s-enantiomers ) or pharmacodynamics ( prothrombin time and serum factor vii ) .
false
druga : in 12 normal-weight subjects , administration of drugn 120 mg three times a day for 16 days did not result in any change in either drugb pharmacokinetics ( both r- and s-enantiomers ) or pharmacodynamics ( prothrombin time and serum factor vii ) .
false
drugn : in 12 normal-weight subjects , administration of druga 120 mg three times a day for 16 days did not result in any change in either drugb pharmacokinetics ( both r- and s-enantiomers ) or pharmacodynamics ( prothrombin time and serum factor vii ) .
false
although undercarboxylated osteocalcin , a marker of vitamin k nutritional status , was unaltered with druga administration , vitamin k levels tended to decline in subjects taking drugb .
false
therefore , as druga absorption may be decreased with drugb , patients on chronic stable doses of drugn who are prescribed drugn should be monitored closely for changes in coagulation parameters .
mechanism
therefore , as druga absorption may be decreased with drugn , patients on chronic stable doses of drugb who are prescribed drugn should be monitored closely for changes in coagulation parameters .
false
therefore , as druga absorption may be decreased with drugn , patients on chronic stable doses of drugn who are prescribed drugb should be monitored closely for changes in coagulation parameters .
false
therefore , as drugn absorption may be decreased with druga , patients on chronic stable doses of drugb who are prescribed drugn should be monitored closely for changes in coagulation parameters .
false
therefore , as drugn absorption may be decreased with druga , patients on chronic stable doses of drugn who are prescribed drugb should be monitored closely for changes in coagulation parameters .
false
therefore , as drugn absorption may be decreased with drugn , patients on chronic stable doses of druga who are prescribed drugb should be monitored closely for changes in coagulation parameters .
advise
potential for druga to affect other drugs drugb is not expected to cause clinically important pharmacokinetic interactions with drugs that are metabolized by cytochrome p450 isozymes .
false
given the primary cns effects of druga , drugb should be used with caution in combination with other drugn and drugn .
false
given the primary cns effects of druga , drugn should be used with caution in combination with other drugb and drugn .
advise
given the primary cns effects of druga , drugn should be used with caution in combination with other drugn and drugb .
advise
given the primary cns effects of drugn , druga should be used with caution in combination with other drugb and drugn .
advise
given the primary cns effects of drugn , druga should be used with caution in combination with other drugn and drugb .
advise
given the primary cns effects of drugn , drugn should be used with caution in combination with other druga and drugb .
false
druga may antagonize the effect of drugb and other drugn .
effect
druga may antagonize the effect of drugn and other drugb .
effect
drugn may antagonize the effect of druga and other drugb .
false
potential for other drugs to affect druga drugb is not a substrate of cyp1a2 , cyp2a6 , cyp2c9 , and cyp2c19 , so that an interaction with inhibitors or inducers of these isozymes is unlikely .
false
other druga should not be used concomitantly with drugb ( drugn usp ) because they may have additive effects .
advise
other druga should not be used concomitantly with drugn ( drugb usp ) because they may have additive effects .
advise
other drugn should not be used concomitantly with druga ( drugb usp ) because they may have additive effects .
false
druga should be administered with caution to patients being treated with drugb or drugn , since the action of drugn on the vascular system may be potentiated .
advise
druga should be administered with caution to patients being treated with drugn or drugb , since the action of drugn on the vascular system may be potentiated .
advise
druga should be administered with caution to patients being treated with drugn or drugn , since the action of drugb on the vascular system may be potentiated .
false
drugn should be administered with caution to patients being treated with druga or drugb , since the action of drugn on the vascular system may be potentiated .
false
drugn should be administered with caution to patients being treated with druga or drugn , since the action of drugb on the vascular system may be potentiated .
false
drugn should be administered with caution to patients being treated with drugn or druga , since the action of drugb on the vascular system may be potentiated .
false
the cns-depressant effect of druga is additive with that of other drugb , including drugn .
effect
the cns-depressant effect of druga is additive with that of other drugn , including drugb .
effect
the cns-depressant effect of drugn is additive with that of other druga , including drugb .
false
such occurrences have been reported when druga was administered to patients on drugb , drugn , or drugn -like drugs .
false
such occurrences have been reported when druga was administered to patients on drugn , drugb , or drugn -like drugs .
false
such occurrences have been reported when druga was administered to patients on drugn , drugn , or drugb -like drugs .
false
such occurrences have been reported when drugn was administered to patients on druga , drugb , or drugn -like drugs .
false
such occurrences have been reported when drugn was administered to patients on druga , drugn , or drugb -like drugs .
false
such occurrences have been reported when drugn was administered to patients on drugn , druga , or drugb -like drugs .
false
druga should be used with care in patients taking other drugs that are capable of causing cns effects such as drugb , drugn , or drugn .
advise
druga should be used with care in patients taking other drugs that are capable of causing cns effects such as drugn , drugb , or drugn .
advise
druga should be used with care in patients taking other drugs that are capable of causing cns effects such as drugn , drugn , or drugb .
advise
drugn should be used with care in patients taking other drugs that are capable of causing cns effects such as druga , drugb , or drugn .
false
drugn should be used with care in patients taking other drugs that are capable of causing cns effects such as druga , drugn , or drugb .
false
drugn should be used with care in patients taking other drugs that are capable of causing cns effects such as drugn , druga , or drugb .
false
e.g. , other druga , drugb ( including drugn ) , drugn , and drugn .
false
e.g. , other druga , drugn ( including drugb ) , drugn , and drugn .
false
e.g. , other druga , drugn ( including drugn ) , drugb , and drugn .
false
e.g. , other druga , drugn ( including drugn ) , drugn , and drugb .
false
e.g. , other drugn , druga ( including drugb ) , drugn , and drugn .
false
e.g. , other drugn , druga ( including drugn ) , drugb , and drugn .
false
e.g. , other drugn , druga ( including drugn ) , drugn , and drugb .
false
e.g. , other drugn , drugn ( including druga ) , drugb , and drugn .
false
e.g. , other drugn , drugn ( including druga ) , drugn , and drugb .
false
e.g. , other drugn , drugn ( including drugn ) , druga , and drugb .
false
in addition to bleeding associated with druga and drugb , drugs that alter platelet function ( such as drugn , drugn , and drugn ) may increase the risk of bleeding if administered prior to or after drugn therapy .
false
in addition to bleeding associated with druga and drugn , drugs that alter platelet function ( such as drugb , drugn , and drugn ) may increase the risk of bleeding if administered prior to or after drugn therapy .
false
in addition to bleeding associated with druga and drugn , drugs that alter platelet function ( such as drugn , drugb , and drugn ) may increase the risk of bleeding if administered prior to or after drugn therapy .
false
in addition to bleeding associated with druga and drugn , drugs that alter platelet function ( such as drugn , drugn , and drugb ) may increase the risk of bleeding if administered prior to or after drugn therapy .
false
in addition to bleeding associated with druga and drugn , drugs that alter platelet function ( such as drugn , drugn , and drugn ) may increase the risk of bleeding if administered prior to or after drugb therapy .
effect
in addition to bleeding associated with drugn and druga , drugs that alter platelet function ( such as drugb , drugn , and drugn ) may increase the risk of bleeding if administered prior to or after drugn therapy .
false
in addition to bleeding associated with drugn and druga , drugs that alter platelet function ( such as drugn , drugb , and drugn ) may increase the risk of bleeding if administered prior to or after drugn therapy .
false
in addition to bleeding associated with drugn and druga , drugs that alter platelet function ( such as drugn , drugn , and drugb ) may increase the risk of bleeding if administered prior to or after drugn therapy .
false
in addition to bleeding associated with drugn and druga , drugs that alter platelet function ( such as drugn , drugn , and drugn ) may increase the risk of bleeding if administered prior to or after drugb therapy .
effect
in addition to bleeding associated with drugn and drugn , drugs that alter platelet function ( such as druga , drugb , and drugn ) may increase the risk of bleeding if administered prior to or after drugn therapy .
false
in addition to bleeding associated with drugn and drugn , drugs that alter platelet function ( such as druga , drugn , and drugb ) may increase the risk of bleeding if administered prior to or after drugn therapy .
false
in addition to bleeding associated with drugn and drugn , drugs that alter platelet function ( such as druga , drugn , and drugn ) may increase the risk of bleeding if administered prior to or after drugb therapy .
effect
in addition to bleeding associated with drugn and drugn , drugs that alter platelet function ( such as drugn , druga , and drugb ) may increase the risk of bleeding if administered prior to or after drugn therapy .
false
in addition to bleeding associated with drugn and drugn , drugs that alter platelet function ( such as drugn , druga , and drugn ) may increase the risk of bleeding if administered prior to or after drugb therapy .
effect
in addition to bleeding associated with drugn and drugn , drugs that alter platelet function ( such as drugn , drugn , and druga ) may increase the risk of bleeding if administered prior to or after drugb therapy .
effect
other eye drops or medications such as druga ( drugb ) and drugn ( drugn , drugn ) may decrease the effects of drugn ophthalmic .
false
other eye drops or medications such as druga ( drugn ) and drugb ( drugn , drugn ) may decrease the effects of drugn ophthalmic .
false
other eye drops or medications such as druga ( drugn ) and drugn ( drugb , drugn ) may decrease the effects of drugn ophthalmic .
false
other eye drops or medications such as druga ( drugn ) and drugn ( drugn , drugb ) may decrease the effects of drugn ophthalmic .
false
other eye drops or medications such as druga ( drugn ) and drugn ( drugn , drugn ) may decrease the effects of drugb ophthalmic .
effect
other eye drops or medications such as drugn ( druga ) and drugb ( drugn , drugn ) may decrease the effects of drugn ophthalmic .
false
other eye drops or medications such as drugn ( druga ) and drugn ( drugb , drugn ) may decrease the effects of drugn ophthalmic .
false
other eye drops or medications such as drugn ( druga ) and drugn ( drugn , drugb ) may decrease the effects of drugn ophthalmic .
false
other eye drops or medications such as drugn ( druga ) and drugn ( drugn , drugn ) may decrease the effects of drugb ophthalmic .
effect
other eye drops or medications such as drugn ( drugn ) and druga ( drugb , drugn ) may decrease the effects of drugn ophthalmic .
false
other eye drops or medications such as drugn ( drugn ) and druga ( drugn , drugb ) may decrease the effects of drugn ophthalmic .
false
other eye drops or medications such as drugn ( drugn ) and druga ( drugn , drugn ) may decrease the effects of drugb ophthalmic .
effect
other eye drops or medications such as drugn ( drugn ) and drugn ( druga , drugb ) may decrease the effects of drugn ophthalmic .
false
other eye drops or medications such as drugn ( drugn ) and drugn ( druga , drugn ) may decrease the effects of drugb ophthalmic .
effect
other eye drops or medications such as drugn ( drugn ) and drugn ( drugn , druga ) may decrease the effects of drugb ophthalmic .
effect
use with other druga : the depressant effects of drugb are potentiated by the presence of other drugn such as drugn , drugn , drugn , or drugn .
false
use with other druga : the depressant effects of drugn are potentiated by the presence of other drugb such as drugn , drugn , drugn , or drugn .
false
use with other druga : the depressant effects of drugn are potentiated by the presence of other drugn such as drugb , drugn , drugn , or drugn .
false
use with other druga : the depressant effects of drugn are potentiated by the presence of other drugn such as drugn , drugb , drugn , or drugn .
false
use with other druga : the depressant effects of drugn are potentiated by the presence of other drugn such as drugn , drugn , drugb , or drugn .
false
use with other druga : the depressant effects of drugn are potentiated by the presence of other drugn such as drugn , drugn , drugn , or drugb .
false
use with other drugn : the depressant effects of druga are potentiated by the presence of other drugb such as drugn , drugn , drugn , or drugn .
effect
use with other drugn : the depressant effects of druga are potentiated by the presence of other drugn such as drugb , drugn , drugn , or drugn .
effect
use with other drugn : the depressant effects of druga are potentiated by the presence of other drugn such as drugn , drugb , drugn , or drugn .
effect
use with other drugn : the depressant effects of druga are potentiated by the presence of other drugn such as drugn , drugn , drugb , or drugn .
effect
use with other drugn : the depressant effects of druga are potentiated by the presence of other drugn such as drugn , drugn , drugn , or drugb .
effect
use with other drugn : the depressant effects of drugn are potentiated by the presence of other druga such as drugb , drugn , drugn , or drugn .
false
use with other drugn : the depressant effects of drugn are potentiated by the presence of other druga such as drugn , drugb , drugn , or drugn .
false
use with other drugn : the depressant effects of drugn are potentiated by the presence of other druga such as drugn , drugn , drugb , or drugn .
false
use with other drugn : the depressant effects of drugn are potentiated by the presence of other druga such as drugn , drugn , drugn , or drugb .
false
use with other drugn : the depressant effects of drugn are potentiated by the presence of other drugn such as druga , drugb , drugn , or drugn .
false
use with other drugn : the depressant effects of drugn are potentiated by the presence of other drugn such as druga , drugn , drugb , or drugn .
false
use with other drugn : the depressant effects of drugn are potentiated by the presence of other drugn such as druga , drugn , drugn , or drugb .
false
use with other drugn : the depressant effects of drugn are potentiated by the presence of other drugn such as drugn , druga , drugb , or drugn .
false
use with other drugn : the depressant effects of drugn are potentiated by the presence of other drugn such as drugn , druga , drugn , or drugb .
false
use with other drugn : the depressant effects of drugn are potentiated by the presence of other drugn such as drugn , drugn , druga , or drugb .
false
use of druga in conjunction with oral drugb may increase the risk of respiratory depression , hypotension and profound sedation or coma .
effect
interaction with druga : drugb ( i.e. , drugn , drugn , drugn , or drugn ) should not be administered to patients who have received or are receiving a course of therapy with a proof drugn .
false
interaction with druga : drugn ( i.e. , drugb , drugn , drugn , or drugn ) should not be administered to patients who have received or are receiving a course of therapy with a proof drugn .
false
interaction with druga : drugn ( i.e. , drugn , drugb , drugn , or drugn ) should not be administered to patients who have received or are receiving a course of therapy with a proof drugn .
false
interaction with druga : drugn ( i.e. , drugn , drugn , drugb , or drugn ) should not be administered to patients who have received or are receiving a course of therapy with a proof drugn .
false
interaction with druga : drugn ( i.e. , drugn , drugn , drugn , or drugb ) should not be administered to patients who have received or are receiving a course of therapy with a proof drugn .
false
interaction with druga : drugn ( i.e. , drugn , drugn , drugn , or drugn ) should not be administered to patients who have received or are receiving a course of therapy with a proof drugb .
false
interaction with drugn : druga ( i.e. , drugb , drugn , drugn , or drugn ) should not be administered to patients who have received or are receiving a course of therapy with a proof drugn .
false
interaction with drugn : druga ( i.e. , drugn , drugb , drugn , or drugn ) should not be administered to patients who have received or are receiving a course of therapy with a proof drugn .
false
interaction with drugn : druga ( i.e. , drugn , drugn , drugb , or drugn ) should not be administered to patients who have received or are receiving a course of therapy with a proof drugn .
false
interaction with drugn : druga ( i.e. , drugn , drugn , drugn , or drugb ) should not be administered to patients who have received or are receiving a course of therapy with a proof drugn .
false
interaction with drugn : druga ( i.e. , drugn , drugn , drugn , or drugn ) should not be administered to patients who have received or are receiving a course of therapy with a proof drugb .
advise
interaction with drugn : drugn ( i.e. , druga , drugb , drugn , or drugn ) should not be administered to patients who have received or are receiving a course of therapy with a proof drugn .
false
interaction with drugn : drugn ( i.e. , druga , drugn , drugb , or drugn ) should not be administered to patients who have received or are receiving a course of therapy with a proof drugn .
false
interaction with drugn : drugn ( i.e. , druga , drugn , drugn , or drugb ) should not be administered to patients who have received or are receiving a course of therapy with a proof drugn .
false
interaction with drugn : drugn ( i.e. , druga , drugn , drugn , or drugn ) should not be administered to patients who have received or are receiving a course of therapy with a proof drugb .
advise
interaction with drugn : drugn ( i.e. , drugn , druga , drugb , or drugn ) should not be administered to patients who have received or are receiving a course of therapy with a proof drugn .
false
interaction with drugn : drugn ( i.e. , drugn , druga , drugn , or drugb ) should not be administered to patients who have received or are receiving a course of therapy with a proof drugn .
false
interaction with drugn : drugn ( i.e. , drugn , druga , drugn , or drugn ) should not be administered to patients who have received or are receiving a course of therapy with a proof drugb .
advise
interaction with drugn : drugn ( i.e. , drugn , drugn , druga , or drugb ) should not be administered to patients who have received or are receiving a course of therapy with a proof drugn .
false
interaction with drugn : drugn ( i.e. , drugn , drugn , druga , or drugn ) should not be administered to patients who have received or are receiving a course of therapy with a proof drugb .
advise
interaction with drugn : drugn ( i.e. , drugn , drugn , drugn , or druga ) should not be administered to patients who have received or are receiving a course of therapy with a proof drugb .
advise
druga may enhance the effects of drugb , drugn and other drugn .
effect
druga may enhance the effects of drugn , drugb and other drugn .
effect
druga may enhance the effects of drugn , drugn and other drugb .
effect
drugn may enhance the effects of druga , drugb and other drugn .
false
drugn may enhance the effects of druga , drugn and other drugb .
false
drugn may enhance the effects of drugn , druga and other drugb .
false
druga reports suggest that drugb may diminish the antihypertensive effect of drugn .
false
druga reports suggest that drugn may diminish the antihypertensive effect of drugb .
false
drugn reports suggest that druga may diminish the antihypertensive effect of drugb .
effect
this interaction should be given consideration in patients taking druga concomitantly with drugb .
advise
druga : concomitant administration of drugb ( 1000 mg tid ) to healthy volunteers tended to increase the auc ( 10 % ) and cmax ( 24 % ) of drugn .
false
druga : concomitant administration of drugn ( 1000 mg tid ) to healthy volunteers tended to increase the auc ( 10 % ) and cmax ( 24 % ) of drugb .
false
drugn : concomitant administration of druga ( 1000 mg tid ) to healthy volunteers tended to increase the auc ( 10 % ) and cmax ( 24 % ) of drugb .
mechanism
however , as with other druga , concomitant administration of drugb and drugn is not generally recommended because of the potential for increased adverse effects .
false
however , as with other druga , concomitant administration of drugn and drugb is not generally recommended because of the potential for increased adverse effects .
advise
however , as with other drugn , concomitant administration of druga and drugb is not generally recommended because of the potential for increased adverse effects .
advise
concomitant administration of low-dose druga with drugb may result in an increased rate of gi ulceration or other complications , compared to use of drugn alone .
effect
concomitant administration of low-dose druga with drugn may result in an increased rate of gi ulceration or other complications , compared to use of drugb alone .
false
concomitant administration of low-dose drugn with druga may result in an increased rate of gi ulceration or other complications , compared to use of drugb alone .
false
druga is not a substitute for drugb for cardiovascular prophylaxis .
false
druga : pretreatment for four days with drugb significantly increased the clearance of drugn by 50 % .
false
druga : pretreatment for four days with drugn significantly increased the clearance of drugb by 50 % .
false
drugn : pretreatment for four days with druga significantly increased the clearance of drugb by 50 % .
mechanism
druga : concomitant administration of 200 mg drugb qid did not alter the single-dose pharmacokinetics of 30 mg drugn .
false
druga : concomitant administration of 200 mg drugn qid did not alter the single-dose pharmacokinetics of 30 mg drugb .
false
drugn : concomitant administration of 200 mg druga qid did not alter the single-dose pharmacokinetics of 30 mg drugb .
false
druga : drugb 15 mg once daily for 7 days did not alter the plasma concentration profile of drugn after b-acetyldigoxin administration for 7 days at clinical doses .
false
druga : drugn 15 mg once daily for 7 days did not alter the plasma concentration profile of drugb after b-acetyldigoxin administration for 7 days at clinical doses .
false
drugn : druga 15 mg once daily for 7 days did not alter the plasma concentration profile of drugb after b-acetyldigoxin administration for 7 days at clinical doses .
false
in vitro testing found no protein binding drug interaction between druga and drugb .
false
druga : clinical studies , as well as post-marketing observations , have shown that drugb can reduce the natriuretic effect of drugn and drugn in some patients .
false
druga : clinical studies , as well as post-marketing observations , have shown that drugn can reduce the natriuretic effect of drugb and drugn in some patients .
false
druga : clinical studies , as well as post-marketing observations , have shown that drugn can reduce the natriuretic effect of drugn and drugb in some patients .
false
drugn : clinical studies , as well as post-marketing observations , have shown that druga can reduce the natriuretic effect of drugb and drugn in some patients .
effect
drugn : clinical studies , as well as post-marketing observations , have shown that druga can reduce the natriuretic effect of drugn and drugb in some patients .
effect
drugn : clinical studies , as well as post-marketing observations , have shown that drugn can reduce the natriuretic effect of druga and drugb in some patients .
false
studies with druga agents and drugb have not demonstrated a reduction in natriuretic effect .
false
druga : single and multiple dose pharmacodynamics and pharmacokinetics are not affected by multiple doses of drugb .
false
nevertheless , during concomitant therapy with druga and drugb , patients should be observed closely for signs of declining renal function , as well as to assure diuretic efficacy .
advise
druga : in clinical trials , drugb have produced an elevation of plasma drugn levels and a reduction in renal drugn clearance .
false
druga : in clinical trials , drugn have produced an elevation of plasma drugb levels and a reduction in renal drugn clearance .
false
druga : in clinical trials , drugn have produced an elevation of plasma drugn levels and a reduction in renal drugb clearance .
false
drugn : in clinical trials , druga have produced an elevation of plasma drugb levels and a reduction in renal drugn clearance .
mechanism
drugn : in clinical trials , druga have produced an elevation of plasma drugn levels and a reduction in renal drugb clearance .
false
drugn : in clinical trials , drugn have produced an elevation of plasma druga levels and a reduction in renal drugb clearance .
false
in a study conducted in healthy subjects , mean pre-dose druga concentration and auc were increased by 21 % in subjects receiving drugb doses ranging from 804 to 1072 mg bid with drugn 15 mg qd as compared to subjects receiving drugn alone .
false
in a study conducted in healthy subjects , mean pre-dose druga concentration and auc were increased by 21 % in subjects receiving drugn doses ranging from 804 to 1072 mg bid with drugb 15 mg qd as compared to subjects receiving drugn alone .
false
in a study conducted in healthy subjects , mean pre-dose druga concentration and auc were increased by 21 % in subjects receiving drugn doses ranging from 804 to 1072 mg bid with drugn 15 mg qd as compared to subjects receiving drugb alone .
false
in a study conducted in healthy subjects , mean pre-dose drugn concentration and auc were increased by 21 % in subjects receiving druga doses ranging from 804 to 1072 mg bid with drugb 15 mg qd as compared to subjects receiving drugn alone .
mechanism
in a study conducted in healthy subjects , mean pre-dose drugn concentration and auc were increased by 21 % in subjects receiving druga doses ranging from 804 to 1072 mg bid with drugn 15 mg qd as compared to subjects receiving drugb alone .
false
in a study conducted in healthy subjects , mean pre-dose drugn concentration and auc were increased by 21 % in subjects receiving drugn doses ranging from 804 to 1072 mg bid with druga 15 mg qd as compared to subjects receiving drugb alone .
false
patients on druga treatment should be closely monitored when drugb is introduced or withdrawn .
advise
druga : a study in 13 rheumatoid arthritis ( ra ) patients evaluated the effects of multiple doses of drugb on the pharmacokinetics of drugn taken once weekly .
false
druga : a study in 13 rheumatoid arthritis ( ra ) patients evaluated the effects of multiple doses of drugn on the pharmacokinetics of drugb taken once weekly .
false
drugn : a study in 13 rheumatoid arthritis ( ra ) patients evaluated the effects of multiple doses of druga on the pharmacokinetics of drugb taken once weekly .
false
druga did not have a significant effect on the pharmacokinetics of single doses of drugb .
false
in vitro , druga did not displace drugb from its human serum binding sites .
false
druga : anticoagulant activity should be monitored , particularly in the first few days after initiating or changing drugb therapy in patients receiving drugn or similar agents , since these patients are at an increased risk of bleeding .
false
druga : anticoagulant activity should be monitored , particularly in the first few days after initiating or changing drugn therapy in patients receiving drugb or similar agents , since these patients are at an increased risk of bleeding .
false
drugn : anticoagulant activity should be monitored , particularly in the first few days after initiating or changing druga therapy in patients receiving drugb or similar agents , since these patients are at an increased risk of bleeding .
advise
the effect of druga on the anticoagulant effect of drugb was studied in a group of healthy subjects receiving daily doses of drugn that produced an inr ( international normalized ratio ) between 1.2 and 1.8 .
false
the effect of druga on the anticoagulant effect of drugn was studied in a group of healthy subjects receiving daily doses of drugb that produced an inr ( international normalized ratio ) between 1.2 and 1.8 .
false
the effect of drugn on the anticoagulant effect of druga was studied in a group of healthy subjects receiving daily doses of drugb that produced an inr ( international normalized ratio ) between 1.2 and 1.8 .
false
in these subjects , druga did not alter drugb pharmacokinetics and the average anticoagulant effect of drugn as determined by prothrombin time .
false
in these subjects , druga did not alter drugn pharmacokinetics and the average anticoagulant effect of drugb as determined by prothrombin time .
false
in these subjects , drugn did not alter druga pharmacokinetics and the average anticoagulant effect of drugb as determined by prothrombin time .
false
caution should be used when administering druga with drugb since patients on drugn may experience changes in inr and an increased risk of bleeding complications when a new medication is introduced .
advise
caution should be used when administering druga with drugn since patients on drugb may experience changes in inr and an increased risk of bleeding complications when a new medication is introduced .
false
caution should be used when administering drugn with druga since patients on drugb may experience changes in inr and an increased risk of bleeding complications when a new medication is introduced .
false
druga : the effects of chronic drugb use on the metabolism of drugn are not known .
false
druga : the effects of chronic drugn use on the metabolism of drugb are not known .
false
drugn : the effects of chronic druga use on the metabolism of drugb are not known .
false
when a single 100 mg dose of druga was administered one hour after the initiation of drugb ( 300 mg four times a day ) , the apparent total drugn clearance of this single dose in normal healthy adults was reduced by 18 % ( compared to the apparent total drugn clearance in the same subjects in the absence of drugn ) .
mechanism
when a single 100 mg dose of druga was administered one hour after the initiation of drugn ( 300 mg four times a day ) , the apparent total drugb clearance of this single dose in normal healthy adults was reduced by 18 % ( compared to the apparent total drugn clearance in the same subjects in the absence of drugn ) .
false
when a single 100 mg dose of druga was administered one hour after the initiation of drugn ( 300 mg four times a day ) , the apparent total drugn clearance of this single dose in normal healthy adults was reduced by 18 % ( compared to the apparent total drugb clearance in the same subjects in the absence of drugn ) .
false
when a single 100 mg dose of druga was administered one hour after the initiation of drugn ( 300 mg four times a day ) , the apparent total drugn clearance of this single dose in normal healthy adults was reduced by 18 % ( compared to the apparent total drugn clearance in the same subjects in the absence of drugb ) .
false
when a single 100 mg dose of drugn was administered one hour after the initiation of druga ( 300 mg four times a day ) , the apparent total drugb clearance of this single dose in normal healthy adults was reduced by 18 % ( compared to the apparent total drugn clearance in the same subjects in the absence of drugn ) .
false
when a single 100 mg dose of drugn was administered one hour after the initiation of druga ( 300 mg four times a day ) , the apparent total drugn clearance of this single dose in normal healthy adults was reduced by 18 % ( compared to the apparent total drugb clearance in the same subjects in the absence of drugn ) .
false
when a single 100 mg dose of drugn was administered one hour after the initiation of druga ( 300 mg four times a day ) , the apparent total drugn clearance of this single dose in normal healthy adults was reduced by 18 % ( compared to the apparent total drugn clearance in the same subjects in the absence of drugb ) .
false
when a single 100 mg dose of drugn was administered one hour after the initiation of drugn ( 300 mg four times a day ) , the apparent total druga clearance of this single dose in normal healthy adults was reduced by 18 % ( compared to the apparent total drugb clearance in the same subjects in the absence of drugn ) .
false
when a single 100 mg dose of drugn was administered one hour after the initiation of drugn ( 300 mg four times a day ) , the apparent total druga clearance of this single dose in normal healthy adults was reduced by 18 % ( compared to the apparent total drugn clearance in the same subjects in the absence of drugb ) .
false
when a single 100 mg dose of drugn was administered one hour after the initiation of drugn ( 300 mg four times a day ) , the apparent total drugn clearance of this single dose in normal healthy adults was reduced by 18 % ( compared to the apparent total druga clearance in the same subjects in the absence of drugb ) .
false
druga : drugb , 100 mg , was given twice daily for 13 days to 12 healthy volunteers .
false
coadministration with druga reduced the peak concentration and auc values for drugb by approximately 11 % .
mechanism
druga : drugb , 100 mg , was given twice daily fro 13 days to 12 healthy volunteers .
false
peak plasma concentrations and auc of druga were reduced approximately 10 % in the presence of drugb .
mechanism
drug interactions : the use of druga ( drugb ) injection before drugn , for the purpose of attenuating some of the side effects of drugn , has not been studied .
false
drug interactions : the use of druga ( drugn ) injection before drugb , for the purpose of attenuating some of the side effects of drugn , has not been studied .
false
drug interactions : the use of druga ( drugn ) injection before drugn , for the purpose of attenuating some of the side effects of drugb , has not been studied .
false
drug interactions : the use of drugn ( druga ) injection before drugb , for the purpose of attenuating some of the side effects of drugn , has not been studied .
false
drug interactions : the use of drugn ( druga ) injection before drugn , for the purpose of attenuating some of the side effects of drugb , has not been studied .
false
drug interactions : the use of drugn ( drugn ) injection before druga , for the purpose of attenuating some of the side effects of drugb , has not been studied .
false
if druga is administered following administration of drugb , it should not be given until recovery from drugn has been observed .
advise
if druga is administered following administration of drugn , it should not be given until recovery from drugb has been observed .
false
if drugn is administered following administration of druga , it should not be given until recovery from drugb has been observed .
false
the median duration of action of druga 0.6 mg/kg administered after a 1 mg/kg dose of drugb when t 1 returned to 75 % of control was 36 minutes ( range 14-57 , n=12 ) vs .
false
there are no controlled studies documenting the use of druga before or after other drugb .
false
druga : excessive reductions in blood pressure may occur in patients on diuretic therapy when drugb are started .
false
the possibility of hypotensive effects with druga can be minimized by discontinuing diuretic therapy for several days or cautiously increasing salt intake before initiation of treatment with drugb . if this is not possible , the starting dose of drugn should be reduced..
false
the possibility of hypotensive effects with druga can be minimized by discontinuing diuretic therapy for several days or cautiously increasing salt intake before initiation of treatment with drugn . if this is not possible , the starting dose of drugb should be reduced..
false
the possibility of hypotensive effects with drugn can be minimized by discontinuing diuretic therapy for several days or cautiously increasing salt intake before initiation of treatment with druga . if this is not possible , the starting dose of drugb should be reduced..
false
druga supplements and drugb : drugn can increase serum potassium because it decreases aldosterone secretion .
false
druga supplements and drugn : drugb can increase serum potassium because it decreases aldosterone secretion .
false
drugn supplements and druga : drugb can increase serum potassium because it decreases aldosterone secretion .
false
use of druga ( drugb , drugn , drugn ) or drugn supplements concomitantly with drugn can increase the risk of hyperkalemia .
false
use of druga ( drugn , drugb , drugn ) or drugn supplements concomitantly with drugn can increase the risk of hyperkalemia .
false
use of druga ( drugn , drugn , drugb ) or drugn supplements concomitantly with drugn can increase the risk of hyperkalemia .
false
use of druga ( drugn , drugn , drugn ) or drugb supplements concomitantly with drugn can increase the risk of hyperkalemia .
false
use of druga ( drugn , drugn , drugn ) or drugn supplements concomitantly with drugb can increase the risk of hyperkalemia .
effect
use of drugn ( druga , drugb , drugn ) or drugn supplements concomitantly with drugn can increase the risk of hyperkalemia .
false
use of drugn ( druga , drugn , drugb ) or drugn supplements concomitantly with drugn can increase the risk of hyperkalemia .
false
use of drugn ( druga , drugn , drugn ) or drugb supplements concomitantly with drugn can increase the risk of hyperkalemia .
false
use of drugn ( druga , drugn , drugn ) or drugn supplements concomitantly with drugb can increase the risk of hyperkalemia .
effect
use of drugn ( drugn , druga , drugb ) or drugn supplements concomitantly with drugn can increase the risk of hyperkalemia .
false
use of drugn ( drugn , druga , drugn ) or drugb supplements concomitantly with drugn can increase the risk of hyperkalemia .
false
use of drugn ( drugn , druga , drugn ) or drugn supplements concomitantly with drugb can increase the risk of hyperkalemia .
effect
use of drugn ( drugn , drugn , druga ) or drugb supplements concomitantly with drugn can increase the risk of hyperkalemia .
false
use of drugn ( drugn , drugn , druga ) or drugn supplements concomitantly with drugb can increase the risk of hyperkalemia .
effect
use of drugn ( drugn , drugn , drugn ) or druga supplements concomitantly with drugb can increase the risk of hyperkalemia .
effect
oral druga : interaction studies with drugb failed to identify any clinically important effect on the serum concentrations of the drugn or on its anticoagulant effect .
false
oral druga : interaction studies with drugn failed to identify any clinically important effect on the serum concentrations of the drugb or on its anticoagulant effect .
false
oral drugn : interaction studies with druga failed to identify any clinically important effect on the serum concentrations of the drugb or on its anticoagulant effect .
false
druga : increased serum drugb levels and symptoms of drugn toxicity have been reported in patients receiving drugn during therapy with drugn .
false
druga : increased serum drugn levels and symptoms of drugb toxicity have been reported in patients receiving drugn during therapy with drugn .
false
druga : increased serum drugn levels and symptoms of drugn toxicity have been reported in patients receiving drugb during therapy with drugn .
false
druga : increased serum drugn levels and symptoms of drugn toxicity have been reported in patients receiving drugn during therapy with drugb .
false
drugn : increased serum druga levels and symptoms of drugb toxicity have been reported in patients receiving drugn during therapy with drugn .
false
drugn : increased serum druga levels and symptoms of drugn toxicity have been reported in patients receiving drugb during therapy with drugn .
false
drugn : increased serum druga levels and symptoms of drugn toxicity have been reported in patients receiving drugn during therapy with drugb .
false
drugn : increased serum drugn levels and symptoms of druga toxicity have been reported in patients receiving drugb during therapy with drugn .
false
drugn : increased serum drugn levels and symptoms of druga toxicity have been reported in patients receiving drugn during therapy with drugb .
false
drugn : increased serum drugn levels and symptoms of drugn toxicity have been reported in patients receiving druga during therapy with drugb .
effect
if a druga is also used , the risk of drugb toxicity may be increased .
effect
other agents : no clinically important pharmacokinetic interactions occurred when druga was administered concomitantly with drugb , drugn , or drugn .
false
other agents : no clinically important pharmacokinetic interactions occurred when druga was administered concomitantly with drugn , drugb , or drugn .
false
other agents : no clinically important pharmacokinetic interactions occurred when druga was administered concomitantly with drugn , drugn , or drugb .
false
other agents : no clinically important pharmacokinetic interactions occurred when drugn was administered concomitantly with druga , drugb , or drugn .
false
other agents : no clinically important pharmacokinetic interactions occurred when drugn was administered concomitantly with druga , drugn , or drugb .
false
other agents : no clinically important pharmacokinetic interactions occurred when drugn was administered concomitantly with drugn , druga , or drugb .
false
druga has been used in clinical trials concomitantly with drugb , drugn , drugn , drugn , oral drugn , and cholesterol-lowering agents .
false
druga has been used in clinical trials concomitantly with drugn , drugb , drugn , drugn , oral drugn , and cholesterol-lowering agents .
false
druga has been used in clinical trials concomitantly with drugn , drugn , drugb , drugn , oral drugn , and cholesterol-lowering agents .
false
druga has been used in clinical trials concomitantly with drugn , drugn , drugn , drugb , oral drugn , and cholesterol-lowering agents .
false
druga has been used in clinical trials concomitantly with drugn , drugn , drugn , drugn , oral drugb , and cholesterol-lowering agents .
false
drugn has been used in clinical trials concomitantly with druga , drugb , drugn , drugn , oral drugn , and cholesterol-lowering agents .
false
drugn has been used in clinical trials concomitantly with druga , drugn , drugb , drugn , oral drugn , and cholesterol-lowering agents .
false
drugn has been used in clinical trials concomitantly with druga , drugn , drugn , drugb , oral drugn , and cholesterol-lowering agents .
false
drugn has been used in clinical trials concomitantly with druga , drugn , drugn , drugn , oral drugb , and cholesterol-lowering agents .
false
drugn has been used in clinical trials concomitantly with drugn , druga , drugb , drugn , oral drugn , and cholesterol-lowering agents .
false
drugn has been used in clinical trials concomitantly with drugn , druga , drugn , drugb , oral drugn , and cholesterol-lowering agents .
false
drugn has been used in clinical trials concomitantly with drugn , druga , drugn , drugn , oral drugb , and cholesterol-lowering agents .
false
drugn has been used in clinical trials concomitantly with drugn , drugn , druga , drugb , oral drugn , and cholesterol-lowering agents .
false
drugn has been used in clinical trials concomitantly with drugn , drugn , druga , drugn , oral drugb , and cholesterol-lowering agents .
false
drugn has been used in clinical trials concomitantly with drugn , drugn , drugn , druga , oral drugb , and cholesterol-lowering agents .
false
drugs affecting hepatic metabolism the metabolism and pharmacokinetics of druga ( drugb ) orally disintegrating tablets may be affected by the induction or inhibition of drug-metab-olizing enzymes .
false
while in vitro studies have shown that druga is not a potent inhibitor of any of these enzymes , an indication that drugb is not likely to have a clinically significant inhibitory effect on the metabolism of other drugs that are substrates for these cytochrome p450 enzymes , the concomitant use of drugn with most other drugs metabolized by these enzymes has not been formally studied .
false
while in vitro studies have shown that druga is not a potent inhibitor of any of these enzymes , an indication that drugn is not likely to have a clinically significant inhibitory effect on the metabolism of other drugs that are substrates for these cytochrome p450 enzymes , the concomitant use of drugb with most other drugs metabolized by these enzymes has not been formally studied .
false
while in vitro studies have shown that drugn is not a potent inhibitor of any of these enzymes , an indication that druga is not likely to have a clinically significant inhibitory effect on the metabolism of other drugs that are substrates for these cytochrome p450 enzymes , the concomitant use of drugb with most other drugs metabolized by these enzymes has not been formally studied .
false
druga : concomitant administration of drugb ( equivalent to 60 g ) had a minimal effect on plasma levels of drugn ( 15 mg ) in 6 healthy male subjects .
false
druga : concomitant administration of drugn ( equivalent to 60 g ) had a minimal effect on plasma levels of drugb ( 15 mg ) in 6 healthy male subjects .
false
drugn : concomitant administration of druga ( equivalent to 60 g ) had a minimal effect on plasma levels of drugb ( 15 mg ) in 6 healthy male subjects .
mechanism
however , the impairment of cognitive and motor skills produced by druga were shown to be additive with those produced by drugb .
effect
accordingly , patients should be advised to avoid druga while taking drugb . drugn : concomitant administration of drugn ( 15 mg ) had a minimal effect on plasma levels of drugn ( 15 mg ) in 12 healthy subjects .
advise
accordingly , patients should be advised to avoid druga while taking drugn . drugb : concomitant administration of drugn ( 15 mg ) had a minimal effect on plasma levels of drugn ( 15 mg ) in 12 healthy subjects .
false
accordingly , patients should be advised to avoid druga while taking drugn . drugn : concomitant administration of drugb ( 15 mg ) had a minimal effect on plasma levels of drugn ( 15 mg ) in 12 healthy subjects .
false
accordingly , patients should be advised to avoid druga while taking drugn . drugn : concomitant administration of drugn ( 15 mg ) had a minimal effect on plasma levels of drugb ( 15 mg ) in 12 healthy subjects .
false
accordingly , patients should be advised to avoid drugn while taking druga . drugb : concomitant administration of drugn ( 15 mg ) had a minimal effect on plasma levels of drugn ( 15 mg ) in 12 healthy subjects .
false
accordingly , patients should be advised to avoid drugn while taking druga . drugn : concomitant administration of drugb ( 15 mg ) had a minimal effect on plasma levels of drugn ( 15 mg ) in 12 healthy subjects .
false
accordingly , patients should be advised to avoid drugn while taking druga . drugn : concomitant administration of drugn ( 15 mg ) had a minimal effect on plasma levels of drugb ( 15 mg ) in 12 healthy subjects .
false
accordingly , patients should be advised to avoid drugn while taking drugn . druga : concomitant administration of drugb ( 15 mg ) had a minimal effect on plasma levels of drugn ( 15 mg ) in 12 healthy subjects .
false
accordingly , patients should be advised to avoid drugn while taking drugn . druga : concomitant administration of drugn ( 15 mg ) had a minimal effect on plasma levels of drugb ( 15 mg ) in 12 healthy subjects .
false
accordingly , patients should be advised to avoid drugn while taking drugn . drugn : concomitant administration of druga ( 15 mg ) had a minimal effect on plasma levels of drugb ( 15 mg ) in 12 healthy subjects .
mechanism
however , the impairment of motor skills produced by druga has been shown to be additive with those caused by drugb .
effect
accordingly , patients should be advised to avoid druga and other similar drugs while taking drugb .
advise
druga : drugb causes a 60 % reduction in the absorption and enterohepatic cycling of drugn and should not be coadministered with drugn .
false
druga : drugn causes a 60 % reduction in the absorption and enterohepatic cycling of drugb and should not be coadministered with drugn .
false
druga : drugn causes a 60 % reduction in the absorption and enterohepatic cycling of drugn and should not be coadministered with drugb .
false
drugn : druga causes a 60 % reduction in the absorption and enterohepatic cycling of drugb and should not be coadministered with drugn .
mechanism
drugn : druga causes a 60 % reduction in the absorption and enterohepatic cycling of drugn and should not be coadministered with drugb .
advise
drugn : drugn causes a 60 % reduction in the absorption and enterohepatic cycling of druga and should not be coadministered with drugb .
false
druga : the coadministration of drugb and drugn has not been assessed under chronic conditions .
false
druga : the coadministration of drugn and drugb has not been assessed under chronic conditions .
false
drugn : the coadministration of druga and drugb has not been assessed under chronic conditions .
false
if druga is given concurrently with drugb , prothrombin time should be monitored .
advise
in vitro , druga did not affect the binding of drugb , drugn , or drugn .
false
in vitro , druga did not affect the binding of drugn , drugb , or drugn .
false
in vitro , druga did not affect the binding of drugn , drugn , or drugb .
false
in vitro , drugn did not affect the binding of druga , drugb , or drugn .
false
in vitro , drugn did not affect the binding of druga , drugn , or drugb .
false
in vitro , drugn did not affect the binding of drugn , druga , or drugb .
false
caution should be used when druga is coadministered with other highly protein-bound drugs , such as drugb , drugn , drugn , drugn , drugn , and drugn .
advise
caution should be used when druga is coadministered with other highly protein-bound drugs , such as drugn , drugb , drugn , drugn , drugn , and drugn .
advise
caution should be used when druga is coadministered with other highly protein-bound drugs , such as drugn , drugn , drugb , drugn , drugn , and drugn .
advise
caution should be used when druga is coadministered with other highly protein-bound drugs , such as drugn , drugn , drugn , drugb , drugn , and drugn .
advise
caution should be used when druga is coadministered with other highly protein-bound drugs , such as drugn , drugn , drugn , drugn , drugb , and drugn .
advise
caution should be used when druga is coadministered with other highly protein-bound drugs , such as drugn , drugn , drugn , drugn , drugn , and drugb .
advise
caution should be used when drugn is coadministered with other highly protein-bound drugs , such as druga , drugb , drugn , drugn , drugn , and drugn .
false
caution should be used when drugn is coadministered with other highly protein-bound drugs , such as druga , drugn , drugb , drugn , drugn , and drugn .
false
caution should be used when drugn is coadministered with other highly protein-bound drugs , such as druga , drugn , drugn , drugb , drugn , and drugn .
false
caution should be used when drugn is coadministered with other highly protein-bound drugs , such as druga , drugn , drugn , drugn , drugb , and drugn .
false
caution should be used when drugn is coadministered with other highly protein-bound drugs , such as druga , drugn , drugn , drugn , drugn , and drugb .
false
caution should be used when drugn is coadministered with other highly protein-bound drugs , such as drugn , druga , drugb , drugn , drugn , and drugn .
false
caution should be used when drugn is coadministered with other highly protein-bound drugs , such as drugn , druga , drugn , drugb , drugn , and drugn .
false
caution should be used when drugn is coadministered with other highly protein-bound drugs , such as drugn , druga , drugn , drugn , drugb , and drugn .
false
caution should be used when drugn is coadministered with other highly protein-bound drugs , such as drugn , druga , drugn , drugn , drugn , and drugb .
false
caution should be used when drugn is coadministered with other highly protein-bound drugs , such as drugn , drugn , druga , drugb , drugn , and drugn .
false
caution should be used when drugn is coadministered with other highly protein-bound drugs , such as drugn , drugn , druga , drugn , drugb , and drugn .
false
caution should be used when drugn is coadministered with other highly protein-bound drugs , such as drugn , drugn , druga , drugn , drugn , and drugb .
false
caution should be used when drugn is coadministered with other highly protein-bound drugs , such as drugn , drugn , drugn , druga , drugb , and drugn .
false
caution should be used when drugn is coadministered with other highly protein-bound drugs , such as drugn , drugn , drugn , druga , drugn , and drugb .
false
caution should be used when drugn is coadministered with other highly protein-bound drugs , such as drugn , drugn , drugn , drugn , druga , and drugb .
false
hypokalemia may develop during concomitant use of druga or drugb .
false
druga may decrease arterial responsiveness to drugb .
effect
druga may increase the responsiveness of drugb .
effect
druga renal clearance is reduced by drugb , increasing the risk of drugn toxicity .
mechanism
druga renal clearance is reduced by drugn , increasing the risk of drugb toxicity .
false
drugn renal clearance is reduced by druga , increasing the risk of drugb toxicity .
false
druga may add to or potentiate the action of other drugb .
effect
potentiation occurs with druga or drugb .
false
druga is not known to interact with other drugs including drugb supplements ;
false
concomitant administration of druga with other chelation therapy , such as drugb is not recommended .
advise
because there is a theoretical basis that these effects may be additive , use of druga -containing or drugb ( like drugn or drugn ) and drugn within 24 hours of each other should be avoided .
false
because there is a theoretical basis that these effects may be additive , use of druga -containing or drugn ( like drugb or drugn ) and drugn within 24 hours of each other should be avoided .
false
because there is a theoretical basis that these effects may be additive , use of druga -containing or drugn ( like drugn or drugb ) and drugn within 24 hours of each other should be avoided .
false
because there is a theoretical basis that these effects may be additive , use of druga -containing or drugn ( like drugn or drugn ) and drugb within 24 hours of each other should be avoided .
advise
because there is a theoretical basis that these effects may be additive , use of drugn -containing or druga ( like drugb or drugn ) and drugn within 24 hours of each other should be avoided .
false
because there is a theoretical basis that these effects may be additive , use of drugn -containing or druga ( like drugn or drugb ) and drugn within 24 hours of each other should be avoided .
false
because there is a theoretical basis that these effects may be additive , use of drugn -containing or druga ( like drugn or drugn ) and drugb within 24 hours of each other should be avoided .
advise
because there is a theoretical basis that these effects may be additive , use of drugn -containing or drugn ( like druga or drugb ) and drugn within 24 hours of each other should be avoided .
false
because there is a theoretical basis that these effects may be additive , use of drugn -containing or drugn ( like druga or drugn ) and drugb within 24 hours of each other should be avoided .
advise
because there is a theoretical basis that these effects may be additive , use of drugn -containing or drugn ( like drugn or druga ) and drugb within 24 hours of each other should be avoided .
advise
druga reduce drugb clearance , significantly increasing systemic exposure .
mechanism
therefore , the use of druga tablets in patients receiving drugb is contraindicated . drugn ( drugn ) ( e.g. , drugn , drugn , drugn , drugn ) have been reported , rarely , to cause weakness , hyperreflexia , and incoordination when coadministered with drugn .
advise
therefore , the use of druga tablets in patients receiving drugn is contraindicated . drugb ( drugn ) ( e.g. , drugn , drugn , drugn , drugn ) have been reported , rarely , to cause weakness , hyperreflexia , and incoordination when coadministered with drugn .
false
therefore , the use of druga tablets in patients receiving drugn is contraindicated . drugn ( drugb ) ( e.g. , drugn , drugn , drugn , drugn ) have been reported , rarely , to cause weakness , hyperreflexia , and incoordination when coadministered with drugn .
false
therefore , the use of druga tablets in patients receiving drugn is contraindicated . drugn ( drugn ) ( e.g. , drugb , drugn , drugn , drugn ) have been reported , rarely , to cause weakness , hyperreflexia , and incoordination when coadministered with drugn .
false
therefore , the use of druga tablets in patients receiving drugn is contraindicated . drugn ( drugn ) ( e.g. , drugn , drugb , drugn , drugn ) have been reported , rarely , to cause weakness , hyperreflexia , and incoordination when coadministered with drugn .
false
therefore , the use of druga tablets in patients receiving drugn is contraindicated . drugn ( drugn ) ( e.g. , drugn , drugn , drugb , drugn ) have been reported , rarely , to cause weakness , hyperreflexia , and incoordination when coadministered with drugn .
false
therefore , the use of druga tablets in patients receiving drugn is contraindicated . drugn ( drugn ) ( e.g. , drugn , drugn , drugn , drugb ) have been reported , rarely , to cause weakness , hyperreflexia , and incoordination when coadministered with drugn .
false
therefore , the use of druga tablets in patients receiving drugn is contraindicated . drugn ( drugn ) ( e.g. , drugn , drugn , drugn , drugn ) have been reported , rarely , to cause weakness , hyperreflexia , and incoordination when coadministered with drugb .
false
therefore , the use of drugn tablets in patients receiving druga is contraindicated . drugb ( drugn ) ( e.g. , drugn , drugn , drugn , drugn ) have been reported , rarely , to cause weakness , hyperreflexia , and incoordination when coadministered with drugn .
false
therefore , the use of drugn tablets in patients receiving druga is contraindicated . drugn ( drugb ) ( e.g. , drugn , drugn , drugn , drugn ) have been reported , rarely , to cause weakness , hyperreflexia , and incoordination when coadministered with drugn .
false
therefore , the use of drugn tablets in patients receiving druga is contraindicated . drugn ( drugn ) ( e.g. , drugb , drugn , drugn , drugn ) have been reported , rarely , to cause weakness , hyperreflexia , and incoordination when coadministered with drugn .
false
therefore , the use of drugn tablets in patients receiving druga is contraindicated . drugn ( drugn ) ( e.g. , drugn , drugb , drugn , drugn ) have been reported , rarely , to cause weakness , hyperreflexia , and incoordination when coadministered with drugn .
false
therefore , the use of drugn tablets in patients receiving druga is contraindicated . drugn ( drugn ) ( e.g. , drugn , drugn , drugb , drugn ) have been reported , rarely , to cause weakness , hyperreflexia , and incoordination when coadministered with drugn .
false
therefore , the use of drugn tablets in patients receiving druga is contraindicated . drugn ( drugn ) ( e.g. , drugn , drugn , drugn , drugb ) have been reported , rarely , to cause weakness , hyperreflexia , and incoordination when coadministered with drugn .
false
therefore , the use of drugn tablets in patients receiving druga is contraindicated . drugn ( drugn ) ( e.g. , drugn , drugn , drugn , drugn ) have been reported , rarely , to cause weakness , hyperreflexia , and incoordination when coadministered with drugb .
false
therefore , the use of drugn tablets in patients receiving drugn is contraindicated . druga ( drugb ) ( e.g. , drugn , drugn , drugn , drugn ) have been reported , rarely , to cause weakness , hyperreflexia , and incoordination when coadministered with drugn .
false
therefore , the use of drugn tablets in patients receiving drugn is contraindicated . druga ( drugn ) ( e.g. , drugb , drugn , drugn , drugn ) have been reported , rarely , to cause weakness , hyperreflexia , and incoordination when coadministered with drugn .
false
therefore , the use of drugn tablets in patients receiving drugn is contraindicated . druga ( drugn ) ( e.g. , drugn , drugb , drugn , drugn ) have been reported , rarely , to cause weakness , hyperreflexia , and incoordination when coadministered with drugn .
false
therefore , the use of drugn tablets in patients receiving drugn is contraindicated . druga ( drugn ) ( e.g. , drugn , drugn , drugb , drugn ) have been reported , rarely , to cause weakness , hyperreflexia , and incoordination when coadministered with drugn .
false
therefore , the use of drugn tablets in patients receiving drugn is contraindicated . druga ( drugn ) ( e.g. , drugn , drugn , drugn , drugb ) have been reported , rarely , to cause weakness , hyperreflexia , and incoordination when coadministered with drugn .
false
therefore , the use of drugn tablets in patients receiving drugn is contraindicated . druga ( drugn ) ( e.g. , drugn , drugn , drugn , drugn ) have been reported , rarely , to cause weakness , hyperreflexia , and incoordination when coadministered with drugb .
effect
therefore , the use of drugn tablets in patients receiving drugn is contraindicated . drugn ( druga ) ( e.g. , drugb , drugn , drugn , drugn ) have been reported , rarely , to cause weakness , hyperreflexia , and incoordination when coadministered with drugn .
false
therefore , the use of drugn tablets in patients receiving drugn is contraindicated . drugn ( druga ) ( e.g. , drugn , drugb , drugn , drugn ) have been reported , rarely , to cause weakness , hyperreflexia , and incoordination when coadministered with drugn .
false
therefore , the use of drugn tablets in patients receiving drugn is contraindicated . drugn ( druga ) ( e.g. , drugn , drugn , drugb , drugn ) have been reported , rarely , to cause weakness , hyperreflexia , and incoordination when coadministered with drugn .
false
therefore , the use of drugn tablets in patients receiving drugn is contraindicated . drugn ( druga ) ( e.g. , drugn , drugn , drugn , drugb ) have been reported , rarely , to cause weakness , hyperreflexia , and incoordination when coadministered with drugn .
false
therefore , the use of drugn tablets in patients receiving drugn is contraindicated . drugn ( druga ) ( e.g. , drugn , drugn , drugn , drugn ) have been reported , rarely , to cause weakness , hyperreflexia , and incoordination when coadministered with drugb .
effect
therefore , the use of drugn tablets in patients receiving drugn is contraindicated . drugn ( drugn ) ( e.g. , druga , drugb , drugn , drugn ) have been reported , rarely , to cause weakness , hyperreflexia , and incoordination when coadministered with drugn .
false
therefore , the use of drugn tablets in patients receiving drugn is contraindicated . drugn ( drugn ) ( e.g. , druga , drugn , drugb , drugn ) have been reported , rarely , to cause weakness , hyperreflexia , and incoordination when coadministered with drugn .
false
therefore , the use of drugn tablets in patients receiving drugn is contraindicated . drugn ( drugn ) ( e.g. , druga , drugn , drugn , drugb ) have been reported , rarely , to cause weakness , hyperreflexia , and incoordination when coadministered with drugn .
false
therefore , the use of drugn tablets in patients receiving drugn is contraindicated . drugn ( drugn ) ( e.g. , druga , drugn , drugn , drugn ) have been reported , rarely , to cause weakness , hyperreflexia , and incoordination when coadministered with drugb .
effect
therefore , the use of drugn tablets in patients receiving drugn is contraindicated . drugn ( drugn ) ( e.g. , drugn , druga , drugb , drugn ) have been reported , rarely , to cause weakness , hyperreflexia , and incoordination when coadministered with drugn .
false
therefore , the use of drugn tablets in patients receiving drugn is contraindicated . drugn ( drugn ) ( e.g. , drugn , druga , drugn , drugb ) have been reported , rarely , to cause weakness , hyperreflexia , and incoordination when coadministered with drugn .
false
therefore , the use of drugn tablets in patients receiving drugn is contraindicated . drugn ( drugn ) ( e.g. , drugn , druga , drugn , drugn ) have been reported , rarely , to cause weakness , hyperreflexia , and incoordination when coadministered with drugb .
effect
therefore , the use of drugn tablets in patients receiving drugn is contraindicated . drugn ( drugn ) ( e.g. , drugn , drugn , druga , drugb ) have been reported , rarely , to cause weakness , hyperreflexia , and incoordination when coadministered with drugn .
false
therefore , the use of drugn tablets in patients receiving drugn is contraindicated . drugn ( drugn ) ( e.g. , drugn , drugn , druga , drugn ) have been reported , rarely , to cause weakness , hyperreflexia , and incoordination when coadministered with drugb .
effect
therefore , the use of drugn tablets in patients receiving drugn is contraindicated . drugn ( drugn ) ( e.g. , drugn , drugn , drugn , druga ) have been reported , rarely , to cause weakness , hyperreflexia , and incoordination when coadministered with drugb .
effect
if concomitant treatment with druga and an drugb is clinically warranted , appropriate observation of the patient is advised .
advise
coadministration of druga with drugb resulted in increased plasma drugn concentrations ( 57 % ) , increased plasma bismuth trough concentrations ( 48 % ) , and increased drugn plasma concentrations ( 31 % ) .
mechanism
coadministration of druga with drugn resulted in increased plasma drugb concentrations ( 57 % ) , increased plasma bismuth trough concentrations ( 48 % ) , and increased drugn plasma concentrations ( 31 % ) .
false
coadministration of druga with drugn resulted in increased plasma drugn concentrations ( 57 % ) , increased plasma bismuth trough concentrations ( 48 % ) , and increased drugb plasma concentrations ( 31 % ) .
false
coadministration of drugn with druga resulted in increased plasma drugb concentrations ( 57 % ) , increased plasma bismuth trough concentrations ( 48 % ) , and increased drugn plasma concentrations ( 31 % ) .
false
coadministration of drugn with druga resulted in increased plasma drugn concentrations ( 57 % ) , increased plasma bismuth trough concentrations ( 48 % ) , and increased drugb plasma concentrations ( 31 % ) .
false
coadministration of drugn with drugn resulted in increased plasma druga concentrations ( 57 % ) , increased plasma bismuth trough concentrations ( 48 % ) , and increased drugb plasma concentrations ( 31 % ) .
false
coadministration with druga results in a slight decrease in the rate of drugb absorption that is clinically unimportant .
false
coadministration with a high dose of druga ( 170 meq ) results in a 28 % decrease in plasma concentrations of drugb and may decrease plasma concentrations of bismuth from drugn .
mechanism
coadministration with a high dose of druga ( 170 meq ) results in a 28 % decrease in plasma concentrations of drugn and may decrease plasma concentrations of bismuth from drugb .
mechanism
coadministration with a high dose of drugn ( 170 meq ) results in a 28 % decrease in plasma concentrations of druga and may decrease plasma concentrations of bismuth from drugb .
false
for information on drug interactions associated with druga , refer to the drugb package insert .
false
drug-drug interactions : the pharmacokinetic and pharmacodynamic interactions between druga capsules and other drugb have not been determined .
false
however , interactions may be expected and druga capsules should not be used in combination with other drugb .
advise
the pharmacokinetic interaction between druga and drugb capsules was investigated .
false
therefore , druga capsules should be used with caution in combination with drugb , particularly at doses higher than 0.4 mg .
advise
results from limited in vitro and in vivo drug-drug interaction studies between druga and drugb are inconclusive .
false
therefore , caution should be exercised with concomitant administration of druga and drugb capsules .
advise
druga are capable of potentiating drugb ( e.g. , drugn , drugn , drugn , drugn , etc . )
effect
druga are capable of potentiating drugn ( e.g. , drugb , drugn , drugn , drugn , etc . )
effect
druga are capable of potentiating drugn ( e.g. , drugn , drugb , drugn , drugn , etc . )
effect
druga are capable of potentiating drugn ( e.g. , drugn , drugn , drugb , drugn , etc . )
effect
druga are capable of potentiating drugn ( e.g. , drugn , drugn , drugn , drugb , etc . )
effect
drugn are capable of potentiating druga ( e.g. , drugb , drugn , drugn , drugn , etc . )
false
drugn are capable of potentiating druga ( e.g. , drugn , drugb , drugn , drugn , etc . )
false
drugn are capable of potentiating druga ( e.g. , drugn , drugn , drugb , drugn , etc . )
false
drugn are capable of potentiating druga ( e.g. , drugn , drugn , drugn , drugb , etc . )
false
drugn are capable of potentiating drugn ( e.g. , druga , drugb , drugn , drugn , etc . )
false
drugn are capable of potentiating drugn ( e.g. , druga , drugn , drugb , drugn , etc . )
false
drugn are capable of potentiating drugn ( e.g. , druga , drugn , drugn , drugb , etc . )
false
drugn are capable of potentiating drugn ( e.g. , drugn , druga , drugb , drugn , etc . )
false
drugn are capable of potentiating drugn ( e.g. , drugn , druga , drugn , drugb , etc . )
false
drugn are capable of potentiating drugn ( e.g. , drugn , drugn , druga , drugb , etc . )
false
as well as druga and drugb .
false
due to its effects on gastric emptying , druga therapy should not be considered for patients taking drugs that alter gastrointestinal motility ( e.g. , drugb such as drugn ) and agents that slow the intestinal absorption of nutrients ( e.g. , drugn ) .
advise
due to its effects on gastric emptying , druga therapy should not be considered for patients taking drugs that alter gastrointestinal motility ( e.g. , drugn such as drugb ) and agents that slow the intestinal absorption of nutrients ( e.g. , drugn ) .
advise
due to its effects on gastric emptying , druga therapy should not be considered for patients taking drugs that alter gastrointestinal motility ( e.g. , drugn such as drugn ) and agents that slow the intestinal absorption of nutrients ( e.g. , drugb ) .
advise
due to its effects on gastric emptying , drugn therapy should not be considered for patients taking drugs that alter gastrointestinal motility ( e.g. , druga such as drugb ) and agents that slow the intestinal absorption of nutrients ( e.g. , drugn ) .
false
due to its effects on gastric emptying , drugn therapy should not be considered for patients taking drugs that alter gastrointestinal motility ( e.g. , druga such as drugn ) and agents that slow the intestinal absorption of nutrients ( e.g. , drugb ) .
false
due to its effects on gastric emptying , drugn therapy should not be considered for patients taking drugs that alter gastrointestinal motility ( e.g. , drugn such as druga ) and agents that slow the intestinal absorption of nutrients ( e.g. , drugb ) .
false
when the rapid onset of a concomitant orally administered agent is a critical determinant of effectiveness ( such as druga ) , the agent should be administered at least 1 hour prior to or 2 hours after drugb injection .
advise
in clinical trials , the concomitant use of druga or drugb did not alter the adverse event profile of drugn .
false
in clinical trials , the concomitant use of druga or drugn did not alter the adverse event profile of drugb .
false
in clinical trials , the concomitant use of drugn or druga did not alter the adverse event profile of drugb .
false
no formal interaction studies have been performed to assess the effect of druga on the kinetics of oral drugb .
false
mixing druga and drugb the pharmacokinetic parameters of drugn were altered when mixed with regular , nph , and 70/30 premixed formulations of recombinant drugn immediately prior to injection .
false
mixing druga and drugn the pharmacokinetic parameters of drugb were altered when mixed with regular , nph , and 70/30 premixed formulations of recombinant drugn immediately prior to injection .
false
mixing druga and drugn the pharmacokinetic parameters of drugn were altered when mixed with regular , nph , and 70/30 premixed formulations of recombinant drugb immediately prior to injection .
false
mixing drugn and druga the pharmacokinetic parameters of drugb were altered when mixed with regular , nph , and 70/30 premixed formulations of recombinant drugn immediately prior to injection .
false
mixing drugn and druga the pharmacokinetic parameters of drugn were altered when mixed with regular , nph , and 70/30 premixed formulations of recombinant drugb immediately prior to injection .
false
mixing drugn and drugn the pharmacokinetic parameters of druga were altered when mixed with regular , nph , and 70/30 premixed formulations of recombinant drugb immediately prior to injection .
mechanism
thus , druga and drugb should not be mixed and must be administered separately .
false
druga should be administered with caution to patients taking drugb because of the possibility of conduction disturbances .
advise
these effects should be considered when anticholinergic properties may be contributing to the therapeutic effect of concomitant medication ( e.g. , druga , inhaled drugb ) .
false
while no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both sj grens efficacy studies : druga , artificial tears , drugb , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , and drugn .
false
while no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both sj grens efficacy studies : druga , artificial tears , drugn , drugb , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , and drugn .
false
while no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both sj grens efficacy studies : druga , artificial tears , drugn , drugn , drugb , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , and drugn .
false
while no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both sj grens efficacy studies : druga , artificial tears , drugn , drugn , drugn , drugb , drugn , drugn , drugn , drugn , drugn , drugn , drugn , and drugn .
false
while no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both sj grens efficacy studies : druga , artificial tears , drugn , drugn , drugn , drugn , drugb , drugn , drugn , drugn , drugn , drugn , drugn , and drugn .
false
while no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both sj grens efficacy studies : druga , artificial tears , drugn , drugn , drugn , drugn , drugn , drugb , drugn , drugn , drugn , drugn , drugn , and drugn .
false
while no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both sj grens efficacy studies : druga , artificial tears , drugn , drugn , drugn , drugn , drugn , drugn , drugb , drugn , drugn , drugn , drugn , and drugn .
false
while no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both sj grens efficacy studies : druga , artificial tears , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugb , drugn , drugn , drugn , and drugn .
false
while no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both sj grens efficacy studies : druga , artificial tears , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugb , drugn , drugn , and drugn .
false
while no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both sj grens efficacy studies : druga , artificial tears , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugb , drugn , and drugn .
false
while no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both sj grens efficacy studies : druga , artificial tears , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugb , and drugn .
false
while no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both sj grens efficacy studies : druga , artificial tears , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , and drugb .
false
while no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both sj grens efficacy studies : drugn , artificial tears , druga , drugb , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , and drugn .
false
while no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both sj grens efficacy studies : drugn , artificial tears , druga , drugn , drugb , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , and drugn .
false
while no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both sj grens efficacy studies : drugn , artificial tears , druga , drugn , drugn , drugb , drugn , drugn , drugn , drugn , drugn , drugn , drugn , and drugn .
false
while no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both sj grens efficacy studies : drugn , artificial tears , druga , drugn , drugn , drugn , drugb , drugn , drugn , drugn , drugn , drugn , drugn , and drugn .
false
while no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both sj grens efficacy studies : drugn , artificial tears , druga , drugn , drugn , drugn , drugn , drugb , drugn , drugn , drugn , drugn , drugn , and drugn .
false
while no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both sj grens efficacy studies : drugn , artificial tears , druga , drugn , drugn , drugn , drugn , drugn , drugb , drugn , drugn , drugn , drugn , and drugn .
false
while no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both sj grens efficacy studies : drugn , artificial tears , druga , drugn , drugn , drugn , drugn , drugn , drugn , drugb , drugn , drugn , drugn , and drugn .
false
while no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both sj grens efficacy studies : drugn , artificial tears , druga , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugb , drugn , drugn , and drugn .
false
while no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both sj grens efficacy studies : drugn , artificial tears , druga , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugb , drugn , and drugn .
false
while no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both sj grens efficacy studies : drugn , artificial tears , druga , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugb , and drugn .
false
while no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both sj grens efficacy studies : drugn , artificial tears , druga , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , and drugb .
false
while no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both sj grens efficacy studies : drugn , artificial tears , drugn , druga , drugb , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , and drugn .
false
while no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both sj grens efficacy studies : drugn , artificial tears , drugn , druga , drugn , drugb , drugn , drugn , drugn , drugn , drugn , drugn , drugn , and drugn .
false
while no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both sj grens efficacy studies : drugn , artificial tears , drugn , druga , drugn , drugn , drugb , drugn , drugn , drugn , drugn , drugn , drugn , and drugn .
false
while no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both sj grens efficacy studies : drugn , artificial tears , drugn , druga , drugn , drugn , drugn , drugb , drugn , drugn , drugn , drugn , drugn , and drugn .
false
while no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both sj grens efficacy studies : drugn , artificial tears , drugn , druga , drugn , drugn , drugn , drugn , drugb , drugn , drugn , drugn , drugn , and drugn .
false
while no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both sj grens efficacy studies : drugn , artificial tears , drugn , druga , drugn , drugn , drugn , drugn , drugn , drugb , drugn , drugn , drugn , and drugn .
false
while no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both sj grens efficacy studies : drugn , artificial tears , drugn , druga , drugn , drugn , drugn , drugn , drugn , drugn , drugb , drugn , drugn , and drugn .
false
while no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both sj grens efficacy studies : drugn , artificial tears , drugn , druga , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugb , drugn , and drugn .
false
while no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both sj grens efficacy studies : drugn , artificial tears , drugn , druga , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugb , and drugn .
false
while no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both sj grens efficacy studies : drugn , artificial tears , drugn , druga , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , and drugb .
false
while no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both sj grens efficacy studies : drugn , artificial tears , drugn , drugn , druga , drugb , drugn , drugn , drugn , drugn , drugn , drugn , drugn , and drugn .
false
while no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both sj grens efficacy studies : drugn , artificial tears , drugn , drugn , druga , drugn , drugb , drugn , drugn , drugn , drugn , drugn , drugn , and drugn .
false
while no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both sj grens efficacy studies : drugn , artificial tears , drugn , drugn , druga , drugn , drugn , drugb , drugn , drugn , drugn , drugn , drugn , and drugn .
false
while no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both sj grens efficacy studies : drugn , artificial tears , drugn , drugn , druga , drugn , drugn , drugn , drugb , drugn , drugn , drugn , drugn , and drugn .
false
while no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both sj grens efficacy studies : drugn , artificial tears , drugn , drugn , druga , drugn , drugn , drugn , drugn , drugb , drugn , drugn , drugn , and drugn .
false
while no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both sj grens efficacy studies : drugn , artificial tears , drugn , drugn , druga , drugn , drugn , drugn , drugn , drugn , drugb , drugn , drugn , and drugn .
false
while no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both sj grens efficacy studies : drugn , artificial tears , drugn , drugn , druga , drugn , drugn , drugn , drugn , drugn , drugn , drugb , drugn , and drugn .
false
while no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both sj grens efficacy studies : drugn , artificial tears , drugn , drugn , druga , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugb , and drugn .
false
while no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both sj grens efficacy studies : drugn , artificial tears , drugn , drugn , druga , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , and drugb .
false
while no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both sj grens efficacy studies : drugn , artificial tears , drugn , drugn , drugn , druga , drugb , drugn , drugn , drugn , drugn , drugn , drugn , and drugn .
false
while no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both sj grens efficacy studies : drugn , artificial tears , drugn , drugn , drugn , druga , drugn , drugb , drugn , drugn , drugn , drugn , drugn , and drugn .
false
while no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both sj grens efficacy studies : drugn , artificial tears , drugn , drugn , drugn , druga , drugn , drugn , drugb , drugn , drugn , drugn , drugn , and drugn .
false
while no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both sj grens efficacy studies : drugn , artificial tears , drugn , drugn , drugn , druga , drugn , drugn , drugn , drugb , drugn , drugn , drugn , and drugn .
false
while no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both sj grens efficacy studies : drugn , artificial tears , drugn , drugn , drugn , druga , drugn , drugn , drugn , drugn , drugb , drugn , drugn , and drugn .
false
while no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both sj grens efficacy studies : drugn , artificial tears , drugn , drugn , drugn , druga , drugn , drugn , drugn , drugn , drugn , drugb , drugn , and drugn .
false
while no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both sj grens efficacy studies : drugn , artificial tears , drugn , drugn , drugn , druga , drugn , drugn , drugn , drugn , drugn , drugn , drugb , and drugn .
false
while no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both sj grens efficacy studies : drugn , artificial tears , drugn , drugn , drugn , druga , drugn , drugn , drugn , drugn , drugn , drugn , drugn , and drugb .
false
while no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both sj grens efficacy studies : drugn , artificial tears , drugn , drugn , drugn , drugn , druga , drugb , drugn , drugn , drugn , drugn , drugn , and drugn .
false
while no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both sj grens efficacy studies : drugn , artificial tears , drugn , drugn , drugn , drugn , druga , drugn , drugb , drugn , drugn , drugn , drugn , and drugn .
false
while no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both sj grens efficacy studies : drugn , artificial tears , drugn , drugn , drugn , drugn , druga , drugn , drugn , drugb , drugn , drugn , drugn , and drugn .
false
while no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both sj grens efficacy studies : drugn , artificial tears , drugn , drugn , drugn , drugn , druga , drugn , drugn , drugn , drugb , drugn , drugn , and drugn .
false
while no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both sj grens efficacy studies : drugn , artificial tears , drugn , drugn , drugn , drugn , druga , drugn , drugn , drugn , drugn , drugb , drugn , and drugn .
false
while no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both sj grens efficacy studies : drugn , artificial tears , drugn , drugn , drugn , drugn , druga , drugn , drugn , drugn , drugn , drugn , drugb , and drugn .
false
while no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both sj grens efficacy studies : drugn , artificial tears , drugn , drugn , drugn , drugn , druga , drugn , drugn , drugn , drugn , drugn , drugn , and drugb .
false
while no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both sj grens efficacy studies : drugn , artificial tears , drugn , drugn , drugn , drugn , drugn , druga , drugb , drugn , drugn , drugn , drugn , and drugn .
false
while no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both sj grens efficacy studies : drugn , artificial tears , drugn , drugn , drugn , drugn , drugn , druga , drugn , drugb , drugn , drugn , drugn , and drugn .
false
while no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both sj grens efficacy studies : drugn , artificial tears , drugn , drugn , drugn , drugn , drugn , druga , drugn , drugn , drugb , drugn , drugn , and drugn .
false
while no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both sj grens efficacy studies : drugn , artificial tears , drugn , drugn , drugn , drugn , drugn , druga , drugn , drugn , drugn , drugb , drugn , and drugn .
false
while no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both sj grens efficacy studies : drugn , artificial tears , drugn , drugn , drugn , drugn , drugn , druga , drugn , drugn , drugn , drugn , drugb , and drugn .
false
while no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both sj grens efficacy studies : drugn , artificial tears , drugn , drugn , drugn , drugn , drugn , druga , drugn , drugn , drugn , drugn , drugn , and drugb .
false
while no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both sj grens efficacy studies : drugn , artificial tears , drugn , drugn , drugn , drugn , drugn , drugn , druga , drugb , drugn , drugn , drugn , and drugn .
false
while no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both sj grens efficacy studies : drugn , artificial tears , drugn , drugn , drugn , drugn , drugn , drugn , druga , drugn , drugb , drugn , drugn , and drugn .
false
while no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both sj grens efficacy studies : drugn , artificial tears , drugn , drugn , drugn , drugn , drugn , drugn , druga , drugn , drugn , drugb , drugn , and drugn .
false
while no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both sj grens efficacy studies : drugn , artificial tears , drugn , drugn , drugn , drugn , drugn , drugn , druga , drugn , drugn , drugn , drugb , and drugn .
false
while no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both sj grens efficacy studies : drugn , artificial tears , drugn , drugn , drugn , drugn , drugn , drugn , druga , drugn , drugn , drugn , drugn , and drugb .
false
while no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both sj grens efficacy studies : drugn , artificial tears , drugn , drugn , drugn , drugn , drugn , drugn , drugn , druga , drugb , drugn , drugn , and drugn .
false
while no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both sj grens efficacy studies : drugn , artificial tears , drugn , drugn , drugn , drugn , drugn , drugn , drugn , druga , drugn , drugb , drugn , and drugn .
false
while no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both sj grens efficacy studies : drugn , artificial tears , drugn , drugn , drugn , drugn , drugn , drugn , drugn , druga , drugn , drugn , drugb , and drugn .
false
while no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both sj grens efficacy studies : drugn , artificial tears , drugn , drugn , drugn , drugn , drugn , drugn , drugn , druga , drugn , drugn , drugn , and drugb .
false
while no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both sj grens efficacy studies : drugn , artificial tears , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , druga , drugb , drugn , and drugn .
false
while no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both sj grens efficacy studies : drugn , artificial tears , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , druga , drugn , drugb , and drugn .
false
while no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both sj grens efficacy studies : drugn , artificial tears , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , druga , drugn , drugn , and drugb .
false
while no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both sj grens efficacy studies : drugn , artificial tears , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , druga , drugb , and drugn .
false
while no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both sj grens efficacy studies : drugn , artificial tears , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , druga , drugn , and drugb .
false
while no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both sj grens efficacy studies : drugn , artificial tears , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , druga , and drugb .
false
to minimize cns depression and possible potentiation , druga , drugb , drugn , drugn or drugn should be used with caution .
false
to minimize cns depression and possible potentiation , druga , drugn , drugb , drugn or drugn should be used with caution .
false
to minimize cns depression and possible potentiation , druga , drugn , drugn , drugb or drugn should be used with caution .
false
to minimize cns depression and possible potentiation , druga , drugn , drugn , drugn or drugb should be used with caution .
false
to minimize cns depression and possible potentiation , drugn , druga , drugb , drugn or drugn should be used with caution .
false
to minimize cns depression and possible potentiation , drugn , druga , drugn , drugb or drugn should be used with caution .
false
to minimize cns depression and possible potentiation , drugn , druga , drugn , drugn or drugb should be used with caution .
false
to minimize cns depression and possible potentiation , drugn , drugn , druga , drugb or drugn should be used with caution .
false
to minimize cns depression and possible potentiation , drugn , drugn , druga , drugn or drugb should be used with caution .
false
to minimize cns depression and possible potentiation , drugn , drugn , drugn , druga or drugb should be used with caution .
false
because druga exhibits some monoamine oxidase inhibitory activity , drugb , drugn drugs ( e.g. , drugn , drugn ) and other drugs and foods with known high drugn content , such as wine , yogurt , ripe cheese and bananas , should be avoided .
advise
because druga exhibits some monoamine oxidase inhibitory activity , drugn , drugb drugs ( e.g. , drugn , drugn ) and other drugs and foods with known high drugn content , such as wine , yogurt , ripe cheese and bananas , should be avoided .
advise
because druga exhibits some monoamine oxidase inhibitory activity , drugn , drugn drugs ( e.g. , drugb , drugn ) and other drugs and foods with known high drugn content , such as wine , yogurt , ripe cheese and bananas , should be avoided .
advise
because druga exhibits some monoamine oxidase inhibitory activity , drugn , drugn drugs ( e.g. , drugn , drugb ) and other drugs and foods with known high drugn content , such as wine , yogurt , ripe cheese and bananas , should be avoided .
advise
because druga exhibits some monoamine oxidase inhibitory activity , drugn , drugn drugs ( e.g. , drugn , drugn ) and other drugs and foods with known high drugb content , such as wine , yogurt , ripe cheese and bananas , should be avoided .
advise
because drugn exhibits some monoamine oxidase inhibitory activity , druga , drugb drugs ( e.g. , drugn , drugn ) and other drugs and foods with known high drugn content , such as wine , yogurt , ripe cheese and bananas , should be avoided .
false
because drugn exhibits some monoamine oxidase inhibitory activity , druga , drugn drugs ( e.g. , drugb , drugn ) and other drugs and foods with known high drugn content , such as wine , yogurt , ripe cheese and bananas , should be avoided .
false
because drugn exhibits some monoamine oxidase inhibitory activity , druga , drugn drugs ( e.g. , drugn , drugb ) and other drugs and foods with known high drugn content , such as wine , yogurt , ripe cheese and bananas , should be avoided .
false
because drugn exhibits some monoamine oxidase inhibitory activity , druga , drugn drugs ( e.g. , drugn , drugn ) and other drugs and foods with known high drugb content , such as wine , yogurt , ripe cheese and bananas , should be avoided .
false
because drugn exhibits some monoamine oxidase inhibitory activity , drugn , druga drugs ( e.g. , drugb , drugn ) and other drugs and foods with known high drugn content , such as wine , yogurt , ripe cheese and bananas , should be avoided .
false
because drugn exhibits some monoamine oxidase inhibitory activity , drugn , druga drugs ( e.g. , drugn , drugb ) and other drugs and foods with known high drugn content , such as wine , yogurt , ripe cheese and bananas , should be avoided .
false
because drugn exhibits some monoamine oxidase inhibitory activity , drugn , druga drugs ( e.g. , drugn , drugn ) and other drugs and foods with known high drugb content , such as wine , yogurt , ripe cheese and bananas , should be avoided .
false
because drugn exhibits some monoamine oxidase inhibitory activity , drugn , drugn drugs ( e.g. , druga , drugb ) and other drugs and foods with known high drugn content , such as wine , yogurt , ripe cheese and bananas , should be avoided .
false
because drugn exhibits some monoamine oxidase inhibitory activity , drugn , drugn drugs ( e.g. , druga , drugn ) and other drugs and foods with known high drugb content , such as wine , yogurt , ripe cheese and bananas , should be avoided .
false
because drugn exhibits some monoamine oxidase inhibitory activity , drugn , drugn drugs ( e.g. , drugn , druga ) and other drugs and foods with known high drugb content , such as wine , yogurt , ripe cheese and bananas , should be avoided .
false
no cross-resistance with other druga , radiotherapy or drugb has been demonstrated .
false
when druga is used with other drugb , potentiation of antihypertensive effect may occur .
effect
patients may require reduced doses of druga when on drugb .
advise
when druga and drugb are given concomitantly the patient should be carefully monitored for symptoms of drugn toxicity .
advise
when druga and drugn are given concomitantly the patient should be carefully monitored for symptoms of drugb toxicity .
false
when drugn and druga are given concomitantly the patient should be carefully monitored for symptoms of drugb toxicity .
false
several studies demonstrate a decrease in the bioavailability of druga when it is ingested with drugb or drugn .
mechanism
several studies demonstrate a decrease in the bioavailability of druga when it is ingested with drugn or drugb .
mechanism
several studies demonstrate a decrease in the bioavailability of drugn when it is ingested with druga or drugb .
false
coadministration of druga with drugb or drugn is not recommended .
advise
coadministration of druga with drugn or drugb is not recommended .
advise
coadministration of drugn with druga or drugb is not recommended .
false
druga does not interfere with measurement of drugb ( drugn ) , a test for pheochromocytoma , by those methods which convert drugn to drugn .
false
druga does not interfere with measurement of drugn ( drugb ) , a test for pheochromocytoma , by those methods which convert drugn to drugn .
false
druga does not interfere with measurement of drugn ( drugn ) , a test for pheochromocytoma , by those methods which convert drugb to drugn .
false
druga does not interfere with measurement of drugn ( drugn ) , a test for pheochromocytoma , by those methods which convert drugn to drugb .
false
drugn does not interfere with measurement of druga ( drugb ) , a test for pheochromocytoma , by those methods which convert drugn to drugn .
false
drugn does not interfere with measurement of druga ( drugn ) , a test for pheochromocytoma , by those methods which convert drugb to drugn .
false
drugn does not interfere with measurement of druga ( drugn ) , a test for pheochromocytoma , by those methods which convert drugn to drugb .
false
drugn does not interfere with measurement of drugn ( druga ) , a test for pheochromocytoma , by those methods which convert drugb to drugn .
false
drugn does not interfere with measurement of drugn ( druga ) , a test for pheochromocytoma , by those methods which convert drugn to drugb .
false
drugn does not interfere with measurement of drugn ( drugn ) , a test for pheochromocytoma , by those methods which convert druga to drugb .
false
while co-administration of druga appeared to increase the clearance of drugb by 70 % , these results are not conclusive because of the small number of subjects studied and because patients took variable doses of drugn .
mechanism
while co-administration of druga appeared to increase the clearance of drugn by 70 % , these results are not conclusive because of the small number of subjects studied and because patients took variable doses of drugb .
false
while co-administration of drugn appeared to increase the clearance of druga by 70 % , these results are not conclusive because of the small number of subjects studied and because patients took variable doses of drugb .
false
combination therapy with druga ( drugb ) and drugn is not indicated .
false
combination therapy with druga ( drugn ) and drugb is not indicated .
advise
combination therapy with drugn ( druga ) and drugb is not indicated .
advise
because druga have been shown to depress plasma prothrombin activity , patients who are on drugb therapy may require downward adjustment of their drugn dosage .
advise
because druga have been shown to depress plasma prothrombin activity , patients who are on drugn therapy may require downward adjustment of their drugb dosage .
false
because drugn have been shown to depress plasma prothrombin activity , patients who are on druga therapy may require downward adjustment of their drugb dosage .
false
since bacteriostatic drugs may interfere with the bactericidal action of druga , it is advisable to avoid giving drugb in conjunction with drugn .
false
since bacteriostatic drugs may interfere with the bactericidal action of druga , it is advisable to avoid giving drugn in conjunction with drugb .
false
since bacteriostatic drugs may interfere with the bactericidal action of drugn , it is advisable to avoid giving druga in conjunction with drugb .
advise
absorption of druga is impaired by drugb containing drugn , drugn or drugn , and drugn -containing preparations .
false
absorption of druga is impaired by drugn containing drugb , drugn or drugn , and drugn -containing preparations .
mechanism
absorption of druga is impaired by drugn containing drugn , drugb or drugn , and drugn -containing preparations .
mechanism
absorption of druga is impaired by drugn containing drugn , drugn or drugb , and drugn -containing preparations .
mechanism
absorption of druga is impaired by drugn containing drugn , drugn or drugn , and drugb -containing preparations .
mechanism
absorption of drugn is impaired by druga containing drugb , drugn or drugn , and drugn -containing preparations .
false
absorption of drugn is impaired by druga containing drugn , drugb or drugn , and drugn -containing preparations .
false
absorption of drugn is impaired by druga containing drugn , drugn or drugb , and drugn -containing preparations .
false
absorption of drugn is impaired by druga containing drugn , drugn or drugn , and drugb -containing preparations .
false
absorption of drugn is impaired by drugn containing druga , drugb or drugn , and drugn -containing preparations .
false
absorption of drugn is impaired by drugn containing druga , drugn or drugb , and drugn -containing preparations .
false
absorption of drugn is impaired by drugn containing druga , drugn or drugn , and drugb -containing preparations .
false
absorption of drugn is impaired by drugn containing drugn , druga or drugb , and drugn -containing preparations .
false
absorption of drugn is impaired by drugn containing drugn , druga or drugn , and drugb -containing preparations .
false
absorption of drugn is impaired by drugn containing drugn , drugn or druga , and drugb -containing preparations .
false
the concurrent use of druga and drugb has been reported to result in fatal renal toxicity .
effect
concurrent use of druga with oral drugb may render oral drugn less effective .
effect
concurrent use of druga with oral drugn may render oral drugb less effective .
false
concurrent use of drugn with oral druga may render oral drugb less effective .
false
prothrombin time or other suitable anticoagulation test should be monitored if druga is administered with drugb .
advise
concurrent use of druga with oral drugb may render oral drugn less effective .
effect
concurrent use of druga with oral drugn may render oral drugb less effective .
false
concurrent use of drugn with oral druga may render oral drugb less effective .
false
although specific drug or food interactions with druga have not been studied , on the basis of this drug s metabolism by cyp 3a4 , it is possible that drugb , drugn , drugn , and grapefruit juice may inhibit its metabolism ( increasing serum levels of drugn ) .
false
although specific drug or food interactions with druga have not been studied , on the basis of this drug s metabolism by cyp 3a4 , it is possible that drugn , drugb , drugn , and grapefruit juice may inhibit its metabolism ( increasing serum levels of drugn ) .
false
although specific drug or food interactions with druga have not been studied , on the basis of this drug s metabolism by cyp 3a4 , it is possible that drugn , drugn , drugb , and grapefruit juice may inhibit its metabolism ( increasing serum levels of drugn ) .
false
although specific drug or food interactions with druga have not been studied , on the basis of this drug s metabolism by cyp 3a4 , it is possible that drugn , drugn , drugn , and grapefruit juice may inhibit its metabolism ( increasing serum levels of drugb ) .
false
although specific drug or food interactions with drugn have not been studied , on the basis of this drug s metabolism by cyp 3a4 , it is possible that druga , drugb , drugn , and grapefruit juice may inhibit its metabolism ( increasing serum levels of drugn ) .
false
although specific drug or food interactions with drugn have not been studied , on the basis of this drug s metabolism by cyp 3a4 , it is possible that druga , drugn , drugb , and grapefruit juice may inhibit its metabolism ( increasing serum levels of drugn ) .
false
although specific drug or food interactions with drugn have not been studied , on the basis of this drug s metabolism by cyp 3a4 , it is possible that druga , drugn , drugn , and grapefruit juice may inhibit its metabolism ( increasing serum levels of drugb ) .
mechanism
although specific drug or food interactions with drugn have not been studied , on the basis of this drug s metabolism by cyp 3a4 , it is possible that drugn , druga , drugb , and grapefruit juice may inhibit its metabolism ( increasing serum levels of drugn ) .
false
although specific drug or food interactions with drugn have not been studied , on the basis of this drug s metabolism by cyp 3a4 , it is possible that drugn , druga , drugn , and grapefruit juice may inhibit its metabolism ( increasing serum levels of drugb ) .
mechanism
although specific drug or food interactions with drugn have not been studied , on the basis of this drug s metabolism by cyp 3a4 , it is possible that drugn , drugn , druga , and grapefruit juice may inhibit its metabolism ( increasing serum levels of drugb ) .
mechanism
furthermore , druga , drugb , st .
false
john s wort , and certain druga ( drugb , drugn , drugn ) may induce drugn metabolism ( lowering serum levels of drugn ) .
false
john s wort , and certain druga ( drugn , drugb , drugn ) may induce drugn metabolism ( lowering serum levels of drugn ) .
false
john s wort , and certain druga ( drugn , drugn , drugb ) may induce drugn metabolism ( lowering serum levels of drugn ) .
false
john s wort , and certain druga ( drugn , drugn , drugn ) may induce drugb metabolism ( lowering serum levels of drugn ) .
mechanism
john s wort , and certain druga ( drugn , drugn , drugn ) may induce drugn metabolism ( lowering serum levels of drugb ) .
false
john s wort , and certain drugn ( druga , drugb , drugn ) may induce drugn metabolism ( lowering serum levels of drugn ) .
false
john s wort , and certain drugn ( druga , drugn , drugb ) may induce drugn metabolism ( lowering serum levels of drugn ) .
false
john s wort , and certain drugn ( druga , drugn , drugn ) may induce drugb metabolism ( lowering serum levels of drugn ) .
mechanism
john s wort , and certain drugn ( druga , drugn , drugn ) may induce drugn metabolism ( lowering serum levels of drugb ) .
false
john s wort , and certain drugn ( drugn , druga , drugb ) may induce drugn metabolism ( lowering serum levels of drugn ) .
false
john s wort , and certain drugn ( drugn , druga , drugn ) may induce drugb metabolism ( lowering serum levels of drugn ) .
mechanism
john s wort , and certain drugn ( drugn , druga , drugn ) may induce drugn metabolism ( lowering serum levels of drugb ) .
false
john s wort , and certain drugn ( drugn , drugn , druga ) may induce drugb metabolism ( lowering serum levels of drugn ) .
mechanism
john s wort , and certain drugn ( drugn , drugn , druga ) may induce drugn metabolism ( lowering serum levels of drugb ) .
false
john s wort , and certain drugn ( drugn , drugn , drugn ) may induce druga metabolism ( lowering serum levels of drugb ) .
false
a total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between druga and drugb , drugn , drugn , drugn , drugn , drugn , drugn , drugn , and drugn .
false
a total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between druga and drugn , drugb , drugn , drugn , drugn , drugn , drugn , drugn , and drugn .
false
a total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between druga and drugn , drugn , drugb , drugn , drugn , drugn , drugn , drugn , and drugn .
false
a total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between druga and drugn , drugn , drugn , drugb , drugn , drugn , drugn , drugn , and drugn .
false
a total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between druga and drugn , drugn , drugn , drugn , drugb , drugn , drugn , drugn , and drugn .
false
a total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between druga and drugn , drugn , drugn , drugn , drugn , drugb , drugn , drugn , and drugn .
false
a total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between druga and drugn , drugn , drugn , drugn , drugn , drugn , drugb , drugn , and drugn .
false
a total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between druga and drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugb , and drugn .
false
a total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between druga and drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , and drugb .
false
a total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between drugn and druga , drugb , drugn , drugn , drugn , drugn , drugn , drugn , and drugn .
false
a total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between drugn and druga , drugn , drugb , drugn , drugn , drugn , drugn , drugn , and drugn .
false
a total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between drugn and druga , drugn , drugn , drugb , drugn , drugn , drugn , drugn , and drugn .
false
a total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between drugn and druga , drugn , drugn , drugn , drugb , drugn , drugn , drugn , and drugn .
false
a total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between drugn and druga , drugn , drugn , drugn , drugn , drugb , drugn , drugn , and drugn .
false
a total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between drugn and druga , drugn , drugn , drugn , drugn , drugn , drugb , drugn , and drugn .
false
a total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between drugn and druga , drugn , drugn , drugn , drugn , drugn , drugn , drugb , and drugn .
false
a total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between drugn and druga , drugn , drugn , drugn , drugn , drugn , drugn , drugn , and drugb .
false
a total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between drugn and drugn , druga , drugb , drugn , drugn , drugn , drugn , drugn , and drugn .
false
a total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between drugn and drugn , druga , drugn , drugb , drugn , drugn , drugn , drugn , and drugn .
false
a total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between drugn and drugn , druga , drugn , drugn , drugb , drugn , drugn , drugn , and drugn .
false
a total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between drugn and drugn , druga , drugn , drugn , drugn , drugb , drugn , drugn , and drugn .
false
a total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between drugn and drugn , druga , drugn , drugn , drugn , drugn , drugb , drugn , and drugn .
false
a total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between drugn and drugn , druga , drugn , drugn , drugn , drugn , drugn , drugb , and drugn .
false
a total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between drugn and drugn , druga , drugn , drugn , drugn , drugn , drugn , drugn , and drugb .
false
a total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between drugn and drugn , drugn , druga , drugb , drugn , drugn , drugn , drugn , and drugn .
false
a total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between drugn and drugn , drugn , druga , drugn , drugb , drugn , drugn , drugn , and drugn .
false
a total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between drugn and drugn , drugn , druga , drugn , drugn , drugb , drugn , drugn , and drugn .
false
a total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between drugn and drugn , drugn , druga , drugn , drugn , drugn , drugb , drugn , and drugn .
false
a total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between drugn and drugn , drugn , druga , drugn , drugn , drugn , drugn , drugb , and drugn .
false
a total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between drugn and drugn , drugn , druga , drugn , drugn , drugn , drugn , drugn , and drugb .
false
a total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between drugn and drugn , drugn , drugn , druga , drugb , drugn , drugn , drugn , and drugn .
false
a total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between drugn and drugn , drugn , drugn , druga , drugn , drugb , drugn , drugn , and drugn .
false
a total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between drugn and drugn , drugn , drugn , druga , drugn , drugn , drugb , drugn , and drugn .
false
a total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between drugn and drugn , drugn , drugn , druga , drugn , drugn , drugn , drugb , and drugn .
false
a total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between drugn and drugn , drugn , drugn , druga , drugn , drugn , drugn , drugn , and drugb .
false
a total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between drugn and drugn , drugn , drugn , drugn , druga , drugb , drugn , drugn , and drugn .
false
a total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between drugn and drugn , drugn , drugn , drugn , druga , drugn , drugb , drugn , and drugn .
false
a total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between drugn and drugn , drugn , drugn , drugn , druga , drugn , drugn , drugb , and drugn .
false
a total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between drugn and drugn , drugn , drugn , drugn , druga , drugn , drugn , drugn , and drugb .
false
a total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between drugn and drugn , drugn , drugn , drugn , drugn , druga , drugb , drugn , and drugn .
false
a total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between drugn and drugn , drugn , drugn , drugn , drugn , druga , drugn , drugb , and drugn .
false
a total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between drugn and drugn , drugn , drugn , drugn , drugn , druga , drugn , drugn , and drugb .
false
a total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between drugn and drugn , drugn , drugn , drugn , drugn , drugn , druga , drugb , and drugn .
false
a total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between drugn and drugn , drugn , drugn , drugn , drugn , drugn , druga , drugn , and drugb .
false
a total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between drugn and drugn , drugn , drugn , drugn , drugn , drugn , drugn , druga , and drugb .
false
there was no effect of a single dose or multiple doses of druga on drugb , drugn , drugn , drugn , and drugn pharmacokinetics .
false
there was no effect of a single dose or multiple doses of druga on drugn , drugb , drugn , drugn , and drugn pharmacokinetics .
false
there was no effect of a single dose or multiple doses of druga on drugn , drugn , drugb , drugn , and drugn pharmacokinetics .
false
there was no effect of a single dose or multiple doses of druga on drugn , drugn , drugn , drugb , and drugn pharmacokinetics .
false
there was no effect of a single dose or multiple doses of druga on drugn , drugn , drugn , drugn , and drugb pharmacokinetics .
false
there was no effect of a single dose or multiple doses of drugn on druga , drugb , drugn , drugn , and drugn pharmacokinetics .
false
there was no effect of a single dose or multiple doses of drugn on druga , drugn , drugb , drugn , and drugn pharmacokinetics .
false
there was no effect of a single dose or multiple doses of drugn on druga , drugn , drugn , drugb , and drugn pharmacokinetics .
false
there was no effect of a single dose or multiple doses of drugn on druga , drugn , drugn , drugn , and drugb pharmacokinetics .
false
there was no effect of a single dose or multiple doses of drugn on drugn , druga , drugb , drugn , and drugn pharmacokinetics .
false
there was no effect of a single dose or multiple doses of drugn on drugn , druga , drugn , drugb , and drugn pharmacokinetics .
false
there was no effect of a single dose or multiple doses of drugn on drugn , druga , drugn , drugn , and drugb pharmacokinetics .
false
there was no effect of a single dose or multiple doses of drugn on drugn , drugn , druga , drugb , and drugn pharmacokinetics .
false
there was no effect of a single dose or multiple doses of drugn on drugn , drugn , druga , drugn , and drugb pharmacokinetics .
false
there was no effect of a single dose or multiple doses of drugn on drugn , drugn , drugn , druga , and drugb pharmacokinetics .
false
druga auc was increased by 21 % with no effect on cmax in the presence of steady-state drugb compared with drugn alone .
mechanism
druga auc was increased by 21 % with no effect on cmax in the presence of steady-state drugn compared with drugb alone .
false
drugn auc was increased by 21 % with no effect on cmax in the presence of steady-state druga compared with drugb alone .
false
druga auc and cmax were increased by 18 % and 42 % , respectively , in the presence of steady-state drugb compared with drugn alone .
mechanism
druga auc and cmax were increased by 18 % and 42 % , respectively , in the presence of steady-state drugn compared with drugb alone .
false
drugn auc and cmax were increased by 18 % and 42 % , respectively , in the presence of steady-state druga compared with drugb alone .
false
patients receiving druga or drugb in combination with drugn should be monitored for drugn or drugn toxicity and drugn or drugn dosage should be reduced if necessary .
false
patients receiving druga or drugn in combination with drugb should be monitored for drugn or drugn toxicity and drugn or drugn dosage should be reduced if necessary .
advise
patients receiving druga or drugn in combination with drugn should be monitored for drugb or drugn toxicity and drugn or drugn dosage should be reduced if necessary .
false
patients receiving druga or drugn in combination with drugn should be monitored for drugn or drugb toxicity and drugn or drugn dosage should be reduced if necessary .
false
patients receiving druga or drugn in combination with drugn should be monitored for drugn or drugn toxicity and drugb or drugn dosage should be reduced if necessary .
false
patients receiving druga or drugn in combination with drugn should be monitored for drugn or drugn toxicity and drugn or drugb dosage should be reduced if necessary .
false
patients receiving drugn or druga in combination with drugb should be monitored for drugn or drugn toxicity and drugn or drugn dosage should be reduced if necessary .
advise
patients receiving drugn or druga in combination with drugn should be monitored for drugb or drugn toxicity and drugn or drugn dosage should be reduced if necessary .
false
patients receiving drugn or druga in combination with drugn should be monitored for drugn or drugb toxicity and drugn or drugn dosage should be reduced if necessary .
false
patients receiving drugn or druga in combination with drugn should be monitored for drugn or drugn toxicity and drugb or drugn dosage should be reduced if necessary .
false
patients receiving drugn or druga in combination with drugn should be monitored for drugn or drugn toxicity and drugn or drugb dosage should be reduced if necessary .
false
patients receiving drugn or drugn in combination with druga should be monitored for drugb or drugn toxicity and drugn or drugn dosage should be reduced if necessary .
false
patients receiving drugn or drugn in combination with druga should be monitored for drugn or drugb toxicity and drugn or drugn dosage should be reduced if necessary .
false
patients receiving drugn or drugn in combination with druga should be monitored for drugn or drugn toxicity and drugb or drugn dosage should be reduced if necessary .
false
patients receiving drugn or drugn in combination with druga should be monitored for drugn or drugn toxicity and drugn or drugb dosage should be reduced if necessary .
false
patients receiving drugn or drugn in combination with drugn should be monitored for druga or drugb toxicity and drugn or drugn dosage should be reduced if necessary .
false
patients receiving drugn or drugn in combination with drugn should be monitored for druga or drugn toxicity and drugb or drugn dosage should be reduced if necessary .
false
patients receiving drugn or drugn in combination with drugn should be monitored for druga or drugn toxicity and drugn or drugb dosage should be reduced if necessary .
false
patients receiving drugn or drugn in combination with drugn should be monitored for drugn or druga toxicity and drugb or drugn dosage should be reduced if necessary .
false
patients receiving drugn or drugn in combination with drugn should be monitored for drugn or druga toxicity and drugn or drugb dosage should be reduced if necessary .
false
patients receiving drugn or drugn in combination with drugn should be monitored for drugn or drugn toxicity and druga or drugb dosage should be reduced if necessary .
false
druga has been studied on a background of drugb and drugn .
false
druga has been studied on a background of drugn and drugb .
false
drugn has been studied on a background of druga and drugb .
false
the use of druga , in combination with drugb and drugn , has been associated with an increase in bleeding compared to drugn and drugn alone ( see
effect
the use of druga , in combination with drugn and drugb , has been associated with an increase in bleeding compared to drugn and drugn alone ( see
effect
the use of druga , in combination with drugn and drugn , has been associated with an increase in bleeding compared to drugb and drugn alone ( see
false
the use of druga , in combination with drugn and drugn , has been associated with an increase in bleeding compared to drugn and drugb alone ( see
false
the use of drugn , in combination with druga and drugb , has been associated with an increase in bleeding compared to drugn and drugn alone ( see
false
the use of drugn , in combination with druga and drugn , has been associated with an increase in bleeding compared to drugb and drugn alone ( see
false
the use of drugn , in combination with druga and drugn , has been associated with an increase in bleeding compared to drugn and drugb alone ( see
false
the use of drugn , in combination with drugn and druga , has been associated with an increase in bleeding compared to drugb and drugn alone ( see
false
the use of drugn , in combination with drugn and druga , has been associated with an increase in bleeding compared to drugn and drugb alone ( see
false
the use of drugn , in combination with drugn and drugn , has been associated with an increase in bleeding compared to druga and drugb alone ( see
false
cyp 3a4 inhibitors ( e.g . druga and drugb ) there have been rare reports of serious adverse events in connection with the coadministration of certain drugn ( e.g . drugn and drugn ) and potent cyp 3a4 inhibitors , resulting in vasospasm leading to cerebral ischemia and/or ischemia of the extremities .
false
cyp 3a4 inhibitors ( e.g . druga and drugn ) there have been rare reports of serious adverse events in connection with the coadministration of certain drugb ( e.g . drugn and drugn ) and potent cyp 3a4 inhibitors , resulting in vasospasm leading to cerebral ischemia and/or ischemia of the extremities .
false
cyp 3a4 inhibitors ( e.g . druga and drugn ) there have been rare reports of serious adverse events in connection with the coadministration of certain drugn ( e.g . drugb and drugn ) and potent cyp 3a4 inhibitors , resulting in vasospasm leading to cerebral ischemia and/or ischemia of the extremities .
false
cyp 3a4 inhibitors ( e.g . druga and drugn ) there have been rare reports of serious adverse events in connection with the coadministration of certain drugn ( e.g . drugn and drugb ) and potent cyp 3a4 inhibitors , resulting in vasospasm leading to cerebral ischemia and/or ischemia of the extremities .
false
cyp 3a4 inhibitors ( e.g . drugn and druga ) there have been rare reports of serious adverse events in connection with the coadministration of certain drugb ( e.g . drugn and drugn ) and potent cyp 3a4 inhibitors , resulting in vasospasm leading to cerebral ischemia and/or ischemia of the extremities .
false
cyp 3a4 inhibitors ( e.g . drugn and druga ) there have been rare reports of serious adverse events in connection with the coadministration of certain drugn ( e.g . drugb and drugn ) and potent cyp 3a4 inhibitors , resulting in vasospasm leading to cerebral ischemia and/or ischemia of the extremities .
false
cyp 3a4 inhibitors ( e.g . drugn and druga ) there have been rare reports of serious adverse events in connection with the coadministration of certain drugn ( e.g . drugn and drugb ) and potent cyp 3a4 inhibitors , resulting in vasospasm leading to cerebral ischemia and/or ischemia of the extremities .
false
cyp 3a4 inhibitors ( e.g . drugn and drugn ) there have been rare reports of serious adverse events in connection with the coadministration of certain druga ( e.g . drugb and drugn ) and potent cyp 3a4 inhibitors , resulting in vasospasm leading to cerebral ischemia and/or ischemia of the extremities .
false
cyp 3a4 inhibitors ( e.g . drugn and drugn ) there have been rare reports of serious adverse events in connection with the coadministration of certain druga ( e.g . drugn and drugb ) and potent cyp 3a4 inhibitors , resulting in vasospasm leading to cerebral ischemia and/or ischemia of the extremities .
false
cyp 3a4 inhibitors ( e.g . drugn and drugn ) there have been rare reports of serious adverse events in connection with the coadministration of certain drugn ( e.g . druga and drugb ) and potent cyp 3a4 inhibitors , resulting in vasospasm leading to cerebral ischemia and/or ischemia of the extremities .
false
examples of some of the more potent cyp 3a4 inhibitors include druga ( e.g. , drugb , drugn , drugn ) , drugn or drugn ( e.g. , drugn , drugn , drugn , drugn ) or drugn ( e.g. , drugn , drugn , drugn ) .
false
examples of some of the more potent cyp 3a4 inhibitors include druga ( e.g. , drugn , drugb , drugn ) , drugn or drugn ( e.g. , drugn , drugn , drugn , drugn ) or drugn ( e.g. , drugn , drugn , drugn ) .
false
examples of some of the more potent cyp 3a4 inhibitors include druga ( e.g. , drugn , drugn , drugb ) , drugn or drugn ( e.g. , drugn , drugn , drugn , drugn ) or drugn ( e.g. , drugn , drugn , drugn ) .
false
examples of some of the more potent cyp 3a4 inhibitors include druga ( e.g. , drugn , drugn , drugn ) , drugb or drugn ( e.g. , drugn , drugn , drugn , drugn ) or drugn ( e.g. , drugn , drugn , drugn ) .
false
examples of some of the more potent cyp 3a4 inhibitors include druga ( e.g. , drugn , drugn , drugn ) , drugn or drugb ( e.g. , drugn , drugn , drugn , drugn ) or drugn ( e.g. , drugn , drugn , drugn ) .
false
examples of some of the more potent cyp 3a4 inhibitors include druga ( e.g. , drugn , drugn , drugn ) , drugn or drugn ( e.g. , drugb , drugn , drugn , drugn ) or drugn ( e.g. , drugn , drugn , drugn ) .
false
examples of some of the more potent cyp 3a4 inhibitors include druga ( e.g. , drugn , drugn , drugn ) , drugn or drugn ( e.g. , drugn , drugb , drugn , drugn ) or drugn ( e.g. , drugn , drugn , drugn ) .
false
examples of some of the more potent cyp 3a4 inhibitors include druga ( e.g. , drugn , drugn , drugn ) , drugn or drugn ( e.g. , drugn , drugn , drugb , drugn ) or drugn ( e.g. , drugn , drugn , drugn ) .
false
examples of some of the more potent cyp 3a4 inhibitors include druga ( e.g. , drugn , drugn , drugn ) , drugn or drugn ( e.g. , drugn , drugn , drugn , drugb ) or drugn ( e.g. , drugn , drugn , drugn ) .
false
examples of some of the more potent cyp 3a4 inhibitors include druga ( e.g. , drugn , drugn , drugn ) , drugn or drugn ( e.g. , drugn , drugn , drugn , drugn ) or drugb ( e.g. , drugn , drugn , drugn ) .
false
examples of some of the more potent cyp 3a4 inhibitors include druga ( e.g. , drugn , drugn , drugn ) , drugn or drugn ( e.g. , drugn , drugn , drugn , drugn ) or drugn ( e.g. , drugb , drugn , drugn ) .
false
examples of some of the more potent cyp 3a4 inhibitors include druga ( e.g. , drugn , drugn , drugn ) , drugn or drugn ( e.g. , drugn , drugn , drugn , drugn ) or drugn ( e.g. , drugn , drugb , drugn ) .
false
examples of some of the more potent cyp 3a4 inhibitors include druga ( e.g. , drugn , drugn , drugn ) , drugn or drugn ( e.g. , drugn , drugn , drugn , drugn ) or drugn ( e.g. , drugn , drugn , drugb ) .
false
examples of some of the more potent cyp 3a4 inhibitors include drugn ( e.g. , druga , drugb , drugn ) , drugn or drugn ( e.g. , drugn , drugn , drugn , drugn ) or drugn ( e.g. , drugn , drugn , drugn ) .
false
examples of some of the more potent cyp 3a4 inhibitors include drugn ( e.g. , druga , drugn , drugb ) , drugn or drugn ( e.g. , drugn , drugn , drugn , drugn ) or drugn ( e.g. , drugn , drugn , drugn ) .
false
examples of some of the more potent cyp 3a4 inhibitors include drugn ( e.g. , druga , drugn , drugn ) , drugb or drugn ( e.g. , drugn , drugn , drugn , drugn ) or drugn ( e.g. , drugn , drugn , drugn ) .
false
examples of some of the more potent cyp 3a4 inhibitors include drugn ( e.g. , druga , drugn , drugn ) , drugn or drugb ( e.g. , drugn , drugn , drugn , drugn ) or drugn ( e.g. , drugn , drugn , drugn ) .
false
examples of some of the more potent cyp 3a4 inhibitors include drugn ( e.g. , druga , drugn , drugn ) , drugn or drugn ( e.g. , drugb , drugn , drugn , drugn ) or drugn ( e.g. , drugn , drugn , drugn ) .
false
examples of some of the more potent cyp 3a4 inhibitors include drugn ( e.g. , druga , drugn , drugn ) , drugn or drugn ( e.g. , drugn , drugb , drugn , drugn ) or drugn ( e.g. , drugn , drugn , drugn ) .
false
examples of some of the more potent cyp 3a4 inhibitors include drugn ( e.g. , druga , drugn , drugn ) , drugn or drugn ( e.g. , drugn , drugn , drugb , drugn ) or drugn ( e.g. , drugn , drugn , drugn ) .
false
examples of some of the more potent cyp 3a4 inhibitors include drugn ( e.g. , druga , drugn , drugn ) , drugn or drugn ( e.g. , drugn , drugn , drugn , drugb ) or drugn ( e.g. , drugn , drugn , drugn ) .
false
examples of some of the more potent cyp 3a4 inhibitors include drugn ( e.g. , druga , drugn , drugn ) , drugn or drugn ( e.g. , drugn , drugn , drugn , drugn ) or drugb ( e.g. , drugn , drugn , drugn ) .
false
examples of some of the more potent cyp 3a4 inhibitors include drugn ( e.g. , druga , drugn , drugn ) , drugn or drugn ( e.g. , drugn , drugn , drugn , drugn ) or drugn ( e.g. , drugb , drugn , drugn ) .
false
examples of some of the more potent cyp 3a4 inhibitors include drugn ( e.g. , druga , drugn , drugn ) , drugn or drugn ( e.g. , drugn , drugn , drugn , drugn ) or drugn ( e.g. , drugn , drugb , drugn ) .
false
examples of some of the more potent cyp 3a4 inhibitors include drugn ( e.g. , druga , drugn , drugn ) , drugn or drugn ( e.g. , drugn , drugn , drugn , drugn ) or drugn ( e.g. , drugn , drugn , drugb ) .
false
examples of some of the more potent cyp 3a4 inhibitors include drugn ( e.g. , drugn , druga , drugb ) , drugn or drugn ( e.g. , drugn , drugn , drugn , drugn ) or drugn ( e.g. , drugn , drugn , drugn ) .
false
examples of some of the more potent cyp 3a4 inhibitors include drugn ( e.g. , drugn , druga , drugn ) , drugb or drugn ( e.g. , drugn , drugn , drugn , drugn ) or drugn ( e.g. , drugn , drugn , drugn ) .
false
examples of some of the more potent cyp 3a4 inhibitors include drugn ( e.g. , drugn , druga , drugn ) , drugn or drugb ( e.g. , drugn , drugn , drugn , drugn ) or drugn ( e.g. , drugn , drugn , drugn ) .
false
examples of some of the more potent cyp 3a4 inhibitors include drugn ( e.g. , drugn , druga , drugn ) , drugn or drugn ( e.g. , drugb , drugn , drugn , drugn ) or drugn ( e.g. , drugn , drugn , drugn ) .
false
examples of some of the more potent cyp 3a4 inhibitors include drugn ( e.g. , drugn , druga , drugn ) , drugn or drugn ( e.g. , drugn , drugb , drugn , drugn ) or drugn ( e.g. , drugn , drugn , drugn ) .
false
examples of some of the more potent cyp 3a4 inhibitors include drugn ( e.g. , drugn , druga , drugn ) , drugn or drugn ( e.g. , drugn , drugn , drugb , drugn ) or drugn ( e.g. , drugn , drugn , drugn ) .
false
examples of some of the more potent cyp 3a4 inhibitors include drugn ( e.g. , drugn , druga , drugn ) , drugn or drugn ( e.g. , drugn , drugn , drugn , drugb ) or drugn ( e.g. , drugn , drugn , drugn ) .
false
examples of some of the more potent cyp 3a4 inhibitors include drugn ( e.g. , drugn , druga , drugn ) , drugn or drugn ( e.g. , drugn , drugn , drugn , drugn ) or drugb ( e.g. , drugn , drugn , drugn ) .
false
examples of some of the more potent cyp 3a4 inhibitors include drugn ( e.g. , drugn , druga , drugn ) , drugn or drugn ( e.g. , drugn , drugn , drugn , drugn ) or drugn ( e.g. , drugb , drugn , drugn ) .
false
examples of some of the more potent cyp 3a4 inhibitors include drugn ( e.g. , drugn , druga , drugn ) , drugn or drugn ( e.g. , drugn , drugn , drugn , drugn ) or drugn ( e.g. , drugn , drugb , drugn ) .
false
examples of some of the more potent cyp 3a4 inhibitors include drugn ( e.g. , drugn , druga , drugn ) , drugn or drugn ( e.g. , drugn , drugn , drugn , drugn ) or drugn ( e.g. , drugn , drugn , drugb ) .
false
examples of some of the more potent cyp 3a4 inhibitors include drugn ( e.g. , drugn , drugn , druga ) , drugb or drugn ( e.g. , drugn , drugn , drugn , drugn ) or drugn ( e.g. , drugn , drugn , drugn ) .
false
examples of some of the more potent cyp 3a4 inhibitors include drugn ( e.g. , drugn , drugn , druga ) , drugn or drugb ( e.g. , drugn , drugn , drugn , drugn ) or drugn ( e.g. , drugn , drugn , drugn ) .
false
examples of some of the more potent cyp 3a4 inhibitors include drugn ( e.g. , drugn , drugn , druga ) , drugn or drugn ( e.g. , drugb , drugn , drugn , drugn ) or drugn ( e.g. , drugn , drugn , drugn ) .
false
examples of some of the more potent cyp 3a4 inhibitors include drugn ( e.g. , drugn , drugn , druga ) , drugn or drugn ( e.g. , drugn , drugb , drugn , drugn ) or drugn ( e.g. , drugn , drugn , drugn ) .
false
examples of some of the more potent cyp 3a4 inhibitors include drugn ( e.g. , drugn , drugn , druga ) , drugn or drugn ( e.g. , drugn , drugn , drugb , drugn ) or drugn ( e.g. , drugn , drugn , drugn ) .
false
examples of some of the more potent cyp 3a4 inhibitors include drugn ( e.g. , drugn , drugn , druga ) , drugn or drugn ( e.g. , drugn , drugn , drugn , drugb ) or drugn ( e.g. , drugn , drugn , drugn ) .
false
examples of some of the more potent cyp 3a4 inhibitors include drugn ( e.g. , drugn , drugn , druga ) , drugn or drugn ( e.g. , drugn , drugn , drugn , drugn ) or drugb ( e.g. , drugn , drugn , drugn ) .
false
examples of some of the more potent cyp 3a4 inhibitors include drugn ( e.g. , drugn , drugn , druga ) , drugn or drugn ( e.g. , drugn , drugn , drugn , drugn ) or drugn ( e.g. , drugb , drugn , drugn ) .
false
examples of some of the more potent cyp 3a4 inhibitors include drugn ( e.g. , drugn , drugn , druga ) , drugn or drugn ( e.g. , drugn , drugn , drugn , drugn ) or drugn ( e.g. , drugn , drugb , drugn ) .
false
examples of some of the more potent cyp 3a4 inhibitors include drugn ( e.g. , drugn , drugn , druga ) , drugn or drugn ( e.g. , drugn , drugn , drugn , drugn ) or drugn ( e.g. , drugn , drugn , drugb ) .
false
examples of some of the more potent cyp 3a4 inhibitors include drugn ( e.g. , drugn , drugn , drugn ) , druga or drugb ( e.g. , drugn , drugn , drugn , drugn ) or drugn ( e.g. , drugn , drugn , drugn ) .
false
examples of some of the more potent cyp 3a4 inhibitors include drugn ( e.g. , drugn , drugn , drugn ) , druga or drugn ( e.g. , drugb , drugn , drugn , drugn ) or drugn ( e.g. , drugn , drugn , drugn ) .
false
examples of some of the more potent cyp 3a4 inhibitors include drugn ( e.g. , drugn , drugn , drugn ) , druga or drugn ( e.g. , drugn , drugb , drugn , drugn ) or drugn ( e.g. , drugn , drugn , drugn ) .
false
examples of some of the more potent cyp 3a4 inhibitors include drugn ( e.g. , drugn , drugn , drugn ) , druga or drugn ( e.g. , drugn , drugn , drugb , drugn ) or drugn ( e.g. , drugn , drugn , drugn ) .
false
examples of some of the more potent cyp 3a4 inhibitors include drugn ( e.g. , drugn , drugn , drugn ) , druga or drugn ( e.g. , drugn , drugn , drugn , drugb ) or drugn ( e.g. , drugn , drugn , drugn ) .
false
examples of some of the more potent cyp 3a4 inhibitors include drugn ( e.g. , drugn , drugn , drugn ) , druga or drugn ( e.g. , drugn , drugn , drugn , drugn ) or drugb ( e.g. , drugn , drugn , drugn ) .
false
examples of some of the more potent cyp 3a4 inhibitors include drugn ( e.g. , drugn , drugn , drugn ) , druga or drugn ( e.g. , drugn , drugn , drugn , drugn ) or drugn ( e.g. , drugb , drugn , drugn ) .
false
examples of some of the more potent cyp 3a4 inhibitors include drugn ( e.g. , drugn , drugn , drugn ) , druga or drugn ( e.g. , drugn , drugn , drugn , drugn ) or drugn ( e.g. , drugn , drugb , drugn ) .
false
examples of some of the more potent cyp 3a4 inhibitors include drugn ( e.g. , drugn , drugn , drugn ) , druga or drugn ( e.g. , drugn , drugn , drugn , drugn ) or drugn ( e.g. , drugn , drugn , drugb ) .
false
examples of some of the more potent cyp 3a4 inhibitors include drugn ( e.g. , drugn , drugn , drugn ) , drugn or druga ( e.g. , drugb , drugn , drugn , drugn ) or drugn ( e.g. , drugn , drugn , drugn ) .
false
examples of some of the more potent cyp 3a4 inhibitors include drugn ( e.g. , drugn , drugn , drugn ) , drugn or druga ( e.g. , drugn , drugb , drugn , drugn ) or drugn ( e.g. , drugn , drugn , drugn ) .
false
examples of some of the more potent cyp 3a4 inhibitors include drugn ( e.g. , drugn , drugn , drugn ) , drugn or druga ( e.g. , drugn , drugn , drugb , drugn ) or drugn ( e.g. , drugn , drugn , drugn ) .
false
examples of some of the more potent cyp 3a4 inhibitors include drugn ( e.g. , drugn , drugn , drugn ) , drugn or druga ( e.g. , drugn , drugn , drugn , drugb ) or drugn ( e.g. , drugn , drugn , drugn ) .
false
examples of some of the more potent cyp 3a4 inhibitors include drugn ( e.g. , drugn , drugn , drugn ) , drugn or druga ( e.g. , drugn , drugn , drugn , drugn ) or drugb ( e.g. , drugn , drugn , drugn ) .
false
examples of some of the more potent cyp 3a4 inhibitors include drugn ( e.g. , drugn , drugn , drugn ) , drugn or druga ( e.g. , drugn , drugn , drugn , drugn ) or drugn ( e.g. , drugb , drugn , drugn ) .
false
examples of some of the more potent cyp 3a4 inhibitors include drugn ( e.g. , drugn , drugn , drugn ) , drugn or druga ( e.g. , drugn , drugn , drugn , drugn ) or drugn ( e.g. , drugn , drugb , drugn ) .
false
examples of some of the more potent cyp 3a4 inhibitors include drugn ( e.g. , drugn , drugn , drugn ) , drugn or druga ( e.g. , drugn , drugn , drugn , drugn ) or drugn ( e.g. , drugn , drugn , drugb ) .
false
examples of some of the more potent cyp 3a4 inhibitors include drugn ( e.g. , drugn , drugn , drugn ) , drugn or drugn ( e.g. , druga , drugb , drugn , drugn ) or drugn ( e.g. , drugn , drugn , drugn ) .
false
examples of some of the more potent cyp 3a4 inhibitors include drugn ( e.g. , drugn , drugn , drugn ) , drugn or drugn ( e.g. , druga , drugn , drugb , drugn ) or drugn ( e.g. , drugn , drugn , drugn ) .
false
examples of some of the more potent cyp 3a4 inhibitors include drugn ( e.g. , drugn , drugn , drugn ) , drugn or drugn ( e.g. , druga , drugn , drugn , drugb ) or drugn ( e.g. , drugn , drugn , drugn ) .
false
examples of some of the more potent cyp 3a4 inhibitors include drugn ( e.g. , drugn , drugn , drugn ) , drugn or drugn ( e.g. , druga , drugn , drugn , drugn ) or drugb ( e.g. , drugn , drugn , drugn ) .
false
examples of some of the more potent cyp 3a4 inhibitors include drugn ( e.g. , drugn , drugn , drugn ) , drugn or drugn ( e.g. , druga , drugn , drugn , drugn ) or drugn ( e.g. , drugb , drugn , drugn ) .
false
examples of some of the more potent cyp 3a4 inhibitors include drugn ( e.g. , drugn , drugn , drugn ) , drugn or drugn ( e.g. , druga , drugn , drugn , drugn ) or drugn ( e.g. , drugn , drugb , drugn ) .
false
examples of some of the more potent cyp 3a4 inhibitors include drugn ( e.g. , drugn , drugn , drugn ) , drugn or drugn ( e.g. , druga , drugn , drugn , drugn ) or drugn ( e.g. , drugn , drugn , drugb ) .
false
examples of some of the more potent cyp 3a4 inhibitors include drugn ( e.g. , drugn , drugn , drugn ) , drugn or drugn ( e.g. , drugn , druga , drugb , drugn ) or drugn ( e.g. , drugn , drugn , drugn ) .
false
examples of some of the more potent cyp 3a4 inhibitors include drugn ( e.g. , drugn , drugn , drugn ) , drugn or drugn ( e.g. , drugn , druga , drugn , drugb ) or drugn ( e.g. , drugn , drugn , drugn ) .
false
examples of some of the more potent cyp 3a4 inhibitors include drugn ( e.g. , drugn , drugn , drugn ) , drugn or drugn ( e.g. , drugn , druga , drugn , drugn ) or drugb ( e.g. , drugn , drugn , drugn ) .
false
examples of some of the more potent cyp 3a4 inhibitors include drugn ( e.g. , drugn , drugn , drugn ) , drugn or drugn ( e.g. , drugn , druga , drugn , drugn ) or drugn ( e.g. , drugb , drugn , drugn ) .
false
examples of some of the more potent cyp 3a4 inhibitors include drugn ( e.g. , drugn , drugn , drugn ) , drugn or drugn ( e.g. , drugn , druga , drugn , drugn ) or drugn ( e.g. , drugn , drugb , drugn ) .
false
examples of some of the more potent cyp 3a4 inhibitors include drugn ( e.g. , drugn , drugn , drugn ) , drugn or drugn ( e.g. , drugn , druga , drugn , drugn ) or drugn ( e.g. , drugn , drugn , drugb ) .
false
examples of some of the more potent cyp 3a4 inhibitors include drugn ( e.g. , drugn , drugn , drugn ) , drugn or drugn ( e.g. , drugn , drugn , druga , drugb ) or drugn ( e.g. , drugn , drugn , drugn ) .
false
examples of some of the more potent cyp 3a4 inhibitors include drugn ( e.g. , drugn , drugn , drugn ) , drugn or drugn ( e.g. , drugn , drugn , druga , drugn ) or drugb ( e.g. , drugn , drugn , drugn ) .
false
examples of some of the more potent cyp 3a4 inhibitors include drugn ( e.g. , drugn , drugn , drugn ) , drugn or drugn ( e.g. , drugn , drugn , druga , drugn ) or drugn ( e.g. , drugb , drugn , drugn ) .
false
examples of some of the more potent cyp 3a4 inhibitors include drugn ( e.g. , drugn , drugn , drugn ) , drugn or drugn ( e.g. , drugn , drugn , druga , drugn ) or drugn ( e.g. , drugn , drugb , drugn ) .
false
examples of some of the more potent cyp 3a4 inhibitors include drugn ( e.g. , drugn , drugn , drugn ) , drugn or drugn ( e.g. , drugn , drugn , druga , drugn ) or drugn ( e.g. , drugn , drugn , drugb ) .
false
examples of some of the more potent cyp 3a4 inhibitors include drugn ( e.g. , drugn , drugn , drugn ) , drugn or drugn ( e.g. , drugn , drugn , drugn , druga ) or drugb ( e.g. , drugn , drugn , drugn ) .
false
examples of some of the more potent cyp 3a4 inhibitors include drugn ( e.g. , drugn , drugn , drugn ) , drugn or drugn ( e.g. , drugn , drugn , drugn , druga ) or drugn ( e.g. , drugb , drugn , drugn ) .
false
examples of some of the more potent cyp 3a4 inhibitors include drugn ( e.g. , drugn , drugn , drugn ) , drugn or drugn ( e.g. , drugn , drugn , drugn , druga ) or drugn ( e.g. , drugn , drugb , drugn ) .
false
examples of some of the more potent cyp 3a4 inhibitors include drugn ( e.g. , drugn , drugn , drugn ) , drugn or drugn ( e.g. , drugn , drugn , drugn , druga ) or drugn ( e.g. , drugn , drugn , drugb ) .
false
examples of some of the more potent cyp 3a4 inhibitors include drugn ( e.g. , drugn , drugn , drugn ) , drugn or drugn ( e.g. , drugn , drugn , drugn , drugn ) or druga ( e.g. , drugb , drugn , drugn ) .
false
examples of some of the more potent cyp 3a4 inhibitors include drugn ( e.g. , drugn , drugn , drugn ) , drugn or drugn ( e.g. , drugn , drugn , drugn , drugn ) or druga ( e.g. , drugn , drugb , drugn ) .
false
examples of some of the more potent cyp 3a4 inhibitors include drugn ( e.g. , drugn , drugn , drugn ) , drugn or drugn ( e.g. , drugn , drugn , drugn , drugn ) or druga ( e.g. , drugn , drugn , drugb ) .
false
examples of some of the more potent cyp 3a4 inhibitors include drugn ( e.g. , drugn , drugn , drugn ) , drugn or drugn ( e.g. , drugn , drugn , drugn , drugn ) or drugn ( e.g. , druga , drugb , drugn ) .
false
examples of some of the more potent cyp 3a4 inhibitors include drugn ( e.g. , drugn , drugn , drugn ) , drugn or drugn ( e.g. , drugn , drugn , drugn , drugn ) or drugn ( e.g. , druga , drugn , drugb ) .
false
examples of some of the more potent cyp 3a4 inhibitors include drugn ( e.g. , drugn , drugn , drugn ) , drugn or drugn ( e.g. , drugn , drugn , drugn , drugn ) or drugn ( e.g. , drugn , druga , drugb ) .
false
less potent inhibitors include druga , drugb , drugn , grapefruit juice , drugn , drugn , drugn , and drugn .
false
less potent inhibitors include druga , drugn , drugb , grapefruit juice , drugn , drugn , drugn , and drugn .
false
less potent inhibitors include druga , drugn , drugn , grapefruit juice , drugb , drugn , drugn , and drugn .
false
less potent inhibitors include druga , drugn , drugn , grapefruit juice , drugn , drugb , drugn , and drugn .
false
less potent inhibitors include druga , drugn , drugn , grapefruit juice , drugn , drugn , drugb , and drugn .
false
less potent inhibitors include druga , drugn , drugn , grapefruit juice , drugn , drugn , drugn , and drugb .
false
less potent inhibitors include drugn , druga , drugb , grapefruit juice , drugn , drugn , drugn , and drugn .
false
less potent inhibitors include drugn , druga , drugn , grapefruit juice , drugb , drugn , drugn , and drugn .
false
less potent inhibitors include drugn , druga , drugn , grapefruit juice , drugn , drugb , drugn , and drugn .
false
less potent inhibitors include drugn , druga , drugn , grapefruit juice , drugn , drugn , drugb , and drugn .
false
less potent inhibitors include drugn , druga , drugn , grapefruit juice , drugn , drugn , drugn , and drugb .
false
less potent inhibitors include drugn , drugn , druga , grapefruit juice , drugb , drugn , drugn , and drugn .
false
less potent inhibitors include drugn , drugn , druga , grapefruit juice , drugn , drugb , drugn , and drugn .
false
less potent inhibitors include drugn , drugn , druga , grapefruit juice , drugn , drugn , drugb , and drugn .
false
less potent inhibitors include drugn , drugn , druga , grapefruit juice , drugn , drugn , drugn , and drugb .
false
less potent inhibitors include drugn , drugn , drugn , grapefruit juice , druga , drugb , drugn , and drugn .
false
less potent inhibitors include drugn , drugn , drugn , grapefruit juice , druga , drugn , drugb , and drugn .
false
less potent inhibitors include drugn , drugn , drugn , grapefruit juice , druga , drugn , drugn , and drugb .
false
less potent inhibitors include drugn , drugn , drugn , grapefruit juice , drugn , druga , drugb , and drugn .
false
less potent inhibitors include drugn , drugn , drugn , grapefruit juice , drugn , druga , drugn , and drugb .
false
less potent inhibitors include drugn , drugn , drugn , grapefruit juice , drugn , drugn , druga , and drugb .
false
caution should be exercised when druga ( drugb ) is used concurrently with other drugn or drugn .
false
caution should be exercised when druga ( drugn ) is used concurrently with other drugb or drugn .
advise
caution should be exercised when druga ( drugn ) is used concurrently with other drugn or drugb .
advise
caution should be exercised when drugn ( druga ) is used concurrently with other drugb or drugn .
advise
caution should be exercised when drugn ( druga ) is used concurrently with other drugn or drugb .
false
caution should be exercised when drugn ( drugn ) is used concurrently with other druga or drugb .
false
administration of druga decreases oral clearance of drugb by about 5 % .
mechanism
although a causal relationship has not been established , there have been reports of bleeding and/or prolonged prothrombin time in patients treated with druga with and without drugb or drugn .
effect
although a causal relationship has not been established , there have been reports of bleeding and/or prolonged prothrombin time in patients treated with druga with and without drugn or drugb .
effect
although a causal relationship has not been established , there have been reports of bleeding and/or prolonged prothrombin time in patients treated with drugn with and without druga or drugb .
false
concomitant administration of druga and drugb -containing drugs leads to increased drugn levels and drugn toxicity in some individuals .
mechanism
concomitant administration of druga and drugn -containing drugs leads to increased drugb levels and drugn toxicity in some individuals .
false
concomitant administration of druga and drugn -containing drugs leads to increased drugn levels and drugb toxicity in some individuals .
false
concomitant administration of drugn and druga -containing drugs leads to increased drugb levels and drugn toxicity in some individuals .
false
concomitant administration of drugn and druga -containing drugs leads to increased drugn levels and drugb toxicity in some individuals .
false
concomitant administration of drugn and drugn -containing drugs leads to increased druga levels and drugb toxicity in some individuals .
false
druga has been used concurrently with drugb , drugn , drugn , drugn , drugn , and drugn , without observed problems .
false
druga has been used concurrently with drugn , drugb , drugn , drugn , drugn , and drugn , without observed problems .
false
druga has been used concurrently with drugn , drugn , drugb , drugn , drugn , and drugn , without observed problems .
false
druga has been used concurrently with drugn , drugn , drugn , drugb , drugn , and drugn , without observed problems .
false
druga has been used concurrently with drugn , drugn , drugn , drugn , drugb , and drugn , without observed problems .
false
druga has been used concurrently with drugn , drugn , drugn , drugn , drugn , and drugb , without observed problems .
false
drugn has been used concurrently with druga , drugb , drugn , drugn , drugn , and drugn , without observed problems .
false
drugn has been used concurrently with druga , drugn , drugb , drugn , drugn , and drugn , without observed problems .
false
drugn has been used concurrently with druga , drugn , drugn , drugb , drugn , and drugn , without observed problems .
false
drugn has been used concurrently with druga , drugn , drugn , drugn , drugb , and drugn , without observed problems .
false
drugn has been used concurrently with druga , drugn , drugn , drugn , drugn , and drugb , without observed problems .
false
drugn has been used concurrently with drugn , druga , drugb , drugn , drugn , and drugn , without observed problems .
false
drugn has been used concurrently with drugn , druga , drugn , drugb , drugn , and drugn , without observed problems .
false
drugn has been used concurrently with drugn , druga , drugn , drugn , drugb , and drugn , without observed problems .
false
drugn has been used concurrently with drugn , druga , drugn , drugn , drugn , and drugb , without observed problems .
false
drugn has been used concurrently with drugn , drugn , druga , drugb , drugn , and drugn , without observed problems .
false
drugn has been used concurrently with drugn , drugn , druga , drugn , drugb , and drugn , without observed problems .
false
drugn has been used concurrently with drugn , drugn , druga , drugn , drugn , and drugb , without observed problems .
false
drugn has been used concurrently with drugn , drugn , drugn , druga , drugb , and drugn , without observed problems .
false
drugn has been used concurrently with drugn , drugn , drugn , druga , drugn , and drugb , without observed problems .
false
drugn has been used concurrently with drugn , drugn , drugn , drugn , druga , and drugb , without observed problems .
false
druga may accentuate the orthostatic hypotension that may occur with drugb .
effect
antihypertensive effects of druga and related compounds may be counteracted when drugb are used concomitantly .
effect
concomitant administration of druga with drugb results in increased plasma levels of both drugs .
mechanism
druga : drugb and probably other drugn given concomitantly with drugn can cause unusually large or prolonged losses of fluid and electrolytes .
false
druga : drugn and probably other drugb given concomitantly with drugn can cause unusually large or prolonged losses of fluid and electrolytes .
false
druga : drugn and probably other drugn given concomitantly with drugb can cause unusually large or prolonged losses of fluid and electrolytes .
false
drugn : druga and probably other drugb given concomitantly with drugn can cause unusually large or prolonged losses of fluid and electrolytes .
false
drugn : druga and probably other drugn given concomitantly with drugb can cause unusually large or prolonged losses of fluid and electrolytes .
effect
drugn : drugn and probably other druga given concomitantly with drugb can cause unusually large or prolonged losses of fluid and electrolytes .
effect
other druga : when drugb tablets are used with other drugn , care must be taken , especially during initial therapy .
false
other druga : when drugn tablets are used with other drugb , care must be taken , especially during initial therapy .
false
other drugn : when druga tablets are used with other drugb , care must be taken , especially during initial therapy .
advise
druga , drugb , and drugn : the hypotensive effects of these drugs may be potentiated by the volume contraction that may be associated with drugn therapy .
false
druga , drugn , and drugb : the hypotensive effects of these drugs may be potentiated by the volume contraction that may be associated with drugn therapy .
false
druga , drugn , and drugn : the hypotensive effects of these drugs may be potentiated by the volume contraction that may be associated with drugb therapy .
false
drugn , druga , and drugb : the hypotensive effects of these drugs may be potentiated by the volume contraction that may be associated with drugn therapy .
false
drugn , druga , and drugn : the hypotensive effects of these drugs may be potentiated by the volume contraction that may be associated with drugb therapy .
false
drugn , drugn , and druga : the hypotensive effects of these drugs may be potentiated by the volume contraction that may be associated with drugb therapy .
false
druga : drugb -induced hypokalemia can increase the sensitivity of the myocardium to drugn .
false
druga : drugn -induced hypokalemia can increase the sensitivity of the myocardium to drugb .
false
drugn : druga -induced hypokalemia can increase the sensitivity of the myocardium to drugb .
effect
druga or drugb : may increase the risk of hypokalemia and increase salt and water retention .
false
druga : serum drugb levels may increase .
false
druga : drugb -induced hypokalemia may enhance neuromuscular blocking effects of drugn ( such as drugn ) the most serious effect would be respiratory depression which could proceed to apnea .
false
druga : drugn -induced hypokalemia may enhance neuromuscular blocking effects of drugb ( such as drugn ) the most serious effect would be respiratory depression which could proceed to apnea .
false
druga : drugn -induced hypokalemia may enhance neuromuscular blocking effects of drugn ( such as drugb ) the most serious effect would be respiratory depression which could proceed to apnea .
false
drugn : druga -induced hypokalemia may enhance neuromuscular blocking effects of drugb ( such as drugn ) the most serious effect would be respiratory depression which could proceed to apnea .
effect
drugn : druga -induced hypokalemia may enhance neuromuscular blocking effects of drugn ( such as drugb ) the most serious effect would be respiratory depression which could proceed to apnea .
effect
drugn : drugn -induced hypokalemia may enhance neuromuscular blocking effects of druga ( such as drugb ) the most serious effect would be respiratory depression which could proceed to apnea .
false
druga and other drugb : may decrease the antihypertensive effects of drugn tablets .
false
druga and other drugn : may decrease the antihypertensive effects of drugb tablets .
effect
drugn and other druga : may decrease the antihypertensive effects of drugb tablets .
effect
druga : drugb may decrease arterial responsiveness to drugn , but this diminution is not sufficient to preclude effectiveness of the pressor agent for therapeutic use .
false
druga : drugn may decrease arterial responsiveness to drugb , but this diminution is not sufficient to preclude effectiveness of the pressor agent for therapeutic use .
false
drugn : druga may decrease arterial responsiveness to drugb , but this diminution is not sufficient to preclude effectiveness of the pressor agent for therapeutic use .
effect
druga : efficacy may be decreased due to urinary alkalizing effect of drugb .
effect
druga : drugb , as well as other drugn , may affect the hypoprothrombinemic response to drugn ;
false
druga : drugn , as well as other drugb , may affect the hypoprothrombinemic response to drugn ;
false
druga : drugn , as well as other drugn , may affect the hypoprothrombinemic response to drugb ;
false
drugn : druga , as well as other drugb , may affect the hypoprothrombinemic response to drugn ;
false
drugn : druga , as well as other drugn , may affect the hypoprothrombinemic response to drugb ;
effect
drugn : drugn , as well as other druga , may affect the hypoprothrombinemic response to drugb ;
false
oral druga has been reported to potentiate the anticoagulant effect of drugb and drugn , resulting in a prolongation of prothrombin time .
effect
oral druga has been reported to potentiate the anticoagulant effect of drugn and drugb , resulting in a prolongation of prothrombin time .
effect
oral drugn has been reported to potentiate the anticoagulant effect of druga and drugb , resulting in a prolongation of prothrombin time .
false
drug interactions should be kept in mind when druga ( drugb gel ) , 1 % is prescribed for patients who are receiving anticoagulant treatment , although they are less likely to occur with topical drugn administration because of low absorption .
false
drug interactions should be kept in mind when druga ( drugn gel ) , 1 % is prescribed for patients who are receiving anticoagulant treatment , although they are less likely to occur with topical drugb administration because of low absorption .
false
drug interactions should be kept in mind when drugn ( druga gel ) , 1 % is prescribed for patients who are receiving anticoagulant treatment , although they are less likely to occur with topical drugb administration because of low absorption .
false
druga and drugb are incompatible with drugn solution .
false
druga and drugn are incompatible with drugb solution .
int
drugn and druga are incompatible with drugb solution .
int
the addition of druga to parenteral solutions containing drugb should be avoided , except where compatibility has been previously established .
false
mutual inhibition of metabolism occurs with concurrent use of druga and drugb ;
mechanism
convulsions have been reported with concurrent use of druga and drugb .
effect
drugs that induce hepatic enzymes such as druga , drugb , and drugn may increase the clearance of drugn and may require increased in drugn dose to achieve the desired response .
false
drugs that induce hepatic enzymes such as druga , drugn , and drugb may increase the clearance of drugn and may require increased in drugn dose to achieve the desired response .
false
drugs that induce hepatic enzymes such as druga , drugn , and drugn may increase the clearance of drugb and may require increased in drugn dose to achieve the desired response .
mechanism
drugs that induce hepatic enzymes such as druga , drugn , and drugn may increase the clearance of drugn and may require increased in drugb dose to achieve the desired response .
advise
drugs that induce hepatic enzymes such as drugn , druga , and drugb may increase the clearance of drugn and may require increased in drugn dose to achieve the desired response .
false
drugs that induce hepatic enzymes such as drugn , druga , and drugn may increase the clearance of drugb and may require increased in drugn dose to achieve the desired response .
mechanism
drugs that induce hepatic enzymes such as drugn , druga , and drugn may increase the clearance of drugn and may require increased in drugb dose to achieve the desired response .
advise
drugs that induce hepatic enzymes such as drugn , drugn , and druga may increase the clearance of drugb and may require increased in drugn dose to achieve the desired response .
mechanism
drugs that induce hepatic enzymes such as drugn , drugn , and druga may increase the clearance of drugn and may require increased in drugb dose to achieve the desired response .
advise
drugs that induce hepatic enzymes such as drugn , drugn , and drugn may increase the clearance of druga and may require increased in drugb dose to achieve the desired response .
false
drugs such as druga and drugb may inhibit the metabolism of drugn and thus decrease its clearance .
false
drugs such as druga and drugn may inhibit the metabolism of drugb and thus decrease its clearance .
mechanism
drugs such as drugn and druga may inhibit the metabolism of drugb and thus decrease its clearance .
mechanism
druga may increase the clearance of chronic high dose drugb .
mechanism
this could lead to decreased druga serum levels or increase the risk of drugb toxicity when drugn is withdrawn .
false
this could lead to decreased druga serum levels or increase the risk of drugn toxicity when drugb is withdrawn .
false
this could lead to decreased drugn serum levels or increase the risk of druga toxicity when drugb is withdrawn .
effect
druga should be used cautiously in conjunction with drugb in patients suffering from hypoprothrombinemia .
advise
the effect of druga on oral drugb is variable .
false
there are reports of enhanced as well as diminished effects of druga when given concurrently with drugb .
effect
drug interactions : inhibitors of cyp3a4 isozymes : caution is advised when druga is administered concomitantly with drugs that are known to inhibit the cytochrome p450 3a4 enzyme system ( ie , some drugs in the drug classes of drugb , drugn , drugn , and drugn ) .
advise
drug interactions : inhibitors of cyp3a4 isozymes : caution is advised when druga is administered concomitantly with drugs that are known to inhibit the cytochrome p450 3a4 enzyme system ( ie , some drugs in the drug classes of drugn , drugb , drugn , and drugn ) .
advise
drug interactions : inhibitors of cyp3a4 isozymes : caution is advised when druga is administered concomitantly with drugs that are known to inhibit the cytochrome p450 3a4 enzyme system ( ie , some drugs in the drug classes of drugn , drugn , drugb , and drugn ) .
advise
drug interactions : inhibitors of cyp3a4 isozymes : caution is advised when druga is administered concomitantly with drugs that are known to inhibit the cytochrome p450 3a4 enzyme system ( ie , some drugs in the drug classes of drugn , drugn , drugn , and drugb ) .
advise
drug interactions : inhibitors of cyp3a4 isozymes : caution is advised when drugn is administered concomitantly with drugs that are known to inhibit the cytochrome p450 3a4 enzyme system ( ie , some drugs in the drug classes of druga , drugb , drugn , and drugn ) .
false
drug interactions : inhibitors of cyp3a4 isozymes : caution is advised when drugn is administered concomitantly with drugs that are known to inhibit the cytochrome p450 3a4 enzyme system ( ie , some drugs in the drug classes of druga , drugn , drugb , and drugn ) .
false
drug interactions : inhibitors of cyp3a4 isozymes : caution is advised when drugn is administered concomitantly with drugs that are known to inhibit the cytochrome p450 3a4 enzyme system ( ie , some drugs in the drug classes of druga , drugn , drugn , and drugb ) .
false
drug interactions : inhibitors of cyp3a4 isozymes : caution is advised when drugn is administered concomitantly with drugs that are known to inhibit the cytochrome p450 3a4 enzyme system ( ie , some drugs in the drug classes of drugn , druga , drugb , and drugn ) .
false
drug interactions : inhibitors of cyp3a4 isozymes : caution is advised when drugn is administered concomitantly with drugs that are known to inhibit the cytochrome p450 3a4 enzyme system ( ie , some drugs in the drug classes of drugn , druga , drugn , and drugb ) .
false
drug interactions : inhibitors of cyp3a4 isozymes : caution is advised when drugn is administered concomitantly with drugs that are known to inhibit the cytochrome p450 3a4 enzyme system ( ie , some drugs in the drug classes of drugn , drugn , druga , and drugb ) .
false
drugs such as druga , drugb , drugn , drugn , drugn and drugn were shown to significantly increase the c max and auc of orally administered drugn .
false
drugs such as druga , drugn , drugb , drugn , drugn and drugn were shown to significantly increase the c max and auc of orally administered drugn .
false
drugs such as druga , drugn , drugn , drugb , drugn and drugn were shown to significantly increase the c max and auc of orally administered drugn .
false
drugs such as druga , drugn , drugn , drugn , drugb and drugn were shown to significantly increase the c max and auc of orally administered drugn .
false
drugs such as druga , drugn , drugn , drugn , drugn and drugb were shown to significantly increase the c max and auc of orally administered drugn .
false
drugs such as druga , drugn , drugn , drugn , drugn and drugn were shown to significantly increase the c max and auc of orally administered drugb .
mechanism
drugs such as drugn , druga , drugb , drugn , drugn and drugn were shown to significantly increase the c max and auc of orally administered drugn .
false
drugs such as drugn , druga , drugn , drugb , drugn and drugn were shown to significantly increase the c max and auc of orally administered drugn .
false
drugs such as drugn , druga , drugn , drugn , drugb and drugn were shown to significantly increase the c max and auc of orally administered drugn .
false
drugs such as drugn , druga , drugn , drugn , drugn and drugb were shown to significantly increase the c max and auc of orally administered drugn .
false
drugs such as drugn , druga , drugn , drugn , drugn and drugn were shown to significantly increase the c max and auc of orally administered drugb .
mechanism
drugs such as drugn , drugn , druga , drugb , drugn and drugn were shown to significantly increase the c max and auc of orally administered drugn .
false
drugs such as drugn , drugn , druga , drugn , drugb and drugn were shown to significantly increase the c max and auc of orally administered drugn .
false
drugs such as drugn , drugn , druga , drugn , drugn and drugb were shown to significantly increase the c max and auc of orally administered drugn .
false
drugs such as drugn , drugn , druga , drugn , drugn and drugn were shown to significantly increase the c max and auc of orally administered drugb .
mechanism
drugs such as drugn , drugn , drugn , druga , drugb and drugn were shown to significantly increase the c max and auc of orally administered drugn .
false
drugs such as drugn , drugn , drugn , druga , drugn and drugb were shown to significantly increase the c max and auc of orally administered drugn .
false
drugs such as drugn , drugn , drugn , druga , drugn and drugn were shown to significantly increase the c max and auc of orally administered drugb .
mechanism
drugs such as drugn , drugn , drugn , drugn , druga and drugb were shown to significantly increase the c max and auc of orally administered drugn .
false
drugs such as drugn , drugn , drugn , drugn , druga and drugn were shown to significantly increase the c max and auc of orally administered drugb .
mechanism
drugs such as drugn , drugn , drugn , drugn , drugn and druga were shown to significantly increase the c max and auc of orally administered drugb .
mechanism
although not studied , the potent cytochrome p450 3a4 inhibitors druga and drugb may cause intense and prolonged sedation and respiratory depression due to a decrease in plasma clearance of drugn .
false
although not studied , the potent cytochrome p450 3a4 inhibitors druga and drugn may cause intense and prolonged sedation and respiratory depression due to a decrease in plasma clearance of drugb .
mechanism
although not studied , the potent cytochrome p450 3a4 inhibitors drugn and druga may cause intense and prolonged sedation and respiratory depression due to a decrease in plasma clearance of drugb .
mechanism
inducers of cyp3a4 isozymes : cytochrome p450 inducers , such as druga , drugb , and drugn , induce metabolism and caused a markedly decreased c max and auc of oral drugn in adult studies .
false
inducers of cyp3a4 isozymes : cytochrome p450 inducers , such as druga , drugn , and drugb , induce metabolism and caused a markedly decreased c max and auc of oral drugn in adult studies .
false
inducers of cyp3a4 isozymes : cytochrome p450 inducers , such as druga , drugn , and drugn , induce metabolism and caused a markedly decreased c max and auc of oral drugb in adult studies .
mechanism
inducers of cyp3a4 isozymes : cytochrome p450 inducers , such as drugn , druga , and drugb , induce metabolism and caused a markedly decreased c max and auc of oral drugn in adult studies .
false
inducers of cyp3a4 isozymes : cytochrome p450 inducers , such as drugn , druga , and drugn , induce metabolism and caused a markedly decreased c max and auc of oral drugb in adult studies .
mechanism
inducers of cyp3a4 isozymes : cytochrome p450 inducers , such as drugn , drugn , and druga , induce metabolism and caused a markedly decreased c max and auc of oral drugb in adult studies .
mechanism
the difficulty in achieving adequate sedation may have been the result of decreased absorption of the druga due to both the gastrointestinal effects and stimulant effects of drugb .
false
the sedative effect of druga is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly drugb ( eg , drugn , drugn and drugn ) , drugn , drugn , drugn , drugn and drugn .
effect
the sedative effect of druga is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly drugn ( eg , drugb , drugn and drugn ) , drugn , drugn , drugn , drugn and drugn .
effect
the sedative effect of druga is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly drugn ( eg , drugn , drugb and drugn ) , drugn , drugn , drugn , drugn and drugn .
effect
the sedative effect of druga is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly drugn ( eg , drugn , drugn and drugb ) , drugn , drugn , drugn , drugn and drugn .
effect
the sedative effect of druga is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly drugn ( eg , drugn , drugn and drugn ) , drugb , drugn , drugn , drugn and drugn .
effect
the sedative effect of druga is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly drugn ( eg , drugn , drugn and drugn ) , drugn , drugb , drugn , drugn and drugn .
effect
the sedative effect of druga is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly drugn ( eg , drugn , drugn and drugn ) , drugn , drugn , drugb , drugn and drugn .
effect
the sedative effect of druga is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly drugn ( eg , drugn , drugn and drugn ) , drugn , drugn , drugn , drugb and drugn .
effect
the sedative effect of druga is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly drugn ( eg , drugn , drugn and drugn ) , drugn , drugn , drugn , drugn and drugb .
effect
the sedative effect of drugn is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly druga ( eg , drugb , drugn and drugn ) , drugn , drugn , drugn , drugn and drugn .
false
the sedative effect of drugn is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly druga ( eg , drugn , drugb and drugn ) , drugn , drugn , drugn , drugn and drugn .
false
the sedative effect of drugn is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly druga ( eg , drugn , drugn and drugb ) , drugn , drugn , drugn , drugn and drugn .
false
the sedative effect of drugn is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly druga ( eg , drugn , drugn and drugn ) , drugb , drugn , drugn , drugn and drugn .
false
the sedative effect of drugn is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly druga ( eg , drugn , drugn and drugn ) , drugn , drugb , drugn , drugn and drugn .
false
the sedative effect of drugn is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly druga ( eg , drugn , drugn and drugn ) , drugn , drugn , drugb , drugn and drugn .
false
the sedative effect of drugn is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly druga ( eg , drugn , drugn and drugn ) , drugn , drugn , drugn , drugb and drugn .
false
the sedative effect of drugn is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly druga ( eg , drugn , drugn and drugn ) , drugn , drugn , drugn , drugn and drugb .
false
the sedative effect of drugn is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly drugn ( eg , druga , drugb and drugn ) , drugn , drugn , drugn , drugn and drugn .
false
the sedative effect of drugn is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly drugn ( eg , druga , drugn and drugb ) , drugn , drugn , drugn , drugn and drugn .
false
the sedative effect of drugn is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly drugn ( eg , druga , drugn and drugn ) , drugb , drugn , drugn , drugn and drugn .
false
the sedative effect of drugn is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly drugn ( eg , druga , drugn and drugn ) , drugn , drugb , drugn , drugn and drugn .
false
the sedative effect of drugn is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly drugn ( eg , druga , drugn and drugn ) , drugn , drugn , drugb , drugn and drugn .
false
the sedative effect of drugn is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly drugn ( eg , druga , drugn and drugn ) , drugn , drugn , drugn , drugb and drugn .
false
the sedative effect of drugn is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly drugn ( eg , druga , drugn and drugn ) , drugn , drugn , drugn , drugn and drugb .
false
the sedative effect of drugn is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly drugn ( eg , drugn , druga and drugb ) , drugn , drugn , drugn , drugn and drugn .
false
the sedative effect of drugn is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly drugn ( eg , drugn , druga and drugn ) , drugb , drugn , drugn , drugn and drugn .
false
the sedative effect of drugn is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly drugn ( eg , drugn , druga and drugn ) , drugn , drugb , drugn , drugn and drugn .
false
the sedative effect of drugn is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly drugn ( eg , drugn , druga and drugn ) , drugn , drugn , drugb , drugn and drugn .
false
the sedative effect of drugn is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly drugn ( eg , drugn , druga and drugn ) , drugn , drugn , drugn , drugb and drugn .
false
the sedative effect of drugn is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly drugn ( eg , drugn , druga and drugn ) , drugn , drugn , drugn , drugn and drugb .
false
the sedative effect of drugn is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly drugn ( eg , drugn , drugn and druga ) , drugb , drugn , drugn , drugn and drugn .
false
the sedative effect of drugn is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly drugn ( eg , drugn , drugn and druga ) , drugn , drugb , drugn , drugn and drugn .
false
the sedative effect of drugn is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly drugn ( eg , drugn , drugn and druga ) , drugn , drugn , drugb , drugn and drugn .
false
the sedative effect of drugn is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly drugn ( eg , drugn , drugn and druga ) , drugn , drugn , drugn , drugb and drugn .
false
the sedative effect of drugn is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly drugn ( eg , drugn , drugn and druga ) , drugn , drugn , drugn , drugn and drugb .
false
the sedative effect of drugn is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly drugn ( eg , drugn , drugn and drugn ) , druga , drugb , drugn , drugn and drugn .
false
the sedative effect of drugn is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly drugn ( eg , drugn , drugn and drugn ) , druga , drugn , drugb , drugn and drugn .
false
the sedative effect of drugn is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly drugn ( eg , drugn , drugn and drugn ) , druga , drugn , drugn , drugb and drugn .
false
the sedative effect of drugn is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly drugn ( eg , drugn , drugn and drugn ) , druga , drugn , drugn , drugn and drugb .
false
the sedative effect of drugn is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly drugn ( eg , drugn , drugn and drugn ) , drugn , druga , drugb , drugn and drugn .
false
the sedative effect of drugn is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly drugn ( eg , drugn , drugn and drugn ) , drugn , druga , drugn , drugb and drugn .
false
the sedative effect of drugn is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly drugn ( eg , drugn , drugn and drugn ) , drugn , druga , drugn , drugn and drugb .
false
the sedative effect of drugn is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly drugn ( eg , drugn , drugn and drugn ) , drugn , drugn , druga , drugb and drugn .
false
the sedative effect of drugn is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly drugn ( eg , drugn , drugn and drugn ) , drugn , drugn , druga , drugn and drugb .
false
the sedative effect of drugn is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly drugn ( eg , drugn , drugn and drugn ) , drugn , drugn , drugn , druga and drugb .
false
no significant adverse interactions with common premedications ( such as druga , drugb , drugn , drugn , drugn , and other drugn ) or local drugn have been observed .
false
no significant adverse interactions with common premedications ( such as druga , drugn , drugb , drugn , drugn , and other drugn ) or local drugn have been observed .
false
no significant adverse interactions with common premedications ( such as druga , drugn , drugn , drugb , drugn , and other drugn ) or local drugn have been observed .
false
no significant adverse interactions with common premedications ( such as druga , drugn , drugn , drugn , drugb , and other drugn ) or local drugn have been observed .
false
no significant adverse interactions with common premedications ( such as druga , drugn , drugn , drugn , drugn , and other drugb ) or local drugn have been observed .
false
no significant adverse interactions with common premedications ( such as druga , drugn , drugn , drugn , drugn , and other drugn ) or local drugb have been observed .
false
no significant adverse interactions with common premedications ( such as drugn , druga , drugb , drugn , drugn , and other drugn ) or local drugn have been observed .
false
no significant adverse interactions with common premedications ( such as drugn , druga , drugn , drugb , drugn , and other drugn ) or local drugn have been observed .
false
no significant adverse interactions with common premedications ( such as drugn , druga , drugn , drugn , drugb , and other drugn ) or local drugn have been observed .
false
no significant adverse interactions with common premedications ( such as drugn , druga , drugn , drugn , drugn , and other drugb ) or local drugn have been observed .
false
no significant adverse interactions with common premedications ( such as drugn , druga , drugn , drugn , drugn , and other drugn ) or local drugb have been observed .
false
no significant adverse interactions with common premedications ( such as drugn , drugn , druga , drugb , drugn , and other drugn ) or local drugn have been observed .
false
no significant adverse interactions with common premedications ( such as drugn , drugn , druga , drugn , drugb , and other drugn ) or local drugn have been observed .
false
no significant adverse interactions with common premedications ( such as drugn , drugn , druga , drugn , drugn , and other drugb ) or local drugn have been observed .
false
no significant adverse interactions with common premedications ( such as drugn , drugn , druga , drugn , drugn , and other drugn ) or local drugb have been observed .
false
no significant adverse interactions with common premedications ( such as drugn , drugn , drugn , druga , drugb , and other drugn ) or local drugn have been observed .
false
no significant adverse interactions with common premedications ( such as drugn , drugn , drugn , druga , drugn , and other drugb ) or local drugn have been observed .
false
no significant adverse interactions with common premedications ( such as drugn , drugn , drugn , druga , drugn , and other drugn ) or local drugb have been observed .
false
no significant adverse interactions with common premedications ( such as drugn , drugn , drugn , drugn , druga , and other drugb ) or local drugn have been observed .
false
no significant adverse interactions with common premedications ( such as drugn , drugn , drugn , drugn , druga , and other drugn ) or local drugb have been observed .
false
no significant adverse interactions with common premedications ( such as drugn , drugn , drugn , drugn , drugn , and other druga ) or local drugb have been observed .
false
based on studies evaluating possible interactions of druga with other drugs , no dosage adjustment is needed with concomitant use of the following : drugb , drugn , drugn , drugn , drugn , drugn ( and its active metabolite , drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , an oral drugn ( drugn / drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , drugn , or drugn .
false
based on studies evaluating possible interactions of druga with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugb , drugn , drugn , drugn , drugn ( and its active metabolite , drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , an oral drugn ( drugn / drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , drugn , or drugn .
false
based on studies evaluating possible interactions of druga with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugb , drugn , drugn , drugn ( and its active metabolite , drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , an oral drugn ( drugn / drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , drugn , or drugn .
false
based on studies evaluating possible interactions of druga with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugb , drugn , drugn ( and its active metabolite , drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , an oral drugn ( drugn / drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , drugn , or drugn .
false
based on studies evaluating possible interactions of druga with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugb , drugn ( and its active metabolite , drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , an oral drugn ( drugn / drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , drugn , or drugn .
false
based on studies evaluating possible interactions of druga with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , drugb ( and its active metabolite , drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , an oral drugn ( drugn / drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , drugn , or drugn .
false
based on studies evaluating possible interactions of druga with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , drugn ( and its active metabolite , drugb ) , drugn , drugn , drugn , drugn , drugn , drugn , an oral drugn ( drugn / drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , drugn , or drugn .
false
based on studies evaluating possible interactions of druga with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , drugn ( and its active metabolite , drugn ) , drugb , drugn , drugn , drugn , drugn , drugn , an oral drugn ( drugn / drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , drugn , or drugn .
false
based on studies evaluating possible interactions of druga with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , drugn ( and its active metabolite , drugn ) , drugn , drugb , drugn , drugn , drugn , drugn , an oral drugn ( drugn / drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , drugn , or drugn .
false
based on studies evaluating possible interactions of druga with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , drugn ( and its active metabolite , drugn ) , drugn , drugn , drugb , drugn , drugn , drugn , an oral drugn ( drugn / drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , drugn , or drugn .
false
based on studies evaluating possible interactions of druga with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , drugn ( and its active metabolite , drugn ) , drugn , drugn , drugn , drugb , drugn , drugn , an oral drugn ( drugn / drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , drugn , or drugn .
false
based on studies evaluating possible interactions of druga with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , drugn ( and its active metabolite , drugn ) , drugn , drugn , drugn , drugn , drugb , drugn , an oral drugn ( drugn / drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , drugn , or drugn .
false
based on studies evaluating possible interactions of druga with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , drugn ( and its active metabolite , drugn ) , drugn , drugn , drugn , drugn , drugn , drugb , an oral drugn ( drugn / drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , drugn , or drugn .
false
based on studies evaluating possible interactions of druga with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , drugn ( and its active metabolite , drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , an oral drugb ( drugn / drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , drugn , or drugn .
false
based on studies evaluating possible interactions of druga with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , drugn ( and its active metabolite , drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , an oral drugn ( drugb / drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , drugn , or drugn .
false
based on studies evaluating possible interactions of druga with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , drugn ( and its active metabolite , drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , an oral drugn ( drugn / drugb ) , drugn , drugn , drugn , drugn , drugn , drugn , drugn , or drugn .
false
based on studies evaluating possible interactions of druga with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , drugn ( and its active metabolite , drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , an oral drugn ( drugn / drugn ) , drugb , drugn , drugn , drugn , drugn , drugn , drugn , or drugn .
false
based on studies evaluating possible interactions of druga with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , drugn ( and its active metabolite , drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , an oral drugn ( drugn / drugn ) , drugn , drugb , drugn , drugn , drugn , drugn , drugn , or drugn .
false
based on studies evaluating possible interactions of druga with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , drugn ( and its active metabolite , drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , an oral drugn ( drugn / drugn ) , drugn , drugn , drugb , drugn , drugn , drugn , drugn , or drugn .
false
based on studies evaluating possible interactions of druga with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , drugn ( and its active metabolite , drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , an oral drugn ( drugn / drugn ) , drugn , drugn , drugn , drugb , drugn , drugn , drugn , or drugn .
false
based on studies evaluating possible interactions of druga with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , drugn ( and its active metabolite , drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , an oral drugn ( drugn / drugn ) , drugn , drugn , drugn , drugn , drugb , drugn , drugn , or drugn .
false
based on studies evaluating possible interactions of druga with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , drugn ( and its active metabolite , drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , an oral drugn ( drugn / drugn ) , drugn , drugn , drugn , drugn , drugn , drugb , drugn , or drugn .
false
based on studies evaluating possible interactions of druga with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , drugn ( and its active metabolite , drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , an oral drugn ( drugn / drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , drugb , or drugn .
false
based on studies evaluating possible interactions of druga with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , drugn ( and its active metabolite , drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , an oral drugn ( drugn / drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , drugn , or drugb .
false
based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : druga , drugb , drugn , drugn , drugn , drugn ( and its active metabolite , drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , an oral drugn ( drugn / drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , drugn , or drugn .
false
based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : druga , drugn , drugb , drugn , drugn , drugn ( and its active metabolite , drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , an oral drugn ( drugn / drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , drugn , or drugn .
false
based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : druga , drugn , drugn , drugb , drugn , drugn ( and its active metabolite , drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , an oral drugn ( drugn / drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , drugn , or drugn .
false
based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : druga , drugn , drugn , drugn , drugb , drugn ( and its active metabolite , drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , an oral drugn ( drugn / drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , drugn , or drugn .
false
based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : druga , drugn , drugn , drugn , drugn , drugb ( and its active metabolite , drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , an oral drugn ( drugn / drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , drugn , or drugn .
false
based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : druga , drugn , drugn , drugn , drugn , drugn ( and its active metabolite , drugb ) , drugn , drugn , drugn , drugn , drugn , drugn , an oral drugn ( drugn / drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , drugn , or drugn .
false
based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : druga , drugn , drugn , drugn , drugn , drugn ( and its active metabolite , drugn ) , drugb , drugn , drugn , drugn , drugn , drugn , an oral drugn ( drugn / drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , drugn , or drugn .
false
based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : druga , drugn , drugn , drugn , drugn , drugn ( and its active metabolite , drugn ) , drugn , drugb , drugn , drugn , drugn , drugn , an oral drugn ( drugn / drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , drugn , or drugn .
false
based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : druga , drugn , drugn , drugn , drugn , drugn ( and its active metabolite , drugn ) , drugn , drugn , drugb , drugn , drugn , drugn , an oral drugn ( drugn / drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , drugn , or drugn .
false
based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : druga , drugn , drugn , drugn , drugn , drugn ( and its active metabolite , drugn ) , drugn , drugn , drugn , drugb , drugn , drugn , an oral drugn ( drugn / drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , drugn , or drugn .
false
based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : druga , drugn , drugn , drugn , drugn , drugn ( and its active metabolite , drugn ) , drugn , drugn , drugn , drugn , drugb , drugn , an oral drugn ( drugn / drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , drugn , or drugn .
false
based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : druga , drugn , drugn , drugn , drugn , drugn ( and its active metabolite , drugn ) , drugn , drugn , drugn , drugn , drugn , drugb , an oral drugn ( drugn / drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , drugn , or drugn .
false
based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : druga , drugn , drugn , drugn , drugn , drugn ( and its active metabolite , drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , an oral drugb ( drugn / drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , drugn , or drugn .
false
based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : druga , drugn , drugn , drugn , drugn , drugn ( and its active metabolite , drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , an oral drugn ( drugb / drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , drugn , or drugn .
false
based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : druga , drugn , drugn , drugn , drugn , drugn ( and its active metabolite , drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , an oral drugn ( drugn / drugb ) , drugn , drugn , drugn , drugn , drugn , drugn , drugn , or drugn .
false
based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : druga , drugn , drugn , drugn , drugn , drugn ( and its active metabolite , drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , an oral drugn ( drugn / drugn ) , drugb , drugn , drugn , drugn , drugn , drugn , drugn , or drugn .
false
based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : druga , drugn , drugn , drugn , drugn , drugn ( and its active metabolite , drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , an oral drugn ( drugn / drugn ) , drugn , drugb , drugn , drugn , drugn , drugn , drugn , or drugn .
false
based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : druga , drugn , drugn , drugn , drugn , drugn ( and its active metabolite , drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , an oral drugn ( drugn / drugn ) , drugn , drugn , drugb , drugn , drugn , drugn , drugn , or drugn .
false
based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : druga , drugn , drugn , drugn , drugn , drugn ( and its active metabolite , drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , an oral drugn ( drugn / drugn ) , drugn , drugn , drugn , drugb , drugn , drugn , drugn , or drugn .
false
based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : druga , drugn , drugn , drugn , drugn , drugn ( and its active metabolite , drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , an oral drugn ( drugn / drugn ) , drugn , drugn , drugn , drugn , drugb , drugn , drugn , or drugn .
false
based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : druga , drugn , drugn , drugn , drugn , drugn ( and its active metabolite , drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , an oral drugn ( drugn / drugn ) , drugn , drugn , drugn , drugn , drugn , drugb , drugn , or drugn .
false
based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : druga , drugn , drugn , drugn , drugn , drugn ( and its active metabolite , drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , an oral drugn ( drugn / drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , drugb , or drugn .
false
based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : druga , drugn , drugn , drugn , drugn , drugn ( and its active metabolite , drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , an oral drugn ( drugn / drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , drugn , or drugb .
false
based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , druga , drugb , drugn , drugn , drugn ( and its active metabolite , drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , an oral drugn ( drugn / drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , drugn , or drugn .
false
based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , druga , drugn , drugb , drugn , drugn ( and its active metabolite , drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , an oral drugn ( drugn / drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , drugn , or drugn .
false
based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , druga , drugn , drugn , drugb , drugn ( and its active metabolite , drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , an oral drugn ( drugn / drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , drugn , or drugn .
false
based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , druga , drugn , drugn , drugn , drugb ( and its active metabolite , drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , an oral drugn ( drugn / drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , drugn , or drugn .
false
based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , druga , drugn , drugn , drugn , drugn ( and its active metabolite , drugb ) , drugn , drugn , drugn , drugn , drugn , drugn , an oral drugn ( drugn / drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , drugn , or drugn .
false
based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , druga , drugn , drugn , drugn , drugn ( and its active metabolite , drugn ) , drugb , drugn , drugn , drugn , drugn , drugn , an oral drugn ( drugn / drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , drugn , or drugn .
false
based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , druga , drugn , drugn , drugn , drugn ( and its active metabolite , drugn ) , drugn , drugb , drugn , drugn , drugn , drugn , an oral drugn ( drugn / drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , drugn , or drugn .
false
based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , druga , drugn , drugn , drugn , drugn ( and its active metabolite , drugn ) , drugn , drugn , drugb , drugn , drugn , drugn , an oral drugn ( drugn / drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , drugn , or drugn .
false
based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , druga , drugn , drugn , drugn , drugn ( and its active metabolite , drugn ) , drugn , drugn , drugn , drugb , drugn , drugn , an oral drugn ( drugn / drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , drugn , or drugn .
false
based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , druga , drugn , drugn , drugn , drugn ( and its active metabolite , drugn ) , drugn , drugn , drugn , drugn , drugb , drugn , an oral drugn ( drugn / drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , drugn , or drugn .
false
based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , druga , drugn , drugn , drugn , drugn ( and its active metabolite , drugn ) , drugn , drugn , drugn , drugn , drugn , drugb , an oral drugn ( drugn / drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , drugn , or drugn .
false
based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , druga , drugn , drugn , drugn , drugn ( and its active metabolite , drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , an oral drugb ( drugn / drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , drugn , or drugn .
false
based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , druga , drugn , drugn , drugn , drugn ( and its active metabolite , drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , an oral drugn ( drugb / drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , drugn , or drugn .
false
based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , druga , drugn , drugn , drugn , drugn ( and its active metabolite , drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , an oral drugn ( drugn / drugb ) , drugn , drugn , drugn , drugn , drugn , drugn , drugn , or drugn .
false
based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , druga , drugn , drugn , drugn , drugn ( and its active metabolite , drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , an oral drugn ( drugn / drugn ) , drugb , drugn , drugn , drugn , drugn , drugn , drugn , or drugn .
false
based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , druga , drugn , drugn , drugn , drugn ( and its active metabolite , drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , an oral drugn ( drugn / drugn ) , drugn , drugb , drugn , drugn , drugn , drugn , drugn , or drugn .
false
based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , druga , drugn , drugn , drugn , drugn ( and its active metabolite , drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , an oral drugn ( drugn / drugn ) , drugn , drugn , drugb , drugn , drugn , drugn , drugn , or drugn .
false
based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , druga , drugn , drugn , drugn , drugn ( and its active metabolite , drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , an oral drugn ( drugn / drugn ) , drugn , drugn , drugn , drugb , drugn , drugn , drugn , or drugn .
false
based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , druga , drugn , drugn , drugn , drugn ( and its active metabolite , drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , an oral drugn ( drugn / drugn ) , drugn , drugn , drugn , drugn , drugb , drugn , drugn , or drugn .
false
based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , druga , drugn , drugn , drugn , drugn ( and its active metabolite , drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , an oral drugn ( drugn / drugn ) , drugn , drugn , drugn , drugn , drugn , drugb , drugn , or drugn .
false
based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , druga , drugn , drugn , drugn , drugn ( and its active metabolite , drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , an oral drugn ( drugn / drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , drugb , or drugn .
false
based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , druga , drugn , drugn , drugn , drugn ( and its active metabolite , drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , an oral drugn ( drugn / drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , drugn , or drugb .
false
based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , druga , drugb , drugn , drugn ( and its active metabolite , drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , an oral drugn ( drugn / drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , drugn , or drugn .
false
based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , druga , drugn , drugb , drugn ( and its active metabolite , drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , an oral drugn ( drugn / drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , drugn , or drugn .
false
based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , druga , drugn , drugn , drugb ( and its active metabolite , drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , an oral drugn ( drugn / drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , drugn , or drugn .
false
based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , druga , drugn , drugn , drugn ( and its active metabolite , drugb ) , drugn , drugn , drugn , drugn , drugn , drugn , an oral drugn ( drugn / drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , drugn , or drugn .
false
based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , druga , drugn , drugn , drugn ( and its active metabolite , drugn ) , drugb , drugn , drugn , drugn , drugn , drugn , an oral drugn ( drugn / drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , drugn , or drugn .
false
based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , druga , drugn , drugn , drugn ( and its active metabolite , drugn ) , drugn , drugb , drugn , drugn , drugn , drugn , an oral drugn ( drugn / drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , drugn , or drugn .
false
based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , druga , drugn , drugn , drugn ( and its active metabolite , drugn ) , drugn , drugn , drugb , drugn , drugn , drugn , an oral drugn ( drugn / drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , drugn , or drugn .
false
based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , druga , drugn , drugn , drugn ( and its active metabolite , drugn ) , drugn , drugn , drugn , drugb , drugn , drugn , an oral drugn ( drugn / drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , drugn , or drugn .
false
based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , druga , drugn , drugn , drugn ( and its active metabolite , drugn ) , drugn , drugn , drugn , drugn , drugb , drugn , an oral drugn ( drugn / drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , drugn , or drugn .
false
based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , druga , drugn , drugn , drugn ( and its active metabolite , drugn ) , drugn , drugn , drugn , drugn , drugn , drugb , an oral drugn ( drugn / drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , drugn , or drugn .
false
based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , druga , drugn , drugn , drugn ( and its active metabolite , drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , an oral drugb ( drugn / drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , drugn , or drugn .
false
based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , druga , drugn , drugn , drugn ( and its active metabolite , drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , an oral drugn ( drugb / drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , drugn , or drugn .
false
based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , druga , drugn , drugn , drugn ( and its active metabolite , drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , an oral drugn ( drugn / drugb ) , drugn , drugn , drugn , drugn , drugn , drugn , drugn , or drugn .
false
based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , druga , drugn , drugn , drugn ( and its active metabolite , drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , an oral drugn ( drugn / drugn ) , drugb , drugn , drugn , drugn , drugn , drugn , drugn , or drugn .
false
based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , druga , drugn , drugn , drugn ( and its active metabolite , drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , an oral drugn ( drugn / drugn ) , drugn , drugb , drugn , drugn , drugn , drugn , drugn , or drugn .
false
based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , druga , drugn , drugn , drugn ( and its active metabolite , drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , an oral drugn ( drugn / drugn ) , drugn , drugn , drugb , drugn , drugn , drugn , drugn , or drugn .
false
based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , druga , drugn , drugn , drugn ( and its active metabolite , drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , an oral drugn ( drugn / drugn ) , drugn , drugn , drugn , drugb , drugn , drugn , drugn , or drugn .
false
based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , druga , drugn , drugn , drugn ( and its active metabolite , drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , an oral drugn ( drugn / drugn ) , drugn , drugn , drugn , drugn , drugb , drugn , drugn , or drugn .
false
based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , druga , drugn , drugn , drugn ( and its active metabolite , drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , an oral drugn ( drugn / drugn ) , drugn , drugn , drugn , drugn , drugn , drugb , drugn , or drugn .
false
based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , druga , drugn , drugn , drugn ( and its active metabolite , drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , an oral drugn ( drugn / drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , drugb , or drugn .
false
based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , druga , drugn , drugn , drugn ( and its active metabolite , drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , an oral drugn ( drugn / drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , drugn , or drugb .
false
based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , druga , drugb , drugn ( and its active metabolite , drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , an oral drugn ( drugn / drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , drugn , or drugn .
false
based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , druga , drugn , drugb ( and its active metabolite , drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , an oral drugn ( drugn / drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , drugn , or drugn .
false
based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , druga , drugn , drugn ( and its active metabolite , drugb ) , drugn , drugn , drugn , drugn , drugn , drugn , an oral drugn ( drugn / drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , drugn , or drugn .
false
based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , druga , drugn , drugn ( and its active metabolite , drugn ) , drugb , drugn , drugn , drugn , drugn , drugn , an oral drugn ( drugn / drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , drugn , or drugn .
false
based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , druga , drugn , drugn ( and its active metabolite , drugn ) , drugn , drugb , drugn , drugn , drugn , drugn , an oral drugn ( drugn / drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , drugn , or drugn .
false
based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , druga , drugn , drugn ( and its active metabolite , drugn ) , drugn , drugn , drugb , drugn , drugn , drugn , an oral drugn ( drugn / drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , drugn , or drugn .
false
based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , druga , drugn , drugn ( and its active metabolite , drugn ) , drugn , drugn , drugn , drugb , drugn , drugn , an oral drugn ( drugn / drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , drugn , or drugn .
false
based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , druga , drugn , drugn ( and its active metabolite , drugn ) , drugn , drugn , drugn , drugn , drugb , drugn , an oral drugn ( drugn / drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , drugn , or drugn .
false
based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , druga , drugn , drugn ( and its active metabolite , drugn ) , drugn , drugn , drugn , drugn , drugn , drugb , an oral drugn ( drugn / drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , drugn , or drugn .
false
based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , druga , drugn , drugn ( and its active metabolite , drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , an oral drugb ( drugn / drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , drugn , or drugn .
false
based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , druga , drugn , drugn ( and its active metabolite , drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , an oral drugn ( drugb / drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , drugn , or drugn .
false
based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , druga , drugn , drugn ( and its active metabolite , drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , an oral drugn ( drugn / drugb ) , drugn , drugn , drugn , drugn , drugn , drugn , drugn , or drugn .
false
based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , druga , drugn , drugn ( and its active metabolite , drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , an oral drugn ( drugn / drugn ) , drugb , drugn , drugn , drugn , drugn , drugn , drugn , or drugn .
false
based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , druga , drugn , drugn ( and its active metabolite , drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , an oral drugn ( drugn / drugn ) , drugn , drugb , drugn , drugn , drugn , drugn , drugn , or drugn .
false
based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , druga , drugn , drugn ( and its active metabolite , drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , an oral drugn ( drugn / drugn ) , drugn , drugn , drugb , drugn , drugn , drugn , drugn , or drugn .
false
based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , druga , drugn , drugn ( and its active metabolite , drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , an oral drugn ( drugn / drugn ) , drugn , drugn , drugn , drugb , drugn , drugn , drugn , or drugn .
false
based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , druga , drugn , drugn ( and its active metabolite , drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , an oral drugn ( drugn / drugn ) , drugn , drugn , drugn , drugn , drugb , drugn , drugn , or drugn .
false
based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , druga , drugn , drugn ( and its active metabolite , drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , an oral drugn ( drugn / drugn ) , drugn , drugn , drugn , drugn , drugn , drugb , drugn , or drugn .
false
based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , druga , drugn , drugn ( and its active metabolite , drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , an oral drugn ( drugn / drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , drugb , or drugn .
false
based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , druga , drugn , drugn ( and its active metabolite , drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , an oral drugn ( drugn / drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , drugn , or drugb .
false
based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , druga , drugb ( and its active metabolite , drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , an oral drugn ( drugn / drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , drugn , or drugn .
false
based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , druga , drugn ( and its active metabolite , drugb ) , drugn , drugn , drugn , drugn , drugn , drugn , an oral drugn ( drugn / drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , drugn , or drugn .
false
based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , druga , drugn ( and its active metabolite , drugn ) , drugb , drugn , drugn , drugn , drugn , drugn , an oral drugn ( drugn / drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , drugn , or drugn .
false
based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , druga , drugn ( and its active metabolite , drugn ) , drugn , drugb , drugn , drugn , drugn , drugn , an oral drugn ( drugn / drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , drugn , or drugn .
false
based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , druga , drugn ( and its active metabolite , drugn ) , drugn , drugn , drugb , drugn , drugn , drugn , an oral drugn ( drugn / drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , drugn , or drugn .
false
based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , druga , drugn ( and its active metabolite , drugn ) , drugn , drugn , drugn , drugb , drugn , drugn , an oral drugn ( drugn / drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , drugn , or drugn .
false
based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , druga , drugn ( and its active metabolite , drugn ) , drugn , drugn , drugn , drugn , drugb , drugn , an oral drugn ( drugn / drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , drugn , or drugn .
false
based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , druga , drugn ( and its active metabolite , drugn ) , drugn , drugn , drugn , drugn , drugn , drugb , an oral drugn ( drugn / drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , drugn , or drugn .
false
based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , druga , drugn ( and its active metabolite , drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , an oral drugb ( drugn / drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , drugn , or drugn .
false
based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , druga , drugn ( and its active metabolite , drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , an oral drugn ( drugb / drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , drugn , or drugn .
false
based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , druga , drugn ( and its active metabolite , drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , an oral drugn ( drugn / drugb ) , drugn , drugn , drugn , drugn , drugn , drugn , drugn , or drugn .
false
based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , druga , drugn ( and its active metabolite , drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , an oral drugn ( drugn / drugn ) , drugb , drugn , drugn , drugn , drugn , drugn , drugn , or drugn .
false
based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , druga , drugn ( and its active metabolite , drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , an oral drugn ( drugn / drugn ) , drugn , drugb , drugn , drugn , drugn , drugn , drugn , or drugn .
false
based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , druga , drugn ( and its active metabolite , drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , an oral drugn ( drugn / drugn ) , drugn , drugn , drugb , drugn , drugn , drugn , drugn , or drugn .
false
based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , druga , drugn ( and its active metabolite , drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , an oral drugn ( drugn / drugn ) , drugn , drugn , drugn , drugb , drugn , drugn , drugn , or drugn .
false
based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , druga , drugn ( and its active metabolite , drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , an oral drugn ( drugn / drugn ) , drugn , drugn , drugn , drugn , drugb , drugn , drugn , or drugn .
false
based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , druga , drugn ( and its active metabolite , drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , an oral drugn ( drugn / drugn ) , drugn , drugn , drugn , drugn , drugn , drugb , drugn , or drugn .
false
based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , druga , drugn ( and its active metabolite , drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , an oral drugn ( drugn / drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , drugb , or drugn .
false
based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , druga , drugn ( and its active metabolite , drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , an oral drugn ( drugn / drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , drugn , or drugb .
false
based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , druga ( and its active metabolite , drugb ) , drugn , drugn , drugn , drugn , drugn , drugn , an oral drugn ( drugn / drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , drugn , or drugn .
false
based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , druga ( and its active metabolite , drugn ) , drugb , drugn , drugn , drugn , drugn , drugn , an oral drugn ( drugn / drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , drugn , or drugn .
false
based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , druga ( and its active metabolite , drugn ) , drugn , drugb , drugn , drugn , drugn , drugn , an oral drugn ( drugn / drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , drugn , or drugn .
false
based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , druga ( and its active metabolite , drugn ) , drugn , drugn , drugb , drugn , drugn , drugn , an oral drugn ( drugn / drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , drugn , or drugn .
false
based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , druga ( and its active metabolite , drugn ) , drugn , drugn , drugn , drugb , drugn , drugn , an oral drugn ( drugn / drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , drugn , or drugn .
false
based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , druga ( and its active metabolite , drugn ) , drugn , drugn , drugn , drugn , drugb , drugn , an oral drugn ( drugn / drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , drugn , or drugn .
false
based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , druga ( and its active metabolite , drugn ) , drugn , drugn , drugn , drugn , drugn , drugb , an oral drugn ( drugn / drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , drugn , or drugn .
false
based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , druga ( and its active metabolite , drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , an oral drugb ( drugn / drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , drugn , or drugn .
false
based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , druga ( and its active metabolite , drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , an oral drugn ( drugb / drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , drugn , or drugn .
false
based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , druga ( and its active metabolite , drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , an oral drugn ( drugn / drugb ) , drugn , drugn , drugn , drugn , drugn , drugn , drugn , or drugn .
false
based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , druga ( and its active metabolite , drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , an oral drugn ( drugn / drugn ) , drugb , drugn , drugn , drugn , drugn , drugn , drugn , or drugn .
false
based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , druga ( and its active metabolite , drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , an oral drugn ( drugn / drugn ) , drugn , drugb , drugn , drugn , drugn , drugn , drugn , or drugn .
false
based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , druga ( and its active metabolite , drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , an oral drugn ( drugn / drugn ) , drugn , drugn , drugb , drugn , drugn , drugn , drugn , or drugn .
false
based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , druga ( and its active metabolite , drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , an oral drugn ( drugn / drugn ) , drugn , drugn , drugn , drugb , drugn , drugn , drugn , or drugn .
false
based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , druga ( and its active metabolite , drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , an oral drugn ( drugn / drugn ) , drugn , drugn , drugn , drugn , drugb , drugn , drugn , or drugn .
false
based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , druga ( and its active metabolite , drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , an oral drugn ( drugn / drugn ) , drugn , drugn , drugn , drugn , drugn , drugb , drugn , or drugn .
false
based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , druga ( and its active metabolite , drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , an oral drugn ( drugn / drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , drugb , or drugn .
false
based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , druga ( and its active metabolite , drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , an oral drugn ( drugn / drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , drugn , or drugb .
false
based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , drugn ( and its active metabolite , druga ) , drugb , drugn , drugn , drugn , drugn , drugn , an oral drugn ( drugn / drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , drugn , or drugn .
false
based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , drugn ( and its active metabolite , druga ) , drugn , drugb , drugn , drugn , drugn , drugn , an oral drugn ( drugn / drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , drugn , or drugn .
false
based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , drugn ( and its active metabolite , druga ) , drugn , drugn , drugb , drugn , drugn , drugn , an oral drugn ( drugn / drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , drugn , or drugn .
false
based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , drugn ( and its active metabolite , druga ) , drugn , drugn , drugn , drugb , drugn , drugn , an oral drugn ( drugn / drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , drugn , or drugn .
false
based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , drugn ( and its active metabolite , druga ) , drugn , drugn , drugn , drugn , drugb , drugn , an oral drugn ( drugn / drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , drugn , or drugn .
false
based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , drugn ( and its active metabolite , druga ) , drugn , drugn , drugn , drugn , drugn , drugb , an oral drugn ( drugn / drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , drugn , or drugn .
false
based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , drugn ( and its active metabolite , druga ) , drugn , drugn , drugn , drugn , drugn , drugn , an oral drugb ( drugn / drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , drugn , or drugn .
false
based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , drugn ( and its active metabolite , druga ) , drugn , drugn , drugn , drugn , drugn , drugn , an oral drugn ( drugb / drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , drugn , or drugn .
false
based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , drugn ( and its active metabolite , druga ) , drugn , drugn , drugn , drugn , drugn , drugn , an oral drugn ( drugn / drugb ) , drugn , drugn , drugn , drugn , drugn , drugn , drugn , or drugn .
false
based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , drugn ( and its active metabolite , druga ) , drugn , drugn , drugn , drugn , drugn , drugn , an oral drugn ( drugn / drugn ) , drugb , drugn , drugn , drugn , drugn , drugn , drugn , or drugn .
false
based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , drugn ( and its active metabolite , druga ) , drugn , drugn , drugn , drugn , drugn , drugn , an oral drugn ( drugn / drugn ) , drugn , drugb , drugn , drugn , drugn , drugn , drugn , or drugn .
false
based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , drugn ( and its active metabolite , druga ) , drugn , drugn , drugn , drugn , drugn , drugn , an oral drugn ( drugn / drugn ) , drugn , drugn , drugb , drugn , drugn , drugn , drugn , or drugn .
false
based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , drugn ( and its active metabolite , druga ) , drugn , drugn , drugn , drugn , drugn , drugn , an oral drugn ( drugn / drugn ) , drugn , drugn , drugn , drugb , drugn , drugn , drugn , or drugn .
false
based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , drugn ( and its active metabolite , druga ) , drugn , drugn , drugn , drugn , drugn , drugn , an oral drugn ( drugn / drugn ) , drugn , drugn , drugn , drugn , drugb , drugn , drugn , or drugn .
false
based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , drugn ( and its active metabolite , druga ) , drugn , drugn , drugn , drugn , drugn , drugn , an oral drugn ( drugn / drugn ) , drugn , drugn , drugn , drugn , drugn , drugb , drugn , or drugn .
false
based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , drugn ( and its active metabolite , druga ) , drugn , drugn , drugn , drugn , drugn , drugn , an oral drugn ( drugn / drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , drugb , or drugn .
false
based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , drugn ( and its active metabolite , druga ) , drugn , drugn , drugn , drugn , drugn , drugn , an oral drugn ( drugn / drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , drugn , or drugb .
false
based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , drugn ( and its active metabolite , drugn ) , druga , drugb , drugn , drugn , drugn , drugn , an oral drugn ( drugn / drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , drugn , or drugn .
false
based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , drugn ( and its active metabolite , drugn ) , druga , drugn , drugb , drugn , drugn , drugn , an oral drugn ( drugn / drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , drugn , or drugn .
false
based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , drugn ( and its active metabolite , drugn ) , druga , drugn , drugn , drugb , drugn , drugn , an oral drugn ( drugn / drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , drugn , or drugn .
false
based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , drugn ( and its active metabolite , drugn ) , druga , drugn , drugn , drugn , drugb , drugn , an oral drugn ( drugn / drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , drugn , or drugn .
false
based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , drugn ( and its active metabolite , drugn ) , druga , drugn , drugn , drugn , drugn , drugb , an oral drugn ( drugn / drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , drugn , or drugn .
false
based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , drugn ( and its active metabolite , drugn ) , druga , drugn , drugn , drugn , drugn , drugn , an oral drugb ( drugn / drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , drugn , or drugn .
false
based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , drugn ( and its active metabolite , drugn ) , druga , drugn , drugn , drugn , drugn , drugn , an oral drugn ( drugb / drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , drugn , or drugn .
false
based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , drugn ( and its active metabolite , drugn ) , druga , drugn , drugn , drugn , drugn , drugn , an oral drugn ( drugn / drugb ) , drugn , drugn , drugn , drugn , drugn , drugn , drugn , or drugn .
false
based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , drugn ( and its active metabolite , drugn ) , druga , drugn , drugn , drugn , drugn , drugn , an oral drugn ( drugn / drugn ) , drugb , drugn , drugn , drugn , drugn , drugn , drugn , or drugn .
false
based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , drugn ( and its active metabolite , drugn ) , druga , drugn , drugn , drugn , drugn , drugn , an oral drugn ( drugn / drugn ) , drugn , drugb , drugn , drugn , drugn , drugn , drugn , or drugn .
false
based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , drugn ( and its active metabolite , drugn ) , druga , drugn , drugn , drugn , drugn , drugn , an oral drugn ( drugn / drugn ) , drugn , drugn , drugb , drugn , drugn , drugn , drugn , or drugn .
false
based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , drugn ( and its active metabolite , drugn ) , druga , drugn , drugn , drugn , drugn , drugn , an oral drugn ( drugn / drugn ) , drugn , drugn , drugn , drugb , drugn , drugn , drugn , or drugn .
false
based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , drugn ( and its active metabolite , drugn ) , druga , drugn , drugn , drugn , drugn , drugn , an oral drugn ( drugn / drugn ) , drugn , drugn , drugn , drugn , drugb , drugn , drugn , or drugn .
false
based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , drugn ( and its active metabolite , drugn ) , druga , drugn , drugn , drugn , drugn , drugn , an oral drugn ( drugn / drugn ) , drugn , drugn , drugn , drugn , drugn , drugb , drugn , or drugn .
false
based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , drugn ( and its active metabolite , drugn ) , druga , drugn , drugn , drugn , drugn , drugn , an oral drugn ( drugn / drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , drugb , or drugn .
false
based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , drugn ( and its active metabolite , drugn ) , druga , drugn , drugn , drugn , drugn , drugn , an oral drugn ( drugn / drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , drugn , or drugb .
false
based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , drugn ( and its active metabolite , drugn ) , drugn , druga , drugb , drugn , drugn , drugn , an oral drugn ( drugn / drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , drugn , or drugn .
false
based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , drugn ( and its active metabolite , drugn ) , drugn , druga , drugn , drugb , drugn , drugn , an oral drugn ( drugn / drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , drugn , or drugn .
false
based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , drugn ( and its active metabolite , drugn ) , drugn , druga , drugn , drugn , drugb , drugn , an oral drugn ( drugn / drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , drugn , or drugn .
false
based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , drugn ( and its active metabolite , drugn ) , drugn , druga , drugn , drugn , drugn , drugb , an oral drugn ( drugn / drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , drugn , or drugn .
false
based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , drugn ( and its active metabolite , drugn ) , drugn , druga , drugn , drugn , drugn , drugn , an oral drugb ( drugn / drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , drugn , or drugn .
false
based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , drugn ( and its active metabolite , drugn ) , drugn , druga , drugn , drugn , drugn , drugn , an oral drugn ( drugb / drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , drugn , or drugn .
false
based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , drugn ( and its active metabolite , drugn ) , drugn , druga , drugn , drugn , drugn , drugn , an oral drugn ( drugn / drugb ) , drugn , drugn , drugn , drugn , drugn , drugn , drugn , or drugn .
false
based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , drugn ( and its active metabolite , drugn ) , drugn , druga , drugn , drugn , drugn , drugn , an oral drugn ( drugn / drugn ) , drugb , drugn , drugn , drugn , drugn , drugn , drugn , or drugn .
false
based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , drugn ( and its active metabolite , drugn ) , drugn , druga , drugn , drugn , drugn , drugn , an oral drugn ( drugn / drugn ) , drugn , drugb , drugn , drugn , drugn , drugn , drugn , or drugn .
false
based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , drugn ( and its active metabolite , drugn ) , drugn , druga , drugn , drugn , drugn , drugn , an oral drugn ( drugn / drugn ) , drugn , drugn , drugb , drugn , drugn , drugn , drugn , or drugn .
false
based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , drugn ( and its active metabolite , drugn ) , drugn , druga , drugn , drugn , drugn , drugn , an oral drugn ( drugn / drugn ) , drugn , drugn , drugn , drugb , drugn , drugn , drugn , or drugn .
false
based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , drugn ( and its active metabolite , drugn ) , drugn , druga , drugn , drugn , drugn , drugn , an oral drugn ( drugn / drugn ) , drugn , drugn , drugn , drugn , drugb , drugn , drugn , or drugn .
false
based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , drugn ( and its active metabolite , drugn ) , drugn , druga , drugn , drugn , drugn , drugn , an oral drugn ( drugn / drugn ) , drugn , drugn , drugn , drugn , drugn , drugb , drugn , or drugn .
false
based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , drugn ( and its active metabolite , drugn ) , drugn , druga , drugn , drugn , drugn , drugn , an oral drugn ( drugn / drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , drugb , or drugn .
false
based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , drugn ( and its active metabolite , drugn ) , drugn , druga , drugn , drugn , drugn , drugn , an oral drugn ( drugn / drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , drugn , or drugb .
false
based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , drugn ( and its active metabolite , drugn ) , drugn , drugn , druga , drugb , drugn , drugn , an oral drugn ( drugn / drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , drugn , or drugn .
false
based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , drugn ( and its active metabolite , drugn ) , drugn , drugn , druga , drugn , drugb , drugn , an oral drugn ( drugn / drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , drugn , or drugn .
false
based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , drugn ( and its active metabolite , drugn ) , drugn , drugn , druga , drugn , drugn , drugb , an oral drugn ( drugn / drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , drugn , or drugn .
false
based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , drugn ( and its active metabolite , drugn ) , drugn , drugn , druga , drugn , drugn , drugn , an oral drugb ( drugn / drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , drugn , or drugn .
false
based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , drugn ( and its active metabolite , drugn ) , drugn , drugn , druga , drugn , drugn , drugn , an oral drugn ( drugb / drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , drugn , or drugn .
false
based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , drugn ( and its active metabolite , drugn ) , drugn , drugn , druga , drugn , drugn , drugn , an oral drugn ( drugn / drugb ) , drugn , drugn , drugn , drugn , drugn , drugn , drugn , or drugn .
false
based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , drugn ( and its active metabolite , drugn ) , drugn , drugn , druga , drugn , drugn , drugn , an oral drugn ( drugn / drugn ) , drugb , drugn , drugn , drugn , drugn , drugn , drugn , or drugn .
false
based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , drugn ( and its active metabolite , drugn ) , drugn , drugn , druga , drugn , drugn , drugn , an oral drugn ( drugn / drugn ) , drugn , drugb , drugn , drugn , drugn , drugn , drugn , or drugn .
false
based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , drugn ( and its active metabolite , drugn ) , drugn , drugn , druga , drugn , drugn , drugn , an oral drugn ( drugn / drugn ) , drugn , drugn , drugb , drugn , drugn , drugn , drugn , or drugn .
false
based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , drugn ( and its active metabolite , drugn ) , drugn , drugn , druga , drugn , drugn , drugn , an oral drugn ( drugn / drugn ) , drugn , drugn , drugn , drugb , drugn , drugn , drugn , or drugn .
false
based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , drugn ( and its active metabolite , drugn ) , drugn , drugn , druga , drugn , drugn , drugn , an oral drugn ( drugn / drugn ) , drugn , drugn , drugn , drugn , drugb , drugn , drugn , or drugn .
false
based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , drugn ( and its active metabolite , drugn ) , drugn , drugn , druga , drugn , drugn , drugn , an oral drugn ( drugn / drugn ) , drugn , drugn , drugn , drugn , drugn , drugb , drugn , or drugn .
false
based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , drugn ( and its active metabolite , drugn ) , drugn , drugn , druga , drugn , drugn , drugn , an oral drugn ( drugn / drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , drugb , or drugn .
false
based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , drugn ( and its active metabolite , drugn ) , drugn , drugn , druga , drugn , drugn , drugn , an oral drugn ( drugn / drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , drugn , or drugb .
false
based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , drugn ( and its active metabolite , drugn ) , drugn , drugn , drugn , druga , drugb , drugn , an oral drugn ( drugn / drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , drugn , or drugn .
false
based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , drugn ( and its active metabolite , drugn ) , drugn , drugn , drugn , druga , drugn , drugb , an oral drugn ( drugn / drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , drugn , or drugn .
false
based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , drugn ( and its active metabolite , drugn ) , drugn , drugn , drugn , druga , drugn , drugn , an oral drugb ( drugn / drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , drugn , or drugn .
false
based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , drugn ( and its active metabolite , drugn ) , drugn , drugn , drugn , druga , drugn , drugn , an oral drugn ( drugb / drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , drugn , or drugn .
false
based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , drugn ( and its active metabolite , drugn ) , drugn , drugn , drugn , druga , drugn , drugn , an oral drugn ( drugn / drugb ) , drugn , drugn , drugn , drugn , drugn , drugn , drugn , or drugn .
false
based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , drugn ( and its active metabolite , drugn ) , drugn , drugn , drugn , druga , drugn , drugn , an oral drugn ( drugn / drugn ) , drugb , drugn , drugn , drugn , drugn , drugn , drugn , or drugn .
false
based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , drugn ( and its active metabolite , drugn ) , drugn , drugn , drugn , druga , drugn , drugn , an oral drugn ( drugn / drugn ) , drugn , drugb , drugn , drugn , drugn , drugn , drugn , or drugn .
false
based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , drugn ( and its active metabolite , drugn ) , drugn , drugn , drugn , druga , drugn , drugn , an oral drugn ( drugn / drugn ) , drugn , drugn , drugb , drugn , drugn , drugn , drugn , or drugn .
false
based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , drugn ( and its active metabolite , drugn ) , drugn , drugn , drugn , druga , drugn , drugn , an oral drugn ( drugn / drugn ) , drugn , drugn , drugn , drugb , drugn , drugn , drugn , or drugn .
false
based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , drugn ( and its active metabolite , drugn ) , drugn , drugn , drugn , druga , drugn , drugn , an oral drugn ( drugn / drugn ) , drugn , drugn , drugn , drugn , drugb , drugn , drugn , or drugn .
false
based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , drugn ( and its active metabolite , drugn ) , drugn , drugn , drugn , druga , drugn , drugn , an oral drugn ( drugn / drugn ) , drugn , drugn , drugn , drugn , drugn , drugb , drugn , or drugn .
false
based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , drugn ( and its active metabolite , drugn ) , drugn , drugn , drugn , druga , drugn , drugn , an oral drugn ( drugn / drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , drugb , or drugn .
false
based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , drugn ( and its active metabolite , drugn ) , drugn , drugn , drugn , druga , drugn , drugn , an oral drugn ( drugn / drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , drugn , or drugb .
false
based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , drugn ( and its active metabolite , drugn ) , drugn , drugn , drugn , drugn , druga , drugb , an oral drugn ( drugn / drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , drugn , or drugn .
false
based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , drugn ( and its active metabolite , drugn ) , drugn , drugn , drugn , drugn , druga , drugn , an oral drugb ( drugn / drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , drugn , or drugn .
false
based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , drugn ( and its active metabolite , drugn ) , drugn , drugn , drugn , drugn , druga , drugn , an oral drugn ( drugb / drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , drugn , or drugn .
false
based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , drugn ( and its active metabolite , drugn ) , drugn , drugn , drugn , drugn , druga , drugn , an oral drugn ( drugn / drugb ) , drugn , drugn , drugn , drugn , drugn , drugn , drugn , or drugn .
false
based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , drugn ( and its active metabolite , drugn ) , drugn , drugn , drugn , drugn , druga , drugn , an oral drugn ( drugn / drugn ) , drugb , drugn , drugn , drugn , drugn , drugn , drugn , or drugn .
false
based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , drugn ( and its active metabolite , drugn ) , drugn , drugn , drugn , drugn , druga , drugn , an oral drugn ( drugn / drugn ) , drugn , drugb , drugn , drugn , drugn , drugn , drugn , or drugn .
false
based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , drugn ( and its active metabolite , drugn ) , drugn , drugn , drugn , drugn , druga , drugn , an oral drugn ( drugn / drugn ) , drugn , drugn , drugb , drugn , drugn , drugn , drugn , or drugn .
false
based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , drugn ( and its active metabolite , drugn ) , drugn , drugn , drugn , drugn , druga , drugn , an oral drugn ( drugn / drugn ) , drugn , drugn , drugn , drugb , drugn , drugn , drugn , or drugn .
false
based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , drugn ( and its active metabolite , drugn ) , drugn , drugn , drugn , drugn , druga , drugn , an oral drugn ( drugn / drugn ) , drugn , drugn , drugn , drugn , drugb , drugn , drugn , or drugn .
false
based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , drugn ( and its active metabolite , drugn ) , drugn , drugn , drugn , drugn , druga , drugn , an oral drugn ( drugn / drugn ) , drugn , drugn , drugn , drugn , drugn , drugb , drugn , or drugn .
false
based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , drugn ( and its active metabolite , drugn ) , drugn , drugn , drugn , drugn , druga , drugn , an oral drugn ( drugn / drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , drugb , or drugn .
false
based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , drugn ( and its active metabolite , drugn ) , drugn , drugn , drugn , drugn , druga , drugn , an oral drugn ( drugn / drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , drugn , or drugb .
false
based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , drugn ( and its active metabolite , drugn ) , drugn , drugn , drugn , drugn , drugn , druga , an oral drugb ( drugn / drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , drugn , or drugn .
false
based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , drugn ( and its active metabolite , drugn ) , drugn , drugn , drugn , drugn , drugn , druga , an oral drugn ( drugb / drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , drugn , or drugn .
false
based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , drugn ( and its active metabolite , drugn ) , drugn , drugn , drugn , drugn , drugn , druga , an oral drugn ( drugn / drugb ) , drugn , drugn , drugn , drugn , drugn , drugn , drugn , or drugn .
false
based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , drugn ( and its active metabolite , drugn ) , drugn , drugn , drugn , drugn , drugn , druga , an oral drugn ( drugn / drugn ) , drugb , drugn , drugn , drugn , drugn , drugn , drugn , or drugn .
false
based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , drugn ( and its active metabolite , drugn ) , drugn , drugn , drugn , drugn , drugn , druga , an oral drugn ( drugn / drugn ) , drugn , drugb , drugn , drugn , drugn , drugn , drugn , or drugn .
false
based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , drugn ( and its active metabolite , drugn ) , drugn , drugn , drugn , drugn , drugn , druga , an oral drugn ( drugn / drugn ) , drugn , drugn , drugb , drugn , drugn , drugn , drugn , or drugn .
false
based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , drugn ( and its active metabolite , drugn ) , drugn , drugn , drugn , drugn , drugn , druga , an oral drugn ( drugn / drugn ) , drugn , drugn , drugn , drugb , drugn , drugn , drugn , or drugn .
false
based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , drugn ( and its active metabolite , drugn ) , drugn , drugn , drugn , drugn , drugn , druga , an oral drugn ( drugn / drugn ) , drugn , drugn , drugn , drugn , drugb , drugn , drugn , or drugn .
false
based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , drugn ( and its active metabolite , drugn ) , drugn , drugn , drugn , drugn , drugn , druga , an oral drugn ( drugn / drugn ) , drugn , drugn , drugn , drugn , drugn , drugb , drugn , or drugn .
false
based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , drugn ( and its active metabolite , drugn ) , drugn , drugn , drugn , drugn , drugn , druga , an oral drugn ( drugn / drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , drugb , or drugn .
false
based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , drugn ( and its active metabolite , drugn ) , drugn , drugn , drugn , drugn , drugn , druga , an oral drugn ( drugn / drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , drugn , or drugb .
false
based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , drugn ( and its active metabolite , drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , an oral druga ( drugb / drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , drugn , or drugn .
false
based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , drugn ( and its active metabolite , drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , an oral druga ( drugn / drugb ) , drugn , drugn , drugn , drugn , drugn , drugn , drugn , or drugn .
false
based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , drugn ( and its active metabolite , drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , an oral druga ( drugn / drugn ) , drugb , drugn , drugn , drugn , drugn , drugn , drugn , or drugn .
false
based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , drugn ( and its active metabolite , drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , an oral druga ( drugn / drugn ) , drugn , drugb , drugn , drugn , drugn , drugn , drugn , or drugn .
false
based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , drugn ( and its active metabolite , drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , an oral druga ( drugn / drugn ) , drugn , drugn , drugb , drugn , drugn , drugn , drugn , or drugn .
false
based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , drugn ( and its active metabolite , drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , an oral druga ( drugn / drugn ) , drugn , drugn , drugn , drugb , drugn , drugn , drugn , or drugn .
false
based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , drugn ( and its active metabolite , drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , an oral druga ( drugn / drugn ) , drugn , drugn , drugn , drugn , drugb , drugn , drugn , or drugn .
false
based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , drugn ( and its active metabolite , drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , an oral druga ( drugn / drugn ) , drugn , drugn , drugn , drugn , drugn , drugb , drugn , or drugn .
false
based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , drugn ( and its active metabolite , drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , an oral druga ( drugn / drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , drugb , or drugn .
false
based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , drugn ( and its active metabolite , drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , an oral druga ( drugn / drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , drugn , or drugb .
false
based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , drugn ( and its active metabolite , drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , an oral drugn ( druga / drugb ) , drugn , drugn , drugn , drugn , drugn , drugn , drugn , or drugn .
false
based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , drugn ( and its active metabolite , drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , an oral drugn ( druga / drugn ) , drugb , drugn , drugn , drugn , drugn , drugn , drugn , or drugn .
false
based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , drugn ( and its active metabolite , drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , an oral drugn ( druga / drugn ) , drugn , drugb , drugn , drugn , drugn , drugn , drugn , or drugn .
false
based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , drugn ( and its active metabolite , drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , an oral drugn ( druga / drugn ) , drugn , drugn , drugb , drugn , drugn , drugn , drugn , or drugn .
false
based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , drugn ( and its active metabolite , drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , an oral drugn ( druga / drugn ) , drugn , drugn , drugn , drugb , drugn , drugn , drugn , or drugn .
false
based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , drugn ( and its active metabolite , drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , an oral drugn ( druga / drugn ) , drugn , drugn , drugn , drugn , drugb , drugn , drugn , or drugn .
false
based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , drugn ( and its active metabolite , drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , an oral drugn ( druga / drugn ) , drugn , drugn , drugn , drugn , drugn , drugb , drugn , or drugn .
false
based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , drugn ( and its active metabolite , drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , an oral drugn ( druga / drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , drugb , or drugn .
false
based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , drugn ( and its active metabolite , drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , an oral drugn ( druga / drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , drugn , or drugb .
false
based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , drugn ( and its active metabolite , drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , an oral drugn ( drugn / druga ) , drugb , drugn , drugn , drugn , drugn , drugn , drugn , or drugn .
false
based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , drugn ( and its active metabolite , drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , an oral drugn ( drugn / druga ) , drugn , drugb , drugn , drugn , drugn , drugn , drugn , or drugn .
false
based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , drugn ( and its active metabolite , drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , an oral drugn ( drugn / druga ) , drugn , drugn , drugb , drugn , drugn , drugn , drugn , or drugn .
false
based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , drugn ( and its active metabolite , drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , an oral drugn ( drugn / druga ) , drugn , drugn , drugn , drugb , drugn , drugn , drugn , or drugn .
false
based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , drugn ( and its active metabolite , drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , an oral drugn ( drugn / druga ) , drugn , drugn , drugn , drugn , drugb , drugn , drugn , or drugn .
false
based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , drugn ( and its active metabolite , drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , an oral drugn ( drugn / druga ) , drugn , drugn , drugn , drugn , drugn , drugb , drugn , or drugn .
false
based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , drugn ( and its active metabolite , drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , an oral drugn ( drugn / druga ) , drugn , drugn , drugn , drugn , drugn , drugn , drugb , or drugn .
false
based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , drugn ( and its active metabolite , drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , an oral drugn ( drugn / druga ) , drugn , drugn , drugn , drugn , drugn , drugn , drugn , or drugb .
false
based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , drugn ( and its active metabolite , drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , an oral drugn ( drugn / drugn ) , druga , drugb , drugn , drugn , drugn , drugn , drugn , or drugn .
false
based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , drugn ( and its active metabolite , drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , an oral drugn ( drugn / drugn ) , druga , drugn , drugb , drugn , drugn , drugn , drugn , or drugn .
false
based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , drugn ( and its active metabolite , drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , an oral drugn ( drugn / drugn ) , druga , drugn , drugn , drugb , drugn , drugn , drugn , or drugn .
false
based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , drugn ( and its active metabolite , drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , an oral drugn ( drugn / drugn ) , druga , drugn , drugn , drugn , drugb , drugn , drugn , or drugn .
false
based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , drugn ( and its active metabolite , drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , an oral drugn ( drugn / drugn ) , druga , drugn , drugn , drugn , drugn , drugb , drugn , or drugn .
false
based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , drugn ( and its active metabolite , drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , an oral drugn ( drugn / drugn ) , druga , drugn , drugn , drugn , drugn , drugn , drugb , or drugn .
false
based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , drugn ( and its active metabolite , drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , an oral drugn ( drugn / drugn ) , druga , drugn , drugn , drugn , drugn , drugn , drugn , or drugb .
false
based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , drugn ( and its active metabolite , drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , an oral drugn ( drugn / drugn ) , drugn , druga , drugb , drugn , drugn , drugn , drugn , or drugn .
false
based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , drugn ( and its active metabolite , drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , an oral drugn ( drugn / drugn ) , drugn , druga , drugn , drugb , drugn , drugn , drugn , or drugn .
false
based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , drugn ( and its active metabolite , drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , an oral drugn ( drugn / drugn ) , drugn , druga , drugn , drugn , drugb , drugn , drugn , or drugn .
false
based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , drugn ( and its active metabolite , drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , an oral drugn ( drugn / drugn ) , drugn , druga , drugn , drugn , drugn , drugb , drugn , or drugn .
false
based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , drugn ( and its active metabolite , drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , an oral drugn ( drugn / drugn ) , drugn , druga , drugn , drugn , drugn , drugn , drugb , or drugn .
false
based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , drugn ( and its active metabolite , drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , an oral drugn ( drugn / drugn ) , drugn , druga , drugn , drugn , drugn , drugn , drugn , or drugb .
false
based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , drugn ( and its active metabolite , drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , an oral drugn ( drugn / drugn ) , drugn , drugn , druga , drugb , drugn , drugn , drugn , or drugn .
false
based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , drugn ( and its active metabolite , drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , an oral drugn ( drugn / drugn ) , drugn , drugn , druga , drugn , drugb , drugn , drugn , or drugn .
false
based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , drugn ( and its active metabolite , drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , an oral drugn ( drugn / drugn ) , drugn , drugn , druga , drugn , drugn , drugb , drugn , or drugn .
false
based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , drugn ( and its active metabolite , drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , an oral drugn ( drugn / drugn ) , drugn , drugn , druga , drugn , drugn , drugn , drugb , or drugn .
false
based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , drugn ( and its active metabolite , drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , an oral drugn ( drugn / drugn ) , drugn , drugn , druga , drugn , drugn , drugn , drugn , or drugb .
false
based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , drugn ( and its active metabolite , drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , an oral drugn ( drugn / drugn ) , drugn , drugn , drugn , druga , drugb , drugn , drugn , or drugn .
false
based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , drugn ( and its active metabolite , drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , an oral drugn ( drugn / drugn ) , drugn , drugn , drugn , druga , drugn , drugb , drugn , or drugn .
false
based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , drugn ( and its active metabolite , drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , an oral drugn ( drugn / drugn ) , drugn , drugn , drugn , druga , drugn , drugn , drugb , or drugn .
false
based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , drugn ( and its active metabolite , drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , an oral drugn ( drugn / drugn ) , drugn , drugn , drugn , druga , drugn , drugn , drugn , or drugb .
false
based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , drugn ( and its active metabolite , drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , an oral drugn ( drugn / drugn ) , drugn , drugn , drugn , drugn , druga , drugb , drugn , or drugn .
false
based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , drugn ( and its active metabolite , drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , an oral drugn ( drugn / drugn ) , drugn , drugn , drugn , drugn , druga , drugn , drugb , or drugn .
false
based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , drugn ( and its active metabolite , drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , an oral drugn ( drugn / drugn ) , drugn , drugn , drugn , drugn , druga , drugn , drugn , or drugb .
false
based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , drugn ( and its active metabolite , drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , an oral drugn ( drugn / drugn ) , drugn , drugn , drugn , drugn , drugn , druga , drugb , or drugn .
false
based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , drugn ( and its active metabolite , drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , an oral drugn ( drugn / drugn ) , drugn , drugn , drugn , drugn , drugn , druga , drugn , or drugb .
false
based on studies evaluating possible interactions of drugn with other drugs , no dosage adjustment is needed with concomitant use of the following : drugn , drugn , drugn , drugn , drugn , drugn ( and its active metabolite , drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , an oral drugn ( drugn / drugn ) , drugn , drugn , drugn , drugn , drugn , drugn , druga , or drugb .
false
therefore , when coadministered with druga , adjustment of the dosage of drugb or of such drugs may not be necessary .
false
there have been postmarketing reports of increased inr and prothrombin time in patients receiving druga , including drugb , and drugn concomitantly .
false
there have been postmarketing reports of increased inr and prothrombin time in patients receiving druga , including drugn , and drugb concomitantly .
effect
there have been postmarketing reports of increased inr and prothrombin time in patients receiving drugn , including druga , and drugb concomitantly .
effect
patients treated with druga and drugb concomitantly should be monitored for increases in inr and prothrombin time .
advise
because of profound and long lasting inhibition of gastric acid secretion , druga may interfere with absorption of drugs where gastric ph is an important determinant of their bioavailability ( eg , drugb , drugn esters , and drugn salts ) .
mechanism
because of profound and long lasting inhibition of gastric acid secretion , druga may interfere with absorption of drugs where gastric ph is an important determinant of their bioavailability ( eg , drugn , drugb esters , and drugn salts ) .
mechanism
because of profound and long lasting inhibition of gastric acid secretion , druga may interfere with absorption of drugs where gastric ph is an important determinant of their bioavailability ( eg , drugn , drugn esters , and drugb salts ) .
mechanism
because of profound and long lasting inhibition of gastric acid secretion , drugn may interfere with absorption of drugs where gastric ph is an important determinant of their bioavailability ( eg , druga , drugb esters , and drugn salts ) .
false
because of profound and long lasting inhibition of gastric acid secretion , drugn may interfere with absorption of drugs where gastric ph is an important determinant of their bioavailability ( eg , druga , drugn esters , and drugb salts ) .
false
because of profound and long lasting inhibition of gastric acid secretion , drugn may interfere with absorption of drugs where gastric ph is an important determinant of their bioavailability ( eg , drugn , druga esters , and drugb salts ) .
false
laboratory tests there have been reports of false-positive urine screening tests for druga ( drugb ) in patients receiving most drugn , including drugn .
false
laboratory tests there have been reports of false-positive urine screening tests for druga ( drugn ) in patients receiving most drugb , including drugn .
false
laboratory tests there have been reports of false-positive urine screening tests for druga ( drugn ) in patients receiving most drugn , including drugb .
false
laboratory tests there have been reports of false-positive urine screening tests for drugn ( druga ) in patients receiving most drugb , including drugn .
false
laboratory tests there have been reports of false-positive urine screening tests for drugn ( druga ) in patients receiving most drugn , including drugb .
false
laboratory tests there have been reports of false-positive urine screening tests for drugn ( drugn ) in patients receiving most druga , including drugb .
false
some druga may interact with drugb .
int
those druga include drugb , drugn , and drugn .
false
those druga include drugn , drugb , and drugn .
false
those druga include drugn , drugn , and drugb .
false
those drugn include druga , drugb , and drugn .
false
those drugn include druga , drugn , and drugb .
false
those drugn include drugn , druga , and drugb .
false
druga may also affect the effects of other drugs , which include some drugb , drugn , certain heart medicines , birth control pills , drugn , drugn and drugn please note that drugn may interact with other drugs that are not listed here .
effect
druga may also affect the effects of other drugs , which include some drugn , drugb , certain heart medicines , birth control pills , drugn , drugn and drugn please note that drugn may interact with other drugs that are not listed here .
effect
druga may also affect the effects of other drugs , which include some drugn , drugn , certain heart medicines , birth control pills , drugb , drugn and drugn please note that drugn may interact with other drugs that are not listed here .
effect
druga may also affect the effects of other drugs , which include some drugn , drugn , certain heart medicines , birth control pills , drugn , drugb and drugn please note that drugn may interact with other drugs that are not listed here .
effect
druga may also affect the effects of other drugs , which include some drugn , drugn , certain heart medicines , birth control pills , drugn , drugn and drugb please note that drugn may interact with other drugs that are not listed here .
effect
druga may also affect the effects of other drugs , which include some drugn , drugn , certain heart medicines , birth control pills , drugn , drugn and drugn please note that drugb may interact with other drugs that are not listed here .
false
drugn may also affect the effects of other drugs , which include some druga , drugb , certain heart medicines , birth control pills , drugn , drugn and drugn please note that drugn may interact with other drugs that are not listed here .
false
drugn may also affect the effects of other drugs , which include some druga , drugn , certain heart medicines , birth control pills , drugb , drugn and drugn please note that drugn may interact with other drugs that are not listed here .
false
drugn may also affect the effects of other drugs , which include some druga , drugn , certain heart medicines , birth control pills , drugn , drugb and drugn please note that drugn may interact with other drugs that are not listed here .
false
drugn may also affect the effects of other drugs , which include some druga , drugn , certain heart medicines , birth control pills , drugn , drugn and drugb please note that drugn may interact with other drugs that are not listed here .
false
drugn may also affect the effects of other drugs , which include some druga , drugn , certain heart medicines , birth control pills , drugn , drugn and drugn please note that drugb may interact with other drugs that are not listed here .
false
drugn may also affect the effects of other drugs , which include some drugn , druga , certain heart medicines , birth control pills , drugb , drugn and drugn please note that drugn may interact with other drugs that are not listed here .
false
drugn may also affect the effects of other drugs , which include some drugn , druga , certain heart medicines , birth control pills , drugn , drugb and drugn please note that drugn may interact with other drugs that are not listed here .
false
drugn may also affect the effects of other drugs , which include some drugn , druga , certain heart medicines , birth control pills , drugn , drugn and drugb please note that drugn may interact with other drugs that are not listed here .
false
drugn may also affect the effects of other drugs , which include some drugn , druga , certain heart medicines , birth control pills , drugn , drugn and drugn please note that drugb may interact with other drugs that are not listed here .
false
drugn may also affect the effects of other drugs , which include some drugn , drugn , certain heart medicines , birth control pills , druga , drugb and drugn please note that drugn may interact with other drugs that are not listed here .
false
drugn may also affect the effects of other drugs , which include some drugn , drugn , certain heart medicines , birth control pills , druga , drugn and drugb please note that drugn may interact with other drugs that are not listed here .
false
drugn may also affect the effects of other drugs , which include some drugn , drugn , certain heart medicines , birth control pills , druga , drugn and drugn please note that drugb may interact with other drugs that are not listed here .
false
drugn may also affect the effects of other drugs , which include some drugn , drugn , certain heart medicines , birth control pills , drugn , druga and drugb please note that drugn may interact with other drugs that are not listed here .
false
drugn may also affect the effects of other drugs , which include some drugn , drugn , certain heart medicines , birth control pills , drugn , druga and drugn please note that drugb may interact with other drugs that are not listed here .
false
drugn may also affect the effects of other drugs , which include some drugn , drugn , certain heart medicines , birth control pills , drugn , drugn and druga please note that drugb may interact with other drugs that are not listed here .
false
in clinical studies of druga , patients taking drugb concomitantly with drugn ( drugn , genentech ) , drugn , inhaled drugn , other drugn , or parenteral drugn demonstrated adverse experience profiles similar to the study population as a whole .
false
in clinical studies of druga , patients taking drugn concomitantly with drugb ( drugn , genentech ) , drugn , inhaled drugn , other drugn , or parenteral drugn demonstrated adverse experience profiles similar to the study population as a whole .
false
in clinical studies of druga , patients taking drugn concomitantly with drugn ( drugb , genentech ) , drugn , inhaled drugn , other drugn , or parenteral drugn demonstrated adverse experience profiles similar to the study population as a whole .
false
in clinical studies of druga , patients taking drugn concomitantly with drugn ( drugn , genentech ) , drugb , inhaled drugn , other drugn , or parenteral drugn demonstrated adverse experience profiles similar to the study population as a whole .
false
in clinical studies of druga , patients taking drugn concomitantly with drugn ( drugn , genentech ) , drugn , inhaled drugb , other drugn , or parenteral drugn demonstrated adverse experience profiles similar to the study population as a whole .
false
in clinical studies of druga , patients taking drugn concomitantly with drugn ( drugn , genentech ) , drugn , inhaled drugn , other drugb , or parenteral drugn demonstrated adverse experience profiles similar to the study population as a whole .
false
in clinical studies of druga , patients taking drugn concomitantly with drugn ( drugn , genentech ) , drugn , inhaled drugn , other drugn , or parenteral drugb demonstrated adverse experience profiles similar to the study population as a whole .
false
in clinical studies of drugn , patients taking druga concomitantly with drugb ( drugn , genentech ) , drugn , inhaled drugn , other drugn , or parenteral drugn demonstrated adverse experience profiles similar to the study population as a whole .
effect
in clinical studies of drugn , patients taking druga concomitantly with drugn ( drugb , genentech ) , drugn , inhaled drugn , other drugn , or parenteral drugn demonstrated adverse experience profiles similar to the study population as a whole .
effect
in clinical studies of drugn , patients taking druga concomitantly with drugn ( drugn , genentech ) , drugb , inhaled drugn , other drugn , or parenteral drugn demonstrated adverse experience profiles similar to the study population as a whole .
effect
in clinical studies of drugn , patients taking druga concomitantly with drugn ( drugn , genentech ) , drugn , inhaled drugb , other drugn , or parenteral drugn demonstrated adverse experience profiles similar to the study population as a whole .
effect
in clinical studies of drugn , patients taking druga concomitantly with drugn ( drugn , genentech ) , drugn , inhaled drugn , other drugb , or parenteral drugn demonstrated adverse experience profiles similar to the study population as a whole .
effect
in clinical studies of drugn , patients taking druga concomitantly with drugn ( drugn , genentech ) , drugn , inhaled drugn , other drugn , or parenteral drugb demonstrated adverse experience profiles similar to the study population as a whole .
effect
in clinical studies of drugn , patients taking drugn concomitantly with druga ( drugb , genentech ) , drugn , inhaled drugn , other drugn , or parenteral drugn demonstrated adverse experience profiles similar to the study population as a whole .
false
in clinical studies of drugn , patients taking drugn concomitantly with druga ( drugn , genentech ) , drugb , inhaled drugn , other drugn , or parenteral drugn demonstrated adverse experience profiles similar to the study population as a whole .
false
in clinical studies of drugn , patients taking drugn concomitantly with druga ( drugn , genentech ) , drugn , inhaled drugb , other drugn , or parenteral drugn demonstrated adverse experience profiles similar to the study population as a whole .
false
in clinical studies of drugn , patients taking drugn concomitantly with druga ( drugn , genentech ) , drugn , inhaled drugn , other drugb , or parenteral drugn demonstrated adverse experience profiles similar to the study population as a whole .
false
in clinical studies of drugn , patients taking drugn concomitantly with druga ( drugn , genentech ) , drugn , inhaled drugn , other drugn , or parenteral drugb demonstrated adverse experience profiles similar to the study population as a whole .
false
in clinical studies of drugn , patients taking drugn concomitantly with drugn ( druga , genentech ) , drugb , inhaled drugn , other drugn , or parenteral drugn demonstrated adverse experience profiles similar to the study population as a whole .
false
in clinical studies of drugn , patients taking drugn concomitantly with drugn ( druga , genentech ) , drugn , inhaled drugb , other drugn , or parenteral drugn demonstrated adverse experience profiles similar to the study population as a whole .
false
in clinical studies of drugn , patients taking drugn concomitantly with drugn ( druga , genentech ) , drugn , inhaled drugn , other drugb , or parenteral drugn demonstrated adverse experience profiles similar to the study population as a whole .
false
in clinical studies of drugn , patients taking drugn concomitantly with drugn ( druga , genentech ) , drugn , inhaled drugn , other drugn , or parenteral drugb demonstrated adverse experience profiles similar to the study population as a whole .
false
in clinical studies of drugn , patients taking drugn concomitantly with drugn ( drugn , genentech ) , druga , inhaled drugb , other drugn , or parenteral drugn demonstrated adverse experience profiles similar to the study population as a whole .
false
in clinical studies of drugn , patients taking drugn concomitantly with drugn ( drugn , genentech ) , druga , inhaled drugn , other drugb , or parenteral drugn demonstrated adverse experience profiles similar to the study population as a whole .
false
in clinical studies of drugn , patients taking drugn concomitantly with drugn ( drugn , genentech ) , druga , inhaled drugn , other drugn , or parenteral drugb demonstrated adverse experience profiles similar to the study population as a whole .
false
in clinical studies of drugn , patients taking drugn concomitantly with drugn ( drugn , genentech ) , drugn , inhaled druga , other drugb , or parenteral drugn demonstrated adverse experience profiles similar to the study population as a whole .
false
in clinical studies of drugn , patients taking drugn concomitantly with drugn ( drugn , genentech ) , drugn , inhaled druga , other drugn , or parenteral drugb demonstrated adverse experience profiles similar to the study population as a whole .
false
in clinical studies of drugn , patients taking drugn concomitantly with drugn ( drugn , genentech ) , drugn , inhaled drugn , other druga , or parenteral drugb demonstrated adverse experience profiles similar to the study population as a whole .
false
some druga can enhance drugb toxicity by altering drugn concentrations in serum and tissue .
effect
some druga can enhance drugn toxicity by altering drugb concentrations in serum and tissue .
false
some drugn can enhance druga toxicity by altering drugb concentrations in serum and tissue .
false
druga should not be administered concomitantly with drugb , drugn , drugn , or drugn .
advise
druga should not be administered concomitantly with drugn , drugb , drugn , or drugn .
advise
druga should not be administered concomitantly with drugn , drugn , drugb , or drugn .
advise
druga should not be administered concomitantly with drugn , drugn , drugn , or drugb .
advise
drugn should not be administered concomitantly with druga , drugb , drugn , or drugn .
false
drugn should not be administered concomitantly with druga , drugn , drugb , or drugn .
false
drugn should not be administered concomitantly with druga , drugn , drugn , or drugb .
false
drugn should not be administered concomitantly with drugn , druga , drugb , or drugn .
false
drugn should not be administered concomitantly with drugn , druga , drugn , or drugb .
false
drugn should not be administered concomitantly with drugn , drugn , druga , or drugb .
false
concomitant use of druga with drugb may result in an adverse drug interaction .
int
an inhibitor of cyp2c8 ( such as druga ) may increase the auc of drugb and an inducer of cyp2c8 ( such as drugn ) may decrease the auc of drugn .
mechanism
an inhibitor of cyp2c8 ( such as druga ) may increase the auc of drugn and an inducer of cyp2c8 ( such as drugb ) may decrease the auc of drugn .
false
an inhibitor of cyp2c8 ( such as druga ) may increase the auc of drugn and an inducer of cyp2c8 ( such as drugn ) may decrease the auc of drugb .
false
an inhibitor of cyp2c8 ( such as drugn ) may increase the auc of druga and an inducer of cyp2c8 ( such as drugb ) may decrease the auc of drugn .
false
an inhibitor of cyp2c8 ( such as drugn ) may increase the auc of druga and an inducer of cyp2c8 ( such as drugn ) may decrease the auc of drugb .
false
an inhibitor of cyp2c8 ( such as drugn ) may increase the auc of drugn and an inducer of cyp2c8 ( such as druga ) may decrease the auc of drugb .
mechanism
drug interactions there are no known drug/drug interactions with oral druga vaccinations with drugb are not recommended in immunocompromised individuals drugn together with high-dose intravenous drugn has caused deaths in children due to haemorrhagic enterocolitis .
false
drug interactions there are no known drug/drug interactions with oral druga vaccinations with drugn are not recommended in immunocompromised individuals drugb together with high-dose intravenous drugn has caused deaths in children due to haemorrhagic enterocolitis .
false
drug interactions there are no known drug/drug interactions with oral druga vaccinations with drugn are not recommended in immunocompromised individuals drugn together with high-dose intravenous drugb has caused deaths in children due to haemorrhagic enterocolitis .
false
drug interactions there are no known drug/drug interactions with oral drugn vaccinations with druga are not recommended in immunocompromised individuals drugb together with high-dose intravenous drugn has caused deaths in children due to haemorrhagic enterocolitis .
false
drug interactions there are no known drug/drug interactions with oral drugn vaccinations with druga are not recommended in immunocompromised individuals drugn together with high-dose intravenous drugb has caused deaths in children due to haemorrhagic enterocolitis .
false
drug interactions there are no known drug/drug interactions with oral drugn vaccinations with drugn are not recommended in immunocompromised individuals druga together with high-dose intravenous drugb has caused deaths in children due to haemorrhagic enterocolitis .
effect
impaired renal function has been described in bone marrow transplant patients who were conditioned with high-dose intravenous druga and who subsequently received drugb to prevent graft-versus-host disease
effect
the in vitro binding of druga to human plasma proteins is unaffected by drugb , and drugn does not alter the prothrombin time of normal volunteers .
false
the in vitro binding of druga to human plasma proteins is unaffected by drugn , and drugb does not alter the prothrombin time of normal volunteers .
false
the in vitro binding of drugn to human plasma proteins is unaffected by druga , and drugb does not alter the prothrombin time of normal volunteers .
false
however , increased prothrombin time and bleeding have been reported in patients on concomitant druga and drugb therapy .
effect
therefore , caution should be exercised when administering druga to patients on drugb .
advise
in adult diabetic patients under treatment with either druga or drugb there is no change in the clinical effects of either drugn or the drugn .
false
in adult diabetic patients under treatment with either druga or drugn there is no change in the clinical effects of either drugb or the drugn .
false
in adult diabetic patients under treatment with either druga or drugn there is no change in the clinical effects of either drugn or the drugb .
false
in adult diabetic patients under treatment with either drugn or druga there is no change in the clinical effects of either drugb or the drugn .
false
in adult diabetic patients under treatment with either drugn or druga there is no change in the clinical effects of either drugn or the drugb .
false
in adult diabetic patients under treatment with either drugn or drugn there is no change in the clinical effects of either druga or the drugb .
false
caution should be used if druga is administered concomitantly with drugb .
advise
druga and other drugb have been reported to reduce the tubular secretion of drugn in an animal model , possibly enhancing the toxicity of drugn .
false
druga and other drugn have been reported to reduce the tubular secretion of drugb in an animal model , possibly enhancing the toxicity of drugn .
mechanism
druga and other drugn have been reported to reduce the tubular secretion of drugn in an animal model , possibly enhancing the toxicity of drugb .
false
drugn and other druga have been reported to reduce the tubular secretion of drugb in an animal model , possibly enhancing the toxicity of drugn .
mechanism
drugn and other druga have been reported to reduce the tubular secretion of drugn in an animal model , possibly enhancing the toxicity of drugb .
false
drugn and other drugn have been reported to reduce the tubular secretion of druga in an animal model , possibly enhancing the toxicity of drugb .
false
druga may enhance the sedative effects of drugb including drugn , drugn , drugn , drugn , drugn , and drugn .
effect
druga may enhance the sedative effects of drugn including drugb , drugn , drugn , drugn , drugn , and drugn .
effect
druga may enhance the sedative effects of drugn including drugn , drugb , drugn , drugn , drugn , and drugn .
effect
druga may enhance the sedative effects of drugn including drugn , drugn , drugb , drugn , drugn , and drugn .
effect
druga may enhance the sedative effects of drugn including drugn , drugn , drugn , drugb , drugn , and drugn .
effect
druga may enhance the sedative effects of drugn including drugn , drugn , drugn , drugn , drugb , and drugn .
effect
druga may enhance the sedative effects of drugn including drugn , drugn , drugn , drugn , drugn , and drugb .
effect
drugn may enhance the sedative effects of druga including drugb , drugn , drugn , drugn , drugn , and drugn .
false
drugn may enhance the sedative effects of druga including drugn , drugb , drugn , drugn , drugn , and drugn .
false
drugn may enhance the sedative effects of druga including drugn , drugn , drugb , drugn , drugn , and drugn .
false
drugn may enhance the sedative effects of druga including drugn , drugn , drugn , drugb , drugn , and drugn .
false
drugn may enhance the sedative effects of druga including drugn , drugn , drugn , drugn , drugb , and drugn .
false
drugn may enhance the sedative effects of druga including drugn , drugn , drugn , drugn , drugn , and drugb .
false
drugn may enhance the sedative effects of drugn including druga , drugb , drugn , drugn , drugn , and drugn .
false
drugn may enhance the sedative effects of drugn including druga , drugn , drugb , drugn , drugn , and drugn .
false
drugn may enhance the sedative effects of drugn including druga , drugn , drugn , drugb , drugn , and drugn .
false
drugn may enhance the sedative effects of drugn including druga , drugn , drugn , drugn , drugb , and drugn .
false
drugn may enhance the sedative effects of drugn including druga , drugn , drugn , drugn , drugn , and drugb .
false
drugn may enhance the sedative effects of drugn including drugn , druga , drugb , drugn , drugn , and drugn .
false
drugn may enhance the sedative effects of drugn including drugn , druga , drugn , drugb , drugn , and drugn .
false
drugn may enhance the sedative effects of drugn including drugn , druga , drugn , drugn , drugb , and drugn .
false
drugn may enhance the sedative effects of drugn including drugn , druga , drugn , drugn , drugn , and drugb .
false
drugn may enhance the sedative effects of drugn including drugn , drugn , druga , drugb , drugn , and drugn .
false
drugn may enhance the sedative effects of drugn including drugn , drugn , druga , drugn , drugb , and drugn .
false
drugn may enhance the sedative effects of drugn including drugn , drugn , druga , drugn , drugn , and drugb .
false
drugn may enhance the sedative effects of drugn including drugn , drugn , drugn , druga , drugb , and drugn .
false
drugn may enhance the sedative effects of drugn including drugn , drugn , drugn , druga , drugn , and drugb .
false
drugn may enhance the sedative effects of drugn including drugn , drugn , drugn , drugn , druga , and drugb .
false
the effects of druga , such as drugb and drugn may be enhanced by the concomitant administration of drugn .
false
the effects of druga , such as drugn and drugb may be enhanced by the concomitant administration of drugn .
false
the effects of druga , such as drugn and drugn may be enhanced by the concomitant administration of drugb .
effect
the effects of drugn , such as druga and drugb may be enhanced by the concomitant administration of drugn .
false
the effects of drugn , such as druga and drugn may be enhanced by the concomitant administration of drugb .
effect
the effects of drugn , such as drugn and druga may be enhanced by the concomitant administration of drugb .
effect
druga and other drugb will be additive to drugn and may increase plasma concentrations of drugn to toxic levels .
false
druga and other drugn will be additive to drugb and may increase plasma concentrations of drugn to toxic levels .
effect
druga and other drugn will be additive to drugn and may increase plasma concentrations of drugb to toxic levels .
false
drugn and other druga will be additive to drugb and may increase plasma concentrations of drugn to toxic levels .
effect
drugn and other druga will be additive to drugn and may increase plasma concentrations of drugb to toxic levels .
false
drugn and other drugn will be additive to druga and may increase plasma concentrations of drugb to toxic levels .
false
druga given concomitantly with drugb may predispose to systemic bleeding .
effect
druga may enhance the hypoglycemic effect of oral drugb of the sulfonylurea class .
effect
druga competes with a number of drugs for protein binding sites , notably drugb , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , and possibly drugn .
mechanism
druga competes with a number of drugs for protein binding sites , notably drugn , drugb , drugn , drugn , drugn , drugn , drugn , drugn , drugn , and possibly drugn .
mechanism
druga competes with a number of drugs for protein binding sites , notably drugn , drugn , drugb , drugn , drugn , drugn , drugn , drugn , drugn , and possibly drugn .
mechanism
druga competes with a number of drugs for protein binding sites , notably drugn , drugn , drugn , drugb , drugn , drugn , drugn , drugn , drugn , and possibly drugn .
mechanism
druga competes with a number of drugs for protein binding sites , notably drugn , drugn , drugn , drugn , drugb , drugn , drugn , drugn , drugn , and possibly drugn .
mechanism
druga competes with a number of drugs for protein binding sites , notably drugn , drugn , drugn , drugn , drugn , drugb , drugn , drugn , drugn , and possibly drugn .
mechanism
druga competes with a number of drugs for protein binding sites , notably drugn , drugn , drugn , drugn , drugn , drugn , drugb , drugn , drugn , and possibly drugn .
mechanism
druga competes with a number of drugs for protein binding sites , notably drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugb , drugn , and possibly drugn .
mechanism
druga competes with a number of drugs for protein binding sites , notably drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugb , and possibly drugn .
mechanism
druga competes with a number of drugs for protein binding sites , notably drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , and possibly drugb .
mechanism
drugn competes with a number of drugs for protein binding sites , notably druga , drugb , drugn , drugn , drugn , drugn , drugn , drugn , drugn , and possibly drugn .
false
drugn competes with a number of drugs for protein binding sites , notably druga , drugn , drugb , drugn , drugn , drugn , drugn , drugn , drugn , and possibly drugn .
false
drugn competes with a number of drugs for protein binding sites , notably druga , drugn , drugn , drugb , drugn , drugn , drugn , drugn , drugn , and possibly drugn .
false
drugn competes with a number of drugs for protein binding sites , notably druga , drugn , drugn , drugn , drugb , drugn , drugn , drugn , drugn , and possibly drugn .
false
drugn competes with a number of drugs for protein binding sites , notably druga , drugn , drugn , drugn , drugn , drugb , drugn , drugn , drugn , and possibly drugn .
false
drugn competes with a number of drugs for protein binding sites , notably druga , drugn , drugn , drugn , drugn , drugn , drugb , drugn , drugn , and possibly drugn .
false
drugn competes with a number of drugs for protein binding sites , notably druga , drugn , drugn , drugn , drugn , drugn , drugn , drugb , drugn , and possibly drugn .
false
drugn competes with a number of drugs for protein binding sites , notably druga , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugb , and possibly drugn .
false
drugn competes with a number of drugs for protein binding sites , notably druga , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , and possibly drugb .
false
drugn competes with a number of drugs for protein binding sites , notably drugn , druga , drugb , drugn , drugn , drugn , drugn , drugn , drugn , and possibly drugn .
false
drugn competes with a number of drugs for protein binding sites , notably drugn , druga , drugn , drugb , drugn , drugn , drugn , drugn , drugn , and possibly drugn .
false
drugn competes with a number of drugs for protein binding sites , notably drugn , druga , drugn , drugn , drugb , drugn , drugn , drugn , drugn , and possibly drugn .
false
drugn competes with a number of drugs for protein binding sites , notably drugn , druga , drugn , drugn , drugn , drugb , drugn , drugn , drugn , and possibly drugn .
false
drugn competes with a number of drugs for protein binding sites , notably drugn , druga , drugn , drugn , drugn , drugn , drugb , drugn , drugn , and possibly drugn .
false
drugn competes with a number of drugs for protein binding sites , notably drugn , druga , drugn , drugn , drugn , drugn , drugn , drugb , drugn , and possibly drugn .
false
drugn competes with a number of drugs for protein binding sites , notably drugn , druga , drugn , drugn , drugn , drugn , drugn , drugn , drugb , and possibly drugn .
false
drugn competes with a number of drugs for protein binding sites , notably drugn , druga , drugn , drugn , drugn , drugn , drugn , drugn , drugn , and possibly drugb .
false
drugn competes with a number of drugs for protein binding sites , notably drugn , drugn , druga , drugb , drugn , drugn , drugn , drugn , drugn , and possibly drugn .
false
drugn competes with a number of drugs for protein binding sites , notably drugn , drugn , druga , drugn , drugb , drugn , drugn , drugn , drugn , and possibly drugn .
false
drugn competes with a number of drugs for protein binding sites , notably drugn , drugn , druga , drugn , drugn , drugb , drugn , drugn , drugn , and possibly drugn .
false
drugn competes with a number of drugs for protein binding sites , notably drugn , drugn , druga , drugn , drugn , drugn , drugb , drugn , drugn , and possibly drugn .
false
drugn competes with a number of drugs for protein binding sites , notably drugn , drugn , druga , drugn , drugn , drugn , drugn , drugb , drugn , and possibly drugn .
false
drugn competes with a number of drugs for protein binding sites , notably drugn , drugn , druga , drugn , drugn , drugn , drugn , drugn , drugb , and possibly drugn .
false
drugn competes with a number of drugs for protein binding sites , notably drugn , drugn , druga , drugn , drugn , drugn , drugn , drugn , drugn , and possibly drugb .
false
drugn competes with a number of drugs for protein binding sites , notably drugn , drugn , drugn , druga , drugb , drugn , drugn , drugn , drugn , and possibly drugn .
false
drugn competes with a number of drugs for protein binding sites , notably drugn , drugn , drugn , druga , drugn , drugb , drugn , drugn , drugn , and possibly drugn .
false
drugn competes with a number of drugs for protein binding sites , notably drugn , drugn , drugn , druga , drugn , drugn , drugb , drugn , drugn , and possibly drugn .
false
drugn competes with a number of drugs for protein binding sites , notably drugn , drugn , drugn , druga , drugn , drugn , drugn , drugb , drugn , and possibly drugn .
false
drugn competes with a number of drugs for protein binding sites , notably drugn , drugn , drugn , druga , drugn , drugn , drugn , drugn , drugb , and possibly drugn .
false
drugn competes with a number of drugs for protein binding sites , notably drugn , drugn , drugn , druga , drugn , drugn , drugn , drugn , drugn , and possibly drugb .
false
drugn competes with a number of drugs for protein binding sites , notably drugn , drugn , drugn , drugn , druga , drugb , drugn , drugn , drugn , and possibly drugn .
false
drugn competes with a number of drugs for protein binding sites , notably drugn , drugn , drugn , drugn , druga , drugn , drugb , drugn , drugn , and possibly drugn .
false
drugn competes with a number of drugs for protein binding sites , notably drugn , drugn , drugn , drugn , druga , drugn , drugn , drugb , drugn , and possibly drugn .
false
drugn competes with a number of drugs for protein binding sites , notably drugn , drugn , drugn , drugn , druga , drugn , drugn , drugn , drugb , and possibly drugn .
false
drugn competes with a number of drugs for protein binding sites , notably drugn , drugn , drugn , drugn , druga , drugn , drugn , drugn , drugn , and possibly drugb .
false
drugn competes with a number of drugs for protein binding sites , notably drugn , drugn , drugn , drugn , drugn , druga , drugb , drugn , drugn , and possibly drugn .
false
drugn competes with a number of drugs for protein binding sites , notably drugn , drugn , drugn , drugn , drugn , druga , drugn , drugb , drugn , and possibly drugn .
false
drugn competes with a number of drugs for protein binding sites , notably drugn , drugn , drugn , drugn , drugn , druga , drugn , drugn , drugb , and possibly drugn .
false
drugn competes with a number of drugs for protein binding sites , notably drugn , drugn , drugn , drugn , drugn , druga , drugn , drugn , drugn , and possibly drugb .
false
drugn competes with a number of drugs for protein binding sites , notably drugn , drugn , drugn , drugn , drugn , drugn , druga , drugb , drugn , and possibly drugn .
false
drugn competes with a number of drugs for protein binding sites , notably drugn , drugn , drugn , drugn , drugn , drugn , druga , drugn , drugb , and possibly drugn .
false
drugn competes with a number of drugs for protein binding sites , notably drugn , drugn , drugn , drugn , drugn , drugn , druga , drugn , drugn , and possibly drugb .
false
drugn competes with a number of drugs for protein binding sites , notably drugn , drugn , drugn , drugn , drugn , drugn , drugn , druga , drugb , and possibly drugn .
false
drugn competes with a number of drugs for protein binding sites , notably drugn , drugn , drugn , drugn , drugn , drugn , drugn , druga , drugn , and possibly drugb .
false
drugn competes with a number of drugs for protein binding sites , notably drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , druga , and possibly drugb .
false
druga may increase the effects of drugb , drugn , and drugn .
effect
druga may increase the effects of drugn , drugb , and drugn .
effect
druga may increase the effects of drugn , drugn , and drugb .
effect
drugn may increase the effects of druga , drugb , and drugn .
false
drugn may increase the effects of druga , drugn , and drugb .
false
drugn may increase the effects of drugn , druga , and drugb .
false
it may also interact with druga ( increased thrombocytopenia ) , drugb ( increased nephrotoxicity ) , drugn ( increased hypoglycemic response ) , drugn ( increased anticoagulant effect ) , drugn ( decreased renal excretion of drugn ) , drugn ( decreased hepatic clearance of drugn ) .
false
it may also interact with druga ( increased thrombocytopenia ) , drugn ( increased nephrotoxicity ) , drugb ( increased hypoglycemic response ) , drugn ( increased anticoagulant effect ) , drugn ( decreased renal excretion of drugn ) , drugn ( decreased hepatic clearance of drugn ) .
false
it may also interact with druga ( increased thrombocytopenia ) , drugn ( increased nephrotoxicity ) , drugn ( increased hypoglycemic response ) , drugb ( increased anticoagulant effect ) , drugn ( decreased renal excretion of drugn ) , drugn ( decreased hepatic clearance of drugn ) .
false
it may also interact with druga ( increased thrombocytopenia ) , drugn ( increased nephrotoxicity ) , drugn ( increased hypoglycemic response ) , drugn ( increased anticoagulant effect ) , drugb ( decreased renal excretion of drugn ) , drugn ( decreased hepatic clearance of drugn ) .
false
it may also interact with druga ( increased thrombocytopenia ) , drugn ( increased nephrotoxicity ) , drugn ( increased hypoglycemic response ) , drugn ( increased anticoagulant effect ) , drugn ( decreased renal excretion of drugb ) , drugn ( decreased hepatic clearance of drugn ) .
false
it may also interact with druga ( increased thrombocytopenia ) , drugn ( increased nephrotoxicity ) , drugn ( increased hypoglycemic response ) , drugn ( increased anticoagulant effect ) , drugn ( decreased renal excretion of drugn ) , drugb ( decreased hepatic clearance of drugn ) .
false
it may also interact with druga ( increased thrombocytopenia ) , drugn ( increased nephrotoxicity ) , drugn ( increased hypoglycemic response ) , drugn ( increased anticoagulant effect ) , drugn ( decreased renal excretion of drugn ) , drugn ( decreased hepatic clearance of drugb ) .
false
it may also interact with drugn ( increased thrombocytopenia ) , druga ( increased nephrotoxicity ) , drugb ( increased hypoglycemic response ) , drugn ( increased anticoagulant effect ) , drugn ( decreased renal excretion of drugn ) , drugn ( decreased hepatic clearance of drugn ) .
false
it may also interact with drugn ( increased thrombocytopenia ) , druga ( increased nephrotoxicity ) , drugn ( increased hypoglycemic response ) , drugb ( increased anticoagulant effect ) , drugn ( decreased renal excretion of drugn ) , drugn ( decreased hepatic clearance of drugn ) .
false
it may also interact with drugn ( increased thrombocytopenia ) , druga ( increased nephrotoxicity ) , drugn ( increased hypoglycemic response ) , drugn ( increased anticoagulant effect ) , drugb ( decreased renal excretion of drugn ) , drugn ( decreased hepatic clearance of drugn ) .
false
it may also interact with drugn ( increased thrombocytopenia ) , druga ( increased nephrotoxicity ) , drugn ( increased hypoglycemic response ) , drugn ( increased anticoagulant effect ) , drugn ( decreased renal excretion of drugb ) , drugn ( decreased hepatic clearance of drugn ) .
false
it may also interact with drugn ( increased thrombocytopenia ) , druga ( increased nephrotoxicity ) , drugn ( increased hypoglycemic response ) , drugn ( increased anticoagulant effect ) , drugn ( decreased renal excretion of drugn ) , drugb ( decreased hepatic clearance of drugn ) .
false
it may also interact with drugn ( increased thrombocytopenia ) , druga ( increased nephrotoxicity ) , drugn ( increased hypoglycemic response ) , drugn ( increased anticoagulant effect ) , drugn ( decreased renal excretion of drugn ) , drugn ( decreased hepatic clearance of drugb ) .
false
it may also interact with drugn ( increased thrombocytopenia ) , drugn ( increased nephrotoxicity ) , druga ( increased hypoglycemic response ) , drugb ( increased anticoagulant effect ) , drugn ( decreased renal excretion of drugn ) , drugn ( decreased hepatic clearance of drugn ) .
false
it may also interact with drugn ( increased thrombocytopenia ) , drugn ( increased nephrotoxicity ) , druga ( increased hypoglycemic response ) , drugn ( increased anticoagulant effect ) , drugb ( decreased renal excretion of drugn ) , drugn ( decreased hepatic clearance of drugn ) .
false
it may also interact with drugn ( increased thrombocytopenia ) , drugn ( increased nephrotoxicity ) , druga ( increased hypoglycemic response ) , drugn ( increased anticoagulant effect ) , drugn ( decreased renal excretion of drugb ) , drugn ( decreased hepatic clearance of drugn ) .
false
it may also interact with drugn ( increased thrombocytopenia ) , drugn ( increased nephrotoxicity ) , druga ( increased hypoglycemic response ) , drugn ( increased anticoagulant effect ) , drugn ( decreased renal excretion of drugn ) , drugb ( decreased hepatic clearance of drugn ) .
false
it may also interact with drugn ( increased thrombocytopenia ) , drugn ( increased nephrotoxicity ) , druga ( increased hypoglycemic response ) , drugn ( increased anticoagulant effect ) , drugn ( decreased renal excretion of drugn ) , drugn ( decreased hepatic clearance of drugb ) .
false
it may also interact with drugn ( increased thrombocytopenia ) , drugn ( increased nephrotoxicity ) , drugn ( increased hypoglycemic response ) , druga ( increased anticoagulant effect ) , drugb ( decreased renal excretion of drugn ) , drugn ( decreased hepatic clearance of drugn ) .
false
it may also interact with drugn ( increased thrombocytopenia ) , drugn ( increased nephrotoxicity ) , drugn ( increased hypoglycemic response ) , druga ( increased anticoagulant effect ) , drugn ( decreased renal excretion of drugb ) , drugn ( decreased hepatic clearance of drugn ) .
false
it may also interact with drugn ( increased thrombocytopenia ) , drugn ( increased nephrotoxicity ) , drugn ( increased hypoglycemic response ) , druga ( increased anticoagulant effect ) , drugn ( decreased renal excretion of drugn ) , drugb ( decreased hepatic clearance of drugn ) .
false
it may also interact with drugn ( increased thrombocytopenia ) , drugn ( increased nephrotoxicity ) , drugn ( increased hypoglycemic response ) , druga ( increased anticoagulant effect ) , drugn ( decreased renal excretion of drugn ) , drugn ( decreased hepatic clearance of drugb ) .
false
it may also interact with drugn ( increased thrombocytopenia ) , drugn ( increased nephrotoxicity ) , drugn ( increased hypoglycemic response ) , drugn ( increased anticoagulant effect ) , druga ( decreased renal excretion of drugb ) , drugn ( decreased hepatic clearance of drugn ) .
false
it may also interact with drugn ( increased thrombocytopenia ) , drugn ( increased nephrotoxicity ) , drugn ( increased hypoglycemic response ) , drugn ( increased anticoagulant effect ) , druga ( decreased renal excretion of drugn ) , drugb ( decreased hepatic clearance of drugn ) .
false
it may also interact with drugn ( increased thrombocytopenia ) , drugn ( increased nephrotoxicity ) , drugn ( increased hypoglycemic response ) , drugn ( increased anticoagulant effect ) , druga ( decreased renal excretion of drugn ) , drugn ( decreased hepatic clearance of drugb ) .
false
it may also interact with drugn ( increased thrombocytopenia ) , drugn ( increased nephrotoxicity ) , drugn ( increased hypoglycemic response ) , drugn ( increased anticoagulant effect ) , drugn ( decreased renal excretion of druga ) , drugb ( decreased hepatic clearance of drugn ) .
false
it may also interact with drugn ( increased thrombocytopenia ) , drugn ( increased nephrotoxicity ) , drugn ( increased hypoglycemic response ) , drugn ( increased anticoagulant effect ) , drugn ( decreased renal excretion of druga ) , drugn ( decreased hepatic clearance of drugb ) .
false
it may also interact with drugn ( increased thrombocytopenia ) , drugn ( increased nephrotoxicity ) , drugn ( increased hypoglycemic response ) , drugn ( increased anticoagulant effect ) , drugn ( decreased renal excretion of drugn ) , druga ( decreased hepatic clearance of drugb ) .
false
co-administration of oral druga 200 mg twice daily increased drugb geometric mean auc ( 0-24 ) and cmax by 81 % after topical application of drugn ointment , 1 % on the abraded skin of healthy adult males .
false
co-administration of oral druga 200 mg twice daily increased drugn geometric mean auc ( 0-24 ) and cmax by 81 % after topical application of drugb ointment , 1 % on the abraded skin of healthy adult males .
mechanism
co-administration of oral drugn 200 mg twice daily increased druga geometric mean auc ( 0-24 ) and cmax by 81 % after topical application of drugb ointment , 1 % on the abraded skin of healthy adult males .
false
due to low systemic exposure to druga following topical application in patients , dosage adjustments for drugb are unnecessary when co-administered with cyp3a4 inhibitors , such as drugn .
false
due to low systemic exposure to druga following topical application in patients , dosage adjustments for drugn are unnecessary when co-administered with cyp3a4 inhibitors , such as drugb .
false
due to low systemic exposure to drugn following topical application in patients , dosage adjustments for druga are unnecessary when co-administered with cyp3a4 inhibitors , such as drugb .
false
based on in vitro p450 inhibition studies and the low systemic exposure observed following topical application of druga , drugb is unlikely to affect the metabolism of other p450 substrates .
false
concurrent use of druga and other drugb may increase the cns depressant effects of drugn or these other medications .
false
concurrent use of druga and other drugn may increase the cns depressant effects of drugb or these other medications .
effect
concurrent use of drugn and other druga may increase the cns depressant effects of drugb or these other medications .
effect
druga competitively inhibits the intracellular phosphorylation of drugb .
effect
therefore , use of druga in combination with drugb should be avoided .
advise
in vitro data indicate that the phosphorylation of druga is also inhibited at relevant concentrations by drugb and drugn .
effect
in vitro data indicate that the phosphorylation of druga is also inhibited at relevant concentrations by drugn and drugb .
effect
in vitro data indicate that the phosphorylation of drugn is also inhibited at relevant concentrations by druga and drugb .
false
the induction dose requirements of druga injectable emulsion may be reduced in patients with intramuscular or intravenous premedication , particularly with drugb ( eg , drugn , drugn , and drugn , etc . )
effect
the induction dose requirements of druga injectable emulsion may be reduced in patients with intramuscular or intravenous premedication , particularly with drugn ( eg , drugb , drugn , and drugn , etc . )
effect
the induction dose requirements of druga injectable emulsion may be reduced in patients with intramuscular or intravenous premedication , particularly with drugn ( eg , drugn , drugb , and drugn , etc . )
effect
the induction dose requirements of druga injectable emulsion may be reduced in patients with intramuscular or intravenous premedication , particularly with drugn ( eg , drugn , drugn , and drugb , etc . )
effect
the induction dose requirements of drugn injectable emulsion may be reduced in patients with intramuscular or intravenous premedication , particularly with druga ( eg , drugb , drugn , and drugn , etc . )
false
the induction dose requirements of drugn injectable emulsion may be reduced in patients with intramuscular or intravenous premedication , particularly with druga ( eg , drugn , drugb , and drugn , etc . )
false
the induction dose requirements of drugn injectable emulsion may be reduced in patients with intramuscular or intravenous premedication , particularly with druga ( eg , drugn , drugn , and drugb , etc . )
false
the induction dose requirements of drugn injectable emulsion may be reduced in patients with intramuscular or intravenous premedication , particularly with drugn ( eg , druga , drugb , and drugn , etc . )
false
the induction dose requirements of drugn injectable emulsion may be reduced in patients with intramuscular or intravenous premedication , particularly with drugn ( eg , druga , drugn , and drugb , etc . )
false
the induction dose requirements of drugn injectable emulsion may be reduced in patients with intramuscular or intravenous premedication , particularly with drugn ( eg , drugn , druga , and drugb , etc . )
false
and combinations of druga and drugb ( eg , drugn , drugn , drugn , drugn , etc . ) .
false
and combinations of druga and drugn ( eg , drugb , drugn , drugn , drugn , etc . ) .
false
and combinations of druga and drugn ( eg , drugn , drugb , drugn , drugn , etc . ) .
false
and combinations of druga and drugn ( eg , drugn , drugn , drugb , drugn , etc . ) .
false
and combinations of druga and drugn ( eg , drugn , drugn , drugn , drugb , etc . ) .
false
and combinations of drugn and druga ( eg , drugb , drugn , drugn , drugn , etc . ) .
false
and combinations of drugn and druga ( eg , drugn , drugb , drugn , drugn , etc . ) .
false
and combinations of drugn and druga ( eg , drugn , drugn , drugb , drugn , etc . ) .
false
and combinations of drugn and druga ( eg , drugn , drugn , drugn , drugb , etc . ) .
false
and combinations of drugn and drugn ( eg , druga , drugb , drugn , drugn , etc . ) .
false
and combinations of drugn and drugn ( eg , druga , drugn , drugb , drugn , etc . ) .
false
and combinations of drugn and drugn ( eg , druga , drugn , drugn , drugb , etc . ) .
false
and combinations of drugn and drugn ( eg , drugn , druga , drugb , drugn , etc . ) .
false
and combinations of drugn and drugn ( eg , drugn , druga , drugn , drugb , etc . ) .
false
and combinations of drugn and drugn ( eg , drugn , drugn , druga , drugb , etc . ) .
false
during maintenance of anesthesia or sedation , the rate of druga injectable emulsion administration should be adjusted according to the desired level of anesthesia or sedation and may be reduced in the presence of supplemental drugb ( eg , drugn or drugn ) .
advise
during maintenance of anesthesia or sedation , the rate of druga injectable emulsion administration should be adjusted according to the desired level of anesthesia or sedation and may be reduced in the presence of supplemental drugn ( eg , drugb or drugn ) .
advise
during maintenance of anesthesia or sedation , the rate of druga injectable emulsion administration should be adjusted according to the desired level of anesthesia or sedation and may be reduced in the presence of supplemental drugn ( eg , drugn or drugb ) .
advise
during maintenance of anesthesia or sedation , the rate of drugn injectable emulsion administration should be adjusted according to the desired level of anesthesia or sedation and may be reduced in the presence of supplemental druga ( eg , drugb or drugn ) .
false
during maintenance of anesthesia or sedation , the rate of drugn injectable emulsion administration should be adjusted according to the desired level of anesthesia or sedation and may be reduced in the presence of supplemental druga ( eg , drugn or drugb ) .
false
during maintenance of anesthesia or sedation , the rate of drugn injectable emulsion administration should be adjusted according to the desired level of anesthesia or sedation and may be reduced in the presence of supplemental drugn ( eg , druga or drugb ) .
false
the concurrent administration of potent inhalational agents ( eg , druga , drugb , and drugn ) during maintenance with drugn injectable emulsion has not been extensively evaluated .
false
the concurrent administration of potent inhalational agents ( eg , druga , drugn , and drugb ) during maintenance with drugn injectable emulsion has not been extensively evaluated .
false
the concurrent administration of potent inhalational agents ( eg , druga , drugn , and drugn ) during maintenance with drugb injectable emulsion has not been extensively evaluated .
false
the concurrent administration of potent inhalational agents ( eg , drugn , druga , and drugb ) during maintenance with drugn injectable emulsion has not been extensively evaluated .
false
the concurrent administration of potent inhalational agents ( eg , drugn , druga , and drugn ) during maintenance with drugb injectable emulsion has not been extensively evaluated .
false
the concurrent administration of potent inhalational agents ( eg , drugn , drugn , and druga ) during maintenance with drugb injectable emulsion has not been extensively evaluated .
false
druga injectable emulsion does not cause a clinically significant change in onset , intensity , or duration of action of the commonly used drugb ( eg , drugn and drugn ) .
false
druga injectable emulsion does not cause a clinically significant change in onset , intensity , or duration of action of the commonly used drugn ( eg , drugb and drugn ) .
false
druga injectable emulsion does not cause a clinically significant change in onset , intensity , or duration of action of the commonly used drugn ( eg , drugn and drugb ) .
false
drugn injectable emulsion does not cause a clinically significant change in onset , intensity , or duration of action of the commonly used druga ( eg , drugb and drugn ) .
false
drugn injectable emulsion does not cause a clinically significant change in onset , intensity , or duration of action of the commonly used druga ( eg , drugn and drugb ) .
false
drugn injectable emulsion does not cause a clinically significant change in onset , intensity , or duration of action of the commonly used drugn ( eg , druga and drugb ) .
false
no significant adverse interactions with commonly used premedications or drugs used during anesthesia or sedation ( including a range of druga , inhalational agents , drugb , and local drugn ) have been observed .
false
no significant adverse interactions with commonly used premedications or drugs used during anesthesia or sedation ( including a range of druga , inhalational agents , drugn , and local drugb ) have been observed .
false
no significant adverse interactions with commonly used premedications or drugs used during anesthesia or sedation ( including a range of drugn , inhalational agents , druga , and local drugb ) have been observed .
false
cyp3a4 inhibitors : druga , an inhibitor of the drug metabolizing enzyme cyp3a4 , significantly increased plasma concentrations of drugb when coadministered to subjects who were poor metabolizers ( see clinical pharmacology , variability in metabolism and drug-drug interactions ) .
mechanism
for patients receiving druga or other potent cyp3a4 inhibitors such as other drugb ( eg , drugn , drugn ) or drugn ( eg , drugn , drugn ) or drugn or drugn , the recommended dose of drugn is 2 mg daily .
false
for patients receiving druga or other potent cyp3a4 inhibitors such as other drugn ( eg , drugb , drugn ) or drugn ( eg , drugn , drugn ) or drugn or drugn , the recommended dose of drugn is 2 mg daily .
false
for patients receiving druga or other potent cyp3a4 inhibitors such as other drugn ( eg , drugn , drugb ) or drugn ( eg , drugn , drugn ) or drugn or drugn , the recommended dose of drugn is 2 mg daily .
false
for patients receiving druga or other potent cyp3a4 inhibitors such as other drugn ( eg , drugn , drugn ) or drugb ( eg , drugn , drugn ) or drugn or drugn , the recommended dose of drugn is 2 mg daily .
false
for patients receiving druga or other potent cyp3a4 inhibitors such as other drugn ( eg , drugn , drugn ) or drugn ( eg , drugb , drugn ) or drugn or drugn , the recommended dose of drugn is 2 mg daily .
false
for patients receiving druga or other potent cyp3a4 inhibitors such as other drugn ( eg , drugn , drugn ) or drugn ( eg , drugn , drugb ) or drugn or drugn , the recommended dose of drugn is 2 mg daily .
false
for patients receiving druga or other potent cyp3a4 inhibitors such as other drugn ( eg , drugn , drugn ) or drugn ( eg , drugn , drugn ) or drugb or drugn , the recommended dose of drugn is 2 mg daily .
false
for patients receiving druga or other potent cyp3a4 inhibitors such as other drugn ( eg , drugn , drugn ) or drugn ( eg , drugn , drugn ) or drugn or drugb , the recommended dose of drugn is 2 mg daily .
false
for patients receiving druga or other potent cyp3a4 inhibitors such as other drugn ( eg , drugn , drugn ) or drugn ( eg , drugn , drugn ) or drugn or drugn , the recommended dose of drugb is 2 mg daily .
advise
for patients receiving drugn or other potent cyp3a4 inhibitors such as other druga ( eg , drugb , drugn ) or drugn ( eg , drugn , drugn ) or drugn or drugn , the recommended dose of drugn is 2 mg daily .
false
for patients receiving drugn or other potent cyp3a4 inhibitors such as other druga ( eg , drugn , drugb ) or drugn ( eg , drugn , drugn ) or drugn or drugn , the recommended dose of drugn is 2 mg daily .
false
for patients receiving drugn or other potent cyp3a4 inhibitors such as other druga ( eg , drugn , drugn ) or drugb ( eg , drugn , drugn ) or drugn or drugn , the recommended dose of drugn is 2 mg daily .
false
for patients receiving drugn or other potent cyp3a4 inhibitors such as other druga ( eg , drugn , drugn ) or drugn ( eg , drugb , drugn ) or drugn or drugn , the recommended dose of drugn is 2 mg daily .
false
for patients receiving drugn or other potent cyp3a4 inhibitors such as other druga ( eg , drugn , drugn ) or drugn ( eg , drugn , drugb ) or drugn or drugn , the recommended dose of drugn is 2 mg daily .
false
for patients receiving drugn or other potent cyp3a4 inhibitors such as other druga ( eg , drugn , drugn ) or drugn ( eg , drugn , drugn ) or drugb or drugn , the recommended dose of drugn is 2 mg daily .
false
for patients receiving drugn or other potent cyp3a4 inhibitors such as other druga ( eg , drugn , drugn ) or drugn ( eg , drugn , drugn ) or drugn or drugb , the recommended dose of drugn is 2 mg daily .
false
for patients receiving drugn or other potent cyp3a4 inhibitors such as other druga ( eg , drugn , drugn ) or drugn ( eg , drugn , drugn ) or drugn or drugn , the recommended dose of drugb is 2 mg daily .
advise
for patients receiving drugn or other potent cyp3a4 inhibitors such as other drugn ( eg , druga , drugb ) or drugn ( eg , drugn , drugn ) or drugn or drugn , the recommended dose of drugn is 2 mg daily .
false
for patients receiving drugn or other potent cyp3a4 inhibitors such as other drugn ( eg , druga , drugn ) or drugb ( eg , drugn , drugn ) or drugn or drugn , the recommended dose of drugn is 2 mg daily .
false
for patients receiving drugn or other potent cyp3a4 inhibitors such as other drugn ( eg , druga , drugn ) or drugn ( eg , drugb , drugn ) or drugn or drugn , the recommended dose of drugn is 2 mg daily .
false
for patients receiving drugn or other potent cyp3a4 inhibitors such as other drugn ( eg , druga , drugn ) or drugn ( eg , drugn , drugb ) or drugn or drugn , the recommended dose of drugn is 2 mg daily .
false
for patients receiving drugn or other potent cyp3a4 inhibitors such as other drugn ( eg , druga , drugn ) or drugn ( eg , drugn , drugn ) or drugb or drugn , the recommended dose of drugn is 2 mg daily .
false
for patients receiving drugn or other potent cyp3a4 inhibitors such as other drugn ( eg , druga , drugn ) or drugn ( eg , drugn , drugn ) or drugn or drugb , the recommended dose of drugn is 2 mg daily .
false
for patients receiving drugn or other potent cyp3a4 inhibitors such as other drugn ( eg , druga , drugn ) or drugn ( eg , drugn , drugn ) or drugn or drugn , the recommended dose of drugb is 2 mg daily .
advise
for patients receiving drugn or other potent cyp3a4 inhibitors such as other drugn ( eg , drugn , druga ) or drugb ( eg , drugn , drugn ) or drugn or drugn , the recommended dose of drugn is 2 mg daily .
false
for patients receiving drugn or other potent cyp3a4 inhibitors such as other drugn ( eg , drugn , druga ) or drugn ( eg , drugb , drugn ) or drugn or drugn , the recommended dose of drugn is 2 mg daily .
false
for patients receiving drugn or other potent cyp3a4 inhibitors such as other drugn ( eg , drugn , druga ) or drugn ( eg , drugn , drugb ) or drugn or drugn , the recommended dose of drugn is 2 mg daily .
false
for patients receiving drugn or other potent cyp3a4 inhibitors such as other drugn ( eg , drugn , druga ) or drugn ( eg , drugn , drugn ) or drugb or drugn , the recommended dose of drugn is 2 mg daily .
false
for patients receiving drugn or other potent cyp3a4 inhibitors such as other drugn ( eg , drugn , druga ) or drugn ( eg , drugn , drugn ) or drugn or drugb , the recommended dose of drugn is 2 mg daily .
false
for patients receiving drugn or other potent cyp3a4 inhibitors such as other drugn ( eg , drugn , druga ) or drugn ( eg , drugn , drugn ) or drugn or drugn , the recommended dose of drugb is 2 mg daily .
advise
for patients receiving drugn or other potent cyp3a4 inhibitors such as other drugn ( eg , drugn , drugn ) or druga ( eg , drugb , drugn ) or drugn or drugn , the recommended dose of drugn is 2 mg daily .
false
for patients receiving drugn or other potent cyp3a4 inhibitors such as other drugn ( eg , drugn , drugn ) or druga ( eg , drugn , drugb ) or drugn or drugn , the recommended dose of drugn is 2 mg daily .
false
for patients receiving drugn or other potent cyp3a4 inhibitors such as other drugn ( eg , drugn , drugn ) or druga ( eg , drugn , drugn ) or drugb or drugn , the recommended dose of drugn is 2 mg daily .
false
for patients receiving drugn or other potent cyp3a4 inhibitors such as other drugn ( eg , drugn , drugn ) or druga ( eg , drugn , drugn ) or drugn or drugb , the recommended dose of drugn is 2 mg daily .
false
for patients receiving drugn or other potent cyp3a4 inhibitors such as other drugn ( eg , drugn , drugn ) or druga ( eg , drugn , drugn ) or drugn or drugn , the recommended dose of drugb is 2 mg daily .
advise
for patients receiving drugn or other potent cyp3a4 inhibitors such as other drugn ( eg , drugn , drugn ) or drugn ( eg , druga , drugb ) or drugn or drugn , the recommended dose of drugn is 2 mg daily .
false
for patients receiving drugn or other potent cyp3a4 inhibitors such as other drugn ( eg , drugn , drugn ) or drugn ( eg , druga , drugn ) or drugb or drugn , the recommended dose of drugn is 2 mg daily .
false
for patients receiving drugn or other potent cyp3a4 inhibitors such as other drugn ( eg , drugn , drugn ) or drugn ( eg , druga , drugn ) or drugn or drugb , the recommended dose of drugn is 2 mg daily .
false
for patients receiving drugn or other potent cyp3a4 inhibitors such as other drugn ( eg , drugn , drugn ) or drugn ( eg , druga , drugn ) or drugn or drugn , the recommended dose of drugb is 2 mg daily .
advise
for patients receiving drugn or other potent cyp3a4 inhibitors such as other drugn ( eg , drugn , drugn ) or drugn ( eg , drugn , druga ) or drugb or drugn , the recommended dose of drugn is 2 mg daily .
false
for patients receiving drugn or other potent cyp3a4 inhibitors such as other drugn ( eg , drugn , drugn ) or drugn ( eg , drugn , druga ) or drugn or drugb , the recommended dose of drugn is 2 mg daily .
false
for patients receiving drugn or other potent cyp3a4 inhibitors such as other drugn ( eg , drugn , drugn ) or drugn ( eg , drugn , druga ) or drugn or drugn , the recommended dose of drugb is 2 mg daily .
advise
for patients receiving drugn or other potent cyp3a4 inhibitors such as other drugn ( eg , drugn , drugn ) or drugn ( eg , drugn , drugn ) or druga or drugb , the recommended dose of drugn is 2 mg daily .
false
for patients receiving drugn or other potent cyp3a4 inhibitors such as other drugn ( eg , drugn , drugn ) or drugn ( eg , drugn , drugn ) or druga or drugn , the recommended dose of drugb is 2 mg daily .
advise
for patients receiving drugn or other potent cyp3a4 inhibitors such as other drugn ( eg , drugn , drugn ) or drugn ( eg , drugn , drugn ) or drugn or druga , the recommended dose of drugb is 2 mg daily .
advise
druga should be used with caution in digitalized patients , since the combination of drugb and drugn may cause ectopic arrhythmias .
false
druga should be used with caution in digitalized patients , since the combination of drugn and drugb may cause ectopic arrhythmias .
false
drugn should be used with caution in digitalized patients , since the combination of druga and drugb may cause ectopic arrhythmias .
effect
druga or drugb may potentiate the action of drugn .
false
druga or drugn may potentiate the action of drugb .
effect
drugn or druga may potentiate the action of drugb .
effect
there is usually complete cross-resistance between druga ( drugb ) and drugn brand drugn .
false
there is usually complete cross-resistance between druga ( drugn ) and drugb brand drugn .
effect
there is usually complete cross-resistance between druga ( drugn ) and drugn brand drugb .
effect
there is usually complete cross-resistance between drugn ( druga ) and drugb brand drugn .
effect
there is usually complete cross-resistance between drugn ( druga ) and drugn brand drugb .
effect
there is usually complete cross-resistance between drugn ( drugn ) and druga brand drugb .
false
as there is in vitro evidence that druga ( e.g. , drugb , drugn , or drugn ) inhibit the tpmt enzyme , they should be administered with caution to patients receiving concurrent drugn therapy .
false
as there is in vitro evidence that druga ( e.g. , drugn , drugb , or drugn ) inhibit the tpmt enzyme , they should be administered with caution to patients receiving concurrent drugn therapy .
false
as there is in vitro evidence that druga ( e.g. , drugn , drugn , or drugb ) inhibit the tpmt enzyme , they should be administered with caution to patients receiving concurrent drugn therapy .
false
as there is in vitro evidence that druga ( e.g. , drugn , drugn , or drugn ) inhibit the tpmt enzyme , they should be administered with caution to patients receiving concurrent drugb therapy .
mechanism
as there is in vitro evidence that drugn ( e.g. , druga , drugb , or drugn ) inhibit the tpmt enzyme , they should be administered with caution to patients receiving concurrent drugn therapy .
false
as there is in vitro evidence that drugn ( e.g. , druga , drugn , or drugb ) inhibit the tpmt enzyme , they should be administered with caution to patients receiving concurrent drugn therapy .
false
as there is in vitro evidence that drugn ( e.g. , druga , drugn , or drugn ) inhibit the tpmt enzyme , they should be administered with caution to patients receiving concurrent drugb therapy .
mechanism
as there is in vitro evidence that drugn ( e.g. , drugn , druga , or drugb ) inhibit the tpmt enzyme , they should be administered with caution to patients receiving concurrent drugn therapy .
false
as there is in vitro evidence that drugn ( e.g. , drugn , druga , or drugn ) inhibit the tpmt enzyme , they should be administered with caution to patients receiving concurrent drugb therapy .
mechanism
as there is in vitro evidence that drugn ( e.g. , drugn , drugn , or druga ) inhibit the tpmt enzyme , they should be administered with caution to patients receiving concurrent drugb therapy .
mechanism
druga may interact with drugb or drugn ( causing too great a decrease in adrenal function ) .
int
druga may interact with drugn or drugb ( causing too great a decrease in adrenal function ) .
int
drugn may interact with druga or drugb ( causing too great a decrease in adrenal function ) .
false
when druga and drugb are used together , the signs of atropinization ( flushing , mydriasis , tachycardia , dryness of the mouth and nose ) may occur earlier than might be expected when drugn is used alone .
effect
when druga and drugn are used together , the signs of atropinization ( flushing , mydriasis , tachycardia , dryness of the mouth and nose ) may occur earlier than might be expected when drugb is used alone .
false
when drugn and druga are used together , the signs of atropinization ( flushing , mydriasis , tachycardia , dryness of the mouth and nose ) may occur earlier than might be expected when drugb is used alone .
false
this is especially true if the total dose of druga has been large and the administration of drugb has been delayed .
false
2 - 4 the following precautions should be kept in mind in the treatment of anticholinesterase poisoning , although they do not bear directly on the use of druga : since drugb are potentiated by the drugn , they should be used cautiously in the treatment of convulsions ;
false
2 - 4 the following precautions should be kept in mind in the treatment of anticholinesterase poisoning , although they do not bear directly on the use of druga : since drugn are potentiated by the drugb , they should be used cautiously in the treatment of convulsions ;
false
2 - 4 the following precautions should be kept in mind in the treatment of anticholinesterase poisoning , although they do not bear directly on the use of drugn : since druga are potentiated by the drugb , they should be used cautiously in the treatment of convulsions ;
effect
druga , drugb , drugn , drugn , drugn , and drugn should be avoided in patients with organophosphate poisoning .
false
druga , drugn , drugb , drugn , drugn , and drugn should be avoided in patients with organophosphate poisoning .
false
druga , drugn , drugn , drugb , drugn , and drugn should be avoided in patients with organophosphate poisoning .
false
druga , drugn , drugn , drugn , drugb , and drugn should be avoided in patients with organophosphate poisoning .
false
druga , drugn , drugn , drugn , drugn , and drugb should be avoided in patients with organophosphate poisoning .
false
drugn , druga , drugb , drugn , drugn , and drugn should be avoided in patients with organophosphate poisoning .
false
drugn , druga , drugn , drugb , drugn , and drugn should be avoided in patients with organophosphate poisoning .
false
drugn , druga , drugn , drugn , drugb , and drugn should be avoided in patients with organophosphate poisoning .
false
drugn , druga , drugn , drugn , drugn , and drugb should be avoided in patients with organophosphate poisoning .
false
drugn , drugn , druga , drugb , drugn , and drugn should be avoided in patients with organophosphate poisoning .
false
drugn , drugn , druga , drugn , drugb , and drugn should be avoided in patients with organophosphate poisoning .
false
drugn , drugn , druga , drugn , drugn , and drugb should be avoided in patients with organophosphate poisoning .
false
drugn , drugn , drugn , druga , drugb , and drugn should be avoided in patients with organophosphate poisoning .
false
drugn , drugn , drugn , druga , drugn , and drugb should be avoided in patients with organophosphate poisoning .
false
drugn , drugn , drugn , drugn , druga , and drugb should be avoided in patients with organophosphate poisoning .
false
caution should be observed in administering druga to patients receiving drugb or drugn because the extrapyramidal effects of these drugs can be expected to be potentiated by inhibition of catecholamine synthesis .
advise
caution should be observed in administering druga to patients receiving drugn or drugb because the extrapyramidal effects of these drugs can be expected to be potentiated by inhibition of catecholamine synthesis .
advise
caution should be observed in administering drugn to patients receiving druga or drugb because the extrapyramidal effects of these drugs can be expected to be potentiated by inhibition of catecholamine synthesis .
false
concurrent use of druga with drugb or other drugn can increase their sedative effects .
effect
concurrent use of druga with drugn or other drugb can increase their sedative effects .
effect
concurrent use of drugn with druga or other drugb can increase their sedative effects .
false
since druga ( drugb ) may interact with concurrently administered drugn , periodic serum level determinations of these drugs may be necessary ( eg drugn may increase the plasma concentrations of drugn and drugn ) .
false
since druga ( drugn ) may interact with concurrently administered drugb , periodic serum level determinations of these drugs may be necessary ( eg drugn may increase the plasma concentrations of drugn and drugn ) .
advise
since druga ( drugn ) may interact with concurrently administered drugn , periodic serum level determinations of these drugs may be necessary ( eg drugb may increase the plasma concentrations of drugn and drugn ) .
false
since druga ( drugn ) may interact with concurrently administered drugn , periodic serum level determinations of these drugs may be necessary ( eg drugn may increase the plasma concentrations of drugb and drugn ) .
false
since druga ( drugn ) may interact with concurrently administered drugn , periodic serum level determinations of these drugs may be necessary ( eg drugn may increase the plasma concentrations of drugn and drugb ) .
false
since drugn ( druga ) may interact with concurrently administered drugb , periodic serum level determinations of these drugs may be necessary ( eg drugn may increase the plasma concentrations of drugn and drugn ) .
advise
since drugn ( druga ) may interact with concurrently administered drugn , periodic serum level determinations of these drugs may be necessary ( eg drugb may increase the plasma concentrations of drugn and drugn ) .
false
since drugn ( druga ) may interact with concurrently administered drugn , periodic serum level determinations of these drugs may be necessary ( eg drugn may increase the plasma concentrations of drugb and drugn ) .
false
since drugn ( druga ) may interact with concurrently administered drugn , periodic serum level determinations of these drugs may be necessary ( eg drugn may increase the plasma concentrations of drugn and drugb ) .
false
since drugn ( drugn ) may interact with concurrently administered druga , periodic serum level determinations of these drugs may be necessary ( eg drugb may increase the plasma concentrations of drugn and drugn ) .
false
since drugn ( drugn ) may interact with concurrently administered druga , periodic serum level determinations of these drugs may be necessary ( eg drugn may increase the plasma concentrations of drugb and drugn ) .
false
since drugn ( drugn ) may interact with concurrently administered druga , periodic serum level determinations of these drugs may be necessary ( eg drugn may increase the plasma concentrations of drugn and drugb ) .
false
since drugn ( drugn ) may interact with concurrently administered drugn , periodic serum level determinations of these drugs may be necessary ( eg druga may increase the plasma concentrations of drugb and drugn ) .
mechanism
since drugn ( drugn ) may interact with concurrently administered drugn , periodic serum level determinations of these drugs may be necessary ( eg druga may increase the plasma concentrations of drugn and drugb ) .
mechanism
since drugn ( drugn ) may interact with concurrently administered drugn , periodic serum level determinations of these drugs may be necessary ( eg drugn may increase the plasma concentrations of druga and drugb ) .
false
druga , such as the drugb ( drugn , drugn , drugn ) or drugn , ordinarily should not be administered concurrently with drugn ( a drugn ) ;
false
druga , such as the drugn ( drugb , drugn , drugn ) or drugn , ordinarily should not be administered concurrently with drugn ( a drugn ) ;
false
druga , such as the drugn ( drugn , drugb , drugn ) or drugn , ordinarily should not be administered concurrently with drugn ( a drugn ) ;
false
druga , such as the drugn ( drugn , drugn , drugb ) or drugn , ordinarily should not be administered concurrently with drugn ( a drugn ) ;
false
druga , such as the drugn ( drugn , drugn , drugn ) or drugb , ordinarily should not be administered concurrently with drugn ( a drugn ) ;
false
druga , such as the drugn ( drugn , drugn , drugn ) or drugn , ordinarily should not be administered concurrently with drugb ( a drugn ) ;
advise
druga , such as the drugn ( drugn , drugn , drugn ) or drugn , ordinarily should not be administered concurrently with drugn ( a drugb ) ;
false
drugn , such as the druga ( drugb , drugn , drugn ) or drugn , ordinarily should not be administered concurrently with drugn ( a drugn ) ;
false
drugn , such as the druga ( drugn , drugb , drugn ) or drugn , ordinarily should not be administered concurrently with drugn ( a drugn ) ;
false
drugn , such as the druga ( drugn , drugn , drugb ) or drugn , ordinarily should not be administered concurrently with drugn ( a drugn ) ;
false
drugn , such as the druga ( drugn , drugn , drugn ) or drugb , ordinarily should not be administered concurrently with drugn ( a drugn ) ;
false
drugn , such as the druga ( drugn , drugn , drugn ) or drugn , ordinarily should not be administered concurrently with drugb ( a drugn ) ;
advise
drugn , such as the druga ( drugn , drugn , drugn ) or drugn , ordinarily should not be administered concurrently with drugn ( a drugb ) ;
false
drugn , such as the drugn ( druga , drugb , drugn ) or drugn , ordinarily should not be administered concurrently with drugn ( a drugn ) ;
false
drugn , such as the drugn ( druga , drugn , drugb ) or drugn , ordinarily should not be administered concurrently with drugn ( a drugn ) ;
false
drugn , such as the drugn ( druga , drugn , drugn ) or drugb , ordinarily should not be administered concurrently with drugn ( a drugn ) ;
false
drugn , such as the drugn ( druga , drugn , drugn ) or drugn , ordinarily should not be administered concurrently with drugb ( a drugn ) ;
advise
drugn , such as the drugn ( druga , drugn , drugn ) or drugn , ordinarily should not be administered concurrently with drugn ( a drugb ) ;
false
drugn , such as the drugn ( drugn , druga , drugb ) or drugn , ordinarily should not be administered concurrently with drugn ( a drugn ) ;
false
drugn , such as the drugn ( drugn , druga , drugn ) or drugb , ordinarily should not be administered concurrently with drugn ( a drugn ) ;
false
drugn , such as the drugn ( drugn , druga , drugn ) or drugn , ordinarily should not be administered concurrently with drugb ( a drugn ) ;
advise
drugn , such as the drugn ( drugn , druga , drugn ) or drugn , ordinarily should not be administered concurrently with drugn ( a drugb ) ;
false
drugn , such as the drugn ( drugn , drugn , druga ) or drugb , ordinarily should not be administered concurrently with drugn ( a drugn ) ;
false
drugn , such as the drugn ( drugn , drugn , druga ) or drugn , ordinarily should not be administered concurrently with drugb ( a drugn ) ;
advise
drugn , such as the drugn ( drugn , drugn , druga ) or drugn , ordinarily should not be administered concurrently with drugn ( a drugb ) ;
false
drugn , such as the drugn ( drugn , drugn , drugn ) or druga , ordinarily should not be administered concurrently with drugb ( a drugn ) ;
advise
drugn , such as the drugn ( drugn , drugn , drugn ) or druga , ordinarily should not be administered concurrently with drugn ( a drugb ) ;
false
drugn , such as the drugn ( drugn , drugn , drugn ) or drugn , ordinarily should not be administered concurrently with druga ( a drugb ) ;
false
because druga is approximately 90 % bound to plasma proteins , caution should be exercised if drugb is coadministered with other drugs known to affect protein binding .
false
the following agents may increase certain actions or side effects of druga : drugb , drugn ( e.g. , drugn ) , drugn , drugn ( e.g. , drugn ) , drugn , drugn , drugn ( e.g. , drugn ) , drugn and drugn , drugn , drugn , and other drugs having anticholinergic activity .
effect
the following agents may increase certain actions or side effects of druga : drugn , drugb ( e.g. , drugn ) , drugn , drugn ( e.g. , drugn ) , drugn , drugn , drugn ( e.g. , drugn ) , drugn and drugn , drugn , drugn , and other drugs having anticholinergic activity .
effect
the following agents may increase certain actions or side effects of druga : drugn , drugn ( e.g. , drugb ) , drugn , drugn ( e.g. , drugn ) , drugn , drugn , drugn ( e.g. , drugn ) , drugn and drugn , drugn , drugn , and other drugs having anticholinergic activity .
effect
the following agents may increase certain actions or side effects of druga : drugn , drugn ( e.g. , drugn ) , drugb , drugn ( e.g. , drugn ) , drugn , drugn , drugn ( e.g. , drugn ) , drugn and drugn , drugn , drugn , and other drugs having anticholinergic activity .
effect
the following agents may increase certain actions or side effects of druga : drugn , drugn ( e.g. , drugn ) , drugn , drugb ( e.g. , drugn ) , drugn , drugn , drugn ( e.g. , drugn ) , drugn and drugn , drugn , drugn , and other drugs having anticholinergic activity .
effect
the following agents may increase certain actions or side effects of druga : drugn , drugn ( e.g. , drugn ) , drugn , drugn ( e.g. , drugb ) , drugn , drugn , drugn ( e.g. , drugn ) , drugn and drugn , drugn , drugn , and other drugs having anticholinergic activity .
effect
the following agents may increase certain actions or side effects of druga : drugn , drugn ( e.g. , drugn ) , drugn , drugn ( e.g. , drugn ) , drugb , drugn , drugn ( e.g. , drugn ) , drugn and drugn , drugn , drugn , and other drugs having anticholinergic activity .
effect
the following agents may increase certain actions or side effects of druga : drugn , drugn ( e.g. , drugn ) , drugn , drugn ( e.g. , drugn ) , drugn , drugb , drugn ( e.g. , drugn ) , drugn and drugn , drugn , drugn , and other drugs having anticholinergic activity .
effect
the following agents may increase certain actions or side effects of druga : drugn , drugn ( e.g. , drugn ) , drugn , drugn ( e.g. , drugn ) , drugn , drugn , drugb ( e.g. , drugn ) , drugn and drugn , drugn , drugn , and other drugs having anticholinergic activity .
effect
the following agents may increase certain actions or side effects of druga : drugn , drugn ( e.g. , drugn ) , drugn , drugn ( e.g. , drugn ) , drugn , drugn , drugn ( e.g. , drugb ) , drugn and drugn , drugn , drugn , and other drugs having anticholinergic activity .
effect
the following agents may increase certain actions or side effects of druga : drugn , drugn ( e.g. , drugn ) , drugn , drugn ( e.g. , drugn ) , drugn , drugn , drugn ( e.g. , drugn ) , drugb and drugn , drugn , drugn , and other drugs having anticholinergic activity .
effect
the following agents may increase certain actions or side effects of druga : drugn , drugn ( e.g. , drugn ) , drugn , drugn ( e.g. , drugn ) , drugn , drugn , drugn ( e.g. , drugn ) , drugn and drugb , drugn , drugn , and other drugs having anticholinergic activity .
effect
the following agents may increase certain actions or side effects of druga : drugn , drugn ( e.g. , drugn ) , drugn , drugn ( e.g. , drugn ) , drugn , drugn , drugn ( e.g. , drugn ) , drugn and drugn , drugb , drugn , and other drugs having anticholinergic activity .
effect
the following agents may increase certain actions or side effects of druga : drugn , drugn ( e.g. , drugn ) , drugn , drugn ( e.g. , drugn ) , drugn , drugn , drugn ( e.g. , drugn ) , drugn and drugn , drugn , drugb , and other drugs having anticholinergic activity .
effect
the following agents may increase certain actions or side effects of drugn : druga , drugb ( e.g. , drugn ) , drugn , drugn ( e.g. , drugn ) , drugn , drugn , drugn ( e.g. , drugn ) , drugn and drugn , drugn , drugn , and other drugs having anticholinergic activity .
false
the following agents may increase certain actions or side effects of drugn : druga , drugn ( e.g. , drugb ) , drugn , drugn ( e.g. , drugn ) , drugn , drugn , drugn ( e.g. , drugn ) , drugn and drugn , drugn , drugn , and other drugs having anticholinergic activity .
false
the following agents may increase certain actions or side effects of drugn : druga , drugn ( e.g. , drugn ) , drugb , drugn ( e.g. , drugn ) , drugn , drugn , drugn ( e.g. , drugn ) , drugn and drugn , drugn , drugn , and other drugs having anticholinergic activity .
false
the following agents may increase certain actions or side effects of drugn : druga , drugn ( e.g. , drugn ) , drugn , drugb ( e.g. , drugn ) , drugn , drugn , drugn ( e.g. , drugn ) , drugn and drugn , drugn , drugn , and other drugs having anticholinergic activity .
false
the following agents may increase certain actions or side effects of drugn : druga , drugn ( e.g. , drugn ) , drugn , drugn ( e.g. , drugb ) , drugn , drugn , drugn ( e.g. , drugn ) , drugn and drugn , drugn , drugn , and other drugs having anticholinergic activity .
false
the following agents may increase certain actions or side effects of drugn : druga , drugn ( e.g. , drugn ) , drugn , drugn ( e.g. , drugn ) , drugb , drugn , drugn ( e.g. , drugn ) , drugn and drugn , drugn , drugn , and other drugs having anticholinergic activity .
false
the following agents may increase certain actions or side effects of drugn : druga , drugn ( e.g. , drugn ) , drugn , drugn ( e.g. , drugn ) , drugn , drugb , drugn ( e.g. , drugn ) , drugn and drugn , drugn , drugn , and other drugs having anticholinergic activity .
false
the following agents may increase certain actions or side effects of drugn : druga , drugn ( e.g. , drugn ) , drugn , drugn ( e.g. , drugn ) , drugn , drugn , drugb ( e.g. , drugn ) , drugn and drugn , drugn , drugn , and other drugs having anticholinergic activity .
false
the following agents may increase certain actions or side effects of drugn : druga , drugn ( e.g. , drugn ) , drugn , drugn ( e.g. , drugn ) , drugn , drugn , drugn ( e.g. , drugb ) , drugn and drugn , drugn , drugn , and other drugs having anticholinergic activity .
false
the following agents may increase certain actions or side effects of drugn : druga , drugn ( e.g. , drugn ) , drugn , drugn ( e.g. , drugn ) , drugn , drugn , drugn ( e.g. , drugn ) , drugb and drugn , drugn , drugn , and other drugs having anticholinergic activity .
false
the following agents may increase certain actions or side effects of drugn : druga , drugn ( e.g. , drugn ) , drugn , drugn ( e.g. , drugn ) , drugn , drugn , drugn ( e.g. , drugn ) , drugn and drugb , drugn , drugn , and other drugs having anticholinergic activity .
false
the following agents may increase certain actions or side effects of drugn : druga , drugn ( e.g. , drugn ) , drugn , drugn ( e.g. , drugn ) , drugn , drugn , drugn ( e.g. , drugn ) , drugn and drugn , drugb , drugn , and other drugs having anticholinergic activity .
false
the following agents may increase certain actions or side effects of drugn : druga , drugn ( e.g. , drugn ) , drugn , drugn ( e.g. , drugn ) , drugn , drugn , drugn ( e.g. , drugn ) , drugn and drugn , drugn , drugb , and other drugs having anticholinergic activity .
false
the following agents may increase certain actions or side effects of drugn : drugn , druga ( e.g. , drugb ) , drugn , drugn ( e.g. , drugn ) , drugn , drugn , drugn ( e.g. , drugn ) , drugn and drugn , drugn , drugn , and other drugs having anticholinergic activity .
false
the following agents may increase certain actions or side effects of drugn : drugn , druga ( e.g. , drugn ) , drugb , drugn ( e.g. , drugn ) , drugn , drugn , drugn ( e.g. , drugn ) , drugn and drugn , drugn , drugn , and other drugs having anticholinergic activity .
false
the following agents may increase certain actions or side effects of drugn : drugn , druga ( e.g. , drugn ) , drugn , drugb ( e.g. , drugn ) , drugn , drugn , drugn ( e.g. , drugn ) , drugn and drugn , drugn , drugn , and other drugs having anticholinergic activity .
false
the following agents may increase certain actions or side effects of drugn : drugn , druga ( e.g. , drugn ) , drugn , drugn ( e.g. , drugb ) , drugn , drugn , drugn ( e.g. , drugn ) , drugn and drugn , drugn , drugn , and other drugs having anticholinergic activity .
false
the following agents may increase certain actions or side effects of drugn : drugn , druga ( e.g. , drugn ) , drugn , drugn ( e.g. , drugn ) , drugb , drugn , drugn ( e.g. , drugn ) , drugn and drugn , drugn , drugn , and other drugs having anticholinergic activity .
false
the following agents may increase certain actions or side effects of drugn : drugn , druga ( e.g. , drugn ) , drugn , drugn ( e.g. , drugn ) , drugn , drugb , drugn ( e.g. , drugn ) , drugn and drugn , drugn , drugn , and other drugs having anticholinergic activity .
false
the following agents may increase certain actions or side effects of drugn : drugn , druga ( e.g. , drugn ) , drugn , drugn ( e.g. , drugn ) , drugn , drugn , drugb ( e.g. , drugn ) , drugn and drugn , drugn , drugn , and other drugs having anticholinergic activity .
false
the following agents may increase certain actions or side effects of drugn : drugn , druga ( e.g. , drugn ) , drugn , drugn ( e.g. , drugn ) , drugn , drugn , drugn ( e.g. , drugb ) , drugn and drugn , drugn , drugn , and other drugs having anticholinergic activity .
false
the following agents may increase certain actions or side effects of drugn : drugn , druga ( e.g. , drugn ) , drugn , drugn ( e.g. , drugn ) , drugn , drugn , drugn ( e.g. , drugn ) , drugb and drugn , drugn , drugn , and other drugs having anticholinergic activity .
false
the following agents may increase certain actions or side effects of drugn : drugn , druga ( e.g. , drugn ) , drugn , drugn ( e.g. , drugn ) , drugn , drugn , drugn ( e.g. , drugn ) , drugn and drugb , drugn , drugn , and other drugs having anticholinergic activity .
false
the following agents may increase certain actions or side effects of drugn : drugn , druga ( e.g. , drugn ) , drugn , drugn ( e.g. , drugn ) , drugn , drugn , drugn ( e.g. , drugn ) , drugn and drugn , drugb , drugn , and other drugs having anticholinergic activity .
false
the following agents may increase certain actions or side effects of drugn : drugn , druga ( e.g. , drugn ) , drugn , drugn ( e.g. , drugn ) , drugn , drugn , drugn ( e.g. , drugn ) , drugn and drugn , drugn , drugb , and other drugs having anticholinergic activity .
false
the following agents may increase certain actions or side effects of drugn : drugn , drugn ( e.g. , druga ) , drugb , drugn ( e.g. , drugn ) , drugn , drugn , drugn ( e.g. , drugn ) , drugn and drugn , drugn , drugn , and other drugs having anticholinergic activity .
false
the following agents may increase certain actions or side effects of drugn : drugn , drugn ( e.g. , druga ) , drugn , drugb ( e.g. , drugn ) , drugn , drugn , drugn ( e.g. , drugn ) , drugn and drugn , drugn , drugn , and other drugs having anticholinergic activity .
false
the following agents may increase certain actions or side effects of drugn : drugn , drugn ( e.g. , druga ) , drugn , drugn ( e.g. , drugb ) , drugn , drugn , drugn ( e.g. , drugn ) , drugn and drugn , drugn , drugn , and other drugs having anticholinergic activity .
false
the following agents may increase certain actions or side effects of drugn : drugn , drugn ( e.g. , druga ) , drugn , drugn ( e.g. , drugn ) , drugb , drugn , drugn ( e.g. , drugn ) , drugn and drugn , drugn , drugn , and other drugs having anticholinergic activity .
false
the following agents may increase certain actions or side effects of drugn : drugn , drugn ( e.g. , druga ) , drugn , drugn ( e.g. , drugn ) , drugn , drugb , drugn ( e.g. , drugn ) , drugn and drugn , drugn , drugn , and other drugs having anticholinergic activity .
false
the following agents may increase certain actions or side effects of drugn : drugn , drugn ( e.g. , druga ) , drugn , drugn ( e.g. , drugn ) , drugn , drugn , drugb ( e.g. , drugn ) , drugn and drugn , drugn , drugn , and other drugs having anticholinergic activity .
false
the following agents may increase certain actions or side effects of drugn : drugn , drugn ( e.g. , druga ) , drugn , drugn ( e.g. , drugn ) , drugn , drugn , drugn ( e.g. , drugb ) , drugn and drugn , drugn , drugn , and other drugs having anticholinergic activity .
false
the following agents may increase certain actions or side effects of drugn : drugn , drugn ( e.g. , druga ) , drugn , drugn ( e.g. , drugn ) , drugn , drugn , drugn ( e.g. , drugn ) , drugb and drugn , drugn , drugn , and other drugs having anticholinergic activity .
false
the following agents may increase certain actions or side effects of drugn : drugn , drugn ( e.g. , druga ) , drugn , drugn ( e.g. , drugn ) , drugn , drugn , drugn ( e.g. , drugn ) , drugn and drugb , drugn , drugn , and other drugs having anticholinergic activity .
false
the following agents may increase certain actions or side effects of drugn : drugn , drugn ( e.g. , druga ) , drugn , drugn ( e.g. , drugn ) , drugn , drugn , drugn ( e.g. , drugn ) , drugn and drugn , drugb , drugn , and other drugs having anticholinergic activity .
false
the following agents may increase certain actions or side effects of drugn : drugn , drugn ( e.g. , druga ) , drugn , drugn ( e.g. , drugn ) , drugn , drugn , drugn ( e.g. , drugn ) , drugn and drugn , drugn , drugb , and other drugs having anticholinergic activity .
false
the following agents may increase certain actions or side effects of drugn : drugn , drugn ( e.g. , drugn ) , druga , drugb ( e.g. , drugn ) , drugn , drugn , drugn ( e.g. , drugn ) , drugn and drugn , drugn , drugn , and other drugs having anticholinergic activity .
false
the following agents may increase certain actions or side effects of drugn : drugn , drugn ( e.g. , drugn ) , druga , drugn ( e.g. , drugb ) , drugn , drugn , drugn ( e.g. , drugn ) , drugn and drugn , drugn , drugn , and other drugs having anticholinergic activity .
false
the following agents may increase certain actions or side effects of drugn : drugn , drugn ( e.g. , drugn ) , druga , drugn ( e.g. , drugn ) , drugb , drugn , drugn ( e.g. , drugn ) , drugn and drugn , drugn , drugn , and other drugs having anticholinergic activity .
false
the following agents may increase certain actions or side effects of drugn : drugn , drugn ( e.g. , drugn ) , druga , drugn ( e.g. , drugn ) , drugn , drugb , drugn ( e.g. , drugn ) , drugn and drugn , drugn , drugn , and other drugs having anticholinergic activity .
false
the following agents may increase certain actions or side effects of drugn : drugn , drugn ( e.g. , drugn ) , druga , drugn ( e.g. , drugn ) , drugn , drugn , drugb ( e.g. , drugn ) , drugn and drugn , drugn , drugn , and other drugs having anticholinergic activity .
false
the following agents may increase certain actions or side effects of drugn : drugn , drugn ( e.g. , drugn ) , druga , drugn ( e.g. , drugn ) , drugn , drugn , drugn ( e.g. , drugb ) , drugn and drugn , drugn , drugn , and other drugs having anticholinergic activity .
false
the following agents may increase certain actions or side effects of drugn : drugn , drugn ( e.g. , drugn ) , druga , drugn ( e.g. , drugn ) , drugn , drugn , drugn ( e.g. , drugn ) , drugb and drugn , drugn , drugn , and other drugs having anticholinergic activity .
false
the following agents may increase certain actions or side effects of drugn : drugn , drugn ( e.g. , drugn ) , druga , drugn ( e.g. , drugn ) , drugn , drugn , drugn ( e.g. , drugn ) , drugn and drugb , drugn , drugn , and other drugs having anticholinergic activity .
false
the following agents may increase certain actions or side effects of drugn : drugn , drugn ( e.g. , drugn ) , druga , drugn ( e.g. , drugn ) , drugn , drugn , drugn ( e.g. , drugn ) , drugn and drugn , drugb , drugn , and other drugs having anticholinergic activity .
false
the following agents may increase certain actions or side effects of drugn : drugn , drugn ( e.g. , drugn ) , druga , drugn ( e.g. , drugn ) , drugn , drugn , drugn ( e.g. , drugn ) , drugn and drugn , drugn , drugb , and other drugs having anticholinergic activity .
false
the following agents may increase certain actions or side effects of drugn : drugn , drugn ( e.g. , drugn ) , drugn , druga ( e.g. , drugb ) , drugn , drugn , drugn ( e.g. , drugn ) , drugn and drugn , drugn , drugn , and other drugs having anticholinergic activity .
false
the following agents may increase certain actions or side effects of drugn : drugn , drugn ( e.g. , drugn ) , drugn , druga ( e.g. , drugn ) , drugb , drugn , drugn ( e.g. , drugn ) , drugn and drugn , drugn , drugn , and other drugs having anticholinergic activity .
false
the following agents may increase certain actions or side effects of drugn : drugn , drugn ( e.g. , drugn ) , drugn , druga ( e.g. , drugn ) , drugn , drugb , drugn ( e.g. , drugn ) , drugn and drugn , drugn , drugn , and other drugs having anticholinergic activity .
false
the following agents may increase certain actions or side effects of drugn : drugn , drugn ( e.g. , drugn ) , drugn , druga ( e.g. , drugn ) , drugn , drugn , drugb ( e.g. , drugn ) , drugn and drugn , drugn , drugn , and other drugs having anticholinergic activity .
false
the following agents may increase certain actions or side effects of drugn : drugn , drugn ( e.g. , drugn ) , drugn , druga ( e.g. , drugn ) , drugn , drugn , drugn ( e.g. , drugb ) , drugn and drugn , drugn , drugn , and other drugs having anticholinergic activity .
false
the following agents may increase certain actions or side effects of drugn : drugn , drugn ( e.g. , drugn ) , drugn , druga ( e.g. , drugn ) , drugn , drugn , drugn ( e.g. , drugn ) , drugb and drugn , drugn , drugn , and other drugs having anticholinergic activity .
false
the following agents may increase certain actions or side effects of drugn : drugn , drugn ( e.g. , drugn ) , drugn , druga ( e.g. , drugn ) , drugn , drugn , drugn ( e.g. , drugn ) , drugn and drugb , drugn , drugn , and other drugs having anticholinergic activity .
false
the following agents may increase certain actions or side effects of drugn : drugn , drugn ( e.g. , drugn ) , drugn , druga ( e.g. , drugn ) , drugn , drugn , drugn ( e.g. , drugn ) , drugn and drugn , drugb , drugn , and other drugs having anticholinergic activity .
false
the following agents may increase certain actions or side effects of drugn : drugn , drugn ( e.g. , drugn ) , drugn , druga ( e.g. , drugn ) , drugn , drugn , drugn ( e.g. , drugn ) , drugn and drugn , drugn , drugb , and other drugs having anticholinergic activity .
false
the following agents may increase certain actions or side effects of drugn : drugn , drugn ( e.g. , drugn ) , drugn , drugn ( e.g. , druga ) , drugb , drugn , drugn ( e.g. , drugn ) , drugn and drugn , drugn , drugn , and other drugs having anticholinergic activity .
false
the following agents may increase certain actions or side effects of drugn : drugn , drugn ( e.g. , drugn ) , drugn , drugn ( e.g. , druga ) , drugn , drugb , drugn ( e.g. , drugn ) , drugn and drugn , drugn , drugn , and other drugs having anticholinergic activity .
false
the following agents may increase certain actions or side effects of drugn : drugn , drugn ( e.g. , drugn ) , drugn , drugn ( e.g. , druga ) , drugn , drugn , drugb ( e.g. , drugn ) , drugn and drugn , drugn , drugn , and other drugs having anticholinergic activity .
false
the following agents may increase certain actions or side effects of drugn : drugn , drugn ( e.g. , drugn ) , drugn , drugn ( e.g. , druga ) , drugn , drugn , drugn ( e.g. , drugb ) , drugn and drugn , drugn , drugn , and other drugs having anticholinergic activity .
false
the following agents may increase certain actions or side effects of drugn : drugn , drugn ( e.g. , drugn ) , drugn , drugn ( e.g. , druga ) , drugn , drugn , drugn ( e.g. , drugn ) , drugb and drugn , drugn , drugn , and other drugs having anticholinergic activity .
false
the following agents may increase certain actions or side effects of drugn : drugn , drugn ( e.g. , drugn ) , drugn , drugn ( e.g. , druga ) , drugn , drugn , drugn ( e.g. , drugn ) , drugn and drugb , drugn , drugn , and other drugs having anticholinergic activity .
false
the following agents may increase certain actions or side effects of drugn : drugn , drugn ( e.g. , drugn ) , drugn , drugn ( e.g. , druga ) , drugn , drugn , drugn ( e.g. , drugn ) , drugn and drugn , drugb , drugn , and other drugs having anticholinergic activity .
false
the following agents may increase certain actions or side effects of drugn : drugn , drugn ( e.g. , drugn ) , drugn , drugn ( e.g. , druga ) , drugn , drugn , drugn ( e.g. , drugn ) , drugn and drugn , drugn , drugb , and other drugs having anticholinergic activity .
false
the following agents may increase certain actions or side effects of drugn : drugn , drugn ( e.g. , drugn ) , drugn , drugn ( e.g. , drugn ) , druga , drugb , drugn ( e.g. , drugn ) , drugn and drugn , drugn , drugn , and other drugs having anticholinergic activity .
false
the following agents may increase certain actions or side effects of drugn : drugn , drugn ( e.g. , drugn ) , drugn , drugn ( e.g. , drugn ) , druga , drugn , drugb ( e.g. , drugn ) , drugn and drugn , drugn , drugn , and other drugs having anticholinergic activity .
false
the following agents may increase certain actions or side effects of drugn : drugn , drugn ( e.g. , drugn ) , drugn , drugn ( e.g. , drugn ) , druga , drugn , drugn ( e.g. , drugb ) , drugn and drugn , drugn , drugn , and other drugs having anticholinergic activity .
false
the following agents may increase certain actions or side effects of drugn : drugn , drugn ( e.g. , drugn ) , drugn , drugn ( e.g. , drugn ) , druga , drugn , drugn ( e.g. , drugn ) , drugb and drugn , drugn , drugn , and other drugs having anticholinergic activity .
false
the following agents may increase certain actions or side effects of drugn : drugn , drugn ( e.g. , drugn ) , drugn , drugn ( e.g. , drugn ) , druga , drugn , drugn ( e.g. , drugn ) , drugn and drugb , drugn , drugn , and other drugs having anticholinergic activity .
false
the following agents may increase certain actions or side effects of drugn : drugn , drugn ( e.g. , drugn ) , drugn , drugn ( e.g. , drugn ) , druga , drugn , drugn ( e.g. , drugn ) , drugn and drugn , drugb , drugn , and other drugs having anticholinergic activity .
false
the following agents may increase certain actions or side effects of drugn : drugn , drugn ( e.g. , drugn ) , drugn , drugn ( e.g. , drugn ) , druga , drugn , drugn ( e.g. , drugn ) , drugn and drugn , drugn , drugb , and other drugs having anticholinergic activity .
false
the following agents may increase certain actions or side effects of drugn : drugn , drugn ( e.g. , drugn ) , drugn , drugn ( e.g. , drugn ) , drugn , druga , drugb ( e.g. , drugn ) , drugn and drugn , drugn , drugn , and other drugs having anticholinergic activity .
false
the following agents may increase certain actions or side effects of drugn : drugn , drugn ( e.g. , drugn ) , drugn , drugn ( e.g. , drugn ) , drugn , druga , drugn ( e.g. , drugb ) , drugn and drugn , drugn , drugn , and other drugs having anticholinergic activity .
false
the following agents may increase certain actions or side effects of drugn : drugn , drugn ( e.g. , drugn ) , drugn , drugn ( e.g. , drugn ) , drugn , druga , drugn ( e.g. , drugn ) , drugb and drugn , drugn , drugn , and other drugs having anticholinergic activity .
false
the following agents may increase certain actions or side effects of drugn : drugn , drugn ( e.g. , drugn ) , drugn , drugn ( e.g. , drugn ) , drugn , druga , drugn ( e.g. , drugn ) , drugn and drugb , drugn , drugn , and other drugs having anticholinergic activity .
false
the following agents may increase certain actions or side effects of drugn : drugn , drugn ( e.g. , drugn ) , drugn , drugn ( e.g. , drugn ) , drugn , druga , drugn ( e.g. , drugn ) , drugn and drugn , drugb , drugn , and other drugs having anticholinergic activity .
false
the following agents may increase certain actions or side effects of drugn : drugn , drugn ( e.g. , drugn ) , drugn , drugn ( e.g. , drugn ) , drugn , druga , drugn ( e.g. , drugn ) , drugn and drugn , drugn , drugb , and other drugs having anticholinergic activity .
false
the following agents may increase certain actions or side effects of drugn : drugn , drugn ( e.g. , drugn ) , drugn , drugn ( e.g. , drugn ) , drugn , drugn , druga ( e.g. , drugb ) , drugn and drugn , drugn , drugn , and other drugs having anticholinergic activity .
false
the following agents may increase certain actions or side effects of drugn : drugn , drugn ( e.g. , drugn ) , drugn , drugn ( e.g. , drugn ) , drugn , drugn , druga ( e.g. , drugn ) , drugb and drugn , drugn , drugn , and other drugs having anticholinergic activity .
false
the following agents may increase certain actions or side effects of drugn : drugn , drugn ( e.g. , drugn ) , drugn , drugn ( e.g. , drugn ) , drugn , drugn , druga ( e.g. , drugn ) , drugn and drugb , drugn , drugn , and other drugs having anticholinergic activity .
false
the following agents may increase certain actions or side effects of drugn : drugn , drugn ( e.g. , drugn ) , drugn , drugn ( e.g. , drugn ) , drugn , drugn , druga ( e.g. , drugn ) , drugn and drugn , drugb , drugn , and other drugs having anticholinergic activity .
false
the following agents may increase certain actions or side effects of drugn : drugn , drugn ( e.g. , drugn ) , drugn , drugn ( e.g. , drugn ) , drugn , drugn , druga ( e.g. , drugn ) , drugn and drugn , drugn , drugb , and other drugs having anticholinergic activity .
false
the following agents may increase certain actions or side effects of drugn : drugn , drugn ( e.g. , drugn ) , drugn , drugn ( e.g. , drugn ) , drugn , drugn , drugn ( e.g. , druga ) , drugb and drugn , drugn , drugn , and other drugs having anticholinergic activity .
false
the following agents may increase certain actions or side effects of drugn : drugn , drugn ( e.g. , drugn ) , drugn , drugn ( e.g. , drugn ) , drugn , drugn , drugn ( e.g. , druga ) , drugn and drugb , drugn , drugn , and other drugs having anticholinergic activity .
false
the following agents may increase certain actions or side effects of drugn : drugn , drugn ( e.g. , drugn ) , drugn , drugn ( e.g. , drugn ) , drugn , drugn , drugn ( e.g. , druga ) , drugn and drugn , drugb , drugn , and other drugs having anticholinergic activity .
false
the following agents may increase certain actions or side effects of drugn : drugn , drugn ( e.g. , drugn ) , drugn , drugn ( e.g. , drugn ) , drugn , drugn , drugn ( e.g. , druga ) , drugn and drugn , drugn , drugb , and other drugs having anticholinergic activity .
false
the following agents may increase certain actions or side effects of drugn : drugn , drugn ( e.g. , drugn ) , drugn , drugn ( e.g. , drugn ) , drugn , drugn , drugn ( e.g. , drugn ) , druga and drugb , drugn , drugn , and other drugs having anticholinergic activity .
false
the following agents may increase certain actions or side effects of drugn : drugn , drugn ( e.g. , drugn ) , drugn , drugn ( e.g. , drugn ) , drugn , drugn , drugn ( e.g. , drugn ) , druga and drugn , drugb , drugn , and other drugs having anticholinergic activity .
false
the following agents may increase certain actions or side effects of drugn : drugn , drugn ( e.g. , drugn ) , drugn , drugn ( e.g. , drugn ) , drugn , drugn , drugn ( e.g. , drugn ) , druga and drugn , drugn , drugb , and other drugs having anticholinergic activity .
false
the following agents may increase certain actions or side effects of drugn : drugn , drugn ( e.g. , drugn ) , drugn , drugn ( e.g. , drugn ) , drugn , drugn , drugn ( e.g. , drugn ) , drugn and druga , drugb , drugn , and other drugs having anticholinergic activity .
false
the following agents may increase certain actions or side effects of drugn : drugn , drugn ( e.g. , drugn ) , drugn , drugn ( e.g. , drugn ) , drugn , drugn , drugn ( e.g. , drugn ) , drugn and druga , drugn , drugb , and other drugs having anticholinergic activity .
false
the following agents may increase certain actions or side effects of drugn : drugn , drugn ( e.g. , drugn ) , drugn , drugn ( e.g. , drugn ) , drugn , drugn , drugn ( e.g. , drugn ) , drugn and drugn , druga , drugb , and other drugs having anticholinergic activity .
false
druga antagonize the effects of drugb .
effect
druga in the presence of increased intraocular pressure may be hazardous when taken concurrently with agents such as drugb .
effect
druga may affect gastrointestinal absorption of various drugs , such as slowly dissolving dosage forms of drugb ;
mechanism
druga may antagonize the effects of drugs that alter gastrointestinal motility , such as drugb .
effect
because druga may interfere with the absorption of drugb , simultaneous use of these drugs should be avoided .
mechanism
catecholamine-depleting drugs ( e.g. , druga ) may have an additive effect when given with drugb .
effect
druga has been used with a variety of drugb , including drugn , drugn , and drugn without unexpected adverse interactions .
false
druga has been used with a variety of drugn , including drugb , drugn , and drugn without unexpected adverse interactions .
false
druga has been used with a variety of drugn , including drugn , drugb , and drugn without unexpected adverse interactions .
false
druga has been used with a variety of drugn , including drugn , drugn , and drugb without unexpected adverse interactions .
false
drugn has been used with a variety of druga , including drugb , drugn , and drugn without unexpected adverse interactions .
false
drugn has been used with a variety of druga , including drugn , drugb , and drugn without unexpected adverse interactions .
false
drugn has been used with a variety of druga , including drugn , drugn , and drugb without unexpected adverse interactions .
false
drugn has been used with a variety of drugn , including druga , drugb , and drugn without unexpected adverse interactions .
false
drugn has been used with a variety of drugn , including druga , drugn , and drugb without unexpected adverse interactions .
false
drugn has been used with a variety of drugn , including drugn , druga , and drugb without unexpected adverse interactions .
false
druga has been shown to increase serum drugb levels when both drugs are co-administered .
mechanism
co-administration of druga with strong inhibitors of the cyp3a4 family ( e.g. , drugb , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn ) may increases drugn concentrations .
mechanism
co-administration of druga with strong inhibitors of the cyp3a4 family ( e.g. , drugn , drugb , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn ) may increases drugn concentrations .
mechanism
co-administration of druga with strong inhibitors of the cyp3a4 family ( e.g. , drugn , drugn , drugb , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn ) may increases drugn concentrations .
mechanism
co-administration of druga with strong inhibitors of the cyp3a4 family ( e.g. , drugn , drugn , drugn , drugb , drugn , drugn , drugn , drugn , drugn , drugn , drugn ) may increases drugn concentrations .
mechanism
co-administration of druga with strong inhibitors of the cyp3a4 family ( e.g. , drugn , drugn , drugn , drugn , drugb , drugn , drugn , drugn , drugn , drugn , drugn ) may increases drugn concentrations .
mechanism
co-administration of druga with strong inhibitors of the cyp3a4 family ( e.g. , drugn , drugn , drugn , drugn , drugn , drugb , drugn , drugn , drugn , drugn , drugn ) may increases drugn concentrations .
mechanism
co-administration of druga with strong inhibitors of the cyp3a4 family ( e.g. , drugn , drugn , drugn , drugn , drugn , drugn , drugb , drugn , drugn , drugn , drugn ) may increases drugn concentrations .
mechanism
co-administration of druga with strong inhibitors of the cyp3a4 family ( e.g. , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugb , drugn , drugn , drugn ) may increases drugn concentrations .
mechanism
co-administration of druga with strong inhibitors of the cyp3a4 family ( e.g. , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugb , drugn , drugn ) may increases drugn concentrations .
mechanism
co-administration of druga with strong inhibitors of the cyp3a4 family ( e.g. , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugb , drugn ) may increases drugn concentrations .
mechanism
co-administration of druga with strong inhibitors of the cyp3a4 family ( e.g. , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugb ) may increases drugn concentrations .
mechanism
co-administration of druga with strong inhibitors of the cyp3a4 family ( e.g. , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn ) may increases drugb concentrations .
false
co-administration of drugn with strong inhibitors of the cyp3a4 family ( e.g. , druga , drugb , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn ) may increases drugn concentrations .
false
co-administration of drugn with strong inhibitors of the cyp3a4 family ( e.g. , druga , drugn , drugb , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn ) may increases drugn concentrations .
false
co-administration of drugn with strong inhibitors of the cyp3a4 family ( e.g. , druga , drugn , drugn , drugb , drugn , drugn , drugn , drugn , drugn , drugn , drugn ) may increases drugn concentrations .
false
co-administration of drugn with strong inhibitors of the cyp3a4 family ( e.g. , druga , drugn , drugn , drugn , drugb , drugn , drugn , drugn , drugn , drugn , drugn ) may increases drugn concentrations .
false
co-administration of drugn with strong inhibitors of the cyp3a4 family ( e.g. , druga , drugn , drugn , drugn , drugn , drugb , drugn , drugn , drugn , drugn , drugn ) may increases drugn concentrations .
false
co-administration of drugn with strong inhibitors of the cyp3a4 family ( e.g. , druga , drugn , drugn , drugn , drugn , drugn , drugb , drugn , drugn , drugn , drugn ) may increases drugn concentrations .
false
co-administration of drugn with strong inhibitors of the cyp3a4 family ( e.g. , druga , drugn , drugn , drugn , drugn , drugn , drugn , drugb , drugn , drugn , drugn ) may increases drugn concentrations .
false
co-administration of drugn with strong inhibitors of the cyp3a4 family ( e.g. , druga , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugb , drugn , drugn ) may increases drugn concentrations .
false
co-administration of drugn with strong inhibitors of the cyp3a4 family ( e.g. , druga , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugb , drugn ) may increases drugn concentrations .
false
co-administration of drugn with strong inhibitors of the cyp3a4 family ( e.g. , druga , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugb ) may increases drugn concentrations .
false
co-administration of drugn with strong inhibitors of the cyp3a4 family ( e.g. , druga , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn ) may increases drugb concentrations .
false
co-administration of drugn with strong inhibitors of the cyp3a4 family ( e.g. , drugn , druga , drugb , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn ) may increases drugn concentrations .
false
co-administration of drugn with strong inhibitors of the cyp3a4 family ( e.g. , drugn , druga , drugn , drugb , drugn , drugn , drugn , drugn , drugn , drugn , drugn ) may increases drugn concentrations .
false
co-administration of drugn with strong inhibitors of the cyp3a4 family ( e.g. , drugn , druga , drugn , drugn , drugb , drugn , drugn , drugn , drugn , drugn , drugn ) may increases drugn concentrations .
false
co-administration of drugn with strong inhibitors of the cyp3a4 family ( e.g. , drugn , druga , drugn , drugn , drugn , drugb , drugn , drugn , drugn , drugn , drugn ) may increases drugn concentrations .
false
co-administration of drugn with strong inhibitors of the cyp3a4 family ( e.g. , drugn , druga , drugn , drugn , drugn , drugn , drugb , drugn , drugn , drugn , drugn ) may increases drugn concentrations .
false
co-administration of drugn with strong inhibitors of the cyp3a4 family ( e.g. , drugn , druga , drugn , drugn , drugn , drugn , drugn , drugb , drugn , drugn , drugn ) may increases drugn concentrations .
false
co-administration of drugn with strong inhibitors of the cyp3a4 family ( e.g. , drugn , druga , drugn , drugn , drugn , drugn , drugn , drugn , drugb , drugn , drugn ) may increases drugn concentrations .
false
co-administration of drugn with strong inhibitors of the cyp3a4 family ( e.g. , drugn , druga , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugb , drugn ) may increases drugn concentrations .
false
co-administration of drugn with strong inhibitors of the cyp3a4 family ( e.g. , drugn , druga , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugb ) may increases drugn concentrations .
false
co-administration of drugn with strong inhibitors of the cyp3a4 family ( e.g. , drugn , druga , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn ) may increases drugb concentrations .
false
co-administration of drugn with strong inhibitors of the cyp3a4 family ( e.g. , drugn , drugn , druga , drugb , drugn , drugn , drugn , drugn , drugn , drugn , drugn ) may increases drugn concentrations .
false
co-administration of drugn with strong inhibitors of the cyp3a4 family ( e.g. , drugn , drugn , druga , drugn , drugb , drugn , drugn , drugn , drugn , drugn , drugn ) may increases drugn concentrations .
false
co-administration of drugn with strong inhibitors of the cyp3a4 family ( e.g. , drugn , drugn , druga , drugn , drugn , drugb , drugn , drugn , drugn , drugn , drugn ) may increases drugn concentrations .
false
co-administration of drugn with strong inhibitors of the cyp3a4 family ( e.g. , drugn , drugn , druga , drugn , drugn , drugn , drugb , drugn , drugn , drugn , drugn ) may increases drugn concentrations .
false
co-administration of drugn with strong inhibitors of the cyp3a4 family ( e.g. , drugn , drugn , druga , drugn , drugn , drugn , drugn , drugb , drugn , drugn , drugn ) may increases drugn concentrations .
false
co-administration of drugn with strong inhibitors of the cyp3a4 family ( e.g. , drugn , drugn , druga , drugn , drugn , drugn , drugn , drugn , drugb , drugn , drugn ) may increases drugn concentrations .
false
co-administration of drugn with strong inhibitors of the cyp3a4 family ( e.g. , drugn , drugn , druga , drugn , drugn , drugn , drugn , drugn , drugn , drugb , drugn ) may increases drugn concentrations .
false
co-administration of drugn with strong inhibitors of the cyp3a4 family ( e.g. , drugn , drugn , druga , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugb ) may increases drugn concentrations .
false
co-administration of drugn with strong inhibitors of the cyp3a4 family ( e.g. , drugn , drugn , druga , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn ) may increases drugb concentrations .
false
co-administration of drugn with strong inhibitors of the cyp3a4 family ( e.g. , drugn , drugn , drugn , druga , drugb , drugn , drugn , drugn , drugn , drugn , drugn ) may increases drugn concentrations .
false
co-administration of drugn with strong inhibitors of the cyp3a4 family ( e.g. , drugn , drugn , drugn , druga , drugn , drugb , drugn , drugn , drugn , drugn , drugn ) may increases drugn concentrations .
false
co-administration of drugn with strong inhibitors of the cyp3a4 family ( e.g. , drugn , drugn , drugn , druga , drugn , drugn , drugb , drugn , drugn , drugn , drugn ) may increases drugn concentrations .
false
co-administration of drugn with strong inhibitors of the cyp3a4 family ( e.g. , drugn , drugn , drugn , druga , drugn , drugn , drugn , drugb , drugn , drugn , drugn ) may increases drugn concentrations .
false
co-administration of drugn with strong inhibitors of the cyp3a4 family ( e.g. , drugn , drugn , drugn , druga , drugn , drugn , drugn , drugn , drugb , drugn , drugn ) may increases drugn concentrations .
false
co-administration of drugn with strong inhibitors of the cyp3a4 family ( e.g. , drugn , drugn , drugn , druga , drugn , drugn , drugn , drugn , drugn , drugb , drugn ) may increases drugn concentrations .
false
co-administration of drugn with strong inhibitors of the cyp3a4 family ( e.g. , drugn , drugn , drugn , druga , drugn , drugn , drugn , drugn , drugn , drugn , drugb ) may increases drugn concentrations .
false
co-administration of drugn with strong inhibitors of the cyp3a4 family ( e.g. , drugn , drugn , drugn , druga , drugn , drugn , drugn , drugn , drugn , drugn , drugn ) may increases drugb concentrations .
false
co-administration of drugn with strong inhibitors of the cyp3a4 family ( e.g. , drugn , drugn , drugn , drugn , druga , drugb , drugn , drugn , drugn , drugn , drugn ) may increases drugn concentrations .
false
co-administration of drugn with strong inhibitors of the cyp3a4 family ( e.g. , drugn , drugn , drugn , drugn , druga , drugn , drugb , drugn , drugn , drugn , drugn ) may increases drugn concentrations .
false
co-administration of drugn with strong inhibitors of the cyp3a4 family ( e.g. , drugn , drugn , drugn , drugn , druga , drugn , drugn , drugb , drugn , drugn , drugn ) may increases drugn concentrations .
false
co-administration of drugn with strong inhibitors of the cyp3a4 family ( e.g. , drugn , drugn , drugn , drugn , druga , drugn , drugn , drugn , drugb , drugn , drugn ) may increases drugn concentrations .
false
co-administration of drugn with strong inhibitors of the cyp3a4 family ( e.g. , drugn , drugn , drugn , drugn , druga , drugn , drugn , drugn , drugn , drugb , drugn ) may increases drugn concentrations .
false
co-administration of drugn with strong inhibitors of the cyp3a4 family ( e.g. , drugn , drugn , drugn , drugn , druga , drugn , drugn , drugn , drugn , drugn , drugb ) may increases drugn concentrations .
false
co-administration of drugn with strong inhibitors of the cyp3a4 family ( e.g. , drugn , drugn , drugn , drugn , druga , drugn , drugn , drugn , drugn , drugn , drugn ) may increases drugb concentrations .
false
co-administration of drugn with strong inhibitors of the cyp3a4 family ( e.g. , drugn , drugn , drugn , drugn , drugn , druga , drugb , drugn , drugn , drugn , drugn ) may increases drugn concentrations .
false
co-administration of drugn with strong inhibitors of the cyp3a4 family ( e.g. , drugn , drugn , drugn , drugn , drugn , druga , drugn , drugb , drugn , drugn , drugn ) may increases drugn concentrations .
false
co-administration of drugn with strong inhibitors of the cyp3a4 family ( e.g. , drugn , drugn , drugn , drugn , drugn , druga , drugn , drugn , drugb , drugn , drugn ) may increases drugn concentrations .
false
co-administration of drugn with strong inhibitors of the cyp3a4 family ( e.g. , drugn , drugn , drugn , drugn , drugn , druga , drugn , drugn , drugn , drugb , drugn ) may increases drugn concentrations .
false
co-administration of drugn with strong inhibitors of the cyp3a4 family ( e.g. , drugn , drugn , drugn , drugn , drugn , druga , drugn , drugn , drugn , drugn , drugb ) may increases drugn concentrations .
false
co-administration of drugn with strong inhibitors of the cyp3a4 family ( e.g. , drugn , drugn , drugn , drugn , drugn , druga , drugn , drugn , drugn , drugn , drugn ) may increases drugb concentrations .
false
co-administration of drugn with strong inhibitors of the cyp3a4 family ( e.g. , drugn , drugn , drugn , drugn , drugn , drugn , druga , drugb , drugn , drugn , drugn ) may increases drugn concentrations .
false
co-administration of drugn with strong inhibitors of the cyp3a4 family ( e.g. , drugn , drugn , drugn , drugn , drugn , drugn , druga , drugn , drugb , drugn , drugn ) may increases drugn concentrations .
false
co-administration of drugn with strong inhibitors of the cyp3a4 family ( e.g. , drugn , drugn , drugn , drugn , drugn , drugn , druga , drugn , drugn , drugb , drugn ) may increases drugn concentrations .
false
co-administration of drugn with strong inhibitors of the cyp3a4 family ( e.g. , drugn , drugn , drugn , drugn , drugn , drugn , druga , drugn , drugn , drugn , drugb ) may increases drugn concentrations .
false
co-administration of drugn with strong inhibitors of the cyp3a4 family ( e.g. , drugn , drugn , drugn , drugn , drugn , drugn , druga , drugn , drugn , drugn , drugn ) may increases drugb concentrations .
false
co-administration of drugn with strong inhibitors of the cyp3a4 family ( e.g. , drugn , drugn , drugn , drugn , drugn , drugn , drugn , druga , drugb , drugn , drugn ) may increases drugn concentrations .
false
co-administration of drugn with strong inhibitors of the cyp3a4 family ( e.g. , drugn , drugn , drugn , drugn , drugn , drugn , drugn , druga , drugn , drugb , drugn ) may increases drugn concentrations .
false
co-administration of drugn with strong inhibitors of the cyp3a4 family ( e.g. , drugn , drugn , drugn , drugn , drugn , drugn , drugn , druga , drugn , drugn , drugb ) may increases drugn concentrations .
false
co-administration of drugn with strong inhibitors of the cyp3a4 family ( e.g. , drugn , drugn , drugn , drugn , drugn , drugn , drugn , druga , drugn , drugn , drugn ) may increases drugb concentrations .
false
co-administration of drugn with strong inhibitors of the cyp3a4 family ( e.g. , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , druga , drugb , drugn ) may increases drugn concentrations .
false
co-administration of drugn with strong inhibitors of the cyp3a4 family ( e.g. , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , druga , drugn , drugb ) may increases drugn concentrations .
false
co-administration of drugn with strong inhibitors of the cyp3a4 family ( e.g. , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , druga , drugn , drugn ) may increases drugb concentrations .
false
co-administration of drugn with strong inhibitors of the cyp3a4 family ( e.g. , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , druga , drugb ) may increases drugn concentrations .
false
co-administration of drugn with strong inhibitors of the cyp3a4 family ( e.g. , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , druga , drugn ) may increases drugb concentrations .
false
co-administration of drugn with strong inhibitors of the cyp3a4 family ( e.g. , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , drugn , druga ) may increases drugb concentrations .
false
co-administration of druga with inducers of the cyp3a4 family ( e.g. , drugb , drugn , drugn , drugn , drugn , drugn , drugn , st. johns wort ) may decrease drugn concentrations .
mechanism
co-administration of druga with inducers of the cyp3a4 family ( e.g. , drugn , drugb , drugn , drugn , drugn , drugn , drugn , st. johns wort ) may decrease drugn concentrations .
mechanism
co-administration of druga with inducers of the cyp3a4 family ( e.g. , drugn , drugn , drugb , drugn , drugn , drugn , drugn , st. johns wort ) may decrease drugn concentrations .
mechanism
co-administration of druga with inducers of the cyp3a4 family ( e.g. , drugn , drugn , drugn , drugb , drugn , drugn , drugn , st. johns wort ) may decrease drugn concentrations .
mechanism
co-administration of druga with inducers of the cyp3a4 family ( e.g. , drugn , drugn , drugn , drugn , drugb , drugn , drugn , st. johns wort ) may decrease drugn concentrations .
mechanism
co-administration of druga with inducers of the cyp3a4 family ( e.g. , drugn , drugn , drugn , drugn , drugn , drugb , drugn , st. johns wort ) may decrease drugn concentrations .
mechanism
co-administration of druga with inducers of the cyp3a4 family ( e.g. , drugn , drugn , drugn , drugn , drugn , drugn , drugb , st. johns wort ) may decrease drugn concentrations .
mechanism
co-administration of druga with inducers of the cyp3a4 family ( e.g. , drugn , drugn , drugn , drugn , drugn , drugn , drugn , st. johns wort ) may decrease drugb concentrations .
false
co-administration of drugn with inducers of the cyp3a4 family ( e.g. , druga , drugb , drugn , drugn , drugn , drugn , drugn , st. johns wort ) may decrease drugn concentrations .
false
co-administration of drugn with inducers of the cyp3a4 family ( e.g. , druga , drugn , drugb , drugn , drugn , drugn , drugn , st. johns wort ) may decrease drugn concentrations .
false
co-administration of drugn with inducers of the cyp3a4 family ( e.g. , druga , drugn , drugn , drugb , drugn , drugn , drugn , st. johns wort ) may decrease drugn concentrations .
false
co-administration of drugn with inducers of the cyp3a4 family ( e.g. , druga , drugn , drugn , drugn , drugb , drugn , drugn , st. johns wort ) may decrease drugn concentrations .
false
co-administration of drugn with inducers of the cyp3a4 family ( e.g. , druga , drugn , drugn , drugn , drugn , drugb , drugn , st. johns wort ) may decrease drugn concentrations .
false
co-administration of drugn with inducers of the cyp3a4 family ( e.g. , druga , drugn , drugn , drugn , drugn , drugn , drugb , st. johns wort ) may decrease drugn concentrations .
false
co-administration of drugn with inducers of the cyp3a4 family ( e.g. , druga , drugn , drugn , drugn , drugn , drugn , drugn , st. johns wort ) may decrease drugb concentrations .
false
co-administration of drugn with inducers of the cyp3a4 family ( e.g. , drugn , druga , drugb , drugn , drugn , drugn , drugn , st. johns wort ) may decrease drugn concentrations .
false
co-administration of drugn with inducers of the cyp3a4 family ( e.g. , drugn , druga , drugn , drugb , drugn , drugn , drugn , st. johns wort ) may decrease drugn concentrations .
false
co-administration of drugn with inducers of the cyp3a4 family ( e.g. , drugn , druga , drugn , drugn , drugb , drugn , drugn , st. johns wort ) may decrease drugn concentrations .
false
co-administration of drugn with inducers of the cyp3a4 family ( e.g. , drugn , druga , drugn , drugn , drugn , drugb , drugn , st. johns wort ) may decrease drugn concentrations .
false
co-administration of drugn with inducers of the cyp3a4 family ( e.g. , drugn , druga , drugn , drugn , drugn , drugn , drugb , st. johns wort ) may decrease drugn concentrations .
false
co-administration of drugn with inducers of the cyp3a4 family ( e.g. , drugn , druga , drugn , drugn , drugn , drugn , drugn , st. johns wort ) may decrease drugb concentrations .
false
co-administration of drugn with inducers of the cyp3a4 family ( e.g. , drugn , drugn , druga , drugb , drugn , drugn , drugn , st. johns wort ) may decrease drugn concentrations .
false
co-administration of drugn with inducers of the cyp3a4 family ( e.g. , drugn , drugn , druga , drugn , drugb , drugn , drugn , st. johns wort ) may decrease drugn concentrations .
false
co-administration of drugn with inducers of the cyp3a4 family ( e.g. , drugn , drugn , druga , drugn , drugn , drugb , drugn , st. johns wort ) may decrease drugn concentrations .
false
co-administration of drugn with inducers of the cyp3a4 family ( e.g. , drugn , drugn , druga , drugn , drugn , drugn , drugb , st. johns wort ) may decrease drugn concentrations .
false
co-administration of drugn with inducers of the cyp3a4 family ( e.g. , drugn , drugn , druga , drugn , drugn , drugn , drugn , st. johns wort ) may decrease drugb concentrations .
false
co-administration of drugn with inducers of the cyp3a4 family ( e.g. , drugn , drugn , drugn , druga , drugb , drugn , drugn , st. johns wort ) may decrease drugn concentrations .
false
co-administration of drugn with inducers of the cyp3a4 family ( e.g. , drugn , drugn , drugn , druga , drugn , drugb , drugn , st. johns wort ) may decrease drugn concentrations .
false
co-administration of drugn with inducers of the cyp3a4 family ( e.g. , drugn , drugn , drugn , druga , drugn , drugn , drugb , st. johns wort ) may decrease drugn concentrations .
false
co-administration of drugn with inducers of the cyp3a4 family ( e.g. , drugn , drugn , drugn , druga , drugn , drugn , drugn , st. johns wort ) may decrease drugb concentrations .
false
co-administration of drugn with inducers of the cyp3a4 family ( e.g. , drugn , drugn , drugn , drugn , druga , drugb , drugn , st. johns wort ) may decrease drugn concentrations .
false
co-administration of drugn with inducers of the cyp3a4 family ( e.g. , drugn , drugn , drugn , drugn , druga , drugn , drugb , st. johns wort ) may decrease drugn concentrations .
false
co-administration of drugn with inducers of the cyp3a4 family ( e.g. , drugn , drugn , drugn , drugn , druga , drugn , drugn , st. johns wort ) may decrease drugb concentrations .
false
co-administration of drugn with inducers of the cyp3a4 family ( e.g. , drugn , drugn , drugn , drugn , drugn , druga , drugb , st. johns wort ) may decrease drugn concentrations .
false
co-administration of drugn with inducers of the cyp3a4 family ( e.g. , drugn , drugn , drugn , drugn , drugn , druga , drugn , st. johns wort ) may decrease drugb concentrations .
false
co-administration of drugn with inducers of the cyp3a4 family ( e.g. , drugn , drugn , drugn , drugn , drugn , drugn , druga , st. johns wort ) may decrease drugb concentrations .
false
the metabolism of druga is accelerated by drugb ;
mechanism
druga inhibits the glucuronidation of drugb and could possibly potentiate drugn toxicity .
mechanism
druga inhibits the glucuronidation of drugn and could possibly potentiate drugb toxicity .
effect
drugn inhibits the glucuronidation of druga and could possibly potentiate drugb toxicity .
false
druga may compete with other drugs , such as drugb , for sites of metabolism in the liver , thus elevating the serum levels of such compounds to potentially toxic levels .
mechanism
therefore , when concomitant use of druga and drugb is anticipated , it may be necessary to monitor blood levels and/or reduce the dosage of such compounds .
advise
concomitant administrations not recommended : - druga and drugb : certain drugn interact with drugn and drugn leading to increased serum concentrations of the latter .
false
concomitant administrations not recommended : - druga and drugn : certain drugb interact with drugn and drugn leading to increased serum concentrations of the latter .
false
concomitant administrations not recommended : - druga and drugn : certain drugn interact with drugb and drugn leading to increased serum concentrations of the latter .
false
concomitant administrations not recommended : - druga and drugn : certain drugn interact with drugn and drugb leading to increased serum concentrations of the latter .
false
concomitant administrations not recommended : - drugn and druga : certain drugb interact with drugn and drugn leading to increased serum concentrations of the latter .
false
concomitant administrations not recommended : - drugn and druga : certain drugn interact with drugb and drugn leading to increased serum concentrations of the latter .
false
concomitant administrations not recommended : - drugn and druga : certain drugn interact with drugn and drugb leading to increased serum concentrations of the latter .
false
concomitant administrations not recommended : - drugn and drugn : certain druga interact with drugb and drugn leading to increased serum concentrations of the latter .
int
concomitant administrations not recommended : - drugn and drugn : certain druga interact with drugn and drugb leading to increased serum concentrations of the latter .
int
concomitant administrations not recommended : - drugn and drugn : certain drugn interact with druga and drugb leading to increased serum concentrations of the latter .
false
although such a reaction has not been demonstrated with druga , concomitant administration of drugb with drugn or drugn is not recommended .
false
although such a reaction has not been demonstrated with druga , concomitant administration of drugn with drugb or drugn is not recommended .
false
although such a reaction has not been demonstrated with druga , concomitant administration of drugn with drugn or drugb is not recommended .
false
although such a reaction has not been demonstrated with drugn , concomitant administration of druga with drugb or drugn is not recommended .
advise
although such a reaction has not been demonstrated with drugn , concomitant administration of druga with drugn or drugb is not recommended .
advise
although such a reaction has not been demonstrated with drugn , concomitant administration of drugn with druga or drugb is not recommended .
false
- druga , drugb : other drugs such as drugn or drugn , which are metabolised by hepatic cyp3a isozymes have been associated with qt interval prolongation and/or cardiac arrythmias ( typically torsades de pointe ) as a result of increase in their serum level subsequent to interaction with significant inhibitors of the isozyme , including some drugn .
false
- druga , drugn : other drugs such as drugb or drugn , which are metabolised by hepatic cyp3a isozymes have been associated with qt interval prolongation and/or cardiac arrythmias ( typically torsades de pointe ) as a result of increase in their serum level subsequent to interaction with significant inhibitors of the isozyme , including some drugn .
false
- druga , drugn : other drugs such as drugn or drugb , which are metabolised by hepatic cyp3a isozymes have been associated with qt interval prolongation and/or cardiac arrythmias ( typically torsades de pointe ) as a result of increase in their serum level subsequent to interaction with significant inhibitors of the isozyme , including some drugn .
false
- druga , drugn : other drugs such as drugn or drugn , which are metabolised by hepatic cyp3a isozymes have been associated with qt interval prolongation and/or cardiac arrythmias ( typically torsades de pointe ) as a result of increase in their serum level subsequent to interaction with significant inhibitors of the isozyme , including some drugb .
false
- drugn , druga : other drugs such as drugb or drugn , which are metabolised by hepatic cyp3a isozymes have been associated with qt interval prolongation and/or cardiac arrythmias ( typically torsades de pointe ) as a result of increase in their serum level subsequent to interaction with significant inhibitors of the isozyme , including some drugn .
false
- drugn , druga : other drugs such as drugn or drugb , which are metabolised by hepatic cyp3a isozymes have been associated with qt interval prolongation and/or cardiac arrythmias ( typically torsades de pointe ) as a result of increase in their serum level subsequent to interaction with significant inhibitors of the isozyme , including some drugn .
false
- drugn , druga : other drugs such as drugn or drugn , which are metabolised by hepatic cyp3a isozymes have been associated with qt interval prolongation and/or cardiac arrythmias ( typically torsades de pointe ) as a result of increase in their serum level subsequent to interaction with significant inhibitors of the isozyme , including some drugb .
mechanism
- drugn , drugn : other drugs such as druga or drugb , which are metabolised by hepatic cyp3a isozymes have been associated with qt interval prolongation and/or cardiac arrythmias ( typically torsades de pointe ) as a result of increase in their serum level subsequent to interaction with significant inhibitors of the isozyme , including some drugn .
false
- drugn , drugn : other drugs such as druga or drugn , which are metabolised by hepatic cyp3a isozymes have been associated with qt interval prolongation and/or cardiac arrythmias ( typically torsades de pointe ) as a result of increase in their serum level subsequent to interaction with significant inhibitors of the isozyme , including some drugb .
mechanism
- drugn , drugn : other drugs such as drugn or druga , which are metabolised by hepatic cyp3a isozymes have been associated with qt interval prolongation and/or cardiac arrythmias ( typically torsades de pointe ) as a result of increase in their serum level subsequent to interaction with significant inhibitors of the isozyme , including some drugb .
false
although such a risk is not verified for druga , combination of drugb with such drugs is not recommended .
false
